

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2008254837 B2**

(54) Title
Chimeric PUFA polyketide synthase systems and uses thereof

(51) International Patent Classification(s)
A01H 5/00 (2006.01) **C12N 1/15** (2006.01)
A61K 48/00 (2006.01) **C12N 1/19** (2006.01)
A61P 1/04 (2006.01) **C12N 1/20** (2006.01)
A61P 1/16 (2006.01) **C12N 1/21** (2006.01)
A61P 3/06 (2006.01) **C12N 5/04** (2006.01)
A61P 9/10 (2006.01) **C12N 5/10** (2006.01)
A61P 11/00 (2006.01) **C12N 9/02** (2006.01)
A61P 15/06 (2006.01) **C12N 15/00** (2006.01)
A61P 19/02 (2006.01) **C12N 15/09** (2006.01)
A61P 19/10 (2006.01) **C12N 15/11** (2006.01)
A61P 25/08 (2006.01) **C12N 15/52** (2006.01)
A61P 25/24 (2006.01) **C12N 15/82** (2006.01)
A61P 25/28 (2006.01) **C12P 1/02** (2006.01)
A61P 29/00 (2006.01) **C12P 7/62** (2006.01)
A61P 31/04 (2006.01) **C12P 7/64** (2006.01)
A61P 35/00 (2006.01) **C12P 21/04** (2006.01)
A61P 37/02 (2006.01) **C12Q 1/02** (2006.01)
A61P 43/00 (2006.01) **C12Q 1/68** (2006.01)
C12N 1/00 (2006.01) **C12R 1/645** (2006.01)
C12N 1/12 (2006.01)

(21) Application No: **2008254837** (22) Date of Filing: **2008.05.16**

(87) WIPO No: **WO08/144473**

(30) Priority Data

(31) Number (32) Date (33) Country
11/749,686 **2007.05.16** **US**

(43) Publication Date: **2008.11.27**

(44) Accepted Journal Date: **2013.09.12**

(71) Applicant(s)
DSM IP Assets B.V.

(72) Inventor(s)
Weaver, Craig A.;Doherty, Daniel H.;Zirkle, Ross;Metz, James G.

(74) Agent / Attorney
Allens Patent & Trade Mark Attorneys, Deutsche Bank Place Corner Hunter and Phillip Streets, SYDNEY, NSW, 2000

(56) Related Art
US 20050100995

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 November 2008 (27.11.2008)

PCT

(10) International Publication Number
WO 2008/144473 A3

(51) International Patent Classification:
C12P 7/64 (2006.01)

(21) International Application Number:
PCT/US2008/063835

(22) International Filing Date: 16 May 2008 (16.05.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/749,686 16 May 2007 (16.05.2007) US

(71) Applicant (for all designated States except US):
MARTEK BIOSCIENCES CORPORATION [US/US];
6480 Dobbin Road, Columbia, MD 21045 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WEAVER, Craig, A.** [US/US]; 4542 Starboard Drive, Boulder, CO 80301 (US). **ZIRKLE, Ross** [US/US]; 974 Wolf Creek Drive, Longmont, CO 80501 (US). **DOHERTY, Daniel, H.** [US/US]; 719 Ithaca Drive, Boulder, CO 80305 (US). **METZ, James, G.** [US/US]; 542 E. 16th Avenue, Longmont, CO 80501 (US).

(74) Agent: **YOERG, Darla, G.**; Sheridan Ross P.C., 1560 Broadway, Suite 1200, Denver, CO 80202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:
15 January 2009

(54) Title: CHIMERIC PUFA POLYKETIDE SYNTHASE SYSTEMS AND USES THEREOF

(57) Abstract: Disclosed are chimeric polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) proteins and chimeric PUFA PKS systems, including chimeric PUFA PKS proteins and systems derived from *Schizochytrium* and *Thraustochytrium*. Disclosed are nucleic acids and proteins encoding such chimeric PUFA PKS proteins and systems, genetically modified organisms comprising such chimeric PUFA PKS proteins and systems, and methods of making and using such chimeric PUFA PKS proteins and systems.



WO 2008/144473 A3

CHIMERIC PUFA POLYKETIDE SYNTHASE SYSTEMS AND USES THEREOF

Related Applications

5 Each of the following patent applications is incorporated herein by reference in its entirety. U.S. Patent Application No. 11/689,438, filed March 21, 2007; U.S. Patent Application No. 10/965,017, filed October 13, 2004, now U.S. Patent No. 7,217,856; U.S. Patent Application Serial No. 10/810,352, filed March 26, 2004, now U.S. Patent No. 7,211,418; U.S. Provisional Application Serial No. 60/457,979, filed March 26, 2003; U.S. Patent Application Serial No. 10/124,800, filed April 16, 2002; U.S. Provisional Application Serial No. 60/284,066, filed April 16, 2001; U.S. Provisional Application Serial No. 60/298,796, filed June 15, 2001; U.S. Provisional Application Serial No. 60/323,269, filed September 18, 2001; U.S. Application Serial No. 09/231,899, filed January 14, 1999, now U.S. Patent No. 6,566,583; U.S. Application No. 11/668,333, filed January 29, 2007; U.S. Patent Application Serial No. 11/452,096, filed June 12, 2006; U.S. Provisional Application No. 60/784,616, filed March 21, 2006; U.S. Provisional Application No. 60/689,167, filed June 10, 2005; U.S. Patent Application No. 11/452,138, filed June 12, 2006; U.S. Provisional Application No. 60/784,616, filed March 21, 2006; U.S. Provisional Application No. 60/689,167, filed June 10, 2005; U.S. Application Serial No. 09/090,793, filed June 4, 1998, now U.S. Patent No. 6,140,486.

Field of the Invention

This invention relates to chimeric polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, and particularly, to chimeric PUFA PKS systems from *Schizochytrium* and *Thraustochytrium*. More particularly, this invention relates to nucleic acids encoding such PUFA PKS systems, to these PUFA PKS systems, to genetically modified organisms comprising such PUFA PKS systems, and to methods of making and using such PUFA PKS systems disclosed herein.

Background of the Invention

Polyketide synthase (PKS) systems are generally known in the art as enzyme complexes related to fatty acid synthase (FAS) systems, but which are often highly modified to produce specialized products that typically show little resemblance to fatty acids. It has now been shown, however, that PKS-like systems, also referred to herein interchangeably as PUFA PKS systems, PUFA synthase systems, or PKS systems for the production of PUFAs, exist in marine bacteria and certain eukaryotic organisms that are

capable of synthesizing polyunsaturated fatty acids (PUFAs) from acetyl-CoA and malonyl-CoA. The PUFA PKS pathways for PUFA synthesis in *Shewanella* and another marine bacteria, *Vibrio marinus*, are described in detail in U.S. Patent No. 6,140,486. The PUFA PKS pathways for PUFA synthesis in the eukaryotic Thraustochytrid, *Schizochytrium*, is described in detail in U.S. Patent No. 6,566,583. The PUFA PKS pathways for PUFA synthesis in eukaryotes such as members of Thraustochytriales, including the additional description of a PUFA PKS system in *Schizochytrium* and the identification of a PUFA PKS system in *Thraustochytrium*, including details regarding uses of these systems, are described in detail in U.S. Patent Application Publication No. 20020194641, published December 19, 2002, and U.S. Patent Application Publication No. 20070089199, published April 19, 2007. U.S. Patent Application Publication No. 20040235127, published November 25, 2004, discloses the detailed structural description of a PUFA PKS system in *Thraustochytrium*, and further detail regarding the production of eicosapentaenoic acid (C20:5, ω -3) (EPA) and other PUFAs using such systems. U.S. Patent Application Publication No. 20050100995, published May 12, 2005, discloses the structural and functional description of PUFA PKS systems in *Shewanella olleyana* and *Shewanella japonica*, and uses of such systems. These applications also disclose the genetic modification of organisms, including microorganisms and plants, with the genes comprising the PUFA PKS pathway and the production of PUFAs by such organisms. Furthermore, PCT Patent Publication No. WO 05/097982 describes a PUFA PKS system in *Ulkenia*, and U.S. Patent Application Publication No. 20050014231 describes PUFA PKS genes and proteins from *Thraustochytrium aureum*. Each of the above-identified applications is incorporated by reference herein in its entirety.

Researchers have attempted to exploit polyketide synthase (PKS) systems that have been traditionally described in the literature as falling into one of three basic types, typically referred to as: Type I (modular or iterative), Type II, and Type III. For purposes of clarity, it is noted that the Type I modular PKS system has previously also been referred to as simply a "modular" PKS system, and the Type I iterative PKS system has previously also been referred to simply as a "Type I" PKS system. The Type II system is characterized by separable proteins, each of which carries out a distinct enzymatic reaction. The enzymes work in concert to produce the end product and each individual enzyme of the system typically participates several times in the production of the end product. This type of system operates in a manner analogous to the fatty acid synthase

(FAS) systems found in plants and bacteria. Type I iterative PKS systems are similar to the Type II system in that the enzymes are used in an iterative fashion to produce the end product. The Type I iterative differs from Type II in that enzymatic activities, instead of being associated with separable proteins, occur as domains of larger proteins. This system
5 is analogous to the Type I FAS systems found in animals and fungi.

In contrast to the Type II systems, in Type I modular PKS systems, each enzyme domain is used only once in the production of the end product. The domains are found in very large proteins and the product of each reaction is passed on to another domain in the PKS protein. Additionally, in the PKS systems described above, if a carbon-carbon
10 double bond is incorporated into the end product, it is usually in the *trans* configuration.

Type III systems have been more recently discovered and belong to the plant chalcone synthase family of condensing enzymes. Type III PKSs are distinct from type I and type II PKS systems and utilize free acyl-CoA substrates in iterative condensation reactions to usually produce a heterocyclic end product.

15 Polyunsaturated fatty acids (PUFAs) are considered to be useful for nutritional, pharmaceutical, industrial, and other purposes. The current supply of PUFAs from natural sources and from chemical synthesis is not sufficient for commercial needs. A major current source for PUFAs is from marine fish; however, fish stocks are declining, and this may not be a sustainable resource. Additionally, contamination, from both heavy metals
20 and toxic organic molecules, is a serious issue with oil derived from marine fish. Vegetable oils derived from oil seed crops are relatively inexpensive and do not have the contamination issues associated with fish oils. However, the PUFAs found in commercially developed plant oils are typically limited to linoleic acid (eighteen carbons with 2 double bonds, in the delta 9 and 12 positions - 18:2 delta 9,12) and linolenic acid
25 (18:3 delta 9,12,15). In the conventional pathway (*i.e.*, the "standard" pathway or "classical" pathway) for PUFA synthesis, medium chain-length saturated fatty acids (products of a fatty acid synthase (FAS) system) are modified by a series of elongation and desaturation reactions. The substrates for the elongation reaction are fatty acyl-CoA (the fatty acid chain to be elongated) and malonyl-CoA (the source of the 2 carbons added
30 during each elongation reaction). The product of the elongase reaction is a fatty acyl-CoA that has two additional carbons in the linear chain. The desaturases create *cis* double bonds in the preexisting fatty acid chain by extraction of 2 hydrogens in an oxygen-dependant reaction. The substrates for the desaturases are either acyl-CoA (in some

animals) or the fatty acid that is esterified to the glycerol backbone of a phospholipid (e.g. phosphatidylcholine).

Therefore, because a number of separate desaturase and elongase enzymes are required for fatty acid synthesis from linoleic and linolenic acids to produce the more unsaturated and longer chain PUFAs, engineering plant host cells for the expression of PUFAs such as EPA and docosahexaenoic acid (DHA) may require expression of several separate enzymes to achieve synthesis. Additionally, for production of useable quantities of such PUFAs, additional engineering efforts may be required. Therefore, it is of interest to obtain genetic material involved in PUFA biosynthesis from species that naturally produce these fatty acids (e.g., from a PUFA PKS system) and to express the isolated material alone or in combination in a heterologous system which can be manipulated to allow production of commercial quantities of PUFAs.

There have been many efforts to produce PUFAs in oil-seed crop plants by modification of the endogenously-produced fatty acids. Genetic modification of these plants with various individual genes for fatty acid elongases and desaturases has produced leaves or seeds containing measurable levels of PUFAs such as EPA, but also containing significant levels of mixed shorter-chain and less unsaturated PUFAs (Qi et al., *Nature Biotech.* 22:739 (2004); PCT Publication No. WO 04/071467; Abbadi et al., *Plant Cell* 16:1 (2004)); Napier and Sayanova, *Proceedings of the Nutrition Society* (2005), 64:387-20 393; Robert et al., *Functional Plant Biology* (2005) 32:473-479; or U.S. Patent Application Publication 2004/0172682.

Improvement in both microbial and plant production of PUFAs is a highly desirable commercial goal. Therefore, there remains a need in the art for a method to efficiently and effectively produce quantities of lipids (e.g., triacylglycerol (TAG) and phospholipid (PL)) enriched in desired PUFAs, particularly in commercially useful organisms such as microorganisms and oil-seed plants.

Summary of the Invention

According to a first aspect there is provided a chimeric PUFA PKS system, wherein an FabA-like β -hydroxyacyl-ACP dehydratase-2 (DH2) domain from a first PUFA PKS system is replaced with a DH2 domain from a different, second PUFA PKS system, to produce a chimeric PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system.

According to a second aspect there is provided a method of altering the omega-3 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system, comprising expressing the chimeric PUFA PKS system of the first aspect in an organism.

According to a third aspect there is provided a genetically modified microorganism or plant or part of the plant, comprising a chimeric PUFA PKS system of the first aspect.

According to a fourth aspect there is provided a method of increasing the production of PUFAs and of altering the omega-3 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system, comprising expressing a chimeric PUFA PKS system in an organism, wherein the Fab A- like β -hydroxyacyl-ACP dehydrase-2 (DH2) domain from a first PUFA PKS system is replaced with a DH2 domain from a different, second PUFA PKS system, to produce a chimeric PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system, and wherein the DH2 domain from the second PUFA PKS system is optimized for the codon usage of the organism from which the first PUFA PKS system is derived.

According to a fifth aspect there is provided an isolated nucleic acid molecule encoding a chimeric OrfC protein that is at least 95% identical to SEQ ID NO: 74 or SEQ ID NO: 75.

According to a sixth aspect there is provided a recombinant nucleic acid molecule comprising the nucleic acid molecule of the fifth aspect.

According to a seventh aspect there is provided a recombinant host cell that has been transfected with the nucleic acid molecule of the fifth aspect. The host cell may be a plant cell or a microorganism such as a *Schizochytrium*, a bacterium, or a yeast.

According to an eighth aspect there is provided a genetically modified plant or part thereof, comprising the plant cell of the seventh aspect.

One embodiment of the invention relates to a chimeric PUFA PKS system, wherein an FabA-like β -hydroxyacyl-ACP dehydrase (DR) domain from a first PUFA PKS system is replaced with a DR domain from a different, second PUFA PKS system, to produce a chimeric PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system. In one aspect, a protein comprising the DR domain from the first PUFA PKS system is replaced with a

homologous protein comprising the DH domain from the second PUFA PKS system. In one aspect, the DH domain from the first or second PUFA PKS system corresponds to a DH2 domain from *Schizochytrium* or *Thraustochytrium*. In one aspect, the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein the second PUFA PKS system is a *Thraustochytrium* PUFA PKS system. In one aspect, the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein OrfC from the *Schizochytrium* PUFA PKS system is replaced with OrfC from a different thraustochytrid.

In one aspect of this embodiment, the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein OrfC from the *Schizochytrium* PUFA PKS system is replaced with OrfC from *Thraustochytrium* 23B. In one aspect, such an OrfC from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage. An exemplary nucleic acid sequence comprises SEQ ID NO:70. In an additional aspect, OrfA from the *Schizochytrium* PUFA PKS system is replaced with OrfA from *Thraustochytrium* 23B. In one aspect, such an OrfA from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage. An exemplary nucleic acid sequence comprises SEQ ID NO:71. In another additional aspect, OrfB from the *Schizochytrium* PUFA PKS system is replaced with OrfB from *Thraustochytrium* 23B. In one aspect, such an OrfB from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage. An exemplary nucleic acid sequence comprises SEQ ID NO:72. Other combinations of OrfsA, B and C will be apparent based on this disclosure to those of skill in the art.

In yet another aspect of this embodiment, the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and the DH2 domain of OrfC from the *Schizochytrium* PUFA PKS system is replaced with the DH2 domain from *Thraustochytrium* 23B. In one aspect, an exemplary nucleic acid sequence comprising the DH2 domain from *Thraustochytrium* 23B comprises SEQ ID NO:73. In one aspect, the DH2 domain from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage. Such a nucleic acid sequence comprising the DH2 domain from *Thraustochytrium* 23B is exemplified by the nucleic acid sequence comprising SEQ ID NO:75.

In yet another aspect of this embodiment, the chimeric PUFA PKS system comprises a protein comprising an amino acid sequence that is at least 95% identical to

SEQ ID NO:74. In one aspect, the chimeric PUFA PKS system comprises a protein comprising an amino acid sequence of SEQ ID NO:74. In one aspect, the chimeric PUFA PKS system comprises SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:74. In another aspect, the chimeric PUFA PKS system comprises SEQ ID NO:39, SEQ ID NO:4 and
5 SEQ ID NO:62. In another aspect, the chimeric PUFA PKS system comprises SEQ ID NO:39, SEQ ID NO:4 and SEQ ID NO:74. In another aspect, the chimeric PUFA PKS system is encoded by nucleic acid molecules comprising: SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:70. In yet another aspect, the chimeric PUFA PKS system is encoded by nucleic acid molecules comprising: SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:73. In
10 another aspect, the chimeric PUFA PKS system is encoded by nucleic acid molecules comprising: SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:75. In another aspect, the chimeric PUFA PKS system is encoded by nucleic acid molecules comprising: SEQ ID NO:71, SEQ ID NO:3 and SEQ ID NO:70.

Another embodiment of the invention relates to a method of altering the omega-3
15 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system, comprising expressing any of the above-described chimeric PUFA PKS systems in an organism. In one aspect, the chimeric PUFA PKS system is expressed by a microorganism. In one aspect, the microorganism is a *Schizochytrium*. In yet another aspect, the microorganism is a yeast. In one aspect, the chimeric PUFA PKS system is
20 expressed by a plant.

Yet another embodiment of the invention relates to a genetically modified microorganism or plant or part of the plant, comprising any of the above-described chimeric PUFA PKS systems.

Another embodiment of the invention relates to a method of increasing the
25 production of PUFAs and of altering the omega-3 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system. The method comprises expressing a chimeric PUFA PKS system in an organism, wherein the FabA-like β -hydroxyacyl-ACP dehydrase (DH) domain from a first PUFA PKS system is replaced with a DH domain from a different, second PUFA PKS system, to produce a chimeric
30 PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system. The DH domain from the second PUFA PKS system is optimized for the codon usage of the organism from which the first PUFA PKS system is derived.

Yet another embodiment of the invention relates to an isolated nucleic acid molecule encoding a chimeric OrfC protein that is at least 95% identical to SEQ ID NO:74. In one aspect, the isolated nucleic acid molecule comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO:73. In one aspect, the nucleic acid sequence is optimized for the codon usage of an organism in which the nucleic acid molecule is to be expressed. As an example, the nucleic acid sequence may be optimized for the codon usage of an organism from which a portion of the chimeric protein is derived. In one embodiment, the nucleic acid sequence is at least 95% identical to SEQ ID NO:75.

Another embodiment of the invention relates to a recombinant nucleic acid molecule comprising any of the above-described nucleic acid molecules.

Yet another embodiment of the invention relates to a recombinant host cell that has been transfected with any of the above-described nucleic acid molecules. In one aspect, cell is a microorganism. In one aspect, the microorganism is a *Schizochytrium*. In one aspect, the microorganism is a bacterium. In one aspect, the microorganism is a yeast. In one aspect, the cell is a plant cell.

Another embodiment of the invention relates to a genetically modified plant or part thereof, comprising any of the above-described recombinant host cells.

Another embodiment of the invention relates to a chimeric PUFA PKS system, comprising: (a) at least one enoyl-ACP reductase (ER) domain; (b) at least four ACP domains; (c) at least two β -ketoacyl-ACP synthase (KS) domains; (d) at least one acyltransferase (AT) domain; (e) at least one β -ketoacyl-ACP reductase (KR) domain; (f) at least two FabA-like β -hydroxyacyl-ACP dehydrase (DH) domains; (g) at least one chain length factor (CLF) domain; and (h) at least one malonyl-CoA:ACP acyltransferase (MAT) domain. At least one of the DH domains is from a first PUFA PKS system, and the remainder of domains (a)-(h) are from a second, different PUFA PKS system.

Another embodiment of the invention relates to a method of increasing PUFA production by an organism that expresses a PUFA PKS system. The method includes modifying a nucleic acid molecule encoding at least one protein in the PUFA PKS system for the optimized codon usage of the organism or of a related organism. In one aspect, the organism expresses a heterologous, recombinant PUFA PKS system. In one aspect, the organism is a *Schizochytrium* and a nucleic acid molecule encoding at least one protein in the endogenous PUFA PKS system is optimized for *Schizochytrium* codon usage.

Brief Description of the Figures

Fig. 1 is a graphical representation of the domain structure of the *Schizochytrium* PUFA PKS system.

Fig. 2A is a schematic drawing showing step 1 of the construction of a plasmid containing a synthetic, *Schizochytrium* codon-optimized nucleic acid sequence encoding OrfC from *Thraustochytrium* 23B (pThOrfC_synPS), as well as intermediate plasmids produced by the process.

Fig. 2B is a schematic drawing showing step 2 of the construction of a plasmid containing a synthetic, *Schizochytrium* codon-optimized nucleic acid sequence encoding OrfC from *Thraustochytrium* 23B (pThOrfC_synPS), as well as intermediate plasmids produced by the process.

Fig. 3A is a schematic drawing showing steps 1-6 of the construction of a plasmid encoding *Schizochytrium* OrfC comprising a native DH2 domain from *Thraustochytrium* 23B (pDS49), as well as intermediate plasmids produced by the process.

Fig. 3B is a schematic drawing showing step 7 of the construction of a plasmid encoding *Schizochytrium* OrfC comprising a native DH2 domain from *Thraustochytrium* 23B (pDS49), as well as intermediate plasmids produced by the process.

Fig. 3C is a schematic drawing showing steps 8-9 of the construction of a plasmid encoding *Schizochytrium* OrfC comprising a native DH2 domain from *Thraustochytrium* 23B (pDS49), as well as intermediate plasmids produced by the process.

Fig. 4A is a schematic drawing showing the construction of plasmid DD21 as the first step in the construction of a plasmid encoding *Schizochytrium* OrfC comprising a synthetic, *Schizochytrium* codon-optimized DH2 domain from *Thraustochytrium* 23B (pDD24), as well as intermediate plasmids produced by the process.

Fig. 4B is a schematic drawing showing the construction of plasmid DD22 as the second step in the construction of a plasmid encoding *Schizochytrium* OrfC comprising a synthetic, *Schizochytrium* codon-optimized DH2 domain from *Thraustochytrium* 23B (pDD24), as well as intermediate plasmids produced by the process.

Fig. 4C is a schematic drawing showing the construction of plasmid pDD24 as the final step in the construction of a plasmid encoding *Schizochytrium* OrfC comprising a synthetic, *Schizochytrium* codon-optimized DH2 domain from *Thraustochytrium* 23B (pDD24), as well as intermediate plasmids produced by the process.

Fig. 5 is a FAME profile of control yeast and yeast expressing *Schizochytrium* OrfsA, OrfsB, OrfC and Het I.

Fig. 6 is the FAME profile for yeast from Fig. 5, expanded to illustrate the production of target PUFAs.

5 Detailed Description of the Invention

The present invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems, also known as PUFA synthase systems, including PUFA PKS systems from thraustochytrids (*e.g.*, *Schizochytrium* and *Thraustochytrium*), labyrinthulids, marine bacteria, and other PUFA PKS-containing organisms, and chimeric
10 PUFA PKS proteins and systems produced therefrom. The present invention relates to genetically modified organisms comprising such PUFA PKS systems, and to methods of making and using such systems for the production of products of interest, including bioactive molecules. In one preferred embodiment, the present invention relates to a method to produce PUFAs in a microorganism or in an oil-seed plant or plant part that has
15 been genetically modified to express a PUFA PKS system of the present invention. The oils produced by the microorganism or plant contain at least one PUFA produced by the PUFA PKS system, and in the case of the plant, are substantially free of the mixed shorter-chain and less unsaturated PUFAs that are fatty acid products produced by the modification of products of the FAS system. The present invention specifically includes
20 methods to modify the amount of PUFAs and the ratio of PUFAs produced by a PUFA PKS system, and in one aspect of the invention, the ratio of omega-3 to omega-6 PUFAs or the ratio of one PUFA to another PUFA(s) (*e.g.*, the ratio of DHA to EPA), which can be applied to the creation and use of any PUFA PKS construct and/or genetically modified organism, as exemplified and described in detail herein.

25 First, the present inventors describe herein a domain of a PUFA PKS system that is both necessary and sufficient for modifying the ratio of PUFAs that are produced by a PUFA PKS system when more than one PUFA is produced, and provide novel chimeric constructs, novel chimeric PUFA PKS systems, novel organisms, and novel methods for producing modified amounts of PUFAs using this discovery. Second, the present
30 inventors describe herein methods, modifications, and a variety of chimeric PUFA PKS systems and constructs for optimizing PUFA PKS expression in heterologous hosts (or in an endogenous host) to increase the PUFA production by the organism. The invention

includes a detailed description of the use of these two discoveries, alone or together, to enhance and direct PUFA production in an organism.

More particularly, with regard to certain embodiments of the invention, previous work by the present inventors and colleagues (see Example 8 in U.S. Patent Application Publication No. 20050100995) demonstrated that the *Thraustochytrium* 23B orfC coding region (represented herein by SEQ ID NO:62) could functionally replace the *Schizochytrium* orfC coding region in the orfC locus in the genome. This was determined by first creating an exact deletion of the *Schizochytrium* orfC coding region containing an antibiotic resistance cassette in its place (denoted Δ orfC::ZEO) resulting in a strain (denoted B32-Z1) with an obligate growth requirement for DHA and resistance to ZeocinTM. A plasmid in which the *Th.23B* orfC coding region was cloned exactly between *Schizochytrium* orfC upstream and downstream non-coding regions was then constructed. Transformation of the *Schizochytrium* Δ orfC::ZEO strain with this *Th.23B* orfC construct resulted in complementation of the deletion and prototrophic (non-DHA-requiring), Zeocin-sensitive transformants. It was determined that these transformants derived from double cross-over recombination events at the orfC locus such that the *Th.23B* orfC coding region had exactly substituted for that from *Schizochytrium*; i.e., gene replacement. Analysis of the fatty acid content of these transformants showed that the DHA/DPA ratio had been changed from ca. 2.3 (in wild type *Schizochytrium* ATCC20888) to ca. 8.3 (approximately that of *Th.23B*). This result indicated that the orfC gene (containing three domains, DH1, DH2 and ER, in *Schizochytrium* and *Thraustochytrium*) plays a major role in determining the n-3/n-6 (omega-3/omega-6) ratio of PUFA products. However, total PUFA production in the *Th.23B* orfC-containing strain, while significant, was lower than that of the wild-type *Schizochytrium* host (ca. 60%).

Examination of these two orfC coding regions led the inventors to consider that the *Th.23B* gene is poorly expressed in *Schizochytrium* due to notably different patterns of codon usage between *Schizochytrium* and *Thraustochytrium*. The inventors have now discovered that by using a "synthetic" *Th.23B* orfC coding region (i.e., a synthetically produced coding region) with codon usage optimized for the *Schizochytrium* pattern, DHA production was enhanced, while the increased n-3/n-6 ratio seen with the non-synthetic *Th.23B* orfC was maintained (see Examples 1 and 4).

The inventors have also previously described the existence of identifiable domains within the OrfC protein for *Schizochytrium* and *Thraustochytrium*: dehydratase 1 (DH1),

dehydratase 2 (DH2), and enoyl reductase (ER) (*e.g.*, see U.S. Patent Application Publication No. 20020194641, *supra*; U.S. Patent Application Publication No. 20040235127, *supra*), and have taught that one or more of the domains in OrfC were believed to be involved in controlling the type and/or ratio of fatty acids produced by the PUFA PKS system. Here, the inventors demonstrate in *Schizochytrium*, *E. coli*, and yeast systems that the DH2 domain *alone* is responsible for most or all of the effect of the PUFA PKS system on the omega-3 to omega-6 (n-3/n-6) fatty acid ratio. In particular, the inventors first performed experiments in which various *Thraustochytrium* 23B OrfC domains were used to replace the corresponding domains in *Schizochytrium* OrfC (data not shown). The inventors found that replacement of the *Schizochytrium* OrfC-ER domain with that from *Thraustochytrium* did not significantly change the DHA/DPA ratio as compared to wild-type *Schizochytrium* (historically, approximately 2.3). However, replacement of both *Schizochytrium* DH domains with the corresponding domains from *Thraustochytrium* significantly increased the DHA/DPA ratio toward that of wild-type *Thraustochytrium* 23B (historically, approximately 8.3-10), and replacement of just the *Schizochytrium* DH2 domain with that from *Thraustochytrium* 23B, was sufficient to achieve effectively the same result. Examples 2, 3, 4, 5, and 6 provide a variety of experimental results demonstrating the effect of the DH2 domain on the omega-3 to omega-6 (n-3/n-6) fatty acid ratio in PUFA PKS systems.

The present inventors also describe the use of a variety of chimeric PUFA PKS systems to increase the production of PUFAs by the host organism, and have made the unexpected discovery that certain chimeric PUFA PKS combinations (*e.g.*, chimeric PUFA PKS systems comprised of particular combinations of Orfs from *Schizochytrium* and *Thraustochytrium*) have significantly higher PUFA production, and in one example, DHA production, than the native organisms or than other chimeric PUFA PKS systems. For example, the inventors demonstrate that a chimeric PUFA PKS system comprised of an OrfA and OrfC from *Thraustochytrium* 23B and an OrfB from *Schizochytrium*, when expressed in a *Schizochytrium* host organism, produces significantly more fatty acids and significantly more DHA specifically, than native *Schizochytrium* or than other chimeric PUFA PKS systems derived from these two organisms (Example 8). Accordingly, the invention provides substantial guidance on the production of several different PUFA PKS systems that have increased PUFA production and improved n-3/n-6 ratios, as compared to some wild-type (non-chimeric) PUFA synthases.

As used herein, a PUFA PKS system (which may also be referred to as a PUFA synthase system, a PUFA synthase, or a PKS-like system for the production of PUFAs) generally has the following identifying features: (1) it produces PUFAs, and particularly, long chain PUFAs, as a natural product of the system; and (2) it comprises several multifunctional proteins assembled into a complex that conducts both iterative processing of the fatty acid chain as well *non-iterative* processing, including *trans-cis* isomerization and enoyl reduction reactions in selected cycles. In addition, the ACP domains present in the PUFA synthase enzymes require activation by attachment of a cofactor (4-phosphopantetheine). Attachment of this cofactor is carried out by phosphopantetheinyl transferases (PPTase). If the endogenous PPTases of the host organism are incapable of activating the PUFA synthase ACP domains, then it is necessary to provide a PPTase that is capable of carrying out that function. The inventors have identified the Het I enzyme of *Nostoc* sp. as an exemplary and suitable PPTase for activating PUFA synthase ACP domains. Reference to a PUFA PKS system or a PUFA synthase refers collectively to all of the genes and their encoded products that work in a complex to produce PUFAs in an organism. Therefore, the PUFA PKS system refers specifically to a PKS system for which the natural products are PUFAs.

More specifically, a PUFA PKS system as referenced herein produces polyunsaturated fatty acids (PUFAs) and particularly, long chain PUFAs, as products. For example, an organism that endogenously (naturally) contains a PUFA PKS system makes PUFAs using this system. According to the present invention, PUFAs are fatty acids with a carbon chain length of at least 16 carbons, and more preferably at least 18 carbons, and more preferably at least 20 carbons, and more preferably 22 or more carbons, with at least 3 or more double bonds, and preferably 4 or more, and more preferably 5 or more, and even more preferably 6 or more double bonds, wherein all double bonds are in the *cis* configuration. Reference to long chain polyunsaturated fatty acids (LCPUFAs) herein more particularly refers to fatty acids of 18 and more carbon chain length, and preferably 20 and more carbon chain length, containing 3 or more double bonds. LCPUFAs of the omega-6 series include: gamma-linolenic acid (C18:3), di-homo-gamma-linolenic acid (C20:3n-6), arachidonic acid (C20:4n-6), adrenic acid (also called docosatetraenoic acid or DTA) (C22:4n-6), and docosapentaenoic acid (C22:5n-6). The LCPUFAs of the omega-3 series include: alpha-linolenic acid (C18:3), eicosatrienoic acid (C20:3n-3), eicosatetraenoic acid (C20:4n-3), eicosapentaenoic acid (C20:5n-3), docosapentaenoic

acid (C22:5n-3), and docosahexaenoic acid (C22:6n-3). The LCPUFAs also include fatty acids with greater than 22 carbons and 4 or more double bonds including but not limited to C28:8(n-3).

Second, a PUFA PKS system according to the present invention comprises several
5 multifunctional proteins (and can include single function proteins, particularly for PUFA
PKS systems from marine bacteria) that are assembled into a complex that conducts both
iterative processing of the fatty acid chain as well *non-iterative* processing, including
trans-cis isomerization and enoyl reduction reactions in selected cycles. These proteins
can also be referred to herein as the core PUFA PKS enzyme complex or the core PUFA
10 PKS system. The general functions of the domains and motifs contained within these
proteins are individually known in the art and have been described in detail with regard to
various PUFA PKS systems from marine bacteria and eukaryotic organisms (see, *e.g.*,
U.S. Patent No. 6,140,486; U.S. Patent No. 6,566,583; Metz et al., *Science* 293:290-293
(2001); U.S. Patent Application Publication No. 20020194641; U.S. Patent Application
15 Publication No. 20040235127; U.S. Patent Application Publication No. 20050100995, and
PCT Publication No. WO 2006/135866). The domains may be found as a single protein
(i.e., the domain and protein are synonymous) or as one of two or more (multiple) domains
in a single protein, as mentioned above.

Before the discovery of a PUFA PKS system in marine bacteria (see U.S. Patent
20 No. 6,140,486), PKS systems were not known to possess this combination of iterative and
selective enzymatic reactions, and they were not thought of as being able to produce
carbon-carbon double bonds in the *cis* configuration. However, the PUFA PKS system
described by the present invention has the capacity to introduce *cis* double bonds and the
capacity to vary the reaction sequence in the cycle.

25 The present inventors propose to use these features of the PUFA PKS system to
produce a range of bioactive molecules that could not be produced by the previously
described (Type I iterative or modular, Type II, or Type III) PKS systems. These
bioactive molecules include, but are not limited to, polyunsaturated fatty acids (PUFAs),
antibiotics or other bioactive compounds, many of which will be discussed below. For
30 example, using the knowledge of the PUFA PKS gene structures described herein, any of
a number of methods can be used to alter the PUFA PKS genes, or combine portions of
these genes with other synthesis systems, including other PKS systems, such that new
products are produced. The inherent ability of this particular type of system to do both

iterative and selective reactions will enable this system to yield products that would not be found if similar methods were applied to other types of PKS systems.

Preferably, a PUFA PKS system of the present invention comprises at least the following biologically active domains that are typically contained on three or more proteins: (a) at least one enoyl-ACP reductase (ER) domain; (b) multiple acyl carrier protein (ACP) domain(s) (*e.g.*, at least from one to four, and preferably at least five ACP domains, and in some embodiments up to six, seven, eight, nine, ten, or more than ten ACP domains); (c) at least two β -ketoacyl-ACP synthase (KS) domains; (d) at least one acyltransferase (AT) domain; (e) at least one β -ketoacyl-ACP reductase (KR) domain; (f) at least two FabA-like β -hydroxyacyl-ACP dehydrase (DH) domains; (g) at least one chain length factor (CLF) domain; (h) at least one malonyl-CoA:ACP acyltransferase (MAT) domain. In one embodiment, a PUFA PKS system according to the present invention also comprises at least one region containing a dehydratase (DH) conserved active site motif.

In one embodiment, a *Schizochytrium* PUFA PKS system comprises at least the following biologically active domains: (a) two enoyl-ACP reductase (ER) domain; (b) between four or five and ten or more acyl carrier protein (ACP) domains, and in one aspect, nine ACP domains; (c) two β -ketoacyl-ACP synthase (KS) domains; (d) one acyltransferase (AT) domain; (e) one β -ketoacyl-ACP reductase (KR) domain; (f) two FabA-like β -hydroxyacyl-ACP dehydrase (DH) domains; (g) one chain length factor (CLF) domain; and (h) one malonyl-CoA:ACP acyltransferase (MAT) domain. In one embodiment, a *Schizochytrium* PUFA PKS system according to the present invention also comprises at least one region or domain containing a dehydratase (DH) conserved active site motif that is not a part of a FabA-like DH domain. The structural and functional characteristics of these domains are generally individually known in the art and will be described in detail below with regard to the PUFA PKS systems of the present invention.

In another preferred embodiment, a *Thraustochytrium* PUFA PKS system comprises at least the following biologically active domains: (a) two enoyl-ACP reductase (ER) domain; (b) between four or five and ten or more acyl carrier protein (ACP) domains, and in one aspect, eight ACP domains; (c) two β -ketoacyl-ACP synthase (KS) domains; (d) one acyltransferase (AT) domain; (e) one β -ketoacyl-ACP reductase (KR) domain; (f) two FabA-like β -hydroxyacyl-ACP dehydrase (DH) domains; (g) one chain length factor (CLF) domain; and (h) one malonyl-CoA:ACP acyltransferase (MAT) domain. In one embodiment, a *Thraustochytrium* PUFA PKS system according to the

present invention also comprises at least one region or domain containing a dehydratase (DH) conserved active site motif that is not a part of a FabA-like DH domain. The structural and functional characteristics of these domains are generally individually known in the art and will be described in detail below with regard to the PUFA PKS systems of the present invention.

A PUFA PKS system can additionally include one or more accessory proteins, which are defined herein as proteins that are not considered to be part of the core PUFA PKS system as described above (*i.e.*, not part of the PUFA synthase enzyme complex itself), but which may be, or are, necessary for PUFA production or at least for efficient PUFA production using the core PUFA synthase enzyme complex of the present invention, particularly in certain host organisms (*e.g.*, plants). For example, in order to produce PUFAs, a PUFA PKS system must work with an accessory protein that transfers a 4'-phosphopantetheinyl moiety from coenzyme A to the acyl carrier protein (ACP) domain(s). Therefore, a PUFA PKS system can be considered to include at least one 4'-phosphopantetheinyl transferase (PPTase) domain, or such a domain can be considered to be an accessory domain or protein to the PUFA PKS system. When genetically modifying organisms (*e.g.*, microorganisms or plants) to express a PUFA PKS system according to the present invention, some host organisms may endogenously express accessory proteins that are needed to work with the PUFA PKS to produce PUFAs (*e.g.*, PPTases). However, some organisms may be transformed with nucleic acid molecules encoding one or more accessory proteins described herein to enable and/or to enhance production of PUFAs by the organism, even if the organism endogenously produces a homologous accessory protein (*i.e.*, some heterologous accessory proteins may operate more effectively or efficiently with the transformed PUFA synthase proteins than the host cells' endogenous accessory protein). The present invention and prior applications provide examples of bacteria and yeast that have been genetically modified with the PUFA PKS system of the present invention that includes an accessory PPTase. Plants that have been genetically modified with the PUFA PKS system that includes an accessory PPTase have been described (see, *e.g.*, U.S. Patent Application Publication No. 20070089199). Structural and functional characteristics of PPTases will be described in more detail below.

The "standard" or "classical" pathway for synthesis of long chain PUFAs (LCPUFAs) in eukaryotic organisms involves the modification of medium chain-length saturated or mono-unsaturated fatty acids (*e.g.*, the products of the FAS system described

above). These modifications consist of elongation steps and desaturation steps. The substrates for the elongation reaction are fatty acyl-CoA (the fatty acid chain to be elongated) and malonyl-CoA (the source of the two carbons added during each elongation reaction). The product of the elongase reaction is a fatty acyl-CoA that has two additional
5 carbons in the linear chain. Free fatty acids (FFAs) do not normally occur in this reaction cycle. The desaturases create *cis* double bonds in the preexisting fatty acid chain by extraction of two hydrogens in an oxygen-dependant reaction. The substrates for the desaturases are either acyl-CoAs (in some animals) or fatty acids that are esterified to the glycerol backbone of a PL (e.g., phosphatidylcholine). Again, FFAs do not occur in this
10 reaction mechanism. Therefore, the only time FFAs occur in "standard" or "classical" LCPUFA synthesis pathways is during release of the fatty acids from some FAS systems. As discussed above, these are typically 16 or 18 carbon fatty acids and usually are either saturated or monounsaturated fatty acids, not longer chain PUFAs such as EPA or DHA. One consequence of this scheme for long chain PUFA production is that intermediates in
15 the pathway often accumulate, often representing the majority of the novel fatty acids produced by the system.

Therefore, according to the present invention, reference to a "standard" or "classical" pathway for the production of PUFAs refers to the fatty acid synthesis pathway where medium chain-length saturated fatty acids (e.g., products of a fatty acid synthase
20 (FAS) system) are modified by a series of elongation and desaturation reactions. The substrates for the elongation reaction are fatty acyl-CoA (the fatty acid chain to be elongated) and malonyl-CoA (the source of the 2 carbons added during each elongation reaction). The product of the elongase reaction is a fatty acyl-CoA that has two additional carbons in the linear chain. The desaturases create *cis* double bonds in the preexisting
25 fatty acid chain by extraction of 2 hydrogens in an oxygen-dependant reaction. Such pathways and the genes involved in such pathways are well-known in the literature.

As used herein, the term "lipid" includes phospholipids (PL); free fatty acids; esters of fatty acids; triacylglycerols (TAG); diacylglycerides; monoacylglycerides; phosphatides; waxes (esters of alcohols and fatty acids); sterols and sterol esters;
30 carotenoids; xanthophylls (e.g., oxycarotenoids); hydrocarbons; and other lipids known to one of ordinary skill in the art. The terms "polyunsaturated fatty acid" and "PUFA" include not only the free fatty acid form, but other forms as well, such as the TAG form and the PL form.

Reference to a "heterologous" organism or "heterologous" host, with respect to the expression of a PUFA PKS protein, domain or system by the organism/host, means that at least one protein, domain, or portion of the PUFA PKS system is not a protein, domain or portion that is naturally (endogenously) expressed by the organism, although the PUFA
5 PKS system may include proteins, domains, or portions thereof that are naturally expressed by host organism (e.g., a chimeric protein as described herein that contains sequences derived from the host organism and from a different organism or different protein).

Certain exemplary nucleic acid molecules (constructs) encoding various chimeric
10 proteins are described herein (see Examples). According to the present invention, a "chimeric protein" is an engineered protein encoded by a nucleic acid sequence that is produced by splicing or linking (ligating) together two or more complete or partial genes or nucleic acid sequences. A "chimeric PUFA PKS system" is a PUFA PKS system that contains proteins and/or domains, including chimeric proteins and/or domains, from two
15 or more different PKS systems. For example, the Examples describe a chimeric PUFA PKS system comprised of the *Schizochytrium* PUFA PKS OrfA and OrfB and the *Thraustochytrium* PUFA PKS OrfC. The Examples also describe a chimeric PUFA PKS system comprised of the *Schizochytrium* PUFA PKS OrfA, OrfB, and all of OrfC except for the DH2 domain, which is the PUFA PKS DH2 domain from a *Thraustochytrium*
20 PUFA PKS. This latter chimeric PUFA PKS system accordingly comprises a chimeric protein (a chimeric OrfC protein). The same chimeras are also described using *Thraustochytrium* nucleic acid sequences that have been optimized for *Schizochytrium* codon usage, illustrating a combination of genetic manipulations that can be used to alter the product produced by a PUFA PKS system (see Examples). The Examples also
25 describe a variety of other chimeric PUFA PKS systems.

As used herein, "codon optimization" or derivative phrases thereof refer to the process of modifying (altering, changing, mutating) a nucleic acid sequence encoding a given protein to replace one or more codons in the sequence with codons that are most frequently used in nucleic acid sequences of a particular organism in which a nucleic acid
30 molecule comprising the nucleic acid sequence is to be expressed. Codon bias and the general idea of codon optimization are understood by the skilled artisan. More particularly, the degree to which a given codon appears in the genetic code can vary significantly between organisms (e.g., including from species to species within a genus).

Any codon that an organism uses a small percentage of the time, or less than another codon for the same amino acid, can cause problems with protein expression. Accordingly, protein expression can improve dramatically when the codon frequency of the nucleic acid sequence being used is matched to that of the host expression system/organism (*e.g.*, by replacing rare or infrequent or less frequently used codons with others that more closely reflect the host system's natural codon bias, without modifying the amino acid sequence).

The present inventors describe herein methods to optimize codon usage of a nucleic acid sequence for that of *Schizochytrium*, although this is just one example of the use of codon optimization in the present invention. According to the present invention, the nucleotide sequence of a nucleic acid molecule encoding a given protein (*e.g.*, a PUFA PKS protein) can be modified (*e.g.*, by synthesis, mutation, recombinant technology, etc.) for the optimal (optimized) codon usage of a host cell or organism in which the nucleic acid molecule is to be expressed, or indeed, for the optimized codon usage of a different organism (*e.g.*, a nucleic acid molecule encoding a *Thraustochytrium* PUFA PKS protein for expression in a *plant* may be optimized for *Schizochytrium* codon usage). Table 1 of the Examples illustrates optimized codon usage for *Schizochytrium*.

In addition, the inventors propose herein the optimization of the nucleic acid sequence of a nucleic acid molecule encoding a given protein for the *same host* from which the nucleic acid sequence was derived, learned or obtained, for expression *in that host* (or in another host). This latter embodiment of the invention represents a “directed” or “accelerated” evolution of sorts, in which, for example, a nucleic acid molecule encoding a protein from an organism (*e.g.*, a PUFA PKS protein from *Schizochytrium*) is modified (*e.g.*, by resynthesizing the nucleic acid sequence and replacing certain nucleotides) to enhance codon usage (optimize the codon usage) that is preferred by the same organism (*Schizochytrium*, in this example). This nucleic acid molecule can then be expressed in *Schizochytrium* (as a recombinant nucleic acid molecule) or in another host cell or organism (*e.g.*, in a plant). In this embodiment, it is proposed that a given nucleic acid sequence from an organism may not use the optimal codons (codon bias) that can be determined for that organism. Accordingly, one may resynthesize the nucleic acid sequence to improve protein expression in that organism.

PUFA PKS systems and proteins or domains thereof that are useful in the present invention include both bacterial and non-bacterial PUFA PKS systems. A non-bacterial PUFA PKS system is a PUFA PKS system that is from or derived from an organism that is

not a bacterium, such as a eukaryote or an archaeobacterium. Eukaryotes are separated from prokaryotes based on the degree of differentiation of the cells, with eukaryotes being more differentiated than prokaryotes. In general, prokaryotes do not possess a nuclear membrane, do not exhibit mitosis during cell division, have only one chromosome, contain
5 70S ribosomes in their cytoplasm, do not possess mitochondria, endoplasmic reticulum, chloroplasts, lysosomes or Golgi apparatus, and may have flagella, which if present, contain a single fibril. In contrast, eukaryotes have a nuclear membrane, exhibit mitosis during cell division, have many chromosomes, contain 80S ribosomes in their cytoplasm, possess mitochondria, endoplasmic reticulum, chloroplasts (in algae), lysosomes and
10 Golgi apparatus, and may have flagella, which if present, contain many fibrils. In general, bacteria are prokaryotes, while algae, fungi, protist, protozoa and higher plants are eukaryotes. According to the present invention, genetically modified organisms can be produced which incorporate non-bacterial PUFA PKS functional domains with bacterial PUFA PKS functional domains, as well as PKS functional domains or proteins from other
15 PKS systems (Type I iterative or modular, Type II, or Type III) or FAS systems.

According to the present invention, a domain or protein having 3-keto acyl-ACP synthase (KS) biological activity (function) is characterized as the enzyme that carries out the initial step of the FAS (and PKS) elongation reaction cycle. The term " β -ketoacyl-ACP synthase" can be used interchangeably with the terms "3-keto acyl-ACP synthase",
20 " β -keto acyl-ACP synthase", and "keto-acyl ACP synthase", and similar derivatives. The acyl group destined for elongation is linked to a cysteine residue at the active site of the enzyme by a thioester bond. In the multi-step reaction, the acyl-enzyme undergoes condensation with malonyl-ACP to form -keto acyl-ACP, CO₂ and free enzyme. The KS plays a key role in the elongation cycle and in many systems has been shown to possess
25 greater substrate specificity than other enzymes of the reaction cycle. For example, *E. coli* has three distinct KS enzymes - each with its own particular role in the physiology of the organism (Magnuson et al., *Microbiol. Rev.* **57**, 522 (1993)). The two KS domains of the PUFA-PKS systems described in marine bacteria and the thraustochytrids described herein may have distinct roles in the PUFA biosynthetic reaction sequence. As a class of
30 enzymes, KS's have been well characterized. The sequences of many verified KS genes are known, the active site motifs have been identified and the crystal structures of several have been determined. Proteins (or domains of proteins) can be readily identified as belonging to the KS family of enzymes by homology to known KS sequences.

According to the present invention, a domain or protein having malonyl-CoA:ACP acyltransferase (MAT) biological activity (function) is characterized as one that transfers the malonyl moiety from malonyl-CoA to ACP. The term "malonyl-CoA:ACP acyltransferase" can be used interchangeably with "malonyl acyltransferase" and similar derivatives. In addition to the active site motif (GxSxG), these enzymes possess an extended motif of R and Q amino acids in key positions that identifies them as MAT enzymes (*e.g.*, in contrast to an AT domain described below). In some PKS systems (but not the PUFA PKS domain) MAT domains will preferentially load methyl- or ethyl-malonate on to the ACP group (from the corresponding CoA ester), thereby introducing branches into the linear carbon chain. MAT domains can be recognized by their homology to known MAT sequences and by their extended motif structure.

According to the present invention, a domain or protein having acyl carrier protein (ACP) biological activity (function) is characterized as being small polypeptides (typically, 80 to 100 amino acids long), that function as carriers for growing fatty acyl chains via a thioester linkage to a covalently bound co-factor of the protein. They occur as separate units or as domains within larger proteins. ACPs are converted from inactive apo-forms to functional holo-forms by transfer of the phosphopantetheinyl moiety of CoA to a highly conserved serine residue of the ACP. Acyl groups are attached to ACP by a thioester linkage at the free terminus of the phosphopantetheinyl moiety. ACPs can be identified by labeling with radioactive pantetheine and by sequence homology to known ACPs. The presence of variations of the above mentioned motif (LGIDS*) is also a signature of an ACP.

According to the present invention, a domain or protein having ketoreductase activity, also referred to as 3-ketoacyl-ACP reductase (KR) biological activity (function), is characterized as one that catalyzes the pyridine-nucleotide-dependent reduction of 3-keto acyl forms of ACP. It is the first reductive step in the *de novo* fatty acid biosynthesis elongation cycle and a reaction often performed in polyketide biosynthesis. The term "β-ketoacyl-ACP reductase" can be used interchangeably with the terms "ketoreductase", "3-ketoacyl-ACP reductase", "keto-acyl ACP reductase" and similar derivatives of the term. Significant sequence similarity is observed with one family of enoyl ACP reductases (ER), the other reductase of FAS (but not the ER family present in the PUFA PKS systems), and the short-chain alcohol dehydrogenase family. Pfam analysis of the PUFA PKS region indicated above reveals the homology to the short-chain alcohol dehydrogenase family in

the core region. Blast analysis of the same region reveals matches in the core area to known KR enzymes as well as an extended region of homology to domains from the other characterized PUFA PKS systems.

According to the present invention, a domain or protein is referred to as a chain length factor (CLF) based on the following rationale. The CLF was originally described as characteristic of Type II (dissociated enzymes) PKS systems and was hypothesized to play a role in determining the number of elongation cycles, and hence the chain length, of the end product. CLF amino acid sequences show homology to KS domains (and are thought to form heterodimers with a KS protein), but they lack the active site cysteine. CLF's role in PKS systems has been controversial. New evidence (C. Bisang et al., *Nature* **401**, 502 (1999)) suggests a role in priming (providing the initial acyl group to be elongated) the PKS systems. In this role the CLF domain is thought to decarboxylate malonate (as malonyl-ACP), thus forming an acetate group that can be transferred to the KS active site. This acetate therefore acts as the 'priming' molecule that can undergo the initial elongation (condensation) reaction. Homologues of the Type II CLF have been identified as 'loading' domains in some modular PKS systems. A domain with the sequence features of the CLF is found in all currently identified PUFA PKS systems and in each case is found as part of a multidomain protein.

An "acyltransferase" or "AT" refers to a general class of enzymes that can carry out a number of distinct acyl transfer reactions. The term "acyltransferase" can be used interchangeably with the term "acyl transferase". The AT domains identified in the PUFA PKS systems described herein show good homology one another and to domains present in all of the other PUFA PKS systems currently examined and very weak homology to some acyltransferases whose specific functions have been identified (e.g. to malonyl-CoA:ACP acyltransferase, MAT). In spite of the weak homology to MAT, this AT domain is not believed to function as a MAT because it does not possess an extended motif structure characteristic of such enzymes (see MAT domain description, above). For the purposes of this disclosure, the possible functions of the AT domain in a PUFA PKS system include, but are not limited to: transfer of the fatty acyl group from the ORFA ACP domain(s) to water (i.e. a thioesterase - releasing the fatty acyl group as a free fatty acid), transfer of a fatty acyl group to an acceptor such as CoA, transfer of the acyl group among the various ACP domains, or transfer of the fatty acyl group to a lipophilic acceptor molecule (e.g. to lysophosphadidic acid).

According to the present invention, this domain has enoyl reductase (ER) biological activity. The ER enzyme reduces the *trans*-double bond (introduced by the DH activity) in the fatty acyl-ACP, resulting in fully saturating those carbons. The ER domain in the PUFA-PKS shows homology to a newly characterized family of ER enzymes (Heath et al., *Nature* **406**, 145 (2000)). Heath and Rock identified this new class of ER enzymes by cloning a gene of interest from *Streptococcus pneumoniae*, purifying a protein expressed from that gene, and showing that it had ER activity in an *in vitro* assay. All of the PUFA PKS systems currently examined contain at least one domain with very high sequence homology to the *Schizochytrium* ER domain, which shows homology to the *S. pneumoniae* ER protein.

According to the present invention, a protein or domain having dehydratase or dehydratase (DH) activity catalyzes a dehydration reaction. As used generally herein, reference to DH activity typically refers to FabA-like β -hydroxyacyl-ACP dehydratase (DH) biological activity. FabA-like β -hydroxyacyl-ACP dehydratase (DH) biological activity removes HOH from a β -ketoacyl-ACP and initially produces a *trans* double bond in the carbon chain. The term "FabA-like β -hydroxyacyl-ACP dehydratase" can be used interchangeably with the terms "FabA-like β -hydroxy acyl-ACP dehydratase", " β -hydroxyacyl-ACP dehydratase", "dehydratase" and similar derivatives. The DH domains of the PUFA PKS systems show homology to bacterial DH enzymes associated with their FAS systems (rather than to the DH domains of other PKS systems). A subset of bacterial DH's, the FabA-like DH's, possesses *cis-trans* isomerase activity (Heath et al., *J. Biol. Chem.*, 271, 27795 (1996)). It is the homology to the FabA-like DH proteins that suggests that one or all of the DH domains described herein is responsible for insertion of the *cis* double bonds in the PUFA PKS products.

A PUFA PKS protein useful of the invention may also have dehydratase activity that is not characterized as FabA-like (e.g., the *cis-trans* activity described above is associated with FabA-like activity), generally referred to herein as non-FabA-like DH activity, or non-FabA-like β -hydroxyacyl-ACP dehydratase (DH) biological activity. More specifically, a conserved active site motif (~13 amino acids long: L*xxHxxxGxxxxP; *in the motif, L can also be I) is found in dehydratase domains in PKS systems (Donadio S, Katz L. *Gene*. 1992 Feb 1;111(1):51-60). This conserved motif, also referred to herein as a dehydratase (DH) conserved active site motif or DH motif, is found in a similar region of all known PUFA-PKS sequences described to date and in the PUFA PKS sequences

described herein, but it is believed that this motif has only recently been detected. This conserved motif is within an uncharacterized region of high homology in the PUFA-PKS sequence. The proposed biosynthesis of PUFAs via the PUFA-PKS requires a non-FabA like dehydration, and this motif may be associated with that reaction.

5 For purposes of illustration, the structure of certain PUFA PKS systems is described in detail below. However, it is to be understood that this invention is not limited to the use of these PUFA PKS systems. For example, a detailed description of bacterial PUFA PKS systems can be found in U.S. Patent No. 6,140,486 and U.S. Patent Application Publication No. 20050100995, and a description of other PUFA PKS genes or
10 systems is found in PCT Patent Publication No. WO 05/097982 and U.S. Patent Application Publication No. 20050014231.

Schizochytrium PUFA PKS System

15 *Schizochytrium* is a thraustochytrid marine microorganism that accumulates large quantities of triacylglycerols rich in DHA and docosapentaenoic acid (DPA; 22:5 ω -6); e.g., 30% DHA + DPA by dry weight (Barclay et al., *J. Appl. Phycol.* **6**, 123 (1994)). In eukaryotes that synthesize 20- and 22-carbon PUFAs by an elongation/desaturation pathway, the pools of 18-, 20- and 22-carbon intermediates are relatively large so that *in*
20 *vivo* labeling experiments using [14 C]-acetate reveal clear precursor-product kinetics for the predicted intermediates (Gellerman et al., *Biochim. Biophys. Acta* 573:23 (1979)). Furthermore, radiolabeled intermediates provided exogenously to such organisms are converted to the final PUFA products. The present inventors have shown that [1- 14 C]-acetate was rapidly taken up by *Schizochytrium* cells and incorporated into fatty acids, but
25 at the shortest labeling time (1 min), DHA contained 31% of the label recovered in fatty acids, and this percentage remained essentially unchanged during the 10-15 min of [14 C]-acetate incorporation and the subsequent 24 hours of culture growth (See U.S. Patent Application Publication No. 20020194641, *supra*). Similarly, DPA represented 10% of the label throughout the experiment. There is no evidence for a precursor-product
30 relationship between 16- or 18-carbon fatty acids and the 22-carbon polyunsaturated fatty acids. These results are consistent with rapid synthesis of DHA from [14 C]-acetate involving very small (possibly enzyme-bound) pools of intermediates.

Fig. 1 is a graphical representation of the three open reading frames from the *Schizochytrium* PUFA PKS system, and includes the domain structure of this PUFA PKS system. There are three open reading frames that form the core *Schizochytrium* PUFA PKS system. The domain structure of each open reading frame is as follows.

5 *Schizochytrium* Open Reading Frame A (OrfA):

The complete nucleotide sequence for OrfA is represented herein as SEQ ID NO:1. OrfA is a 8730 nucleotide sequence (not including the stop codon) which encodes a 2910 amino acid sequence, represented herein as SEQ ID NO:2. Within OrfA are twelve domains: (a) one β -keto acyl-ACP synthase (KS) domain; (b) one malonyl-CoA:ACP
10 acyltransferase (MAT) domain; (c) nine acyl carrier protein (ACP) domains; and (d) one ketoreductase (KR) domain. Genomic DNA clones (plasmids) encoding OrfA from both *Schizochytrium* sp. ATCC 20888 and a daughter strain of ATCC 20888, denoted *Schizochytrium* sp., strain N230D, have been isolated and sequenced. N230D was one of more than 1,000 randomly-chosen survivors of chemically mutagenised (NTG; 1-methyl-
15 3-nitro-1-nitrosoguanidine) *Schizochytrium* ATCC 20888 screened for variations in fatty acid content. This particular strain was valued for its improved DHA productivity.

A genomic clone described herein as JK1126, isolated from *Schizochytrium* sp. ATCC 20888, comprises, to the best of the present inventors' knowledge, the nucleotide sequence spanning from position 1 to 8730 of SEQ ID NO:1, and encodes the
20 corresponding amino acid sequence of SEQ ID NO:2. Genomic clone pJK1126 (denoted pJK1126 OrfA genomic clone, in the form of an *E. coli* plasmid vector containing "OrfA" gene from *Schizochytrium* ATCC 20888) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No. PTA-7648. The nucleotide sequence of
25 pJK1126 OrfA genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

Two genomic clones described herein as pJK306 OrfA genomic clone and pJK320 OrfA genomic clone, isolated from *Schizochytrium* sp. N230D, together (overlapping clones) comprise, to the best of the present inventors' knowledge, the nucleotide sequence
30 of SEQ ID NO:1, and encode the amino acid sequence of SEQ ID NO:2. Genomic clone pJK306 (denoted pJK306 OrfA genomic clone, in the form of an *E. coli* plasmid containing 5' portion of OrfA gene from *Schizochytrium* sp. N230D (2.2kB overlap with pJK320)) was deposited with the American Type Culture Collection (ATCC), 10801

University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No. PTA-7641. The nucleotide sequence of pJK306 OrfA genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention. Genomic clone pJK320 (denoted pJK320 OrfA genomic clone, in the form of an *E. coli* plasmid containing 3' portion of OrfA gene from *Schizochytrium* sp. N230D (2.2kB overlap with pJK306)) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No. PTA-7644. The nucleotide sequence of pJK320 OrfA genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in OrfA is a KS domain, also referred to herein as ORFA-KS, and the nucleotide sequence containing the sequence encoding the ORFA-KS domain is represented herein as SEQ ID NO:7 (positions 1-1500 of SEQ ID NO:1). The amino acid sequence containing the ORFA-KS domain is represented herein as SEQ ID NO:8 (positions 1-500 of SEQ ID NO:2). It is noted that the ORFA-KS domain contains an active site motif: DXAC* (*acyl binding site C₂₁₅). Also, a characteristic motif at the end of the *Schizochytrium* KS region, GFGG, is present in this domain in SEQ ID NO:2 and accordingly, in SEQ ID NO:8.

The second domain in OrfA is a MAT domain, also referred to herein as ORFA-MAT, and the nucleotide sequence containing the sequence encoding the ORFA-MAT domain is represented herein as SEQ ID NO:9 (positions 1723-3000 of SEQ ID NO:1). The amino acid sequence containing the ORFA-MAT domain is represented herein as SEQ ID NO:10 (positions 575-1000 of SEQ ID NO:2). The MAT domain comprises an aspartate at position 93 and a histidine at position 94 (corresponding to positions 667 and 668, respectively, of SEQ ID NO:2). It is noted that the ORFA-MAT domain contains an active site motif: GHS*XG (*acyl binding site S₇₀₆), represented herein as SEQ ID NO:11.

Domains 3-11 of OrfA are nine tandem ACP domains, also referred to herein as ORFA-ACP (the first domain in the sequence is ORFA-ACP1, the second domain is ORFA-ACP2, the third domain is ORFA-ACP3, etc.). The first ACP domain, ORFA-ACP1, is contained within the nucleotide sequence spanning from about position 3343 to about position 3600 of SEQ ID NO:1 (OrfA). The nucleotide sequence containing the sequence encoding the ORFA-ACP1 domain is represented herein as SEQ ID NO:12

(positions 3343-3600 of SEQ ID NO:1). The amino acid sequence containing the first ACP domain spans from about position 1115 to about position 1200 of SEQ ID NO:2. The amino acid sequence containing the ORFA-ACP1 domain is represented herein as SEQ ID NO:13 (positions 1115-1200 of SEQ ID NO:2). It is noted that the ORFA-ACP1 domain contains an active site motif: LGIDS* (*pantetheine binding motif S₁₁₅₇),
 5 represented herein by SEQ ID NO:14.

The nucleotide and amino acid sequences of all nine ACP domains are highly conserved and therefore, the sequence for each domain is not represented herein by an individual sequence identifier. However, based on the information disclosed herein, one
 10 of skill in the art can readily determine the sequence containing each of the other eight ACP domains. All nine ACP domains together span a region of OrfA of from about position 3283 to about position 6288 of SEQ ID NO:1, which corresponds to amino acid positions of from about 1095 to about 2096 of SEQ ID NO:2. The nucleotide sequence for the entire ACP region containing all nine domains is represented herein as SEQ ID NO:16.
 15 The region represented by SEQ ID NO:16 includes the linker segments between individual ACP domains. The repeat interval for the nine domains is approximately every 330 nucleotides of SEQ ID NO:16 (the actual number of amino acids measured between adjacent active site serines ranges from 104 to 116 amino acids). Each of the nine ACP domains contains a pantetheine binding motif LGIDS* (represented herein by SEQ ID
 20 NO:14), wherein S* is the pantetheine binding site serine (S). The pantetheine binding site serine (S) is located near the center of each ACP domain sequence. At each end of the ACP domain region and between each ACP domain is a region that is highly enriched for proline (P) and alanine (A), which is believed to be a linker region. For example, between ACP domains 1 and 2 is the sequence: APAPVKAAAPAAPVASAPAPA, represented
 25 herein as SEQ ID NO:15. The locations of the active site serine residues (i.e., the pantetheine binding site) for each of the nine ACP domains, with respect to the amino acid sequence of SEQ ID NO:2, are as follows: ACP1 = S₁₁₅₇; ACP2 = S₁₂₆₆; ACP3 = S₁₃₇₇; ACP4 = S₁₄₈₈; ACP5 = S₁₆₀₄; ACP6 = S₁₇₁₅; ACP7 = S₁₈₁₉; ACP8 = S₁₉₃₀; and ACP9 = S₂₀₃₄. Given that the average size of an ACP domain is about 85 amino acids, excluding
 30 the linker, and about 110 amino acids including the linker, with the active site serine being approximately in the center of the domain, one of skill in the art can readily determine the positions of each of the nine ACP domains in OrfA.

Domain 12 in OrfA is a KR domain, also referred to herein as ORFA-KR, and the nucleotide sequence containing the sequence encoding the ORFA-KR domain is represented herein as SEQ ID NO:17 (positions 6598-8730 of SEQ ID NO:1). The amino acid sequence containing the ORFA-KR domain is represented herein as SEQ ID NO:18
5 (positions 2200-2910 of SEQ ID NO:2). Within the KR domain is a core region with homology to short chain aldehyde-dehydrogenases (KR is a member of this family). This core region spans from about position 7198 to about position 7500 of SEQ ID NO:1, which corresponds to amino acid positions 2400-2500 of SEQ ID NO:2.

Schizochytrium Open Reading Frame B (OrfB):

10 The complete nucleotide sequence for OrfB is represented herein as SEQ ID NO:3. OrfB is a 6177 nucleotide sequence (not including the stop codon) which encodes a 2059 amino acid sequence, represented herein as SEQ ID NO:4. Within OrfB are four domains: (a) one, -keto acyl-ACP synthase (KS) domain; (b) one chain length factor (CLF) domain; (c) one acyl transferase (AT) domain; and, (d) one enoyl ACP-reductase (ER) domain.

15 Genomic DNA clones (plasmids) encoding OrfB from both *Schizochytrium* sp. ATCC 20888 and a daughter strain of ATCC 20888, denoted *Schizochytrium* sp., strain N230D, have been isolated and sequenced.

A genomic clone described herein as pJK1129, isolated from *Schizochytrium* sp. ATCC 20888, comprises, to the best of the present inventors' knowledge, the nucleotide
20 sequence of SEQ ID NO:3, and encodes the amino acid sequence of SEQ ID NO:4. Genomic clone pJK1129 (denoted pJK1129 OrfB genomic clone, in the form of an *E. coli* plasmid vector containing "OrfB" gene from *Schizochytrium* ATCC 20888) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No.
25 PTA-7649. The nucleotide sequence of pJK1126 OrfB genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

A genomic clone described herein as pJK324 OrfB genomic clone, isolated from *Schizochytrium* sp. N230D, comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:3, and encodes the amino acid sequence of SEQ ID
30 NO:4. Genomic clone pJK324 (denoted pJK324 OrfB genomic clone, in the form of an *E. coli* plasmid containing the OrfB gene sequence from *Schizochytrium* sp. N230D) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC

Accession No. PTA-7643. The nucleotide sequence of pJK324 OrfB genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in OrfB is a KS domain, also referred to herein as ORFB-KS, and the nucleotide sequence containing the sequence encoding the ORFB-KS domain is represented herein as SEQ ID NO:19 (positions 1-1350 of SEQ ID NO:3). The amino acid sequence containing the ORFB-KS domain is represented herein as SEQ ID NO:20 (positions 1-450 of SEQ ID NO:4). This KS domain comprises a valine at position 371 of SEQ ID NO:20 (also position 371 of SEQ ID NO:20). It is noted that the ORFB-KS domain contains an active site motif: DXAC* (*acyl binding site C₁₉₆). Also, a characteristic motif at the end of this KS region, GFGG, is present in this domain in SEQ ID NO:4 and accordingly, in SEQ ID NO:20.

The second domain in OrfB is a CLF domain, also referred to herein as ORFB-CLF, and the nucleotide sequence containing the sequence encoding the ORFB-CLF domain is represented herein as SEQ ID NO:21 (positions 1378-2700 of SEQ ID NO:3). The amino acid sequence containing the ORFB-CLF domain is represented herein as SEQ ID NO:22 (positions 460-900 of SEQ ID NO:4). It is noted that the ORFB-CLF domain contains a KS active site motif without the acyl-binding cysteine.

The third domain in OrfB is an AT domain, also referred to herein as ORFB-AT, and the nucleotide sequence containing the sequence encoding the ORFB-AT domain is represented herein as SEQ ID NO:23 (positions 2701-4200 of SEQ ID NO:3). The amino acid sequence containing the ORFB-AT domain is represented herein as SEQ ID NO:24 (positions 901-1400 of SEQ ID NO:4). It is noted that the ORFB-AT domain contains an active site motif of GxS*xG (*acyl binding site S₁₁₄₀) that is characteristic of acyltransferase (AT) proteins.

The fourth domain in OrfB is an ER domain, also referred to herein as ORFB-ER, and the nucleotide sequence containing the sequence encoding the ORFB-ER domain is represented herein as SEQ ID NO:25 (positions 4648-6177 of SEQ ID NO:3). The amino acid sequence containing the ORFB-ER domain is represented herein as SEQ ID NO:26 (positions 1550-2059 of SEQ ID NO:4).

Schizochytrium Open Reading Frame C (OrfC):

The complete nucleotide sequence for OrfC is represented herein as SEQ ID NO:5. OrfC is a 4506 nucleotide sequence (not including the stop codon) which encodes a 1502

amino acid sequence, represented herein as SEQ ID NO:6. Within OrfC are three domains: (a) two FabA-like, -hydroxy acyl-ACP dehydrase (DH) domains; and (b) one enoyl ACP-reductase (ER) domain.

Genomic DNA clones (plasmids) encoding OrfC from both *Schizochytrium* sp. ATCC 20888 and a daughter strain of ATCC 20888, denoted *Schizochytrium* sp., strain N230D, have been isolated and sequenced.

A genomic clone described herein as pJK1131, isolated from *Schizochytrium* sp. ATCC 20888, comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:5, and encodes the amino acid sequence of SEQ ID NO:6. Genomic clone pJK1131 (denoted pJK1131 OrfC genomic clone, in the form of an *E. coli* plasmid vector containing "OrfC" gene from *Schizochytrium* ATCC 20888) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No. PTA-7650. The nucleotide sequence of pJK1131 OrfC genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

A genomic clone described herein as pBR002 OrfC genomic clone, isolated from *Schizochytrium* sp. N230D, comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:5, and encodes the amino acid sequence of SEQ ID NO:6. Genomic clone pBR002 (denoted pBR002 OrfC genomic clone, in the form of an *E. coli* plasmid vector containing the OrfC gene sequence from *Schizochytrium* sp. N230D) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on June 8, 2006, and assigned ATCC Accession No. PTA-7642. The nucleotide sequence of pBR002 OrfC genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in OrfC is a DH domain, also referred to herein as ORFC-DH1. This is one of two DH domains in OrfC, and therefore is designated DH1. The nucleotide sequence containing the sequence encoding the ORFC-DH1 domain is represented herein as SEQ ID NO:27 (positions 1-1350 of SEQ ID NO:5). The amino acid sequence containing the ORFC-DH1 domain is represented herein as SEQ ID NO:28 (positions 1-450 of SEQ ID NO:6).

The second domain in OrfC is a DH domain, also referred to herein as ORFC-DH2. This is the second of two DH domains in OrfC, and therefore is designated DH2.

The nucleotide sequence containing the sequence encoding the ORFC-DH2 domain is represented herein as SEQ ID NO:29 (positions 1351-2847 of SEQ ID NO:5). The amino acid sequence containing the ORFC-DH2 domain is represented herein as SEQ ID NO:30 (positions 451-949 of SEQ ID NO:6). This DH domain comprises the amino acids H-G-I-A-N-P-T-F-V-H-A-P-G-K-I (positions 876-890 of SEQ ID NO:6) at positions 426-440 of SEQ ID NO:30.

The third domain in OrfC is an ER domain, also referred to herein as ORFC-ER, and the nucleotide sequence containing the sequence encoding the ORFC-ER domain is represented herein as SEQ ID NO:31 (positions 2995-4506 of SEQ ID NO:5). The amino acid sequence containing the ORFC-ER domain is represented herein as SEQ ID NO:32 (positions 999-1502 of SEQ ID NO:6).

Thraustochytrium PUFA PKS System

There are three open reading frames that form the core *Thraustochytrium* 23B PUFA PKS system. The domain organization is the same as that of *Schizochytrium* with the exception that the *Th.* 23B Orf A has 8 adjacent ACP domains, while *Schizochytrium* Orf A has 9 adjacent ACP domains. The domain structure of each open reading frame is as follows.

Thraustochytrium 23B Open Reading Frame A (OrfA):

The complete nucleotide sequence for *Th.* 23B OrfA is represented herein as SEQ ID NO:38. *Th.* 23B OrfA is a 8433 nucleotide sequence (not including the stop codon) which encodes a 2811 amino acid sequence, represented herein as SEQ ID NO:39. SEQ ID NO:38 encodes the following domains in *Th.* 23B OrfA: (a) one β -ketoacyl-ACP synthase (KS) domain; (b) one malonyl-CoA:ACP acyltransferase (MAT) domain; (c) eight acyl carrier protein (ACP) domains; and (d) one β -ketoacyl-ACP reductase (KR) domain.

Two genomic clones described herein as Th23BOrfA_pBR812.1 and Th23BOrfA_pBR811 (OrfA genomic clones), isolated from *Thraustochytrium* 23B, together (overlapping clones) comprise, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:38, and encodes the amino acid sequence of SEQ ID NO:39. Genomic clone Th23BOrfA_pBR812.1 (denoted Th23BOrfA_pBR812.1 genomic clone, in the form of an *E. coli* plasmid vector containing the OrfA gene sequence from *Thraustochytrium* 23B) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on

March 1, 2007, and assigned ATCC Accession No. PTA-8232. The nucleotide sequence of Th23BOrfA_pBR812.1, an OrfA genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention. Genomic clone Th23BOrfA_pBR811 (denoted Th23BOrfA_pBR811 genomic clone, in the form of an *E. coli* plasmid vector containing the OrfA gene sequence from *Thraustochytrium 23B*) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8231. The nucleotide sequence of Th23BOrfA_pBR811, an OrfA genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in *Th. 23B OrfA* is a KS domain, also referred to herein as *Th. 23B OrfA-KS*, and is contained within the nucleotide sequence spanning from about position 1 to about position 1500 of SEQ ID NO:38, represented herein as SEQ ID NO:40. The amino acid sequence containing the *Th. 23B KS* domain is a region of SEQ ID NO:39 spanning from about position 1 to about position 500 of SEQ ID NO:39, represented herein as SEQ ID NO:41. This region of SEQ ID NO:39 has a Pfam match to FabB (β -ketoacyl-ACP synthase) spanning from position 1 to about position 450 of SEQ ID NO:39 (also positions 1 to about 450 of SEQ ID NO:41). It is noted that the *Th. 23B OrfA-KS* domain contains an active site motif: DXAC* (*acyl binding site C₂₀₇). Also, a characteristic motif at the end of the *Th. 23B KS* region, GFGG, is present in positions 453-456 of SEQ ID NO:39 (also positions 453-456 of SEQ ID NO:41).

The second domain in *Th. 23B OrfA* is a MAT domain, also referred to herein as *Th. 23B OrfA-MAT*, and is contained within the nucleotide sequence spanning from between about position 1503 and about position 3000 of SEQ ID NO:38, represented herein as SEQ ID NO:42. The amino acid sequence containing the *Th. 23B MAT* domain is a region of SEQ ID NO:39 spanning from about position 501 to about position 1000, represented herein by SEQ ID NO:43. This region of SEQ ID NO:39 has a Pfam match to FabD (malonyl-CoA:ACP acyltransferase) spanning from about position 580 to about position 900 of SEQ ID NO:39 (positions 80-400 of SEQ ID NO:43). It is noted that the *Th. 23B OrfA-MAT* domain contains an active site motif: GHS*XG (*acyl binding site S₆₉₇), represented by positions 695-699 of SEQ ID NO:39.

Domains 3-10 of *Th. 23B OrfA* are eight tandem ACP domains, also referred to herein as *Th. 23B OrfA-ACP* (the first domain in the sequence is OrfA-ACP1, the second

domain is OrfA-ACP2, the third domain is OrfA-ACP3, etc.). The first *Th.* 23B ACP domain, *Th.* 23B OrfA-ACP1, is contained within the nucleotide sequence spanning from about position 3205 to about position 3555 of SEQ ID NO:38 (OrfA), represented herein as SEQ ID NO:44. The amino acid sequence containing the first *Th.* 23B ACP domain is
5 a region of SEQ ID NO:39 spanning from about position 1069 to about position 1185 of SEQ ID NO:39, represented herein by SEQ ID NO:45.

The eight ACP domains in *Th.* 23B OrfA are adjacent to one another and can be identified by the presence of the phosphopantetheine binding site motif, LGXDS* (represented by SEQ ID NO:46), wherein the S* is the phosphopantetheine attachment
10 site. The amino acid position of each of the eight S* sites, with reference to SEQ ID NO:39, are 1128 (ACP1), 1244 (ACP2), 1360 (ACP3), 1476 (ACP4), 1592 (ACP5), 1708 (ACP6), 1824 (ACP7) and 1940 (ACP8). The nucleotide and amino acid sequences of all eight *Th.* 23B ACP domains are highly conserved and therefore, the sequence for each domain is not represented herein by an individual sequence identifier. However, based on
15 the information disclosed herein, one of skill in the art can readily determine the sequence containing each of the other seven ACP domains in SEQ ID NO:38 and SEQ ID NO:39.

All eight *Th.* 23B ACP domains together span a region of *Th.* 23B OrfA of from about position 3205 to about position 5994 of SEQ ID NO:38, which corresponds to amino acid positions of from about 1069 to about 1998 of SEQ ID NO:39. The nucleotide
20 sequence for the entire ACP region containing all eight domains is represented herein as SEQ ID NO:47. SEQ ID NO:47 encodes an amino acid sequence represented herein by SEQ ID NO:48. SEQ ID NO:48 includes the linker segments between individual ACP domains. The repeat interval for the eight domains is approximately every 116 amino acids of SEQ ID NO:48, and each domain can be considered to consist of about 116 amino
25 acids centered on the active site motif (described above).

The last domain in *Th.* 23B OrfA is a KR domain, also referred to herein as *Th.* 23B OrfA-KR, which is contained within the nucleotide sequence spanning from between about position 6001 to about position 8433 of SEQ ID NO:38, represented herein by SEQ ID NO:49. The amino acid sequence containing the *Th.* 23B KR domain is a region of
30 SEQ ID NO:39 spanning from about position 2001 to about position 2811 of SEQ ID NO:39, represented herein by SEQ ID NO:50. This region of SEQ ID NO:39 has a Pfam match to FabG (β -ketoacyl-ACP reductase) spanning from about position 2300 to about 2550 of SEQ ID NO:39 (positions 300-550 of SEQ ID NO:50).

Thraustochytrium. 23B Open Reading Frame B (OrfB):

The complete nucleotide sequence for *Th*. 23B OrfB is represented herein as SEQ ID NO:51, which is a 5805 nucleotide sequence (not including the stop codon) that encodes a 1935 amino acid sequence, represented herein as SEQ ID NO:52. SEQ ID NO:51 encodes the following domains in *Th*. 23B OrfB: (a) one β -ketoacyl-ACP synthase (KS) domain; (b) one chain length factor (CLF) domain; (c) one acyltransferase (AT) domain; and, (d) one enoyl-ACP reductase (ER) domain.

A genomic clone described herein as Th23BOrfB_pBR800 (OrfB genomic clone), isolated from *Thraustochytrium* 23B, comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:51, and encodes the amino acid sequence of SEQ ID NO:52. Genomic clone Th23BOrfB_pBR800 (denoted Th23BOrfB_pBR800 genomic clone, in the form of an *E. coli* plasmid vector containing the OrfB gene sequence from *Thraustochytrium* 23B) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8227. The nucleotide sequence of Th23BOrfB_pBR800, an OrfB genomic clone, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in the *Th*. 23B OrfB is a KS domain, also referred to herein as *Th*. 23B OrfB-KS, which is contained within the nucleotide sequence spanning from between about position 1 and about position 1500 of SEQ ID NO:51 (*Th*. 23B OrfB), represented herein as SEQ ID NO:53. The amino acid sequence containing the *Th*. 23B KS domain is a region of SEQ ID NO: 52 spanning from about position 1 to about position 500 of SEQ ID NO:52, represented herein as SEQ ID NO:54. This region of SEQ ID NO:52 has a Pfam match to FabB (β -ketoacyl-ACP synthase) spanning from about position 1 to about position 450 (positions 1-450 of SEQ ID NO:54). It is noted that the *Th*. 23B OrfB-KS domain contains an active site motif: DXAC*, where C* is the site of acyl group attachment and wherein the C* is at position 201 of SEQ ID NO:52. Also, a characteristic motif at the end of the KS region, GFGG is present in amino acid positions 434-437 of SEQ ID NO:52.

The second domain in *Th*. 23B OrfB is a CLF domain, also referred to herein as *Th*. 23B OrfB-CLF, which is contained within the nucleotide sequence spanning from between about position 1501 and about position 3000 of SEQ ID NO:51 (OrfB), represented herein as SEQ ID NO:55. The amino acid sequence containing the CLF

domain is a region of SEQ ID NO: 52 spanning from about position 501 to about position 1000 of SEQ ID NO:52, represented herein as SEQ ID NO:56. This region of SEQ ID NO:52 has a Pfam match to FabB (β -ketoacyl-ACP synthase) spanning from about position 550 to about position 910 (positions 50-410 of SEQ ID NO:56). Although CLF
 5 has homology to KS proteins, it lacks an active site cysteine to which the acyl group is attached in KS proteins.

The third domain in *Th. 23B OrfB* is an AT domain, also referred to herein as *Th. 23B OrfB-AT*, which is contained within the nucleotide sequence spanning from between about position 3001 and about position 4500 of SEQ ID NO:51 (*Th. 23B OrfB*),
 10 represented herein as SEQ ID NO:58. The amino acid sequence containing the *Th. 23B AT* domain is a region of SEQ ID NO: 52 spanning from about position 1001 to about position 1500 of SEQ ID NO:52, represented herein as SEQ ID NO:58. This region of SEQ ID NO:52 has a Pfam match to FabD (malonyl-CoA:ACP acyltransferase) spanning from about position 1100 to about position 1375 (positions 100-375 of SEQ ID NO:58).
 15 Although this AT domain of the PUFA synthases has homology to MAT proteins, it lacks the extended motif of the MAT (key arginine and glutamine residues) and it is not thought to be involved in malonyl-CoA transfers. The GX S^* XG motif of acyltransferases is present, with the S * being the site of acyl attachment and located at position 1123 with respect to SEQ ID NO:52.

20 The fourth domain in *Th. 23B OrfB* is an ER domain, also referred to herein as *Th. 23B OrfB-ER*, which is contained within the nucleotide sequence spanning from between about position 4501 and about position 5805 of SEQ ID NO:51 (*OrfB*), represented herein as SEQ ID NO:59. The amino acid sequence containing the *Th. 23B ER* domain is a region of SEQ ID NO: 52 spanning from about position 1501 to about position 1935 of
 25 SEQ ID NO:52, represented herein as SEQ ID NO:60. This region of SEQ ID NO:52 has a Pfam match to a family of dioxygenases related to 2-nitropropane dioxygenases spanning from about position 1501 to about position 1810 (positions 1-310 of SEQ ID NO:60). That this domain functions as an ER can be further predicted due to homology to a newly characterized ER enzyme from *Streptococcus pneumoniae*.

30 *Thraustochytrium. 23B Open Reading Frame C (OrfC)*:

The complete nucleotide sequence for *Th. 23B OrfC* is represented herein as SEQ ID NO:61, which is a 4410 nucleotide sequence (not including the stop codon) that encodes a 1470 amino acid sequence, represented herein as SEQ ID NO:62. SEQ ID

NO:61 encodes the following domains in *Th. 23B OrfC*: (a) two FabA-like β -hydroxyacyl-ACP dehydrase (DH) domains, both with homology to the FabA protein (an enzyme that catalyzes the synthesis of *trans*-2-decenoyl-ACP and the reversible isomerization of this product to *cis*-3-decenoyl-ACP); and (b) one enoyl-ACP reductase
5 (ER) domain with high homology to the ER domain of *Schizochytrium OrfB*.

A genomic clone described herein as Th23BOrfC_pBR709A (OrfC genomic clone), isolated from *Thraustochytrium 23B*, comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:61, and encodes the amino acid sequence of SEQ ID NO:62. Genomic clone Th23BOrfC_pBR709A (denoted
10 Th23BOrfC_pBR709A genomic clone, in the form of an *E. coli* plasmid vector containing the OrfC gene sequence from *Thraustochytrium 23B*) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8228. The nucleotide sequence of Th23BOrfC_pBR709A, an OrfC genomic clone, and the amino
15 acid sequence encoded by this plasmid are encompassed by the present invention.

The first domain in *Th. 23B OrfC* is a DH domain, also referred to herein as *Th. 23B OrfC-DH1*, which is contained within the nucleotide sequence spanning from between about position 1 to about position 1500 of SEQ ID NO:61 (OrfC), represented herein as SEQ ID NO:63. The amino acid sequence containing the *Th. 23B DH1* domain
20 is a region of SEQ ID NO: 62 spanning from about position 1 to about position 500 of SEQ ID NO:62, represented herein as SEQ ID NO:64. This region of SEQ ID NO:62 has a Pfam match to FabA, as mentioned above, spanning from about position 275 to about position 400 (positions 275-400 of SEQ ID NO:64).

The second domain in *Th. 23B OrfC* is also a DH domain, also referred to herein
25 as *Th. 23B OrfC-DH2*, which is contained within the nucleotide sequence spanning from between about position 1501 to about 3000 of SEQ ID NO:61 (OrfC), represented herein as SEQ ID NO:65. The amino acid sequence containing the *Th. 23B DH2* domain is a region of SEQ ID NO: 62 spanning from about position 501 to about position 1000 of SEQ ID NO:62, represented herein as SEQ ID NO:66. This region of SEQ ID NO:62 has
30 a Pfam match to FabA, as mentioned above, spanning from about position 800 to about position 925 (positions 300-425 of SEQ ID NO:66).

The third domain in *Th. 23B OrfC* is an ER domain, also referred to herein as *Th. 23B OrfC-ER*, which is contained within the nucleotide sequence spanning from between

about position 3001 to about position 4410 of SEQ ID NO:61 (OrfC), represented herein as SEQ ID NO:67. The amino acid sequence containing the *Th. 23B* ER domain is a region of SEQ ID NO: 62 spanning from about position 1001 to about position 1470 of SEQ ID NO:62, represented herein as SEQ ID NO:68. This region of SEQ ID NO:62 has a Pfam match to the dioxygenases related to 2-nitropropane dioxygenases, as mentioned above, spanning from about position 1025 to about position 1320 (positions 25-320 of SEQ ID NO:68). This domain function as an ER can also be predicted due to homology to a newly characterized ER enzyme from *Streptococcus pneumoniae*.

Synthetic, Codon-Optimized Constructs

The invention also encompasses resynthesized versions of any of the nucleic acid sequences described herein, primarily having optimized codon usage for a heterologous organism (heterologous host), wherein the encoded amino acid sequence is not changed with reference to the natural, wild-type, or source amino acid sequence. The present inventors have discovered that resynthesizing nucleic acid sequences for optimal codon usage is an effective way to improve PUFA production in a heterologous host that is transformed with nucleic acid molecules from a PUFA PKS system. Resynthesis of all nucleic acid molecules in a PUFA PKS system is not necessarily required for optimal expression and PUFA production in a heterologous host. Indeed, the inventors have found that resynthesis of only some of the nucleic acid molecules is sufficient to improve PUFA production. For example, while resynthesis of *Schizochytrium* Orfs A and B improved PUFA synthase expression and PUFA production in yeast, use of the native *Schizochytrium* OrfC and native *Nostoc* HetI PPTase were sufficient. Moreover, codon optimization of a construct for use in one heterologous host may also be useful for improving the PUFA production in a different heterologous host (e.g., optimization of codon usage of an OrfC-encoding sequence from *Thraustochytrium* for use in *Schizochytrium* may also be effective for boosting PUFA production in another heterologous host organism, such as plants).

In addition, the use of synthetic, codon-optimized constructs can be useful in the production of chimeric PUFA PKS constructs and/or chimeric PUFA PKS systems, where a domain or protein from one PUFA PKS system (e.g., from a first organism) is introduced into a second PUFA PKS system (e.g., from a second organism). In such systems, not only can the PUFA profile be manipulated (e.g., by the use of the chimeric constructs and/or chimeric PUFA PKS systems), but the PUFA production can also be

improved by the use of synthetic, codon-optimized chimeric constructs. Indeed, the combination of the two concepts (chimeras and codon optimization) may produce a synergistic result with respect to PUFA profiles and/or PUFA production. Chimeric systems containing some sequences that are codon-optimized for the host and some that
5 are not codon-optimized for the host are included in the invention.

Certain codon-optimized sequences are described below by way of example. Other codon-optimized sequences will be apparent to those of skill in the art following this description.

sOrfA

10 SEQ ID NO:35, denoted sOrfA, represents the nucleic acid sequence encoding OrfA from *Schizochytrium* (SEQ ID NO:1) that has been resynthesized for optimized codon usage in yeast. SEQ ID NO:1 and SEQ ID NO:35 each encode SEQ ID NO:2.

sOrfB

15 SEQ ID NO:36, denoted sOrfB, represents the nucleic acid sequence encoding OrfB from *Schizochytrium* (SEQ ID NO:3) that has been resynthesized for optimized codon usage in yeast. SEQ ID NO:3 and SEQ ID NO:36 each encode SEQ ID NO:4.

OrfB*

SEQ ID NO:37, denoted OrfB* (pJK962), represents a nucleic acid sequence encoding OrfB from *Schizochytrium* (SEQ ID NO:4) that has been resynthesized within a
20 portion of SEQ ID NO:3 (nucleotide sequence encoding SEQ ID NO:4) for use in plant cells, and that was derived from a very similar sequence initially developed for optimized codon usage in *E. coli*, also referred to as OrfB* (pJK780), which is described below. OrfB* in both forms (for *E. coli* and for plants) is identical to SEQ ID NO:3 with the exception of a resynthesized BspHI (nucleotide 4415 of SEQ ID NO:3) to a SacII
25 fragment (unique site in SEQ ID NO:3). Both versions (*E. coli* and plant) have two other codon modifications near the start of the gene as compared with the original genomic sequence of orfB (SEQ ID NO:3). First, the fourth codon, arginine (R), was changed from CGG in the genomic sequence to CGC in orfB*. Second, the fifth codon, asparagine (N), was changed from AAT in the genomic sequence to AAC in orf B*. In order to facilitate
30 cloning of this gene into the plant vectors to create SEQ ID NO:37, a PstI site (CTGCAG) was also engineered into the *E. coli* orfB* sequence 20 bases from the start of the gene. This change did not alter the amino acid sequence of the encoded protein. Both SEQ ID

NO:37 and SEQ ID NO:3 (as well as the OrfB* form for *E. coli*, described in SEQ ID NO:69 below) encode SEQ ID NO:4.

5 SEQ ID NO:69, denoted OrfB* (pJK780), represents a nucleic acid sequence encoding OrfB from *Schizochytrium* (SEQ ID NO:4) that has been resynthesized within a portion of SEQ ID NO:3 (nucleotide sequence encoding SEQ ID NO:4) for use in *E. coli*. The sequence of the OrfB* construct in both forms (for *E. coli* and for plants) has been described above. SEQ ID NO:69 and SEQ ID NO:3 encode SEQ ID NO:4.

10 The plasmid described herein as OrfB*_pJK780 comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:69, and encodes the amino acid sequence of SEQ ID NO:4. Plasmid OrfB*_pJK780 (denoted OrfB*_pJK780 clone, in the form of an *E. coli* plasmid vector) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8225. The nucleotide sequence of OrfB*_pJK780 and the amino acid sequence encoded by this plasmid are
15 encompassed by the present invention.

pThOrfC-synPS

20 SEQ ID NO:70 represents a nucleic acid sequence encoding a *Thraustochytrium* 23B OrfC (SEQ ID NO:61, encoding SEQ ID NO:62) that has been resynthesized for optimized codon usage in *Schizochytrium*. Positions 2000-6412 of SEQ ID NO:70 represents the coding region for the *Thraustochytrium* 23B OrfC protein (including stop codon). Positions 1-1999 and 6413-8394 of SEQ ID NO:70 represent upstream and downstream *Schizochytrium* OrfC sequences (non-coding regions), respectively. The construction of the plasmid containing SEQ ID NO:70, denoted pThOrfC-synPS, is described in detail in Example 1. SEQ ID NO:70 and SEQ ID NO:61 each encode SEQ
25 ID NO:62. pThOrfC-syn PS is designed to exactly replace the coding region (CDS) of *Schizochytrium* orfC (SEQ ID NO:5) with the coding region for the *Thraustochytrium* 23B orfC, resynthesized as discussed above (SEQ ID NO:70). The production and use of organisms that have been transformed with this construct are described in detail below and in the Examples.

30 The plasmid described above as pThOrfC-synPS comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:70, and encodes the corresponding amino acid sequence of SEQ ID NO:62. Plasmid pThOrfC-synPS (denoted pThOrfC-synPS, in the form of an *E. coli* plasmid vector containing a "perfect stitch"

synthetic *Thraustochytrium* 23B PUFA PKS OrfC codon optimized for expression in *Schizochytrium* or other heterologous hosts) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8229. The nucleotide
5 sequence of pThOrfC-synPS, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

pDD26

SEQ ID NO:71 represents a nucleic acid sequence encoding a *Thraustochytrium* 23B OrfA (SEQ ID NO:38, encoding SEQ ID NO:39) that has been resynthesized for
10 optimized codon usage in *Schizochytrium*. Positions 2044-10479 of SEQ ID NO:71 represents the coding region for the *Thraustochytrium* 23B OrfA protein (including stop codon). Positions 1-2043 and 10480-12495 of SEQ ID NO:71 represent upstream and downstream *Schizochytrium* OrfA sequences (non-coding regions), respectively. The construction of the plasmid containing SEQ ID NO:71, denoted pDD26, is described in
15 detail in Example 8. SEQ ID NO:71 and SEQ ID NO:38 each encode SEQ ID NO:39. pDD26 is designed to exactly replace the coding region (CDS) of *Schizochytrium* orfA (SEQ ID NO:1) with the coding region for the *Thraustochytrium* 23B orfC, resynthesized as discussed above (SEQ ID NO:71). The production and use of organisms that have been transformed with this construct are described in detail below and in the Examples.

20 The plasmid described above as pDD26 comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:71, and encodes the corresponding amino acid sequence of SEQ ID NO:39. Plasmid pDD26 (denoted pDD26, in the form of an *E. coli* plasmid vector) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on
25 May 8, 2007, and assigned ATCC Accession No. PTA-8411. The nucleotide sequence of pDD26, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

pDD32

SEQ ID NO:72 represents a nucleic acid sequence encoding a *Thraustochytrium*
30 23B OrfB (SEQ ID NO:51, encoding SEQ ID NO:52) that has been resynthesized for optimized codon usage in *Schizochytrium*. Positions 1452-7259 of SEQ ID NO:72 represent the coding region for the *Thraustochytrium* 23B OrfB protein (including stop codon). Positions 1-1451 and 7260-8647 of SEQ ID NO:72 represent upstream and

downstream *Schizochytrium* OrfB sequences (non-coding regions), respectively. The construction of the plasmid containing SEQ ID NO:72, denoted pDD32, is described in detail in Example 8. SEQ ID NO:72 and SEQ ID NO:51 each encode SEQ ID NO:52. pDD32 is designed to exactly replace the coding region (CDS) of *Schizochytrium* orfB (SEQ ID NO:3) with the coding region for the *Thraustochytrium* 23B orfC, resynthesized as discussed above (SEQ ID NO:72). The production and use of organisms that have been transformed with this construct are described in detail below and in the Examples.

The plasmid described above as pDD32 comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:72, and encodes the corresponding amino acid sequence of SEQ ID NO:52. Plasmid pDD32 (denoted pDD32, in the form of an *E. coli* plasmid vector) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on May 8, 2007, and assigned ATCC Accession No. PTA-8412. The nucleotide sequence of pDD32, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

Chimeric PUFA PKS Constructs

The invention also encompasses chimeric constructs using portions of two or more different PUFA PKS nucleic acid sequences, such as those described herein, to produce chimeric PUFA PKS proteins. The present inventors demonstrate herein in several different examples that by "mixing and matching" domains or portions of PUFA PKS proteins from different organisms (*i.e.*, creating chimeric PUFA PKS proteins comprised of domains or polypeptides from two or more different organisms), the profile of the PUFAs produced by an organism expressing a PUFA PKS system containing such chimeric proteins can be modified, as compared to a native (naturally occurring) PUFA PKS system. For example, the present inventors describe herein the use of the DH2 domain from a *Thraustochytrium* PUFA PKS system in the OrfC protein of a *Schizochytrium* protein, so that the resulting chimeric OrfC protein contains the DH1 and ER domains from *Schizochytrium*, and the DH2 domain from *Thraustochytrium*. The chimeric construct is further modified by the use of a codon-optimized (for *Schizochytrium*) *Thraustochytrium* DH2 domain in one construct, and a native *Thraustochytrium* DH2 domain in another construct, which demonstrates the flexibility and effects of the various modifications described herein.

Certain chimeric constructs are described below by way of example. Other chimeric constructs will be apparent to those of skill in the art following this description.

pDS49

SEQ ID NO:73 represents a nucleic acid sequence encoding a chimeric protein comprising a *Schizochytrium* OrfC protein (SEQ ID NO:6) in which the DH2 domain (SEQ ID NO:30) has been replaced with the DH2 domain (sequence including SEQ ID NO:66) from *Thraustochytrium* 23B OrfC (SEQ ID NO:62). In this chimeric construct, the DH2-encoding sequence from *Thraustochytrium* is the native (non-codon-optimized) sequence. The construction of the plasmid containing SEQ ID NO:73, denoted pDS49, is described in detail in Example 2. The *Schizochytrium* OrfC upstream and downstream non-coding sequences that flank SEQ ID NO:73 in pDS49 are the same as those described above with respect to SEQ ID NO:70 (not represented in SEQ ID NO:73). SEQ ID NO:73 encodes an amino acid sequence of SEQ ID NO:74. Referring to SEQ ID NO:74, the chimeric OrfC polypeptide is 1493 amino acid residues in length. The DH2 region, defined as amino acids 516–1041 of SEQ ID NO:74, consists of the amino acid sequence of the DH2 region of the *Th.23B* OrfC protein, that is, amino acids 491–1016 of SEQ ID NO:62, which includes all of SEQ ID NO:66 and some flanking amino acid sequence from SEQ ID NO:62. With respect to the remainder of the chimeric OrfC amino acid sequence, residues 1–515 and 1042–1493 of SEQ ID NO:74 are identical to *Schizochytrium* OrfC residues 1–515 and 1051–1502 of SEQ ID NO:6, respectively. The production and use of organisms that have been transformed with this construct are described in detail below and in the Examples.

The plasmid described above as pDS49 comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:73, and encodes the corresponding amino acid sequence of SEQ ID NO:74. Plasmid pDS49 (denoted pDS49, in the form of an *E. coli* plasmid vector) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8230. The nucleotide sequence of pDS49, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

pDD24

SEQ ID NO:75 represents another nucleic acid sequence encoding a chimeric protein comprising a *Schizochytrium* OrfC protein (SEQ ID NO:6) in which the DH2

domain (SEQ ID NO:30) has been replaced with the DH2 domain (sequence including SEQ ID NO:66) from *Thraustochytrium* 23B OrfC (SEQ ID NO:62). In this chimeric construct, the DH2-encoding sequence from *Thraustochytrium* is a codon-optimized sequence for use in *Schizochytrium*. The construction of the plasmid containing SEQ ID NO:75, denoted pDD24, is described in detail in Example 3. The *Schizochytrium* OrfC upstream and downstream non-coding sequences that flank SEQ ID NO:75 in pDD24 are the same as those described above with respect to SEQ ID NO:70 (not represented in SEQ ID NO:75). SEQ ID NO:75 encodes an amino acid sequence of SEQ ID NO:74. SEQ ID NO:74 has been described in detail above with respect to SEQ ID NO:73, which also encodes SEQ ID NO:74. However, in this construct, as discussed above the nucleotide sequence encoding amino acids 516–1041 of SEQ ID NO:74 was derived from the “synthetic gene sequence” for OrfC of *Thraustochytrium*.23B that is contained in plasmid pThOrfC-synPS (see Example 1 and SEQ ID NO:70) and which employs codons that are preferred for gene expression in *Schizochytrium*. The production and use of organisms that have been transformed with this construct are described in detail below and in the Examples.

The plasmid described above as pDD24 comprises, to the best of the present inventors' knowledge, the nucleotide sequence of SEQ ID NO:75, and encodes the corresponding amino acid sequence of SEQ ID NO:74. Plasmid pDD24 (denoted pDD24, in the form of an *E. coli* plasmid vector) was deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110-2209 USA on March 1, 2007, and assigned ATCC Accession No. PTA-8226. The nucleotide sequence of pDD24, and the amino acid sequence encoded by this plasmid are encompassed by the present invention.

Chimeric PUFA PKS Systems

In addition to the use of codon-optimization and chimeric constructs described above, the invention includes the production and use of chimeric PUFA PKS systems. Chimeric PUFA PKS systems include the use of the chimeric constructs described above, where a chimeric PUFA PKS protein is created and used in a PUFA PKS system, but such systems also encompass PUFA PKS systems where one or more entire protein or proteins from one or more PUFA PKS system(s) are exchanged for or added to the corresponding entire protein or proteins from another PUFA PKS system, such that the resulting PUFA PKS system comprises proteins from two or more different PUFA PKS systems. Such

systems can also include the use of chimeric proteins, as described above (e.g., chimeric proteins, and substitutions of whole proteins). For example, the construct described above as pTh23B_synPS (comprising a *Thraustochytrium* 23B OrfC-encoding sequence, optimized for *Schizochytrium* codon usage) can be substituted into a *Schizochytrium* PUFA PKS system to perfectly replace the native *Schizochytrium* OrfC-encoding sequence, thereby creating a chimeric PUFA PKS system. As another example, the native *Thraustochytrium* 23B OrfC-encoding sequence (not codon-optimized) can be substituted into a *Schizochytrium* PUFA PKS system to perfectly replace the native *Schizochytrium* OrfC-encoding sequence, thereby creating another chimeric PUFA PKS system. As yet another example, the native *Thraustochytrium* 23B OrfA- and OrfC-encoding sequences (codon-optimized, or not) can be substituted into a *Schizochytrium* PUFA PKS system to perfectly replace the native *Schizochytrium* OrfA- and OrfC-encoding sequences, respectively, thereby creating yet another chimeric PUFA PKS system. These and other chimeric PUFA PKS systems are described in the Examples below. Included in the Examples are *Schizochytrium* hosts expressing chimeric PUFA PKS systems comprised of: (1) *Schizochytrium* (S) OrfA, SOrfB, and *Thraustochytrium* (Th) OrfC; (2) SOrfA, ThOrfB, and SOrfC; (3) ThOrfA, SOrfB, and SOrfC; (4) SOrfA, ThOrfB, and ThOrfC; (5) ThOrfA, SOrfB, and ThOrfC; (6) ThOrfA, ThOrfB, and SOrfC; and (7) ThOrfA, ThOrfB, and ThOrfC.

Based on the discussion and exemplary experiments provided herein, it is now possible to improve and/or modify PUFA production by selected resynthesis of PUFA PKS nucleic acid molecules for host codon usage, and/or the use of chimeric PUFA PKS constructs and/or chimeric PUFA PKS systems in various host organisms, including in host organisms that do not endogenously have a PUFA PKS system for the production of PUFAs.

Phosphopantetheinyl transferase (PPTase)

According to the present invention, a PUFA PKS system for production and/or accumulation of PUFAs in a heterologous host or improved production and/or accumulation of PUFAs in an endogenous host may make use of various accessory proteins, which are defined herein as proteins that are not considered to be part of the core PUFA PKS system as described above (i.e., not part of the PUFA synthase enzyme complex itself), but which may be, or are, necessary for PUFA production or at least for

efficient PUFA production using the core PUFA synthase enzyme complex of the present invention.

In order to produce PUFAs, a PUFA PKS system must work with an accessory protein that transfers a 4'-phosphopantetheinyl moiety from coenzyme A to the acyl carrier protein (ACP) domain(s). Therefore, a PUFA PKS system can be considered to include at least one 4'-phosphopantetheinyl transferase (PPTase) domain, or such a domain can be considered to be an accessory domain or protein to the PUFA PKS system. Structural and functional characteristics of PPTases have been described in detail, for example, in U.S. Patent Application Publication No. 20020194641; U.S. Patent Application Publication No. 20040235127; and U.S. Patent Application Publication No. 20050100995.

According to the present invention, a domain or protein having 4'-phosphopantetheinyl transferase (PPTase) biological activity (function) is characterized as the enzyme that transfers a 4'-phosphopantetheinyl moiety from Coenzyme A to the acyl carrier protein (ACP). This transfer to an invariant serine residue of the ACP activates the inactive apo-form to the holo-form. In both polyketide and fatty acid synthesis, the phosphopantetheine group forms thioesters with the growing acyl chains. The PPTases are a family of enzymes that have been well characterized in fatty acid synthesis, polyketide synthesis, and non-ribosomal peptide synthesis. The sequences of many PPTases are known, and crystal structures have been determined (e.g., Reuter K, Mofid MR, Marahiel MA, Ficner R. "Crystal structure of the surfactin synthetase-activating enzyme sfp: a prototype of the 4'-phosphopantetheinyl transferase superfamily" EMBO J. 1999 Dec 1;18(23):6823-31) as well as mutational analysis of amino acid residues important for activity (Mofid MR, Finking R, Essen LO, Marahiel MA. "Structure-based mutational analysis of the 4'-phosphopantetheinyl transferases Sfp from *Bacillus subtilis*: carrier protein recognition and reaction mechanism" Biochemistry. 2004 Apr 13;43(14):4128-36). These invariant and highly conserved amino acids in PPTases are contained within the pfaE ORFs from both *Shewanella* strains described above.

One heterologous PPTase which has been demonstrated previously to recognize the OrfA ACP domains described herein as substrates is the Het I protein of *Nostoc* sp. PCC 7120 (formerly called *Anabaena* sp. PCC 7120). Het I is present in a cluster of genes in *Nostoc* known to be responsible for the synthesis of long chain hydroxy-fatty acids that are a component of a glyco-lipid layer present in heterocysts of that organism (Black and

Wolk, 1994, *J. Bacteriol.* 176, 2282-2292; Campbell et al., 1997, *Arch. Microbiol.* 167, 251-258). Het I is likely to activate the ACP domains of a protein, Hgl E, present in that cluster. The two ACP domains of Hgl E have a high degree of sequence homology to the ACP domains found in *Schizochytrium* Orf A. SEQ ID NO:34 represents the amino acid
5 sequence of the Nostoc Het I protein, and is a functional PPTase that can be used with a PUFA PKS system described herein, including the PUFA PKS systems from *Schizochytrium* and *Thraustochytrium*. SEQ ID NO:34 is encoded by SEQ ID NO:33. The endogenous start codon of Het I has not been identified (there is no methionine present in the putative protein). There are several potential alternative start codons (e.g.,
10 TTG and ATT) near the 5' end of the open reading frame. No methionine codons (ATG) are present in the sequence. However, the construction of a Het I expression construct was completed using PCR to replace the furthest 5' potential alternative start codon (TTG) with a methionine codon (ATG, as part of an NdeI restriction enzyme recognition site), and introducing an XhoI site at the 3' end of the coding sequence, and the encoded PPTase
15 (SEQ ID NO:34) has been shown to be functional.

Another heterologous PPTase which has been demonstrated previously to recognize the OrfA ACP domains described herein as substrates is sfp, derived from *Bacillus subtilis*. Sfp has been well characterized, and is widely used due to its ability to recognize a broad range of substrates. Based on published sequence information (Nakana,
20 et al., 1992, *Molecular and General Genetics* 232: 313-321), an expression vector was previously produced for sfp by cloning the coding region, along with defined up- and downstream flanking DNA sequences, into a pACYC-184 cloning vector. This construct encodes a functional PPTase as demonstrated by its ability to be co-expressed with *Schizochytrium* Orfs A, B*, and C in *E. coli* which, under appropriate conditions, resulted
25 in the accumulation of DHA in those cells (see U.S. Patent Application Publication No. 20040235127).

When genetically modifying organisms (e.g., microorganisms or plants) to express a PUFA PKS system according to the present invention, some host organisms may endogenously express accessory proteins that are needed to work with the PUFA PKS to
30 produce PUFAs (e.g., PPTases). However, some organisms may be transformed with nucleic acid molecules encoding one or more accessory proteins described herein to enable and/or to enhance production of PUFAs by the organism, even if the organism endogenously produces a homologous accessory protein (i.e., some heterologous

accessory proteins may operate more effectively or efficiently with the transformed PUFA synthase proteins than the host cells' endogenous accessory protein). In one embodiment, such an accessory protein includes an accessory PPTase.

One embodiment of the present invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence from a PUFA PKS system, a homologue thereof, a fragment thereof, and/or a nucleic acid sequence that is complementary to any of such nucleic acid sequences. In one aspect, the present invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of: (a) a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:39, SEQ ID NO:52, SEQ ID NO:62, and biologically active fragments thereof; (b) a nucleic acid sequence encoding an amino acid sequence selected from the group consisting of: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, and biologically active fragments thereof; (c) a nucleic acid sequence encoding an amino acid sequence that is at least about 60% identical to at least 500 consecutive amino acids of any of the amino acid sequences of (a), wherein the amino acid sequence has a biological activity of at least one, two, three or more domains of a polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) system; (d) a nucleic acid sequence encoding an amino acid sequence that is at least about 60% identical to any of the amino acid sequences of (b), wherein said amino acid sequence has a biological activity of at least one domain of a polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) system; or (e) a nucleic acid sequence that is fully complementary to the nucleic acid sequence of (a), (b), (c), or (d). In a further embodiment, nucleic acid sequences including a sequence encoding the active site domains or other functional motifs described above for several of the PUFA PKS domains are encompassed by the invention.

Particularly preferred embodiments of the present invention include isolated nucleic acid molecules encoding chimeric proteins useful in a PUFA PKS system as described herein. The present invention includes the use of any domain or protein from or derived from one PUFA PKS system in a domain and/or with proteins from or derived

from another PUFA PKS system in order to create novel PUFA PKS systems with unique qualities.

For example, one embodiment of the present invention relates to the use of a DH2 domain from a PUFA PKS system to modify a PUFA PKS system comprised of proteins/domains from a different organism or organisms, wherein the introduction of the DH2 domain (*e.g.*, in one embodiment, by substitution for the endogenous DH2 domain or similar domain in the host) modifies the ratio of PUFAs produced by the system, and particularly the ratio of omega-3 to omega-6 PUFAs produced by the system. This embodiment is described in detail below.

Some preferred nucleic acid molecules include a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO:74, and biologically active fragments thereof, a nucleic acid sequence encoding an amino acid sequence that is at least about 60% identical to SEQ ID NO:74 having biological activity of at least one, two, three or more domains of a polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) system, or a nucleic acid sequence that is fully complementary to the nucleic acid sequences above. In one embodiment, the nucleic acid molecule includes a nucleic acid sequence selected from SEQ ID NO:73 and SEQ ID NO:75. In one embodiment, the nucleic acid molecule includes a nucleic acid sequence encoding the amino acid sequence encoded by a plasmid selected from the group of pDS49 and pDD24. In one embodiment, the nucleic acid molecule includes the nucleic acid sequence of a plasmid selected from the group of pDS49 and pDD24 that encodes a chimeric OrfC protein.

Other preferred embodiments including nucleic acid molecules comprising a nucleic acid sequence encoding a PUFA PKS protein or domain or homologue thereof from one PUFA PKS system, wherein the nucleic acid sequence is optimized for the codon usage of a different organism, such as a host in which the nucleic acid sequence is to be expressed. Examples of such nucleic acid sequences are described herein, and include, but are not limited to, the nucleic acid sequences represented by SEQ ID NO:70, SEQ ID NO:71, and SEQ ID NO:72, as well as SEQ ID NO:75. Codon optimized nucleic acid sequences encoding any PUFA PKS protein or domain, and particularly, any of the amino acid sequences described herein are encompassed by the invention. In one embodiment, such a nucleic acid molecule includes a nucleic acid sequence encoding the amino acid sequence encoded by a plasmid selected from the group of pThOrfC-synPS, pDD26, pDD32, or pDD24. In one embodiment, the nucleic acid molecule includes the

nucleic acid sequence of a plasmid selected from pThOrfC-synPS, pDD26, pDD32, or pDD24 that encodes a protein or chimeric protein useful in a PUFA PKS system.

According to the present invention, an amino acid sequence that has a biological activity of at least one domain of a PUFA PKS system is an amino acid sequence that has the biological activity of at least one domain of the PUFA PKS system described in detail herein, as exemplified by the *Schizochytrium* and *Thraustochytrium* PUFA PKS systems, and as further exemplified by the described biological activities of any of the proteins and domains in any of the PUFA PKS systems described in U.S. Patent No. 6,140,486, U.S. Patent No. 6,566,583, U.S. Patent Application Publication No. 20020194641, U.S. Patent Application Publication No. 20070089199, U.S. Patent Application Publication No. 20040235127, U.S. Patent Application Publication No. 20050100995, PCT Patent Publication No. WO 05/097982, or U.S. Patent Application Publication No. 20050014231, *supra*.

Accordingly, an isolated nucleic acid molecule of the present invention can encode the translation product of any PUFA PKS open reading frame, PUFA PKS domain, biologically active fragment thereof, or any homologue of a naturally occurring PUFA PKS open reading frame or domain which has biological activity. A homologue of given protein or domain is a protein or polypeptide that has an amino acid sequence which differs from the naturally occurring reference amino acid sequence (i.e., of the reference protein or domain) in that at least one or a few, but not limited to one or a few, amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide or fragment), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitation, amidation and/or addition of glycosylphosphatidyl inositol). Preferred homologues of a PUFA PKS protein or domain are described in detail below. It is noted that homologues can include synthetically produced homologues, naturally occurring allelic variants of a given protein or domain, or homologous sequences from organisms other than the organism from which the reference sequence was derived.

In general, the biological activity or biological action of a protein or domain refers to any function(s) exhibited or performed by the protein or domain that is ascribed to the naturally occurring form of the protein or domain as measured or observed *in vivo* (i.e., in the natural physiological environment of the protein) or *in vitro* (i.e., under laboratory conditions). Biological activities of PUFA PKS systems and the individual

proteins/domains that make up a PUFA PKS system have been described in detail elsewhere herein. Modifications of a protein or domain, such as in a homologue or mimetic (discussed below), may result in proteins or domains having the same biological activity as the naturally occurring protein or domain, or in proteins or domains having
5 decreased or increased biological activity as compared to the naturally occurring protein or domain. Modifications which result in a decrease in expression or a decrease in the activity of the protein or domain, can be referred to as inactivation (complete or partial), down-regulation, or decreased action of a protein or domain. Similarly, modifications which result in an increase in expression or an increase in the activity of the protein or
10 domain, can be referred to as amplification, overproduction, activation, enhancement, up-regulation or increased action of a protein or domain. A functional domain of a PUFA PKS system is a domain (i.e., a domain can be a portion of a protein) that is capable of performing a biological function (i.e., has biological activity).

In accordance with the present invention, an isolated nucleic acid molecule is a
15 nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation), its natural milieu being the genome or chromosome in which the nucleic acid molecule is found in nature. As such, "isolated" does not necessarily reflect the extent to which the nucleic acid molecule has been purified, but indicates that the molecule does not include an entire genome or an entire chromosome in
20 which the nucleic acid molecule is found in nature. An isolated nucleic acid molecule can include a gene. An isolated nucleic acid molecule that includes a gene is not a fragment of a chromosome that includes such gene, but rather includes the coding region and regulatory regions associated with the gene, but typically no additional genes naturally found on the same chromosome, although some nucleic acid molecules may include
25 nearby/linked genes that are not necessarily a part of the PUFA PKS gene or system. An isolated nucleic acid molecule can also include a specified nucleic acid sequence flanked by (i.e., at the 5' and/or the 3' end of the sequence) additional nucleic acids that do not normally flank the specified nucleic acid sequence in nature (i.e., heterologous sequences). Isolated nucleic acid molecule can include DNA, RNA (e.g., mRNA), or derivatives of
30 either DNA or RNA (e.g., cDNA). Although the phrase "nucleic acid molecule" primarily refers to the physical nucleic acid molecule and the phrase "nucleic acid sequence" primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two

phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding a protein or domain of a protein.

Preferably, an isolated nucleic acid molecule of the present invention is produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated nucleic acid molecules include natural nucleic acid molecules and homologues thereof, including, but not limited to, natural allelic variants and modified nucleic acid molecules in which nucleotides have been inserted, deleted, substituted, and/or inverted in such a manner that such modifications provide the desired effect on PUFA PKS system biological activity as described herein. Protein homologues (e.g., proteins encoded by nucleic acid homologues) have been discussed in detail above.

A nucleic acid molecule homologue can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, 1989). For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, PCR amplification and/or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologues can be selected from a mixture of modified nucleic acids by screening for the function of the protein encoded by the nucleic acid and/or by hybridization with a wild-type gene.

The minimum size of a nucleic acid molecule of the present invention is a size sufficient to form a probe or oligonucleotide primer that is capable of forming a stable hybrid (e.g., under moderate, high or very high stringency conditions) with the complementary sequence of a nucleic acid molecule useful in the present invention, or of a size sufficient to encode an amino acid sequence having a biological activity of at least one domain of a PUFA PKS system according to the present invention. As such, the size of the nucleic acid molecule encoding such a protein can be dependent on nucleic acid composition and percent homology or identity between the nucleic acid molecule and complementary sequence as well as upon hybridization conditions *per se* (e.g., temperature, salt concentration, and formamide concentration). The minimal size of a

nucleic acid molecule that is used as an oligonucleotide primer or as a probe is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 18 bases in length if they are AT-rich. There is no limit, other than a practical limit, on the maximal size of a nucleic acid molecule of the present invention, in that the nucleic acid molecule can include a sequence sufficient to encode a biologically active fragment of a domain of a PUFA PKS system, an entire domain of a PUFA PKS system, several domains within an open reading frame (Orf) of a PUFA PKS system, an entire Orf of a PUFA PKS system, or more than one Orf of a PUFA PKS system.

10 In one embodiment of the present invention, an isolated nucleic acid molecule comprises, consists essentially of, or consists of a nucleic acid sequence encoding an amino acid sequence selected from the group of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO: 62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, or SEQ ID NO:74, or biologically active fragments thereof. In one aspect, the nucleic acid sequence is selected from: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:75.

20 In one embodiment of the present invention, any of the above-described PUFA PKS amino acid sequences, as well as homologues of such sequences, can be produced with from at least one, and up to about 20, additional heterologous amino acids flanking each of the C- and/or N-terminal end of the given amino acid sequence. The resulting protein or polypeptide can be referred to as "consisting essentially of" a given amino acid sequence. According to the present invention, the heterologous amino acids are a sequence of amino acids that are not naturally found (i.e., not found in nature, *in vivo*)

flanking the given amino acid sequence or which would not be encoded by the nucleotides that flank the naturally occurring nucleic acid sequence encoding the given amino acid sequence as it occurs in the gene, if such nucleotides in the naturally occurring sequence were translated using standard codon usage for the organism from which the given amino acid sequence is derived. Similarly, the phrase "consisting essentially of", when used with reference to a nucleic acid sequence herein, refers to a nucleic acid sequence encoding a given amino acid sequence that can be flanked by from at least one, and up to as many as about 60, additional heterologous nucleotides at each of the 5' and/or the 3' end of the nucleic acid sequence encoding the given amino acid sequence. The heterologous nucleotides are not naturally found (i.e., not found in nature, *in vivo*) flanking the nucleic acid sequence encoding the given amino acid sequence as it occurs in the natural gene.

The present invention also includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence having a biological activity of at least one domain of a PUFA PKS system. In one aspect, such a nucleic acid sequence encodes a homologue of any of the PUFA PKS proteins or domains described above, wherein the homologue has a biological activity of at least one (or two, three, four or more) domain of a PUFA PKS system as described previously herein.

In one aspect of the invention, a homologue of a PUFA PKS protein or domain encompassed by the present invention comprises an amino acid sequence that is at least about 60% identical to at least 500 consecutive amino acids of an amino acid sequence chosen from: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:39, SEQ ID NO:52, SEQ ID NO:62 or SEQ ID NO:74; wherein said amino acid sequence has a biological activity of at least one domain of a PUFA PKS system. In a further aspect, the amino acid sequence of the homologue is at least about 60% identical to at least about 600 consecutive amino acids, and more preferably to at least about 700 consecutive amino acids, and more preferably to at least about 800 consecutive amino acids, and more preferably to at least about 900 consecutive amino acids, and more preferably to at least about 1000 consecutive amino acids, and more preferably to at least about 1100 consecutive amino acids, and more preferably to at least about 1200 consecutive amino acids, and more preferably to at least about 1300 consecutive amino acids, and more preferably to at least about 1400 consecutive amino acids, and more preferably to at least about 1500 consecutive amino acids of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:39, SEQ ID NO:52, SEQ ID NO:62, or SEQ ID NO:74, or to the full

length of SEQ ID NO:6, SEQ ID NO:62, or SEQ ID NO:74. In a further aspect, the amino acid sequence of the homologue is at least about 60% identical to at least about 1600 consecutive amino acids, and more preferably to at least about 1700 consecutive amino acids, and more preferably to at least about 1800 consecutive amino acids, and more preferably to at least about 1900 consecutive amino acids, and more preferably to at least about 2000 consecutive amino acids of any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:39, or SEQ ID NO:52 or to the full length of SEQ ID NO:4 or SEQ ID NO:52. In a further aspect, the amino acid sequence of the homologue is at least about 60% identical to at least about 2100 consecutive amino acids, and more preferably to at least about 2200 consecutive amino acids, and more preferably to at least about 2300 consecutive amino acids, and more preferably to at least about 2400 consecutive amino acids, and more preferably to at least about 2500 consecutive amino acids, and more preferably to at least about 2600 consecutive amino acids, and more preferably to at least about 2700 consecutive amino acids, and more preferably to at least about 2800 consecutive amino acids, and even more preferably, to the full length of SEQ ID NO:2 or SEQ ID NO:39.

In another aspect, a homologue of a PUFA PKS protein or domain encompassed by the present invention comprises an amino acid sequence that is at least about 65% identical, and more preferably at least about 70% identical, and more preferably at least about 75% identical, and more preferably at least about 80% identical, and more preferably at least about 85% identical, and more preferably at least about 90% identical, and more preferably at least about 95% identical, and more preferably at least about 96% identical, and more preferably at least about 97% identical, and more preferably at least about 98% identical, and more preferably at least about 99% identical to any of the above-described amino acid sequences, over any of the consecutive amino acid lengths described in the paragraphs above, wherein the amino acid sequence has a biological activity of at least one domain of a PUFA PKS system.

In one aspect of the invention, a homologue of a PUFA PKS protein or domain encompassed by the present invention comprises an amino acid sequence that is at least about 60% identical to an amino acid sequence chosen from: SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:66,

SEQ ID NO:68, or amino acid sequences comprising combinations of any of such amino acid sequences, wherein said amino acid sequence has a biological activity of at least one domain of a PUFA PKS system or accessory protein thereof. In a further aspect, the amino acid sequence of the homologue is at least about 65% identical, and more preferably at least about 70% identical, and more preferably at least about 75% identical, and more preferably at least about 80% identical, and more preferably at least about 85% identical, and more preferably at least about 90% identical, and more preferably at least about 95% identical, and more preferably at least about 96% identical, and more preferably at least about 97% identical, and more preferably at least about 98% identical, and more preferably at least about 99% identical to any of the above-described amino acid sequences, wherein the amino acid sequence has a biological activity of at least one domain of a PUFA PKS system or accessory protein thereof.

According to the present invention, the term "contiguous" or "consecutive", with regard to nucleic acid or amino acid sequences described herein, means to be connected in an unbroken sequence. For example, for a first sequence to comprise 30 contiguous (or consecutive) amino acids of a second sequence, means that the first sequence includes an unbroken sequence of 30 amino acid residues that is 100% identical to an unbroken sequence of 30 amino acid residues in the second sequence. Similarly, for a first sequence to have "100% identity" with a second sequence means that the first sequence exactly matches the second sequence with no gaps between nucleotides or amino acids.

As used herein, unless otherwise specified, reference to a percent (%) identity refers to an evaluation of homology which is performed using: (1) a BLAST 2.0 Basic BLAST homology search using blastp for amino acid searches, blastn for nucleic acid searches, and blastX for nucleic acid searches and searches of translated amino acids in all 6 open reading frames, all with standard default parameters, wherein the query sequence is filtered for low complexity regions by default (described in Altschul, S.F., Madden, T.L., Schääffer, A.A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D.J. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs." Nucleic Acids Res. 25:3389-3402, incorporated herein by reference in its entirety); (2) a BLAST 2 alignment (using the parameters described below); (3) and/or PSI-BLAST with the standard default parameters (Position-Specific Iterated BLAST). It is noted that due to some differences in the standard parameters between BLAST 2.0 Basic BLAST and BLAST 2, two specific sequences might be recognized as having significant homology

using the BLAST 2 program, whereas a search performed in BLAST 2.0 Basic BLAST using one of the sequences as the query sequence may not identify the second sequence in the top matches. In addition, PSI-BLAST provides an automated, easy-to-use version of a "profile" search, which is a sensitive way to look for sequence homologues. The program first performs a gapped BLAST database search. The PSI-BLAST program uses the information from any significant alignments returned to construct a position-specific score matrix, which replaces the query sequence for the next round of database searching. Therefore, it is to be understood that percent identity can be determined by using any one of these programs.

Two specific sequences can be aligned to one another using BLAST 2 sequence as described in Tatusova and Madden, (1999), "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", *FEMS Microbiol Lett.* 174:247-250, incorporated herein by reference in its entirety. BLAST 2 sequence alignment is performed in blastp or blastn using the BLAST 2.0 algorithm to perform a Gapped BLAST search (BLAST 2.0) between the two sequences allowing for the introduction of gaps (deletions and insertions) in the resulting alignment. For purposes of clarity herein, a BLAST 2 sequence alignment is performed using the standard default parameters as follows.

For blastn, using 0 BLOSUM62 matrix:

Reward for match = 1

Penalty for mismatch = -2

Open gap (5) and extension gap (2) penalties

gap x_dropoff (50) expect (10) word size (11) filter (on)

For blastp, using 0 BLOSUM62 matrix:

Open gap (11) and extension gap (1) penalties

gap x_dropoff (50) expect (10) word size (3) filter (on).

In another embodiment of the invention, an amino acid sequence having the biological activity of at least one domain of a PUFA PKS system of the present invention includes an amino acid sequence that is sufficiently similar to a naturally occurring PUFA PKS protein or polypeptide that a nucleic acid sequence encoding the amino acid sequence is capable of hybridizing under moderate, high, or very high stringency conditions (described below) to (i.e., with) a nucleic acid molecule encoding the naturally occurring PUFA PKS protein or polypeptide (i.e., to the complement of the nucleic acid strand encoding the naturally occurring PUFA PKS protein or polypeptide). Preferably, an amino acid sequence having the biological activity of at least one domain of a PUFA PKS

system of the present invention is encoded by a nucleic acid sequence that hybridizes under moderate, high or very high stringency conditions to the complement of a nucleic acid sequence that encodes a protein comprising an amino acid sequence represented by any of the amino acid sequences described herein.

5 In another embodiment of the invention, a nucleotide sequence of the present invention is a nucleotide sequence isolated from (obtainable from), identical to, or a homologue of, the nucleotide sequence from a *Schizochytrium*, wherein the nucleotide sequence from a *Schizochytrium* (including either strand of a DNA molecule from *Schizochytrium*) hybridizes under moderate, high, or very high stringency conditions to a
10 nucleotide sequence encoding an amino acid sequence represented by any of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:32. In one embodiment, the *Schizochytrium* is *Schizochytrium* ATCC 20888. In another embodiment, the *Schizochytrium* is a daughter
15 strain of *Schizochytrium* 20888, including mutated strains thereof (e.g., N230D). In one embodiment, the nucleic acid sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence selected from: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ
20 ID NO:29, or SEQ ID NO:31.

 In another embodiment of the invention, a nucleotide sequence of the present invention is a nucleotide sequence isolated from (obtainable from), identical to, or a homologue of, the nucleotide sequence from a *Thraustochytrium*, wherein the nucleotide sequence from a *Thraustochytrium* (including either strand of a DNA molecule from
25 *Thraustochytrium*) hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence encoding an amino acid sequence represented by any of SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68. In one embodiment, the
30 *Thraustochytrium* is *Thraustochytrium* 23B (ATCC 20892). In one embodiment, the nucleic acid sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence selected from: SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ

ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, or SEQ ID NO:67.

In yet another embodiment, a nucleotide sequence of the present invention is a nucleotide sequence isolated from (obtainable from), identical to, or a homologue of, the
5 nucleotide sequence from a eukaryotic organism (*e.g.*, a thraustochytrid or a labyrinthulid) or a marine bacterium, wherein the nucleotide sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence encoding any of the amino acid sequences represented herein.

In another embodiment, a nucleotide sequence of the present invention is a
10 nucleotide sequence isolated from (obtainable from), identical to, or a homologue of, any nucleotide sequence encoding an accessory protein described herein (including either strand of a DNA molecule), where, in one embodiment, the nucleotide sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence encoding an amino acid sequence represented by SEQ ID NO:34. In one
15 embodiment, the nucleic acid sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence represented by SEQ ID NO:33.

In another embodiment, a nucleotide sequence of the present invention is a nucleotide sequence isolated from (obtainable from), identical to, or a homologue of, any codon-optimized or chimeric nucleotide sequence described herein (including either strand
20 of a DNA molecule), where, in one embodiment, the nucleotide sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence encoding an amino acid sequence represented by SEQ ID NO:74. In one embodiment, the nucleic acid sequence hybridizes under moderate, high, or very high stringency conditions to a nucleotide sequence selected from SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ
25 ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:75.

Methods to deduce a complementary sequence are known to those skilled in the art. It should be noted that since amino acid sequencing and nucleic acid sequencing technologies are not entirely error-free, the sequences presented herein, at best, represent
30 apparent sequences of PUFA PKS domains and proteins of the present invention, or of the nucleotide sequences encoding such amino acid sequences.

As used herein, hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules are used to identify similar nucleic acid molecules.

Such standard conditions are disclosed, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press, 1989. Sambrook et al., *ibid.*, is incorporated by reference herein in its entirety (see specifically, pages 9.31-9.62). In addition, formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting varying degrees of mismatch of nucleotides are disclosed, for example, in Meinkoth et al., 1984, *Anal. Biochem.* 138, 267-284; Meinkoth et al., *ibid.*, is incorporated by reference herein in its entirety.

More particularly, moderate stringency hybridization and washing conditions, as referred to herein, refer to conditions which permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction (i.e., conditions permitting about 30% or less mismatch of nucleotides). High stringency hybridization and washing conditions, as referred to herein, refer to conditions which permit isolation of nucleic acid molecules having at least about 80% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction (i.e., conditions permitting about 20% or less mismatch of nucleotides). Very high stringency hybridization and washing conditions, as referred to herein, refer to conditions which permit isolation of nucleic acid molecules having at least about 90% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction (i.e., conditions permitting about 10% or less mismatch of nucleotides). As discussed above, one of skill in the art can use the formulae in Meinkoth et al., *ibid.* to calculate the appropriate hybridization and wash conditions to achieve these particular levels of nucleotide mismatch. Such conditions will vary, depending on whether DNA:RNA or DNA:DNA hybrids are being formed. Calculated melting temperatures for DNA:DNA hybrids are 10°C less than for DNA:RNA hybrids. In particular embodiments, stringent hybridization conditions for DNA:DNA hybrids include hybridization at an ionic strength of 6X SSC (0.9 M Na⁺) at a temperature of between about 20°C and about 35°C (lower stringency), more preferably, between about 28°C and about 40°C (more stringent), and even more preferably, between about 35°C and about 45°C (even more stringent), with appropriate wash conditions. In particular embodiments, stringent hybridization conditions for DNA:RNA hybrids include hybridization at an ionic strength of 6X SSC (0.9 M Na⁺) at a temperature of between about 30°C and about 45°C, more preferably, between about 38°C and about 50°C, and even more preferably, between about 45°C and about 55°C, with similarly stringent wash

conditions. These values are based on calculations of a melting temperature for molecules larger than about 100 nucleotides, 0% formamide and a G + C content of about 40%. Alternatively, T_m can be calculated empirically as set forth in Sambrook et al., *supra*, pages 9.31 to 9.62. In general, the wash conditions should be as stringent as possible, and should be appropriate for the chosen hybridization conditions. For example, hybridization conditions can include a combination of salt and temperature conditions that are approximately 20-25°C below the calculated T_m of a particular hybrid, and wash conditions typically include a combination of salt and temperature conditions that are approximately 12-20°C below the calculated T_m of the particular hybrid. One example of hybridization conditions suitable for use with DNA:DNA hybrids includes a 2-24 hour hybridization in 6X SSC (50% formamide) at about 42°C, followed by washing steps that include one or more washes at room temperature in about 2X SSC, followed by additional washes at higher temperatures and lower ionic strength (e.g., at least one wash as about 37°C in about 0.1X-0.5X SSC, followed by at least one wash at about 68°C in about 0.1X-0.5X SSC).

Yet another embodiment of the present invention includes a nucleic acid molecule comprising, consisting essentially of, or consisting of, a nucleic acid sequence that is identical to, or that is a homologue of (as defined above) the nucleic acid sequence of a plasmid selected from: pJK1126 (ATCC Accession No. PTA-7648), pJK1129 (ATCC Accession No. PTA-7649), pJK1131 (ATCC Accession No. PTA-7650), pJK306 (ATCC Accession No. PTA-7641), pJK320 (ATCC Accession No. PTA-7644), pJK324 (ATCC Accession No. PTA-7643), pBR002 (ATCC Accession No. PTA-7642), Th23BOrfA_pBR812.1 (ATCC Accession No. PTA-8232) Th23BOrfA_pBR811 (ATCC Accession No. PTA-8231), Th23BOrfB_pBR800 (ATCC Accession No. PTA-8227) or Th23BOrfC_pBR709A (ATCC Accession No. PTA-8228).

In another embodiment, the present invention includes a nucleic acid molecule comprising, consisting essentially of, or consisting of, a nucleic acid sequence that is identical to, or that is a homologue of (as defined above), the nucleic acid sequence of a plasmid selected from: pThOrfC-synPS (ATCC Accession No. PTA-8229), pDS49 (ATCC Accession No. PTA-8230), pDD24 (ATCC Accession No. PTA-8226), pDD26 (ATCC Accession No. PTA-8411), pDD32 (ATCC Accession No. PTA-8412), or OrfB*_pJK780 (ATCC Accession No. PTA-8225).

Yet another embodiment of the present invention includes a nucleic acid molecule comprising, consisting essentially of, or consisting of, a nucleic acid sequence that encodes an amino acid sequence that is identical to, or that is a homologue of (as defined above) the amino acid sequence encoded by a plasmid selected from: pJK1126 (ATCC
5 Accession No. PTA-7648), pJK1129 (ATCC Accession No. PTA-7649), pJK1131 (ATCC Accession No. PTA-7650), pJK306 (ATCC Accession No. PTA-7641), pJK320 (ATCC Accession No. PTA-7644), pJK324 (ATCC Accession No. PTA-7643), pBR002 (ATCC Accession No. PTA-7642), Th23BOrfA_pBR812.1 (ATCC Accession No. PTA-8232) Th23BOrfA_pBR811 (ATCC Accession No. PTA-8231), Th23BOrfB_pBR800 (ATCC
10 Accession No. PTA-8227) or Th23BOrfC_pBR709A (ATCC Accession No. PTA-8228).

In another embodiment, the present invention includes a nucleic acid molecule comprising, consisting essentially of, or consisting of, a nucleic acid sequence that encodes an amino acid sequence that is identical to, or that is a homologue of (as defined above) the amino acid sequence encoded by a plasmid selected from: pThOrfC-synPS
15 (ATCC Accession No. PTA-8229), pDS49 (ATCC Accession No. PTA-8230), pDD24 (ATCC Accession No. PTA-8226), pDD26 (ATCC Accession No. PTA-8411), pDD32 (ATCC Accession No. PTA-8412), or OrfB*_pJK780 (ATCC Accession No. PTA-8225).

Another embodiment of the present invention includes a recombinant nucleic acid molecule comprising a recombinant vector and a nucleic acid molecule comprising a
20 nucleic acid sequence encoding an amino acid sequence having a biological activity of at least one domain or protein of a PUFA PKS system as described herein. Such nucleic acid sequences and domains or proteins are described in detail above. According to the present invention, a recombinant vector is an engineered (i.e., artificially produced) nucleic acid molecule that is used as a tool for manipulating a nucleic acid sequence of choice and for
25 introducing such a nucleic acid sequence into a host cell. The recombinant vector is therefore suitable for use in cloning, sequencing, and/or otherwise manipulating the nucleic acid sequence of choice, such as by expressing and/or delivering the nucleic acid sequence of choice into a host cell to form a recombinant cell. Such a vector typically contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not
30 naturally found adjacent to nucleic acid sequence to be cloned or delivered, although the vector can also contain regulatory nucleic acid sequences (e.g., promoters, untranslated regions) which are naturally found adjacent to nucleic acid molecules of the present invention or which are useful for expression of the nucleic acid molecules of the present

invention (discussed in detail below). The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a plasmid. The vector can be maintained as an extrachromosomal element (e.g., a plasmid) or it can be integrated into the chromosome of a recombinant organism (e.g., a microbe or a plant). The entire vector can remain in place
5 within a host cell, or under certain conditions, the plasmid DNA can be deleted, leaving behind the nucleic acid molecule of the present invention. The integrated nucleic acid molecule can be under chromosomal promoter control, under native or plasmid promoter control, or under a combination of several promoter controls. Single or multiple copies of the nucleic acid molecule can be integrated into the chromosome. A recombinant vector
10 of the present invention can contain at least one selectable marker.

In one embodiment, a recombinant vector used in a recombinant nucleic acid molecule of the present invention is an expression vector. As used herein, the phrase "expression vector" is used to refer to a vector that is suitable for production of an encoded product (e.g., a protein of interest). In this embodiment, a nucleic acid sequence encoding
15 the product to be produced (e.g., a PUFA PKS domain) is inserted into the recombinant vector to produce a recombinant nucleic acid molecule. The nucleic acid sequence encoding the protein to be produced is inserted into the vector in a manner that operatively links the nucleic acid sequence to regulatory sequences in the vector which enable the transcription and translation of the nucleic acid sequence within the recombinant host cell.

20 In another embodiment, a recombinant vector used in a recombinant nucleic acid molecule of the present invention is a targeting vector. As used herein, the phrase "targeting vector" is used to refer to a vector that is used to deliver a particular nucleic acid molecule into a recombinant host cell, wherein the nucleic acid molecule is used to delete or inactivate an endogenous gene within the host cell or microorganism (i.e., used for
25 targeted gene disruption or knock-out technology). Such a vector may also be known in the art as a "knock-out" vector. In one aspect of this embodiment, a portion of the vector, but more typically, the nucleic acid molecule inserted into the vector (i.e., the insert), has a nucleic acid sequence that is homologous to a nucleic acid sequence of a target gene in the host cell (i.e., a gene which is targeted to be deleted or inactivated). The nucleic acid
30 sequence of the vector insert is designed to bind to the target gene such that the target gene and the insert undergo homologous recombination, whereby the endogenous target gene is deleted, inactivated or attenuated (i.e., by at least a portion of the endogenous target gene being mutated or deleted).

Typically, a recombinant nucleic acid molecule includes at least one nucleic acid molecule of the present invention operatively linked to one or more transcription control sequences. As used herein, the phrase "recombinant molecule" or "recombinant nucleic acid molecule" primarily refers to a nucleic acid molecule or nucleic acid sequence
5 operatively linked to a transcription control sequence, but can be used interchangeably with the phrase "nucleic acid molecule", when such nucleic acid molecule is a recombinant molecule as discussed herein. According to the present invention, the phrase "operatively linked" refers to linking a nucleic acid molecule to a transcription control sequence in a manner such that the molecule is able to be expressed when transfected (i.e.,
10 transformed, transduced, transfected, conjugated or conducted) into a host cell. Transcription control sequences are sequences which control the initiation, elongation, or termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription
15 control sequence that can function in a host cell or organism into which the recombinant nucleic acid molecule is to be introduced.

Recombinant nucleic acid molecules of the present invention can also contain additional regulatory sequences, such as translation regulatory sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell.
20 In one embodiment, a recombinant molecule of the present invention, including those which are integrated into the host cell chromosome, also contains secretory signals (i.e., signal segment nucleic acid sequences) to enable an expressed protein to be secreted from the cell that produces the protein. Suitable signal segments include a signal segment that is naturally associated with the protein to be expressed or any heterologous signal segment
25 capable of directing the secretion of the protein according to the present invention. In another embodiment, a recombinant molecule of the present invention comprises a leader sequence to enable an expressed protein to be delivered to and inserted into the membrane of a host cell. Suitable leader sequences include a leader sequence that is naturally associated with the protein, or any heterologous leader sequence capable of directing the
30 delivery and insertion of the protein to the membrane of a cell.

The present inventors have found that the *Schizochytrium* and *Thraustochytrium* PUFA PKS Orfs A and B are closely linked in the genome and the region between the Orfs has been sequenced. In *Schizochytrium*, the Orfs are oriented in opposite directions

and 4244 base pairs separate the start (ATG) codons (i.e. they are arranged as follows: 3'OrfA5'-4244 bp-5'OrfB3'). Examination of the 4244 bp intergenic region did not reveal any obvious Orfs (no significant matches were found on a BlastX search). Both Orfs A and B are highly expressed in *Schizochytrium*, at least during the time of oil production, implying that active promoter elements are embedded in this intergenic region. These genetic elements are believed to have utility as a bi-directional promoter sequence for transgenic applications. For example, in a preferred embodiment, one could clone this region, place any genes of interest at each end and introduce the construct into *Schizochytrium* (or some other host in which the promoters can be shown to function). It is predicted that the regulatory elements, under the appropriate conditions, would provide for coordinated, high level expression of the two introduced genes. The complete nucleotide sequence for the regulatory region containing *Schizochytrium* PUFA PKS regulatory elements (e.g., a promoter) is represented herein as SEQ ID NO:76.

In a similar manner, OrfC is highly expressed in *Schizochytrium* during the time of oil production and regulatory elements are expected to reside in the region upstream of its start codon. A region of genomic DNA upstream of OrfC has been cloned and sequenced and is represented herein as (SEQ ID NO:77). This sequence contains the 3886 nt immediately upstream of the OrfC start codon. Examination of this region did not reveal any obvious Orfs (i.e., no significant matches were found on a BlastX search). It is believed that regulatory elements contained in this region, under the appropriate conditions, will provide for high-level expression of a gene placed behind them. Additionally, under the appropriate conditions, the level of expression may be coordinated with genes under control of the A-B intergenic region (SEQ ID NO:76).

Therefore, in one embodiment, a recombinant nucleic acid molecule useful in the present invention, as disclosed herein, can include a PUFA PKS regulatory region contained within SEQ ID NO:76 and/or SEQ ID NO:77. Such a regulatory region can include any portion (fragment) of SEQ ID NO:76 and/or SEQ ID NO:77 that has at least basal PUFA PKS transcriptional activity (at least basal promoter activity).

One or more recombinant molecules of the present invention can be used to produce an encoded product (e.g., a PUFA PKS domain, protein, or system) of the present invention. In one embodiment, an encoded product is produced by expressing a nucleic acid molecule as described herein under conditions effective to produce the protein. A preferred method to produce an encoded protein is by transfecting a host cell with one or

more recombinant molecules to form a recombinant cell. Suitable host cells to transfect include, but are not limited to, any bacterial, fungal (e.g., yeast), insect, plant or animal cell that can be transfected. Host cells can be either untransfected cells or cells that are already transfected with at least one other recombinant nucleic acid molecule.

5 According to the present invention, the term "transfection" is used to refer to any method by which an exogenous nucleic acid molecule (i.e., a recombinant nucleic acid molecule) can be inserted into a cell. The term "transformation" can be used interchangeably with the term "transfection" when such term is used to refer to the introduction of nucleic acid molecules into microbial cells, such as algae, bacteria and
10 yeast. In microbial systems, the term "transformation" is used to describe an inherited change due to the acquisition of exogenous nucleic acids by the microorganism and is essentially synonymous with the term "transfection." However, in animal cells, transformation has acquired a second meaning which can refer to changes in the growth properties of cells in culture after they become cancerous, for example. Therefore, to
15 avoid confusion, the term "transfection" is preferably used with regard to the introduction of exogenous nucleic acids into animal cells, and the term "transfection" will be used herein to generally encompass transfection of animal cells, plant cells and transformation of microbial cells, to the extent that the terms pertain to the introduction of exogenous nucleic acids into a cell. Therefore, transfection techniques include, but are not limited to,
20 transformation, particle bombardment, electroporation, microinjection, lipofection, adsorption, infection and protoplast fusion.

 It will be appreciated by one skilled in the art that use of recombinant DNA technologies can improve control of expression of transfected nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within the
25 host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Additionally, the promoter sequence might be genetically engineered to improve the level of expression as compared to the native promoter. Recombinant techniques useful for controlling the expression of nucleic acid molecules
30 include, but are not limited to, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites,

Shine-Dalgarno sequences), modification of nucleic acid molecules to correspond to the codon usage of the host cell, and deletion of sequences that destabilize transcripts.

General discussion above with regard to recombinant nucleic acid molecules and transfection of host cells is intended to be applied to any recombinant nucleic acid molecule discussed herein, including those encoding any amino acid sequence having a biological activity of at least one domain from a PUFA PKS, those encoding amino acid sequences from other PKS systems, and those encoding other proteins or domains.

This invention also relates to PUFA PKS systems (and proteins or domains thereof) from microorganisms other than those described specifically herein that are homologous in structure, domain organization and/or function to any of the PUFA PKS system (and proteins or domains thereof) as described herein. In addition, this invention relates to use of these microorganisms and the PUFA PKS systems or components thereof (e.g., DH2 domains) from these microorganisms in the various applications for a PUFA PKS system (e.g., genetically modified organisms and methods of producing bioactive molecules) according to the present invention. A screening process for identification of microorganisms comprising a PUFA PKS system is described in detail in U.S. Patent Application Publication No. 20020194641, *supra*. The knowledge of the structure and function of the PUFA PKS proteins and domains described herein, and the nucleotide sequence encoding the same, are useful tools for the identification, confirmation, and/or isolation of homologues of such proteins or polynucleotides.

According to the present invention, the term "thraustochytrid" refers to any members of the order Thraustochytriales, which includes the family Thraustochytriaceae, and the term "labyrinthulid" refers to any member of the order Labyrinthulales, which includes the family Labyrinthulaceae. The members of the family Labyrinthulaceae were at one time considered to be members of the order Thraustochytriales, but in more recent revisions of the taxonomy of such organisms, the family is now considered to be a member of the order Labyrinthulales, and both Labyrinthulales and Thraustochytriales are considered to be members of the phylum Labyrinthulomycota. Developments have resulted in frequent revision of the taxonomy of the thraustochytrids and labyrinthulids. However, taxonomic theorists now generally place both of these groups of microorganisms with the algae or algae-like protists within the Stramenopile lineage. The current taxonomic placement of the thraustochytrids and labyrinthulids can be summarized as follows:

Realm: Stramenopila (Chromista)

Phylum: Labyrinthulomycota

Class: Labyrinthulomycetes

Order: Labyrinthulales

5 Family: Labyrinthulaceae

Order: Thraustochytriales

Family: Thraustochytriaceae

However, because of remaining taxonomic uncertainties it would be best for the purposes of the present invention to consider the strains described in the present invention as thraustochytrids to include the following organisms: Order: Thraustochytriales; Family: Thraustochytriaceae; Genera: *Thraustochytrium* (Species: *sp.*, *arudimentale*, *aureum*, *benthicola*, *globosum*, *kinnei*, *motivum*, *multirudimentale*, *pachydermum*, *proliferum*, *roseum*, *striatum*), *Ulkenia* (Species: *sp.*, *amoeboidea*, *kerguelensis*, *minuta*, *profunda*, *radiata*, *sailens*, *sarkariana*, *schizochytops*, *visurgensis*, *yorkensis*), *Schizochytrium* (Species: *sp.*, *aggregatum*, *limnaceum*, *mangrovei*, *minutum*, *octosporum*), *Japonochytrium* (Species: *sp.*, *marinum*), *Aplanochytrium* (Species: *sp.*, *haliotidis*, *kerguelensis*, *profunda*, *stocchinoi*), *Althornia* (Species: *sp.*, *crouchii*), or *Elina* (Species: *sp.*, *marisalba*, *sinorifica*). It is to be noted that the original description of the genus *Ulkenia* was not published in a peer-reviewed journal so some questions remain as to the validity of this genus and the species placed within it. For the purposes of this invention, species described within *Ulkenia* will be considered to be members of the genus *Thraustochytrium*.

Strains described in the present invention as Labyrinthulids include the following organisms: Order: Labyrinthulales, Family: Labyrinthulaceae, Genera: *Labyrinthula* (Species: *sp.*, *algeriensis*, *coenocystis*, *chattonii*, *macrocystis*, *macrocystis atlantica*, *macrocystis macrocystis*, *marina*, *minuta*, *roscoffensis*, *valkanovii*, *vitellina*, *vitellina pacifica*, *vitellina vitellina*, *zopfii*), *Labyrinthuloides* (Species: *sp.*, *haliotidis*, *yorkensis*), *Labyrinthomyxa* (Species: *sp.*, *marina*), *Diplophrys* (Species: *sp.*, *archeri*), *Pyrrhosorus* (Species: *sp.*, *marinus*), *Sorodiplophrys* (Species: *sp.*, *stercorea*) or *Chlamydomyxa* (Species: *sp.*, *labyrinthuloides*, *montana*) (although there is currently not a consensus on the exact taxonomic placement of *Pyrrhosorus*, *Sorodiplophrys* or *Chlamydomyxa*).

To produce significantly high yields of various bioactive molecules using the PUFA PKS system of the present invention, an organism, preferably a microorganism or a

plant or plant part (*e.g.*, a plant cell), can be genetically modified to affect the activity of a PUFA PKS system. In one aspect, such an organism can endogenously contain and express a PUFA PKS system, and the genetic modification can be a genetic modification of one or more of the functional domains of the endogenous PUFA PKS system, whereby
5 the modification has some effect on the activity of the PUFA PKS system. In another aspect, such an organism can endogenously contain and express a PUFA PKS system, and the genetic modification can be an introduction of at least one exogenous nucleic acid sequence (*e.g.*, a recombinant nucleic acid molecule), wherein the exogenous nucleic acid sequence encodes at least one biologically active domain or protein from the same or a
10 second PKS system and/or a protein that affects the activity of said PUFA PKS system (*e.g.*, a phosphopantetheinyl transferases (PPTase), discussed below). In yet another aspect, the organism does not necessarily endogenously (naturally) contain a PUFA PKS system, but is genetically modified to introduce at least one recombinant nucleic acid molecule encoding an amino acid sequence having the biological activity of at least one
15 domain of a PUFA PKS system. In this aspect, PUFA PKS activity is affected by introducing or increasing PUFA PKS activity in the organism. Various embodiments associated with each of these aspects will be discussed in greater detail below.

Therefore, according to the present invention, one embodiment relates to a genetically modified microorganism, wherein the microorganism expresses a PKS system
20 comprising at least one biologically active domain of a polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) system. The at least one domain of the PUFA PKS system is encoded by a nucleic acid sequence described herein. The genetic modification affects the activity of the PKS system in the organism. The genetically modified microorganism can include any one or more of the above-identified nucleic acid sequences, and/or any of the
25 other homologues of any of the PUFA PKS ORFs or domains as described in detail above.

As used herein, a genetically modified microorganism can include a genetically modified bacterium, protist, microalgae, fungus, or other microbe, and particularly, any of the genera of the order Thraustochytriales (*e.g.*, a thraustochytrid) described herein. Such a genetically modified microorganism has a genome which is modified (*i.e.*, mutated or
30 changed) from its normal (*i.e.*, wild-type or naturally occurring) form such that the desired result is achieved (*i.e.*, increased or modified PUFA PKS activity and/or production of a desired product using the PUFA PKS system or component thereof). Genetic modification of a microorganism can be accomplished using classical strain development and/or

molecular genetic techniques. Such techniques known in the art and are generally disclosed for microorganisms, for example, in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Labs Press. The reference Sambrook et al., *ibid.*, is incorporated by reference herein in its entirety. A genetically modified
5 microorganism can include a microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), in such a manner that such modifications provide the desired effect within the microorganism.

Preferred microorganism host cells to modify according to the present invention
10 include, but are not limited to, any bacteria, protist, microalga, fungus, or protozoa. In one aspect, preferred microorganisms to genetically modify include, but are not limited to, any microorganism of the order Thraustochytriales or any microorganism of the order Labyrinthulales. Particularly preferred host cells for use in the present invention could include microorganisms from a genus including, but not limited to: *Thraustochytrium*,
15 *Ulkenia*, *Schizochytrium*, *Japonochytrium*, *Aplanochytrium*, *Althornia*, *Elina*, *Labyrinthula*, *Labyrinthuloides*, *Labyrinthomyxa*, *Diplophrys*, *Pyrrhosorus*, *Sorodiplophrys* or *Chlamydomyxa*. Other examples of suitable host microorganisms for genetic modification include, but are not limited to, yeast including *Saccharomyces cerevisiae*, *Saccharomyces carlsbergensis*, or other yeast such as *Candida*,
20 *Kluyveromyces*, or other fungi, for example, filamentous fungi such as *Aspergillus*, *Neurospora*, *Penicillium*, etc. Bacterial cells also may be used as hosts. This includes *Escherichia coli*, which can be useful in fermentation processes. Alternatively, a host such as a *Lactobacillus* species or *Bacillus* species can be used as a host.

Another embodiment of the present invention relates to a genetically modified
25 plant or part of a plant (e.g., wherein the plant has been genetically modified to express a PUFA PKS system described herein), which includes at least the core PUFA PKS enzyme complex and, in one embodiment, at least one PUFA PKS accessory protein, (e.g., a PPTase), so that the plant produces PUFAs. Preferably, the plant is an oil seed plant, wherein the oil seeds or oil in the oil seeds contain PUFAs produced by the PUFA PKS
30 system. Such oils contain a detectable amount of at least one target or primary PUFA that is the product of the PUFA PKS system. Plants are not known to endogenously contain a PUFA PKS system, and therefore, the PUFA PKS systems of the present invention represent an opportunity to produce plants with unique fatty acid production capabilities.

It is a particularly preferred embodiment of the present invention to genetically engineer plants to produce one or more PUFAs in the same plant, including, EPA, DHA, DPA (n-3 and/or n-6), ARA, GLA, SDA and others. The present invention offers the ability to create any one of a number of "designer oils" in various ratios and forms.

5 Methods for the genetic engineering of plants are well known in the art. For instance, numerous methods for plant transformation have been developed, including biological and physical transformation protocols. See, for example, Miki et al., "Procedures for Introducing Foreign DNA into Plants" in *Methods in Plant Molecular Biology and Biotechnology*, Glick, B.R. and Thompson, J.E. Eds. (CRC Press, Inc., Boca
10 Raton, 1993) pp. 67-88. In addition, vectors and *in vitro* culture methods for plant cell or tissue transformation and regeneration of plants are available. See, for example, Gruber et al., "Vectors for Plant Transformation" in *Methods in Plant Molecular Biology and Biotechnology*, Glick, B.R. and Thompson, J.E. Eds. (CRC Press, Inc., Boca Raton, 1993) pp. 89-119.

15 The most widely utilized method for introducing an expression vector into plants is based on the natural transformation system of *Agrobacterium*. See, for example, Horsch et al., *Science* **227**:1229 (1985). *A. tumefaciens* and *A. rhizogenes* are plant pathogenic soil bacteria which genetically transform plant cells. The Ti and Ri plasmids of *A. tumefaciens* and *A. rhizogenes*, respectively, carry genes responsible for genetic
20 transformation of the plant. See, for example, Kado, C.I., *Crit. Rev. Plant. Sci.* **10**:1 (1991). Descriptions of *Agrobacterium* vector systems and methods for *Agrobacterium*-mediated gene transfer are provided by numerous references, including Gruber et al., supra, Miki et al., supra, Moloney et al., *Plant Cell Reports* **8**:238 (1989), and U.S. Patents Nos. 4,940,838 and 5,464,763.

25 Another generally applicable method of plant transformation is microprojectile-mediated transformation wherein DNA is carried on the surface of microprojectiles. The expression vector is introduced into plant tissues with a biolistic device that accelerates the microprojectiles to speeds sufficient to penetrate plant cell walls and membranes. Sanford et al., *Part. Sci. Technol.* **5**:27 (1987), Sanford, J.C., *Trends Biotech.* **6**:299 (1988),
30 Sanford, J.C., *Physiol. Plant* **79**:206 (1990), Klein et al., *Biotechnology* **10**:268 (1992).

 Another method for physical delivery of DNA to plants is sonication of target cells. Zhang et al., *Bio/Technology* **9**:996 (1991). Alternatively, liposome or spheroplast fusion have been used to introduce expression vectors into plants. Deshayes et al., *EMBO*

J., 4:2731 (1985), Christou et al., *Proc Natl. Acad. Sci. USA* **84**:3962 (1987). Direct uptake of DNA into protoplasts using CaCl₂ precipitation, polyvinyl alcohol or poly-L-ornithine have also been reported. Hain et al., *Mol. Gen. Genet.* **199**:161 (1985) and Draper et al., *Plant Cell Physiol.* **23**:451 (1982). Electroporation of protoplasts and whole
5 cells and tissues have also been described. Donn et al., In Abstracts of VIIIth International Congress on Plant Cell and Tissue Culture IAPTC, A2-38, p. 53 (1990); D'Halluin et al., *Plant Cell* **4**:1495-1505 (1992) and Spencer et al., *Plant Mol. Biol.* **24**:51-61 (1994).

Following the introduction of the genetic construct into plant cells, plant cells are grown and upon emergence of differentiating tissue such as shoots and roots, mature
10 plants are generated. Typically a plurality of plants is generated. Methodologies for regenerating plants will be generally known to those skilled in the art and may be found in for example: *Plant Cell and Tissue Culture*, 1994, Vasil and Thorpe Eds. Kluwer Academic Publishers and in: Plant Cell Culture Protocols (Methods in Molecular Biology 111, 1999 Hall Eds Humana Press).

15 As used herein, a genetically modified plant can include any genetically modified plant including higher plants and particularly, any consumable plants or plants useful for producing a desired bioactive molecule of the present invention. "Plant parts", as used herein, include any parts of a plant, including, but not limited to, seeds (immature or mature), oils, pollen, embryos, flowers, fruits, shoots, leaves, roots, stems, explants, etc. A
20 genetically modified plant has a genome that is modified (i.e., mutated or changed) from its normal (i.e., wild-type or naturally occurring) form such that the desired result is achieved (e.g., PUFA PKS activity and production of PUFAs). Genetic modification of a plant can be accomplished using classical strain development and/or molecular genetic techniques. Methods for producing a transgenic plant, wherein a recombinant nucleic acid
25 molecule encoding a desired amino acid sequence is incorporated into the genome of the plant, are known in the art. A preferred plant to genetically modify according to the present invention is preferably a plant suitable for consumption by animals, including humans.

Preferred plants to genetically modify according to the present invention (*i.e.*, plant
30 host cells) include, but are not limited to any higher plants, including both dicotyledonous and monocotyledonous plants, and particularly consumable plants, including crop plants and especially plants used for their oils. Such plants can include, but are not limited to, for example: canola, soybeans, rapeseed, linseed, corn, safflowers, sunflowers and tobacco.

Thus, any plant species or plant cell may be selected. Particular cells used herein, and plants grown or derived therefrom, include, but are not limited to, cells obtainable from canola (*Brassica rapa* L.); soybean (*Glycine max*); rapeseed (*Brassica spp.*); linseed/flax (*Linum usitatissimum*); maize (corn) (*Zea mays*); safflower (*Carthamus tinctorius*);
5 sunflower (*Helianthus annuus*); tobacco (*Nicotiana tabacum*); *Arabidopsis thaliana*, Brazil nut (*Betholettia excelsa*); castor bean (*Ricinus communis*); coconut (*Cocos nucifera*); coriander (*Coriandrum sativum*); cotton (*Gossypium spp.*); groundnut (*Arachis hypogaea*); jojoba (*Simmondsia chinensis*); mustard (*Brassica spp.* and *Sinapis alba*); oil palm (*Elaeis guineensis*); olive (*Olea europaea*); rice (*Oryza sativa*); squash (*Cucurbita*
10 *maxima*); barley (*Hordeum vulgare*); wheat (*Triticum aestivum*); and duckweed (*Lemnaceae sp.*). It should be noted that in accordance herewith the genetic background within a plant species may vary.

Other preferred plants include those plants that are known to produce compounds used as pharmaceutical agents, flavoring agents, nutraceutical agents, functional food
15 ingredients or cosmetically active agents or plants that are genetically engineered to produce these compounds/agents.

In a further embodiment plant cell cultures may be used in accordance herewith. In such embodiments plant cells are not grown into differentiated plants and cultivated using ordinary agricultural practices, but instead grown and maintained in a liquid medium.

20 According to the present invention, a genetically modified microorganism or plant includes a microorganism or plant that has been modified using recombinant technology. As used herein, genetic modifications that result in a decrease in gene expression, in the function of the gene, or in the function of the gene product (i.e., the protein encoded by the gene) can be referred to as inactivation (complete or partial), deletion, interruption,
25 blockage or down-regulation of a gene. For example, a genetic modification in a gene which results in a decrease in the function of the protein encoded by such gene, can be the result of a complete deletion of the gene (i.e., the gene does not exist, and therefore the protein does not exist), a mutation in the gene which results in incomplete or no translation of the protein (e.g., the protein is not expressed), or a mutation in the gene which
30 decreases or abolishes the natural function of the protein (e.g., a protein is expressed which has decreased or no enzymatic activity or action). Genetic modifications that result in an increase in gene expression or function can be referred to as amplification,

overproduction, overexpression, activation, enhancement, addition, or up-regulation of a gene.

The genetic modification of a microorganism or plant according to the present invention preferably affects the activity of the PKS system expressed by the plant, whether
5 the PKS system is endogenous and genetically modified, endogenous with the introduction of recombinant nucleic acid molecules into the organism, or provided completely by recombinant technology. According to the present invention, to "affect the activity of a PKS system" includes any genetic modification that causes any detectable or measurable change or modification in the PKS system expressed by the organism as compared to in
10 the absence of the genetic modification. A detectable change or modification in the PKS system can include, but is not limited to: the introduction of PKS system activity into an organism such that the organism now has measurable/detectable PKS system activity (i.e., the organism did not contain a PKS system prior to the genetic modification), the introduction into the organism of a functional domain from a different PKS system than a
15 PKS system endogenously expressed by the organism such that the PKS system activity is modified (e.g., DH2 domain from one PUFA PKS system is introduced into the PUFA PKS system of an different organism), a change in the amount of a bioactive molecule produced by the PKS system (e.g., the system produces more (increased amount) or less (decreased amount) of a given product as compared to in the absence of the genetic
20 modification), a change in the type of a bioactive molecule produced by the PKS system (e.g., the system produces a new or different product, or a variant of a product that is naturally produced by the system), and/or a change in the ratio of multiple bioactive molecules produced by the PKS system (e.g., the system produces a different ratio of one PUFA to another PUFA, produces a completely different lipid profile as compared to in
25 the absence of the genetic modification, or places various PUFAs in different positions in a triacylglycerol as compared to the natural configuration). Such a genetic modification includes any type of genetic modification and specifically includes modifications made by recombinant technology and by classical mutagenesis.

It should be noted that reference to increasing the activity of a functional domain
30 or protein in a PUFA PKS system refers to any genetic modification in the organism containing the domain or protein (or into which the domain or protein is to be introduced) which results in increased functionality of the domain or protein system and can include higher activity of the domain or protein (e.g., specific activity or *in vivo* enzymatic

activity), reduced inhibition or degradation of the domain or protein system, and overexpression of the domain or protein. For example, gene copy number can be increased, expression levels can be increased by use of a promoter that gives higher levels of expression than that of the native promoter, or a gene can be altered by genetic engineering or classical mutagenesis to increase the activity of the domain or protein encoded by the gene.

Similarly, reference to decreasing the activity of a functional domain or protein in a PUFA PKS system refers to any genetic modification in the organism containing such domain or protein (or into which the domain or protein is to be introduced) which results in decreased functionality of the domain or protein and includes decreased activity of the domain or protein, increased inhibition or degradation of the domain or protein and a reduction or elimination of expression of the domain or protein. For example, the action of a domain or protein of the present invention can be decreased by blocking or reducing the production of the domain or protein, "knocking out" the gene or portion thereof encoding the domain or protein, reducing domain or protein activity, or inhibiting the activity of the domain or protein. Blocking or reducing the production of a domain or protein can include placing the gene encoding the domain or protein under the control of a promoter that requires the presence of an inducing compound in the growth medium. By establishing conditions such that the inducer becomes depleted from the medium, the expression of the gene encoding the domain or protein (and therefore, of protein synthesis) could be turned off. Blocking or reducing the activity of domain or protein could also include using an excision technology approach similar to that described in U.S. Patent No. 4,743,546, incorporated herein by reference. To use this approach, the gene encoding the protein of interest is cloned between specific genetic sequences that allow specific, controlled excision of the gene from the genome. Excision could be prompted by, for example, a shift in the cultivation temperature of the culture, as in U.S. Patent No. 4,743,546, or by some other physical or nutritional signal.

In one embodiment of the present invention, a genetic modification includes a modification of a nucleic acid sequence encoding protein or domain of an endogenously (naturally) expressed PUFA PKS system, whereby a microorganism that naturally contains such a system is genetically modified by, for example, classical mutagenesis and selection techniques and/or molecular genetic techniques, include genetic engineering techniques. Genetic engineering techniques can include, for example, using a targeting recombinant

vector to delete a portion of an endogenous gene, or to replace a portion of an endogenous gene with a heterologous sequence. Examples of heterologous sequences that could be introduced into a host genome include sequences encoding at least one functional domain from another PKS system, such as a different PUFA PKS system (bacterial or non-
5 bacterial), a type I PKS system (iterative or modular), a type II PKS system, or a type III PKS system. Other heterologous sequences to introduce into the genome of a host includes a sequence encoding a protein or functional domain that is not a domain of a core PKS system, but which will affect the activity of the endogenous PKS system. For example, one could introduce into the host genome a nucleic acid molecule encoding a
10 phosphopantetheinyl transferase (discussed below). Specific modifications that could be made to an endogenous PUFA PKS system are discussed in detail below.

In another aspect of this embodiment of the invention, the genetic modification includes: (1) the introduction into a homologous or heterologous host cell or organism of a recombinant nucleic acid molecule encoding an amino acid sequence having a biological
15 activity of at least one domain of a PUFA PKS system; and/or (2) the introduction into a host cell or organism of a recombinant nucleic acid molecule encoding a protein or functional domain that affects the activity of a PUFA PKS system. The host can include: (1) a host cell or organism that does not express any PKS system for the production of PUFAs, wherein all functional domains of a PUFA PKS system are introduced into the
20 host cell; (2) a host cell that expresses a PKS system for the production of PUFAs (endogenous or recombinant), wherein at least one additional PUFA PKS domain or protein is introduced into the cell or organism. In other words, the present invention intends to encompass any genetically modified cell or organism (e.g., microorganism or plant), wherein the organism comprises at least one PUFA PKS domain or protein
25 described herein, or has been modified to produce a resynthesized and/or chimeric PUFA PKS domain or protein as described herein.

Therefore, using the guidance provided herein, as well as the description of the PUFA PKS systems described herein and known prior to the invention, gene mixing (or mixing of nucleic acid molecules), for example, by the production of chimeric proteins
30 and/or chimeric PUFA PKS systems as described in detail herein, can be used to extend the range of PUFA products, ratios thereof, and production levels thereof, by an organism expressing the PUFA PKS system. For example, the teachings provided herein can be used to improve the amounts of PUFAs produced, to change the ratio of one PUFA to

another, including the ratio of omega-3 to omega-6 PUFAs, and to extend the range of PUFA PKS products to include EPA, DPA (n-3 or n-6), DHA, ARA, GLA, SDA and others, as well as to produce a wide variety of bioactive molecules, including antibiotics, other pharmaceutical compounds, and other desirable products. The method to obtain
5 these improvements includes not only the mixing of genes from various organisms but also various methods of genetically modifying the PUFA PKS genes and nucleic acid molecules disclosed herein. Knowledge of the genetic basis and domain structure of the PUFA PKS systems as described herein provides a basis for designing novel genetically modified organisms. By way of example, various possible manipulations of the PUFA
10 PKS system are discussed in U.S. Patent Application Publication No. 20020194641, U.S. Patent Application Publication No. 20040235127, and U.S. Patent Application Publication No. 20050100995, *supra* with regard to genetic modification and bioactive molecule production. However, this invention provides novel embodiments regarding the manipulation of PUFA production levels by a host organism and the manipulation of the
15 ratio of PUFAs produced by a host organism.

Accordingly, encompassed by the present invention are methods to genetically modify microbial or plant cells by: genetically modifying at least one nucleic acid sequence in the organism that encodes an amino acid sequence having the biological activity of at least one functional domain of a PUFA PKS system according to the present
20 invention, and/or expressing at least one recombinant nucleic acid molecule comprising a nucleic acid sequence encoding such amino acid sequence. Various embodiments of such sequences, methods to genetically modify an organism, and specific modifications have been described in detail above. Typically, the method is used to produce a particular genetically modified organism that produces a particular bioactive molecule or molecules.

25 In one embodiment of the present invention, it is contemplated that a mutagenesis program could be combined with a selective screening process to obtain bioactive molecules of interest. This would include methods to search for a range of bioactive compounds. This search would not be restricted to production of those molecules with *cis* double bonds. The mutagenesis methods could include, but are not limited to: chemical
30 mutagenesis, gene shuffling, switching regions of the genes encoding specific enzymatic domains, or mutagenesis restricted to specific regions of those genes, as well as other methods.

For example, high throughput mutagenesis methods could be used to influence or optimize production of the desired bioactive molecule. Once an effective model system has been developed, one could modify these genes in a high throughput manner. Utilization of these technologies can be envisioned on two levels. First, if a sufficiently selective screen for production of a product of interest (e.g., ARA) can be devised, it could be used to attempt to alter the system to produce this product (e.g., in lieu of, or in concert with, other strategies such as those discussed above). Additionally, if the strategies outlined above resulted in a set of genes that did produce the product of interest, the high throughput technologies could then be used to optimize the system. For example, if the introduced domain only functioned at relatively low temperatures, selection methods could be devised to permit removing that limitation.

It is recognized that many genetic alterations, either random or directed, which one may introduce into a native (endogenous, natural) PUFA PKS system, will result in an inactivation of enzymatic functions. A preferred embodiment of the invention includes a system to select for only those modifications that do not block the ability of the PUFA PKS system to produce a product. For example, the FabB- strain of *E. coli* is incapable of synthesizing unsaturated fatty acids and requires supplementation of the medium with fatty acids that can substitute for its normal unsaturated fatty acids in order to grow (see Metz et al., 2001, *supra*). However, this requirement (for supplementation of the medium) can be removed when the strain is transformed with a functional PUFA PKS system (*i.e.* one that produces a PUFA product in the *E. coli* host - see (Metz et al., 2001, *supra*, Figure 2A). The transformed FabB- strain now requires a functional PUFA-PKS system (to produce the unsaturated fatty acids) for growth without supplementation. The key element in this example is that production of a wide range of unsaturated fatty acids will suffice (even unsaturated fatty acid substitutes, such as branched chain fatty acids). Therefore, in another preferred embodiment of the invention, one can create a large number of mutations in one or more of the PUFA PKS genes disclosed herein, and then transform the appropriately modified FabB- strain (e.g. create mutations in an expression construct containing an ER domain and transform a FabB- strain having the other essential domains on a separate plasmid – or integrated into the chromosome) and select only for those transformants that grow without supplementation of the medium (*i.e.*, that still possessed an ability to produce a molecule that could complement the FabB- defect). Additional screens can be developed to look for particular compounds (e.g. use of GC for

fatty acids) being produced in this selective subset of an active PKS system. One could envision a number of similar selective screens for bioactive molecules of interest.

In one embodiment of invention, a genetically modified organism has a modification that changes at least one product produced by the endogenous PKS system, as compared to a wild-type organism. Novel constructs used to produce such modified organisms, as well as the proteins and organisms produced using such constructs, and the methods associated with such modifications, are all encompassed by the invention.

In one preferred embodiment, a genetically modified organism expresses a PUFA PKS system comprising a genetic modification in a β -hydroxy acyl-ACP dehydrase (DH) domain corresponding to the DH2 domain of *Schizochytrium* or *Thraustochytrium*, wherein the modification alters the ratio of long chain fatty acids, and particularly, the ratio of omega-3 to omega-6 long chain fatty acids, produced by the PUFA PKS system, as compared to in the absence of the modification. In one aspect of this embodiment, the modification is selected from the group consisting of a deletion of all or a part of the domain, a substitution of all or part of the domain with a homologous domain or part thereof from a different organism (e.g., a different organism that naturally produces different ratios and/or amounts of PUFAs), and a mutation of the domain.

More specifically, as illustrated herein, the comparison of the *Schizochytrium* and *Thraustochytrium* PUFA PKS architecture (domain organization) with other PUFA PKS system architecture illustrates nature's ability to alter domain order as well as incorporate new domains to create novel end products, or alter the ratios of end products, for example. In addition, the genes can now be manipulated in the laboratory to create new products, as described in the Examples. The inventors have now demonstrated the ability to harness this ability and use it to create novel organisms with novel PUFA profiles and production amounts. Described herein is the manipulation of PUFA PKS systems in either a directed or random manner to influence the end products. For example, in a preferred embodiment, substitution of a DH (FabA-like) domain or biologically active portion thereof of a first PUFA PKS system, and specifically, the DH2 domain described herein, for the homologous DH domain or biologically active portion thereof in a different, second PUFA PKS system is used to alter the ratio of PUFAs produced by the second PUFA PKS system, and particularly, to manipulate the ratio of omega-3 to omega-6 fatty acids produced by the second PUFA PKS system. A similar result can be achieved by substituting an entire protein or any biologically active portion thereof containing such

DH2 domain (*e.g.*, OrfC from *Thraustochytrium* 23B) from a first PUFA PKS system for the homologous protein or portion thereof in a second PUFA PKS system. While the examples described herein utilize the PUFA PKS systems from *Schizochytrium* and *Thraustochytrium*, the similar manipulation of *any* PKS or PKS-like system for the production of PUFAs by modification of the DH2 protein or DH2-like domain is encompassed by the invention. Such modification can be performed alone or in conjunction with other modifications to a PUFA PKS system.

Accordingly, one embodiment of the present invention comprises a chimeric PUFA PKS system and an organism expressing such chimeric PUFA PKS system. In one aspect, the chimeric PUFA PKS system comprises a first PUFA PKS system, wherein the domain or protein of the first PUFA PKS system that corresponds to the DH2 domain or biologically active portion thereof (*e.g.*, from *Schizochytrium* or *Thraustochytrium* described herein) has been modified or substituted with a DH2 domain or protein or biologically active portion thereof from a second, different PUFA PKS system. By "different PUFA PKS system" is meant a PUFA PKS system from a different strain, species, genus or organism, or even a homologue of a natural or wild-type PUFA PKS system. The goal of producing this chimeric protein is to alter the ratio of PUFAs, and particularly the ratio of omega-3 to omega-6 PUFAs, produced by the PUFA PKS system. Therefore, the selection of the different PUFA PKS system should be based on the selection of a second system producing a different, or desired, ratio of PUFAs than the first PUFA PKS system.

In one aspect of the invention, such a chimeric PUFA PKS system comprises a *Schizochytrium* OrfA (SEQ ID NO:2) and OrfB (SEQ ID NO:4) protein as described herein, and a *Thraustochytrium* OrfC (SEQ ID NO:62) protein as described herein. *Schizochytrium*, *E. coli*, and yeast organisms expressing such chimeric PUFA PKS systems are described in the Examples and are encompassed by the present invention, in addition to plants and plant parts expressing such chimeric PUFA PKS systems. In other embodiments, exemplified in the Examples, chimeric PUFA PKS systems are produced comprising all combinations of the *Schizochytrium* and *Thraustochytrium* OrfsA, B and C.

In another aspect of the invention, a chimeric PUFA PKS system comprises a *Schizochytrium* OrfA (SEQ ID NO:2) and OrfB (SEQ ID NO:4) protein as described herein, and a chimeric OrfC protein (encoded by a nucleic acid sequence represented herein by SEQ ID NO:74, encoded by SEQ ID NO:73). The chimeric OrfC polypeptide is

1493 amino acid residues in length. The DH2 region, defined as amino acids 516–1041 of SEQ ID NO:74, consists of the amino acid sequence of the DH2 region of the *Th.23B* OrfC protein, that is, amino acids 491–1016 of SEQ ID NO:62, which includes all of SEQ ID NO:66 and some flanking amino acid sequence from SEQ ID NO:62. With respect to
5 the remainder of the chimeric OrfC amino acid sequence, residues 1–515 and 1042–1493 of SEQ ID NO:74 are identical to *Schizochytrium* OrfC residues 1–515 and 1051–1502 of SEQ ID NO:6, respectively.

In another embodiment of the invention, a genetically modified cell or organism has been modified to express a PUFA PKS system or portion thereof, including a chimeric
10 PUFA PKS system, wherein the nucleic acid sequence(s) encoding the PUFA PKS system or portion thereof is optimized entirely or in part to utilize the preferred codon usage of the host cell or organism. This embodiment is exemplified below and illustrates how production of a bioactive molecule (*e.g.*, a PUFA) can be increased by making such modifications. This embodiment can be utilized together with the other genetic
15 modifications described herein (*e.g.*, the chimeric PUFA PKS and protein embodiments), to improve production of a bioactive molecule in a host organism.

In one aspect of this embodiment, a chimeric PUFA PKS system comprises a *Schizochytrium* OrfA (SEQ ID NO:2) and OrfB (SEQ ID NO:4) protein as described herein, and a *Thraustochytrium* OrfC (SEQ ID NO:62) protein as described herein,
20 wherein the nucleic acid sequence encoding SEQ ID NO:62 is optimized for the host codon usage. An example of such molecule optimized for expression in *Schizochytrium* is described in the Examples, with such nucleic acid sequence encoding *Thraustochytrium* OrfC (synthetic, or codon-optimized, OrfC) represented herein by SEQ ID NO:70. In another embodiment, *Thraustochytrium* OrfA (SEQ ID NO:39) and/or *Thraustochytrium*
25 OrfB (SEQ ID NO:52) can be combined with any one or more of the *Schizochytrium* OrfsA, B, and/or C, and/or with the *Thraustochytrium* OrfC, for expression in *Schizochytrium*. Again, in this example, the nucleic acid molecule encoding the *Thraustochytrium* OrfA and/or *Thraustochytrium* OrfB can be optimized for the host codon usage. Examples of such molecules optimized for expression in *Schizochytrium* are
30 described in the Examples, with the nucleic acid sequence encoding *Thraustochytrium* OrfA (synthetic, or codon-optimized, OrfA) represented herein by SEQ ID NO:71, and with the nucleic acid sequence encoding *Thraustochytrium* OrfB (synthetic, or codon-optimized, OrfB) represented herein by SEQ ID NO:72.

In another aspect of this embodiment, a chimeric PUFA PKS system comprises a *Schizochytrium* OrfA (SEQ ID NO:2) and OrfB (SEQ ID NO:4) protein as described herein, and a chimeric, *and* partially codon-optimized OrfC protein (encoded by a nucleic acid sequence represented herein by SEQ ID NO:75). The protein encoded by SEQ ID
5 NO:75 is also represented by SEQ ID NO:74, which is described above with respect to SEQ ID NO:73. In this case, however, the portion of the nucleic acid sequence encoding SEQ ID NO:66 (DH2 domain), which is derived from *Thraustochytrium*, is optimized for expression in *Schizochytrium* as described in the Examples.

Other codon-optimized nucleic acid sequences for use in *E. coli*, yeast and plants
10 are described above and below in the Examples.

In another embodiment, a genetically modified organism has been modified by transfecting the organism with a recombinant nucleic acid molecule encoding a protein that regulates the chain length of fatty acids produced by the PUFA PKS system. For example, the protein that regulates the chain length of fatty acids produced by the PUFA
15 PKS system can be a chain length factor that directs the synthesis of C20 units and/or C22 units.

In another embodiment, a genetically modified organism expresses a PUFA PKS system comprising a modification in an enoyl-ACP reductase (ER) domain, wherein the modification results in the production of a different compound as compared to in the
20 absence of the modification. In one aspect of this embodiment, the modification is selected from the group consisting of a deletion of all or a part of an ER domain, a substitution of an ER domain from a different organism for the ER domain, and a mutation of an ER domain.

In one embodiment of the invention, the genetically modified organism produces a
25 polyunsaturated fatty acid (PUFA) profile that differs from the naturally occurring organism without a genetic modification.

Many other genetic modifications useful for producing bioactive molecules will be apparent to those of skill in the art, given the present disclosure, and various other modifications have been discussed previously herein. The present invention contemplates
30 any genetic modification related to a PUFA PKS system as described herein which results in the production of a desired bioactive molecule.

As described above, in one embodiment of the present invention, a genetically modified organism, such as a genetically modified microorganism or plant, includes an

organism which has an enhanced ability to synthesize desired bioactive molecules (products) or which has a newly introduced ability to synthesize specific products (*e.g.*, to synthesize PUFAs, to synthesize a different profile of PUFAs, or to synthesize a specific antibiotic). According to the present invention, "an enhanced ability to synthesize" a
5 product refers to any enhancement, or up-regulation, in a pathway related to the synthesis of the product such that the microorganism or plant produces an increased amount of the product (including any production of a product where there was none before) as compared to the wild-type microorganism or plant, cultured or grown, under the same conditions. Methods to produce such genetically modified organisms have been described in detail
10 above. In one preferred embodiment, the present invention relates to a genetically modified plant or part of a plant (*e.g.*, wherein the plant has been genetically modified to express a PUFA PKS system, including a chimeric PUFA PKS system, described herein), which includes at least the core PUFA PKS enzyme complex and, in one embodiment, at least one PUFA PKS accessory protein, (*e.g.*, a PPTase), so that the plant produces
15 PUFAs. Preferably, the plant is an oil seed plant, wherein the oil seeds or oil in the oil seeds contain PUFAs produced by the PUFA PKS system. Such oils contain a detectable amount of at least one target or primary PUFA that is the product of the PUFA PKS system.

The present inventors have demonstrated the production of PUFAs in a plant that
20 has been genetically modified to express the genes encoding a PUFA PKS system from *Schizochytrium* and a PUFA PKS accessory enzyme, 4'-phosphopantetheinyl transferase (PPTase) (*e.g.*, see U.S. Patent Application Publication No. 20070089199, *supra*). The oils produced by these plants contain significant quantities of both DHA (docosahexaenoic acid (C22:6, n-3)) and DPA (docosapentaenoic acid (C22:5, n-6), which are the
25 predominant PUFAs (the primary PUFAs) produced by the *Schizochytrium* from which the PUFA PKS genes were derived. Significantly, oils from plants that produce PUFAs using the PUFA PKS pathway have a different fatty acid profile than plants that are genetically engineered to produce the same PUFAs by the "standard" pathway described above. In particular, oils from plants that have been genetically engineered to produce
30 specific PUFAs by the PUFA PKS pathway are substantially free of the various intermediate products and side products that accumulate in oils that are produced as a result of the use of the standard PUFA synthesis pathway. This characteristic is discussed in detail below.

More particularly, efforts to produce long chain PUFAs in plants by the "standard" pathway (described above) have taken the same basic approach, which is dictated by this synthesis pathway. These efforts relied on modification of the plants' endogenous fatty acids by introduction of genes encoding various elongases and desaturases. Plants typically produce 18 carbon fatty acids (e.g., oleic acid, linoleic acid, linolenic acid) via the Type II fatty acid synthase (FAS) in its plastids. Often, a single double bond is formed while that fatty acid is attached to ACP, and then the oleic acid (18:1) is cleaved from the ACP by the action of an acyl-ACP thioesterase. The free fatty acid is exported from the plastid and converted to an acyl-CoA. The 18:1 can be esterified to phosphatidylcholine (PC) and up to two more *cis* double bonds can be added. The newly introduced elongases can utilize substrates in the acyl-CoA pool to add carbons in two-carbon increments. Newly introduced desaturases can utilize either fatty acids esterified to PC, or those in the acyl-CoA pool, depending on the source of the enzyme. One consequence of this scheme for long chain PUFA production, however, is that intermediates or side products in the pathway accumulate, which often represent the majority of the novel fatty acids in the plant oil, rather than the target long chain PUFA.

For example, using the standard or classical pathway as described above, when the target PUFA product (i.e., the PUFA product that one is targeting for production, trying to produce, attempting to produce, by using the standard pathway) is DHA or EPA, for example (e.g., produced using elongases and desaturases that will produce the DHA or EPA from the products of the FAS system), a variety of intermediate products and side products will be produced in addition to the DHA or EPA, and these intermediate or side products frequently represent the majority of the products produced by the pathway, or are at least present in significant amounts in the lipids of the production organism. Such intermediate and side products include, but are not limited to, fatty acids having fewer carbons and/or fewer double bonds than the target, or primary PUFA, and can include unusual fatty acid side products that may have the same number of carbons as the target or primary PUFA, but which may have double bonds in unusual positions. By way of example, in the production of EPA using the standard pathway (e.g., see U.S. Patent Application Publication 2004/0172682), while the target PUFA of the pathway is EPA (i.e., due to the use of elongases and desaturases that specifically act on the products of the FAS system to produce EPA), the oils produced by the system include a variety of intermediate and side products including: gamma-linolenic acid (GLA; 18:3, n-6);

stearidonic acid (STA or SDA; 18:4, n-3); dihomogamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6); eicosatrienoic acid (ETA; 20:3, n-9) and various other intermediate or side products, such as 20:0; 20:1 ($\Delta 5$); 20:1 ($\Delta 11$); 20:2 ($\Delta 8,11$); 20:2 ($\Delta 11,14$); 20:3 ($\Delta 5,11,14$); 20:3 ($\Delta 11,14,17$); mead acid (20:3; $\Delta 5,8,11$); or 20:4 ($\Delta 5,1,14,17$). Intermediates of the system can also include long chain PUFAs that are not the target of the genetic modification (e.g., a standard pathway enzyme system for producing DHA can actually produce more EPA as an intermediate product than DHA).

In contrast, the PUFA PKS synthase of the present invention does not utilize the fatty acid products of FAS systems. Instead, it produces the final PUFA product (the primary PUFA product) from the same small precursor molecule that is utilized by FASs and elongases (malonyl-CoA). Therefore, intermediates in the synthesis cycle are not released in any significant amount, and the PUFA product (also referred to herein as the primary PUFA product) is efficiently transferred to phospholipids (PL) and triacylglycerol (TAG) fractions of the lipids. Indeed, a PUFA PKS system may produce two target or primary PUFA products (e.g., the PUFA PKS system from *Schizochytrium* produces both DHA and DPAn-6 as primary products), but DPA is not an intermediate in the pathway to produce DHA. Rather, each is a separate product of the same PUFA PKS system. Therefore, the PUFA PKS genes of the present invention are an excellent means of producing oils containing PUFAs, and particularly, LCPUFAs in a heterologous host, such as a plant, wherein the oils are substantially free (defined below) of the intermediates and side products that contaminate oils produced by the "standard" PUFA pathway.

Therefore, it is an object of the present invention to produce, via the genetic manipulation of plants as described herein, polyunsaturated fatty acids and, by extension, oils obtained from such plants (e.g., obtained from the oil seeds of such plants) comprising these PUFAs. Examples of PUFAs that can be produced by the present invention include, but are not limited to, DHA (docosahexaenoic acid (C22:6, n-3)), ARA (eicosatetraenoic acid or arachidonic acid (C20:4, n-6)), DPA (docosapentaenoic acid (C22:5, n-6 or n-3)), and EPA (eicosapentaenoic acid (C20:5, n-3)). The present invention allows for the production of commercially valuable lipids enriched in one or more desired (target or primary) PUFAs by the present inventors' development of genetically modified plants through the use of the polyketide synthase system of the present invention, as well as components thereof, that produces PUFAs.

According to the present invention, reference to a "primary PUFA", "target PUFA", "intended PUFA", or "desired PUFA" refers to the particular PUFA or PUFAs that are the intended or targeted product of the enzyme pathway that is used to produce the PUFA(s). For example, when using elongases and desaturases to modify products of the FAS system, one can select particular combinations of elongases and desaturases that, when used together, will produce a target or desired PUFA (e.g., DHA or EPA). As discussed above, such target or desired PUFA produced by the standard pathway may not actually be a "primary" PUFA in terms of the amount of PUFA as a percentage of total fatty acids produced by the system, due to the formation of intermediates and side products that can actually represent the majority of products produced by the system. However, one may use the term "primary PUFA" even in that instance to refer to the target or intended PUFA product produced by the elongases or desaturases used in the system.

When using a PUFA PKS system as preferred in the present invention, a given PUFA PKS system derived from a particular organism will produce particular PUFA(s), such that selection of a PUFA PKS system from a particular organism will result in the production of specified target or primary PUFAs. For example, use of a PUFA PKS system from *Schizochytrium* will result in the production of DHA and DPAn-6 as the target or primary PUFAs. Use of a PUFA PKS system from various *Shewanella* species, on the other hand, will result in the production of EPA as the target or primary PUFA. It is noted that the ratio of the primary or target PUFAs can differ depending on the selection of the particular PUFA PKS system and on how that system responds to the specific conditions in which it is expressed. For example, use of a PUFA PKS system from *Thraustochytrium* 23B (ATCC No. 20892) will also result in the production of DHA and DPAn-6 as the target or primary PUFAs; however, in the case of *Thraustochytrium* 23B, the ratio of DHA to DPAn-6 is about 10:1 (and can range from about 8:1 to about 40:1), whereas in *Schizochytrium*, the ratio is typically about 2.5:1. Therefore, use of a *Thraustochytrium* PUFA PKS system or proteins or domains can alter the ratio of PUFAs produced by an organism as compared to *Schizochytrium* even though the target PUFAs are the same. However, as in detail above, the use of various proteins and domains with proteins and domains from other PUFA PKS systems or other PKS systems (that produce bioactive molecules other than PUFAs) can be combined ("mixed and matched") to produce chimeric proteins and/or chimeric PUFA PKS systems (described above),

resulting in the production of different PUFA profiles, including different PUFA types, amounts, and/or ratios of one PUFA to another.

When using a PUFA PKS system of the present invention, oils produced by the organism, such as a plant, are substantially free of intermediate or side products that are not the target or primary PUFA products and that are not naturally produced by the endogenous FAS system in the wild-type organism (*e.g.*, wild-type plants produce some shorter or medium chain PUFAs, such as 18 carbon PUFAs, via the FAS system, but there will be new, or additional, fatty acids produced in the plant as a result of genetic modification with a PUFA PKS system). In other words, as compared to the profile of total fatty acids from the wild-type plant (not genetically modified) or the parent plant used as a recipient for the indicated genetic modification, the majority of *additional* fatty acids in the profile of total fatty acids produced by plants that have been genetically modified with the PUFA PKS system of the present invention (or a component thereof), comprise the target or intended PUFA products of the PUFA PKS system (*i.e.*, the majority of additional fatty acids in the total fatty acids that are produced by the genetically modified plant are the target PUFA(s)).

According to the present invention, reference to "intermediate products" or "side products" of an enzyme system that produces PUFAs refers to any products, and particularly, fatty acid products, that are produced by the enzyme system as a result of the production of the target or primary PUFA(s) of the system, but which are not the primary or target PUFA(s). In one embodiment, intermediate and side products may include non-target fatty acids that are naturally produced by the wild-type plant, or by the parent plant used as a recipient for the indicated genetic modification, but are now classified as intermediate or side products because they are produced in greater levels as a result of the genetic modification, as compared to the levels produced by the wild-type plant, or by the parent plant used as a recipient for the indicated genetic modification. Intermediate and side products are particularly significant in the standard pathway for PUFA synthesis and are substantially less significant in the PUFA PKS pathway, as discussed above. It is noted that a primary or target PUFA of one enzyme system may be an intermediate of a different enzyme system where the primary or target product is a different PUFA, and this is particularly true of products of the standard pathway of PUFA production, since the PUFA PKS system substantially avoids the production of intermediates. For example, when using the standard pathway to produce EPA, fatty acids such as GLA, DGLA and

SDA are produced as intermediate products in significant quantities (e.g., U.S. Patent Application Publication 2004/0172682 illustrates this point). Similarly, and also illustrated by U.S. Patent Application Publication 2004/0172682, when using the standard pathway to produce DHA, in addition to the fatty acids mentioned above, ETA and EPA (notably the target PUFA in the first example above) are produced in significant quantities and in fact, may be present in significantly greater quantities relative to the total fatty acid product than the target PUFA itself. This latter point is also shown in U.S. Patent Application Publication 2004/0172682, where a plant that was engineered to produce DHA by the standard pathway produces more EPA as a percentage of total fatty acids than the targeted DHA.

Furthermore, to be "substantially free" of intermediate or side products of the system for synthesizing PUFAs, or to not have intermediate or side products present in substantial amounts, means that any intermediate or side product fatty acids (non-target PUFAs) that are produced in the genetically modified plant (and/or parts of plants and/or seed oil fraction) as a result of the introduction or presence of the enzyme system for producing PUFAs (i.e., that are not produced by the wild-type plant or the parent plant used as a recipient for the indicated genetic modification), are present in a quantity that is less than about 10% by weight of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% by weight of the total fatty acids produced by the plant, and more preferably less than about 0.5% by weight of the total fatty acids produced by the plant.

In a preferred embodiment, to be "substantially free" of intermediate or side products of the system for synthesizing PUFAs, or to not have intermediate or side products present in substantial amounts, means that any intermediate or side product fatty acids that are produced in the genetically modified plant (and/or parts of plants and/or in seed oil fraction) as a result of the enzyme system for producing PUFAS (i.e., that are not produced by the wild-type plant or by the parent plant used as a recipient for the indicated genetic modification for production of target PUFAs), are present in a quantity that is less than about 10% by weight of the total additional fatty acids produced by the plant

(additional fatty acids being defined as those fatty acids or levels of fatty acids that are not naturally produced by the wild-type plant or by the parent plant that is used as a recipient for the indicated genetic modification for production of target PUFAs), and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of the total additional fatty acids produced by the plant. Therefore, in contrast to the fatty acid profile of plants that have been genetically modified to produce PUFAs via the standard pathway, the majority of fatty acid products resulting from the genetic modification with a PUFA PKS system will be the target or intended fatty acid products.

When the target product of a PUFA PKS system is a long chain PUFA, such as DHA or DPA (n-6 or n-3) produced by the PUFA PKS system of the invention described herein, intermediate products and side products that are not present in substantial amounts in the total lipids of plants genetically modified with such PUFA PKS can include, but are not limited to: gamma-linolenic acid (GLA; 18:3, n-6); stearidonic acid (STA or SDA; 18:4, n-3); dihomo-gamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6); eicosatrienoic acid (ETA; 20:3, n-9) and various other intermediate or side products, such as 20:0; 20:1 ($\Delta 5$); 20:1 ($\Delta 11$); 20:2 ($\Delta 8,11$); 20:2 ($\Delta 11,14$); 20:3 ($\Delta 5,11,14$); 20:3 ($\Delta 11,14,17$); mead acid (20:3; $\Delta 5,8,11$); or 20:4 ($\Delta 5,1,14,17$). In addition, when the target product is a particular PUFA, such as DHA, the intermediate products and side products that are not present in substantial amounts in the total lipids of the genetically modified plants also include other PUFAs, including other PUFAs that are a natural product of a different PUFA PKS system, such as EPA in this example. In some systems, a PUFA PKS system may make more than one PUFA, such as both a C22 and a C20 PUFA, and such combinations of PUFA may represent the target product, while other PUFAs may represent intermediate or side products. It is to be noted that the PUFA PKS system of the present invention can also be used, if desired, to produce as a target PUFA a PUFA that can include GLA, SDA or DGLA (referring to embodiments where oils are produced using components of a PUFA PKS system described herein).

Using the knowledge of the genetic basis and domain structure of the PUFA PKS system described herein, the present inventors have designed and produced constructs

encoding such a PUFA PKS system and have successfully produced transgenic plants expressing the PUFA PKS system. The transgenic plants produce oils containing PUFAs, and the oils are substantially free of intermediate products that accumulate in a standard PUFA pathway (see U.S. Patent Application Publication No. 20070089199, *supra*). The present inventors have also demonstrated the use of the constructs to produce PUFAs in *E. coli*, and also in another eukaryote, yeast, as a proof-of-concept experiment prior to the production of the transgenic plants (U.S. Patent Application Publication No. 20070089199, *supra*). The examples demonstrate that transformation of both yeast and plants with a PUFA PKS system that produces DHA and DPAn-6 as the target PUFAs produces both of these PUFAs as the primary additional fatty acids in the total fatty acids of the plant (*i.e.*, subtracting fatty acids that are produced in the wild-type plant), and in the yeast and further, that any other fatty acids that are not present in the fatty acids of the wild-type plant are virtually undetectable. Specific characteristics of genetically modified plants and parts and oils thereof of the present invention are described in detail elsewhere herein.

Accordingly, one embodiment of the present invention is a method to produce desired bioactive molecules (also referred to as products or compounds) by growing or culturing a genetically modified microorganism or a genetically modified plant of the present invention (described in detail above). Such a method includes the step of culturing in a growth or fermentation medium or growing in a suitable environment, such as soil, a microorganism or plant, respectively, that has a genetic modification as described previously herein and in accordance with the present invention. In a preferred embodiment, the method to produce bioactive molecules of the present invention includes the step of culturing under conditions effective to produce the bioactive molecule a genetically modified organism that expresses a PKS system comprising at least one biologically active domain of a polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) system as described herein.

In the method of production of desired bioactive compounds of the present invention, a genetically modified microorganism is cultured or grown in a suitable medium, under conditions effective to produce the bioactive compound. An appropriate, or effective, medium refers to any medium in which a genetically modified microorganism of the present invention, when cultured, is capable of producing the desired product. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and

phosphate sources. Such a medium can also include appropriate salts, minerals, metals and other nutrients. Microorganisms of the present invention can be cultured in conventional fermentation bioreactors. The microorganisms can be cultured by any fermentation process which includes, but is not limited to, batch, fed-batch, cell recycle, and continuous fermentation. Preferred growth conditions for potential host microorganisms according to the present invention are well known in the art. The desired bioactive molecules produced by the genetically modified microorganism can be recovered from the fermentation medium using conventional separation and purification techniques. For example, the fermentation medium can be filtered or centrifuged to remove microorganisms, cell debris and other particulate matter, and the product can be recovered from the cell-free supernatant by conventional methods, such as, for example, ion exchange, chromatography, extraction, solvent extraction, membrane separation, electrodialysis, reverse osmosis, distillation, chemical derivatization and crystallization. Alternatively, microorganisms producing the desired compound, or extracts and various fractions thereof, can be used without removal of the microorganism components from the product.

In the method for production of desired bioactive compounds of the present invention, a genetically modified plant or plant part (including a plant cell) is cultured in a growth medium or grown in a suitable medium such as soil, as appropriate. An appropriate, or effective, growth or culture medium has been discussed in detail above. A suitable growth medium for higher plants includes any growth medium for plants, including, but not limited to, soil, sand, any other particulate media that support root growth (e.g. vermiculite, perlite, etc.) or Hydroponic culture, as well as suitable light, water and nutritional supplements which optimize the growth of the higher plant. The genetically modified plants of the present invention are engineered to produce significant quantities of the desired product through the activity of the PUFA PKS system that is genetically modified according to the present invention. The compounds can be recovered through purification processes which extract the compounds from the plant. In a preferred embodiment, the compound is recovered by harvesting the plant. In a particularly preferred embodiment, PUFAs are recovered from the plant or plant part by harvesting the oil from the plant or plant part (e.g., from the oil seeds). In this embodiment, the plant can be consumed in its natural state or further processed into consumable products.

Bioactive molecules, according to the present invention, include any molecules (compounds, products, etc.) that have a biological activity, and that can be produced by a PKS system that comprises at least one amino acid sequence having a biological activity of at least one functional domain of a non-bacterial PUFA PKS system as described
5 herein. Such bioactive molecules can include, but are not limited to: a polyunsaturated fatty acid (PUFA), an anti-inflammatory formulation, a chemotherapeutic agent, an active excipient, an osteoporosis drug, an anti-depressant, an anti-convulsant, an anti-*Helicobacter pylori* drug, a drug for treatment of neurodegenerative disease, a drug for treatment of degenerative liver disease, an antibiotic, and a cholesterol lowering formulation. One
10 advantage of the non-bacterial PUFA PKS system of the present invention is the ability of such a system to introduce carbon-carbon double bonds in the *cis* configuration, and molecules including a double bond at every third carbon. This ability can be utilized to produce a variety of compounds.

With respect to microorganisms, preferably, bioactive compounds of interest are
15 produced by the genetically modified microorganism in an amount that is greater than about 0.05%, and preferably greater than about 0.1%, and more preferably greater than about 0.25%, and more preferably greater than about 0.5%, and more preferably greater than about 0.75%, and more preferably greater than about 1%, and more preferably greater than about 2.5%, and more preferably greater than about 5%, and more preferably greater
20 than about 10%, and more preferably greater than about 15%, and even more preferably greater than about 20% of the dry weight of the microorganism. For lipid compounds, preferably, such compounds are produced in an amount that is greater than about 5% of the dry weight of the microorganism. Other bioactive compounds, such as antibiotics or compounds that are synthesized in smaller amounts may be produced in quantities known
25 to those of skill in the art, and those strains possessing such compounds are identified as predictably containing a novel PKS system of the type described herein.

In some embodiments, particular bioactive molecules (compounds) are secreted by the microorganism, rather than accumulating in the cells. Therefore, such bioactive molecules are generally recovered from the culture medium and the concentration of the
30 molecule produced will vary depending on the microorganism and the size of the culture., and may be measured in g/L, rather than by dry cell weight.

Preferably, a genetically modified organism (*e.g.*, microorganism or plant) of the invention produces one or more polyunsaturated fatty acids including, but not limited to,

EPA (C20:5, n-3), DHA (C22:6, n-3), DPA (C22:5, n-6 or n-3), ARA (C20:4, n-6), GLA (C18:3, n-6), ALA (C18:3, n-3), and/or SDA (C18:4, n-3)), and more preferably, one or more long chain fatty acids (LCPUFAs), including, but not limited to, EPA (C20:5, n-3), DHA (C22:6, n-3), DPA (C22:5, n-6 or n-3), or DTA (C22:4, n-6). In a particularly preferred embodiment, a genetically modified organism of the invention produces one or more polyunsaturated fatty acids including, but not limited to, EPA (C20:5, n-3), DHA (C22:6, n-3), and/or DPA (C22:5, n-6 or n-3).

Preferably, a genetically modified organism of the invention produces at least one PUFA (the target PUFA), wherein the total fatty acid profile in the organism (or a part of the organism that accumulates PUFAs, such as mature seeds or oil from such seeds, if the organism is an oil seed plant), comprises a detectable amount of this PUFA or PUFAs. Preferably, the PUFA is at least a 20 carbon PUFA and comprises at least 3 double bonds, and more preferably at least 4 double bonds, and even more preferably, at least 5 double bonds. In one embodiment, the PUFA is a PUFA that is not naturally produced by the organism in detectable or significant quantities (*e.g.*, the wild-type organism in the absence of genetic modification, or the parent organism used as a recipient for the indicated genetic modification).

Preferably, the total fatty acid profile in the organism (or part of the organism that accumulates PUFAs) comprises at least 0.1% of the target PUFA(s) by weight of the total fatty acids, and more preferably at least about 0.2%, and more preferably at least about 0.3%, and more preferably at least about 0.4%, and more preferably at least about 0.5%, and more preferably at least about 1%, and more preferably at least about 2 %, and more preferably at least about 3%, and more preferably at least about 4%, and more preferably at least about 5%, and more preferably at least about 10%, and more preferably at least about 15%, and more preferably at least about 20%, and more preferably at least about 25%, and more preferably at least about 30%, and more preferably at least about 35%, and more preferably at least about 40%, and more preferably at least about 45%, and more preferably at least about 50%, and more preferably at least about 55%, and more preferably at least about 60%, and more preferably at least about 65%, and more preferably at least about 70%, and more preferably at least about 75%, and more preferably more than 75% of at least one polyunsaturated fatty acid (the target PUFA) by weight of the total fatty acids, or any percentage from 0.1% to 75%, or greater than 75% (up to 100% or about 100%), in 0.1% increments, of the target PUFA(s). As generally

used herein, reference to a percentage amount of PUFA production is by weight of the total fatty acids produced by the organism, unless otherwise stated (*e.g.*, in some cases, percentage by weight is relative to the total fatty acids produced by an enzyme complex, such as a PUFA PKS system). In one embodiment, total fatty acids produced by a plant
5 are presented as a weight percent as determined by gas chromatography (GC) analysis of a fatty acid methyl ester (FAME) preparation.

As described above, it is an additional characteristic of the total fatty acids produced by the above-described plant (and/or parts of plants or seed oil fraction) that these total fatty acids produced by the plant comprise less than (or do not contain any
10 more than) about 10% by weight of any fatty acids, other than the target PUFA(s) that are produced by the enzyme complex that produces the target PUFA(s). Preferably, any fatty acids that are produced by the enzyme complex that produces the target PUFA(s) (*e.g.*, as a result of genetic modification of the plant with the enzyme or enzyme complex that produces the target PUFA(s)), other than the target PUFA(s), are present at less than about
15 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% by weight of the total fatty acids produced by the plant.

20 In another embodiment, any fatty acids that are produced by the enzyme complex that produces the target PUFA(s) other than the target PUFA(s) are present at less than (or do not contain any more than) about 10% by weight of the total fatty acids that are produced by the enzyme complex that produces the target PUFA(s) in the plant (*i.e.*, this measurement is limited to those total fatty acids that are produced by the enzyme complex
25 that produces the target PUFAs), and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% by weight of the
30 total fatty acids, and more preferably less than about 0.5% by weight of the total fatty acids that are produced by the enzyme complex that produces the target PUFA(s) in the plant.

In another aspect of this embodiment of the invention, the total fatty acids produced by the plant (and/or parts of plants or seed oil fraction) contain less than (or do not contain any more than) 10% PUFAs having 18 or more carbons by weight of the total fatty acids produced by the plant, other than the target PUFA(s) or the PUFAs that are present in the wild-type plant (not genetically modified) or in the parent plant used as a recipient for the indicated (initial or sequential) genetic modification. In further aspects, the total fatty acids produced by the plant (and/or parts of plants or seed oil fraction) contain less than 9% PUFAs having 18 or more carbons, or less than 8% PUFAs having 18 or more carbons, or less than 7% PUFAs having 18 or more carbons, or less than 6% PUFAs having 18 or more carbons, or less than 5% PUFAs having 18 or more carbons, or less than 4% PUFAs having 18 or more carbons, or less than 3% PUFAs having 18 or more carbons, or less than 2% PUFAs having 18 or more carbons, or less than 1% PUFAs having 18 or more carbons by weight of the total fatty acids produced by the plant, other than the target PUFA(s) or the PUFAs that are present in the wild-type plant (not genetically modified) or the parent plant used as a recipient for the indicated genetic modification.

In another aspect of this embodiment of the invention, the total fatty acids produced by the plant (and/or parts of plants or seed oil fraction) contain less than (or do not contain any more than) 10% PUFAs having 20 or more carbons by weight of the total fatty acids produced by the plant, other than the target PUFA(s) or the PUFAs that are present in the wild-type plant (not genetically modified) or the parent plant used as a recipient for the indicated (initial or sequential) genetic modification. In further aspects, the total fatty acids produced by the plant (and/or parts of plants or seed oil fraction) contain less than 9% PUFAs having 20 or more carbons, or less than 8% PUFAs having 20 or more carbons, or less than 7% PUFAs having 20 or more carbons, or less than 6% PUFAs having 20 or more carbons, or less than 5% PUFAs having 20 or more carbons, or less than 4% PUFAs having 20 or more carbons, or less than 3% PUFAs having 20 or more carbons, or less than 2% PUFAs having 20 or more carbons, or less than 1% PUFAs having 20 or more carbons by weight of the total fatty acids produced by the plant, other than the target PUFA(s) or the PUFAs that are present in the wild-type plant (not genetically modified) or the parent plant used as a recipient for the indicated genetic modification.

In one embodiment, the total fatty acids in the plant (and/or parts of plants or seed oil fraction) contain less than about 10% by weight of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of a fatty acid selected from any one or more of: gamma-linolenic acid (GLA; 18:3, n-6); stearidonic acid (STA or SDA; 18:4, n-3); dihomo-gamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6); eicosatrienoic acid (ETA; 20:3, n-9) and various other fatty acids, such as 20:0; 20:1 (Δ 5); 20:1 (Δ 11); 20:2 (Δ 8,11); 20:2 (Δ 11,14); 20:3 (Δ 5,11,14); 20:3 (Δ 11,14,17); mead acid (20:3; Δ 5,8,11); or 20:4 (Δ 5,1,14,17).

In another embodiment, the fatty acids that are produced by the enzyme system that produces the long chain PUFAs in the plant contain less than about 10% by weight of a fatty acid selected from: gamma-linolenic acid (GLA; 18:3, n-6); stearidonic acid (STA or SDA; 18:4, n-3); dihomo-gamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6); eicosatrienoic acid (ETA; 20:3, n-9) and various other fatty acids, such as 20:0; 20:1 (Δ 5); 20:1 (Δ 11); 20:2 (Δ 8,11); 20:2 (Δ 11,14); 20:3 (Δ 5,11,14); 20:3 (Δ 11,14,17); mead acid (20:3; Δ 5,8,11); or 20:4 (Δ 5,1,14,17), as a percentage of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of a fatty acid selected from: gamma-linolenic acid (GLA; 18:3, n-6); stearidonic acid (STA or SDA; 18:4, n-3); dihomo-gamma-linolenic acid (DGLA or HGLA; 20:3, n-6), arachidonic acid (ARA, C20:4, n-6); eicosatrienoic acid (ETA; 20:3, n-9) and various other fatty acids, such as 20:0; 20:1 (Δ 5); 20:1 (Δ 11); 20:2 (Δ 8,11); 20:2 (Δ 11,14); 20:3 (Δ 5,11,14); 20:3 (Δ 11,14,17); mead acid (20:3; Δ 5,8,11); or 20:4 (Δ 5,1,14,17).

In another embodiment, the fatty acids that are produced by the enzyme system that produces the long chain PUFAs in the plant contain less than about 10% by weight of all of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three

carbon-carbon double bonds, and PUFAs having 22 carbons and two or three carbon-carbon double bonds, as a percentage of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of all of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three carbon-carbon double bonds, and PUFAs having 22 carbons and two or three carbon-carbon double bonds.

In another embodiment, the fatty acids that are produced by the enzyme system that produces the long chain PUFAs in the plant contain less than about 10% by weight of each of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three carbon-carbon double bonds, and PUFAs having 22 carbons and two or three carbon-carbon double bonds, as a percentage of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of each of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three carbon-carbon double bonds, and PUFAs having 22 carbons and two or three carbon-carbon double bonds.

In another embodiment, the fatty acids that are produced by the enzyme system that produces the long chain PUFAs in the plant contain less than about 10% by weight of any one or more of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three carbon-carbon double bonds, and PUFAs having 22 carbons and two or three carbon-carbon double bonds, as a percentage of the total fatty acids produced by the plant, and more preferably less than about 9%, and more preferably less than about 8%, and more preferably less than about 7%, and more preferably less than about 6%, and more preferably less than about 5%, and more preferably less than about 4%, and more

preferably less than about 3%, and more preferably less than about 2%, and more preferably less than about 1% of any one or more of the following PUFAs: gamma-linolenic acid (GLA; 18:3, n-6), PUFAs having 18 carbons and four carbon-carbon double bonds, PUFAs having 20 carbons and three carbon-carbon double bonds, and PUFAs
5 having 22 carbons and two or three carbon-carbon double bonds.

In one aspect of this embodiment of the invention, the plant produces at least two target PUFAs, and the total fatty acid profile in the plant, or the part of the plant that accumulates PUFAs (including oils from the oil seeds), comprises a detectable amount of these PUFAs. In this embodiment, the PUFAs are preferably each at least a 20 carbon
10 PUFA and comprise at least 3 double bonds, and more preferably at least 4 double bonds, and even more preferably, at least 5 double bonds. Such PUFAs are most preferably chosen from DHA, DPA n-6 and EPA. In one aspect, the plant produces DHA and DPA n-6, and the ratio of DHA to DPA n-6 is from about 1:10 to about 10:1 or greater, including any ratio in between. In a one embodiment, the ratio of DHA to DPA is from about 1:1 to
15 about 3:1, and in another embodiment, about 2.5:1. In one embodiment, the plant produces DHA and EPA.

The invention further includes any seeds produced by the plants described above, as well as any plant parts, oils produced by the plants or seeds produced by the plants. The invention also includes any products produced using the plants, plant parts, seed or
20 oils described herein.

One embodiment of the present invention relates to a method to modify an endproduct containing at least one fatty acid, comprising adding to said endproduct an oil produced by a recombinant host cell that expresses at least one recombinant nucleic acid molecule comprising a nucleic acid sequence encoding at least one biologically active
25 domain of a PUFA PKS system as described herein.

Preferably, the endproduct is selected from the group consisting of a food, a dietary supplement, a pharmaceutical formulation, a humanized animal milk, and an infant formula. Suitable pharmaceutical formulations include, but are not limited to, an anti-inflammatory formulation, a chemotherapeutic agent, an active excipient, an osteoporosis
30 drug, an anti-depressant, an anti-convulsant, an anti-*Helicobacter pylori* drug, a drug for treatment of neurodegenerative disease, a drug for treatment of degenerative liver disease, an antibiotic, and a cholesterol lowering formulation. In one embodiment, the endproduct is used to treat a condition selected from the group consisting of: chronic inflammation,

acute inflammation, gastrointestinal disorder, cancer, cachexia, cardiac restenosis, neurodegenerative disorder, degenerative disorder of the liver, blood lipid disorder, osteoporosis, osteoarthritis, autoimmune disease, preeclampsia, preterm birth, age related maculopathy, pulmonary disorder, and peroxisomal disorder.

Suitable food products include, but are not limited to, fine bakery wares, bread and rolls, breakfast cereals, processed and unprocessed cheese, condiments (ketchup, mayonnaise, etc.), dairy products (milk, yogurt), puddings and gelatine desserts, carbonated drinks, teas, powdered beverage mixes, processed fish products, fruit-based drinks, chewing gum, hard confectionery, frozen dairy products, processed meat products, nut and nut-based spreads, pasta, processed poultry products, gravies and sauces, potato chips and other chips or crisps, chocolate and other confectionery, soups and soup mixes, soya based products (milks, drinks, creams, whiteners), vegetable oil-based spreads, and vegetable-based drinks.

Yet another embodiment of the present invention relates to a method to produce a humanized animal milk. This method includes the steps of genetically modifying milk producing cells of a milk-producing animal with at least one recombinant nucleic acid molecule comprising a nucleic acid sequence encoding at least one biologically active domain of a PUFA PKS system as described herein.

Methods to genetically modify a host cell and to produce a genetically modified non-human, milk-producing animal, are known in the art. Examples of host animals to modify include cattle, sheep, pigs, goats, yaks, etc., which are amenable to genetic manipulation and cloning for rapid expansion of a transgene expressing population. For animals, PKS-like transgenes can be adapted for expression in target organelles, tissues and body fluids through modification of the gene regulatory regions. Of particular interest is the production of PUF As in the breast milk of the host animal.

Each publication or reference cited herein is incorporated herein by reference in its entirety.

Any reference to or discussion of any document, act or item of knowledge in this specification is included solely for the purpose of providing a context for the present invention.

It is not suggested or represented that any of these matters or any combination thereof formed at the priority date part of the common general knowledge, or was known to be relevant to an attempt to solve any problem with which this specification is concerned.

5 It is to be noted that, throughout the description and claims of this specification, the word 'comprise' and variations of the word, such as 'comprising' and 'comprises', is not intended to exclude other variants or additional components, integers or steps. Modifications and improvements to the invention will be readily apparent to those skilled in the art. Such modifications and improvements are intended to be within the scope of this invention.

The following examples are provided for the purpose of illustration and are not intended to limit the scope of the present invention.

Examples

0 Example 1

The following example describes the construction of a synthetic *Th.23B* OrfC cloning vector for use in *Schizochytrium*.

Codon usage data for four large genes from *Schizochytrium* (e.g., ATCC 20888 or *Schizochytrium* N230D) (orfA, orfB, orfC, and FAS; described in U.S. Patent Application Publication No. 20020194641, U.S. Patent Application Publication No. 20070089199, or U.S. Patent Application Publication No. 20050191679) were combined. Given that *Schizochytrium* ATCC 20888 produces high levels of fatty acids, it is expected that these genes are highly expressed. Codons with less than about 3% representation (within those for a given amino acid) were eliminated, and the relative usage of the remaining codons was adjusted. Table 1 shows *Schizochytrium* codon usage, adjusted usage, and codon usage for non-synthetic *Th.23B* orfC. DNA2.0 (Menlo Park, CA) was used to analyze these codon usage data to design and synthesize a coding region for *Thraustochytrium* 23B orfC. Nucleotides were added to both ends of the coding region to encode restriction enzyme recognition sites that would facilitate subsequent manipulation of the synthetic gene. A small number of codons were adjusted (without changing the encoded amino acid of SEQ ID NO:62) to eliminate or add certain restriction enzyme recognition sequences (see below for an example). The resultant synthetic sequence was developed by DNA2.0 within a plasmid vector and is shown in Fig. 2B as “pThOrfC synth”. Table 1 shows the codon usage of the synthetic coding region.

Table 1.

amino acid	codon	Schizo A, B & C plus FAS		Adjusted/Target Usage	Th.23B orfC		synthetic Th.23B orfC	
		number	fraction		number	fraction	number	fraction
Arg	CGG	7	0.013	0	13	0.18	0	0
Arg	CGA	6	0.011	0	13	0.18	0	0
Arg	CGT	94	0.173	0.21	17	0.24	11	0.15
Arg	CGC	436	0.803	0.79	17	0.24	61	0.85
Arg	AGG	0	0.000	0.00	9	0.13	0	0
Arg	AGA	0	0.000	0.00	3	0.04	0	0
Ser	TCG	244	0.327	0.34	19	0.19	32	0.33
Ser	TCA	10	0.013	0.00	16	0.16	0	0
Ser	TCT	64	0.086	0.10	12	0.12	10	0.10
Ser	TCC	230	0.308	0.29	19	0.19	32	0.33
Ser	AGT	19	0.025	0.00	12	0.12	0	0
Ser	AGC	179	0.240	0.27	20	0.20	24	0.24
Leu	CTG	111	0.123	0.13	36	0.28	13	0.10
Leu	CTA	2	0.002	0.00	7	0.05	0	0
Leu	CTT	148	0.164	0.18	33	0.26	33	0.26

amino acid	codon	Schizo A, B & C plus FAS		Adjusted/Target Usage	Th.23B orfC		synthetic Th.23B orfC	
		number	fraction	fraction	number	fraction	number	fraction
Leu	CTC	623	0.690	0.69	27	0.21	82	0.64
Leu	TTG	18	0.020	0.00	21	0.16	0	0
Leu	TTA	1	0.001	0.00	4	0.03	0	0
Gly	GGG	7	0.009	0.00	21	0.18	0	0
Gly	GGA	38	0.047	0.04	33	0.29	5	0.04
Gly	GGT	174	0.216	0.25	17	0.15	35	0.30
Gly	GGC	585	0.728	0.71	44	0.38	75	0.65
Val	GTG	198	0.242	0.29	44	0.38	29	0.25
Val	GTA	4	0.005	0.00	14	0.12	0	0
Val	GTT	103	0.126	0.13	34	0.29	18	0.16
Val	GTC	512	0.627	0.58	24	0.21	69	0.59
Ala	GCG	214	0.159	0.17	21	0.18	20	0.17
Ala	GCA	41	0.031	0.00	36	0.31	0	0
Ala	GCT	236	0.176	0.21	33	0.28	25	0.22
Ala	GCC	853	0.635	0.62	26	0.22	71	0.61
Thr	ACG	156	0.297	0.28	19	0.30	21	0.33
Thr	ACA	13	0.025	0.00	8	0.13	0	0
Thr	ACT	71	0.135	0.22	16	0.25	10	0.16
Thr	ACC	285	0.543	0.50	20	0.32	32	0.51
Pro	CCG	195	0.340	0.32	19	0.24	27	0.35
Pro	CCA	12	0.021	0.00	17	0.22	0	0
Pro	CCT	116	0.202	0.27	29	0.37	19	0.24
Pro	CCC	250	0.436	0.41	13	0.17	32	0.41
Ile	ATA	0	0.000	0.00	2	0.03	0	0
Ile	ATT	136	0.298	0.28	40	0.57	16	0.23
Ile	ATC	320	0.702	0.72	28	0.40	54	0.77
Glu	GAG	683	0.912	0.90	47	0.56	77	0.92
Glu	GAA	66	0.088	0.10	37	0.44	7	0.08
Asp	GAT	143	0.237	0.26	33	0.37	22	0.24
Asp	GAC	460	0.763	0.74	57	0.63	68	0.76
Lys	AAG	551	0.960	0.90	40	0.48	73	0.88
Lys	AAA	23	0.040	0.10	43	0.52	10	0.12
Asn	AAT	22	0.062	0.11	12	0.21	6	0.10
Asn	AAC	331	0.938	0.89	46	0.79	52	0.90
Cys	TGT	7	0.050	0.06	12	0.36	4	0.12
Cys	TGC	134	0.950	0.94	21	0.64	29	0.88
Tyr	TAT	13	0.057	0.39	15	0.34	14	0.32

amino acid	codon	Schizo A, B & C plus FAS		Adjusted/Target Usage	Th.23B orfC		synthetic Th.23B orfC	
		number	fraction	fraction	number	fraction	number	fraction
Tyr	TAC	214	0.943	0.61	29	0.66	30	0.68
Phe	TTT	160	0.451	0.47	44	0.62	28	0.39
Phe	TTC	195	0.549	0.43	27	0.38	43	0.61
Gln	CAG	306	0.924	0.90	26	0.47	50	0.91
Gln	CAA	25	0.076	0.10	29	0.53	5	0.09
His	CAT	29	0.173	0.15	10	0.32	7	0.23
His	CAC	139	0.827	0.85	21	0.68	24	0.77
Met	ATG	291	1.00	1	46	1	46	1
Trp	TGG	104	1.00	1	19	1	19	1

As described above, previous work by the present inventors and colleagues (see Example 8 in U.S. Patent Application Publication No. 20050100995) resulted in the creation of a plasmid in which the (non-synthetic) *Th.23B* orfC coding region was cloned between the *Schizochytrium* orfC upstream and downstream non-coding regions such that a “perfect stitch” with the *Th.23B* coding region was generated. Intermediate plasmids in this process can be used to clone the synthetic *Th.23B* orfC coding region (see Figs. 2A and 2B). In order to most easily utilize one of these intermediate constructs, a 283bp nucleotide sequence was designed by the inventors and synthesized by DNA2.0 to create the “perfect stitch” junctions and to utilize restriction sites within the *Schizochytrium* orfC upstream/downstream regions and designed into the synthetic *Th.23B* orfC gene for subsequent cloning reactions. This short DNA sequence was designated “Th23B synth orfC INT” and was contained within the plasmid “pThOrfC stitch INT”.

The 283bp “Th23B synth orfC INT” consists of five segments. The first segment consists of the final 102 bp of the *Schizochytrium* orfC upstream (non-coding) region from a *SpeI* site up to but not including the ATG start codon of *Schizochytrium* orfC (see SEQ ID NO:77). The second segment consists of the initial 9 bp of the synthetic *Th.23B* orfC coding region (SEQ ID NO:61) and contains the start ATG overlapping a designed *SanDI* site (GGGTCCC). These segments create the upstream “perfect stitch” junction. The third segment is a 6bp *BamHI* restriction site (GGATCC) that functions as a spacer. The fourth segment consists of the final 45bp of the *Th.23B* orfC coding region (SEQ ID NO:61) from a designed *ClaI* site to the TAA stop codon. The fifth segment consists of

the initial 121bp of the *Schizochytrium* orfC (non-coding) downstream region (not including the stop codon) to a “reverse” *BsmI* site. The final six nucleotides of the “Th23B synth orfC INT” fragment in the “forward” orientation are 5’>GCATTC>3’. The reverse complement 5’>GAATGC>3’ is the recognition sequence for *BsmI*. The fourth and fifth segments create the downstream “perfect stitch” junction.

Construction details of the “perfect stitch” version of the synthetic *Th.23B* orfC coding sequence is given below (see also Figs. 2A and 2B).

Step 1 (Fig. 2A). The “Th23B synth orfC INT” fragment from pThOrfC stitch INT was removed by digestion with *SpeI* and *BsmI* restriction enzymes, and the fragment was purified by agarose gel electrophoresis (GeneClean Turbo kit, QBioGene). Similarly, the large *SpeI/BsmI* vector fragment from pREZ22 (see U.S. Patent Application Publication No. 20050100995), containing about 2000bp each of the *Schizochytrium* orfC upstream and downstream regions separated by a *BamHI* recognition site spacer cloned into pBlueScriptII SK(+) was obtained. These two fragments were ligated and transformed into *E. coli* XL-1 Blue (Stratagene, La Jolla, CA). Clones containing the desired plasmid, “pREZ22 orfC INT”, were identified by restriction digests and partial DNA sequencing. This plasmid contains the *Schizochytrium* orfC upstream and downstream regions perfectly stitched to the 5-prime and 3-prime regions, respectively, of the synthetic orfC coding region, but is lacking the bulk of the coding region.

Step 2 (Fig. 2B). The bulk of the synthetic *Th.23B* orfC coding region was obtained from “pThOrfC synth” by digestion with *SalDI* and *ClaI* restriction enzymes and purification of the desired DNA fragment (as above). This fragment was ligated into a similarly obtained vector fragment from pREZ22 orfC INT and cloned into *E. coli* (as above). The resulting plasmid, “pThOrfC-synPS”, contains the full length synthetic *Th.23B* orfC coding region perfectly stitched to the upstream and downstream regions of the *Schizochytrium* orfC gene. The nucleotide sequence of the coding region of pThOrfC-synPS is represented herein by SEQ ID NO:70. SEQ ID NO:70 encodes SEQ ID NO:62. pThOrfC-synPS has been deposited as ATCC Accession No. PTA-8229, as described previously herein.

Example 2

The following example describes the creation of a construct encoding *Schizochytrium* OrfC comprising a DH2 domain from *Thraustochytrium* 23B.

The DH2 region of *Schizochytrium* ATCC20888 OrfC (SEQ ID NO:30) was replaced with that from *Thraustochytrium* 23B ATCC 20892 (SEQ ID NO:66) at specific 5-prime and 3-prime cross-over points by a combination of PCR-based overlap extension (“Splicing by Overlap Extension” or “SOEing” (Horton, R.M., (1993) *In Vitro* 5 Recombination and Mutagenesis of DNA. SOEing together tailor-made genes. *Methods in molecular Biology* Vol. 15: *PCR Protocols: Current Methods and Applications* Chapter 25 pp 251-266 (B.A. White, Ed.) Humana Press, Totawa, NJ)) and restriction cloning.

More specifically, in this example, the inventors constructed a nucleic acid molecule encoding a hybrid (chimeric) OrfC polypeptide (amino acid sequence 10 represented herein by SEQ ID NO:74), 1493 amino acid residues in length, in which the DH2 region, defined as amino acids 516–1041 of this hybrid, consists of the amino acid sequence of the DH2 region of the *Th.23B* OrfC protein; that is, amino acids 491–1016 of SEQ ID NO:62, which includes all of SEQ ID NO:66 (described as the DH2 domain of *Thraustochytrium* 23B herein). The remainder of the hybrid OrfC amino acid sequence, 15 residues 1–515 and 1042–1493 of SEQ ID NO:74, are identical to *Schizochytrium* OrfC residues 1–515 and 1051–1502 of SEQ ID NO:6, respectively.

The construction of the plasmid encoding this chimeric protein is illustrated in Figs. 3A-3C.

Step 1 Primers prREZ197 (SEQ ID NO:78) and prREZ198 (SEQ ID NO:79) were 20 used to amplify approximately 1.5Kb of the *Schizochytrium* orfC reading frame upstream of the DH2 region using the unmodified *Schizochytrium* orfC gene as a template:

prREZ197 CATATGGCGCTCCGTGTCAA

prREZ198 GCCAGGAAGCTTTGACATGGGGTGCCAGGACATCT

Primer prREZ197 created an *NdeI* site (underlined) at the start ATG codon. 25 Reverse primer prREZ198 (35mer) contained the 5-prime cross-over point generated by 20bp of homology to *Schizochytrium* OrfC sequence (bold type) and 15bp of homology to *Th.23B* OrfC sequence. PCR conditions: 50μL reaction, 1μL *PfuUltra* polymerase (Stratagene) and 1X *PfuUltra* buffer, 2% DMSO, 0.5μM each dNTP, 0.4μM each prRZ197 and prRZ198, 10ng template (cloned *Schizochytrium* orfC coding region), 1 min. 30 initial denaturation at 94°C, 20 cycles of 1 min. denaturation at 94°C, 1 min. annealing at 52°C, 90 sec. extension at 72°C, and 10 min. final extension. The PCR product was purified following agarose gel electrophoresis using the QIAquick® Gel Extraction Kit (Qiagen, Valencia, CA).

Step 2 Primers prREZ199 (SEQ ID NO:80) and prREZ200 (SEQ ID NO:81) were used to amplify the *Th.23B* DH2 region (approximately 1.5Kb) using the *Th.23B* orfC gene as a template.

prREZ199 **TCCTGGCACCCCATGTCAAAGCTTCCTGGCAACCCTA**

5 prREZ200 AGTATACAGAGGTGCTGACA

Primer prREZ199 (37mer) contained the 5-prime cross-over point generated by 22bp of homology to *Th.23B* orfC (DH2) sequence and 15bp of homology to *Schizochytrium* orfC sequence (bold). These latter 15bp also provided overlap with prREZ198 and thus the PCR product of Step 1. Reverse primer prREZ200 incorporated a natural *Bst*Z17I site in *Th.23B* orfC at the 3-prime cross-over point (underline). PCR conditions and fragment purification were as above except primers prREZ199 and prREZ200 were used with 10ng on cloned *Th.23B* orfC coding region as the template.

Step 3. Overlap extension was used to create the full-length fusion between the 5-prime end of the *Schizochytrium* orfC coding region and the *Th.23B* DH2 region. PCR was performed with the product of Step 1 (prREZ197 x prREZ198) and Step 2 (prREZ199 x prREZ200) as templates and the outside primers prREZ197 and prREZ200. PCR conditions: 50μL reaction, 1μL PfuUltra polymerase (Stratagene) and 1X PfuUltra buffer, 2% DMSO, 0.5μM each dNTP, 0.4μM each prRZ197 and prRZ200, 50ng each PCR product from Steps 1 and 2, 1 min. initial denaturation at 94°C, 20 cycles of 1 min. denaturation at 94°C, 1 min. annealing at 52°C, 3.5 min. extension at 72°C, and 10 min. final extension. The PCR product was purified as in Step 1.

Step 4 The product of the PCR reaction in Step 3 was cloned into pCR-BluntII-TOPO (Invitrogen) and transformed into TOP10 *E. coli* (Invitrogen) using the manufacturer's recommended conditions to create pREZ171. The sequence of the insert DNA was confirmed to be as designed.

Step 5 Using restriction sites in the respective vector sequences, the cloned DNA in pREZ171 was transferred to vector pBC KS(+) (Stratagene) as an *Xba*I/*Spe*I fragment to create pREZ175.

Step 6 Plasmid pREZ175 was digested (linearized) with *Bst*Z17I, then partially digested with *Nde*I. A ca. 6Kb fragment representing the fused *Schizochytrium* orfC 5-prime region and *Th.23B* DH2 region was cloned into the pREZ172 *Nde*I/*Bst*Z17I vector fragment creating pREZ177. Plasmid pREZ172 contains the entire *Schizochytrium* orfC coding region cloned into the *E. coli* expression vector pColADuet-1 (Novagen) such that

the start ATG codon incorporates an *NdeI* site. It derives from pREZ101 (see Example 5), and had been modified by site-directed mutagenesis (Quik Change kit, Stratagene) to insert an amino acid-neutral *BstZ17I* site at the 3-prime cross-over site. Specifically, the TAC tyrosine codon at amino acid position 1051 was modified to TAT.

5 *Step 7* Upon analysis of pREZ177 by DNA sequencing, it was discovered that a single base pair at the *BstZ17I* site had been deleted. Specifically, the expected <GTATAC> was instead <GTAAC>. To correct this error, a *PciI* restriction fragment containing the correct *BstZ17I* cross-over point from pDS26 was used to replace the defective *PciI* fragment in pREZ177. Plasmid pDS26 contains a hybrid orfC coding
10 region that had been previously created for other purposes. The resulting plasmid, pREZ179, therefore contains an entire orfC coding region that is predominantly from *Schizochytrium* but contains a precise replacement of the DH2 region with that from *Th.23B* (the amino acid sequence represented herein by SEQ ID NO:74). Plasmid pREZ179 further represents a unique tool to study function of the hybrid gene in *E. coli*
15 and provides a starting point for the development of expression vectors for other organisms.

The following additional steps (see Fig. 3C) describe the transfer of the hybrid gene from pREZ179 to a vector for gene replacement in *Schizochytrium*.

20 *Step 8* The (unmodified) *Schizochytrium* orfC coding region plus short portions of upstream and downstream flanking sequences was isolated from pBR002 (a clone of the orfC genomic region) as a *NheI/BspEI* fragment. This fragment was then cloned into the vector portion of *NheI/BspEI*-digested pREZ31 (functionally equivalent to pREZ33 described in U.S. Patent Application Publication No. 20050100995, Example 8). The resulting plasmid, pDS48, contains the (unmodified) *Schizochytrium* orfC coding region
25 plus the same upstream and downstream sequences that have been used to drive gene replacement at the orfC locus.

30 *Step 9* A portion of the hybrid orfC reading frame containing the entire exchanged *Th.23B* DH2 region was isolated from pREZ179 as a *PstI/PfIMI* fragment. This fragment was cloned into the vector portion of *PstI/PfIMI*-digested pDS48 to yield pDS49. As a result, plasmid pDS49 contains the hybrid orfC within the same context as pREZ33 (full-length *Th.23B* orfC coding region as a “perfect stitch” gene replacement; see U.S. Patent Application Publication No. 20050100995, Example 8). The nucleotide sequence of the coding region of pDS49 is represented herein by SEQ ID NO:73. SEQ ID NO:73 encodes

SEQ ID NO:74. Plasmid pDS49 was deposited as ATCC Accession No. PTA-8230, as described in detail previously herein.

Example 3

The following example describes the construction of a construct encoding
 5 *Schizochytrium* OrfC comprising a DH2 domain from *Thraustochytrium* 23B, wherein the DH2 domain has been resynthesized to be optimized for *Schizochytrium* codon usage.

In this example, the inventors constructed a nucleic acid molecule encoding a hybrid OrfC polypeptide (SEQ ID NO:74), 1493 amino acid residues in length, in which the DH2 region, defined as amino acids 516–1041 of this hybrid, consists of the amino
 10 acid sequence of the DH2 region of the *Th.23B* OrfC protein; that is, amino acids 491–1016 of SEQ ID NO:62, which includes all of SEQ ID NO:66 (described as the DH2 domain of *Thraustochytrium* 23B herein). The remainder of the hybrid OrfC amino acid sequence, residues 1–515 and 1042–1493 of SEQ ID NO:74, are identical to *Schizochytrium* OrfC residues 1–515 and 1051–1502 of SEQ ID NO:6, respectively.
 15 Moreover, in this construct, the DNA sequence encoding amino acids 516–1041 was derived from the “synthetic gene sequence” for OrfC of *Th.23B* that is contained in plasmid pThOrfC synth and pThOrfC_synPS (see Example 1 and SEQ ID NO:70) and which employs codons that are preferred for gene expression in *Schizochytrium*. The construction details are illustrated in Figs. 4A–4C and described below.

20 The DNA sequences encoding the DH2 region of the T23B OrfC polypeptide were amplified by PCR (Rxn 59/60) from pThOrfC synth using oligonucleotide primers dhd59 (5' > G CAC CCC ATG AGC AAG CTC CCC GGC AAC >3; SEQ ID NO:82) and dhd60 (5' > GT ATA CAG AGG CGC AGA CAC GTT GTA AG >3; SEQ ID NO:83). The “forward” or sense-strand primer dhd59 overlaps the DNA sequence encoding amino acid
 25 residues 491–501 (WHPMSKLPGNP; positions 491–501 of SEQ ID NO:62) of the *Th.23B* OrfC protein. The “reverse” or antisense-strand primer dhd60 overlaps the DNA sequence encoding amino acid residues 1008–1017 (TYNVSAPLYT; positions 1008–1017 of SEQ ID NO:62) of the *Th.23B* OrfC protein. Primer dhd60 contains two mismatches with the pThOrfC synth sequence which are indicated by the boxed residues in the dhd60
 30 sequence above. These changes created a *Bst*Z17 I restriction endonuclease site, indicated by the double-underlined portion of the dhd60 sequence above, in order to facilitate subsequent cloning steps and also introduced two “silent mutations” into the coding sequence of the hybrid protein: CTT(L) to CTG(L) and TAC(Y) to TAT(Y). This

amplification was carried out in a reaction volume of 40 µl of 1X *PfuUltra*TM HF reaction buffer (Stratagene, LaJolla, CA) containing dhd59 and dhd60 at 0.5 µM each, 200 µM dNTPs, 2 units of *PfuUltra*TM high-fidelity DNA polymerase (Stratagene, LaJolla, CA) and 1 ng of pThOrfC synth DNA. Cycling parameters were: 1X [1 min @ 94°C], 28X [(1
5 min @ 94°C), (0.5 min @ 60°C), (1.5 min @ 72°C)], 1X [8.5 min @ 72°C], and hold @ 4°C. The reaction was performed in a Perkin Elmer GeneAmp® PCR System 2400 thermocycler (Applied Biosystems, Foster City, CA).

The DNA sequence encoding amino acid residues 331–522 of the hybrid OrfC protein encoded by pREZ179 was amplified by PCR (Rxn 57/58) from pREZ179 using
10 oligonucleotide primers dhd57 (5' > C TGC AGC CAG ATG CTC AAG ATG TAC ATG >3; SEQ ID NO:84) and dhd58 (5' > G GAG CTT GCT CAT GGG GTG CCA GGA CAT CTC >3; SEQ ID NO:85). The “forward” or sense-strand primer dhd57 overlaps the DNA sequence encoding amino acid residues 330–339 (GCSQMLKMYM; positions 330–339 of SEQ ID NO:74) of the hybrid OrfC protein encoded by pREZ179. The “reverse” or
15 antisense-strand primer dhd58 overlaps the DNA sequence encoding amino acid residues 513–523 (EMSWHPMSKLP; positions 513–523 of SEQ ID NO:74) of the hybrid OrfC protein. The 5' end of the forward primer, dhd57, overlaps the *Pst* I site present in the hybrid OrfC coding sequence contained in pREZ179. This amplification was carried out in a reaction volume of 40 µl of 1X *PfuUltra*TM HF reaction buffer (Stratagene, LaJolla,
20 CA) containing dhd57 and dhd58 at 0.5 µM each, 200 µM dNTPS, 2 units of *PfuUltra*TM high-fidelity DNA polymerase (Stratagene, LaJolla, CA) and 1 ng of pREZ179 DNA. Cycling parameters were: 1X [1 min @ 94°C], 28X [(1 min @ 94°C), (0.5 min @ 60°C), (1.5 min @ 72°C)], 1X [8.5 min @ 72°C], and hold @ 4°C. The reaction was performed in a Perkin Elmer GeneAmp System 2400 thermocycler.

25 Four microliters of each of the 57/58 and 59/60 reactions were run out on 1.2% agarose gel. DNA bands were observed in each case that were consistent with the expected product sizes: 578 bp for the 57/58 product and 1578 bp for the 59/60 product. These bands were excised from the gel and the DNA recovered from the agarose slices using a QIAquick® Gel Extraction Kit (QIAGEN, Inc. Valencia, CA) according to the
30 vendor protocol. The PCR products were recovered in 40 µl of elution buffer.

The 5' 20 nucleotides of the reverse primer dhd58 (underlined above) comprise the reverse complement of the 5' 20 nucleotides of dhd59, also underlined above. As a result, there is a 20 bp identical overlap between the 3' end of the Rxn 57/58 product and the 5'

end of the Rxn 59/60 product and this overlap allows subsequent PCR splicing of these two products by the technique of PCR “Splicing by Overlap Extension” or “SOEing” [Horton, R.M., (1993) *In Vitro* Recombination and Mutagenesis of DNA. SOEing together tailor-made genes. *Methods in molecular Biology* Vol. 15: *PCR Protocols: Current*
5 *Methods and Applications* Chapter 25 pp 251-266 (B.A. White, Ed.) Humana Press, Totawa, NJ]. This spliced fragment then contains useful restriction sites at (*Bst*Z17 I & *Pst* I) or near (*Bsi*W I) its ends.

The PCR splicing reaction (Rxn 57/60) was performed as follows. A 40 µl reaction volume of 1X *PfuUltra*TM HF reaction buffer contained primers dhd57 and dhd60
10 each at 0.5 µM, 200 µM dNTPS, 2 units of *PfuUltra*TM high-fidelity DNA polymerase (Stratagene, LaJolla, CA) and 0.8 µl of a 50-fold dilution of each of the gel-purified PCR products 57/58 and 59/60. A series of PCR splicing reactions was performed in which the annealing temperature was varied in 1°C increments between 66-70°C. Other cycling parameters were constant: 1X [1 min @ 98°C], 33X [(1 min @ 98°C), (1 min @ 66-
15 70°C), (2.5 min @ 72°C)], 1X [7.5 min @ 72°C], and hold @ 6°C. The reaction was performed in a RoboCycler® Temperature Cycler (Stratagene, LaJolla, CA). Aliquots of these reactions were run out on 1% agarose gel and it was observed that all reactions contained a product consistent in size with the expected product (2136 bp) but other bands were also observed at all annealing temperatures. Therefore, the 3 reactions with
20 annealings at 67, 68 and 69°C were pooled, run out on a 1% agarose gel and the approximately 2.1 kb band of interest was excised and the DNA fragment recovered using a QIAquick® Gel Extraction Kit (QIAGEN, Inc. Valencia, CA) according to the vendor protocol. Eluted DNA was recovered in 30 µl of elution buffer and cloned into the PCR fragment cloning vector pCR®-Blunt II TOPO® (Invitrogen Corp., Carlsbad, CA) using
25 the Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen Corp., Carlsbad, CA) according to the vendor protocols. Products of the TOPO cloning reaction were used to transform One Shot® TOP10 Chemically Competent *E. coli* (Invitrogen) according to the vendor protocol. Eight of the resulting transformants were grown overnight and plasmid DNAs were prepared and analyzed by restriction endonuclease digestion and agarose gel
30 electrophoresis. Seven of the eight were found to contain the cloned 2.1 kb PCR product 57/60. The cloned PCR 57/60 product of one isolate was sequenced and shown to exactly match the expected sequence. DNA sequencing was performed by the Biotechnology Resource Center of Cornell University (Ithaca, New York) on a fee for service basis using

the Applied Biosystems Automated 3730 DNA Analyzer, with Big Dye Terminator chemistry and AmpliTaq-FS DNA Polymerase (Applied Biosystems, Foster City, CA). The plasmid containing the sequence-verified insert was designated pDD21 and was used in further construction steps described below.

5 The DNA segment encoding the *Th.23B* DH2 domain optimized for *Schizochytrium* codon usage was excised from pDD21 and cloned into pREZ179 (see Example 2) so that it replaced the native *Th.23B* DH2 domain coding sequence present in that construct. The resulting plasmid, pDD22, was constructed as follows. Purified pDD21 DNA was digested with *Bsi*WI and *Bst*Z17I (New England BioLabs, Beverly MA) according to the vendor protocols. The reaction was subsequently subjected to treatment using the QIAquick® Spin Purification Procedure and QIAquick® PCR Purification Kit (QIAGEN Inc., Valencia, CA) according to the vendor protocol. The purified digestion products were run out on a 1% agarose gel and the 1940 bp *Bsi*WI - *Bst*Z17I fragment was excised and eluted from the agarose using a QIAEX II Gel Extraction Kit (QIAGEN Inc., Valencia, CA) according to the vendor protocol. Purified pREZ179 DNA was also digested *Bsi*WI and *Bst*Z17I and subsequently treated with Antarctic Phosphatase (New England BioLabs, Beverly, MA) according to the vendor protocol. The phosphatased digestion products were also subjected to treatment using the QIAquick® procedure as described above and run out on a 0.7% agarose gel. The ~6.1 Kb *Bsi*WI - *Bst*Z17I vector fragment was excised from the gel and eluted from the agarose using the QIAEX II Gel Extraction Kit described above. These two fragments were ligated in 1X T4 Ligase Reaction Buffer using T4 Ligase, both from New England BioLabs (Beverly, MA). Liagation products were used to transform One Shot® TOP10 Chemically Competent *E. coli* (Invitrogen) according to the vendor protocol. Plasmids DNA from three of the resulting transformants were analyzed by restriction endonuclease digestion and agarose gel electrophoresis and all three were found to have the structure of the expected recombinant. One plasmid was designated pDD22 and was employed in further constructions.

30 In order to facilitate the introduction of the DNA encoding the hybrid OrfC containing the *Th.23B* DH2 region encoded by *Schizochytrium*-preferred codons into the *Schizochytrium* genome, a *Pst*I-*Pf*MI DNA segment spanning the sequence encoding the DH2 region was excised from pDD22 and cloned into pDS48 (see Example 2), a vector designed for gene replacement at sequences at the *orfC* gene locus in *Schizochytrium*. The

resulting plasmid, pDD24, which was used to in subsequent gene replacements, was constructed as follows. The DNA segment encoding T23B DH2 domain and with optimized codon usage was excised from pDD22 and cloned into pDS48 so that it replaced the native *Schizochytrium* DH2 domain coding sequence present in that construct.

5 Purified pDD22 DNA was digested with *Pst*I, *Pfl*MI and *Cla*I (New England BioLabs, Beverly MA) according to the vendor protocols. Digestion with *Cla*I cleaved a *Pfl*MI-*Pfl*MI fragment that would otherwise migrate close to the position of the *Pst*I – *Pfl*MI ~3.2 Kb fragment of interest. The reaction was subsequently subjected to treatment using the QIAquick® Spin Purification Procedure and QIAquick® PCR Purification Kit (QIAGEN

10 Inc., Valencia, CA) according to the vendor protocol. The purified digestion products were run out on a 0.7% agarose gel and the ~ 3.2 Kb *Pst*I – *Pfl*MI fragment of interest was excised and eluted from the agarose using a QIAEX II Gel Extraction Kit (QIAGEN Inc., Valencia, CA) according to the vendor protocol. Purified pDS48 DNA was similarly digested with *Pfl*MI and *Pst*I, subjected to the QIAquick® treatment as described above

15 and run out on a 0.7% agarose gel. The ~8.0 Kb *Pst*I - *Pfl*MI vector fragment was excised from the gel and eluted from the agarose using the QIAEX II Gel Extraction Kit described above. These two fragments were ligated in 1X T4 Ligase Reaction Buffer using T4 Ligase, both from New England BioLabs (Beverly, MA). Liagation products were used to transform One Shot® TOP10 Chemically Competent *E. coli* (Invitrogen) according top the

20 vendor protocol. Resulting transformants were grown overnight in liquid culture of LB media containing 100 µg / ml of ampicillin at 30°C. Propagation of these transformants at 37°C in liquid cultures was found to result in plasmid instability under some circumstances. Plasmid DNAs from three of the resulting transformants were analyzed by restriction endonuclease digestion and agarose gel electrophoresis and all three were found

25 to have the structure of the expected recombinant. One plasmid was designated pDD24 and subjected to additional restriction endonuclease analysis and was employed in gene replacement experiments in *Schizochytrium* (see Example 4). The nucleotide sequence of the coding region of pDD24 is represented herein by SEQ ID NO:75. SEQ ID NO:75 encodes SEQ ID NO:74. The plasmid pDD24 was deposited as ATCC Accession No.

30 PTA-8226, as described previously herein.

Example 4

The following example describes the expression of various *Th. 23B orfC* constructs described in Examples 1-3 above in *Schizochytrium*, and the analysis of PUFAs produced by such organisms.

Expression of Variant *Th.23B orfC* genes in *Schizochytrium*

5 *Schizochytrium* strain B32-Z1 (see above and Example 8 in U.S. Patent Application Publication No. 20050100995), which is a *Schizochytrium* with an exact deletion of the *Schizochytrium orfC* coding region, was transformed with plasmid pThOrfC-synPS (full length synthetic *Th.23B orfC*; see Example 1), pDS49 (non-synthetic *Th.23B DH2* region; see Example 2), and pDD24 (synthetic *Th.23B DH2* region; see
10 Example 3) by particle bombardment using techniques previously described (see U.S. Patent Application Publication No. 2003/0166207). Prototrophic Zeocin™-sensitive transformants were obtained. Such transformants arose from double cross-over gene replacement events as confirmed by Southern blot and/or PCR for selected strains.

Briefly, particle bombardment utilized the BioRad (Hercules, CA) Biolistic® PDS-
15 1000/He Particle Delivery System. *Schizochytrium* strains for transformation were grown at 29-30°C in M2B medium (plus DHA where appropriate) on a gyratory platform (200rpm) to OD600 = 1 to 2.5 (BioPhotometer, Eppendorf). Cells were collected by centrifugation (3000rpm, 5 min.) and re-suspended in sterile 7.5g/L Na₂SO₄ to OD600 = 30. A 150µL volume of suspended cells were spread in a circular patch (6cm diameter) on
20 a Petri plate containing M2B agar (without DHA). For growth of PUFA auxotrophs, M2B was supplemented with DHA to 0.25mM from a stock of 25mM DHA in 40% (w/v) randomly methylated β-cyclodextrin (CTD Inc, High Springs, FL.). When performing bombardments for complementation of DHA auxotrophy, DHA was omitted from the agar medium. Bombardments were carried out in laminar flow hood using 1100psi rupture
25 discs, a 0.25in gap between the disc retaining cap and the macrocarrier cover lid, and the stopping screen support in the middle position. The target shelf is in the L2 (6cm) position. Petri plates containing bombarded DHA auxotrophic *Schizochytrium* strains were incubated at 29-30°C until (prospective prototrophic) colonies develop (3-5 days). Randomly chosen colonies were streaked to M2B agar plates. After growth, several well-
30 isolated colonies were transferred to M2B plates with and without Zeocin® (50µg/mL). Zeocin-sensitive DHA prototrophs (suggestive of a gene replacement event) were selected for further study.

Growth of *Schizochytrium* for Fatty Acid Analysis

Erlenmeyer flasks (250mL) containing 50mL of M50-20 medium were inoculated with the contents (1mL) of a cryovial of the indicated strain. The flasks were incubated at 29-30°C on a rotating shaker at 200rpm for 72 hours. Similar flasks containing SSFM medium were inoculated with 0.5mL of the M50-20 culture and incubated as above for 5 days. Cells were harvested by centrifugation (4000g, 5 min) after dilution of the broth with an equal volume of 70% isopropanol. The resulting cell pellets were suspended in an original volume of 35% isopropanol water and re-centrifuged. The washed cell pellets were immediately frozen at -70°C followed by lyophilization. The fatty acid content of the dried biomass was determined by preparing fatty acid methyl esters (FAMES) using acidic methanol, extracting them into hexane and analyzing by gas-liquid chromatography.

M50-20 Medium

The components per liter of M50-20 medium are as follows: 12.5g NaCl, 2.5g MgSO₄·7H₂O, 0.5g KCl, 0.05g CaCl₂, 20.0g glucose, 20.0g Na-glutamate, 0.4g KH₂PO₄, 1.0g yeast extract, 0.4g NaHCO₃, 5ml PII trace metals (200X PII trace metal solution contains per liter: 6.0g Na₂EDTA, 0.29g FeCl₃·6H₂O, 6.84g H₃BO₃, 0.86g MnCl₂·4H₂O, 60mg ZnCl₂, 26mg CoCl₂·6H₂O, 52mg NiSO₄·6H₂O, 2mg CuSO₄·5H₂O, and 5mg NaMoO₄·2H₂O, pH 8.0), 1ml PII vitamin mix (1000X PII vitamin mix contains per liter: 100mg thiamin, 0.5mg biotin, and 0.5mg vitamin B₁₂), pH7.0.

SSFM Medium

The components per liter of SSFM medium are as follows: 13.62g Na₂SO₄, 0.72g K₂SO₄, 0.56g KCl, 2.27g MgSO₄·7H₂O, 0.19g CaCl₂, 0.0565g KH₂PO₄, 0.57g (NH₄)₂SO₄, 0.13g Na-glutamate, 100mM MES (4-morpholine ethanesulfonic acid) pH 6.0, 50.0g glucose, 0.16mg vitamin B₁₂, 9.75mg thiamin, 3.33mg calcium pantothenate, 10.3mg FeSO₄·7H₂O, 3.1mg MnCl₂·4H₂O, 1.93mg ZnSO₄·7H₂O, 0.04mg CoCl₂·6H₂O, 0.04mg NaMoO₄·2H₂O, 2.07mg CuSO₄·5H₂O, 2.07mg NiSO₄·6H₂O, 2.0mg citric acid.

M2B Medium

The components of M2B medium are as follows (per liter): glucose 10g, (NH₄)₂SO₄ 0.8g, Na₂SO₄ 5.0g, MgSO₄·7H₂O 2.0g, KH₂PO₄ 0.5g, KCl 0.5g, CaCl₂·2H₂O 0.1g, vitamin B₁₂ 0.05mg, thiamine·HCl, 0.2mg, calcium pantothenate 0.2mg, FeSO₄·7H₂O 3.0mg, MnCl₂·4H₂O 1.0mg, ZnSO₄·7H₂O 0.8mg, CoCl₂·6H₂O 0.02mg, Na₂MoO₄·2H₂O 0.01mg, CuSO₄·5H₂O 0.6mg, NiSO₄·6H₂O 0.8mg, MES buffer 0.1M, pH 6.0 (adjusted with NaOH).

PUFA Analysis of Recombinant Schizochytrium Strains

Table 2 shows the total fatty acid, DHA, and DPAn-6 content (expressed as FAME (fatty acid methyl ester)) of *Schizochytrium* ATCC 20888 and derivative strains in which the native orfC coding region is replaced by all or part of the orfC coding region of *Thraustochytrium* 23B (described in Examples 1-3). Replacement of the entire *Schizochytrium* ATCC 20888 orfC coding region with that from *Th.23B* (strain B34-1) results in a higher DHA/DPAn-6 ratio (closer to that of *Th.23B*) but less total PUFA content. That protein expression is the likely cause of lower total PUFA content is demonstrated by use of the codon-optimized (synthetic) *Th.23B* orfC coding region (*e.g.*, in strain B67-5; transformed with pThOrfC_syn-PS) in which PUFA production is increased over wild-type levels while the enhanced DHA/DPAn-6 ratio is maintained. Substitutions of just the *Schizochytrium* DH2 region with that of *Thraustochytrium* show a similar pattern. The strain with the codon-optimized *Th.23B* DH2 region (B69-2; transformed with pDD24) yields higher PUFA than the strain with the non-optimized DH2 region (B105-1A1; transformed with pDS49). However, the DHA/DPA ratio in strain B105-1A1 (non-optimized DH2 region) was notably high.

Interestingly, strain B69-6 produces high levels of DHA and a relatively high DHA/DPA ratio. This strain resulted from the same transformation of strain B32-Z1 with plasmid pDD24 that produced strain B69-2. However, strain B69-6 does not have a correct integration/gene replacement of the modified orfC coding region (as determined by PCR analysis), although the exact nature of the discrepancy is not known.

Given these data, production-scale fermentations can be developed with strain B69-2 to achieve maximal DHA production, or strains B69-6 or B105-1A1 if the greatest DHA/DPA ratio is desired.

Table 2. Summary of orfC Variants

Strain	FAME (%dcw)	DHA (%dcw)	DPAn-6 (%dcw)	DHA (%FAME)	DHA/DPA	strain description
ATCC20888	71.4	16.5	3.64	22.9	4.5	wild type <i>Schizochytrium</i>
B34-1	78.4	13.4	1.24	17.0	10.8	(non-synth.) <i>Th.23B</i> orfC
B67-5	73.0	21.3	1.85	28.9	11.5	synth. <i>Th.23B</i> orfC
B105-1A1	73.5	19.4	1.31	26.4	14.8	(non-synth.) <i>Th.23B</i> DH2
B69-2	73.0	23.0	2.31	31.6	10.0	synth. <i>Th.23B</i> DH2
B69-6	73.8	22.4	1.76	30.3	12.7	synth. <i>Th.23B</i> DH2

Dcw

dry cell weight

FAME

fatty acid methyl ester

Th.23B

Thraustochytrium sp. 23B; ATCC20892Example 5

The following example describes the production of DHA and DPA in *E. coli* by a multi-plasmid system, and further illustrates that the DH2 domain of the PUFA PKS
5 system controls the ratio of fatty acid production by the system.

The inventors have previously demonstrated production of DHA and DPA in *E. coli* by the use of T7 inducible system to express OrfA, OrfB*, OrfC from *Schizochytrium* and HetI from *Nostoc* (Example 3, page 41, U.S. Patent Application Publication No. 20050100995). In this previous example, OrfA, OrfB* and OrfC were contained on a
10 single plasmid. In order to create a system more amenable to genetic manipulation, the individual coding regions from *Schizochytrium* were cloned on a set of compatible expression plasmids designed for the coexpression of multiple target genes. The expression of the target genes is similarly driven by the inducible T7 promoter on this Duet series of plasmids (Novagen). *Schizochytrium* orfA was cloned as an *NdeI* – *XbaI*
15 fragment from pBR115L1 into the expression vector pETDuet-1 to create pREZ91 (pBR115L1 is referenced in the generation of the final expression plasmid in Example 3, page 41, U.S. Patent Application Publication No. 20050100995). *Schizochytrium* orfB* was cloned as an *NdeI* – *XbaI* fragment from pJK780 into the expression vector pCDFDuet-1 to create pREZ96 (pJK780 is referenced in the generation of the final
20 expression plasmid in Example 3, page 41, U.S. Patent Application Publication No. 20050100995). *Schizochytrium* orfC was cloned as an *NdeI*-*XbaI* fragment from pJK510 into pColADuet-1 to create pREZ101 (pJK510 is referenced in the generation of the final expression plasmid in Example 3, page 41, U.S. Patent Application Publication No. 20050100995). The required accessory gene *hetI*, encoding a phosphopantetheine
25 transferase (PPTase), was supplied on a pACYC184-based plasmid pJK737 previously described (Example 3, page 41, U.S. Patent Application Publication No. 20050100995). OrfA, OrfB*, OrfC and *hetI*, contained separately on plasmids pREZ91, pREZ96, pREZ101 and pJK737 respectively, were transformed into *E. coli* stain BLR (DE3) (Novagen) which contains an inducible T7 RNA polymerase.

30 Production of DHA and DPA was detected in *E. coli* cells grown in Luria Broth (LB) at both 25°C and 30°C (see Table 3 below) using these multi-plasmid strains. Single colonies were inoculated into LB broth supplemented with antibiotics to maintain each

plasmid in the given strain and grown overnight at the desired temperature (25°C or 30°C). Volumes of 300µL of these cultures were then used to inoculate main cultures of 30mL LB with appropriate antibiotics. The main cultures were grown at the indicated temperature until OD600 (BioPhotometer, Eppendorf) was between 0.45 and 0.55, at
5 which point the cultures were induced with IPTG to a final concentration of 1 mM. The cultures were then maintained under these expression conditions for 24 hours after which the cells were collected by centrifugation and prepared for FAME analysis. The typical level of PUFA produced (as percentages of total FAME) at 30°C was 10% DHA and 6% DPA (16% total PUFA) for the strain carrying *Schizochytrium* orfC. The DHA/DPA ratio
10 of 1.7 approximates that seen in *Schizochytrium* (see Table 2 below).

The expression of the *Schizochytrium* genes required for DHA and DPA production in *E. coli* on separate plasmids provided the inventors with the ability to more easily study and manipulate PUFA biosynthetic genes. As described in U.S. Patent Application Publication No. 2005/0100995, Example 8, it was demonstrated that in
15 *Schizochytrium*, the replacement of orfC with the homologous gene from *Thraustochytrium* 23B altered the PUFAs profile with a shift in the DHA to DPA ratio. The similar experiment was carried out with the *E. coli* multi-plasmid expression system described above, in which the *Schizochytrium* orfC expression plasmid (pREZ101) was replaced with a similar *Thraustochytrium* 23B orfC expression plasmid (pREZ142).

20 To create pREZ142, the *Th.23B* orfC coding region from pREZ31 was cloned as an *NcoI/SaI* fragment into the Duet vector pColADuet-1. Plasmid pREZ31 is a variant of pREZ33, the “perfect stitch” gene replacement vector (described in Example 1 above and in Example 8 of U.S. Patent Application Publication No. 2005/0100995), in which a *Bam*HI restriction site (underlined below) was engineered just upstream of the start ATG
25 (lower case below). This engineering fortuitously created in pREZ31 an *NcoI* restriction site (italicized below) containing the start ATG which was composed of the last two bases of the *Bam*HI site and the first four bases of the *Th.23B* orfC coding region:

GGATCC*atgG* (SEQ ID NO:86)

The *SaI* restriction site used in this cloning is native to the *Schizochytrium* orfC
30 downstream region and is about 250bp downstream of the TAA stop codon. This replacement in the *E. coli* expression system or the *Th.23B* orfC for the *Schizochytrium* orfC resulted in an altered PUFA profile with a shift of the DHA to DPA ratio from 1.5 to

6.8 and the total amount of DHA + DPA was reduced from 10% to 4% when strains were grown and induced at 25°C (see Table below).

Hybrid orfC coding regions were generated in order to determine the region or domain of the gene responsible for control the ratio of DHA to DPA. The hybrid orfC in the expression plasmid pREZ179 contains a central DH2 region derived from *Thraustochytrium* 23B orfC and is flanked upstream and downstream by *Schizochytrium* orfC sequences (see Example 2). When pREZ179 was expressed in the above system in place of pREZ101, a DHA to DPA ratio of 6.5 was seen, while the total PUFA amount was 9% when expressed and induced at 25°C (see Table below). This shift in DHA to DPA ratio in the *E. coli* model expression and maintenance of yield indicated that the central DH2 region of orfC controls the most or all of the ratio of DHA to DPA in PUFA biosynthesis. When this construct was then modified with additional flanking DNA and transformed into *Schizochytrium* to replace the native orfC, a similar shift in DHA to DPA ratio was seen as well as no decrease in production (see Example 4). Similarly when the hybrid orfC was expressed in a yeast system, a shift in DHA to DPA ratio was again seen (see Example 6).

Table 3

orfC form (temperature)	orfC plasmid	DHA + DPA	DHA/DPA
<i>Schizochytrium</i> (30°)	pREZ101	16%	1.7
<i>Schizochytrium</i> (25°)	pREZ101	10%	1.5
<i>Th.23B</i> (25°)	pREZ142	4%	6.8
<i>Th.23B</i> DH2 (25°)	pREZ179	9%	6.5

20 Use of multiple expression plasmid system

The above examples, in which the *E. coli* and yeast multi-plasmid expression model systems were used to elucidate the role of orfC and, in particular, the DH2 region, in controlling DHA to DPA ratio in PUFA biosynthesis, demonstrates the utility of these heterologous systems. The results seen in *E. coli* and yeast parallel those seen in *Schizochytrium* in terms of relative effect of the orfC source on DHA/DPA ratio. In a similar manner, the multi-plasmid expression model systems in *E. coli* and yeast are described herein to investigate and engineer other aspects of PUFA biosynthesis including PUFA chain length, degree of fatty acid saturation, and positioning of double bonds. These systems will also allow for the easy expression of genes involved in other types of fatty acid modification such as hydroxylation and glycosylation. In a similar manner, other PUFA biosynthetic genes from a single organism (as has been done for the

Shewanella japonica cluster described in Example 2, U.S. Patent Application Publication No. 2005/0100995) or from more than one organism can be cloned into this *E. coli* system to facilitate study.

Example 6

5 The following example describes the method by which *Schizochytrium*'s PUFA synthase subunits A, B and C and *Nostoc hetI* were expressed in yeast, and further illustrates that the DH2 domain of the PUFA PKS system controls the ratio of fatty acid production by the system.

Part A

10 Preliminary expression experiments indicated that *Schizochytrium* OrfC and Het I could be produced as full length proteins in yeast using the native coding regions. In contrast, expression of the native coding regions for *Schizochytrium* OrfsA and B did not result in production of detectable amounts of the expected proteins. The problem seemed to be associated with the translation of the mRNA. (Northern blots showed the presence
15 of mRNAs of the correct size.) Accordingly, synthetic versions of those two coding regions were made with the goal of improving their expression in yeast. The amino acid sequences of the proteins encoded by the synthetic genes are identical to those encoded by the native genes (*i.e.*, SEQ ID NO:2 and SEQ ID NO:4). Initial gene design and complete gene synthesis of orfA and orfB were conducted by Blue Heron Biotechnology, Inc.
20 (Bothell, WA). Codon optimization took into consideration the codon preferences of *S. cerevisiae*. The complete sequences of the synthetic coding regions (designated; sOrfA and sOrfB) are listed as SEQ ID NO:35 (sOrfA) and SEQ ID NO:36 (sOrfB). Each synthetic coding region was appended as follows with DNA to facilitate cloning in the yeast transformation vectors:

25 upstream sequence (SEQ ID NO:87)
AAGCTTGTGCAGTCAAGTGCGCAAAACCATG

 downstream sequence (SEQ ID NO:88)
30 TAACCCGGGTCTAGA.

 The start and stop codon positions are underlined and the restriction enzyme recognition sites for *HindIII* (upstream) and *XbaI* (downstream) are shown in bold.

 The *S. cerevisiae* strain InvSC1 (MATa *his3-Δ1*, *leu2*, *trp1-289*, *ura3-52*) (Invitrogen, Carlsbad, CA) was used for these experiments. The strain was maintained
35 and transformed as per supplier's recommendations. Transformants were grown on

glucose solid medium, raffinose broth and galactose induction medium as per the manufacturer's instructions (Invitrogen). All yeast media components were purchased from Q-BIOgene (Carlsbad, CA).

The *Schizochytrium* PUFA synthase genes and *hetI* were cloned into the following transformation vectors: pYES-Leu* (sOrfA; SEQ ID NO:35), pYES3-Tryp (sOrfB; SEQ ID NO:36), pYES2/CT (OrfC; SEQ ID NO:5) and pYES-His* (*hetI*; SEQ ID NO:33). Creation of these vectors is described in detail below. Some of the vectors and genes were modified to accommodate specific cloning and expression requirements (described in detail below). Appropriate selection media were used, depending on the particular experiment. The genes were cloned in each case behind GAL1 promoter and expression was induced by re-suspension of washed cells in media containing galactose according to guidelines provide by Invitrogen. Cells were grown at 30°C and harvested (by centrifugation) at the indicated times after being transferred to the induction medium. The cell pellets were freeze dried and FAMES were prepared using acidic methanol, extracted into hexane, and analyzed by GC.

sOrfA expression construct: The sOrfA was cloned into a customized vector, pYES-Leu/CT, constructed as follows. A pYES6/CT vector (Invitrogen) was modified by replacing a region of its DNA containing a blasticidin resistance gene with a segment of DNA containing a *leu2* gene (for selection on media lacking leucine). The blasticidin gene was removed by digesting pYES6/CT with *Bgl*II and *Nhe*I and gel purifying the resulting ~4913 bp vector fragment. The *leu2* gene was obtained from the yeast vector pRS425 (ATCC 77106, GenBank # U03452). The primers PO-Leu5' (SEQ ID NO:89) and PO-Leu3' (SEQ ID NO:90) were used in a PCR reaction with pRS425 as template to generate an ~1812 bp DNA fragment (from bp 664 to 2475 of pRS425) which contains the *leu2* gene.

PO-Leu5' GACTGCTAGCTTAAGCAAGGATTTTCTTAAC
PO-Leu3' GACTGGATCCTCCTGATGCGGTATTTCTCC

Restriction enzyme recognition sites were incorporated into the primers to facilitate cloning (5' *Nhe*I and 3' *Bam*HI underlined). The PCR fragment was digested with *Bam*HI and *Nhe*I and ligated to the 4913 bp vector fragment obtained from the pYES6/CT *Bgl*II/*Nhe*I digest to form pYES6-Leu. This vector was digested with *Hind*III and *Xba*I in preparation for insertion of sOrfA. The plasmid from Blue Heron containing the sOrfA

and appropriate flanking DNA was digested with *Hind*III and *Xba*I. The 8.8 kb fragment with the complete sOrfA was gel purified and ligated to the prepared pYES6-Leu vector to form pBR882 (pYES6-Leu:sOrfA).

5 *sOrf B expression construct*: The inventors wished to clone the sOrfB into the pYES3 yeast expression vector which has a tryptophan selection marker. Since the pYES3 vector contains a second *Xba*I restriction site (the second site is in the *trp1* gene), that restriction enzyme could not conveniently be used for introduction of the sOrf B DNA fragment. The region containing the *Xba*I site downstream of the sOrf B was modified to introduce a unique *Not*I site (also available as a gene insertion cloning site in pYES3) as
10 follows. The plasmid containing the sOrfB fragment from Blue Heron was digested with *Hind*III and *Xba*I and the resulting 6.2 kb fragment of interest was gel purified. That fragment was ligated into pYES2/CT (Invitrogen) which had been cut with those same enzymes, yielding the plasmid pBR879. This plasmid was opened by cutting at the unique *Xba*I site. The self complementary oligo linker 5'-CTAGGCGGCCGC-3' (SEQ ID
15 NO:91) was used to create a unique *Not*I site (underlined; it also eliminated the *Xba*I site). This yielded the plasmid pJK894. This construct was digested with *Hind*III and *Not*I and the resulting 6.2 kb fragment of interest was gel purified. That fragment was ligated into pYES3/CT (Invitrogen) which had been cut with those same enzymes to form pJK908 (pYES3:sOrfB).

20 *OrfC expression construct*: The native orfC had previously been cloned in a bacterial expression vector, and this served as the source for the gene for yeast expression. The bacterial vector was pBluescript II KS (Stratagene), and the coding region plus flanking DNA was cloned into the *Eco*RI (5') and *Xba*I (3') sites of the vector. The insert DNA included an *Nde*I restriction site as part of the ATG initiation codon and the TAA
25 stop codon just prior to the *Xba*I site. A bacterial ribosomal binding site sequence was included in the region between the *Eco*RI site and the *Nde*I site containing the initiation codon. Prior to cloning in the yeast vector, the ribosome binding site DNA was removed and replaced with DNA appropriate for expression in the yeast system. The pBluescript plasmid harboring orfC was digested with *Eco*RI and *Nde*I and ligated to the
30 oligonucleotide linkers FL5' (AATTCAA) and FL3' (TATTG). The resulting plasmid (designated pKCFL) was digested with *Hind*III (just upstream of the *Eco*RI site in the pBluescript KS polylinker) and *Xba*I to liberate an ~4526 bp fragment. This fragment was ligated to *Hind*III/*Xba*I-digested pYES2/CT to generate: pYES2/ORFCwt (pYES2:OrfC).

HetI construct: The *hetI* gene from *Nostoc*, encoding a PPTase, was cloned into a customized vector, pYES6-His/CT, which was constructed as follows. A pYES6/CT vector (Invitrogen) was modified by replacing a region of its DNA containing a blasticidin resistance gene with a segment of DNA containing a *his3* gene (for selection on media lacking histidine). The blasticidin gene was removed by digesting pYES6/CT with *Bg/II* and *NheI* and gel purifying the resulting ~4913 bp vector fragment. The *his3* gene was amplified from the yeast vector pRS423 (ATCC 77104, GenBank # U03454) using the primers PO-His5' (SEQ ID NO:92) and PO-His3 (SEQ ID NO:93).

10 PO-His5' GACTACTAGTCTAAGAAACCATTATTATCAT
PO-His3' GACTGGATCCAGCTTTAAATAATCGGTGTCA

This generated an ~1251 bp region of the pRS423 plasmid that contained the *his3* gene. Restriction enzyme recognition sites were incorporated into the primers to facilitate cloning (5' *SpeI*, and 3' *BamHI*, underlined). The PCR fragment was digested with *SpeI* and *BamHI* and ligated to the ~4913 bp vector fragment obtained from pYES6/CT to form pYES6-His. This vector was digested with *BamHI* and *XbaI* in preparation for insertion of the *hetI* gene.

The *hetI* gene had previously been cloned and used with the *Schizochytrium* PUFA synthase genes for PUFA production in *E. coli* (U.S. Patent Application Publication No. 20040235127, Example 2). As indicated in that application, there are no methionine codons present in the open reading frame, but there are several potential alternative start codons (TTG and ATT) near the 5' end (Black and Wolk, 1994, JBC 176, 2282 – 2292). PCR was used to amplify the Orf from *Nostoc* genomic DNA. The 5' primer was designed so that the first T of the furthest 5' TTG codon was replaced with an A to create a methionine codon (ATG). The 3' primer included the TGA stop codon. The amplified region extended from the bp 3994 to 3282 of the *Nostoc* nucleotide sequence deposited as GenBank # L22883 (with nucleotide 3994 being the second T of the TTG codon altered to form the ATG codon). This amplified *hetI* Orf was cloned in a pACYC184 vector along with flanking regulatory elements for expression in *E. coli*. This clone of the *hetI* Orf was used as template DNA to amplify the gene in preparation for cloning into pYES6-His. The primers HetI 5' (SEQ ID NO:94) and HetI 3' (SEQ ID NO:95) were used to create a 740bp fragment containing the *hetI* Orf.

35 HetI 5' GACTGGATCCGCCACCATGTTGCAGCATACTTGGCTACCAAAACCC

HetI 3' GACTTCTAGATCAATAATGCCAGAATTTTGGCTGC

Restriction enzyme recognition sites were incorporated into the primers to facilitate cloning (5' *Bam*HI and 3' *Xba*I, underlined). The ATG methionine start codon (5' primer) and the TGA stop codon (shown as the reverse TCA triplet in the 3' primer) are shown in bold. The PCR product was digested with *Bam*HI and *Xba*I and ligated into the previously prepared pYES6-His vector to form pYES-His/Het/CT (pYES6-His:HetI).

Results of expressing pYES6-Leu:sOrfA, pYES3:sOrfB, pYES2:OrfC and pYES6-His:HetI in yeast.

Fig. 7 shows a comparison of GC profiles of FAMES derived from yeast cells expressing the *Schizochytrium* PUFA synthase system (sOrfA, sOrfB, OrfC and *hetI*) and one obtained from control cells (lacking the sOrfA gene), such yeast strains denoted herein as strains BRY 4.5 and BRY 3.3, respectively. Cells were collected ~20 hrs after induction. It can be seen that two novel FAME peaks have appeared in the profile of the strain expressing the complete PUFA synthase system. These two peaks were identified as DPAn-6 and DHA by comparison of the elution time with authentic standards and subsequently by MS analyses. As predicted from our characterization of the *Schizochytrium* PUFA synthase, aside from DHA and DPAn-6, no other novel peaks are evident in the profile. Fig. 8 shows the region of the GC chromatogram of Fig. 8 which contains the PUFA FAMES. Both the control cells and the cell expressing the PUFA synthase contain a peak that elutes near the DHA FAME. This has been identified as C26:0 FAME (by Mass Spectrum analysis) and is likely derived from sphingolipids. Although it elutes close to the DHA peak, the resolution is sufficient so that it does not interfere with the quantitation of DHA. The DPAn-6 peak is well separated from other endogenous yeast lipids in the FAME profile. In this particular example of strain BRY 4.5, the cells expressing the *Schizochytrium* PUFA synthase system accumulated 2.4% DHA and 2.0% DPAn-6 (as a percentage of the total FAMES; see Table 4 below). The sum of DHA and DPAn-6 is 4.4% of the measured fatty acids in the cells. The ratio of DHA to DPAn-6 observed in the cells was ~1.2:1.

The results presented above showing expression of the *Schizochytrium* PUFA synthase in yeast provide a confirmation of the pathway proposed in the previous applications as well as the predictions in terms of the alterations to the fatty acid profiles that can be expected in yeast and also in plants.

Part B

Expression of Schizochytrium's PUFA synthase Orfs A, B and Nostoc Het I in yeast in combination with a hybrid gene encoding a OrfC containing a DH2 region derived from the orfC homolog of Thraustochytrium 23B, and the effects on the PUFAs produced in those cells.

Expression of hybrid Schizochytrium/Th.23B OrfC genes in yeast: As described in other sections of this application, the inventors have discovered that the main determinants of the ratio of n-3 to n-6 PUFA products of PUFA synthases reside in the OrfC protein and more specifically in the DH2 region of that protein. Gene replacement experiments in both *E. coli* and in *Schizochytrium* using the OrfC homolog derived from Th.23B in combination with the *Schizochytrium*-derived PUFA synthase genes resulted in alteration of the DHA to DPAn-6 ratio produced by those mixed systems. In *E. coli*, the products of the PUFA synthase accumulate as free fatty acids with presumably no influence on the accumulation of the primary products of the enzyme by lipid synthesis enzymes of the host organism. In *Schizochytrium*, the PUFA products accumulate in the esterified lipids, but the endogenous lipid synthesis enzymes are likely to be able to readily accommodate both DHA and DPAn-6 since those are major components of the lipid fraction of the unmodified host. Expression of the mixed PUFA synthase system in yeast would provide a model for heterologous eukaryotic hosts (e.g., plants).

Attempts to express the non-synthetic or fully synthetic *Th.23B* orfC genes in yeast were unsuccessful, as the expected proteins could not be detected. In contrast, expression of the hybrid orfC constructs (described below) resulted in production of active proteins.

Hybrid Schizochytrium / Th.23B OrfCs in pYES2: The plasmid containing the native *Schizochytrium* orfC, pYES2:OrfC (described above), was digested with *Bsi*WI and *Pml*I to remove the section of DNA encoding the DH2 region and some flanking DNA. The region removed was from ~1179 bp (the *Bsi*WI site) to ~3256 bp (the *Pml*I site) of the *Schizochytrium* orfC sequence (SEQ ID NO:5). The resulting 8.4 kb fragment (containing the vector as well as the 5' and 3' portions of orfC) was gel purified. A previously described plasmid (see Example 2) containing a hybrid *Schizochytrium/Th.23B* orfC (pREZ179 = pColA DUET-*Schizo.* orfC-*Th.23B* DH2 hybrid) was digested with *Bsi*WI and *Pml*I and a 2 kb fragment containing the *Th.23B* DH2 region and flanking *Schizochytrium* DNA was gel purified. The two purified fragments were ligated together to form pYES2: OrfC-23BDH2.

A similar strategy was used to create pYES2: OrfC-s23BDH2. In this case the plasmid used as the source for the synthetic *Th.23B* DH2 region (pDD22; see Example 3) was a hybrid orfC in which the DNA encoding the *Th.23B* DH2 domain was derived from a synthetic coding region whose codons had been modified to more closely match the preferences of *Schizochytrium* (see Example 3).

Results of expressing pYES6-Leu::sOrf A, pYES3:sOrf B, pYES6-His:HetI and pYES2:OrfC-23BDH2 or pYES2: OrfC-s23BDH2 in yeast: Table 4 shows the PUFAs produced in yeast expressing hybrid Orf C constructs in conjunction with the *Schizochytrium* subunits A and B and *Nostoc* HetI. As observed above in part A, the only novel peaks detected in these yeast samples were DHA and DPAn-6. Growth conditions and sample preparation were as described above. Only the relevant PUFA data are shown (as FAMES given as area %). Samples labeled as BRY 4.21 contain the hybrid orfC with the native *Th.23B* DH2 region, while the sample labeled BRY 4.23 contains the hybrid orfC with the *Th.23B* DH2 region derived from the synthetic gene. Two samples (a and b, from independent isolates) were tested for the BRY 4.21 strain while one isolate of the BRY 4.23 strain was tested. Relative to the cells expressing the *Schizochytrium* orfC, those cells expressing either form of the hybrid orfC have a higher DHA/DPAn-6 ratio (an average of ~2.6 for those with the native *Th.23B* DH2 and a value of ~2.9 for the sample with synthetic *Th.23B* DH2). The expression of the hybrid orfC gene in yeast clearly resulted in an increase in the DHA to DPAn-6 ratio relative to yeast expressing the native *Schizochytrium* orfC gene. The fact that the DHA/DPAn-6 ratio in *Th.23B* cells or in *Schizochytrium* expressing the hybrid orf C is much higher (~8-10) indicates that other factors are contributing to the bias towards accumulation of DHA over DPAn-6. The observation that the ratio did increase in yeast indicates that this construct is a useful model for expressing a PUFA synthase system in heterologous eukaryotic hosts (*e.g.*, yeast or plants).

Table 4

Strain	orfC form	DHA	DPAn-6	DHA + DPA	DHA/DPA
BRY 4.5	<i>Schizo.</i>	2.4	2.0	4.4	1.2
BRY 4.21a	<i>Th.23B</i> DH2	4.30	1.51	5.81	2.85
BRY 4.21b	<i>Th.23B</i> DH2	4.36	1.67	6.03	2.61
BRY 4.23	synth. <i>Th.23B</i> DH2	2.71	0.92	3.63	2.95

Example 7

The following example demonstrates the production of PUFAs in fermentation scale experiments using various genetically modified *Schizochytrium* strains described in Example 4.

5 Experiment 1

Using 2-liter fermentors under typical fermentation conditions, two cultures of a wild-type *Schizochytrium* (ATCC 20888) and two cultures of a transgenic *Schizochytrium* (B67-5, having a codon-optimized (synthetic) *Th.23B* orfC coding region in place of the native *Schizochytrium* orfC coding region; see Example 4) were cultivated to compare the fatty acid profiles. Each strain was fermented in a medium containing carbon, nitrogen, phosphorus, salts, trace metals, and vitamins. Each fermentor was inoculated with a typical seed culture, then cultivated for 80 hours, and fed both a carbon source and a nitrogen source during cultivation. The nitrogen source was fed and consumed only during the growth phase, while the carbon source was fed and consumed throughout the fermentation. After 80 hours, samples from each fermentor were centrifuged, lyophilized and analyzed by gas chromatography for fatty acid content.

Typical fermentation conditions:

20 Temperature: 28 - 30°C
 pH: 5.0 - 7.5
 agitation: 100 - 300 cps
 airflow: 0.25 - 2.0 vvm
 glucose: 5 - 35 g/L (concentration)
 25 inoculum: 7.5% - 15%

The results were as shown in Table 5 below:

30 **Table 5**

Strain	Wild-type	Wild-type	Transgenic	Transgenic
log hour	20888	20888	B67-5	B67-5
fermentor	80	80	80	80
	BN25	BN28	BN26	BN27
% 10:0	0.02	0.01	0.01	0.01
% 12:0	0.20	0.18	0.20	0.20
% 13:0	0.00	0.00	0.07	0.00
% 14:0	9.57	8.89	9.76	9.80
% 16:0	33.68	32.58	34.62	34.51
% 16:1	0.13	0.12	0.18	0.17
% 17:0	0.08	0.09	0.07	0.07

Strain log hour fermentor	Wild- type 20888 80 BN25	Wild- type 20888 80 BN28	Transgenic B67-5 80 BN26	Transgenic B67-5 80 BN27
% 18:0	0.78	0.76	0.77	0.76
% 18:1 n-9	0.00	0.00	0.08	0.08
% 18:1 n-7	0.14	0.12	0.11	0.11
% 18:3 n-6	0.14	0.15	0.08	0.08
% 18:3 n-3	0.03	0.04	0.08	0.08
% 20:0	0.09	0.08	0.08	0.08
% 20:3 n-6	0.32	0.33	0.09	0.09
% 20:4 ARA	0.25	0.30	0.10	0.11
% 20:5 EPA	0.36	0.38	0.60	0.60
% 22:5 n-6	14.98	15.37	6.52	6.52
% 22:5 n-3	0.00	0.00	0.21	0.21
% 22:6 DHA	37.32	38.64	44.47	44.58
DHA / DPA	2.49	2.51	6.82	6.84

As shown in Table 5, strain B67-5 containing the synthetic *Thraustochytrium* 23B orfC coding region in place of the native *Schizochytrium* coding region produced more DHA and had a greater ration of DHA to DPA n-6 than the wild-type *Schizochytrium* strain.

Experiment 2

Using 10-liter fermentors under typical fermentation conditions, one culture of a wild-type *Schizochytrium* (ATCC 20888) and one culture of transgenic *Schizochytrium* (B105-1A1; containing a non-codon-optimized (*Thraustochytrium* native) *Th.23B* DH2 coding region in place of the native *Schizochytrium* DH2 region; see Example 4) were cultivated to compare the fatty acid profiles. Each strain was grown in a medium containing carbon, nitrogen, phosphorus, salts, trace metals, and vitamins. Each fermentor was inoculated with a typical seed culture, then cultivated for 72 hours, and fed both a carbon source and a nitrogen source during cultivation. The nitrogen source was fed and consumed only during the growth phase, while the carbon source was fed and consumed throughout the fermentation. After 72 hours, samples from each fermentor were centrifuged, lyophilized and analyzed by gas chromatography for fatty acid content.

Typical fermentation conditions:

Temperature: 28 - 30°C
 pH: 5.0 - 7.5
 agitation: 100 - 300 cps
 airflow: 0.25 - 2.0 vvm
 glucose: 5 - 35 g/L (concentration)
 inoculum: 7.5% - 15%

The results are shown in Table 6.

Table 6

Strain Log Hour Vessel	Wild-type 20888 72 BN23	Transgenic B105-1A-1 72 BN24
% 10:0	0.00	0.00
% 12:0	0.26	0.28
% 13:0	0.09	0.10
% 14:0	11.36	12.39
% 16:0	37.10	40.02
% 16:1	0.13	0.15
% 17:0	0.07	0.06
% 18:0	0.83	0.86
% 18:1 n-9	0.00	0.11
% 18:1 n-7	0.08	0.08
% 18:3 n-6	0.13	0.05
% 18:3 n-3	0.00	0.00
% 20:0	0.08	0.10
% 20:3 n-6	0.28	0.00
% 20:4 ARA	0.26	0.00
% 20:5 EPA	0.34	0.35
% 22:5 n-6	13.48	4.40
% 22:5 n-3	0.00	0.00
% 22:6 DHA	34.07	39.56
DHA/DPA	2.53	8.98

5 Table 6 shows that the strain comprising a *Thraustochytrium* 23B DH2 region in place of the *Schizochytrium* DH2 region has a much higher DHA/DPA n-6 ratio, again illustrating the improved DHA ratio achieved by use of chimeric PUFA PKS systems described herein.

Example 8

10 This example describes the construction and evaluation of all combinations of synthetic codon-optimized *Th.23B* orfA, orf B, and orfC coding regions expressed in *Schizochytrium*.

15 Detailed descriptions of methods for the exact replacement of the *Schizochytrium* orfC coding region with the *Th.23B* synthetic codon-optimized orfC coding region have been given above (Examples 1 and 4). Those skilled in the art recognize that these techniques can generally be applied to most genes of interest. Those skilled in the art further recognize that such gene designs and replacements can be achieved by variations on these methods or other methods altogether. For example, multiple genes/coding regions can be deleted simultaneously and replaced simultaneously. In *Schizochytrium*,
20 the orfA and ofB genes are found close together ("linked") in the genome separated by an intergenic region (comprising SEQ ID NO:76). These two coding regions (along with the

intergenic region) can be simultaneously deleted by methods analogous to those described previously for orfC (U.S. Patent Application Publication No. 20050100995). Methods similar to those described in Examples 1 and 4 above can then be used to simultaneously create “perfect stitch” replacements of synthetic codon-optimized *Th.23B* orfA and orfB
5 coding regions (including the entire *Schizochytrium* intergenic region) into the *Schizochytrium* orfA/orfB locus. Strains such as B80-1 and B80-20 (Table 7) were created in this way.

In another example, coding region deletions can be created by a “two-step” method in which a plasmid carrying the marked deletion structure plus a second selectable marker
10 initially recombines in its entirety by a single cross-over event into the target locus. Then, the integrant structure “resolves” by a single cross-over event at a site on the opposite side of the deletion structure such that the second selectable marker is lost and the deletion structure remains in place of the original gene structure (Rothstein R., “Targeting, Disruption, Replacement, and Allele Rescue: Integrative DNA Transformation in Yeast”,
15 pp281-301 in Methods in Enzymology, vol. 194 (1991), Elsevier/Academic Press, Amsterdam). The precursor to strain B71-1 (Table 7) was created in this manner.

By the methods outlined here, a set of *Schizochytrium* strains in which all combinations of the synthetic (codon-optimized) *Th.23B* orfA, orfB, and orfC coding regions have replaced the cognate *Schizochytrium* coding regions has been created. The
20 set member containing no *Th.23B* genes is the wild type *Schizochytrium* ATCC20888, and the set member containing only the (full length) synthetic codon-optimized *Th.23B* orfC coding region, B67-5, was described in Example 4 and Table 1 above. This set of eight strains was evaluated for fatty acid production during growth in SSFM medium as described in Example 4 above, and the data are given in Table 7.

25 Plasmid pDD26 contains the full length synthetic *Th.23B* orfA coding region perfectly stitched to the upstream and downstream regions of the *Schizochytrium* orfA gene. The nucleotide sequence of the coding region of pDD26 is represented herein by SEQ ID NO:71. SEQ ID NO:71 encodes SEQ ID NO:39. pDD26 has been deposited as ATCC Accession No. PTA-8411, as described previously herein.).

30 Plasmid pDD32 contains the full length synthetic *Th.23B* orfB coding region perfectly stitched to the upstream and downstream regions of the *Schizochytrium* orfB gene. The nucleotide sequence of the coding region of pDD32 is represented herein by

SEQ ID NO:72. SEQ ID NO:72 encodes SEQ ID NO:52. pDD32 has been deposited as ATCC Accession No. PTA-8412, as described previously herein.).

The protein products of all three synthetic codon-optimized *Th.23B* orf coding regions function in *Schizochytrium* and successfully interact with other PUFA synthase components regardless of source. Expression of the *Th.23B* OrfC protein (strain B67-5) causes an increase in the DHA/DPA ratio to a value that approximates that in the native *Th.23B* strain, a result previously demonstrated in Example 4. This phenomenon is seen for all combinations expressing the *Th.23B* OrfC protein (B67-5, B79-11, B79-1, and B80-20). Surprisingly, the combination of synthetic codon-optimized *Th.23B* orfC plus synthetic codon-optimized *Th.23B* orfA coding regions (strain B79-1) leads to the highest level of DHA production, while maintaining the high DHA/DPA ratio. The increased DHA production in this *Schizochytrium* strain appears to be due to both the increased n-3/n-6 ratio caused by *Th.23B* OrfC and increased total PUFA production caused by the interaction of *Th.23B* OrfA with *Th.23B* OrfC.

These data demonstrate that components of the PUFA synthase complex from different organisms can successfully co-function and can confer specific characteristics of the source organism to a new host. Furthermore, manipulation of the source and expression levels of PUFA synthase components can lead to novel profiles, higher productivities, and lower costs of target fatty acids.

Table 7

strain	<i>Th. 23B</i> orf gene(s)	FAME (%dcw)	DHA (%dcw)	DPA (%dcw)	DHA (%FAME)	DHA/DPA
ATCC20888	(none)	73.9	16.4	5.4	22.1	3.04
B71-1	A	74.2	17.2	5.15	23.2	3.34
B82-3	B	67.9	15.4	4.93	22.7	3.12
B67-5	C	76.2	22.2	2.88	29.2	7.71
B80-1	AB	77.9	12.8	3.20	16.4	4.00
B79-11	BC	79.1	23.4	2.72	29.6	8.60
B79-1	AC	79.0	31.1	2.90	39.4	10.72
B80-20	ABC	77.4	20.9	2.32	27.0	9.01

Each reference cited herein is incorporated herein by reference in its entirety.

While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those

skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

The claims defining the invention are as follows:


1. A chimeric PUFA PKS system, wherein an FabA-like β -hydroxyacyl-ACP dehydrase-2 (DH2) domain from a first PUFA PKS system is replaced with a DH2 domain from a different, second PUFA PKS system, to produce a chimeric PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system.
2. The chimeric PUFA PKS system of Claim 1, wherein a protein comprising the DH2 domain from the first PUFA PKS system is replaced with a homologous protein comprising the DH2 domain from the second PUFA PKS system.
3. The chimeric PUFA PKS system of Claim 1 or Claim 2, wherein the DH2 domain from the first or second PUFA PKS system comprises a DH2 domain from *Schizochytrium* or *Thraustochytrium*.
4. The chimeric PUFA PKS system of any one of Claims 1 to 3, wherein the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein the second PUFA PKS system is a *Thraustochytrium* PUFA PKS system.
5. The chimeric PUFA PKS system of any one of Claims 1 to 3, wherein the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein OrfC from the *Schizochytrium* PUFA PKS system is replaced with OrfC from a different thraustochytrid.
6. The chimeric PUFA PKS system of any one of Claims 1 to 3, wherein the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein OrfC from the *Schizochytrium* PUFA PKS system is replaced with OrfC from *Thraustochytrium* 23B.
7. The chimeric PUFA PKS system of Claim 6, wherein the OrfC from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage.
8. The chimeric PUFA PKS system of Claim 7, wherein the nucleic acid sequence comprises SEQ ID NO: 70.
9. The chimeric PUFA PKS system of Claim 6, wherein OrfA from the *Schizochytrium* PUFA PKS system is replaced with OrfA from *Thraustochytrium* 23B.
10. The chimeric PUFA PKS system of Claim 9, wherein the OrfA from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage.
11. The chimeric PUFA PKS system of Claim 10, wherein the nucleic acid sequence comprises SEQ ID NO:71.
12. The chimeric PUFA PKS system of Claim 6, wherein OrfB from the *Schizochytrium* PUFA PKS system is replaced with OrfB from *Thraustochytrium* 23B.
13. The chimeric PUFA PKS system of Claim 12, wherein OrfB from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage.


14. The chimeric PUFA PKS system of Claim 13, wherein the nucleic acid sequence comprises SEQ ID NO: 72.
15. The chimeric PUFA PKS system of any one of Claims 1 to 3, wherein the first PUFA PKS system is a *Schizochytrium* PUFA PKS system, and wherein the DH2 domain of OrfC from the *Schizochytrium* PUFA PKS system is replaced with the DH2 domain from *Thraustochytrium* 23B.
16. The chimeric PUFA PKS system of Claim 15, wherein the nucleic acid sequence comprising the DH2 domain from *Thraustochytrium* 23B comprises SEQ ID NO:73.
17. The chimeric PUFA PKS system of Claim 15, wherein the DH2 from *Thraustochytrium* 23B is encoded by a nucleic acid sequence that is optimized for *Schizochytrium* codon usage.
18. The chimeric PUFA PKS system of Claim 17, wherein the nucleic acid sequence comprising the DH2 domain from *Thraustochytrium* 23B comprises SEQ ID NO:75.
19. The chimeric PUFA PKS system of Claim 1, wherein the chimeric PUFA PKS system comprises:
 - (a) a protein comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 74;
 - (b) a protein comprising an amino acid sequence of SEQ ID NO: 74;
 - (c) SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:74;
 - (d) SEQ ID NO:39, SEQ ID NO:4 and SEQ ID NO:62; or
 - (e) SEQ ID NO:39, SEQ ID NO:4 and SEQ ID NO:74.
20. The chimeric PUFA PKS system of Claim 1, wherein the chimeric PUFA PKS system is encoded by nucleic acid molecules comprising:
 - (a) SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:70;
 - (b) SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:73;
 - (c) SEQ ID NO:1, SEQ ID NO:3 and SEQ ID NO:75; or
 - (d) SEQ ID NO:71, SEQ ID NO:3 and SEQ ID NO:70.
21. A method of altering the omega-3 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system, comprising expressing the chimeric PUFA PKS system of any one of Claims 1 to 21 in an organism.
22. The method of Claim 21, wherein the chimeric PUFA PKS system is expressed by a microorganism.


23. The method of Claim 22, wherein the microorganism is a *Schizochytrium* or a yeast.
24. The method of Claim 21, wherein the chimeric PUFA PKS system is expressed by a plant.
25. A genetically modified microorganism or plant or part of the plant, comprising a chimeric PUFA PKS system of any one of Claims 1 to 20.
26. A method of increasing the production of PUFAs and of altering the omega-3 to omega-6 ratio of polyunsaturated fatty acids (PUFAs) produced by a first PUFA PKS system, comprising expressing a chimeric PUFA PKS system in an organism, wherein the Fab A- like β -hydroxyacyl-ACP dehydrase-2 (DH2) domain from a first PUFA PKS system is replaced with a DH2 domain from a different, second PUFA PKS system, to produce a chimeric PUFA PKS system that produces a different ratio of omega-3 to omega-6 PUFAs as compared to the first PUFA PKS system, and wherein the DH2 domain from the second PUFA PKS system is optimized for the codon usage of the organism from which the first PUFA PKS system is derived.
27. An isolated nucleic acid molecule encoding a chimeric OrfC protein that is at least 95% identical to SEQ ID NO: 74.
28. The isolated nucleic acid molecule of Claim 27, wherein the isolated nucleic acid molecule comprises a nucleic acid sequence that is at least 95% identical to SEQ ID NO:73.
29. The isolated nucleic acid molecule of Claim 27 or Claim 28, wherein the nucleic acid sequence is optimized for the codon usage of an organism in which the nucleic acid molecule is to be expressed.
30. The isolated nucleic acid molecule of Claim 27 or Claim 28, wherein the nucleic acid sequence is optimized for the codon usage of an organism from which a portion of the chimeric protein is derived.
31. The isolated nucleic acid molecule of Claim 27, wherein the nucleic acid sequence is at least 95% identical to SEQ ID NO: 75.
32. A recombinant nucleic acid molecule comprising the nucleic acid molecule of any one of Claims 27 to 31.
33. A recombinant host cell that has been transfected with the nucleic acid molecule of any one of Claims 27 to 32.
34. The recombinant host cell of Claim 33, wherein the cell is a microorganism or a plant cell.
35. The recombinant host cell of Claim 34, wherein the microorganism is a *Schizochytrium*, a bacterium, or a yeast.


36. A genetically modified plant or part thereof, comprising the plant cell of Claim 34.

FIG. 1














FIG. 3B


PciI fragment replaced from pDS26
- previous hybrid clone -
to generate pPREZ179






Step 8

FIG. 3C




Step 1: Construction of pDD21

FIG. 4A



Step 2: Construction of pDD22



Step 3: Construction of pDD24

FIG. 4C




FIG. 5





FIG. 6



2997-49-2-pct_ST25
SEQUENCE LISTING

<110> Martek Biosciences Corporation
<120> CHIMERIC PUFA POLYKETIDE SYNTHASE SYSTEMS
<130> 2997-49-2-PCT
<150> 11/749,686
<151> 2007-05-16
<160> 95
<170> PatentIn version 3.4
<210> 1
<211> 8733
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(8733)

<400> 1	
atg gcg gcc cgt ctg cag gag caa aag gga ggc gag atg gat acc cgc	48
Met Ala Ala Arg Leu Gln Glu Gln Lys Gly Gly Glu Met Asp Thr Arg	
1 5 10 15	
att gcc atc atc ggc atg tcg gcc atc ctc ccc tgc ggc acg acc gtg	96
Ile Ala Ile Ile Gly Met Ser Ala Ile Leu Pro Cys Gly Thr Thr Val	
20 25 30	
cgc gag tcg tgg gag acc atc cgc gcc ggc atc gac tgc ctg tcg gat	144
Arg Glu Ser Trp Glu Thr Ile Arg Ala Gly Ile Asp Cys Leu Ser Asp	
35 40 45	
ctc ccc gag gac cgc gtc gac gtg acg gcg tac ttt gac ccc gtc aag	192
Leu Pro Glu Asp Arg Val Asp Val Thr Ala Tyr Phe Asp Pro Val Lys	
50 55 60	
acc acc aag gac aag atc tac tgc aag cgc ggt ggc ttc att ccc gag	240
Thr Thr Lys Asp Lys Ile Tyr Cys Lys Arg Gly Gly Phe Ile Pro Glu	
65 70 75 80	
tac gac ttt gac gcc cgc gag ttc gga ctc aac atg ttc cag atg gag	288
Tyr Asp Phe Asp Ala Arg Glu Phe Gly Leu Asn Met Phe Gln Met Glu	
85 90 95	
gac tcg gac gca aac cag acc atc tcg ctt ctc aag gtc aag gag gcc	336
Asp Ser Asp Ala Asn Gln Thr Ile Ser Leu Leu Lys Val Lys Glu Ala	
100 105 110	
ctc cag gac gcc ggc atc gac gcc ctc ggc aag gaa aag aag aac atc	384
Leu Gln Asp Ala Gly Ile Asp Ala Leu Gly Lys Glu Lys Lys Asn Ile	
115 120 125	
ggc tgc gtg ctc ggc att ggc ggc ggc caa aag tcc agc cac gag ttc	432
Gly Cys Val Leu Gly Ile Gly Gly Gly Gln Lys Ser Ser His Glu Phe	
130 135 140	
tac tcg cgc ctt aat tat gtt gtc gtg gag aag gtc ctc cgc aag atg	480
Tyr Ser Arg Leu Asn Tyr Val Val Val Glu Lys Val Leu Arg Lys Met	
145 150 155 160	
ggc atg ccc gag gag gac gtc aag gtc gcc gtc gaa aag tac aag gcc	528
Gly Met Pro Glu Glu Asp Val Lys Val Ala Val Glu Lys Tyr Lys Ala	

2997-49-2-pct_ST25																
165				170				175								
aac Asn	ttc Phe	ccc Pro	gag Glu 180	tgg Trp	cgc Arg	ctc Leu	gac Asp	tcc Ser 185	ttc Phe	cct Pro	ggc Gly	ttc Phe	ctc Leu 190	ggc Gly	aac Asn	576
gtc Val	acc Thr	gcc Ala 195	ggc Gly	cgc Arg	tgc Cys	acc Thr	aac Asn 200	acc Thr	ttc Phe	aac Asn	ctc Leu	gac Asp 205	ggc Gly	atg Met	aac Asn	624
tgc Cys	gtt Val 210	gtc Val	gac Asp	gcc Ala	gca Ala	tgc Cys 215	gcc Ala	tcg Ser	tcc Ser	ctc Leu	atc Ile 220	gcc Ala	gtc Val	aag Lys	gtc Val	672
gcc Ala 225	atc Ile	gac Asp	gag Glu	ctg Leu	ctc Leu 230	tac Tyr	ggc Gly	gac Asp	tgc Cys	gac Asp 235	atg Met	atg Met	gtc Val	acc Thr	ggc Gly 240	720
gcc Ala	acc Thr	tgc Cys	acg Thr	gat Asp 245	aac Asn	tcc Ser	atc Ile	ggc Gly	atg Met 250	tac Tyr	atg Met	gcc Ala	ttc Phe	tcc Ser 255	aag Lys	768
acc Thr	ccc Pro	gtg Val	ttc Phe 260	tcc Ser	acg Thr	gac Asp	ccc Pro	agc Ser 265	gtg Val	cgc Arg	gcc Ala	tac Tyr	gac Asp 270	gaa Glu	aag Lys	816
aca Thr	aag Lys	ggc Gly 275	atg Met	ctc Leu	atc Ile	ggc Gly	gag Glu 280	ggc Gly	tcc Ser	gcc Ala	atg Met	ctc Leu 285	gtc Val	ctc Leu	aag Lys	864
cgc Arg	tac Tyr 290	gcc Ala	gac Asp	gcc Ala	gtc Val	cgc Arg 295	gac Asp	ggc Gly	gat Asp	gag Glu	atc Ile 300	cac His	gct Ala	gtt Val	att Ile	912
cgc Arg 305	ggc Gly	tgc Cys	gcc Ala	tcc Ser	tcc Ser 310	agt Ser	gat Asp	ggc Gly	aag Lys	gcc Ala 315	gcc Ala	ggc Gly	atc Ile	tac Tyr	acg Thr 320	960
ccc Pro	acc Thr	att Ile	tcg Ser	ggc Gly 325	cag Gln	gag Glu	gag Glu	gcc Ala	ctc Leu 330	cgc Arg	cgc Arg	gcc Ala	tac Tyr	aac Asn 335	cgc Arg	1008
gcc Ala	tgt Cys	gtc Val	gac Asp 340	ccg Pro	gcc Ala	acc Thr	gtc Val	act Thr 345	ctc Leu	gtc Val	gag Glu	ggc Gly	cac His 350	ggc Gly	acc Thr	1056
ggc Gly	act Thr	ccc Pro 355	gtt Val	ggc Gly	gac Asp	cgc Arg	atc Ile 360	gag Glu	ctc Leu	acc Thr	gcc Ala	ttg Leu 365	cgc Arg	aac Asn	ctc Leu	1104
ttt Phe	gac Asp 370	aag Lys	gcc Ala	tac Tyr	ggc Gly	gag Glu 375	ggc Gly	aac Asn	acc Thr	gaa Glu	aag Lys 380	gtc Val	gct Ala	gtg Val	ggc Gly	1152
agc Ser 385	atc Ile	aag Lys	tcc Ser	agc Ser	atc Ile 390	ggc Gly	cat His	ctc Leu	aag Lys	gcc Ala 395	gtc Val	gcc Ala	ggc Gly	ctc Leu	gcc Ala 400	1200
ggc Gly	atg Met	atc Ile	aag Lys	gtc Val 405	atc Ile	atg Met	gcg Ala	ctc Leu	aag Lys 410	cac His	aag Lys	act Thr	ctc Leu	ccg Pro 415	ggc Gly	1248
acc Thr	atc Ile	aac Asn	gtc Val 420	gac Asp	aac Asn	cca Pro	ccc Pro	aac Asn 425	ctc Leu	tac Tyr	gac Asp	aac Asn	acg Thr 430	ccc Pro	atc Ile	1296
aac Asn	gag Glu	tcc Ser	tcg Ser	ctc Leu	tac Tyr	att Ile	aac Asn	acc Thr	atg Met	aac Asn	cgc Arg	ccc Pro	tgg Trp	ttc Phe	ccg Pro	1344

2997-49-2-pct_ST25																
435				440				445								
ccc Pro	cct Pro 450	ggt Gly	gtg Val	ccc Pro	cgc Arg	cgc Arg 455	gcc Ala	ggc Gly	att Ile	tcg Ser	agc Ser 460	ttt Phe	ggc Gly	ttt Phe	ggt Gly	1392
ggc Gly 465	gcc Ala	aac Asn	tac Tyr	cac His	gcc Ala 470	gtc Val	ctc Leu	gag Glu	gag Glu	gcc Ala 475	gag Glu	ccc Pro	gag Glu	cac His	acg Thr 480	1440
acc Thr	gcg Ala	tac Tyr	cgc Arg	ctc Leu 485	aac Asn	aag Lys	cgc Arg	ccg Pro	cag Gln 490	ccc Pro	gtg Val	ctc Leu	atg Met	atg Met 495	gcc Ala	1488
gcc Ala	acg Thr	ccc Pro	gcg Ala 500	gcc Ala	ctc Leu	cag Gln	tcg Ser	ctc Leu 505	tgc Cys	gag Glu	gcc Ala	cag Gln	ctc Leu 510	aag Lys	gag Glu	1536
ttc Phe	gag Glu	gcc Ala 515	gcc Ala	atc Ile	aag Lys	gag Glu	aac Asn 520	gag Glu	acc Thr	gtc Val	aag Lys	aac Asn 525	acc Thr	gcc Ala	tac Tyr	1584
atc Ile	aag Lys 530	tgc Cys	gtc Val	aag Lys	ttc Phe	ggc Gly 535	gag Glu	cag Gln	ttc Phe	aaa Lys	ttc Phe 540	cct Pro	ggc Gly	tcc Ser	atc Ile	1632
ccg Pro 545	gcc Ala	aca Thr	aac Asn	gcg Ala	cgc Arg 550	ctc Leu	ggc Gly	ttc Phe	ctc Leu	gtc Val 555	aag Lys	gat Asp	gct Ala	gag Glu	gat Asp 560	1680
gcc Ala	tgc Cys	tcc Ser	acc Thr	ctc Leu 565	cgt Arg	gcc Ala	atc Ile	tgc Cys	gcc Ala 570	caa Gln	ttc Phe	gcc Ala	aag Lys	gat Asp 575	gtc Val	1728
acc Thr	aag Lys	gag Glu	gcc Ala 580	tgg Trp	cgc Arg	ctc Leu	ccc Pro	cgc Arg 585	gag Glu	ggc Gly	gtc Val	agc Ser	ttc Phe 590	cgc Arg	gcc Ala	1776
aag Lys	ggc Gly	atc Ile 595	gcc Ala	acc Thr	aac Asn	ggc Gly	gct Ala 600	gtc Val	gcc Ala	gcg Ala	ctc Leu	ttc Phe 605	tcc Ser	ggc Gly	cag Gln	1824
ggc Gly 610	gcg Ala	cag Gln	tac Tyr	acg Thr	cac His	atg Met 615	ttt Phe	agc Ser	gag Glu	gtg Val	gcc Ala 620	atg Met	aac Asn	tgg Trp	ccc Pro	1872
cag Gln 625	ttc Phe	cgc Arg	cag Gln	agc Ser	att Ile 630	gcc Ala	gcc Ala	atg Met	gac Asp	gcc Ala 635	gcc Ala	cag Gln	tcc Ser	aag Lys	gtc Val 640	1920
gct Ala	gga Gly	agc Ser	gac Asp	aag Lys 645	gac Asp	ttt Phe	gag Glu	cgc Arg	gtc Val 650	tcc Ser	cag Gln	gtc Val	ctc Leu	tac Tyr 655	ccg Pro	1968
cgc Arg	aag Lys	ccg Pro	tac Tyr 660	gag Glu	cgt Arg	gag Glu	ccc Pro	gag Glu 665	cag Gln	gac Asp	cac His	aag Lys	aag Lys 670	atc Ile	tcc Ser	2016
ctc Leu	acc Thr	gcc Ala 675	tac Tyr	tcg Ser	cag Gln	ccc Pro	tcg Ser 680	acc Thr	ctg Leu	gcc Ala	tgc Cys	gct Ala 685	ctc Leu	ggt Gly	gcc Ala	2064
ttt Phe 690	gag Glu	atc Ile	ttc Phe	aag Lys	gag Glu	gcc Ala 695	ggc Gly	ttc Phe	acc Thr	ccg Pro	gac Asp 700	ttt Phe	gcc Ala	gcc Ala	ggc Gly	2112
cat His	tcg Ser	ctc Leu	ggt Gly	gag Glu	ttc Phe	gcc Ala	gcc Ala	ctc Leu	tac Tyr	gcc Ala	gcg Ala	ggc Gly	tgc Cys	gtc Val	gac Asp	2160

2997-49-2-pct_ST25																	
705						710	715					720					
cgc Arg	gac Asp	gag Glu	ctc Leu	ttt Phe 725	gag Glu	ctt Leu	gtc Val	tgc Cys	cgc Arg 730	cgc Arg	gcc Ala	cgc Arg	atc Ile	atg Met 735	ggc Gly	2208	
ggc Gly	aag Lys	gac Asp	gca Ala 740	ccg Pro	gcc Ala	acc Thr	ccc Pro	aag Lys 745	ggc Gly	tgc Cys	atg Met	gcc Ala	gcc Ala 750	gtc Val	att Ile	2256	
ggc Gly	ccc Pro	aac Asn 755	gcc Ala	gag Glu	aac Asn	atc Ile	aag Lys 760	gtc Val	cag Gln	gcc Ala	gcc Ala	aac Asn 765	gtc Val	tgg Trp	ctc Leu	2304	
ggc Gly	aac Asn 770	tcc Ser	aac Asn	tcg Ser	cct Pro	tcg Ser 775	cag Gln	acc Thr	gtc Val	atc Ile	acc Thr 780	ggc Gly	tcc Ser	gtc Val	gaa Glu	2352	
ggt Gly 785	atc Ile	cag Gln	gcc Ala	gag Glu	agc Ser 790	gcc Ala	cgc Arg	ctc Leu	cag Gln	aag Lys 795	gag Glu	ggc Gly	ttc Phe	cgc Arg	gtc Val 800	2400	
gtg Val	cct Pro	ctt Leu	gcc Ala	tgc Cys 805	gag Glu	agc Ser	gcc Ala	ttc Phe	cac His 810	tcg Ser	ccc Pro	cag Gln	atg Met	gag Glu 815	aac Asn	2448	
gcc Ala	tcg Ser	tcg Ser	gcc Ala 820	ttc Phe	aag Lys	gac Asp	gtc Val	atc Ile 825	tcc Ser	aag Lys	gtc Val	tcc Ser	ttc Phe 830	cgc Arg	acc Thr	2496	
ccc Pro	aag Lys	gcc Ala 835	gag Glu	acc Thr	aag Lys	ctc Leu	ttc Phe 840	agc Ser	aac Asn	gtc Val	tct Ser	ggc Gly 845	gag Glu	acc Thr	tac Tyr	2544	
ccc Pro	acg Thr 850	gac Asp	gcc Ala	cgc Arg	gag Glu	atg Met 855	ctt Leu	acg Thr	cag Gln	cac His	atg Met 860	acc Thr	agc Ser	agc Ser	gtc Val	2592	
aag Lys 865	ttc Phe	ctc Leu	acc Thr	cag Gln	gtc Val 870	cgc Arg	aac Asn	atg Met	cac His	cag Gln 875	gcc Ala	ggt Gly	gcg Ala	cgc Arg	atc Ile 880	2640	
ttt Phe	gtc Val	gag Glu	ttc Phe	gga Gly 885	ccc Pro	aag Lys	cag Gln	gtg Val	ctc Leu 890	tcc Ser	aag Lys	ctt Leu	gtc Val	tcc Ser 895	gag Glu	2688	
acc Thr	ctc Leu	aag Lys	gat Asp 900	gac Asp	ccc Pro	tcg Ser	gtt Val	gtc Val 905	acc Thr	gtc Val	tct Ser	gtc Val	aac Asn 910	ccg Pro	gcc Ala	2736	
tcg Ser	ggc Gly	acg Thr 915	gat Asp	tcg Ser	gac Asp	atc Ile	cag Gln 920	ctc Leu	cgc Arg	gac Asp	gcg Ala	gcc Ala 925	gtc Val	cag Gln	ctc Leu	2784	
gtt Val 930	gtc Val	gct Ala	ggc Gly	gtc Val	aac Asn	ctt Leu 935	cag Gln	ggc Gly	ttt Phe	gac Asp	aag Lys 940	tgg Trp	gac Asp	gcc Ala	ccc Pro	2832	
gat Asp 945	gcc Ala	acc Thr	cgc Arg	atg Met	cag Gln 950	gcc Ala	atc Ile	aag Lys	aag Lys	aag Lys 955	cgc Arg	act Thr	acc Thr	ctc Leu	cgc Arg 960	2880	
ctt Leu	tcg Ser	gcc Ala	gcc Ala	acc Thr 965	tac Tyr	gtc Val	tcg Ser	gac Asp	aag Lys 970	acc Thr	aag Lys	aag Lys	gtc Val	cgc Arg 975	gac Asp	2928	
gcc Ala	gcc Ala	atg Met	aac Asn	gat Asp	ggc Gly	cgc Arg	tgc Cys	gtc Val	acc Thr	tac Tyr	ctc Leu	aag Lys	ggc Gly	gcc Ala	gca Ala	2976	

990

2997-49-2-pct_ST25															
1235						1240						1245			
act Thr	gac Asp 1250	atg Met	atc Ile	gag Glu	tcc Ser	gac Asp 1255	atg Met	gag Glu	ctc Leu	gag Glu	act Thr 1260	gag Glu	ctc Leu	ggc Gly	3789
att Ile	gac Asp 1265	tcc Ser	atc Ile	aag Lys	cgt Arg	gtc Val 1270	gag Glu	atc Ile	ctc Leu	tcc Ser	gag Glu 1275	gtt Val	cag Gln	gcc Ala	3834
atg Met	ctc Leu 1280	aac Asn	gtc Val	gag Glu	gcc Ala	aag Lys 1285	gac Asp	gtc Val	gac Asp	gct Ala	ctc Leu 1290	agc Ser	cgc Arg	act Thr	3879
cgc Arg	act Thr 1295	gtg Val	ggg Gly	gag Glu	gtc Val	gtc Val 1300	aac Asn	gcc Ala	atg Met	aag Lys	gct Ala 1305	gag Glu	atc Ile	gct Ala	3924
ggg Gly	ggc Gly 1310	tct Ser	gcc Ala	ccg Pro	gcg Ala	cct Pro 1315	gcc Ala	gcc Ala	gct Ala	gcc Ala	cca Pro 1320	ggg Gly	ccg Pro	gct Ala	3969
gct Ala	gcc Ala 1325	gcc Ala	cct Pro	gcg Ala	cct Pro	gcc Ala 1330	gcc Ala	gcc Ala	gcc Ala	cct Pro	gct Ala 1335	gtc Val	tcg Ser	aac Asn	4014
gag Glu	ctt Leu 1340	ctt Leu	gag Glu	aag Lys	gcc Ala	gag Glu 1345	acc Thr	gtc Val	gtc Val	atg Met	gag Glu 1350	gtc Val	ctc Leu	gcc Ala	4059
gcc Ala	aag Lys 1355	act Thr	ggc Gly	tac Tyr	gag Glu	act Thr 1360	gac Asp	atg Met	atc Ile	gag Glu	tcc Ser 1365	gac Asp	atg Met	gag Glu	4104
ctc Leu	gag Glu 1370	acc Thr	gag Glu	ctc Leu	ggc Gly	att Ile 1375	gac Asp	tcc Ser	atc Ile	aag Lys	cgt Arg 1380	gtc Val	gag Glu	att Ile	4149
ctc Leu	tcc Ser 1385	gag Glu	gtc Val	cag Gln	gcc Ala	atg Met 1390	ctc Leu	aac Asn	gtc Val	gag Glu	gcc Ala 1395	aag Lys	gac Asp	gtc Val	4194
gac Asp	gct Ala 1400	ctc Leu	agc Ser	cgc Arg	acc Thr	cgc Arg 1405	act Thr	gtt Val	ggc Gly	gag Glu	gtc Val 1410	gtc Val	gat Asp	gcc Ala	4239
atg Met	aag Lys 1415	gcc Ala	gag Glu	atc Ile	gct Ala	ggg Gly 1420	ggc Gly	tct Ser	gcc Ala	ccg Pro	gcg Ala 1425	cct Pro	gcc Ala	gcc Ala	4284
gct Ala	gct Ala 1430	cct Pro	gct Ala	ccg Pro	gct Ala	gct Ala 1435	gcc Ala	gcc Ala	cct Pro	gcg Ala	cct Pro 1440	gcc Ala	gcc Ala	cct Pro	4329
gcg Ala	cct Pro 1445	gct Ala	gtc Val	tcg Ser	agc Ser	gag Glu 1450	ctt Leu	ctc Leu	gag Glu	aag Lys	gcc Ala 1455	gag Glu	act Thr	gtc Val	4374
gtc Val	atg Met 1460	gag Glu	gtc Val	ctc Leu	gcc Ala	gcc Ala 1465	aag Lys	act Thr	ggc Gly	tac Tyr	gag Glu 1470	act Thr	gac Asp	atg Met	4419
atc Ile	gag Glu 1475	tcc Ser	gac Asp	atg Met	gag Glu	ctc Leu 1480	gag Glu	acc Thr	gag Glu	ctc Leu	ggc Gly 1485	att Ile	gac Asp	tcc Ser	4464
atc Ile	aag Lys	cgt Arg	gtc Val	gag Glu	att Ile	ctc Leu	tcc Ser	gag Glu	gtc Val	cag Gln	gcc Ala	atg Met	ctc Leu	aac Asn	4509

2997-49-2-pct_ST25															
1490						1495						1500			
gtc Val	gag Glu 1505	gcc Ala	aag Lys	gac Asp	gtc Val	gac Asp 1510	gct Ala	ctc Leu	agc Ser	cgc Arg	acc Thr 1515	cgc Arg	act Thr	gtt Val	4554
ggc Gly	gag Glu 1520	gtc Val	gtc Val	gat Asp	gcc Ala	atg Met 1525	aag Lys	gcc Ala	gag Glu	atc Ile	gct Ala 1530	ggc Gly	ggc Gly	tct Ser	4599
gcc Ala	ccg Pro 1535	gcg Ala	cct Pro	gcc Ala	gcc Ala	gct Ala 1540	gct Ala	cct Pro	gct Ala	ccg Pro	gct Ala 1545	gct Ala	gcc Ala	gcc Ala	4644
cct Pro	gcg Ala 1550	cct Pro	gcc Ala	gcc Ala	cct Pro	gcg Ala 1555	cct Pro	gcc Ala	gcc Ala	cct Pro	gcg Ala 1560	cct Pro	gct Ala	gtc Val	4689
tcg Ser	agc Ser 1565	gag Glu	ctt Leu	ctc Leu	gag Glu	aag Lys 1570	gcc Ala	gag Glu	act Thr	gtc Val	gtc Val 1575	atg Met	gag Glu	gtc Val	4734
ctc Leu	gcc Ala 1580	gcc Ala	aag Lys	act Thr	ggc Gly	tac Tyr 1585	gag Glu	act Thr	gac Asp	atg Met	att Ile 1590	gag Glu	tcc Ser	gac Asp	4779
atg Met	gag Glu 1595	ctc Leu	gag Glu	acc Thr	gag Glu	ctc Leu 1600	ggc Gly	att Ile	gac Asp	tcc Ser	atc Ile 1605	aag Lys	cgt Arg	gtc Val	4824
gag Glu	att Ile 1610	ctc Leu	tcc Ser	gag Glu	gtt Val	cag Gln 1615	gcc Ala	atg Met	ctc Leu	aac Asn	gtc Val 1620	gag Glu	gcc Ala	aag Lys	4869
gac Asp	gtc Val 1625	gac Asp	gct Ala	ctc Leu	agc Ser	cgc Arg 1630	act Thr	cgc Arg	act Thr	gtt Val	ggc Gly 1635	gag Glu	gtc Val	gtc Val	4914
gat Asp	gcc Ala 1640	atg Met	aag Lys	gct Ala	gag Glu	atc Ile 1645	gct Ala	ggc Gly	agc Ser	tcc Ser	gcc Ala 1650	tcg Ser	gcg Ala	cct Pro	4959
gcc Ala	gcc Ala 1655	gct Ala	gct Ala	cct Pro	gct Ala	ccg Pro 1660	gct Ala	gct Ala	gcc Ala	gct Ala	cct Pro 1665	gcg Ala	ccc Pro	gct Ala	5004
gcc Ala	gcc Ala 1670	gcc Ala	cct Pro	gct Ala	gtc Val	tcg Ser 1675	aac Asn	gag Glu	ctt Leu	ctc Leu	gag Glu 1680	aaa Lys	gcc Ala	gag Glu	5049
act Thr	gtc Val 1685	gtc Val	atg Met	gag Glu	gtc Val	ctc Leu 1690	gcc Ala	gcc Ala	aag Lys	act Thr	ggc Gly 1695	tac Tyr	gag Glu	act Thr	5094
gac Asp	atg Met 1700	atc Ile	gag Glu	tcc Ser	gac Asp	atg Met 1705	gag Glu	ctc Leu	gag Glu	act Thr	gag Glu 1710	ctc Leu	ggc Gly	att Ile	5139
gac Asp	tcc Ser 1715	atc Ile	aag Lys	cgt Arg	gtc Val	gag Glu 1720	atc Ile	ctc Leu	tcc Ser	gag Glu	gtt Val 1725	cag Gln	gcc Ala	atg Met	5184
ctc Leu	aac Asn 1730	gtc Val	gag Glu	gcc Ala	aag Lys	gac Asp 1735	gtc Val	gat Asp	gcc Ala	ctc Leu	agc Ser 1740	cgc Arg	acc Thr	cgc Arg	5229
act Thr	gtt Val	ggc Gly	gag Glu	gtt Val	gtc Val	gat Asp	gcc Ala	atg Met	aag Lys	gcc Ala	gag Glu	atc Ile	gct Ala	ggc Gly	5274

2997-49-2-pct_ST25															
1745						1750						1755			
ggc Gly	tct Ser 1760	gcc Ala	ccg Pro	gcg Ala	cct Pro	gcc Ala 1765	gcc Ala	gct Ala	gcc Ala	cct Pro	gct Ala 1770	ccg Pro	gct Ala	gcc Ala	5319
gcc Ala	gcc Ala 1775	cct Pro	gct Ala	gtc Val	tcg Ser	aac Asn 1780	gag Glu	ctt Leu	ctc Leu	gag Glu	aag Lys 1785	gcc Ala	gag Glu	act Thr	5364
gtc Val	gtc Val 1790	atg Met	gag Glu	gtc Val	ctc Leu	gcc Ala 1795	gcc Ala	aag Lys	act Thr	ggc Gly	tac Tyr 1800	gag Glu	acc Thr	gac Asp	5409
atg Met	atc Ile 1805	gag Glu	tcc Ser	gac Asp	atg Met	gag Glu 1810	ctc Leu	gag Glu	acc Thr	gag Glu	ctc Leu 1815	ggc Gly	att Ile	gac Asp	5454
tcc Ser	atc Ile 1820	aag Lys	cgt Arg	gtc Val	gag Glu	att Ile 1825	ctc Leu	tcc Ser	gag Glu	gtt Val	cag Gln 1830	gcc Ala	atg Met	ctc Leu	5499
aac Asn	gtc Val 1835	gag Glu	gcc Ala	aag Lys	gac Asp	gtc Val 1840	gat Asp	gct Ala	ctc Leu	agc Ser	cgc Arg 1845	act Thr	cgc Arg	act Thr	5544
gtt Val	ggc Gly 1850	gag Glu	gtc Val	gtc Val	gat Asp	gcc Ala 1855	atg Met	aag Lys	gct Ala	gag Glu	atc Ile 1860	gcc Ala	ggc Gly	agc Ser	5589
tcc Ser	gcc Ala 1865	ccg Pro	gcg Ala	cct Pro	gcc Ala	gcc Ala 1870	gct Ala	gct Ala	cct Pro	gct Ala	ccg Pro 1875	gct Ala	gct Ala	gcc Ala	5634
gct Ala	cct Pro 1880	gcg Ala	ccc Pro	gct Ala	gcc Ala	gct Ala 1885	gcc Ala	cct Pro	gct Ala	gtc Val	tcg Ser 1890	agc Ser	gag Glu	ctt Leu	5679
ctc Leu	gag Glu 1895	aag Lys	gcc Ala	gag Glu	acc Thr	gtc Val 1900	gtc Val	atg Met	gag Glu	gtc Val	ctc Leu 1905	gcc Ala	gcc Ala	aag Lys	5724
act Thr	ggc Gly 1910	tac Tyr	gag Glu	act Thr	gac Asp	atg Met 1915	att Ile	gag Glu	tcc Ser	gac Asp	atg Met 1920	gag Glu	ctc Leu	gag Glu	5769
act Thr	gag Glu 1925	ctc Leu	ggc Gly	att Ile	gac Asp	tcc Ser 1930	atc Ile	aag Lys	cgt Arg	gtc Val	gag Glu 1935	atc Ile	ctc Leu	tcc Ser	5814
gag Glu	gtt Val 1940	cag Gln	gcc Ala	atg Met	ctc Leu	aac Asn 1945	gtc Val	gag Glu	gcc Ala	aag Lys	gac Asp 1950	gtc Val	gat Asp	gcc Ala	5859
ctc Leu	agc Ser 1955	cgc Arg	acc Thr	cgc Arg	act Thr	gtt Val 1960	ggc Gly	gag Glu	gtt Val	gtc Val	gat Asp 1965	gcc Ala	atg Met	aag Lys	5904
gcc Ala	gag Glu 1970	atc Ile	gct Ala	ggt Gly	ggc Gly	tct Ser 1975	gcc Ala	ccg Pro	gcg Ala	cct Pro	gcc Ala 1980	gcc Ala	gct Ala	gcc Ala	5949
cct Pro	gct Ala 1985	ccg Pro	gct Ala	gcc Ala	gcc Ala	gcc Ala 1990	cct Pro	gct Ala	gtc Val	tcg Ser	aac Asn 1995	gag Glu	ctt Leu	ctt Leu	5994
gag Glu	aag Lys	gcc Ala	gag Glu	acc Thr	gtc Val	gtc Val	atg Met	gag Glu	gtc Val	ctc Leu	gcc Ala	gcc Ala	aag Lys	act Thr	6039

2997-49-2-pct_ST25															
2000						2005						2010			
gag Glu	ctc Leu	gag Glu	acc Thr	gac Asp	atg Met	atc Ile	gag Glu	tcc Ser	gac Asp	atg Met	gag Glu	ctc Leu	gag Glu	acc Thr	6084
gag Glu	ctc Leu	gag Glu	att Ile	gac Asp	tcc Ser	atc Ile	aag Lys	cgt Arg	gtc Val	gag Glu	att Ile	ctc Leu	tcc Ser	gag Glu	6129
gtt Val	cag Gln	gcc Ala	atg Met	ctc Leu	aac Asn	gtc Val	gag Glu	gcc Ala	aag Lys	gac Asp	gtc Val	gac Asp	gct Ala	ctc Leu	6174
agc Ser	cgc Arg	act Thr	cgc Arg	act Thr	gtt Val	ggc Gly	gag Glu	gtc Val	gtc Val	gat Asp	gcc Ala	atg Met	aag Lys	gct Ala	6219
gag Glu	atc Ile	gct Ala	ggc Gly	ggc Gly	tct Ser	gcc Ala	ccg Pro	gcg Ala	cct Pro	gcc Ala	gcc Ala	gct Ala	gct Ala	cct Pro	6264
gcc Ala	tcg Ser	gct Ala	ggc Gly	gcc Ala	gcg Ala	cct Pro	gcg Ala	gtc Val	aag Lys	att Ile	gac Asp	tcg Ser	gtc Val	cac His	6309
ggc Gly	gct Ala	gac Asp	tgt Cys	gat Asp	gat Asp	ctt Leu	tcc Ser	ctg Leu	atg Met	cac His	gcc Ala	aag Lys	gtg Val	gtt Val	6354
gac Asp	atc Ile	cgc Arg	cgc Arg	ccg Pro	gac Asp	gag Glu	ctc Leu	atc Ile	ctg Leu	gag Glu	cgc Arg	ccc Pro	gag Glu	aac Asn	6399
cgc Arg	ccc Pro	gtt Val	ctc Leu	gtt Val	gtc Val	gat Asp	gac Asp	ggc Gly	agc Ser	gag Glu	ctc Leu	acc Thr	ctc Leu	gcc Ala	6444
ctg Leu	gtc Val	cgc Arg	gtc Val	ctc Leu	ggc Gly	gcc Ala	tgc Cys	gcc Ala	gtt Val	gtc Val	ctg Leu	acc Thr	ttt Phe	gag Glu	6489
ggc Gly	ctc Leu	cag Gln	ctc Leu	gct Ala	cag Gln	cgc Arg	gct Ala	ggc Gly	gcc Ala	gct Ala	gcc Ala	atc Ile	cgc Arg	cac His	6534
gtg Val	ctc Leu	gcc Ala	aag Lys	gat Asp	ctt Leu	tcc Ser	gcg Ala	gag Glu	agc Ser	gcc Ala	gag Glu	aag Lys	gcc Ala	atc Ile	6579
aag Lys	gag Glu	gcc Ala	gag Glu	cag Gln	cgc Arg	ttt Phe	ggc Gly	gct Ala	ctc Leu	ggc Gly	ggc Gly	ttc Phe	atc Ile	tcg Ser	6624
cag Gln	cag Gln	gcg Ala	gag Glu	cgc Arg	ttc Phe	gag Glu	ccc Pro	gcc Ala	gaa Glu	atc Ile	ctc Leu	ggc Gly	ttc Phe	acg Thr	6669
ctc Leu	atg Met	tgc Cys	gcc Ala	aag Lys	ttc Phe	gcc Ala	aag Lys	gct Ala	tcc Ser	ctc Leu	tgc Cys	acg Thr	gct Ala	gtg Val	6714
gct Ala	ggc Gly	ggc Gly	cgc Arg	ccg Pro	gcc Ala	ttt Phe	atc Ile	ggc Gly	gtg Val	gcg Ala	cgc Arg	ctt Leu	gac Asp	ggc Gly	6759
cgc Arg	ctc Leu	gga Gly	ttc Phe	act Thr	tcg Ser	cag Gln	ggc Gly	act Thr	tct Ser	gac Asp	gcg Ala	ctc Leu	aag Lys	cgt Arg	6804

2997-49-2-pct_ST25															
2255						2260						2265			
gcc Ala	cag Gln 2270	cgt Arg	ggt Gly	gcc Ala	atc Ile	ttt Phe 2275	ggc Gly	ctc Leu	tgc Cys	aag Lys	acc Thr 2280	atc Ile	ggc Gly	ctc Leu	6849
gag Glu	tgg Trp 2285	tcc Ser	gag Glu	tct Ser	gac Asp	gtc Val 2290	ttt Phe	tcc Ser	cgc Arg	ggc Gly	gtg Val 2295	gac Asp	att Ile	gct Ala	6894
cag Gln	ggc Gly 2300	atg Met	cac His	ccc Pro	gag Glu	gat Asp 2305	gcc Ala	gcc Ala	gtg Val	gcg Ala	att Ile 2310	gtg Val	cgc Arg	gag Glu	6939
atg Met	gcg Ala 2315	tgc Cys	gct Ala	gac Asp	att Ile	cgc Arg 2320	att Ile	cgc Arg	gag Glu	gtc Val	ggc Gly 2325	att Ile	ggc Gly	gca Ala	6984
aac Asn	cag Gln 2330	cag Gln	cgc Arg	tgc Cys	acg Thr	atc Ile 2335	cgt Arg	gcc Ala	gcc Ala	aag Lys	ctc Leu 2340	gag Glu	acc Thr	ggc Gly	7029
aac Asn	ccg Pro 2345	cag Gln	cgc Arg	cag Gln	atc Ile	gcc Ala 2350	aag Lys	gac Asp	gac Asp	gtg Val	ctg Leu 2355	ctc Leu	gtt Val	tct Ser	7074
ggc Gly	ggc Gly 2360	gct Ala	cgc Arg	ggc Gly	atc Ile	acg Thr 2365	cct Pro	ctt Leu	tgc Cys	atc Ile	cgg Arg 2370	gag Glu	atc Ile	acg Thr	7119
cgc Arg	cag Gln 2375	atc Ile	gcg Ala	ggc Gly	ggc Gly	aag Lys 2380	tac Tyr	att Ile	ctg Leu	ctt Leu	ggc Gly 2385	cgc Arg	agc Ser	aag Lys	7164
gtc Val	tct Ser 2390	gcg Ala	agc Ser	gaa Glu	ccg Pro	gca Ala 2395	tgg Trp	tgc Cys	gct Ala	ggc Gly	atc Ile 2400	act Thr	gac Asp	gag Glu	7209
aag Lys	gct Ala 2405	gtg Val	caa Gln	aag Lys	gct Ala	gct Ala 2410	acc Thr	cag Gln	gag Glu	ctc Leu	aag Lys 2415	cgc Arg	gcc Ala	ttt Phe	7254
agc Ser	gct Ala 2420	ggc Gly	gag Glu	ggc Gly	ccc Pro	aag Lys 2425	ccc Pro	acg Thr	ccc Pro	cgc Arg	gct Ala 2430	gtc Val	act Thr	aag Lys	7299
ctt Leu	gtg Val 2435	ggc Gly	tct Ser	gtt Val	ctt Leu	ggc Gly 2440	gct Ala	cgc Arg	gag Glu	gtg Val	cgc Arg 2445	agc Ser	tct Ser	att Ile	7344
gct Ala	gcg Ala 2450	att Ile	gaa Glu	gcg Ala	ctc Leu	ggc Gly 2455	ggc Gly	aag Lys	gcc Ala	atc Ile	tac Tyr 2460	tcg Ser	tcg Ser	tgc Cys	7389
gac Asp	gtg Val 2465	aac Asn	tct Ser	gcc Ala	gcc Ala	gac Asp 2470	gtg Val	gcc Ala	aag Lys	gcc Ala	gtg Val 2475	cgc Arg	gat Asp	gcc Ala	7434
gag Glu	tcc Ser 2480	cag Gln	ctc Leu	ggt Gly	gcc Ala	cgc Arg 2485	gtc Val	tcg Ser	ggc Gly	atc Ile	gtt Val 2490	cat His	gcc Ala	tcg Ser	7479
ggc Gly	gtg Val 2495	ctc Leu	cgc Arg	gac Asp	cgt Arg	ctc Leu 2500	atc Ile	gag Glu	aag Lys	aag Lys	ctc Leu 2505	ccc Pro	gac Asp	gag Glu	7524
ttc Phe	gac Asp	gcc Ala	gtc Val	ttt Phe	ggc Gly	acc Thr	aag Lys	gtc Val	acc Thr	ggt Gly	ctc Leu	gag Glu	aac Asn	ctc Leu	7569

2997-49-2-pct_ST25														
2510						2515						2520		
ctc Leu	gcc Ala 2525	gcc Ala	gtc Val	gac Asp	cgc Arg	gcc Ala 2530	aac Asn	ctc Leu	aag Lys	cac His	atg Met 2535	gtc Val	ctc Leu	ttc Phe
7614														
agc Ser	tcg Ser 2540	ctc Leu	gcc Ala	ggc Gly	ttc Phe	cac His 2545	ggc Gly	aac Asn	gtc Val	ggc Gly	cag Gln 2550	tct Ser	gac Asp	tac Tyr
7659														
gcc Ala	atg Met 2555	gcc Ala	aac Asn	gag Glu	gcc Ala	ctt Leu 2560	aac Asn	aag Lys	atg Met	ggc Gly	ctc Leu 2565	gag Glu	ctc Leu	gcc Ala
7704														
aag Lys	gac Asp 2570	gtc Val	tcg Ser	gtc Val	aag Lys	tcg Ser 2575	atc Ile	tgc Cys	ttc Phe	ggc Gly	ccc Pro 2580	tgg Trp	gac Asp	ggc Gly
7749														
ggc Gly	atg Met 2585	gtg Val	acg Thr	ccg Pro	cag Gln	ctc Leu 2590	aag Lys	aag Lys	cag Gln	ttc Phe	cag Gln 2595	gag Glu	atg Met	ggc Gly
7794														
gtg Val	cag Gln 2600	atc Ile	atc Ile	ccc Pro	cgc Arg	gag Glu 2605	ggc Gly	ggc Gly	gct Ala	gat Asp	acc Thr 2610	gtg Val	gcg Ala	cgc Arg
7839														
atc Ile	gtg Val 2615	ctc Leu	ggc Gly	tcc Ser	tcg Ser	ccg Pro 2620	gct Ala	gag Glu	atc Ile	ctt Leu	gtc Val 2625	ggc Gly	aac Asn	tgg Trp
7884														
cgc Arg	acc Thr 2630	ccg Pro	tcc Ser	aag Lys	aag Lys	gtc Val 2635	ggc Gly	tcg Ser	gac Asp	acc Thr	atc Ile 2640	acc Thr	ctg Leu	cac His
7929														
cgc Arg	aag Lys 2645	att Ile	tcc Ser	gcc Ala	aag Lys	tcc Ser 2650	aac Asn	ccc Pro	ttc Phe	ctc Leu	gag Glu 2655	gac Asp	cac His	gtc Val
7974														
atc Ile	cag Gln 2660	ggc Gly	cgc Arg	cgc Arg	gtg Val	ctg Leu 2665	ccc Pro	atg Met	acg Thr	ctg Leu	gcc Ala 2670	att Ile	ggc Gly	tcg Ser
8019														
ctc Leu	gcg Ala 2675	gag Glu	acc Thr	tgc Cys	ctc Leu	ggc Gly 2680	ctc Leu	ttc Phe	ccc Pro	ggc Gly	tac Tyr 2685	tcg Ser	ctc Leu	tgg Trp
8064														
gcc Ala	att Ile 2690	gac Asp	gac Asp	gcc Ala	cag Gln	ctc Leu 2695	ttc Phe	aag Lys	ggc Gly	gtc Val	act Thr 2700	gtc Val	gac Asp	ggc Gly
8109														
gac Asp	gtc Val 2705	aac Asn	tgc Cys	gag Glu	gtg Val	acc Thr 2710	ctc Leu	acc Thr	ccg Pro	tcg Ser	acg Thr 2715	gcg Ala	ccc Pro	tcg Ser
8154														
ggc Gly	cgc Arg 2720	gtc Val	aac Asn	gtc Val	cag Gln	gcc Ala 2725	acg Thr	ctc Leu	aag Lys	acc Thr	ttt Phe 2730	tcc Ser	agc Ser	ggc Gly
8199														
aag Lys	ctg Leu 2735	gtc Val	ccg Pro	gcc Ala	tac Tyr	cgc Arg 2740	gcc Ala	gtc Val	atc Ile	gtg Val	ctc Leu 2745	tcc Ser	aac Asn	cag Gln
8244														
ggc Gly	gcg Ala 2750	ccc Pro	ccg Pro	gcc Ala	aac Asn	gcc Ala 2755	acc Thr	atg Met	cag Gln	ccg Pro	ccc Pro 2760	tcg Ser	ctc Leu	gat Asp
8289														
gcc Ala	gat Asp	ccg Pro	gcg Ala	ctc Leu	cag Gln	ggc Gly	tcc Ser	gtc Val	tac Tyr	gac Asp	ggc Gly	aag Lys	acc Thr	ctc Leu
8334														

2997-49-2-pct_ST25

2765		2770	2775												
ttc	cac	ggc	ccg	gcc	ttc	cgc	ggc	atc	gat	gac	gtg	ctc	tcg	tgc	8379
Phe	His	Gly	Pro	Ala	Phe	Arg	Gly	Ile	Asp	Asp	Val	Leu	Ser	Cys	
	2780					2785					2790				
acc	aag	agc	cag	ctt	gtg	gcc	aag	tgc	agc	gct	gtc	ccc	ggc	tcc	8424
Thr	Lys	Ser	Gln	Leu	Val	Ala	Lys	Cys	Ser	Ala	Val	Pro	Gly	Ser	
	2795					2800					2805				
gac	gcc	gct	cgc	ggc	gag	ttt	gcc	acg	gac	act	gac	gcc	cat	gac	8469
Asp	Ala	Ala	Arg	Gly	Glu	Phe	Ala	Thr	Asp	Thr	Asp	Ala	His	Asp	
	2810					2815					2820				
ccc	ttc	gtg	aac	gac	ctg	gcc	ttt	cag	gcc	atg	ctc	gtc	tgg	gtg	8514
Pro	Phe	Val	Asn	Asp	Leu	Ala	Phe	Gln	Ala	Met	Leu	Val	Trp	Val	
	2825					2830					2835				
cgc	cgc	acg	ctc	ggc	cag	gct	gcg	ctc	ccc	aac	tcg	atc	cag	cgc	8559
Arg	Arg	Thr	Leu	Gly	Gln	Ala	Ala	Leu	Pro	Asn	Ser	Ile	Gln	Arg	
	2840					2845					2850				
atc	gtc	cag	cac	cgc	ccg	gtc	ccg	cag	gac	aag	ccc	ttc	tac	att	8604
Ile	Val	Gln	His	Arg	Pro	Val	Pro	Gln	Asp	Lys	Pro	Phe	Tyr	Ile	
	2855					2860					2865				
acc	ctc	cgc	tcc	aac	cag	tcg	ggc	ggt	cac	tcc	cag	cac	aag	cac	8649
Thr	Leu	Arg	Ser	Asn	Gln	Ser	Gly	Gly	His	Ser	Gln	His	Lys	His	
	2870					2875					2880				
gcc	ctt	cag	ttc	cac	aac	gag	cag	ggc	gat	ctc	ttc	att	gat	gtc	8694
Ala	Leu	Gln	Phe	His	Asn	Glu	Gln	Gly	Asp	Leu	Phe	Ile	Asp	Val	
	2885					2890					2895				
cag	gct	tcg	gtc	atc	gcc	acg	gac	agc	ctt	gcc	ttc	taa			8733
Gln	Ala	Ser	Val	Ile	Ala	Thr	Asp	Ser	Leu	Ala	Phe				
	2900					2905					2910				

<210> 2
 <211> 2910
 <212> PRT
 <213> Schizochytrium sp.

<400> 2

Met Ala Ala Arg Leu Gln Glu Gln Lys Gly Gly Glu Met Asp Thr Arg
 1 5 10 15

Ile Ala Ile Ile Gly Met Ser Ala Ile Leu Pro Cys Gly Thr Thr Val
 20 25 30

Arg Glu Ser Trp Glu Thr Ile Arg Ala Gly Ile Asp Cys Leu Ser Asp
 35 40 45

Leu Pro Glu Asp Arg Val Asp Val Thr Ala Tyr Phe Asp Pro Val Lys
 50 55 60

Thr Thr Lys Asp Lys Ile Tyr Cys Lys Arg Gly Gly Phe Ile Pro Glu
 65 70 75 80

Tyr Asp Phe Asp Ala Arg Glu Phe Gly Leu Asn Met Phe Gln Met Glu
 85 90 95

2997-49-2-pct_ST25

Asp Ser Asp Ala Asn Gln Thr Ile Ser Leu Leu Lys Val Lys Glu Ala
 100 105 110
 Leu Gln Asp Ala Gly Ile Asp Ala Leu Gly Lys Glu Lys Lys Asn Ile
 115 120 125
 Gly Cys Val Leu Gly Ile Gly Gly Gly Gln Lys Ser Ser His Glu Phe
 130 135 140
 Tyr Ser Arg Leu Asn Tyr Val Val Val Glu Lys Val Leu Arg Lys Met
 145 150 155 160
 Gly Met Pro Glu Glu Asp Val Lys Val Ala Val Glu Lys Tyr Lys Ala
 165 170 175
 Asn Phe Pro Glu Trp Arg Leu Asp Ser Phe Pro Gly Phe Leu Gly Asn
 180 185 190
 Val Thr Ala Gly Arg Cys Thr Asn Thr Phe Asn Leu Asp Gly Met Asn
 195 200 205
 Cys Val Val Asp Ala Ala Cys Ala Ser Ser Leu Ile Ala Val Lys Val
 210 215 220
 Ala Ile Asp Glu Leu Leu Tyr Gly Asp Cys Asp Met Met Val Thr Gly
 225 230 235 240
 Ala Thr Cys Thr Asp Asn Ser Ile Gly Met Tyr Met Ala Phe Ser Lys
 245 250 255
 Thr Pro Val Phe Ser Thr Asp Pro Ser Val Arg Ala Tyr Asp Glu Lys
 260 265 270
 Thr Lys Gly Met Leu Ile Gly Glu Gly Ser Ala Met Leu Val Leu Lys
 275 280 285
 Arg Tyr Ala Asp Ala Val Arg Asp Gly Asp Glu Ile His Ala Val Ile
 290 295 300
 Arg Gly Cys Ala Ser Ser Ser Asp Gly Lys Ala Ala Gly Ile Tyr Thr
 305 310 315 320
 Pro Thr Ile Ser Gly Gln Glu Glu Ala Leu Arg Arg Ala Tyr Asn Arg
 325 330 335
 Ala Cys Val Asp Pro Ala Thr Val Thr Leu Val Glu Gly His Gly Thr
 340 345 350
 Gly Thr Pro Val Gly Asp Arg Ile Glu Leu Thr Ala Leu Arg Asn Leu
 355 360 365

2997-49-2-pct_ST25

Phe Asp Lys Ala Tyr Gly Glu Gly Asn Thr Glu Lys Val Ala Val Gly
 370 375 380
 Ser Ile Lys Ser Ser Ile Gly His Leu Lys Ala Val Ala Gly Leu Ala
 385 390 395 400
 Gly Met Ile Lys Val Ile Met Ala Leu Lys His Lys Thr Leu Pro Gly
 405 410 415
 Thr Ile Asn Val Asp Asn Pro Pro Asn Leu Tyr Asp Asn Thr Pro Ile
 420 425 430
 Asn Glu Ser Ser Leu Tyr Ile Asn Thr Met Asn Arg Pro Trp Phe Pro
 435 440 445
 Pro Pro Gly Val Pro Arg Arg Ala Gly Ile Ser Ser Phe Gly Phe Gly
 450 455 460
 Gly Ala Asn Tyr His Ala Val Leu Glu Glu Ala Glu Pro Glu His Thr
 465 470 475 480
 Thr Ala Tyr Arg Leu Asn Lys Arg Pro Gln Pro Val Leu Met Met Ala
 485 490 495
 Ala Thr Pro Ala Ala Leu Gln Ser Leu Cys Glu Ala Gln Leu Lys Glu
 500 505 510
 Phe Glu Ala Ala Ile Lys Glu Asn Glu Thr Val Lys Asn Thr Ala Tyr
 515 520 525
 Ile Lys Cys Val Lys Phe Gly Glu Gln Phe Lys Phe Pro Gly Ser Ile
 530 535 540
 Pro Ala Thr Asn Ala Arg Leu Gly Phe Leu Val Lys Asp Ala Glu Asp
 545 550 555 560
 Ala Cys Ser Thr Leu Arg Ala Ile Cys Ala Gln Phe Ala Lys Asp Val
 565 570 575
 Thr Lys Glu Ala Trp Arg Leu Pro Arg Glu Gly Val Ser Phe Arg Ala
 580 585 590
 Lys Gly Ile Ala Thr Asn Gly Ala Val Ala Ala Leu Phe Ser Gly Gln
 595 600 605
 Gly Ala Gln Tyr Thr His Met Phe Ser Glu Val Ala Met Asn Trp Pro
 610 615 620
 Gln Phe Arg Gln Ser Ile Ala Ala Met Asp Ala Ala Gln Ser Lys Val
 625 630 635 640

2997-49-2-pct_ST25

Ala Gly Ser Asp Lys Asp Phe Glu Arg Val Ser Gln Val Leu Tyr Pro
645 650 655

Arg Lys Pro Tyr Glu Arg Glu Pro Glu Gln Asp His Lys Lys Ile Ser
660 665 670

Leu Thr Ala Tyr Ser Gln Pro Ser Thr Leu Ala Cys Ala Leu Gly Ala
675 680 685

Phe Glu Ile Phe Lys Glu Ala Gly Phe Thr Pro Asp Phe Ala Ala Gly
690 695 700

His Ser Leu Gly Glu Phe Ala Ala Leu Tyr Ala Ala Gly Cys Val Asp
705 710 715 720

Arg Asp Glu Leu Phe Glu Leu Val Cys Arg Arg Ala Arg Ile Met Gly
725 730 735

Gly Lys Asp Ala Pro Ala Thr Pro Lys Gly Cys Met Ala Ala Val Ile
740 745 750

Gly Pro Asn Ala Glu Asn Ile Lys Val Gln Ala Ala Asn Val Trp Leu
755 760 765

Gly Asn Ser Asn Ser Pro Ser Gln Thr Val Ile Thr Gly Ser Val Glu
770 775 780

Gly Ile Gln Ala Glu Ser Ala Arg Leu Gln Lys Glu Gly Phe Arg Val
785 790 795 800

Val Pro Leu Ala Cys Glu Ser Ala Phe His Ser Pro Gln Met Glu Asn
805 810 815

Ala Ser Ser Ala Phe Lys Asp Val Ile Ser Lys Val Ser Phe Arg Thr
820 825 830

Pro Lys Ala Glu Thr Lys Leu Phe Ser Asn Val Ser Gly Glu Thr Tyr
835 840 845

Pro Thr Asp Ala Arg Glu Met Leu Thr Gln His Met Thr Ser Ser Val
850 855 860

Lys Phe Leu Thr Gln Val Arg Asn Met His Gln Ala Gly Ala Arg Ile
865 870 875 880

Phe Val Glu Phe Gly Pro Lys Gln Val Leu Ser Lys Leu Val Ser Glu
885 890 895

Thr Leu Lys Asp Asp Pro Ser Val Val Thr Val Ser Val Asn Pro Ala
900 905 910

2997-49-2-pct_ST25

Ser Gly Thr Asp Ser Asp Ile Gln Leu Arg Asp Ala Ala Val Gln Leu
915 920 925

Val Val Ala Gly Val Asn Leu Gln Gly Phe Asp Lys Trp Asp Ala Pro
930 935 940

Asp Ala Thr Arg Met Gln Ala Ile Lys Lys Lys Arg Thr Thr Leu Arg
945 950 955 960

Leu Ser Ala Ala Thr Tyr Val Ser Asp Lys Thr Lys Lys Val Arg Asp
965 970 975

Ala Ala Met Asn Asp Gly Arg Cys Val Thr Tyr Leu Lys Gly Ala Ala
980 985 990

Pro Leu Ile Lys Ala Pro Glu Pro Val Val Asp Glu Ala Ala Lys Arg
995 1000 1005

Glu Ala Glu Arg Leu Gln Lys Glu Leu Gln Asp Ala Gln Arg Gln
1010 1015 1020

Leu Asp Asp Ala Lys Arg Ala Ala Ala Glu Ala Asn Ser Lys Leu
1025 1030 1035

Ala Ala Ala Lys Glu Glu Ala Lys Thr Ala Ala Ala Ser Ala Lys
1040 1045 1050

Pro Ala Val Asp Thr Ala Val Val Glu Lys His Arg Ala Ile Leu
1055 1060 1065

Lys Ser Met Leu Ala Glu Leu Asp Gly Tyr Gly Ser Val Asp Ala
1070 1075 1080

Ser Ser Leu Gln Gln Gln Gln Gln Gln Gln Thr Ala Pro Ala Pro
1085 1090 1095

Val Lys Ala Ala Ala Pro Ala Ala Pro Val Ala Ser Ala Pro Ala
1100 1105 1110

Pro Ala Val Ser Asn Glu Leu Leu Glu Lys Ala Glu Thr Val Val
1115 1120 1125

Met Glu Val Leu Ala Ala Lys Thr Gly Tyr Glu Thr Asp Met Ile
1130 1135 1140

Glu Ala Asp Met Glu Leu Glu Thr Glu Leu Gly Ile Asp Ser Ile
1145 1150 1155

Lys Arg Val Glu Ile Leu Ser Glu Val Gln Ala Met Leu Asn Val
1160 1165 1170

2997-49-2-pct_ST25

Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Arg	Thr	Val	Gly
	1175					1180					1185			
Glu	Val	Val	Asn	Ala	Met	Lys	Ala	Glu	Ile	Ala	Gly	Ser	Ser	Ala
	1190					1195					1200			
Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Lys	Ala	Ala	Pro
	1205					1210					1215			
Ala	Ala	Ala	Ala	Pro	Ala	Val	Ser	Asn	Glu	Leu	Leu	Glu	Lys	Ala
	1220					1225					1230			
Glu	Thr	Val	Val	Met	Glu	Val	Leu	Ala	Ala	Lys	Thr	Gly	Tyr	Glu
	1235					1240					1245			
Thr	Asp	Met	Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu	Thr	Glu	Leu	Gly
	1250					1255					1260			
Ile	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser	Glu	Val	Gln	Ala
	1265					1270					1275			
Met	Leu	Asn	Val	Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr
	1280					1285					1290			
Arg	Thr	Val	Gly	Glu	Val	Val	Asn	Ala	Met	Lys	Ala	Glu	Ile	Ala
	1295					1300					1305			
Gly	Gly	Ser	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Gly	Pro	Ala
	1310					1315					1320			
Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Val	Ser	Asn
	1325					1330					1335			
Glu	Leu	Leu	Glu	Lys	Ala	Glu	Thr	Val	Val	Met	Glu	Val	Leu	Ala
	1340					1345					1350			
Ala	Lys	Thr	Gly	Tyr	Glu	Thr	Asp	Met	Ile	Glu	Ser	Asp	Met	Glu
	1355					1360					1365			
Leu	Glu	Thr	Glu	Leu	Gly	Ile	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile
	1370					1375					1380			
Leu	Ser	Glu	Val	Gln	Ala	Met	Leu	Asn	Val	Glu	Ala	Lys	Asp	Val
	1385					1390					1395			
Asp	Ala	Leu	Ser	Arg	Thr	Arg	Thr	Val	Gly	Glu	Val	Val	Asp	Ala
	1400					1405					1410			
Met	Lys	Ala	Glu	Ile	Ala	Gly	Gly	Ser	Ala	Pro	Ala	Pro	Ala	Ala
	1415					1420					1425			

2997-49-2-pct_ST25

Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Pro
	1430					1435					1440			
Ala	Pro	Ala	Val	Ser	Ser	Glu	Leu	Leu	Glu	Lys	Ala	Glu	Thr	Val
	1445					1450					1455			
Val	Met	Glu	Val	Leu	Ala	Ala	Lys	Thr	Gly	Tyr	Glu	Thr	Asp	Met
	1460					1465					1470			
Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu	Thr	Glu	Leu	Gly	Ile	Asp	Ser
	1475					1480					1485			
Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser	Glu	Val	Gln	Ala	Met	Leu	Asn
	1490					1495					1500			
Val	Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Arg	Thr	Val
	1505					1510					1515			
Gly	Glu	Val	Val	Asp	Ala	Met	Lys	Ala	Glu	Ile	Ala	Gly	Gly	Ser
	1520					1525					1530			
Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala
	1535					1540					1545			
Pro	Ala	Pro	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Pro	Ala	Pro	Ala	Val
	1550					1555					1560			
Ser	Ser	Glu	Leu	Leu	Glu	Lys	Ala	Glu	Thr	Val	Val	Met	Glu	Val
	1565					1570					1575			
Leu	Ala	Ala	Lys	Thr	Gly	Tyr	Glu	Thr	Asp	Met	Ile	Glu	Ser	Asp
	1580					1585					1590			
Met	Glu	Leu	Glu	Thr	Glu	Leu	Gly	Ile	Asp	Ser	Ile	Lys	Arg	Val
	1595					1600					1605			
Glu	Ile	Leu	Ser	Glu	Val	Gln	Ala	Met	Leu	Asn	Val	Glu	Ala	Lys
	1610					1615					1620			
Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Arg	Thr	Val	Gly	Glu	Val	Val
	1625					1630					1635			
Asp	Ala	Met	Lys	Ala	Glu	Ile	Ala	Gly	Ser	Ser	Ala	Ser	Ala	Pro
	1640					1645					1650			
Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala
	1655					1660					1665			
Ala	Ala	Ala	Pro	Ala	Val	Ser	Asn	Glu	Leu	Leu	Glu	Lys	Ala	Glu
	1670					1675					1680			

2997-49-2-pct_ST25

Thr	Val	Val	Met	Glu	Val	Leu	Ala	Ala	Lys	Thr	Gly	Tyr	Glu	Thr
	1685					1690					1695			
Asp	Met	Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu	Thr	Glu	Leu	Gly	Ile
	1700					1705					1710			
Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser	Glu	Val	Gln	Ala	Met
	1715					1720					1725			
Leu	Asn	Val	Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Arg
	1730					1735					1740			
Thr	Val	Gly	Glu	Val	Val	Asp	Ala	Met	Lys	Ala	Glu	Ile	Ala	Gly
	1745					1750					1755			
Gly	Ser	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala
	1760					1765					1770			
Ala	Ala	Pro	Ala	Val	Ser	Asn	Glu	Leu	Leu	Glu	Lys	Ala	Glu	Thr
	1775					1780					1785			
Val	Val	Met	Glu	Val	Leu	Ala	Ala	Lys	Thr	Gly	Tyr	Glu	Thr	Asp
	1790					1795					1800			
Met	Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu	Thr	Glu	Leu	Gly	Ile	Asp
	1805					1810					1815			
Ser	Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser	Glu	Val	Gln	Ala	Met	Leu
	1820					1825					1830			
Asn	Val	Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Arg	Thr
	1835					1840					1845			
Val	Gly	Glu	Val	Val	Asp	Ala	Met	Lys	Ala	Glu	Ile	Ala	Gly	Ser
	1850					1855					1860			
Ser	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Pro	Ala	Ala	Ala
	1865					1870					1875			
Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Val	Ser	Ser	Glu	Leu
	1880					1885					1890			
Leu	Glu	Lys	Ala	Glu	Thr	Val	Val	Met	Glu	Val	Leu	Ala	Ala	Lys
	1895					1900					1905			
Thr	Gly	Tyr	Glu	Thr	Asp	Met	Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu
	1910					1915					1920			
Thr	Glu	Leu	Gly	Ile	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser
	1925					1930					1935			

2997-49-2-pct_ST25

Glu	Val	Gln	Ala	Met	Leu	Asn	Val	Glu	Ala	Lys	Asp	Val	Asp	Ala
1940						1945					1950			
Leu	Ser	Arg	Thr	Arg	Thr	Val	Gly	Glu	Val	Val	Asp	Ala	Met	Lys
1955						1960					1965			
Ala	Glu	Ile	Ala	Gly	Gly	Ser	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala
1970						1975					1980			
Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro	Ala	Val	Ser	Asn	Glu	Leu	Leu
1985						1990					1995			
Glu	Lys	Ala	Glu	Thr	Val	Val	Met	Glu	Val	Leu	Ala	Ala	Lys	Thr
2000						2005					2010			
Gly	Tyr	Glu	Thr	Asp	Met	Ile	Glu	Ser	Asp	Met	Glu	Leu	Glu	Thr
2015						2020					2025			
Glu	Leu	Gly	Ile	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Leu	Ser	Glu
2030						2035					2040			
Val	Gln	Ala	Met	Leu	Asn	Val	Glu	Ala	Lys	Asp	Val	Asp	Ala	Leu
2045						2050					2055			
Ser	Arg	Thr	Arg	Thr	Val	Gly	Glu	Val	Val	Asp	Ala	Met	Lys	Ala
2060						2065					2070			
Glu	Ile	Ala	Gly	Gly	Ser	Ala	Pro	Ala	Pro	Ala	Ala	Ala	Ala	Pro
2075						2080					2085			
Ala	Ser	Ala	Gly	Ala	Ala	Pro	Ala	Val	Lys	Ile	Asp	Ser	Val	His
2090						2095					2100			
Gly	Ala	Asp	Cys	Asp	Asp	Leu	Ser	Leu	Met	His	Ala	Lys	Val	Val
2105						2110					2115			
Asp	Ile	Arg	Arg	Pro	Asp	Glu	Leu	Ile	Leu	Glu	Arg	Pro	Glu	Asn
2120						2125					2130			
Arg	Pro	Val	Leu	Val	Val	Asp	Asp	Gly	Ser	Glu	Leu	Thr	Leu	Ala
2135						2140					2145			
Leu	Val	Arg	Val	Leu	Gly	Ala	Cys	Ala	Val	Val	Leu	Thr	Phe	Glu
2150						2155					2160			
Gly	Leu	Gln	Leu	Ala	Gln	Arg	Ala	Gly	Ala	Ala	Ala	Ile	Arg	His
2165						2170					2175			
Val	Leu	Ala	Lys	Asp	Leu	Ser	Ala	Glu	Ser	Ala	Glu	Lys	Ala	Ile
2180						2185					2190			

2997-49-2-pct_ST25

Lys	Glu	Ala	Glu	Gln	Arg	Phe	Gly	Ala	Leu	Gly	Gly	Phe	Ile	Ser
	2195					2200					2205			
Gln	Gln	Ala	Glu	Arg	Phe	Glu	Pro	Ala	Glu	Ile	Leu	Gly	Phe	Thr
	2210					2215					2220			
Leu	Met	Cys	Ala	Lys	Phe	Ala	Lys	Ala	Ser	Leu	Cys	Thr	Ala	Val
	2225					2230					2235			
Ala	Gly	Gly	Arg	Pro	Ala	Phe	Ile	Gly	Val	Ala	Arg	Leu	Asp	Gly
	2240					2245					2250			
Arg	Leu	Gly	Phe	Thr	Ser	Gln	Gly	Thr	Ser	Asp	Ala	Leu	Lys	Arg
	2255					2260					2265			
Ala	Gln	Arg	Gly	Ala	Ile	Phe	Gly	Leu	Cys	Lys	Thr	Ile	Gly	Leu
	2270					2275					2280			
Glu	Trp	Ser	Glu	Ser	Asp	Val	Phe	Ser	Arg	Gly	Val	Asp	Ile	Ala
	2285					2290					2295			
Gln	Gly	Met	His	Pro	Glu	Asp	Ala	Ala	Val	Ala	Ile	Val	Arg	Glu
	2300					2305					2310			
Met	Ala	Cys	Ala	Asp	Ile	Arg	Ile	Arg	Glu	Val	Gly	Ile	Gly	Ala
	2315					2320					2325			
Asn	Gln	Gln	Arg	Cys	Thr	Ile	Arg	Ala	Ala	Lys	Leu	Glu	Thr	Gly
	2330					2335					2340			
Asn	Pro	Gln	Arg	Gln	Ile	Ala	Lys	Asp	Asp	Val	Leu	Leu	Val	Ser
	2345					2350					2355			
Gly	Gly	Ala	Arg	Gly	Ile	Thr	Pro	Leu	Cys	Ile	Arg	Glu	Ile	Thr
	2360					2365					2370			
Arg	Gln	Ile	Ala	Gly	Gly	Lys	Tyr	Ile	Leu	Leu	Gly	Arg	Ser	Lys
	2375					2380					2385			
Val	Ser	Ala	Ser	Glu	Pro	Ala	Trp	Cys	Ala	Gly	Ile	Thr	Asp	Glu
	2390					2395					2400			
Lys	Ala	Val	Gln	Lys	Ala	Ala	Thr	Gln	Glu	Leu	Lys	Arg	Ala	Phe
	2405					2410					2415			
Ser	Ala	Gly	Glu	Gly	Pro	Lys	Pro	Thr	Pro	Arg	Ala	Val	Thr	Lys
	2420					2425					2430			
Leu	Val	Gly	Ser	Val	Leu	Gly	Ala	Arg	Glu	Val	Arg	Ser	Ser	Ile
	2435					2440					2445			

2997-49-2-pct_ST25

Ala	Ala	Ile	Glu	Ala	Leu	Gly	Gly	Lys	Ala	Ile	Tyr	Ser	Ser	Cys
	2450					2455					2460			
Asp	Val	Asn	Ser	Ala	Ala	Asp	Val	Ala	Lys	Ala	Val	Arg	Asp	Ala
	2465					2470					2475			
Glu	Ser	Gln	Leu	Gly	Ala	Arg	Val	Ser	Gly	Ile	Val	His	Ala	Ser
	2480					2485					2490			
Gly	Val	Leu	Arg	Asp	Arg	Leu	Ile	Glu	Lys	Lys	Leu	Pro	Asp	Glu
	2495					2500					2505			
Phe	Asp	Ala	Val	Phe	Gly	Thr	Lys	Val	Thr	Gly	Leu	Glu	Asn	Leu
	2510					2515					2520			
Leu	Ala	Ala	Val	Asp	Arg	Ala	Asn	Leu	Lys	His	Met	Val	Leu	Phe
	2525					2530					2535			
Ser	Ser	Leu	Ala	Gly	Phe	His	Gly	Asn	Val	Gly	Gln	Ser	Asp	Tyr
	2540					2545					2550			
Ala	Met	Ala	Asn	Glu	Ala	Leu	Asn	Lys	Met	Gly	Leu	Glu	Leu	Ala
	2555					2560					2565			
Lys	Asp	Val	Ser	Val	Lys	Ser	Ile	Cys	Phe	Gly	Pro	Trp	Asp	Gly
	2570					2575					2580			
Gly	Met	Val	Thr	Pro	Gln	Leu	Lys	Lys	Gln	Phe	Gln	Glu	Met	Gly
	2585					2590					2595			
Val	Gln	Ile	Ile	Pro	Arg	Glu	Gly	Gly	Ala	Asp	Thr	Val	Ala	Arg
	2600					2605					2610			
Ile	Val	Leu	Gly	Ser	Ser	Pro	Ala	Glu	Ile	Leu	Val	Gly	Asn	Trp
	2615					2620					2625			
Arg	Thr	Pro	Ser	Lys	Lys	Val	Gly	Ser	Asp	Thr	Ile	Thr	Leu	His
	2630					2635					2640			
Arg	Lys	Ile	Ser	Ala	Lys	Ser	Asn	Pro	Phe	Leu	Glu	Asp	His	Val
	2645					2650					2655			
Ile	Gln	Gly	Arg	Arg	Val	Leu	Pro	Met	Thr	Leu	Ala	Ile	Gly	Ser
	2660					2665					2670			
Leu	Ala	Glu	Thr	Cys	Leu	Gly	Leu	Phe	Pro	Gly	Tyr	Ser	Leu	Trp
	2675					2680					2685			
Ala	Ile	Asp	Asp	Ala	Gln	Leu	Phe	Lys	Gly	Val	Thr	Val	Asp	Gly
	2690					2695					2700			

2997-49-2-pct_ST25

Asp	Val	Asn	Cys	Glu	Val	Thr	Leu	Thr	Pro	Ser	Thr	Ala	Pro	Ser
	2705					2710					2715			
Gly	Arg	Val	Asn	Val	Gln	Ala	Thr	Leu	Lys	Thr	Phe	Ser	Ser	Gly
	2720					2725					2730			
Lys	Leu	Val	Pro	Ala	Tyr	Arg	Ala	Val	Ile	Val	Leu	Ser	Asn	Gln
	2735					2740					2745			
Gly	Ala	Pro	Pro	Ala	Asn	Ala	Thr	Met	Gln	Pro	Pro	Ser	Leu	Asp
	2750					2755					2760			
Ala	Asp	Pro	Ala	Leu	Gln	Gly	Ser	Val	Tyr	Asp	Gly	Lys	Thr	Leu
	2765					2770					2775			
Phe	His	Gly	Pro	Ala	Phe	Arg	Gly	Ile	Asp	Asp	Val	Leu	Ser	Cys
	2780					2785					2790			
Thr	Lys	Ser	Gln	Leu	Val	Ala	Lys	Cys	Ser	Ala	Val	Pro	Gly	Ser
	2795					2800					2805			
Asp	Ala	Ala	Arg	Gly	Glu	Phe	Ala	Thr	Asp	Thr	Asp	Ala	His	Asp
	2810					2815					2820			
Pro	Phe	Val	Asn	Asp	Leu	Ala	Phe	Gln	Ala	Met	Leu	Val	Trp	Val
	2825					2830					2835			
Arg	Arg	Thr	Leu	Gly	Gln	Ala	Ala	Leu	Pro	Asn	Ser	Ile	Gln	Arg
	2840					2845					2850			
Ile	Val	Gln	His	Arg	Pro	Val	Pro	Gln	Asp	Lys	Pro	Phe	Tyr	Ile
	2855					2860					2865			
Thr	Leu	Arg	Ser	Asn	Gln	Ser	Gly	Gly	His	Ser	Gln	His	Lys	His
	2870					2875					2880			
Ala	Leu	Gln	Phe	His	Asn	Glu	Gln	Gly	Asp	Leu	Phe	Ile	Asp	Val
	2885					2890					2895			
Gln	Ala	Ser	Val	Ile	Ala	Thr	Asp	Ser	Leu	Ala	Phe			
	2900					2905					2910			

<210> 3
 <211> 6180
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(6180)

<400>	3															
atg Met 1	gcc Ala	gct Ala	cgg Arg	aat Asn 5	gtg Val	agc Ser	gcc Ala	gcg Ala	cat His 10	gag Glu	atg Met	cac His	gat Asp	gaa Glu 15	aag Lys	48
cgc Arg	atc Ile	gcc Ala	gtc Val 20	gtc Val	ggc Gly	atg Met	gcc Ala	gtc Val 25	cag Gln	tac Tyr	gcc Ala	gga Gly	tgc Cys 30	aaa Lys	acc Thr	96
aag Lys	gac Asp	gag Glu 35	ttc Phe	tgg Trp	gag Glu	gtg Val	ctc Leu 40	atg Met	aac Asn	ggc Gly	aag Lys	gtc Val 45	gag Glu	tcc Ser	aag Lys	144
gtg Val	atc Ile 50	agc Ser	gac Asp	aaa Lys	cga Arg	ctc Leu 55	ggc Gly	tcc Ser	aac Asn	tac Tyr	cgc Arg 60	gcc Ala	gag Glu	cac His	tac Tyr	192
aaa Lys 65	gca Ala	gag Glu	cgc Arg	agc Ser	aag Lys 70	tat Tyr	gcc Ala	gac Asp	acc Thr	ttt Phe 75	tgc Cys	aac Asn	gaa Glu	acg Thr	tac Tyr 80	240
ggc Gly	acc Thr	ctt Leu	gac Asp	gag Glu 85	aac Asn	gag Glu	atc Ile	gac Asp	aac Asn 90	gag Glu	cac His	gaa Glu	ctc Leu	ctc Leu 95	ctc Leu	288
aac Asn	ctc Leu	gcc Ala	aag Lys 100	cag Gln	gca Ala	ctc Leu	gca Ala	gag Glu 105	aca Thr	tcc Ser	gtc Val	aaa Lys	gac Asp 110	tcg Ser	aca Thr	336
cgc Arg	tgc Cys	ggc Gly 115	atc Ile	gtc Val	agc Ser	ggc Gly	tgc Cys 120	ctc Leu	tcg Ser	ttc Phe	ccc Pro	atg Met 125	gac Asp	aac Asn	ctc Leu	384
cag Gln	ggt Gly 130	gaa Glu	ctc Leu	ctc Leu	aac Asn	gtg Val 135	tac Tyr	caa Gln	aac Asn	cat His	gtc Val 140	gag Glu	aaa Lys	aag Lys	ctc Leu	432
ggg Gly 145	gcc Ala	cgc Arg	gtc Val	ttc Phe	aag Lys 150	gac Asp	gcc Ala	tcc Ser	cat His	tgg Trp 155	tcc Ser	gaa Glu	cgc Arg	gag Glu	cag Gln 160	480
tcc Ser	aac Asn	aaa Lys	ccc Pro	gag Glu 165	gcc Ala	ggt Gly	gac Asp	cgc Arg	cgc Arg 170	atc Ile	ttc Phe	atg Met	gac Asp	ccg Pro 175	gcc Ala	528
tcc Ser	ttc Phe	gtc Val	gcc Ala 180	gaa Glu	gaa Glu	ctc Leu	aac Asn	ctc Leu 185	ggc Gly	gcc Ala	ctt Leu	cac His	tac Tyr 190	tcc Ser	gtc Val	576
gac Asp	gca Ala	gca Ala 195	tgc Cys	gcc Ala	acg Thr	gcg Ala	ctc Leu 200	tac Tyr	gtg Val	ctc Leu	cgc Arg	ctc Leu 205	gcg Ala	cag Gln	gat Asp	624
cat His	ctc Leu 210	gtc Val	tcc Ser	ggc Gly	gcc Ala	gcc Ala 215	gac Asp	gtc Val	atg Met	ctc Leu	tgc Cys 220	ggt Gly	gcc Ala	acc Thr	tgc Cys	672
ctg Leu 225	ccg Pro	gag Glu	ccc Pro	ttt Phe	ttc Phe 230	atc Ile	ctt Leu	tcg Ser	ggc Gly	ttt Phe 235	tcc Ser	acc Thr	ttc Phe	cag Gln	gcc Ala 240	720
atg Met	ccc Pro	gtc Val	ggc Gly	acg Thr 245	ggc Gly	cag Gln	aac Asn	gtg Val	tcc Ser 250	atg Met	ccg Pro	ctg Leu	cac His	aag Lys 255	gac Asp	768
agc Ser	cag Gln	ggc Gly	ctc Leu 260	acc Thr	ccg Pro	ggt Gly	gag Glu	ggc Gly 265	ggc Gly	tcc Ser	atc Ile	atg Met	gtc Val 270	ctc Leu	aag Lys	816

2997-49-2-pct_ST25

cgt Arg	ctc Leu	gat Asp 275	gat Asp	gcc Ala	atc Ile	cgc Arg	gac Asp 280	ggc Gly	gac Asp	cac His	atc Ile	tac Tyr 285	ggc Gly	acc Thr	ctt Leu	864
ctc Leu	ggc Gly 290	gcc Ala	aat Asn	gtc Val	agc Ser	aac Asn 295	tcc Ser	ggc Gly	aca Thr	ggt Gly	ctg Leu 300	ccc Pro	ctc Leu	aag Lys	ccc Pro	912
ctt Leu 305	ctc Leu	ccc Pro	agc Ser	gag Glu	aaa Lys 310	aag Lys	tgc Cys	ctc Leu	atg Met	gac Asp 315	acc Thr	tac Tyr	acg Thr	cgc Arg	att Ile 320	960
aac Asn	gtg Val	cac His	ccg Pro	cac His 325	aag Lys	att Ile	cag Gln	tac Tyr	gtc Val 330	gag Glu	tgc Cys	cac His	gcc Ala	acc Thr 335	ggc Gly	1008
acg Thr	ccc Pro	cag Gln	ggt Gly 340	gat Asp	cgt Arg	gtg Val	gaa Glu	atc Ile 345	gac Asp	gcc Ala	gtc Val	aag Lys	gcc Ala 350	tgc Cys	ttt Phe	1056
gaa Glu	ggc Gly	aag Lys 355	gtc Val	ccc Pro	cgt Arg	ttc Phe	ggt Gly 360	acc Thr	aca Thr	aag Lys	ggc Gly	aac Asn 365	ttt Phe	gga Gly	cac His	1104
acc Thr	ctc Leu 370	gtc Val	gca Ala	gcc Ala	ggc Gly	ttt Phe 375	gcc Ala	ggt Gly	atg Met	tgc Cys	aag Lys 380	gtc Val	ctc Leu	ctc Leu	tcc Ser	1152
atg Met 385	aag Lys	cat His	ggc Gly	atc Ile	atc Ile 390	ccg Pro	ccc Pro	acc Thr	ccg Pro	ggt Gly 395	atc Ile	gat Asp	gac Asp	gag Glu	acc Thr 400	1200
aag Lys	atg Met	gac Asp	cct Pro	ctc Leu 405	gtc Val	gtc Val	tcc Ser	ggt Gly	gag Glu 410	gcc Ala	atc Ile	cca Pro	tgg Trp	cca Pro 415	gag Glu	1248
acc Thr	aac Asn	ggc Gly	gag Glu 420	ccc Pro	aag Lys	cgc Arg	gcc Ala	ggt Gly 425	ctc Leu	tgc Ser	gcc Ala	ttt Phe	ggc Gly 430	ttt Phe	ggt Gly	1296
ggc Gly	acc Thr	aac Asn 435	gcc Ala	cat His	gcc Ala	gtc Val	ttt Phe 440	gag Glu	gag Glu	cat His	gac Asp	ccc Pro 445	tcc Ser	aac Asn	gcc Ala	1344
gcc Ala	tgc Cys 450	acg Thr	ggc Gly	cac His	gac Asp	tcc Ser 455	att Ile	tct Ser	gcg Ala	ctc Leu	tgc Ser 460	gcc Ala	cgc Arg	tgc Cys	ggc Gly	1392
ggt Gly 465	gaa Glu	agc Ser	aac Asn	atg Met	cgc Arg 470	atc Ile	gcc Ala	atc Ile	act Thr	ggt Gly 475	atg Met	gac Asp	gcc Ala	acc Thr	ttt Phe 480	1440
ggc Gly	gct Ala	ctc Leu	aag Lys	gga Gly 485	ctc Leu	gac Asp	gcc Ala	ttc Phe	gag Glu 490	cgc Arg	gcc Ala	att Ile	tac Tyr	acc Thr 495	ggc Gly	1488
gct Ala	cac His	ggt Gly	gcc Ala 500	atc Ile	cca Pro	ctc Leu	cca Pro	gaa Glu 505	aag Lys	cgc Arg	tgg Trp	cgc Arg	ttt Phe 510	ctc Leu	ggc Gly	1536
aag Lys	gac Asp	aag Lys 515	gac Asp	ttt Phe	ctt Leu	gac Asp	ctc Leu 520	tgc Cys	ggc Gly	gtc Val	aag Lys	gcc Ala 525	acc Thr	ccg Pro	cac His	1584
ggc Gly	tgc Cys 530	tac Tyr	att Ile	gaa Glu	gat Asp	gtt Val 535	gag Glu	gtc Val	gac Asp	ttc Phe	cag Gln 540	cgc Arg	ctc Leu	cgc Arg	acg Thr	1632

2997-49-2-pct_ST25

ccc Pro 545	atg Met	acc Thr	cct Pro	gaa Glu	gac Asp 550	atg Met	ctc Leu	ctc Leu	cct Pro	cag Gln 555	cag Gln	ctt Leu	ctg Leu	gcc Ala	gtc Val 560	1680
acc Thr	acc Thr	att Ile	gac Asp	cgc Arg 565	gcc Ala	atc Ile	ctc Leu	gac Asp	tcg Ser 570	gga Gly	atg Met	aaa Lys	aag Lys	ggt Gly 575	ggc Gly	1728
aat Asn	gtc Val	gcc Ala	gtc Val 580	ttt Phe	gtc Val	ggc Gly	ctc Leu	ggc Gly 585	acc Thr	gac Asp	ctc Leu	gag Glu	ctc Leu 590	tac Tyr	cgt Arg	1776
cac His	cgt Arg	gct Ala 595	cgc Arg	gtc Val	gct Ala	ctc Leu	aag Lys 600	gag Glu	cgc Arg	gtc Val	cgc Arg	cct Pro 605	gaa Glu	gcc Ala	tcc Ser	1824
aag Lys	aag Lys 610	ctc Leu	aat Asn	gac Asp	atg Met	atg Met 615	cag Gln	tac Tyr	att Ile	aac Asn	gac Asp 620	tgc Cys	ggc Gly	aca Thr	tcc Ser	1872
aca Thr 625	tcg Ser	tac Tyr	acc Thr	tcg Ser	tac Tyr 630	att Ile	ggc Gly	aac Asn	ctc Leu	gtc Val 635	gcc Ala	acg Thr	cgc Arg	gtc Val	tcg Ser 640	1920
tcg Ser	cag Gln	tgg Trp	ggc Gly	ttc Phe 645	acg Thr	ggc Gly	ccc Pro	tcc Ser	ttt Phe 650	acg Thr	atc Ile	acc Thr	gag Glu	ggc Gly 655	aac Asn	1968
aac Asn	tcc Ser	gtc Val	tac Tyr 660	cgc Arg	tgc Cys	gcc Ala	gag Glu	ctc Leu 665	ggc Gly	aag Lys	tac Tyr	ctc Leu	ctc Leu 670	gag Glu	acc Thr	2016
ggc Gly	gag Glu	gtc Val 675	gat Asp	ggc Gly	gtc Val	gtc Val	gtt Val 680	gcg Ala	ggc Gly	gtc Val	gat Asp	ctc Leu 685	tgc Cys	ggc Gly	agt Ser	2064
gcc Ala	gaa Glu 690	aac Asn	ctt Leu	tac Tyr	gtc Val	aag Lys 695	tct Ser	cgc Arg	cgc Arg	ttc Phe	aag Lys 700	gtg Val	tcc Ser	acc Thr	tcc Ser	2112
gat Asp 705	acc Thr	ccg Pro	cgc Arg	gcc Ala	agc Ser 710	ttt Phe	gac Asp	gcc Ala	gcc Ala 715	gcc Ala	gat Asp	ggc Gly	tac Tyr	ttt Phe	gtc Val 720	2160
ggc Gly	gag Glu	ggc Gly	tgc Cys	ggt Gly 725	gcc Ala	ttt Phe	gtg Val	ctc Leu	aag Lys 730	cgt Arg	gag Glu	act Thr	agc Ser	tgc Cys 735	acc Thr	2208
aag Lys	gac Asp	gac Asp	cgt Arg 740	atc Ile	tac Tyr	gct Ala	tgc Cys	atg Met 745	gat Asp	gcc Ala	atc Ile	gtc Val	cct Pro 750	ggc Gly	aac Asn	2256
gtc Val	cct Pro	agc Ser 755	gcc Ala	tgc Cys	ttg Leu	cgc Arg	gag Glu 760	gcc Ala	ctc Leu	gac Asp	cag Gln	gcg Ala 765	cgc Arg	gtc Val	aag Lys	2304
ccg Pro	ggc Gly 770	gat Asp	atc Ile	gag Glu	atg Met	ctc Leu 775	gag Glu	ctc Leu	agc Ser	gcc Ala	gac Asp 780	tcc Ser	gcc Ala	cgc Arg	cac His	2352
ctc Leu 785	aag Lys	gac Asp	ccg Pro	tcc Ser	gtc Val 790	ctg Leu	ccc Pro	aag Lys	gag Glu	ctc Leu 795	act Thr	gcc Ala	gag Glu	gag Glu	gaa Glu 800	2400
atc Ile	ggc Gly	ggc Gly	ctt Leu	cag Gln 805	acg Thr	atc Ile	ctt Leu	cgt Arg	gac Asp 810	gat Asp	gac Asp	aag Lys	ctc Leu	ccg Pro 815	cgc Arg	2448

2997-49-2-pct_ST25

aac Asn	gtc Val	gca Ala	acg Thr 820	ggc Gly	agt Ser	gtc Val	aag Lys	gcc Ala 825	acc Thr	gtc Val	ggt Gly	gac Asp 830	acc Thr	ggt Gly	tat Tyr	2496
gcc Ala	tct Ser	ggt Gly 835	gct Ala	gcc Ala	agc Ser	ctc Leu	atc Ile 840	aag Lys	gct Ala	gcg Ala	ctt Leu	tgc Cys 845	atc Ile	tac Tyr	aac Asn	2544
cgc Arg	tac Tyr 850	ctg Leu	ccc Pro	agc Ser	aac Asn	ggc Gly 855	gac Asp	gac Asp	tgg Trp	gat Asp	gaa Glu 860	ccc Pro	gcc Ala	cct Pro	gag Glu	2592
gcg Ala 865	ccc Pro	tgg Trp	gac Asp	agc Ser	acc Thr 870	ctc Leu	ttt Phe	gcg Ala	tgc Cys	cag Gln 875	acc Thr	tcg Ser	cgc Arg	gct Ala	tgg Trp 880	2640
ctc Leu	aag Lys	aac Asn	cct Pro	ggc Gly 885	gag Glu	cgt Arg	cgc Arg	tat Tyr	gcg Ala 890	gcc Ala	gtc Val	tcg Ser	ggc Gly	gtc Val 895	tcc Ser	2688
gag Glu	acg Thr	cgc Arg	tcg Ser 900	tgc Cys	tat Tyr	tcc Ser	gtg Val	ctc Leu 905	ctc Leu	tcc Ser	gaa Glu	gcc Ala	gag Glu 910	ggc Gly	cac His	2736
tac Tyr	gag Glu	cgc Arg 915	gag Glu	aac Asn	cgc Arg	atc Ile	tcg Ser 920	ctc Leu	gac Asp	gag Glu	gag Glu	gcg Ala 925	ccc Pro	aag Lys	ctc Leu	2784
att Ile	gtg Val 930	ctt Leu	cgc Arg	gcc Ala	gac Asp	tcc Ser 935	cac His	gag Glu	gag Glu	atc Ile	ctt Leu 940	ggt Gly	cgc Arg	ctc Leu	gac Asp	2832
aag Lys 945	atc Ile	cgc Arg	gag Glu	cgc Arg	ttc Phe 950	ttg Leu	cag Gln	ccc Pro	acg Thr	ggc Gly 955	gcc Ala	gcc Ala	ccg Pro	cgc Arg	gag Glu 960	2880
tcc Ser	gag Glu	ctc Leu	aag Lys	gcg Ala 965	cag Gln	gcc Ala	cgc Arg	cgc Arg	atc Ile 970	ttc Phe	ctc Leu	gag Glu	ctc Leu	ctc Leu 975	ggc Gly	2928
gag Glu	acc Thr	ctt Leu	gcc Ala 980	cag Gln	gat Asp	gcc Ala	gct Ala 985	tct Ser	tca Ser	ggc Gly	tcg Ser	caa Gln 990	aag Lys	ccc Pro	ctc Leu	2976
gct Ala	ctc Leu	agc Ser 995	ctc Leu	gtc Val	tcc Ser	acg Thr	ccc Pro 1000	tcc Ser	aag Lys	ctc Leu	cag Gln	cgc Arg 1005	gag Glu	gtc Val	gag Glu	3024
ctc Leu	gcg Ala 1010	gcc Ala	aag Lys	ggt Gly	atc Ile	ccg Pro 1015	cgc Arg	tgc Cys	ctc Leu	aag Lys	atg Met 1020	cgc Arg	cgc Arg	gat Asp		3069
tgg Trp	agc Ser 1025	tcc Ser	cct Pro	gct Ala	ggc Gly	agc Ser 1030	cgc Arg	tac Tyr	gcg Ala	cct Pro	gag Glu 1035	ccg Pro	ctc Leu	gcc Ala		3114
agc Ser	gac Asp 1040	cgc Arg	gtc Val	gcc Ala	ttc Phe	atg Met 1045	tac Tyr	ggc Gly	gaa Glu	ggt Gly	cgc Arg 1050	agc Ser	cct Pro	tac Tyr		3159
tac Tyr	ggc Gly 1055	atc Ile	acc Thr	caa Gln	gac Asp	att Ile 1060	cac His	cgc Arg	att Ile	tgg Trp	ccc Pro 1065	gaa Glu	ctc Leu	cac His		3204
gag Glu	gtc Val 1070	atc Ile	aac Asn	gaa Glu	aag Lys	acg Thr 1075	aac Asn	cgt Arg	ctc Leu	tgg Trp	gcc Ala 1080	gaa Glu	ggc Gly	gac Asp		3249

2997-49-2-pct_ST25

cgc Arg	tgg Trp 1085	gtc Val	atg Met	ccg Pro	cgc Arg	gcc Ala 1090	agc Ser	ttc Phe	aag Lys	tcg Ser	gag Glu 1095	ctc Leu	gag Glu	agc Ser	3294
cag Gln	cag Gln 1100	caa Gln	gag Glu	ttt Phe	gat Asp	cgc Arg 1105	aac Asn	atg Met	att Ile	gaa Glu	atg Met 1110	ttc Phe	cgt Arg	ctt Leu	3339
gga Gly	atc Ile 1115	ctc Leu	acc Thr	tca Ser	att Ile	gcc Ala 1120	ttc Phe	acc Thr	aat Asn	ctg Leu	gcg Ala 1125	cgc Arg	gac Asp	gtt Val	3384
ctc Leu	aac Asn 1130	atc Ile	acg Thr	ccc Pro	aag Lys	gcc Ala 1135	gcc Ala	ttt Phe	ggc Gly	ctc Leu	agt Ser 1140	ctt Leu	ggc Gly	gag Glu	3429
att Ile	tcc Ser 1145	atg Met	att Ile	ttt Phe	gcc Ala	ttt Phe 1150	tcc Ser	aag Lys	aag Lys	aac Asn	ggt Gly 1155	ctc Leu	atc Ile	tcc Ser	3474
gac Asp	cag Gln 1160	ctc Leu	acc Thr	aag Lys	gat Asp	ctt Leu 1165	cgc Arg	gag Glu	tcc Ser	gac Asp	gtg Val 1170	tgg Trp	aac Asn	aag Lys	3519
gct Ala	ctg Leu 1175	gcc Ala	gtt Val	gaa Glu	ttt Phe	aat Asn 1180	gcg Ala	ctg Leu	cgc Arg	gag Glu	gcc Ala 1185	tgg Trp	ggc Gly	att Ile	3564
cca Pro	cag Gln 1190	agt Ser	gtc Val	ccc Pro	aag Lys	gac Asp 1195	gag Glu	ttc Phe	tgg Trp	caa Gln	ggc Gly 1200	tac Tyr	att Ile	gtg Val	3609
cgc Arg	ggc Gly 1205	acc Thr	aag Lys	cag Gln	gat Asp	atc Ile 1210	gag Glu	gcg Ala	gcc Ala	atc Ile	gcc Ala 1215	ccg Pro	gac Asp	agc Ser	3654
aag Lys	tac Tyr 1220	gtg Val	cgc Arg	ctc Leu	acc Thr	atc Ile 1225	atc Ile	aat Asn	gat Asp	gcc Ala	aac Asn 1230	acc Thr	gcc Ala	ctc Leu	3699
att Ile	agc Ser 1235	ggc Gly	aag Lys	ccc Pro	gac Asp	gcc Ala 1240	tgc Cys	aag Lys	gct Ala	gcg Ala	atc Ile 1245	gcg Ala	cgt Arg	ctc Leu	3744
ggt Gly	ggc Gly 1250	aac Asn	att Ile	cct Pro	gcg Ala	ctt Leu 1255	ccc Pro	gtg Val	acc Thr	cag Gln	ggc Gly 1260	atg Met	tgc Cys	ggc Gly	3789
cac His	tgc Cys 1265	ccc Pro	gag Glu	gtg Val	gga Gly	cct Pro 1270	tat Tyr	acc Thr	aag Lys	gat Asp	atc Ile 1275	gcc Ala	aag Lys	atc Ile	3834
cat His	gcc Ala 1280	aac Asn	ctt Leu	gag Glu	ttc Phe	ccc Pro 1285	gtt Val	gtc Val	gac Asp	ggc Gly	ctt Leu 1290	gac Asp	ctc Leu	tgg Trp	3879
acc Thr	aca Thr 1295	atc Ile	aac Asn	cag Gln	aag Lys	cgc Arg 1300	ctc Leu	gtg Val	cca Pro	cgc Arg	gcc Ala 1305	acg Thr	ggc Gly	gcc Ala	3924
aag Lys	gac Asp 1310	gaa Glu	tgg Trp	gcc Ala	cct Pro	tct Ser 1315	tcc Ser	ttt Phe	ggc Gly	gag Glu	tac Tyr 1320	gcc Ala	ggc Gly	cag Gln	3969
ctc Leu	tac Tyr 1325	gag Glu	aag Lys	cag Gln	gct Ala	aac Asn 1330	ttc Phe	ccc Pro	caa Gln	atc Ile	gtc Val 1335	gag Glu	acc Thr	att Ile	4014

2997-49-2-pct_ST25

tac Tyr	aag Lys 1340	caa Gln	aac Asn	tac Tyr	gac Asp	gtc Val 1345	ttt Phe	gtc Val	gag Glu	gtt Val	ggg Gly 1350	ccc Pro	aac Asn	aac Asn	4059
cac His	cgt Arg 1355	agc Ser	acc Thr	gca Ala	gtg Val	cgc Arg 1360	acc Thr	acg Thr	ctt Leu	ggt Gly	ccc Pro 1365	cag Gln	cgc Arg	aac Asn	4104
cac His	ctt Leu 1370	gct Ala	ggc Gly	gcc Ala	atc Ile	gac Asp 1375	aag Lys	cag Gln	aac Asn	gag Glu	gat Asp 1380	gct Ala	tgg Trp	acg Thr	4149
acc Thr	atc Ile 1385	gtc Val	aag Lys	ctt Leu	gtg Val	gct Ala 1390	tcg Ser	ctc Leu	aag Lys	gcc Ala	cac His 1395	ctt Leu	gtt Val	cct Pro	4194
ggc Gly	gtc Val 1400	acg Thr	atc Ile	tcg Ser	ccg Pro	ctg Leu 1405	tac Tyr	cac His	tcc Ser	aag Lys	ctt Leu 1410	gtg Val	gcg Ala	gag Glu	4239
gct Ala	gag Glu 1415	gct Ala	tgc Cys	tac Tyr	gct Ala	gcg Ala 1420	ctc Leu	tgc Cys	aag Lys	ggt Gly	gaa Glu 1425	aag Lys	ccc Pro	aag Lys	4284
aag Lys	aac Asn 1430	aag Lys	ttt Phe	gtg Val	cgc Arg	aag Lys 1435	att Ile	cag Gln	ctc Leu	aac Asn	ggt Gly 1440	cgc Arg	ttc Phe	aac Asn	4329
agc Ser	aag Lys 1445	gcg Ala	gac Asp	ccc Pro	atc Ile	tcc Ser 1450	tcg Ser	gcc Ala	gat Asp	ctt Leu	gcc Ala 1455	agc Ser	ttt Phe	ccg Pro	4374
cct Pro	gcg Ala 1460	gac Asp	cct Pro	gcc Ala	att Ile	gaa Glu 1465	gcc Ala	gcc Ala	atc Ile	tcg Ser	agc Ser 1470	cgc Arg	atc Ile	atg Met	4419
aag Lys	cct Pro 1475	gtc Val	gct Ala	ccc Pro	aag Lys	ttc Phe 1480	tac Tyr	gcg Ala	cgt Arg	ctc Leu	aac Asn 1485	att Ile	gac Asp	gag Glu	4464
cag Gln	gac Asp 1490	gag Glu	acc Thr	cga Arg	gat Asp	ccg Pro 1495	atc Ile	ctc Leu	aac Asn	aag Lys	gac Asp 1500	aac Asn	gcg Ala	ccg Pro	4509
tct Ser	tct Ser 1505	tct Ser	tct Ser	tct Ser	tct Ser	tct Ser 1510	tct Ser	tct Ser	tct Ser	tct Ser	tct Ser 1515	tct Ser	tct Ser	tct Ser	4554
ccg Pro	tcg Ser 1520	cct Pro	gct Ala	cct Pro	tcg Ser	gcc Ala 1525	ccc Pro	gtg Val	caa Gln	aag Lys	aag Lys 1530	gct Ala	gct Ala	ccc Pro	4599
gcc Ala	gcg Ala 1535	gag Glu	acc Thr	aag Lys	gct Ala	gtt Val 1540	gct Ala	tcg Ser	gct Ala	gac Asp	gca Ala 1545	ctt Leu	cgc Arg	agt Ser	4644
gcc Ala	ctg Leu 1550	ctc Leu	gat Asp	ctc Leu	gac Asp	agt Ser 1555	atg Met	ctt Leu	gcg Ala	ctg Leu	agc Ser 1560	tct Ser	gcc Ala	agt Ser	4689
gcc Ala	tcc Ser 1565	ggc Gly	aac Asn	ctt Leu	gtt Val	gag Glu 1570	act Thr	gcg Ala	cct Pro	agc Ser	gac Asp 1575	gcc Ala	tcg Ser	gtc Val	4734
att Ile	gtg Val 1580	ccg Pro	ccc Pro	tgc Cys	aac Asn	att Ile 1585	gcg Ala	gat Asp	ctc Leu	ggc Gly	agc Ser 1590	cgc Arg	gcc Ala	ttc Phe	4779

2997-49-2-pct_ST25

atg Met	aaa Lys 1595	acg Thr	tac Tyr	ggt Gly	gtt Val	tcg Ser 1600	gcg Ala	cct Pro	ctg Leu	tac Tyr	acg Thr 1605	ggc Gly	gcc Ala	atg Met	4824
gcc Ala	aag Lys 1610	ggc Gly	att Ile	gcc Ala	tct Ser	gcg Ala 1615	gac Asp	ctc Leu	gtc Val	att Ile	gcc Ala 1620	gcc Ala	ggc Gly	cgc Arg	4869
cag Gln	ggc Gly 1625	atc Ile	ctt Leu	gcg Ala	tcc Ser	ttt Phe 1630	ggc Gly	gcc Ala	ggc Gly	gga Gly	ctt Leu 1635	ccc Pro	atg Met	cag Gln	4914
gtt Val	gtg Val 1640	cgt Arg	gag Glu	tcc Ser	atc Ile	gaa Glu 1645	aag Lys	att Ile	cag Gln	gcc Ala	gcc Ala 1650	ctg Leu	ccc Pro	aat Asn	4959
ggc Gly	ccg Pro 1655	tac Tyr	gct Ala	gtc Val	aac Asn	ctt Leu 1660	atc Ile	cat His	tct Ser	ccc Pro	ttt Phe 1665	gac Asp	agc Ser	aac Asn	5004
ctc Leu	gaa Glu 1670	aag Lys	ggc Gly	aat Asn	gtc Val	gat Asp 1675	ctc Leu	ttc Phe	ctc Leu	gag Glu	aag Lys 1680	ggg Gly	gtc Val	acc Thr	5049
ttt Phe	gtc Val 1685	gag Glu	gcc Ala	tcg Ser	gcc Ala	ttt Phe 1690	atg Met	acg Thr	ctc Leu	acc Thr	ccg Pro 1695	cag Gln	gtc Val	gtg Val	5094
cgg Arg	tac Tyr 1700	cgc Arg	gcg Ala	gct Ala	ggc Gly	ctc Leu 1705	acg Thr	cgc Arg	aac Asn	gcc Ala	gac Asp 1710	ggc Gly	tcg Ser	gtc Val	5139
aac Asn	atc Ile 1715	cgc Arg	aac Asn	cgt Arg	atc Ile	att Ile 1720	ggc Gly	aag Lys	gtc Val	tcg Ser	cgc Arg 1725	acc Thr	gag Glu	ctc Leu	5184
gcc Ala	gag Glu 1730	atg Met	ttc Phe	atg Met	cgt Arg	cct Pro 1735	gcg Ala	ccc Pro	gag Glu	cac His	ctt Leu 1740	ctt Leu	cag Gln	aag Lys	5229
ctc Leu	att Ile 1745	gct Ala	tcc Ser	ggc Gly	gag Glu	atc Ile 1750	aac Asn	cag Gln	gag Glu	cag Gln	gcc Ala 1755	gag Glu	ctc Leu	gcc Ala	5274
cgc Arg	cgt Arg 1760	gtt Val	ccc Pro	gtc Val	gct Ala	gac Asp 1765	gac Asp	atc Ile	gcg Ala	gtc Val	gaa Glu 1770	gct Ala	gac Asp	tcg Ser	5319
ggg Gly	ggc Gly 1775	cac His	acc Thr	gac Asp	aac Asn	cgc Arg 1780	ccc Pro	atc Ile	cac His	gtc Val	att Ile 1785	ctg Leu	ccc Pro	ctc Leu	5364
atc Ile	atc Ile 1790	aac Asn	ctt Leu	cgc Arg	gac Asp	cgc Arg 1795	ctt Leu	cac His	cgc Arg	gag Glu	tgc Cys 1800	ggc Gly	tac Tyr	ccg Pro	5409
gcc Ala	aac Asn 1805	ctt Leu	cgc Arg	gtc Val	cgt Arg	gtg Val 1810	ggc Gly	gcc Ala	ggc Gly	ggt Gly	ggc Gly 1815	att Ile	ggg Gly	tgc Cys	5454
ccc Pro	cag Gln 1820	gcg Ala	gcg Ala	ctg Leu	gcc Ala	acc Thr 1825	ttc Phe	aac Asn	atg Met	ggt Gly	gcc Ala 1830	tcc Ser	ttt Phe	att Ile	5499
gtc Val	acc Thr 1835	ggc Gly	acc Thr	gtg Val	aac Asn	cag Gln 1840	gtc Val	gcc Ala	aag Lys	cag Gln	tcg Ser 1845	ggc Gly	acg Thr	tgc Cys	5544

2997-49-2-pct_ST25

gac Asp	aat Asn 1850	gtg Val	cgc Arg	aag Lys	cag Gln	ctc Leu 1855	gcg Ala	aag Lys	gcc Ala	act Thr	tac Tyr 1860	tcg Ser	gac Asp	gta Val	5589
tgc Cys	atg Met 1865	gcc Ala	ccg Pro	gct Ala	gcc Ala	gac Asp 1870	atg Met	ttc Phe	gag Glu	gaa Glu	ggc Gly 1875	gtc Val	aag Lys	ctt Leu	5634
cag Gln	gtc Val 1880	ctc Leu	aag Lys	aag Lys	gga Gly	acc Thr 1885	atg Met	ttt Phe	ccc Pro	tcg Ser	cgc Arg 1890	gcc Ala	aac Asn	aag Lys	5679
ctc Leu	tac Tyr 1895	gag Glu	ctc Leu	ttt Phe	tgc Cys	aag Lys 1900	tac Tyr	gac Asp	tcg Ser	ttc Phe	gag Glu 1905	tcc Ser	atg Met	ccc Pro	5724
ccc Pro	gca Ala 1910	gag Glu	ctt Leu	gcg Ala	cgc Arg	gtc Val 1915	gag Glu	aag Lys	cgc Arg	atc Ile	ttc Phe 1920	agc Ser	cgc Arg	gcg Ala	5769
ctc Leu	gaa Glu 1925	gag Glu	gtc Val	tgg Trp	gac Asp	gag Glu 1930	acc Thr	aaa Lys	aac Asn	ttt Phe	tac Tyr 1935	att Ile	aac Asn	cgt Arg	5814
ctt Leu	cac His 1940	aac Asn	ccg Pro	gag Glu	aag Lys	atc Ile 1945	cag Gln	cgc Arg	gcc Ala	gag Glu	cgc Arg 1950	gac Asp	ccc Pro	aag Lys	5859
ctc Leu	aag Lys 1955	atg Met	tcg Ser	ctg Leu	tgc Cys	ttt Phe 1960	cgc Arg	tgg Trp	tac Tyr	ctg Leu	agc Ser 1965	ctg Leu	gcg Ala	agc Ser	5904
cgc Arg	tgg Trp 1970	gcc Ala	aac Asn	act Thr	gga Gly	gct Ala 1975	tcc Ser	gat Asp	cgc Arg	gtc Val	atg Met 1980	gac Asp	tac Tyr	cag Gln	5949
gtc Val	tgg Trp 1985	tgc Cys	ggc Gly	cct Pro	gcc Ala	att Ile 1990	ggc Gly	tcc Ser	ttc Phe	aac Asn	gat Asp 1995	ttc Phe	atc Ile	aag Lys	5994
gga Gly	act Thr 2000	tac Tyr	ctt Leu	gat Asp	ccg Pro	gcc Ala 2005	gtc Val	gca Ala	aac Asn	gag Glu	tac Tyr 2010	ccg Pro	tgc Cys	gtc Val	6039
gtt Val	cag Gln 2015	att Ile	aac Asn	aag Lys	cag Gln	atc Ile 2020	ctt Leu	cgt Arg	gga Gly	gcg Ala	tgc Cys 2025	ttc Phe	ttg Leu	cgc Arg	6084
cgt Arg	ctc Leu 2030	gaa Glu	att Ile	ctg Leu	cgc Arg	aac Asn 2035	gca Ala	cgc Arg	ctt Leu	tcc Ser	gat Asp 2040	ggc Gly	gct Ala	gcc Ala	6129
gct Ala	ctt Leu 2045	gtg Val	gcc Ala	agc Ser	atc Ile	gat Asp 2050	gac Asp	aca Thr	tac Tyr	gtc Val	ccg Pro 2055	gcc Ala	gag Glu	aag Lys	6174
ctg Leu	taa														6180

<210> 4
 <211> 2059
 <212> PRT
 <213> Schizochytrium sp.

<400> 4

2997-49-2-pct_ST25

Met Ala Ala Arg Asn Val Ser Ala Ala His Glu Met His Asp Glu Lys
 1 5 10 15
 Arg Ile Ala Val Val Gly Met Ala Val Gln Tyr Ala Gly Cys Lys Thr
 20 25 30
 Lys Asp Glu Phe Trp Glu Val Leu Met Asn Gly Lys Val Glu Ser Lys
 35 40 45
 Val Ile Ser Asp Lys Arg Leu Gly Ser Asn Tyr Arg Ala Glu His Tyr
 50 55 60
 Lys Ala Glu Arg Ser Lys Tyr Ala Asp Thr Phe Cys Asn Glu Thr Tyr
 65 70 75 80
 Gly Thr Leu Asp Glu Asn Glu Ile Asp Asn Glu His Glu Leu Leu Leu
 85 90 95
 Asn Leu Ala Lys Gln Ala Leu Ala Glu Thr Ser Val Lys Asp Ser Thr
 100 105 110
 Arg Cys Gly Ile Val Ser Gly Cys Leu Ser Phe Pro Met Asp Asn Leu
 115 120 125
 Gln Gly Glu Leu Leu Asn Val Tyr Gln Asn His Val Glu Lys Lys Leu
 130 135 140
 Gly Ala Arg Val Phe Lys Asp Ala Ser His Trp Ser Glu Arg Glu Gln
 145 150 155 160
 Ser Asn Lys Pro Glu Ala Gly Asp Arg Arg Ile Phe Met Asp Pro Ala
 165 170 175
 Ser Phe Val Ala Glu Glu Leu Asn Leu Gly Ala Leu His Tyr Ser Val
 180 185 190
 Asp Ala Ala Cys Ala Thr Ala Leu Tyr Val Leu Arg Leu Ala Gln Asp
 195 200 205
 His Leu Val Ser Gly Ala Ala Asp Val Met Leu Cys Gly Ala Thr Cys
 210 215 220
 Leu Pro Glu Pro Phe Phe Ile Leu Ser Gly Phe Ser Thr Phe Gln Ala
 225 230 235 240
 Met Pro Val Gly Thr Gly Gln Asn Val Ser Met Pro Leu His Lys Asp
 245 250 255
 Ser Gln Gly Leu Thr Pro Gly Glu Gly Gly Ser Ile Met Val Leu Lys
 260 265 270

2997-49-2-pct_ST25

Arg Leu Asp Asp Ala Ile Arg Asp Gly Asp His Ile Tyr Gly Thr Leu
275 280 285

Leu Gly Ala Asn Val Ser Asn Ser Gly Thr Gly Leu Pro Leu Lys Pro
290 295 300

Leu Leu Pro Ser Glu Lys Lys Cys Leu Met Asp Thr Tyr Thr Arg Ile
305 310 315 320

Asn Val His Pro His Lys Ile Gln Tyr Val Glu Cys His Ala Thr Gly
325 330 335

Thr Pro Gln Gly Asp Arg Val Glu Ile Asp Ala Val Lys Ala Cys Phe
340 345 350

Glu Gly Lys Val Pro Arg Phe Gly Thr Thr Lys Gly Asn Phe Gly His
355 360 365

Thr Leu Val Ala Ala Gly Phe Ala Gly Met Cys Lys Val Leu Leu Ser
370 375 380

Met Lys His Gly Ile Ile Pro Pro Thr Pro Gly Ile Asp Asp Glu Thr
385 390 395 400

Lys Met Asp Pro Leu Val Val Ser Gly Glu Ala Ile Pro Trp Pro Glu
405 410 415

Thr Asn Gly Glu Pro Lys Arg Ala Gly Leu Ser Ala Phe Gly Phe Gly
420 425 430

Gly Thr Asn Ala His Ala Val Phe Glu Glu His Asp Pro Ser Asn Ala
435 440 445

Ala Cys Thr Gly His Asp Ser Ile Ser Ala Leu Ser Ala Arg Cys Gly
450 455 460

Gly Glu Ser Asn Met Arg Ile Ala Ile Thr Gly Met Asp Ala Thr Phe
465 470 475 480

Gly Ala Leu Lys Gly Leu Asp Ala Phe Glu Arg Ala Ile Tyr Thr Gly
485 490 495

Ala His Gly Ala Ile Pro Leu Pro Glu Lys Arg Trp Arg Phe Leu Gly
500 505 510

Lys Asp Lys Asp Phe Leu Asp Leu Cys Gly Val Lys Ala Thr Pro His
515 520 525

Gly Cys Tyr Ile Glu Asp Val Glu Val Asp Phe Gln Arg Leu Arg Thr
530 535 540

2997-49-2-pct_ST25

Pro Met Thr Pro Glu Asp Met Leu Leu Pro Gln Gln Leu Leu Ala Val
 545 550 555 560
 Thr Thr Ile Asp Arg Ala Ile Leu Asp Ser Gly Met Lys Lys Gly Gly
 565 570 575
 Asn Val Ala Val Phe Val Gly Leu Gly Thr Asp Leu Glu Leu Tyr Arg
 580 585 590
 His Arg Ala Arg Val Ala Leu Lys Glu Arg Val Arg Pro Glu Ala Ser
 595 600 605
 Lys Lys Leu Asn Asp Met Met Gln Tyr Ile Asn Asp Cys Gly Thr Ser
 610 615 620
 Thr Ser Tyr Thr Ser Tyr Ile Gly Asn Leu Val Ala Thr Arg Val Ser
 625 630 635 640
 Ser Gln Trp Gly Phe Thr Gly Pro Ser Phe Thr Ile Thr Glu Gly Asn
 645 650 655
 Asn Ser Val Tyr Arg Cys Ala Glu Leu Gly Lys Tyr Leu Leu Glu Thr
 660 665 670
 Gly Glu Val Asp Gly Val Val Val Ala Gly Val Asp Leu Cys Gly Ser
 675 680 685
 Ala Glu Asn Leu Tyr Val Lys Ser Arg Arg Phe Lys Val Ser Thr Ser
 690 695 700
 Asp Thr Pro Arg Ala Ser Phe Asp Ala Ala Ala Asp Gly Tyr Phe Val
 705 710 715 720
 Gly Glu Gly Cys Gly Ala Phe Val Leu Lys Arg Glu Thr Ser Cys Thr
 725 730 735
 Lys Asp Asp Arg Ile Tyr Ala Cys Met Asp Ala Ile Val Pro Gly Asn
 740 745 750
 Val Pro Ser Ala Cys Leu Arg Glu Ala Leu Asp Gln Ala Arg Val Lys
 755 760 765
 Pro Gly Asp Ile Glu Met Leu Glu Leu Ser Ala Asp Ser Ala Arg His
 770 775 780
 Leu Lys Asp Pro Ser Val Leu Pro Lys Glu Leu Thr Ala Glu Glu Glu
 785 790 795 800
 Ile Gly Gly Leu Gln Thr Ile Leu Arg Asp Asp Asp Lys Leu Pro Arg
 805 810 815

2997-49-2-pct_ST25

Asn Val Ala Thr Gly Ser Val Lys Ala Thr Val Gly Asp Thr Gly Tyr
 820 825 830
 Ala Ser Gly Ala Ala Ser Leu Ile Lys Ala Ala Leu Cys Ile Tyr Asn
 835 840 845
 Arg Tyr Leu Pro Ser Asn Gly Asp Asp Trp Asp Glu Pro Ala Pro Glu
 850 855 860
 Ala Pro Trp Asp Ser Thr Leu Phe Ala Cys Gln Thr Ser Arg Ala Trp
 865 870 875 880
 Leu Lys Asn Pro Gly Glu Arg Arg Tyr Ala Ala Val Ser Gly Val Ser
 885 890 895
 Glu Thr Arg Ser Cys Tyr Ser Val Leu Leu Ser Glu Ala Glu Gly His
 900 905 910
 Tyr Glu Arg Glu Asn Arg Ile Ser Leu Asp Glu Glu Ala Pro Lys Leu
 915 920 925
 Ile Val Leu Arg Ala Asp Ser His Glu Glu Ile Leu Gly Arg Leu Asp
 930 935 940
 Lys Ile Arg Glu Arg Phe Leu Gln Pro Thr Gly Ala Ala Pro Arg Glu
 945 950 955 960
 Ser Glu Leu Lys Ala Gln Ala Arg Arg Ile Phe Leu Glu Leu Leu Gly
 965 970 975
 Glu Thr Leu Ala Gln Asp Ala Ala Ser Ser Gly Ser Gln Lys Pro Leu
 980 985 990
 Ala Leu Ser Leu Val Ser Thr Pro Ser Lys Leu Gln Arg Glu Val Glu
 995 1000 1005
 Leu Ala Ala Lys Gly Ile Pro Arg Cys Leu Lys Met Arg Arg Asp
 1010 1015 1020
 Trp Ser Ser Pro Ala Gly Ser Arg Tyr Ala Pro Glu Pro Leu Ala
 1025 1030 1035
 Ser Asp Arg Val Ala Phe Met Tyr Gly Glu Gly Arg Ser Pro Tyr
 1040 1045 1050
 Tyr Gly Ile Thr Gln Asp Ile His Arg Ile Trp Pro Glu Leu His
 1055 1060 1065
 Glu Val Ile Asn Glu Lys Thr Asn Arg Leu Trp Ala Glu Gly Asp
 1070 1075 1080

2997-49-2-pct_ST25

Arg	Trp	Val	Met	Pro	Arg	Ala	Ser	Phe	Lys	Ser	Glu	Leu	Glu	Ser
	1085					1090					1095			
Gln	Gln	Gln	Glu	Phe	Asp	Arg	Asn	Met	Ile	Glu	Met	Phe	Arg	Leu
	1100					1105					1110			
Gly	Ile	Leu	Thr	Ser	Ile	Ala	Phe	Thr	Asn	Leu	Ala	Arg	Asp	Val
	1115					1120					1125			
Leu	Asn	Ile	Thr	Pro	Lys	Ala	Ala	Phe	Gly	Leu	Ser	Leu	Gly	Glu
	1130					1135					1140			
Ile	Ser	Met	Ile	Phe	Ala	Phe	Ser	Lys	Lys	Asn	Gly	Leu	Ile	Ser
	1145					1150					1155			
Asp	Gln	Leu	Thr	Lys	Asp	Leu	Arg	Glu	Ser	Asp	Val	Trp	Asn	Lys
	1160					1165					1170			
Ala	Leu	Ala	Val	Glu	Phe	Asn	Ala	Leu	Arg	Glu	Ala	Trp	Gly	Ile
	1175					1180					1185			
Pro	Gln	Ser	Val	Pro	Lys	Asp	Glu	Phe	Trp	Gln	Gly	Tyr	Ile	Val
	1190					1195					1200			
Arg	Gly	Thr	Lys	Gln	Asp	Ile	Glu	Ala	Ala	Ile	Ala	Pro	Asp	Ser
	1205					1210					1215			
Lys	Tyr	Val	Arg	Leu	Thr	Ile	Ile	Asn	Asp	Ala	Asn	Thr	Ala	Leu
	1220					1225					1230			
Ile	Ser	Gly	Lys	Pro	Asp	Ala	Cys	Lys	Ala	Ala	Ile	Ala	Arg	Leu
	1235					1240					1245			
Gly	Gly	Asn	Ile	Pro	Ala	Leu	Pro	Val	Thr	Gln	Gly	Met	Cys	Gly
	1250					1255					1260			
His	Cys	Pro	Glu	Val	Gly	Pro	Tyr	Thr	Lys	Asp	Ile	Ala	Lys	Ile
	1265					1270					1275			
His	Ala	Asn	Leu	Glu	Phe	Pro	Val	Val	Asp	Gly	Leu	Asp	Leu	Trp
	1280					1285					1290			
Thr	Thr	Ile	Asn	Gln	Lys	Arg	Leu	Val	Pro	Arg	Ala	Thr	Gly	Ala
	1295					1300					1305			
Lys	Asp	Glu	Trp	Ala	Pro	Ser	Ser	Phe	Gly	Glu	Tyr	Ala	Gly	Gln
	1310					1315					1320			
Leu	Tyr	Glu	Lys	Gln	Ala	Asn	Phe	Pro	Gln	Ile	Val	Glu	Thr	Ile
	1325					1330					1335			

2997-49-2-pct_ST25

Tyr	Lys 1340	Gln	Asn	Tyr	Asp	Val 1345	Phe	Val	Glu	Val	Gly 1350	Pro	Asn	Asn
His	Arg 1355	Ser	Thr	Ala	Val	Arg 1360	Thr	Thr	Leu	Gly	Pro 1365	Gln	Arg	Asn
His	Leu 1370	Ala	Gly	Ala	Ile	Asp 1375	Lys	Gln	Asn	Glu	Asp 1380	Ala	Trp	Thr
Thr	Ile 1385	Val	Lys	Leu	Val	Ala 1390	Ser	Leu	Lys	Ala	His 1395	Leu	Val	Pro
Gly	Val 1400	Thr	Ile	Ser	Pro	Leu 1405	Tyr	His	Ser	Lys	Leu 1410	Val	Ala	Glu
Ala	Glu 1415	Ala	Cys	Tyr	Ala	Ala 1420	Leu	Cys	Lys	Gly	Glu 1425	Lys	Pro	Lys
Lys	Asn 1430	Lys	Phe	Val	Arg	Lys 1435	Ile	Gln	Leu	Asn	Gly 1440	Arg	Phe	Asn
Ser	Lys 1445	Ala	Asp	Pro	Ile	Ser 1450	Ser	Ala	Asp	Leu	Ala 1455	Ser	Phe	Pro
Pro	Ala 1460	Asp	Pro	Ala	Ile	Glu 1465	Ala	Ala	Ile	Ser	Ser 1470	Arg	Ile	Met
Lys	Pro 1475	Val	Ala	Pro	Lys	Phe 1480	Tyr	Ala	Arg	Leu	Asn 1485	Ile	Asp	Glu
Gln	Asp 1490	Glu	Thr	Arg	Asp	Pro 1495	Ile	Leu	Asn	Lys	Asp 1500	Asn	Ala	Pro
Ser	Ser 1505	Ser	Ser	Ser	Ser	Ser 1510	Ser	Ser	Ser	Ser	Ser 1515	Ser	Ser	Ser
Pro	Ser 1520	Pro	Ala	Pro	Ser	Ala 1525	Pro	Val	Gln	Lys	Lys 1530	Ala	Ala	Pro
Ala	Ala 1535	Glu	Thr	Lys	Ala	Val 1540	Ala	Ser	Ala	Asp	Ala 1545	Leu	Arg	Ser
Ala	Leu 1550	Leu	Asp	Leu	Asp	Ser 1555	Met	Leu	Ala	Leu	Ser 1560	Ser	Ala	Ser
Ala	Ser 1565	Gly	Asn	Leu	Val	Glu 1570	Thr	Ala	Pro	Ser	Asp 1575	Ala	Ser	Val
Ile	Val 1580	Pro	Pro	Cys	Asn	Ile 1585	Ala	Asp	Leu	Gly	Ser 1590	Arg	Ala	Phe

2997-49-2-pct_ST25

Met	Lys 1595	Thr	Tyr	Gly	Val	Ser 1600	Ala	Pro	Leu	Tyr	Thr 1605	Gly	Ala	Met
Ala	Lys 1610	Gly	Ile	Ala	Ser	Ala 1615	Asp	Leu	Val	Ile	Ala 1620	Ala	Gly	Arg
Gln	Gly 1625	Ile	Leu	Ala	Ser	Phe 1630	Gly	Ala	Gly	Gly	Leu 1635	Pro	Met	Gln
Val	Val 1640	Arg	Glu	Ser	Ile	Glu 1645	Lys	Ile	Gln	Ala	Ala 1650	Leu	Pro	Asn
Gly	Pro 1655	Tyr	Ala	Val	Asn	Leu 1660	Ile	His	Ser	Pro	Phe 1665	Asp	Ser	Asn
Leu	Glu 1670	Lys	Gly	Asn	Val	Asp 1675	Leu	Phe	Leu	Glu	Lys 1680	Gly	Val	Thr
Phe	Val 1685	Glu	Ala	Ser	Ala	Phe 1690	Met	Thr	Leu	Thr	Pro 1695	Gln	Val	Val
Arg	Tyr 1700	Arg	Ala	Ala	Gly	Leu 1705	Thr	Arg	Asn	Ala	Asp 1710	Gly	Ser	Val
Asn	Ile 1715	Arg	Asn	Arg	Ile	Ile 1720	Gly	Lys	Val	Ser	Arg 1725	Thr	Glu	Leu
Ala	Glu 1730	Met	Phe	Met	Arg	Pro 1735	Ala	Pro	Glu	His	Leu 1740	Leu	Gln	Lys
Leu	Ile 1745	Ala	Ser	Gly	Glu	Ile 1750	Asn	Gln	Glu	Gln	Ala 1755	Glu	Leu	Ala
Arg	Arg 1760	Val	Pro	Val	Ala	Asp 1765	Asp	Ile	Ala	Val	Glu 1770	Ala	Asp	Ser
Gly	Gly 1775	His	Thr	Asp	Asn	Arg 1780	Pro	Ile	His	Val	Ile 1785	Leu	Pro	Leu
Ile	Ile 1790	Asn	Leu	Arg	Asp	Arg 1795	Leu	His	Arg	Glu	Cys 1800	Gly	Tyr	Pro
Ala	Asn 1805	Leu	Arg	Val	Arg	Val 1810	Gly	Ala	Gly	Gly	Gly 1815	Ile	Gly	Cys
Pro	Gln 1820	Ala	Ala	Leu	Ala	Thr 1825	Phe	Asn	Met	Gly	Ala 1830	Ser	Phe	Ile
Val	Thr 1835	Gly	Thr	Val	Asn	Gln 1840	Val	Ala	Lys	Gln	Ser 1845	Gly	Thr	Cys

2997-49-2-pct_ST25

Asp	Asn 1850	Val	Arg	Lys	Gln	Leu 1855	Ala	Lys	Ala	Thr	Tyr 1860	Ser	Asp	Val
Cys	Met 1865	Ala	Pro	Ala	Ala	Asp 1870	Met	Phe	Glu	Glu	Gly 1875	Val	Lys	Leu
Gln	Val 1880	Leu	Lys	Lys	Gly	Thr 1885	Met	Phe	Pro	Ser	Arg 1890	Ala	Asn	Lys
Leu	Tyr 1895	Glu	Leu	Phe	Cys	Lys 1900	Tyr	Asp	Ser	Phe	Glu 1905	Ser	Met	Pro
Pro	Ala 1910	Glu	Leu	Ala	Arg	Val 1915	Glu	Lys	Arg	Ile	Phe 1920	Ser	Arg	Ala
Leu	Glu 1925	Glu	Val	Trp	Asp	Glu 1930	Thr	Lys	Asn	Phe	Tyr 1935	Ile	Asn	Arg
Leu	His 1940	Asn	Pro	Glu	Lys	Ile 1945	Gln	Arg	Ala	Glu	Arg 1950	Asp	Pro	Lys
Leu	Lys 1955	Met	Ser	Leu	Cys	Phe 1960	Arg	Trp	Tyr	Leu	Ser 1965	Leu	Ala	Ser
Arg	Trp 1970	Ala	Asn	Thr	Gly	Ala 1975	Ser	Asp	Arg	Val	Met 1980	Asp	Tyr	Gln
Val	Trp 1985	Cys	Gly	Pro	Ala	Ile 1990	Gly	Ser	Phe	Asn	Asp 1995	Phe	Ile	Lys
Gly	Thr 2000	Tyr	Leu	Asp	Pro	Ala 2005	Val	Ala	Asn	Glu	Tyr 2010	Pro	Cys	Val
Val	Gln 2015	Ile	Asn	Lys	Gln	Ile 2020	Leu	Arg	Gly	Ala	Cys 2025	Phe	Leu	Arg
Arg	Leu 2030	Glu	Ile	Leu	Arg	Asn 2035	Ala	Arg	Leu	Ser	Asp 2040	Gly	Ala	Ala
Ala	Leu 2045	Val	Ala	Ser	Ile	Asp 2050	Asp	Thr	Tyr	Val	Pro 2055	Ala	Glu	Lys

Leu

<210> 5
 <211> 4509
 <212> DNA
 <213> Schizochytrium sp.

<220>

2997-49-2-pct_ST25

<221> CDS
 <222> (1)..(4509)

<400> 5

atg gcg ctc cgt gtc aag acg aac aag aag cca tgc tgg gag atg acc	48
Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr	
1 5 10 15	
aag gag gag ctg acc agc ggc aag acc gag gtg ttc aac tat gag gaa	96
Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu	
20 25 30	
ctc ctc gag ttc gca gag ggc gac atc gcc aag gtc ttc gga ccc gag	144
Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu	
35 40 45	
ttc gcc gtc atc gac aag tac ccg cgc cgc gtg cgc ctg ccc gcc cgc	192
Phe Ala Val Ile Asp Lys Tyr Pro Arg Arg Val Arg Leu Pro Ala Arg	
50 55 60	
gag tac ctg ctc gtg acc cgc gtc acc ctc atg gac gcc gag gtc aac	240
Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Asn	
65 70 75 80	
aac tac cgc gtc ggc gcc cgc atg gtc acc gag tac gat ctc ccc gtc	288
Asn Tyr Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Leu Pro Val	
85 90 95	
aac gga gag ctc tcc gag ggc gga gac tgc ccc tgg gcc gtc ctg gtc	336
Asn Gly Glu Leu Ser Glu Gly Gly Asp Cys Pro Trp Ala Val Leu Val	
100 105 110	
gag agt ggc cag tgc gat ctc atg ctc atc tcc tac atg ggc att gac	384
Glu Ser Gly Gln Cys Asp Leu Met Leu Ile Ser Tyr Met Gly Ile Asp	
115 120 125	
ttc cag aac cag ggc gac cgc gtc tac cgc ctg ctc aac acc acg ctc	432
Phe Gln Asn Gln Gly Asp Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu	
130 135 140	
acc ttt tac ggc gtg gcc cac gag ggc gag acc ctc gag tac gac att	480
Thr Phe Tyr Gly Val Ala His Glu Gly Glu Thr Leu Glu Tyr Asp Ile	
145 150 155 160	
cgc gtc acc ggc ttc gcc aag cgt ctc gac ggc ggc atc tcc atg ttc	528
Arg Val Thr Gly Phe Ala Lys Arg Leu Asp Gly Gly Ile Ser Met Phe	
165 170 175	
ttc ttc gag tac gac tgc tac gtc aac ggc cgc ctc ctc atc gag atg	576
Phe Phe Glu Tyr Asp Cys Tyr Val Asn Gly Arg Leu Leu Ile Glu Met	
180 185 190	
cgc gat ggc tgc gcc gcc ttc ttc acc aac gag gag ctc gac gcc ggc	624
Arg Asp Gly Cys Ala Gly Phe Phe Thr Asn Glu Glu Leu Asp Ala Gly	
195 200 205	
aag ggc gtc gtc ttc acc cgc ggc gac ctc gcc gcc cgc gcc aag atc	672
Lys Gly Val Val Phe Thr Arg Gly Asp Leu Ala Ala Arg Ala Lys Ile	
210 215 220	
cca aag cag gac gtc tcc ccc tac gcc gtc gcc ccc tgc ctc cac aag	720
Pro Lys Gln Asp Val Ser Pro Tyr Ala Val Ala Pro Cys Leu His Lys	
225 230 235 240	
acc aag ctc aac gaa aag gag atg cag acc ctc gtc gac aag gac tgg	768
Thr Lys Leu Asn Glu Lys Glu Met Gln Thr Leu Val Asp Lys Asp Trp	
245 250 255	

2997-49-2-pct_ST25

gca	tcc	gtc	ttt	ggc	tcc	aag	aac	ggc	atg	ccg	gaa	atc	aac	tac	aaa	816
Ala	Ser	Val	Phe	Gly	Ser	Lys	Asn	Gly	Met	Pro	Glu	Ile	Asn	Tyr	Lys	
			260					265					270			
ctc	tgc	gcg	cgt	aag	atg	ctc	atg	att	gac	cg	gtc	acc	agc	att	gac	864
Leu	Cys	Ala	Arg	Lys	Met	Leu	Met	Ile	Asp	Arg	Val	Thr	Ser	Ile	Asp	
		275					280					285				
cac	aag	ggc	ggt	gtc	tac	ggc	ctc	ggt	cag	ctc	gtc	ggt	gaa	aag	atc	912
His	Lys	Gly	Gly	Val	Tyr	Gly	Leu	Gly	Gln	Leu	Val	Gly	Glu	Lys	Ile	
	290					295					300					
ctc	gag	cg	gac	cac	tgg	tac	ttt	ccc	tgc	cac	ttt	gtc	aag	gat	cag	960
Leu	Glu	Arg	Asp	His	Trp	Tyr	Phe	Pro	Cys	His	Phe	Val	Lys	Asp	Gln	
	305				310					315					320	
gtc	atg	gcc	gga	tcc	ctc	gtc	tcc	gac	ggc	tgc	agc	cag	atg	ctc	aag	1008
Val	Met	Ala	Gly	Ser	Leu	Val	Ser	Asp	Gly	Cys	Ser	Gln	Met	Leu	Lys	
				325					330					335		
atg	tac	atg	atc	tgg	ctc	ggc	ctc	cac	ctc	acc	acc	gga	ccc	ttt	gac	1056
Met	Tyr	Met	Ile	Trp	Leu	Gly	Leu	His	Leu	Thr	Thr	Gly	Pro	Phe	Asp	
			340					345					350			
ttc	cg	ccg	gtc	aac	ggc	cac	ccc	aac	aag	gtc	cg	tgc	cg	ggc	caa	1104
Phe	Arg	Pro	Val	Asn	Gly	His	Pro	Asn	Lys	Val	Arg	Cys	Arg	Gly	Gln	
		355					360					365				
atc	tcc	ccg	cac	aag	ggc	aag	ctc	gtc	tac	gtc	atg	gag	atc	aag	gag	1152
Ile	Ser	Pro	His	Lys	Gly	Lys	Leu	Val	Tyr	Val	Met	Glu	Ile	Lys	Glu	
	370					375					380					
atg	ggc	ttc	gac	gag	gac	aac	gac	ccg	tac	gcc	att	gcc	gac	gtc	aac	1200
Met	Gly	Phe	Asp	Glu	Asp	Asn	Asp	Pro	Tyr	Ala	Ile	Ala	Asp	Val	Asn	
	385				390					395					400	
atc	att	gat	gtc	gac	ttc	gaa	aag	ggc	cag	gac	ttt	agc	ctc	gac	cg	1248
Ile	Ile	Asp	Val	Asp	Phe	Glu	Lys	Gly	Gln	Asp	Phe	Ser	Leu	Asp	Arg	
				405					410					415		
atc	agc	gac	tac	ggc	aag	ggc	gac	ctc	aac	aag	aag	atc	gtc	gtc	gac	1296
Ile	Ser	Asp	Tyr	Gly	Lys	Gly	Asp	Leu	Asn	Lys	Lys	Ile	Val	Val	Asp	
			420					425					430			
ttt	aag	ggc	atc	gct	ctc	aag	atg	cag	aag	cg	tcc	acc	aac	aag	aac	1344
Phe	Lys	Gly	Ile	Ala	Leu	Lys	Met	Gln	Lys	Arg	Ser	Thr	Asn	Lys	Asn	
		435					440					445				
ccc	tcc	aag	ggt	cag	ccc	gtc	ttt	gcc	aac	ggc	gcc	gcc	act	gtc	ggc	1392
Pro	Ser	Lys	Val	Gln	Pro	Val	Phe	Ala	Asn	Gly	Ala	Ala	Thr	Val	Gly	
	450					455					460					
ccc	gag	gcc	tcc	aag	gct	tcc	tcc	ggc	gcc	agc	gcc	agc	gcc	agc	gcc	1440
Pro	Glu	Ala	Ser	Lys	Ala	Ser	Ser	Gly	Ala	Ser	Ala	Ser	Ala	Ser	Ala	
	465				470				475						480	
gcc	ccg	gcc	aag	cct	gcc	ttc	agc	gcc	gat	ggt	ctt	gcg	ccc	aag	ccc	1488
Ala	Pro	Ala	Lys	Pro	Ala	Phe	Ser	Ala	Asp	Val	Leu	Ala	Pro	Lys	Pro	
				485					490					495		
ggt	gcc	ctt	ccc	gag	cac	atc	ctc	aag	ggc	gac	gcc	ctc	gcc	ccc	aag	1536
Val	Ala	Leu	Pro	Glu	His	Ile	Leu	Lys	Gly	Asp	Ala	Leu	Ala	Pro	Lys	
			500					505					510			
gag	atg	tcc	tgg	cac	ccc	atg	gcc	cg	atc	ccg	ggc	aac	ccg	acg	ccc	1584
Glu	Met	Ser	Trp	His	Pro	Met	Ala	Arg	Ile	Pro	Gly	Asn	Pro	Thr	Pro	
		515					520					525				

2997-49-2-pct_ST25																
tct Ser	ttt Phe 530	gcg Ala	ccc Pro	tcg Ser	gcc Ala	tac Tyr 535	aag Lys	ccg Pro	cgc Arg	aac Asn	atc Ile 540	gcc Ala	ttt Phe	acg Thr	ccc Pro	1632
ttc Phe 545	ccc Pro	ggc Gly	aac Asn	ccc Pro	aac Asn 550	gat Asp	aac Asn	gac Asp	cac His	acc Thr 555	ccg Pro	ggc Gly	aag Lys	atg Met	ccg Pro 560	1680
ctc Leu	acc Thr	tgg Trp	ttc Phe	aac Asn 565	atg Met	gcc Ala	gag Glu	ttc Phe	atg Met 570	gcc Ala	ggc Gly	aag Lys	gtc Val	agc Ser 575	atg Met	1728
tgc Cys	ctc Leu	ggc Gly	ccc Pro 580	gag Glu	ttc Phe	gcc Ala	aag Lys	ttc Phe 585	gac Asp	gac Asp	tcg Ser	aac Asn	acc Thr 590	agc Ser	cgc Arg	1776
agc Ser	ccc Pro	gct Ala 595	tgg Trp	gac Asp	ctc Leu	gct Ala	ctc Leu 600	gtc Val	acc Thr	cgc Arg	gcc Ala	gtg Val 605	tct Ser	gtg Val	tct Ser	1824
gac Asp	ctc Leu 610	aag Lys	cac His	gtc Val	aac Asn	tac Tyr 615	cgc Arg	aac Asn	atc Ile	gac Asp	ctc Leu 620	gac Asp	ccc Pro	tcc Ser	aag Lys	1872
ggc Gly 625	acc Thr	atg Met	gtc Val	ggc Gly	gag Glu 630	ttc Phe	gac Asp	tgc Cys	ccc Pro	gcg Ala 635	gac Asp	gcc Ala	tgg Trp	ttc Phe	tac Tyr 640	1920
aag Lys	ggc Gly	gcc Ala	tgc Cys	aac Asn 645	gat Asp	gcc Ala	cac His	atg Met	ccg Pro 650	tac Tyr	tcg Ser	atc Ile	ctc Leu	atg Met 655	gag Glu	1968
atc Ile	gcc Ala	ctc Leu	cag Gln 660	acc Thr	tcg Ser	ggt Gly	gtg Val	ctc Leu 665	acc Thr	tcg Ser	gtg Val	ctc Leu	aag Lys 670	gcg Ala	ccc Pro	2016
ctg Leu	acc Thr	atg Met 675	gag Glu	aag Lys	gac Asp	gac Asp	atc Ile 680	ctc Leu	ttc Phe	cgc Arg	aac Asn	ctc Leu 685	gac Asp	gcc Ala	aac Asn	2064
gcc Ala 690	gag Glu	ttc Phe	gtg Val	cgc Arg	gcc Ala	gac Asp 695	ctc Leu	gac Asp	tac Tyr	cgc Arg	ggc Gly 700	aag Lys	act Thr	atc Ile	cgc Arg	2112
aac Asn 705	gtc Val	acc Thr	aag Lys	tgc Cys	act Thr 710	ggc Gly	tac Tyr	agc Ser	atg Met	ctc Leu 715	ggc Gly	gag Glu	atg Met	ggc Gly	gtc Val 720	2160
cac His	cgc Arg	ttc Phe	acc Thr	ttt Phe 725	gag Glu	ctc Leu	tac Tyr	gtc Val	gat Asp 730	gat Asp	gtg Val	ctc Leu	ttt Phe	tac Tyr 735	aag Lys	2208
ggc Gly	tcg Ser	acc Thr	tcg Ser 740	ttc Phe	ggc Gly	tgg Trp	ttc Phe	gtg Val 745	ccc Pro	gag Glu	gtc Val	ttt Phe	gcc Ala 750	gcc Ala	cag Gln	2256
gcc Ala	ggc Gly 755	ctc Leu	gac Asp	aac Asn	ggc Gly	cgc Arg	aag Lys 760	tcg Ser	gag Glu	ccc Pro	tgg Trp	ttc Phe 765	att Ile	gag Glu	aac Asn	2304
aag Lys	gtt Val 770	ccg Pro	gcc Ala	tcg Ser	cag Gln	gtc Val 775	tcc Ser	tcc Ser	ttt Phe	gac Asp	gtg Val 780	cgc Arg	ccc Pro	aac Asn	ggc Gly	2352
agc Ser 785	ggc Gly	cgc Arg	acc Thr	gcc Ala	atc Ile 790	ttc Phe	gcc Ala	aac Asn	gcc Ala	ccc Pro 795	agc Ser	ggc Gly	gcc Ala	cag Gln	ctc Leu 800	2400

2997-49-2-pct_ST25

aac Asn	cgc Arg	cgc Arg	acg Thr	gac Asp 805	cag Gln	ggc Gly	cag Gln	tac Tyr	ctc Leu 810	gac Asp	gcc Ala	gtc Val	gac Asp	att Ile 815	gtc Val	2448
tcc Ser	ggc Gly	agc Ser	ggc Gly 820	aag Lys	aag Lys	agc Ser	ctc Leu	ggc Gly 825	tac Tyr	gcc Ala	cac His	ggt Gly	tcc Ser 830	aag Lys	acg Thr	2496
gtc Val	aac Asn	ccg Pro 835	aac Asn	gac Asp	tgg Trp	ttc Phe	ttc Phe 840	tcg Ser	tgc Cys	cac His	ttt Phe	tgg Trp 845	ttt Phe	gac Asp	tcg Ser	2544
gtc Val	atg Met 850	ccc Pro	gga Gly	agt Ser	ctc Leu	ggc Gly 855	gtc Val	gag Glu	tcc Ser	atg Met	ttc Phe 860	cag Gln	ctc Leu	gtc Val	gag Glu	2592
gcc Ala 865	atc Ile	gcc Ala	gcc Ala	cac His	gag Glu 870	gat Asp	ctc Leu	gct Ala	ggc Gly	aag Lys 875	cac His	ggc Gly	att Ile	gcc Ala	aac Asn 880	2640
ccc Pro	acc Thr	ttt Phe	gtg Val	cac His 885	gcc Ala	ccg Pro	ggc Gly	aag Lys	atc Ile 890	agc Ser	tgg Trp	aag Lys	tac Tyr	cgc Arg 895	ggc Gly	2688
cag Gln	ctc Leu	acg Thr	ccc Pro 900	aag Lys	agc Ser	aag Lys	aag Lys	atg Met 905	gac Asp	tcg Ser	gag Glu	gtc Val	cac His 910	atc Ile	gtg Val	2736
tcc Ser	gtg Val	gac Asp 915	gcc Ala	cac His	gac Asp	ggc Gly	ggt Val 920	gtc Val	gac Asp	ctc Leu	gtc Val	gcc Ala 925	gac Asp	ggc Gly	ttc Phe	2784
ctc Leu	tgg Trp 930	gcc Ala	gac Asp	agc Ser	ctc Leu	cgc Arg 935	gtc Val	tac Tyr	tcg Ser	gtg Val	agc Ser	aac Asn	att Ile	cgc Arg	gtg Val	2832
cgc Arg 945	atc Ile	gcc Ala	tcc Ser	ggt Gly	gag Glu 950	gcc Ala	cct Pro	gcc Ala	gcc Ala	gcc Ala 955	tcc Ser	tcc Ser	gcc Ala	gcc Ala	tct Ser 960	2880
gtg Val	ggc Gly	tcc Ser	tcg Ser	gct Ala 965	tcg Ser	tcc Ser	gtc Val	gag Glu	cgc Arg 970	acg Thr	cgc Arg	tcg Ser	agc Ser	ccc Pro 975	gct Ala	2928
gtc Val	gcc Ala	tcc Ser	ggc Gly 980	ccg Pro	gcc Ala	cag Gln	acc Thr	atc Ile 985	gac Asp	ctc Leu	aag Lys	cag Gln	ctc Leu	aag Lys	acc Thr	2976
gag Glu	ctc Leu	ctc Leu 995	gag Glu	ctc Leu	gat Asp	gcc Ala	ccg Pro 1000	ctc Leu	tac Tyr	ctc Leu	tcg Ser	cag Gln 1005	gac Asp	ccg Pro	acc Thr	3024
agc Ser	ggc Gly 1010	cag Gln	ctc Leu	aag Lys	aag Lys	cac His 1015	acc Thr	gac Asp	gtg Val	gcc Ala	tcc Ser 1020	ggc Gly	cag Gln	gcc Ala		3069
acc Thr	atc Ile 1025	gtg Val	cag Gln	ccc Pro	tgc Cys	acg Thr 1030	ctc Leu	ggc Gly	gac Asp	ctc Leu	ggt Gly 1035	gac Asp	cgc Arg	tcc Ser		3114
ttc Phe	atg Met 1040	gag Glu	acc Thr	tac Tyr	ggc Gly	gtc Val 1045	gtc Val	gcc Ala	ccg Pro	ctg Leu	tac Tyr 1050	acg Thr	ggc Gly	gcc Ala		3159
atg Met	gcc Ala 1055	aag Lys	ggc Gly	att Ile	gcc Ala	tcg Ser 1060	gcg Ala	gac Asp	ctc Leu	gtc Val	atc Ile 1065	gcc Ala	gcc Ala	ggc Gly		3204

2997-49-2-pct_ST25															
aag Lys	cgc Arg 1070	aag Lys	atc Ile	ctc Leu	ggc Gly	tcc Ser 1075	ttt Phe	ggc Gly	gcc Ala	ggc Gly 1080	ctc Leu	ccc Pro	atg Met	3249	
cac His	cac His 1085	gtg Val	cgc Arg	gcc Ala	gcc Ala	ctc Leu 1090	gag Glu	aag Lys	atc Ile	cag Gln	gcc Ala 1095	gcc Ala	ctg Leu	cct Pro	3294
cag Gln	ggc Gly 1100	ccc Pro	tac Tyr	gcc Ala	gtc Val	aac Asn 1105	ctc Leu	atc Ile	cac His	tcg Ser	cct Pro 1110	ttt Phe	gac Asp	agc Ser	3339
aac Asn	ctc Leu 1115	gag Glu	aag Lys	ggc Gly	aac Asn	gtc Val 1120	gat Asp	ctc Leu	ttc Phe	ctc Leu	gag Glu 1125	aag Lys	ggc Gly	gtc Val	3384
act Thr	gtg Val 1130	gtg Val	gag Glu	gcc Ala	tcg Ser	gca Ala 1135	ttc Phe	atg Met	acc Thr	ctc Leu	acc Thr 1140	ccg Pro	cag Gln	gtc Val	3429
gtg Val	cgc Arg 1145	tac Tyr	cgc Arg	gcc Ala	gcc Ala	ggc Gly 1150	ctc Leu	tcg Ser	cgc Arg	aac Asn	gcc Ala 1155	gac Asp	ggg Gly	tcg Ser	3474
gtc Val	aac Asn 1160	atc Ile	cgc Arg	aac Asn	cgc Arg	atc Ile 1165	atc Ile	ggc Gly	aag Lys	gtc Val	tcg Ser 1170	cgc Arg	acc Thr	gag Glu	3519
ctc Leu	gcc Ala 1175	gag Glu	atg Met	ttc Phe	atc Ile	cgc Arg 1180	ccg Pro	gcc Ala	ccg Pro	gag Glu	cac His 1185	ctc Leu	ctc Leu	gag Glu	3564
aag Lys	ctc Leu 1190	atc Ile	gcc Ala	tcg Ser	ggc Gly	gag Glu 1195	atc Ile	acc Thr	cag Gln	gag Glu	cag Gln 1200	gcc Ala	gag Glu	ctc Leu	3609
gcg Ala	cgc Arg 1205	cgc Arg	gtt Val	ccc Pro	gtc Val	gcc Ala 1210	gac Asp	gat Asp	atc Ile	gct Ala	gtc Val 1215	gag Glu	gct Ala	gac Asp	3654
tcg Ser	ggc Gly 1220	ggc Gly	cac His	acc Thr	gac Asp	aac Asn 1225	cgc Arg	ccc Pro	atc Ile	cac His	gtc Val 1230	atc Ile	ctc Leu	ccg Pro	3699
ctc Leu	atc Ile 1235	atc Ile	aac Asn	ctc Leu	cgc Arg	aac Asn 1240	cgc Arg	ctg Leu	cac His	cgc Arg	gag Glu 1245	tgc Cys	ggc Gly	tac Tyr	3744
ccc Pro	gcg Ala 1250	cac His	ctc Leu	cgc Arg	gtc Val	cgc Arg 1255	gtt Val	ggc Gly	gcc Ala	ggc Gly	ggg Gly 1260	ggc Gly	gtc Val	ggc Gly	3789
tgc Cys	ccg Pro 1265	cag Gln	gcc Ala	gcc Ala	gcc Ala	gcc Ala 1270	gcg Ala	ctc Leu	acc Thr	atg Met	ggc Gly 1275	gcc Ala	gcc Ala	ttc Phe	3834
atc Ile	gtc Val 1280	acc Thr	ggc Gly	act Thr	gtc Val	aac Asn 1285	cag Gln	gtc Val	gcc Ala	aag Lys	cag Gln 1290	tcc Ser	ggc Gly	acc Thr	3879
tgc Cys	gac Asp 1295	aac Asn	gtg Val	cgc Arg	aag Lys	cag Gln 1300	ctc Leu	tcg Ser	cag Gln	gcc Ala	acc Thr 1305	tac Tyr	tcg Ser	gat Asp	3924
atc Ile	tgc Cys 1310	atg Met	gcc Ala	ccg Pro	gcc Ala	gcc Ala 1315	gac Asp	atg Met	ttc Phe	gag Glu	gag Glu 1320	ggc Gly	gtc Val	aag Lys	3969

2997-49-2-pct_ST25

ctc Leu	cag Gln 1325	gtc Val	ctc Leu	aag Lys	aag Lys	gga Gly 1330	acc Thr	atg Met	ttc Phe	ccc Pro	tcg Ser 1335	cgc Arg	gcc Ala	aac Asn	4014
aag Lys	ctc Leu 1340	tac Tyr	gag Glu	ctc Leu	ttt Phe	tgc Cys 1345	aag Lys	tac Tyr	gac Asp	tcc Ser	ttc Phe 1350	gac Asp	tcc Ser	atg Met	4059
cct Pro	cct Pro 1355	gcc Ala	gag Glu	ctc Leu	gag Glu	cgc Arg 1360	atc Ile	gag Glu	aag Lys	cgt Arg	atc Ile 1365	ttc Phe	aag Lys	cgc Arg	4104
gca Ala	ctc Leu 1370	cag Gln	gag Glu	gtc Val	tgg Trp	gag Glu 1375	gag Glu	acc Thr	aag Lys	gac Asp	ttt Phe 1380	tac Tyr	att Ile	aac Asn	4149
ggt Gly	ctc Leu 1385	aag Lys	aac Asn	ccg Pro	gag Glu	aag Lys 1390	atc Ile	cag Gln	cgc Arg	gcc Ala	gag Glu 1395	cac His	gac Asp	ccc Pro	4194
aag Lys	ctc Leu 1400	aag Lys	atg Met	tcg Ser	ctc Leu	tgc Cys 1405	ttc Phe	cgc Arg	tgg Trp	tac Tyr	ctt Leu 1410	ggt Gly	ctt Leu	gcc Ala	4239
agc Ser	cgc Arg 1415	tgg Trp	gcc Ala	aac Asn	atg Met	ggc Gly 1420	gcc Ala	ccg Pro	gac Asp	cgc Arg	gtc Val 1425	atg Met	gac Asp	tac Tyr	4284
cag Gln	gtc Val 1430	tgg Trp	tgt Cys	ggc Gly	ccg Pro	gcc Ala 1435	att Ile	ggc Gly	gcc Ala	ttc Phe	aac Asn 1440	gac Asp	ttc Phe	atc Ile	4329
aag Lys	ggc Gly 1445	acc Thr	tac Tyr	ctc Leu	gac Asp	ccc Pro 1450	gct Ala	gtc Val	tcc Ser	aac Asn	gag Glu 1455	tac Tyr	ccc Pro	tgt Cys	4374
gtc Val	gtc Val 1460	cag Gln	atc Ile	aac Asn	ctg Leu	caa Gln 1465	atc Ile	ctc Leu	cgt Arg	ggg Gly	gcc Ala 1470	tgc Cys	tac Tyr	ctg Leu	4419
cgc Arg	cgt Arg 1475	ctc Leu	aac Asn	gcc Ala	ctg Leu	cgc Arg 1480	aac Asn	gac Asp	ccg Pro	cgc Arg	att Ile 1485	gac Asp	ctc Leu	gag Glu	4464
acc Thr	gag Glu 1490	gat Asp	gct Ala	gcc Ala	ttt Phe	gtc Val 1495	tac Tyr	gag Glu	ccc Pro	acc Thr	aac Asn 1500	gcg Ala	ctc Leu	taa	4509

<210> 6
 <211> 1502
 <212> PRT
 <213> Schizochytrium sp.

<400> 6

Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr
1 5 10 15

Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu
20 25 30

Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu
35 40 45

2997-49-2-pct_ST25

Phe Ala Val Ile Asp Lys Tyr Pro Arg Arg Val Arg Leu Pro Ala Arg
 50 55 60
 Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Asn
 65 70 75 80
 Asn Tyr Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Leu Pro Val
 85 90 95
 Asn Gly Glu Leu Ser Glu Gly Gly Asp Cys Pro Trp Ala Val Leu Val
 100 105 110
 Glu Ser Gly Gln Cys Asp Leu Met Leu Ile Ser Tyr Met Gly Ile Asp
 115 120 125
 Phe Gln Asn Gln Gly Asp Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
 130 135 140
 Thr Phe Tyr Gly Val Ala His Glu Gly Glu Thr Leu Glu Tyr Asp Ile
 145 150 155 160
 Arg Val Thr Gly Phe Ala Lys Arg Leu Asp Gly Gly Ile Ser Met Phe
 165 170 175
 Phe Phe Glu Tyr Asp Cys Tyr Val Asn Gly Arg Leu Leu Ile Glu Met
 180 185 190
 Arg Asp Gly Cys Ala Gly Phe Phe Thr Asn Glu Glu Leu Asp Ala Gly
 195 200 205
 Lys Gly Val Val Phe Thr Arg Gly Asp Leu Ala Ala Arg Ala Lys Ile
 210 215 220
 Pro Lys Gln Asp Val Ser Pro Tyr Ala Val Ala Pro Cys Leu His Lys
 225 230 235 240
 Thr Lys Leu Asn Glu Lys Glu Met Gln Thr Leu Val Asp Lys Asp Trp
 245 250 255
 Ala Ser Val Phe Gly Ser Lys Asn Gly Met Pro Glu Ile Asn Tyr Lys
 260 265 270
 Leu Cys Ala Arg Lys Met Leu Met Ile Asp Arg Val Thr Ser Ile Asp
 275 280 285
 His Lys Gly Gly Val Tyr Gly Leu Gly Gln Leu Val Gly Glu Lys Ile
 290 295 300
 Leu Glu Arg Asp His Trp Tyr Phe Pro Cys His Phe Val Lys Asp Gln
 305 310 315 320

2997-49-2-pct_ST25

Val Met Ala Gly Ser₃₂₅ Leu Val Ser Asp Gly₃₃₀ Cys Ser Gln Met₃₃₅ Leu Lys
 Met Tyr Met Ile₃₄₀ Trp Leu Gly Leu His₃₄₅ Leu Thr Thr Gly₃₅₀ Pro Phe Asp
 Phe Arg Pro₃₅₅ Val Asn Gly His₃₆₀ Pro Asn Lys Val Arg Cys₃₆₅ Arg Gly Gln
 Ile Ser₃₇₀ Pro His Lys Gly₃₇₅ Lys Leu Val Tyr Val₃₈₀ Met Glu Ile Lys Glu
 Met₃₈₅ Gly Phe Asp Glu₃₉₀ Asp Asn Asp Pro Tyr Ala₃₉₅ Ile Ala Asp Val₄₀₀ Asn
 Ile Ile Asp Val₄₀₅ Asp Phe Glu Lys Gly₄₁₀ Gln Asp Phe Ser Leu₄₁₅ Asp Arg
 Ile Ser Asp Tyr₄₂₀ Gly Lys Gly Asp₄₂₅ Leu Asn Lys Lys Ile Val₄₃₀ Val Asp
 Phe Lys Gly₄₃₅ Ile Ala Leu Lys₄₄₀ Met Gln Lys Arg Ser Thr₄₄₅ Asn Lys Asn
 Pro Ser₄₅₀ Lys Val Gln Pro Val₄₅₅ Phe Ala Asn Gly₄₆₀ Ala Ala Thr Val Gly
 Pro Glu Ala Ser Lys₄₇₀ Ala Ser Ser Gly Ala₄₇₅ Ser Ala Ser Ala Ser Ala₄₈₀
 Ala Pro Ala Lys₄₈₅ Pro Ala Phe Ser Ala₄₉₀ Asp Val Leu Ala Pro₄₉₅ Lys Pro
 Val Ala Leu Pro₅₀₀ Glu His Ile Leu Lys₅₀₅ Gly Asp Ala Leu Ala₅₁₀ Pro Lys
 Glu Met Ser₅₁₅ Trp His Pro Met Ala₅₂₀ Arg Ile Pro Gly₅₂₅ Asn Pro Thr Pro
 Ser Phe₅₃₀ Ala Pro Ser Ala Tyr₅₃₅ Lys Pro Arg Asn Ile₅₄₀ Ala Phe Thr Pro
 Phe Pro Gly Asn Pro₅₅₀ Asn Asp Asn Asp His Thr₅₅₅ Pro Gly Lys Met₅₆₀ Pro
 Leu Thr Trp Phe₅₆₅ Asn Met Ala Glu Phe Met₅₇₀ Ala Gly Lys Val Ser₅₇₅ Met
 Cys Leu Gly Pro₅₈₀ Glu Phe Ala Lys Phe₅₈₅ Asp Asp Ser Asn Thr₅₉₀ Ser Arg

2997-49-2-pct_ST25

Ser Pro Ala Trp Asp Leu Ala Leu Val Thr Arg Ala Val Ser Val Ser
 595 600 605

Asp Leu Lys His Val Asn Tyr Arg Asn Ile Asp Leu Asp Pro Ser Lys
 610 615 620

Gly Thr Met Val Gly Glu Phe Asp Cys Pro Ala Asp Ala Trp Phe Tyr
 625 630 635 640

Lys Gly Ala Cys Asn Asp Ala His Met Pro Tyr Ser Ile Leu Met Glu
 645 650 655

Ile Ala Leu Gln Thr Ser Gly Val Leu Thr Ser Val Leu Lys Ala Pro
 660 665 670

Leu Thr Met Glu Lys Asp Asp Ile Leu Phe Arg Asn Leu Asp Ala Asn
 675 680 685

Ala Glu Phe Val Arg Ala Asp Leu Asp Tyr Arg Gly Lys Thr Ile Arg
 690 695 700

Asn Val Thr Lys Cys Thr Gly Tyr Ser Met Leu Gly Glu Met Gly Val
 705 710 715 720

His Arg Phe Thr Phe Glu Leu Tyr Val Asp Asp Val Leu Phe Tyr Lys
 725 730 735

Gly Ser Thr Ser Phe Gly Trp Phe Val Pro Glu Val Phe Ala Ala Gln
 740 745 750

Ala Gly Leu Asp Asn Gly Arg Lys Ser Glu Pro Trp Phe Ile Glu Asn
 755 760 765

Lys Val Pro Ala Ser Gln Val Ser Ser Phe Asp Val Arg Pro Asn Gly
 770 775 780

Ser Gly Arg Thr Ala Ile Phe Ala Asn Ala Pro Ser Gly Ala Gln Leu
 785 790 795 800

Asn Arg Arg Thr Asp Gln Gly Gln Tyr Leu Asp Ala Val Asp Ile Val
 805 810 815

Ser Gly Ser Gly Lys Lys Ser Leu Gly Tyr Ala His Gly Ser Lys Thr
 820 825 830

Val Asn Pro Asn Asp Trp Phe Phe Ser Cys His Phe Trp Phe Asp Ser
 835 840 845

Val Met Pro Gly Ser Leu Gly Val Glu Ser Met Phe Gln Leu Val Glu
 850 855 860

2997-49-2-pct_ST25

Ala Ile Ala Ala His Glu Asp Leu Ala Gly Lys His Gly Ile Ala Asn
 865 870 875 880

 Pro Thr Phe Val His Ala Pro Gly Lys Ile Ser Trp Lys Tyr Arg Gly
 885 890 895

 Gln Leu Thr Pro Lys Ser Lys Lys Met Asp Ser Glu Val His Ile Val
 900 905 910

 Ser Val Asp Ala His Asp Gly Val Val Asp Leu Val Ala Asp Gly Phe
 915 920 925

 Leu Trp Ala Asp Ser Leu Arg Val Tyr Ser Val Ser Asn Ile Arg Val
 930 935 940

 Arg Ile Ala Ser Gly Glu Ala Pro Ala Ala Ala Ser Ser Ala Ala Ser
 945 950 955 960

 Val Gly ser ser Ala Ser ser Val Glu Arg Thr Arg Ser ser Pro Ala
 965 970 975

 Val Ala Ser Gly Pro Ala Gln Thr Ile Asp Leu Lys Gln Leu Lys Thr
 980 985 990

 Glu Leu Leu Glu Leu Asp Ala Pro Leu Tyr Leu Ser Gln Asp Pro Thr
 995 1000 1005

 Ser Gly Gln Leu Lys Lys His Thr Asp Val Ala Ser Gly Gln Ala
 1010 1015 1020

 Thr Ile Val Gln Pro Cys Thr Leu Gly Asp Leu Gly Asp Arg Ser
 1025 1030 1035

 Phe Met Glu Thr Tyr Gly Val Val Ala Pro Leu Tyr Thr Gly Ala
 1040 1045 1050

 Met Ala Lys Gly Ile Ala Ser Ala Asp Leu Val Ile Ala Ala Gly
 1055 1060 1065

 Lys Arg Lys Ile Leu Gly Ser Phe Gly Ala Gly Gly Leu Pro Met
 1070 1075 1080

 His His Val Arg Ala Ala Leu Glu Lys Ile Gln Ala Ala Leu Pro
 1085 1090 1095

 Gln Gly Pro Tyr Ala Val Asn Leu Ile His Ser Pro Phe Asp Ser
 1100 1105 1110

 Asn Leu Glu Lys Gly Asn Val Asp Leu Phe Leu Glu Lys Gly Val
 1115 1120 1125

2997-49-2-pct_ST25

Thr	Val 1130	Val	Glu	Ala	Ser	Ala 1135	Phe	Met	Thr	Leu	Thr 1140	Pro	Gln	Val
Val	Arg 1145	Tyr	Arg	Ala	Ala	Gly 1150	Leu	Ser	Arg	Asn	Ala 1155	Asp	Gly	Ser
Val	Asn 1160	Ile	Arg	Asn	Arg	Ile 1165	Ile	Gly	Lys	Val	Ser 1170	Arg	Thr	Glu
Leu	Ala 1175	Glu	Met	Phe	Ile	Arg 1180	Pro	Ala	Pro	Glu	His 1185	Leu	Leu	Glu
Lys	Leu 1190	Ile	Ala	Ser	Gly	Glu 1195	Ile	Thr	Gln	Glu	Gln 1200	Ala	Glu	Leu
Ala	Arg 1205	Arg	Val	Pro	Val	Ala 1210	Asp	Asp	Ile	Ala	Val 1215	Glu	Ala	Asp
Ser	Gly 1220	Gly	His	Thr	Asp	Asn 1225	Arg	Pro	Ile	His	Val 1230	Ile	Leu	Pro
Leu	Ile 1235	Ile	Asn	Leu	Arg	Asn 1240	Arg	Leu	His	Arg	Glu 1245	Cys	Gly	Tyr
Pro	Ala 1250	His	Leu	Arg	Val	Arg 1255	Val	Gly	Ala	Gly	Gly 1260	Gly	Val	Gly
Cys	Pro 1265	Gln	Ala	Ala	Ala	Ala 1270	Ala	Leu	Thr	Met	Gly 1275	Ala	Ala	Phe
Ile	Val 1280	Thr	Gly	Thr	Val	Asn 1285	Gln	Val	Ala	Lys	Gln 1290	Ser	Gly	Thr
Cys	Asp 1295	Asn	Val	Arg	Lys	Gln 1300	Leu	Ser	Gln	Ala	Thr 1305	Tyr	Ser	Asp
Ile	Cys 1310	Met	Ala	Pro	Ala	Ala 1315	Asp	Met	Phe	Glu	Glu 1320	Gly	Val	Lys
Leu	Gln 1325	Val	Leu	Lys	Lys	Gly 1330	Thr	Met	Phe	Pro	Ser 1335	Arg	Ala	Asn
Lys	Leu 1340	Tyr	Glu	Leu	Phe	Cys 1345	Lys	Tyr	Asp	Ser	Phe 1350	Asp	Ser	Met
Pro	Pro 1355	Ala	Glu	Leu	Glu	Arg 1360	Ile	Glu	Lys	Arg	Ile 1365	Phe	Lys	Arg
Ala	Leu 1370	Gln	Glu	Val	Trp	Glu 1375	Glu	Thr	Lys	Asp	Phe 1380	Tyr	Ile	Asn

2997-49-2-pct_ST25

Gly Leu Lys Asn Pro Glu Lys Ile Gln Arg Ala Glu His Asp Pro
1385 1390 1395

Lys Leu Lys Met Ser Leu Cys Phe Arg Trp Tyr Leu Gly Leu Ala
1400 1405 1410

Ser Arg Trp Ala Asn Met Gly Ala Pro Asp Arg Val Met Asp Tyr
1415 1420 1425

Gln Val Trp Cys Gly Pro Ala Ile Gly Ala Phe Asn Asp Phe Ile
1430 1435 1440

Lys Gly Thr Tyr Leu Asp Pro Ala Val Ser Asn Glu Tyr Pro Cys
1445 1450 1455

Val Val Gln Ile Asn Leu Gln Ile Leu Arg Gly Ala Cys Tyr Leu
1460 1465 1470

Arg Arg Leu Asn Ala Leu Arg Asn Asp Pro Arg Ile Asp Leu Glu
1475 1480 1485

Thr Glu Asp Ala Ala Phe Val Tyr Glu Pro Thr Asn Ala Leu
1490 1495 1500

<210> 7
<211> 1500
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(1500)

<400> 7
atg gcg gcc cgt ctg cag gag caa aag gga ggc gag atg gat acc cgc 48
Met Ala Ala Arg Leu Gln Glu Gln Lys Gly Gly Glu Met Asp Thr Arg
1 5 10 15
att gcc atc atc ggc atg tcg gcc atc ctc ccc tgc ggc acg acc gtg 96
Ile Ala Ile Ile Gly Met Ser Ala Ile Leu Pro Cys Gly Thr Thr Val
20 25 30
cgc gag tcg tgg gag acc atc cgc gcc ggc atc gac tgc ctg tcg gat 144
Arg Glu Ser Trp Glu Thr Ile Arg Ala Gly Ile Asp Cys Leu Ser Asp
35 40 45
ctc ccc gag gac cgc gtc gac gtg acg gcg tac ttt gac ccc gtc aag 192
Leu Pro Glu Asp Arg Val Asp Val Thr Ala Tyr Phe Asp Pro Val Lys
50 55 60
acc acc aag gac aag atc tac tgc aag cgc ggt ggc ttc att ccc gag 240
Thr Thr Lys Asp Lys Ile Tyr Cys Lys Arg Gly Gly Phe Ile Pro Glu
65 70 75 80
tac gac ttt gac gcc cgc gag ttc gga ctc aac atg ttc cag atg gag 288
Tyr Asp Phe Asp Ala Arg Glu Phe Gly Leu Asn Met Phe Gln Met Glu
85 90 95
gac tcg gac gca aac cag acc atc tcg ctt ctc aag gtc aag gag gcc 336

2997-49-2-pct_ST25															
Asp	Ser	Asp	Ala 100	Asn	Gln	Thr	Ile	Ser 105	Leu	Leu	Lys	Val	Lys 110	Glu	Ala
ctc Leu	cag Gln	gac Asp 115	gcc Ala	ggc Gly	atc Ile	gac Asp	gcc Ala 120	ctc Leu	ggc Gly	aag Lys	gaa Glu	aag Lys 125	aag Lys	aac Asn	atc Ile
ggc Gly	tgc Cys 130	gtg Val	ctc Leu	ggc Gly	att Ile	ggc Gly 135	ggc Gly	ggc Gly	caa Gln	aag Lys	tcc Ser 140	agc Ser	cac His	gag Glu	ttc Phe
tac Tyr 145	tcg Ser	cgc Arg	ctt Leu	aat Asn	tat Tyr 150	gtt Val	gtc Val	gtg Val	gag Glu	aag Lys 155	gtc Val	ctc Leu	cgc Arg	aag Lys	atg Met 160
ggc Gly	atg Met	ccc Pro	gag Glu	gag Glu 165	gac Asp	gtc Val	aag Lys	gtc Val	gcc Ala 170	gtc Val	gaa Glu	aag Lys	tac Tyr	aag Lys 175	gcc Ala
aac Asn	ttc Phe	ccc Pro	gag Glu 180	tgg Trp	cgc Arg	ctc Leu	gac Asp	tcc Ser 185	ttc Phe	cct Pro	ggc Gly	ttc Phe	ctc Leu 190	ggc Gly	aac Asn
gtc Val	acc Thr	gcc Ala 195	ggt Gly	cgc Arg	tgc Cys	acc Thr	aac Asn 200	acc Thr	ttc Phe	aac Asn	ctc Leu	gac Asp 205	ggc Gly	atg Met	aac Asn
tgc Cys 210	gtt Val	gtc Val	gac Asp	gcc Ala	gca Ala	tgc Cys 215	gcc Ala	tcg Ser	tcc Ser	ctc Leu	atc Ile 220	gcc Ala	gtc Val	aag Lys	gtc Val
gcc Ala 225	atc Ile	gac Asp	gag Glu	ctg Leu	ctc Leu 230	tac Tyr	ggt Gly	gac Asp	tgc Cys	gac Asp 235	atg Met	atg Met	gtc Val	acc Thr	ggt Gly 240
gcc Ala	acc Thr	tgc Cys	acg Thr	gat Asp 245	aac Asn	tcc Ser	atc Ile	ggc Gly	atg Met 250	tac Tyr	atg Met	gcc Ala	ttc Phe	tcc Ser 255	aag Lys
acc Thr	ccc Pro	gtg Val	ttc Phe 260	tcc Ser	acg Thr	gac Asp	ccc Pro	agc Ser 265	gtg Val	cgc Arg	gcc Ala	tac Tyr	gac Asp 270	gaa Glu	aag Lys
aca Thr	aag Lys	ggc Gly 275	atg Met	ctc Leu	atc Ile	ggc Gly	gag Glu 280	ggc Gly	tcc Ser	gcc Ala	atg Met 285	ctc Leu	gtc Val	ctc Leu	aag Lys
cgc Arg	tac Tyr 290	gcc Ala	gac Asp	gcc Ala	gtc Val	cgc Arg 295	gac Asp	ggc Gly	gat Asp	gag Glu	atc Ile 300	cac His	gct Ala	gtt Val	att Ile
cgc Arg 305	ggc Gly	tgc Cys	gcc Ala	tcc Ser 310	tcc Ser	agt Ser	gat Asp	ggc Gly	aag Lys	gcc Ala 315	gcc Ala	ggc Gly	atc Ile	tac Tyr	acg Thr 320
ccc Pro	acc Thr	att Ile	tcg Ser	ggc Gly 325	cag Gln	gag Glu	gag Glu	gcc Ala	ctc Leu 330	cgc Arg	cgc Arg	gcc Ala	tac Tyr	aac Asn 335	cgc Arg
gcc Ala	tgt Cys	gtc Val	gac Asp 340	ccg Pro	gcc Ala	acc Thr	gtc Val	act Thr 345	ctc Leu	gtc Val	gag Glu	ggt Gly	cac His 350	ggc Gly	acc Thr
ggt Gly	act Thr	ccc Pro 355	gtt Val	ggc Gly	gac Asp	cgc Arg	atc Ile 360	gag Glu	ctc Leu	acc Thr	gcc Ala	ttg Leu 365	cgc Arg	aac Asn	ctc Leu
ttt	gac	aag	gcc	tac	ggc	gag	ggc	aac	acc	gaa	aag	gtc	gct	gtg	ggc

2997-49-2-pct_ST25

Phe	Asp	Lys	Ala	Tyr	Gly	Glu	Gly	Asn	Thr	Glu	Lys	Val	Ala	Val	Gly		
370						375					380						
agc	atc	aag	tcc	agc	atc	ggc	cat	ctc	aag	gcc	gtc	gcc	ggc	ctc	gcc	1200	
Ser	Ile	Lys	Ser	Ser	Ile	Gly	His	Leu	Lys	Ala	Val	Ala	Gly	Leu	Ala		
385					390					395					400		
ggc	atg	atc	aag	gtc	atc	atg	gcg	ctc	aag	cac	aag	act	ctc	ccg	ggc	1248	
Gly	Met	Ile	Lys	Val	Ile	Met	Ala	Leu	Lys	His	Lys	Thr	Leu	Pro	Gly		
				405					410					415			
acc	atc	aac	gtc	gac	aac	cca	ccc	aac	ctc	tac	gac	aac	acg	ccc	atc	1296	
Thr	Ile	Asn	Val	Asp	Asn	Pro	Pro	Asn	Leu	Tyr	Asp	Asn	Thr	Pro	Ile		
			420					425					430				
aac	gag	tcc	tgc	ctc	tac	att	aac	acc	atg	aac	cgc	ccc	tgg	ttc	ccg	1344	
Asn	Glu	Ser	Ser	Leu	Tyr	Ile	Asn	Thr	Met	Asn	Arg	Pro	Trp	Phe	Pro		
		435					440					445					
ccc	cct	ggc	gtg	ccc	cgc	cgc	gcc	ggc	att	tgc	agc	ttt	ggc	ttt	ggc	1392	
Pro	Pro	Gly	Val	Pro	Arg	Arg	Ala	Gly	Ile	Ser	Ser	Phe	Gly	Phe	Gly		
	450					455					460						
ggc	gcc	aac	tac	cac	gcc	gtc	ctc	gag	gag	gcc	gag	ccc	gag	cac	acg	1440	
Gly	Ala	Asn	Tyr	His	Ala	Val	Leu	Glu	Glu	Ala	Glu	Pro	Glu	His	Thr		
465					470					475					480		
acc	gcg	tac	cgc	ctc	aac	aag	cgc	ccg	cag	ccc	gtg	ctc	atg	atg	gcc	1488	
Thr	Ala	Tyr	Arg	Leu	Asn	Lys	Arg	Pro	Gln	Pro	Val	Leu	Met	Met	Ala		
				485					490					495			
gcc	acg	ccc	gcg													1500	
Ala	Thr	Pro	Ala														
			500														

<210> 8
 <211> 500
 <212> PRT
 <213> Schizochytrium sp.

<400> 8

Met	Ala	Ala	Arg	Leu	Gln	Glu	Gln	Lys	Gly	Gly	Glu	Met	Asp	Thr	Arg
1				5					10					15	
Ile	Ala	Ile	Ile	Gly	Met	Ser	Ala	Ile	Leu	Pro	Cys	Gly	Thr	Thr	Val
			20					25					30		
Arg	Glu	Ser	Trp	Glu	Thr	Ile	Arg	Ala	Gly	Ile	Asp	Cys	Leu	Ser	Asp
		35					40					45			
Leu	Pro	Glu	Asp	Arg	Val	Asp	Val	Thr	Ala	Tyr	Phe	Asp	Pro	Val	Lys
	50					55					60				
Thr	Thr	Lys	Asp	Lys	Ile	Tyr	Cys	Lys	Arg	Gly	Gly	Phe	Ile	Pro	Glu
65					70					75					80
Tyr	Asp	Phe	Asp	Ala	Arg	Glu	Phe	Gly	Leu	Asn	Met	Phe	Gln	Met	Glu
				85					90					95	
Asp	Ser	Asp	Ala	Asn	Gln	Thr	Ile	Ser	Leu	Leu	Lys	Val	Lys	Glu	Ala

100

105

110

Leu Gln Asp₁₁₅ Ala Gly Ile Asp Ala₁₂₀ Leu Gly Lys Glu Lys₁₂₅ Lys Asn Ile

Gly Cys₁₃₀ Val Leu Gly Ile Gly₁₃₅ Gly Gly Gln Lys Ser₁₄₀ Ser His Glu Phe

Tyr₁₄₅ Ser Arg Leu Asn Tyr₁₅₀ Val Val Val Glu Lys₁₅₅ Val Leu Arg Lys Met₁₆₀

Gly Met Pro Glu Glu₁₆₅ Asp Val Lys Val Ala₁₇₀ Val Glu Lys Tyr Lys₁₇₅ Ala

Asn Phe Pro Glu₁₈₀ Trp Arg Leu Asp Ser₁₈₅ Phe Pro Gly Phe Leu₁₉₀ Gly Asn

Val Thr Ala₁₉₅ Gly Arg Cys Thr Asn₂₀₀ Thr Phe Asn Leu Asp₂₀₅ Gly Met Asn

Cys Val₂₁₀ Val Asp Ala Ala Cys₂₁₅ Ala Ser Ser Leu Ile₂₂₀ Ala Val Lys Val

Ala Ile Asp Glu Leu Leu₂₃₀ Tyr Gly Asp Cys Asp₂₃₅ Met Met Val Thr Gly₂₄₀

Ala Thr Cys Thr Asp₂₄₅ Asn Ser Ile Gly Met₂₅₀ Tyr Met Ala Phe Ser₂₅₅ Lys

Thr Pro Val Phe₂₆₀ Ser Thr Asp Pro Ser₂₆₅ Val Arg Ala Tyr Asp₂₇₀ Glu Lys

Thr Lys Gly₂₇₅ Met Leu Ile Gly Glu₂₈₀ Gly Ser Ala Met Leu₂₈₅ Val Leu Lys

Arg Tyr₂₉₀ Ala Asp Ala Val Arg₂₉₅ Asp Gly Asp Glu Ile₃₀₀ His Ala Val Ile

Arg Gly Cys Ala Ser Ser₃₁₀ Ser Asp Gly Lys Ala₃₁₅ Ala Gly Ile Tyr Thr₃₂₀

Pro Thr Ile Ser Gly₃₂₅ Gln Glu Glu Ala Leu₃₃₀ Arg Arg Ala Tyr Asn₃₃₅ Arg

Ala Cys Val Asp₃₄₀ Pro Ala Thr Val Thr₃₄₅ Leu Val Glu Gly His₃₅₀ Gly Thr

Gly Thr Pro₃₅₅ Val Gly Asp Arg Ile₃₆₀ Glu Leu Thr Ala Leu₃₆₅ Arg Asn Leu

Phe Asp Lys Ala Tyr Gly Glu Gly Asn Thr Glu Lys Val Ala Val Gly

370

375

380

Ser Ile Lys Ser Ser Ile Gly His Leu Lys Ala Val Ala Gly Leu Ala
 385 390 395 400

Gly Met Ile Lys Val Ile Met Ala Leu Lys His Lys Thr Leu Pro Gly
 405 410 415

Thr Ile Asn Val Asp Asn Pro Pro Asn Leu Tyr Asp Asn Thr Pro Ile
 420 425 430

Asn Glu Ser Ser Leu Tyr Ile Asn Thr Met Asn Arg Pro Trp Phe Pro
 435 440 445

Pro Pro Gly Val Pro Arg Arg Ala Gly Ile Ser Ser Phe Gly Phe Gly
 450 455 460

Gly Ala Asn Tyr His Ala Val Leu Glu Glu Ala Glu Pro Glu His Thr
 465 470 475 480

Thr Ala Tyr Arg Leu Asn Lys Arg Pro Gln Pro Val Leu Met Met Ala
 485 490 495

Ala Thr Pro Ala
 500

<210> 9
 <211> 1278
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1278)

<400> 9
 gat gtc acc aag gag gcc tgg cgc ctc ccc cgc gag ggc gtc agc ttc 48
 Asp Val Thr Lys Glu Ala Trp Arg Leu Pro Arg Glu Gly Val Ser Phe
 1 5 10 15

cgc gcc aag ggc atc gcc acc aac ggc gct gtc gcc gcg ctc ttc tcc 96
 Arg Ala Lys Gly Ile Ala Thr Asn Gly Ala Val Ala Ala Leu Phe Ser
 20 25 30

ggc cag ggc gcg cag tac acg cac atg ttt agc gag gtg gcc atg aac 144
 Gly Gln Gly Ala Gln Tyr Thr His Met Phe Ser Glu Val Ala Met Asn
 35 40 45

tgg ccc cag ttc cgc cag agc att gcc gcc atg gac gcc gcc cag tcc 192
 Trp Pro Gln Phe Arg Gln Ser Ile Ala Ala Met Asp Ala Ala Gln Ser
 50 55 60

aag gtc gct gga agc gac aag gac ttt gag cgc gtc tcc cag gtc ctc 240
 Lys Val Ala Gly Ser Asp Lys Asp Phe Glu Arg Val Ser Gln Val Leu
 65 70 75 80

tac ccg cgc aag ccg tac gag cgt gag ccc gag cag gac cac aag aag 288
 Tyr Pro Arg Lys Pro Tyr Glu Arg Glu Pro Glu Gln Asp His Lys Lys

2997-49-2-pct_ST25																
85								90				95				
atc Ile	tcc Ser	ctc Leu	acc Thr 100	gcc Ala	tac Tyr	tcg Ser	cag Gln	ccc Pro 105	tcg Ser	acc Thr	ctg Leu	gcc Ala	tgc Cys 110	gct Ala	ctc Leu	336
ggt Gly	gcc Ala	ttt Phe 115	gag Glu	atc Ile	ttc Phe	aag Lys	gag Glu 120	gcc Ala	ggc Gly	ttc Phe	acc Thr	ccg Pro 125	gac Asp	ttt Phe	gcc Ala	384
gcc Ala	ggc Gly 130	cat His	tcg Ser	ctc Leu	ggt Gly	gag Glu 135	ttc Phe	gcc Ala	gcc Ala	ctc Leu	tac Tyr 140	gcc Ala	gcg Ala	ggc Gly	tgc Cys	432
gtc Val 145	gac Asp	cgc Arg	gac Asp	gag Glu	ctc Leu 150	ttt Phe	gag Glu	ctt Leu	gtc Val	tgc Cys 155	cgc Arg	cgc Arg	gcc Ala	cgc Arg	atc Ile 160	480
atg Met	ggc Gly	ggc Gly	aag Lys	gac Asp 165	gca Ala	ccg Pro	gcc Ala	acc Thr	ccc Pro 170	aag Lys	ggc Gly	tgc Cys	atg Met	gcc Ala 175	gcc Ala	528
gtc Val	att Ile	ggc Gly	ccc Pro 180	aac Asn	gcc Ala	gag Glu	aac Asn	atc Ile 185	aag Lys	gtc Val	cag Gln	gcc Ala	gcc Ala 190	aac Asn	gtc Val	576
tgg Trp	ctc Leu	ggc Gly 195	aac Asn	tcc Ser	aac Asn	tcg Ser	cct Pro 200	tcg Ser	cag Gln	acc Thr	gtc Val	atc Ile 205	acc Thr	ggc Gly	tcc Ser	624
gtc Val	gaa Glu 210	ggt Gly	atc Ile	cag Gln	gcc Ala	gag Glu 215	agc Ser	gcc Ala	cgc Arg	ctc Leu	cag Gln 220	aag Lys	gag Glu	ggc Gly	ttc Phe	672
cgc Arg 225	gtc Val	gtg Val	cct Pro	ctt Leu	gcc Ala 230	tgc Cys	gag Glu	agc Ser	gcc Ala	ttc Phe 235	cac His	tcg Ser	ccc Pro	cag Gln	atg Met 240	720
gag Glu	aac Asn	gcc Ala	tcg Ser	tcg Ser 245	gcc Ala	ttc Phe	aag Lys	gac Asp	gtc Val 250	atc Ile	tcc Ser	aag Lys	gtc Val	tcc Ser 255	ttc Phe	768
cgc Arg	acc Thr	ccc Pro	aag Lys 260	gcc Ala	gag Glu	acc Thr	aag Lys	ctc Leu 265	ttc Phe	agc Ser	aac Asn	gtc Val	tct Ser 270	ggc Gly	gag Glu	816
acc Thr	tac Tyr	ccc Pro 275	acg Thr	gac Asp	gcc Ala	cgc Arg	gag Glu 280	atg Met	ctt Leu	acg Thr	cag Gln	cac His 285	atg Met	acc Thr	agc Ser	864
agc Ser	gtc Val 290	aag Lys	ttc Phe	ctc Leu	acc Thr	cag Gln 295	gtc Val	cgc Arg	aac Asn	atg Met	cac His 300	cag Gln	gcc Ala	ggt Gly	gcg Ala	912
cgc Arg 305	atc Ile	ttt Phe	gtc Val	gag Glu	ttc Phe 310	gga Gly	ccc Pro	aag Lys	cag Gln	gtg Val 315	ctc Leu	tcc Ser	aag Lys	ctt Leu	gtc Val 320	960
tcc Ser	gag Glu	acc Thr	ctc Leu	aag Lys 325	gat Asp	gac Asp	ccc Pro	tcg Ser	gtt Val 330	gtc Val	acc Thr	gtc Val	tct Ser	gtc Val 335	aac Asn	1008
ccg Pro	gcc Ala	tcg Ser	ggc Gly 340	acg Thr	gat Asp	tcg Ser	gac Asp	atc Ile 345	cag Gln	ctc Leu	cgc Arg	gac Asp	gcg Ala 350	gcc Ala	gtc Val	1056
cag Gln	ctc Leu	gtt Val	gtc Val	gct Ala	ggc Gly	gtc Val	aac Asn	ctt Leu	cag Gln	ggc Gly	ttt Phe	gac Asp	aag Lys	tgg Trp	gac Asp	1104

2997-49-2-pct_ST25

355	gcc ccc gat gcc acc cgc atg cag gcc atc aag aag aag cgc act acc	1152
	Ala Pro Asp Ala Thr Arg Met Gln Ala Ile Lys Lys Lys Arg Thr Thr	
	370 375 380	
	ctc cgc ctt tcg gcc gcc acc tac gtc tcg gac aag acc aag aag gtc	1200
	Leu Arg Leu Ser Ala Ala Thr Tyr Val Ser Asp Lys Thr Lys Lys Val	
	385 390 395 400	
	cgc gac gcc gcc atg aac gat ggc cgc tgc gtc acc tac ctc aag ggc	1248
	Arg Asp Ala Ala Met Asn Asp Gly Arg Cys Val Thr Tyr Leu Lys Gly	
	405 410 415	
	gcc gca ccg ctc atc aag gcc ccg gag ccc	1278
	Ala Ala Pro Leu Ile Lys Ala Pro Glu Pro	
	420 425	

<210> 10
 <211> 426
 <212> PRT
 <213> Schizochytrium sp.

<400> 10

Asp Val Thr Lys Glu Ala Trp Arg Leu Pro Arg Glu Gly Val Ser Phe
1 5 10 15
Arg Ala Lys Gly Ile Ala Thr Asn Gly Ala Val Ala Ala Leu Phe Ser
20 25 30
Gly Gln Gly Ala Gln Tyr Thr His Met Phe Ser Glu Val Ala Met Asn
35 40 45
Trp Pro Gln Phe Arg Gln Ser Ile Ala Ala Met Asp Ala Ala Gln Ser
50 55 60
Lys Val Ala Gly Ser Asp Lys Asp Phe Glu Arg Val Ser Gln Val Leu
65 70 75 80
Tyr Pro Arg Lys Pro Tyr Glu Arg Glu Pro Glu Gln Asp His Lys Lys
85 90 95
Ile Ser Leu Thr Ala Tyr Ser Gln Pro Ser Thr Leu Ala Cys Ala Leu
100 105 110
Gly Ala Phe Glu Ile Phe Lys Glu Ala Gly Phe Thr Pro Asp Phe Ala
115 120 125
Ala Gly His Ser Leu Gly Glu Phe Ala Ala Leu Tyr Ala Ala Gly Cys
130 135 140
Val Asp Arg Asp Glu Leu Phe Glu Leu Val Cys Arg Arg Ala Arg Ile
145 150 155 160
Met Gly Gly Lys Asp Ala Pro Ala Thr Pro Lys Gly Cys Met Ala Ala
165 170 175

2997-49-2-pct_ST25

Val Ile Gly Pro Asn Ala Glu Asn Ile Lys Val Gln Ala Ala Asn Val
180 185 190

Trp Leu Gly Asn Ser Asn Ser Pro Ser Gln Thr Val Ile Thr Gly Ser
195 200 205

Val Glu Gly Ile Gln Ala Glu Ser Ala Arg Leu Gln Lys Glu Gly Phe
210 215 220

Arg Val Val Pro Leu Ala Cys Glu Ser Ala Phe His Ser Pro Gln Met
225 230 235 240

Glu Asn Ala Ser Ser Ala Phe Lys Asp Val Ile Ser Lys Val Ser Phe
245 250 255

Arg Thr Pro Lys Ala Glu Thr Lys Leu Phe Ser Asn Val Ser Gly Glu
260 265 270

Thr Tyr Pro Thr Asp Ala Arg Glu Met Leu Thr Gln His Met Thr Ser
275 280 285

Ser Val Lys Phe Leu Thr Gln Val Arg Asn Met His Gln Ala Gly Ala
290 295 300

Arg Ile Phe Val Glu Phe Gly Pro Lys Gln Val Leu Ser Lys Leu Val
305 310 315 320

Ser Glu Thr Leu Lys Asp Asp Pro Ser Val Val Thr Val Ser Val Asn
325 330 335

Pro Ala Ser Gly Thr Asp Ser Asp Ile Gln Leu Arg Asp Ala Ala Val
340 345 350

Gln Leu Val Val Ala Gly Val Asn Leu Gln Gly Phe Asp Lys Trp Asp
355 360 365

Ala Pro Asp Ala Thr Arg Met Gln Ala Ile Lys Lys Lys Arg Thr Thr
370 375 380

Leu Arg Leu Ser Ala Ala Thr Tyr Val Ser Asp Lys Thr Lys Lys Val
385 390 395 400

Arg Asp Ala Ala Met Asn Asp Gly Arg Cys Val Thr Tyr Leu Lys Gly
405 410 415

Ala Ala Pro Leu Ile Lys Ala Pro Glu Pro
420 425

<210> 11
<211> 5

<212> PRT
 <213> Schizochytrium sp.

<220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> X = any amino acid

<400> 11

Gly His Ser Xaa Gly
 1 5

<210> 12
 <211> 258
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(258)

<400> 12
 gct gtc tcg aac gag ctt ctt gag aag gcc gag act gtc gtc atg gag 48
 Ala Val Ser Asn Glu Leu Leu Glu Lys Ala Glu Thr Val Val Met Glu
 1 5 10 15
 gtc ctc gcc gcc aag acc ggc tac gag acc gac atg atc gag gct gac 96
 Val Leu Ala Ala Lys Thr Gly Tyr Glu Thr Asp Met Ile Glu Ala Asp
 20 25 30
 atg gag ctc gag acc gag ctc ggc att gac tcc atc aag cgt gtc gag 144
 Met Glu Leu Glu Thr Glu Leu Gly Ile Asp Ser Ile Lys Arg Val Glu
 35 40 45
 atc ctc tcc gag gtc cag gcc atg ctc aat gtc gag gcc aag gat gtc 192
 Ile Leu Ser Glu Val Gln Ala Met Leu Asn Val Glu Ala Lys Asp Val
 50 55 60
 gat gcc ctc agc cgc act cgc act gtt ggt gag gtt gtc aac gcc atg 240
 Asp Ala Leu Ser Arg Thr Arg Thr Val Gly Glu Val Val Asn Ala Met
 65 70 75 80
 aag gcc gag atc gct ggc 258
 Lys Ala Glu Ile Ala Gly
 85

<210> 13
 <211> 86
 <212> PRT
 <213> Schizochytrium sp.

<400> 13

Ala Val Ser Asn Glu Leu Leu Glu Lys Ala Glu Thr Val Val Met Glu
 1 5 10 15
 Val Leu Ala Ala Lys Thr Gly Tyr Glu Thr Asp Met Ile Glu Ala Asp
 20 25 30
 Met Glu Leu Glu Thr Glu Leu Gly Ile Asp Ser Ile Lys Arg Val Glu
 35 40 45

Ile Leu Ser Glu Val Gln Ala Met Leu Asn Val Glu Ala Lys Asp Val
 50 55 60

Asp Ala Leu Ser Arg Thr Arg Thr Val Gly Glu Val Val Asn Ala Met
 65 70 75 80

Lys Ala Glu Ile Ala Gly
 85

<210> 14
 <211> 5
 <212> PRT
 <213> Schizochytrium sp.

<400> 14

Leu Gly Ile Asp Ser
 1 5

<210> 15
 <211> 21
 <212> PRT
 <213> Schizochytrium sp.

<400> 15

Ala Pro Ala Pro Val Lys Ala Ala Ala Pro Ala Ala Pro Val Ala Ser
 1 5 10 15

Ala Pro Ala Pro Ala
 20

<210> 16
 <211> 3006
 <212> DNA
 <213> Schizochytrium sp.

<400> 16
 gccccgccc cgggtcaaggc tgctgcgccct gccgcccccg ttgcctcggc ccctgccccg 60
 gctgtctcga acgagcttct tgagaaggcc gagactgtcg tcatggaggt cctcgccgcc 120
 aagaccggct acgagaccga catgatcgag gctgacatgg agctcgagac cgagctcggc 180
 attgactcca tcaagcgtgt cgagatcctc tccgaggtcc aggccatgct caatgtcgag 240
 gccaaggatg tcgatgccct cagccgcact cgcactgttg gtgaggttgt caacgccatg 300
 aaggccgaga tcgctggcag ctctgccccg gcgcctgctg ccgctgctcc ggctccggcc 360
 aaggctgccc ctgccgccgc tgcgcctgct gtctcgaacg agcttctcga gaaggccgag 420
 accgtcgtca tggaggtcct cgccgccaag actggctacg agactgacat gatcgagtcc 480
 gacatggagc tcgagactga gctcggcatt gactccatca agcgtgtcga gatcctctcc 540
 gaggttcagg ccatgtctaa cgtcgaggcc aaggacgtcg acgctctcag ccgcactcgc 600
 actgtgggtg aggtcgtcaa cgccatgaag gctgagatcg ctggtggctc tgccccggcg 660

2997-49-2-pct_ST25

cctgccgccg	ctgccccagg	tccggctgct	gccgcccctg	cgctgccgc	cgccgcccct	720
gctgtctcga	acgagcttct	tgagaaggcc	gagaccgtcg	tcatggaggt	cctcgccgcc	780
aagactggct	acgagactga	catgatcgag	tccgacatgg	agctcgagac	cgagctcggc	840
attgactcca	tcaagcgtgt	cgagattctc	tccgaggtcc	aggccatgct	caacgtcgag	900
gccaaggacg	tcgacgtctt	cagccgcacc	cgcactgttg	gcgaggtcgt	cgatgccatg	960
aaggccgaga	tcgtgtgttg	ctctgccccg	gcgcctgccg	ccgtgtctcc	tgctccggct	1020
gctgccgccc	ctgcgcctgc	cgccttgcg	cctgctgtct	cgagcgagct	tctcgagaag	1080
gccgagactg	tcgtcatgga	ggctctcgcc	gccaagactg	gctacgagac	tgacatgata	1140
gagtcgcaca	tggagctcga	gaccgagctc	ggcattgact	ccatcaagcg	tgctcgagatt	1200
ctctccgagg	tccaggccat	gctcaacgtc	gaggccaagg	acgtcgacgc	tctcagccgc	1260
acccgcactg	ttggcgaggt	cgctgatgcc	atgaaggccg	agatcgctgg	tggtcttgcc	1320
ccggcgcttg	ccgccgtgc	tcctgtctcg	gctgtgccg	cccctgcgcc	tgccgcccct	1380
gcgcctgccg	cccctgcgcc	tgctgtctcg	agcgagcttc	tcgagaaggc	cgagactgtc	1440
gtcatggagg	tcctcgccgc	caagactggc	tacgagactg	acatgattga	gtccgacatg	1500
gagctcgaga	ccgagctcgg	cattgactcc	atcaagcgtg	tcgagattct	ctccgaggtt	1560
caggccatgc	tcaacgtcga	ggccaaggac	gtcgacgtc	tcagccgcac	tcgactgtt	1620
ggtgaggtcg	tcgatgccat	gaaggctgag	atcgctggca	gctccgcctc	ggcgcttgcc	1680
gccgtgtctc	ctgtctccgg	tgctgccgct	cctgcgcccg	ctgccgccgc	ccctgtgtgc	1740
tcgaacgagc	ttctcgagaa	agccgagact	gtcgtcatgg	aggctctcgc	cgccaagact	1800
ggctacgaga	ctgacatgat	cgagtccgac	atggagctcg	agactgagct	cggcattgac	1860
tccatcaagc	gtgtcgagat	cctctccgag	gttcaggcca	tgctcaacgt	cgaggccaag	1920
gacgtcgatg	ccctcagccg	cacccgact	gttggcgagg	ttgtcgatgc	catgaaggcc	1980
gagatcgctg	gtggctctgc	cccggcgct	gccgcccgtg	cccctgtctc	ggctgccgcc	2040
gcccctgctg	tctcgaacga	gcttctcgag	aaggccgaga	ctgtcgatcat	ggaggtcctc	2100
gccgccaaga	ctggctacga	gaccgacatg	atcgagtccg	acatggagct	cgagaccgag	2160
ctcggcattg	actccatcaa	gcgtgtcgag	attctctccg	aggttcaggc	catgtctaac	2220
gtcgaggcca	aggacgtcga	tgctctcagc	cgcactcgca	ctgttggcga	ggctgtcgat	2280
gcatgaagg	ctgagatcgc	cggcagctcc	gccccggcgc	ctgccgccgc	tgctcctgct	2340
ccggctgtctg	ccgtctctgc	gcccgtgcc	gctgcccctg	ctgtctcgag	cgagcttctc	2400
gagaaggccg	agaccgtcgt	catggaggtc	ctcgccgcca	agactggcta	cgagactgac	2460
atgattgagt	ccgacatgga	gctcgagact	gagctcgga	ttgactccat	caagcgtgtc	2520
gagatcctct	ccgaggttca	ggccatgtc	aacgtcgagg	ccaaggacgt	cgatgccctc	2580
agccgcaccc	gactgtttgg	cgaggttgtc	gatgccatga	aggccgagat	cgctggtggc	2640
tctgccccgg	gcctgccgc	cgctgcccct	gctccggctg	ccgccgcccc	tgctgtctcg	2700

2997-49-2-pct_ST25

aacgagcttc ttgagaaggc cgagaccgtc gtcattggagg tcctcgccgc caagactggc 2760
 tacgagaccg acatgatcga gtccgacatg gagctcgaga ccgagctcgg cattgactcc 2820
 atcaagcgtg tcgagattct ctccgaggtt caggccatgc tcaacgtcga ggccaaggac 2880
 gtcgacgctc tcagccgcac tcgcactgtt ggcgaggctc tcgatgccat gaaggctgag 2940
 atcgctggtg gctctgcccc ggcgccctgcc gccgctgctc ctgcctcggc tggcgccgcg 3000
 cctgcg 3006

<210> 17
 <211> 2133
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(2133)

<400> 17
 ttt ggc gct ctc ggc ggc ttc atc tcg cag cag gcg gag cgc ttc gag 48
 Phe Gly Ala Leu Gly Gly Phe Ile Ser Gln Gln Ala Glu Arg Phe Glu
 1 5 10 15
 ccc gcc gaa atc ctc ggc ttc acg ctc atg tgc gcc aag ttc gcc aag 96
 Pro Ala Glu Ile Leu Gly Phe Thr Leu Met Cys Ala Lys Phe Ala Lys
 20 25 30
 gct tcc ctc tgc acg gct gtg gct ggc ggc cgc ccg gcc ttt atc ggt 144
 Ala Ser Leu Cys Thr Ala Val Ala Gly Gly Arg Pro Ala Phe Ile Gly
 35 40 45
 gtg gcg cgc ctt gac ggc cgc ctc gga ttc act tcg cag ggc act tct 192
 Val Ala Arg Leu Asp Gly Arg Leu Gly Phe Thr Ser Gln Gly Thr Ser
 50 55 60
 gac gcg ctc aag cgt gcc cag cgt ggt gcc atc ttt ggc ctc tgc aag 240
 Asp Ala Leu Lys Arg Ala Gln Arg Gly Ala Ile Phe Gly Leu Cys Lys
 65 70 75 80
 acc atc ggc ctc gag tgg tcc gag tct gac gtc ttt tcc cgc ggc gtg 288
 Thr Ile Gly Leu Glu Trp Ser Glu Ser Asp Val Phe Ser Arg Gly Val
 85 90 95
 gac att gct cag ggc atg cac ccc gag gat gcc gcc gtg gcg att gtg 336
 Asp Ile Ala Gln Gly Met His Pro Glu Asp Ala Ala Val Ala Ile Val
 100 105 110
 cgc gag atg gcg tgc gct gac att cgc att cgc gag gtc ggc att ggc 384
 Arg Glu Met Ala Cys Ala Asp Ile Arg Ile Arg Glu Val Gly Ile Gly
 115 120 125
 gca aac cag cag cgc tgc acg atc cgt gcc gcc aag ctc gag acc ggc 432
 Ala Asn Gln Gln Arg Cys Thr Ile Arg Ala Ala Lys Leu Glu Thr Gly
 130 135 140
 aac ccg cag cgc cag atc gcc aag gac gac gtg ctg ctc gtt tct ggc 480
 Asn Pro Gln Arg Gln Ile Ala Lys Asp Asp Val Leu Leu Val Ser Gly
 145 150 155 160
 ggc gct cgc ggc atc acg cct ctt tgc atc cgg gag atc acg cgc cag 528
 Gly Ala Arg Gly Ile Thr Pro Leu Cys Ile Arg Glu Ile Thr Arg Gln
 165 170 175

2997-49-2-pct_ST25

atc Ile	gcg Ala	ggc Gly	ggc Gly 180	aag Lys	tac Tyr	att Ile	ctg Leu	ctt Leu 185	ggc Gly	cgc Arg	agc Ser	aag Lys	gtc Val 190	tct Ser	gcg Ala	576
agc Ser	gaa Glu	ccg Pro 195	gca Ala	tgg Trp	tgc Cys	gct Ala	ggc Gly 200	atc Ile	act Thr	gac Asp	gag Glu	aag Lys 205	gct Ala	gtg Val	caa Gln	624
aag Lys	gct Ala 210	gct Ala	acc Thr	cag Gln	gag Glu	ctc Leu 215	aag Lys	cgc Arg	gcc Ala	ttt Phe	agc Ser 220	gct Ala	ggc Gly	gag Glu	ggc Gly	672
ccc Pro 225	aag Lys	ccc Pro	acg Thr	ccc Pro	cgc Arg 230	gct Ala	gtc Val	act Thr	aag Lys	ctt Leu 235	gtg Val	ggc Gly	tct Ser	gtt Val	ctt Leu 240	720
ggc Gly	gct Ala	cgc Arg	gag Glu	gtg Val 245	cgc Arg	agc Ser	tct Ser	att Ile	gct Ala 250	gcg Ala	att Ile	gaa Glu	gcg Ala	ctc Leu 255	ggc Gly	768
ggc Gly	aag Lys	gcc Ala	atc Ile 260	tac Tyr	tcg Ser	tcg Ser	tgc Cys	gac Asp 265	gtg Val	aac Asn	tct Ser	gcc Ala	gcc Ala 270	gac Asp	gtg Val	816
gcc Ala	aag Lys	gcc Ala 275	gtg Val	cgc Arg	gat Asp	gcc Ala	gag Glu 280	tcc Ser	cag Gln	ctc Leu	ggc Gly	gcc Ala 285	cgc Arg	gtc Val	tcg Ser	864
ggc Gly	atc Ile 290	gtt Val	cat His	gcc Ala	tcg Ser	ggc Gly 295	gtg Val	ctc Leu	cgc Arg	gac Asp	cgt Arg 300	ctc Leu	atc Ile	gag Glu	aag Lys	912
aag Lys 305	ctc Leu	ccc Pro	gac Asp	gag Glu	ttc Phe 310	gac Asp	gcc Ala	gtc Val	ttt Phe	ggc Gly 315	acc Thr	aag Lys	gtc Val	acc Thr	ggc Gly 320	960
ctc Leu	gag Glu	aac Asn	ctc Leu	ctc Leu 325	gcc Ala	gcc Ala	gtc Val	gac Asp	cgc Arg 330	gcc Ala	aac Asn	ctc Leu	aag Lys	cac His 335	atg Met	1008
gtc Val	ctc Leu	ttc Phe	agc Ser 340	tcg Ser	ctc Leu	gcc Ala	ggc Gly	ttc Phe 345	cac His	ggc Gly	aac Asn	gtc Val	ggc Gly 350	cag Gln	tct Ser	1056
gac Asp	tac Tyr	gcc Ala 355	atg Met	gcc Ala	aac Asn	gag Glu	gcc Ala 360	ctt Leu	aac Asn	aag Lys	atg Met	ggc Gly 365	ctc Leu	gag Glu	ctc Leu	1104
gcc Ala	aag Lys 370	gac Asp	gtc Val	tcg Ser	gtc Val	aag Lys 375	tcg Ser	atc Ile	tgc Cys	ttc Phe	ggc Gly 380	ccc Pro	tgg Trp	gac Asp	ggc Gly	1152
ggc Gly 385	atg Met	gtg Val	acg Thr	ccg Pro	cag Gln 390	ctc Leu	aag Lys	aag Lys	cag Gln	ttc Phe 395	cag Gln	gag Glu	atg Met	ggc Gly	gtg Val 400	1200
cag Gln	atc Ile	atc Ile	ccc Pro	cgc Arg 405	gag Glu	ggc Gly	ggc Gly	gct Ala	gat Asp 410	acc Thr	gtg Val	gcg Ala	cgc Arg	atc Ile 415	gtg Val	1248
ctc Leu	ggc Gly	tcc Ser	tcg Ser 420	ccg Pro	gct Ala	gag Glu	atc Ile	ctt Leu 425	gtc Val	ggc Gly	aac Asn	tgg Trp	cgc Arg 430	acc Thr	ccg Pro	1296
tcc Ser	aag Lys	aag Lys 435	gtc Val	ggc Gly	tcg Ser	gac Asp	acc Thr 440	atc Ile	acc Thr	ctg Leu	cac His	cgc Arg 445	aag Lys	att Ile	tcc Ser	1344

2997-49-2-pct_ST25																
gcc Ala 450	aag Lys 450	tcc Ser	aac Asn	ccc Pro	ttc Phe 455	ctc Leu 455	gag Glu	gac Asp	cac His	gtc Val	atc Ile 460	cag Gln	ggc Gly	cgc Arg	cgc Arg	1392
gtg Val 465	ctg Leu	ccc Pro	atg Met	acg Thr	ctg Leu 470	gcc Ala	att Ile	ggc Gly	tcg Ser	ctc Leu 475	gcg Ala	gag Glu	acc Thr	tgc Cys	ctc Leu 480	1440
ggc Gly	ctc Leu	ttc Phe	ccc Pro	ggc Gly 485	tac Tyr	tcg Ser	ctc Leu	tgg Trp	gcc Ala 490	att Ile	gac Asp	gac Asp	gcc Ala	cag Gln 495	ctc Leu	1488
ttc Phe	aag Lys	ggc Gly	gtc Val 500	act Thr	gtc Val	gac Asp	ggc Gly	gac Asp 505	gtc Val	aac Asn	tgc Cys	gag Glu	gtg Val 510	acc Thr	ctc Leu	1536
acc Thr	ccg Pro	tcg Ser 515	acg Thr	gcg Ala	ccc Pro	tcg Ser	ggc Gly 520	cgc Arg	gtc Val	aac Asn	gtc Val	cag Gln 525	gcc Ala	acg Thr	ctc Leu	1584
aag Lys 530	acc Thr	ttt Phe	tcc Ser	agc Ser	ggc Gly	aag Lys 535	ctg Leu	gtc Val	ccg Pro	gcc Ala	tac Tyr 540	cgc Arg	gcc Ala	gtc Val	atc Ile	1632
gtg Val 545	ctc Leu	tcc Ser	aac Asn	cag Gln	ggc Gly 550	gcg Ala	ccc Pro	ccg Pro	gcc Ala	aac Asn 555	gcc Ala	acc Thr	atg Met	cag Gln	ccg Pro 560	1680
ccc Pro	tcg Ser	ctc Leu	gat Asp	gcc Ala 565	gat Asp	ccg Pro	gcg Ala	ctc Leu	cag Gln 570	ggc Gly	tcc Ser	gtc Val	tac Tyr	gac Asp 575	ggc Gly	1728
aag Lys	acc Thr	ctc Leu	ttc Phe 580	cac His	ggc Gly	ccg Pro	gcc Ala	ttc Phe 585	cgc Arg	ggc Gly	atc Ile	gat Asp	gac Asp 590	gtg Val	ctc Leu	1776
tcg Ser	tgc Cys	acc Thr 595	aag Lys	agc Ser	cag Gln	ctt Leu	gtg Val 600	gcc Ala	aag Lys	tgc Cys	agc Ser	gct Ala 605	gtc Val	ccc Pro	ggc Gly	1824
tcc Ser 610	gac Asp	gcc Ala	gct Ala	cgc Arg	ggc Gly	gag Glu 615	ttt Phe	gcc Ala	acg Thr	gac Asp	act Thr 620	gac Asp	gcc Ala	cat His	gac Asp	1872
ccc Pro 625	ttc Phe	gtg Val	aac Asn	gac Asp	ctg Leu 630	gcc Ala	ttt Phe	cag Gln	gcc Ala	atg Met 635	ctc Leu	gtc Val	tgg Trp	gtg Val	cgc Arg 640	1920
cgc Arg	acg Thr	ctc Leu	ggc Gly	cag Gln 645	gct Ala	gcg Ala	ctc Leu	ccc Pro	aac Asn 650	tcg Ser	atc Ile	cag Gln	cgc Arg	atc Ile 655	gtc Val	1968
cag Gln	cac His	cgc Arg	ccg Pro 660	gtc Val	ccg Pro	cag Gln	gac Asp	aag Lys 665	ccc Pro	ttc Phe	tac Tyr	att Ile	acc Thr 670	ctc Leu	cgc Arg	2016
tcc Ser	aac Asn	cag Gln 675	tcg Ser	ggc Gly	ggc Gly	cac His	tcc Ser 680	cag Gln	cac His	aag Lys	cac His	gcc Ala 685	ctt Leu	cag Gln	ttc Phe	2064
cac His 690	aac Asn	gag Glu	cag Gln	ggc Gly	gat Asp	ctc Leu 695	ttc Phe	att Ile	gat Asp	gtc Val	cag Gln 700	gct Ala	tcg Ser	gtc Val	atc Ile	2112
gcc Ala 705	acg Thr	gac Asp	agc Ser	ctt Leu	gcc Ala 710	ttc Phe										2133

<210> 18
 <211> 711
 <212> PRT
 <213> Schizochytrium sp.

<400> 18

Phe Gly Ala Leu Gly Gly Phe Ile Ser Gln Gln Ala Glu Arg Phe Glu
 1 5 10 15

Pro Ala Glu Ile Leu Gly Phe Thr Leu Met Cys Ala Lys Phe Ala Lys
 20 25 30

Ala Ser Leu Cys Thr Ala Val Ala Gly Gly Arg Pro Ala Phe Ile Gly
 35 40 45

Val Ala Arg Leu Asp Gly Arg Leu Gly Phe Thr Ser Gln Gly Thr Ser
 50 55 60

Asp Ala Leu Lys Arg Ala Gln Arg Gly Ala Ile Phe Gly Leu Cys Lys
 65 70 75 80

Thr Ile Gly Leu Glu Trp Ser Glu Ser Asp Val Phe Ser Arg Gly Val
 85 90 95

Asp Ile Ala Gln Gly Met His Pro Glu Asp Ala Ala Val Ala Ile Val
 100 105 110

Arg Glu Met Ala Cys Ala Asp Ile Arg Ile Arg Glu Val Gly Ile Gly
 115 120 125

Ala Asn Gln Gln Arg Cys Thr Ile Arg Ala Ala Lys Leu Glu Thr Gly
 130 135 140

Asn Pro Gln Arg Gln Ile Ala Lys Asp Asp Val Leu Leu Val Ser Gly
 145 150 155 160

Gly Ala Arg Gly Ile Thr Pro Leu Cys Ile Arg Glu Ile Thr Arg Gln
 165 170 175

Ile Ala Gly Gly Lys Tyr Ile Leu Leu Gly Arg Ser Lys Val Ser Ala
 180 185 190

Ser Glu Pro Ala Trp Cys Ala Gly Ile Thr Asp Glu Lys Ala Val Gln
 195 200 205

Lys Ala Ala Thr Gln Glu Leu Lys Arg Ala Phe Ser Ala Gly Glu Gly
 210 215 220

Pro Lys Pro Thr Pro Arg Ala Val Thr Lys Leu Val Gly Ser Val Leu
 225 230 235 240

2997-49-2-pct_ST25

Gly Ala Arg Glu Val Arg Ser Ser Ile Ala Ala Ile Glu Ala Leu Gly
245 250 255

Gly Lys Ala Ile Tyr Ser Ser Cys Asp Val Asn Ser Ala Ala Asp Val
260 265 270

Ala Lys Ala Val Arg Asp Ala Glu Ser Gln Leu Gly Ala Arg Val Ser
275 280 285

Gly Ile Val His Ala Ser Gly Val Leu Arg Asp Arg Leu Ile Glu Lys
290 295 300

Lys Leu Pro Asp Glu Phe Asp Ala Val Phe Gly Thr Lys Val Thr Gly
305 310 315 320

Leu Glu Asn Leu Leu Ala Ala Val Asp Arg Ala Asn Leu Lys His Met
325 330 335

Val Leu Phe Ser Ser Leu Ala Gly Phe His Gly Asn Val Gly Gln Ser
340 345 350

Asp Tyr Ala Met Ala Asn Glu Ala Leu Asn Lys Met Gly Leu Glu Leu
355 360 365

Ala Lys Asp Val Ser Val Lys Ser Ile Cys Phe Gly Pro Trp Asp Gly
370 375 380

Gly Met Val Thr Pro Gln Leu Lys Lys Gln Phe Gln Glu Met Gly Val
385 390 395 400

Gln Ile Ile Pro Arg Glu Gly Gly Ala Asp Thr Val Ala Arg Ile Val
405 410 415

Leu Gly Ser Ser Pro Ala Glu Ile Leu Val Gly Asn Trp Arg Thr Pro
420 425 430

Ser Lys Lys Val Gly Ser Asp Thr Ile Thr Leu His Arg Lys Ile Ser
435 440 445

Ala Lys Ser Asn Pro Phe Leu Glu Asp His Val Ile Gln Gly Arg Arg
450 455 460

Val Leu Pro Met Thr Leu Ala Ile Gly Ser Leu Ala Glu Thr Cys Leu
465 470 475 480

Gly Leu Phe Pro Gly Tyr Ser Leu Trp Ala Ile Asp Asp Ala Gln Leu
485 490 495

Phe Lys Gly Val Thr Val Asp Gly Asp Val Asn Cys Glu Val Thr Leu
500 505 510

2997-49-2-pct_ST25

Thr Pro Ser Thr Ala Pro Ser Gly Arg Val Asn Val Gln Ala Thr Leu
515 520 525

Lys Thr Phe Ser Ser Gly Lys Leu Val Pro Ala Tyr Arg Ala Val Ile
530 535 540

Val Leu Ser Asn Gln Gly Ala Pro Pro Ala Asn Ala Thr Met Gln Pro
545 550 555 560

Pro Ser Leu Asp Ala Asp Pro Ala Leu Gln Gly Ser Val Tyr Asp Gly
565 570 575

Lys Thr Leu Phe His Gly Pro Ala Phe Arg Gly Ile Asp Asp Val Leu
580 585 590

Ser Cys Thr Lys Ser Gln Leu Val Ala Lys Cys Ser Ala Val Pro Gly
595 600 605

Ser Asp Ala Ala Arg Gly Glu Phe Ala Thr Asp Thr Asp Ala His Asp
610 615 620

Pro Phe Val Asn Asp Leu Ala Phe Gln Ala Met Leu Val Trp Val Arg
625 630 635 640

Arg Thr Leu Gly Gln Ala Ala Leu Pro Asn Ser Ile Gln Arg Ile Val
645 650 655

Gln His Arg Pro Val Pro Gln Asp Lys Pro Phe Tyr Ile Thr Leu Arg
660 665 670

Ser Asn Gln Ser Gly Gly His Ser Gln His Lys His Ala Leu Gln Phe
675 680 685

His Asn Glu Gln Gly Asp Leu Phe Ile Asp Val Gln Ala Ser Val Ile
690 695 700

Ala Thr Asp Ser Leu Ala Phe
705 710

<210> 19
<211> 1350
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(1350)

<400> 19
atg gcc gct cgg aat gtg agc gcc gcg cat gag atg cac gat gaa aag 48
Met Ala Ala Arg Asn Val Ser Ala Ala His Glu Met His Asp Glu Lys
1 5 10 15

cgc atc gcc gtc gtc ggc atg gcc gtc cag tac gcc gga tgc aaa acc 96
Page 67

2997-49-2-pct_ST25																
Arg	Ile	Ala	Val 20	Val	Gly	Met	Ala 25	Val	Gln	Tyr	Ala	Gly	Cys 30	Lys	Thr	
aag Lys	gac Asp	gag Glu 35	ttc Phe	tgg Trp	gag Glu	gtg Val	ctc Leu 40	atg Met	aac Asn	ggc Gly	aag Lys	gtc Val 45	gag Glu	tcc Ser	aag Lys	144
gtg Val	atc Ile 50	agc Ser	gac Asp	aaa Lys	cga Arg	ctc Leu 55	ggc Gly	tcc Ser	aac Asn	tac Tyr	cgc Arg 60	gcc Ala	gag Glu	cac His	tac Tyr	192
aaa Lys 65	gca Ala	gag Glu	cgc Arg	agc Ser	aag Lys 70	tat Tyr	gcc Ala	gac Asp	acc Thr	ttt Phe 75	tgc Cys	aac Asn	gaa Glu	acg Thr	tac Tyr 80	240
ggc Gly	acc Thr	ctt Leu	gac Asp	gag Glu 85	aac Asn	gag Glu	atc Ile	gac Asp	aac Asn 90	gag Glu	cac His	gaa Glu	ctc Leu	ctc Leu 95	ctc Leu	288
aac Asn	ctc Leu	gcc Ala	aag Lys 100	cag Gln	gca Ala	ctc Leu	gca Ala	gag Glu 105	aca Thr	tcc Ser	gtc Val	aaa Lys	gac Asp 110	tcg Ser	aca Thr	336
cgc Arg	tgc Cys	ggc Gly 115	atc Ile	gtc Val	agc Ser	ggc Gly	tgc Cys 120	ctc Leu	tcg Ser	ttc Phe	ccc Pro	atg Met 125	gac Asp	aac Asn	ctc Leu	384
cag Gln	ggt Gly 130	gaa Glu	ctc Leu	ctc Leu	aac Asn	gtg Val 135	tac Tyr	caa Gln	aac Asn	cat His	gtc Val 140	gag Glu	aaa Lys	aag Lys	ctc Leu	432
ggg Gly 145	gcc Ala	cgc Arg	gtc Val	ttc Phe	aag Lys 150	gac Asp	gcc Ala	tcc Ser	cat His	tgg Trp 155	tcc Ser	gaa Glu	cgc Arg	gag Glu	cag Gln 160	480
tcc Ser	aac Asn	aaa Lys	ccc Pro	gag Glu 165	gcc Ala	ggt Gly	gac Asp	cgc Arg	cgc Arg 170	atc Ile	ttc Phe	atg Met	gac Asp	ccg Pro 175	gcc Ala	528
tcc Ser	ttc Phe	gtc Val	gcc Ala 180	gaa Glu	gaa Glu	ctc Leu	aac Asn	ctc Leu 185	ggc Gly	gcc Ala	ctt Leu	cac His	tac Tyr 190	tcc Ser	gtc Val	576
gac Asp	gca Ala	gca Ala 195	tgc Cys	gcc Ala	acg Thr	gcg Ala	ctc Leu 200	tac Tyr	gtg Val	ctc Leu	cgc Arg	ctc Leu 205	gcg Ala	cag Gln	gat Asp	624
cat His	ctc Leu 210	gtc Val	tcc Ser	ggc Gly	gcc Ala	gcc Ala 215	gac Asp	gtc Val	atg Met	ctc Leu	tgc Cys 220	ggt Gly	gcc Ala	acc Thr	tgc Cys	672
ctg Leu 225	ccg Pro	gag Glu	ccc Pro	ttt Phe	ttc Phe 230	atc Ile	ctt Leu	tcg Ser	ggc Gly	ttt Phe 235	tcc Ser	acc Thr	ttc Phe	cag Gln	gcc Ala 240	720
atg Met	ccc Pro	gtc Val	ggc Gly	acg Thr 245	ggc Gly	cag Gln	aac Asn	gtg Val	tcc Ser 250	atg Met	ccg Pro	ctg Leu	cac His	aag Lys 255	gac Asp	768
agc Ser	cag Gln	ggc Gly	ctc Leu 260	acc Thr	ccg Pro	ggt Gly	gag Glu	ggc Gly 265	ggc Gly	tcc Ser	atc Ile	atg Met	gtc Val 270	ctc Leu	aag Lys	816
cgt Arg	ctc Leu	gat Asp 275	gat Asp	gcc Ala	atc Ile	cgc Arg	gac Asp 280	ggc Gly	gac Asp	cac His	atc Ile	tac Tyr 285	ggc Gly	acc Thr	ctt Leu	864
ctc	ggc	gcc	aat	gtc	agc	aac	tcc	ggc	aca	ggt	ctg	ccc	ctc	aag	ccc	912

65

70

75

80

Gly Thr Leu Asp Glu₈₅ Asn Glu Ile Asp Asn₉₀ Glu His Glu Leu₉₅ Leu Leu

Asn Leu Ala Lys₁₀₀ Gln Ala Leu Ala Glu₁₀₅ Thr Ser Val Lys Asp₁₁₀ Ser Thr

Arg Cys Gly₁₁₅ Ile Val Ser Gly Cys₁₂₀ Leu Ser Phe Pro Met₁₂₅ Asp Asn Leu

Gln Gly₁₃₀ Glu Leu Leu Asn Val₁₃₅ Tyr Gln Asn His Val₁₄₀ Glu Lys Lys Leu

Gly₁₄₅ Ala Arg Val Phe Lys₁₅₀ Asp Ala Ser His Trp₁₅₅ Ser Glu Arg Glu Gln₁₆₀

Ser Asn Lys Pro Glu₁₆₅ Ala Gly Asp Arg Arg₁₇₀ Ile Phe Met Asp Pro₁₇₅ Ala

Ser Phe Val Ala₁₈₀ Glu Glu Leu Asn Leu₁₈₅ Gly Ala Leu His Tyr₁₉₀ Ser Val

Asp Ala Ala₁₉₅ Cys Ala Thr Ala Leu₂₀₀ Tyr Val Leu Arg Leu₂₀₅ Ala Gln Asp

His Leu₂₁₀ Val Ser Gly Ala Ala₂₁₅ Asp Val Met Leu Cys₂₂₀ Gly Ala Thr Cys

Leu₂₂₅ Pro Glu Pro Phe Phe₂₃₀ Ile Leu Ser Gly Phe₂₃₅ Ser Thr Phe Gln Ala₂₄₀

Met Pro Val Gly₂₄₅ Thr Gly Gln Asn Val Ser₂₅₀ Met Pro Leu His Lys₂₅₅ Asp

Ser Gln Gly₂₆₀ Leu Thr Pro Gly Glu Gly₂₆₅ Gly Ser Ile Met Val₂₇₀ Leu Lys

Arg Leu Asp₂₇₅ Asp Ala Ile Arg Asp₂₈₀ Gly Asp His Ile Tyr₂₈₅ Gly Thr Leu

Leu Gly₂₉₀ Ala Asn Val Ser Asn₂₉₅ Ser Gly Thr Gly Leu₃₀₀ Pro Leu Lys Pro

Leu₃₀₅ Leu Pro Ser Glu Lys₃₁₀ Lys Cys Leu Met Asp₃₁₅ Thr Tyr Thr Arg Ile₃₂₀

Asn Val His Pro His₃₂₅ Lys Ile Gln Tyr Val₃₃₀ Glu Cys His Ala Thr₃₃₅ Gly

Thr Pro Gln Gly Asp Arg Val Glu Ile Asp Ala Val Lys Ala Cys Phe

340

345

350

Glu Gly Lys Val Pro Arg Phe Gly Thr Thr Lys Gly Asn Phe Gly His
 355 360 365
 Thr Leu Val Ala Ala Gly Phe Ala Gly Met Cys Lys Val Leu Leu Ser
 370 375 380
 Met Lys His Gly Ile Ile Pro Pro Thr Pro Gly Ile Asp Asp Glu Thr
 385 390 395 400
 Lys Met Asp Pro Leu Val Val Ser Gly Glu Ala Ile Pro Trp Pro Glu
 405 410 415
 Thr Asn Gly Glu Pro Lys Arg Ala Gly Leu Ser Ala Phe Gly Phe Gly
 420 425 430
 Gly Thr Asn Ala His Ala Val Phe Glu Glu His Asp Pro Ser Asn Ala
 435 440 445
 Ala Cys
 450

<210> 21
 <211> 1323
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1323)

<400> 21
 tcg gcc cgc tgc ggc ggt gaa agc aac atg cgc atc gcc atc act ggt 48
 Ser Ala Arg Cys Gly Gly Glu Ser Asn Met Arg Ile Ala Ile Thr Gly
 1 5 10 15
 atg gac gcc acc ttt ggc gct ctc aag gga ctc gac gcc ttc gag cgc 96
 Met Asp Ala Thr Phe Gly Ala Leu Lys Gly Leu Asp Ala Phe Glu Arg
 20 25 30
 gcc att tac acc ggc gct cac ggt gcc atc cca ctc cca gaa aag cgc 144
 Ala Ile Tyr Thr Gly Ala His Gly Ala Ile Pro Leu Pro Glu Lys Arg
 35 40 45
 tgg cgc ttt ctc ggc aag gac aag gac ttt ctt gac ctc tgc ggc gtc 192
 Trp Arg Phe Leu Gly Lys Asp Lys Asp Phe Leu Asp Leu Cys Gly Val
 50 55 60
 aag gcc acc ccg cac ggc tgc tac att gaa gat gtt gag gtc gac ttc 240
 Lys Ala Thr Pro His Gly Cys Tyr Ile Glu Asp Val Glu Val Asp Phe
 65 70 75 80
 cag cgc ctc cgc acg ccc atg acc cct gaa gac atg ctc ctc cct cag 288
 Gln Arg Leu Arg Thr Pro Met Thr Pro Glu Asp Met Leu Leu Pro Gln
 85 90 95
 cag ctt ctg gcc gtc acc acc att gac cgc gcc atc ctc gac tcg gga 336
 Gln Leu Leu Ala Val Thr Thr Ile Asp Arg Ala Ile Leu Asp Ser Gly

2997-49-2-pct_ST25																
100				105				110								
atg Met	aaa Lys	aag Lys 115	ggt Gly	ggc Gly	aat Asn	gtc Val	gcc Ala 120	gtc Val	ttt Phe	gtc Val	ggc Gly	ctc Leu 125	ggc Gly	acc Thr	gac Asp	384
ctc Leu	gag Glu 130	ctc Leu	tac Tyr	cgt Arg	cac His	cgt Arg 135	gct Ala	cgc Arg	gtc Val	gct Ala	ctc Leu 140	aag Lys	gag Glu	cgc Arg	gtc Val	432
cgc Arg 145	cct Pro	gaa Glu	gcc Ala	tcc Ser	aag Lys 150	aag Lys	ctc Leu	aat Asn	gac Asp	atg Met 155	atg Met	cag Gln	tac Tyr	att Ile	aac Asn 160	480
gac Asp	tgc Cys	ggc Gly	aca Thr	tcc Ser 165	aca Thr	tcg Ser	tac Tyr	acc Thr	tcg Ser 170	tac Tyr	att Ile	ggc Gly	aac Asn	ctc Leu 175	gtc Val	528
gcc Ala	acg Thr	cgc Arg	gtc Val 180	tcg Ser	tcg Ser	cag Gln	tgg Trp	ggc Gly 185	ttc Phe	acg Thr	ggc Gly	ccc Pro	tcc Ser 190	ttt Phe	acg Thr	576
atc Ile	acc Thr	gag Glu 195	ggc Gly	aac Asn	aac Asn	tcc Ser	gtc Val 200	tac Tyr	cgc Arg	tgc Cys	gcc Ala	gag Glu 205	ctc Leu	ggc Gly	aag Lys	624
tac Tyr	ctc Leu 210	ctc Leu	gag Glu	acc Thr	ggc Gly	gag Glu 215	gtc Val	gat Asp	ggc Gly	gtc Val	gtc Val 220	ggt Val	gcg Ala	ggt Gly	gtc Val	672
gat Asp 225	ctc Leu	tgc Cys	ggc Gly	agt Ser	gcc Ala 230	gaa Glu	aac Asn	ctt Leu	tac Tyr	gtc Val 235	aag Lys	tct Ser	cgc Arg	cgc Arg	ttc Phe 240	720
aag Lys	gtg Val	tcc Ser	acc Thr	tcc Ser 245	gat Asp	acc Thr	ccg Pro	cgc Arg	gcc Ala 250	agc Ser	ttt Phe	gac Asp	gcc Ala	gcc Ala 255	gcc Ala	768
gat Asp	ggc Gly	tac Tyr	ttt Phe 260	gtc Val	ggc Gly	gag Glu	ggc Gly	tgc Cys 265	ggt Gly	gcc Ala	ttt Phe	gtg Val	ctc Leu 270	aag Lys	cgt Arg	816
gag Glu	act Thr	agc Ser 275	tgc Cys	acc Thr	aag Lys	gac Asp	gac Asp 280	cgt Arg	atc Ile	tac Tyr	gct Ala	tgc Cys 285	atg Met	gat Asp	gcc Ala	864
atc Ile	gtc Val 290	cct Pro	ggc Gly	aac Asn	gtc Val	cct Pro 295	agc Ser	gcc Ala	tgc Cys	ttg Leu	cgc Arg 300	gag Glu	gcc Ala	ctc Leu	gac Asp	912
cag Gln 305	gcg Ala	cgc Arg	gtc Val	aag Lys	ccg Pro 310	ggc Gly	gat Asp	atc Ile	gag Glu	atg Met 315	ctc Leu	gag Glu	ctc Leu	agc Ser	gcc Ala 320	960
gac Asp	tcc Ser	gcc Ala	cgc Arg	cac His 325	ctc Leu	aag Lys	gac Asp	ccg Pro	tcc Ser 330	gtc Val	ctg Leu	ccc Pro	aag Lys	gag Glu 335	ctc Leu	1008
act Thr	gcc Ala	gag Glu	gag Glu 340	gaa Glu	atc Ile	ggc Gly	ggc Gly	ctt Leu 345	cag Gln	acg Thr	atc Ile	ctt Leu	cgt Arg 350	gac Asp	gat Asp	1056
gac Asp	aag Lys	ctc Leu 355	ccg Pro	cgc Arg	aac Asn	gtc Val	gca Ala 360	acg Thr	ggc Gly	agt Ser	gtc Val	aag Lys 365	gcc Ala	acc Thr	gtc Val	1104
ggt Gly	gac Asp	acc Thr	ggt Gly	tat Tyr	gcc Ala	tct Ser	ggt Gly	gct Ala	gcc Ala	agc Ser	ctc Leu	atc Ile	aag Lys	gct Ala	gcg Ala	1152

2997-49-2-pct_ST25

370		375	380	
ctt tgc atc tac aac cgc tac ctg ccc agc aac ggc gac gac tgg gat	1200			
Leu Cys Ile Tyr Asn Arg Tyr Leu Pro Ser Asn Gly Asp Asp Trp Asp				
385 390 395 400				
gaa ccc gcc cct gag gcg ccc tgg gac agc acc ctc ttt gcg tgc cag	1248			
Glu Pro Ala Pro Glu Ala Pro Trp Asp Ser Thr Leu Phe Ala Cys Gln				
405 410 415				
acc tcg cgc gct tgg ctc aag aac cct ggc gag cgt cgc tat gcg gcc	1296			
Thr Ser Arg Ala Trp Leu Lys Asn Pro Gly Glu Arg Arg Tyr Ala Ala				
420 425 430				
gtc tcg ggc gtc tcc gag acg cgc tcg	1323			
Val Ser Gly Val Ser Glu Thr Arg Ser				
435 440				

<210> 22
 <211> 441
 <212> PRT
 <213> Schizochytrium sp.

<400> 22

Ser Ala Arg Cys Gly Gly Glu Ser Asn Met Arg Ile Ala Ile Thr Gly
1 5 10 15
Met Asp Ala Thr Phe Gly Ala Leu Lys Gly Leu Asp Ala Phe Glu Arg
20 25 30
Ala Ile Tyr Thr Gly Ala His Gly Ala Ile Pro Leu Pro Glu Lys Arg
35 40 45
Trp Arg Phe Leu Gly Lys Asp Lys Asp Phe Leu Asp Leu Cys Gly Val
50 55 60
Lys Ala Thr Pro His Gly Cys Tyr Ile Glu Asp Val Glu Val Asp Phe
65 70 75 80
Gln Arg Leu Arg Thr Pro Met Thr Pro Glu Asp Met Leu Leu Pro Gln
85 90 95
Gln Leu Leu Ala Val Thr Thr Ile Asp Arg Ala Ile Leu Asp Ser Gly
100 105 110
Met Lys Lys Gly Gly Asn Val Ala Val Phe Val Gly Leu Gly Thr Asp
115 120 125
Leu Glu Leu Tyr Arg His Arg Ala Arg Val Ala Leu Lys Glu Arg Val
130 135 140
Arg Pro Glu Ala Ser Lys Lys Leu Asn Asp Met Met Gln Tyr Ile Asn
145 150 155 160
Asp Cys Gly Thr Ser Thr Ser Tyr Thr Ser Tyr Ile Gly Asn Leu Val
165 170 175

2997-49-2-pct_ST25

Ala Thr Arg Val Ser Ser Gln Trp Gly Phe Thr Gly Pro Ser Phe Thr
 180 185 190
 Ile Thr Glu Gly Asn Asn Ser Val Tyr Arg Cys Ala Glu Leu Gly Lys
 195 200 205
 Tyr Leu Leu Glu Thr Gly Glu Val Asp Gly Val Val Val Ala Gly Val
 210 215 220
 Asp Leu Cys Gly Ser Ala Glu Asn Leu Tyr Val Lys Ser Arg Arg Phe
 225 230 235 240
 Lys Val Ser Thr Ser Asp Thr Pro Arg Ala Ser Phe Asp Ala Ala Ala
 245 250 255
 Asp Gly Tyr Phe Val Gly Glu Gly Cys Gly Ala Phe Val Leu Lys Arg
 260 265 270
 Glu Thr Ser Cys Thr Lys Asp Asp Arg Ile Tyr Ala Cys Met Asp Ala
 275 280 285
 Ile Val Pro Gly Asn Val Pro Ser Ala Cys Leu Arg Glu Ala Leu Asp
 290 295 300
 Gln Ala Arg Val Lys Pro Gly Asp Ile Glu Met Leu Glu Leu Ser Ala
 305 310 315 320
 Asp Ser Ala Arg His Leu Lys Asp Pro Ser Val Leu Pro Lys Glu Leu
 325 330 335
 Thr Ala Glu Glu Glu Ile Gly Gly Leu Gln Thr Ile Leu Arg Asp Asp
 340 345 350
 Asp Lys Leu Pro Arg Asn Val Ala Thr Gly Ser Val Lys Ala Thr Val
 355 360 365
 Gly Asp Thr Gly Tyr Ala Ser Gly Ala Ala Ser Leu Ile Lys Ala Ala
 370 375 380
 Leu Cys Ile Tyr Asn Arg Tyr Leu Pro Ser Asn Gly Asp Asp Trp Asp
 385 390 395 400
 Glu Pro Ala Pro Glu Ala Pro Trp Asp Ser Thr Leu Phe Ala Cys Gln
 405 410 415
 Thr Ser Arg Ala Trp Leu Lys Asn Pro Gly Glu Arg Arg Tyr Ala Ala
 420 425 430
 Val Ser Gly Val Ser Glu Thr Arg Ser
 435 440

<210> 23
 <211> 1500
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1500)

<400> 23
 tgc tat tcc gtg ctc ctc tcc gaa gcc gag ggc cac tac gag cgc gag 48
 Cys Tyr Ser Val Leu Leu Ser Glu Ala Glu Gly His Tyr Glu Arg Glu
 1 5 10 15
 aac cgc atc tcg ctc gac gag gag gcg ccc aag ctc att gtg ctt cgc 96
 Asn Arg Ile Ser Leu Asp Glu Glu Ala Pro Lys Leu Ile Val Leu Arg
 20 25 30
 gcc gac tcc cac gag gag atc ctt ggt cgc ctc gac aag atc cgc gag 144
 Ala Asp Ser His Glu Glu Ile Leu Gly Arg Leu Asp Lys Ile Arg Glu
 35 40 45
 cgc ttc ttg cag ccc acg ggc gcc gcc ccg cgc gag tcc gag ctc aag 192
 Arg Phe Leu Gln Pro Thr Gly Ala Ala Pro Arg Glu Ser Glu Leu Lys
 50 55 60
 gcg cag gcc cgc cgc atc ttc ctc gag ctc ctc ggc gag acc ctt gcc 240
 Ala Gln Ala Arg Arg Ile Phe Leu Glu Leu Leu Gly Glu Thr Leu Ala
 65 70 75 80
 cag gat gcc gct tct tca ggc tcg caa aag ccc ctc gct ctc agc ctc 288
 Gln Asp Ala Ala Ser Ser Gly Ser Gln Lys Pro Leu Ala Leu Ser Leu
 85 90 95
 gtc tcc acg ccc tcc aag ctc cag cgc gag gtc gag ctc gcg gcc aag 336
 Val Ser Thr Pro Ser Lys Leu Gln Arg Glu Val Glu Leu Ala Ala Lys
 100 105 110
 ggt atc ccg cgc tgc ctc aag atg cgc cgc gat tgg agc tcc cct gct 384
 Gly Ile Pro Arg Cys Leu Lys Met Arg Arg Asp Trp Ser Pro Ala
 115 120 125
 ggc agc cgc tac gcg cct gag ccg ctc gcc agc gac cgc gtc gcc ttc 432
 Gly Ser Arg Tyr Ala Pro Glu Pro Leu Ala Ser Asp Arg Val Ala Phe
 130 135 140
 atg tac ggc gaa ggt cgc agc cct tac tac ggc atc acc caa gac att 480
 Met Tyr Gly Glu Gly Arg Ser Pro Tyr Tyr Gly Ile Thr Gln Asp Ile
 145 150 155 160
 cac cgc att tgg ccc gaa ctc cac gag gtc atc aac gaa aag acg aac 528
 His Arg Ile Trp Pro Glu Leu His Glu Val Ile Asn Glu Lys Thr Asn
 165 170 175
 cgt ctc tgg gcc gaa ggc gac cgc tgg gtc atg ccg cgc gcc agc ttc 576
 Arg Leu Trp Ala Glu Gly Asp Arg Trp Val Met Pro Arg Ala Ser Phe
 180 185 190
 aag tcg gag ctc gag agc cag cag caa gag ttt gat cgc aac atg att 624
 Lys Ser Glu Leu Glu Ser Gln Gln Gln Glu Phe Asp Arg Asn Met Ile
 195 200 205
 gaa atg ttc cgt ctt gga atc ctc acc tca att gcc ttc acc aat ctg 672
 Glu Met Phe Arg Leu Gly Ile Leu Thr Ser Ile Ala Phe Thr Asn Leu
 210 215 220

2997-49-2-pct_ST25

gcg Ala 225	cg Arg	gac Asp	gtt Val	ctc Leu	aac Asn 230	atc Ile	acg Thr	ccc Pro	aag Lys	gcc Ala 235	gcc Ala	ttt Phe	ggc Gly	ctc Leu	agt Ser 240	720
ctt Leu	ggc Gly	gag Glu	att Ile	tcc Ser 245	atg Met	att Ile	ttt Phe	gcc Ala 250	ttt Phe	tcc Ser	aag Lys	aag Lys	aac Asn	ggg Gly 255	ctc Leu	768
atc Ile	tcc Ser	gac Asp	cag Gln 260	ctc Leu	acc Thr	aag Lys	gat Asp	ctt Leu 265	cg Arg	gag Glu	tcc Ser	gac Asp	gtg Val 270	tgg Trp	aac Asn	816
aag Lys	gct Ala	ctg Leu 275	gcc Ala	gtt Val	gaa Glu	ttt Phe	aat Asn 280	gcg Ala	ctg Leu	cg Arg	gag Glu	gcc Ala 285	tgg Trp	ggc Gly	att Ile	864
cca Pro	cag Gln 290	agt Ser	gtc Val	ccc Pro	aag Lys	gac Asp 295	gag Glu	ttc Phe	tgg Trp	caa Gln	ggc Gly 300	tac Tyr	att Ile	gtg Val	cg Arg	912
ggc Gly 305	acc Thr	aag Lys	cag Gln	gat Asp	atc Ile 310	gag Glu	gcg Ala	gcc Ala	atc Ile	gcc Ala 315	ccg Pro	gac Asp	agc Ser	aag Lys	tac Tyr 320	960
gtg Val	cg Arg	ctc Leu	acc Thr	atc Ile 325	atc Ile	aat Asn	gat Asp	gcc Ala	aac Asn 330	acc Thr	gcc Ala	ctc Leu	att Ile	agc Ser 335	ggc Gly	1008
aag Lys	ccc Pro	gac Asp	gcc Ala 340	tgc Cys	aag Lys	gct Ala	gcg Ala	atc Ile 345	gcg Ala	cgt Arg	ctc Leu	ggg Gly 350	aac Asn	att Ile		1056
cct Pro	gcg Ala	ctt Leu 355	ccc Pro	gtg Val	acc Thr	cag Gln	ggc Gly 360	atg Met	tgc Cys	ggc Gly	cac His	tgc Cys 365	ccc Pro	gag Glu	gtg Val	1104
gga Gly 370	cct Pro	tat Tyr	acc Thr	aag Lys	gat Asp	atc Ile 375	gcc Ala	aag Lys	atc Ile	cat His	gcc Ala 380	aac Asn	ctt Leu	gag Glu	ttc Phe	1152
ccc Pro 385	gtt Val	gtc Val	gac Asp	ggc Gly	ctt Leu 390	gac Asp	ctc Leu	tgg Trp	acc Thr	aca Thr 395	atc Ile	aac Asn	cag Gln	aag Lys	cg Arg 400	1200
ctc Leu	gtg Val	cca Pro	cg Arg	gcc Ala 405	acg Thr	ggc Gly	gcc Ala	aag Lys	gac Asp 410	gaa Glu	tgg Trp	gcc Ala	cct Pro	tct Ser 415	tcc Ser	1248
ttt Phe	ggc Gly	gag Glu	tac Tyr 420	gcc Ala	ggc Gly	cag Gln	ctc Leu	tac Tyr 425	gag Glu	aag Lys	cag Gln	gct Ala	aac Asn 430	ttc Phe	ccc Pro	1296
caa Gln	atc Ile	gtc Val 435	gag Glu	acc Thr	att Ile	tac Tyr	aag Lys 440	caa Gln	aac Asn	tac Tyr	gac Asp	gtc Val 445	ttt Phe	gtc Val	gag Glu	1344
gtt Val	ggg Gly 450	ccc Pro	aac Asn	aac Asn	cac His	cgt Arg 455	agc Ser	acc Thr	gca Ala	gtg Val	cg Arg 460	acc Thr	acg Thr	ctt Leu	ggg Gly	1392
ccc Pro 465	cag Gln	cg Arg	aac Asn	cac His	ctt Leu 470	gct Ala	ggc Gly	gcc Ala	atc Ile	gac Asp 475	aag Lys	cag Gln	aac Asn	gag Glu	gat Asp 480	1440
gct Ala	tgg Trp	acg Thr	acc Thr	atc Ile 485	gtc Val	aag Lys	ctt Leu	gtg Val	gct Ala 490	tgc Ser	ctc Leu	aag Lys	gcc Ala	cac His 495	ctt Leu	1488

gtt cct ggc gtc
Val Pro Gly Val
500

<210> 24
<211> 500
<212> PRT
<213> Schizochytrium sp.

<400> 24

Cys Tyr Ser Val Leu Leu Ser Glu Ala Glu Gly His Tyr Glu Arg Glu
1 5 10 15

Asn Arg Ile Ser Leu Asp Glu Glu Ala Pro Lys Leu Ile Val Leu Arg
20 25 30

Ala Asp Ser His Glu Glu Ile Leu Gly Arg Leu Asp Lys Ile Arg Glu
35 40 45

Arg Phe Leu Gln Pro Thr Gly Ala Ala Pro Arg Glu Ser Glu Leu Lys
50 55 60

Ala Gln Ala Arg Arg Ile Phe Leu Glu Leu Leu Gly Glu Thr Leu Ala
65 70 75 80

Gln Asp Ala Ala Ser Ser Gly Ser Gln Lys Pro Leu Ala Leu Ser Leu
85 90 95

Val Ser Thr Pro Ser Lys Leu Gln Arg Glu Val Glu Leu Ala Ala Lys
100 105 110

Gly Ile Pro Arg Cys Leu Lys Met Arg Arg Asp Trp Ser Ser Pro Ala
115 120 125

Gly Ser Arg Tyr Ala Pro Glu Pro Leu Ala Ser Asp Arg Val Ala Phe
130 135 140

Met Tyr Gly Glu Gly Arg Ser Pro Tyr Tyr Gly Ile Thr Gln Asp Ile
145 150 155 160

His Arg Ile Trp Pro Glu Leu His Glu Val Ile Asn Glu Lys Thr Asn
165 170 175

Arg Leu Trp Ala Glu Gly Asp Arg Trp Val Met Pro Arg Ala Ser Phe
180 185 190

Lys Ser Glu Leu Glu Ser Gln Gln Gln Glu Phe Asp Arg Asn Met Ile
195 200 205

Glu Met Phe Arg Leu Gly Ile Leu Thr Ser Ile Ala Phe Thr Asn Leu
210 215 220

2997-49-2-pct_ST25

Ala Arg Asp Val Leu Asn Ile Thr Pro Lys Ala Ala Phe Gly Leu Ser
225 230 235 240

Leu Gly Glu Ile Ser Met Ile Phe Ala Phe Ser Lys Lys Asn Gly Leu
245 250 255

Ile Ser Asp Gln Leu Thr Lys Asp Leu Arg Glu Ser Asp Val Trp Asn
260 265 270

Lys Ala Leu Ala Val Glu Phe Asn Ala Leu Arg Glu Ala Trp Gly Ile
275 280 285

Pro Gln Ser Val Pro Lys Asp Glu Phe Trp Gln Gly Tyr Ile Val Arg
290 295 300

Gly Thr Lys Gln Asp Ile Glu Ala Ala Ile Ala Pro Asp Ser Lys Tyr
305 310 315 320

Val Arg Leu Thr Ile Ile Asn Asp Ala Asn Thr Ala Leu Ile Ser Gly
325 330 335

Lys Pro Asp Ala Cys Lys Ala Ala Ile Ala Arg Leu Gly Gly Asn Ile
340 345 350

Pro Ala Leu Pro Val Thr Gln Gly Met Cys Gly His Cys Pro Glu Val
355 360 365

Gly Pro Tyr Thr Lys Asp Ile Ala Lys Ile His Ala Asn Leu Glu Phe
370 375 380

Pro Val Val Asp Gly Leu Asp Leu Trp Thr Thr Ile Asn Gln Lys Arg
385 390 395 400

Leu Val Pro Arg Ala Thr Gly Ala Lys Asp Glu Trp Ala Pro Ser Ser
405 410 415

Phe Gly Glu Tyr Ala Gly Gln Leu Tyr Glu Lys Gln Ala Asn Phe Pro
420 425 430

Gln Ile Val Glu Thr Ile Tyr Lys Gln Asn Tyr Asp Val Phe Val Glu
435 440 445

Val Gly Pro Asn Asn His Arg Ser Thr Ala Val Arg Thr Thr Leu Gly
450 455 460

Pro Gln Arg Asn His Leu Ala Gly Ala Ile Asp Lys Gln Asn Glu Asp
465 470 475 480

Ala Trp Thr Thr Ile Val Lys Leu Val Ala Ser Leu Lys Ala His Leu
485 490 495

Val Pro Gly Val
500

<210> 25
<211> 1530
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(1530)

<400> 25
ctg ctc gat ctc gac agt atg ctt gcg ctg agc tct gcc agt gcc tcc 48
Leu Leu Asp Leu Asp Ser Met Leu Ala Leu Ser Ser Ala Ser Ala Ser
1 5 10 15

ggc aac ctt gtt gag act gcg cct agc gac gcc tcg gtc att gtg ccg 96
Gly Asn Leu Val Glu Thr Ala Pro Ser Asp Ala Ser Val Ile Val Pro
20 25 30

ccc tgc aac att gcg gat ctc ggc agc cgc gcc ttc atg aaa acg tac 144
Pro Cys Asn Ile Ala Asp Leu Gly Ser Arg Ala Phe Met Lys Thr Tyr
35 40 45

ggc gtt tcg gcg cct ctg tac acg ggc gcc atg gcc aag ggc att gcc 192
Gly Val Ser Ala Pro Leu Tyr Thr Gly Ala Met Ala Lys Gly Ile Ala
50 55 60

tct gcg gac ctc gtc att gcc gcc ggc cgc cag ggc atc ctt gcg tcc 240
Ser Ala Asp Leu Val Ile Ala Ala Gly Arg Gln Gly Ile Leu Ala Ser
65 70 75 80

ttt ggc gcc ggc gga ctt ccc atg cag gtt gtg cgt gag tcc atc gaa 288
Phe Gly Ala Gly Gly Leu Pro Met Gln Val Val Arg Glu Ser Ile Glu
85 90 95

aag att cag gcc gcc ctg ccc aat ggc ccg tac gct gtc aac ctt atc 336
Lys Ile Gln Ala Ala Leu Pro Asn Gly Pro Tyr Ala Val Asn Leu Ile
100 105 110

cat tct ccc ttt gac agc aac ctc gaa aag ggc aat gtc gat ctc ttc 384
His Ser Pro Phe Asp Ser Asn Leu Glu Lys Gly Asn Val Asp Leu Phe
115 120 125

ctc gag aag ggt gtc acc ttt gtc gag gcc tcg gcc ttt atg acg ctc 432
Leu Glu Lys Gly Val Thr Phe Val Glu Ala Ser Ala Phe Met Thr Leu
130 135 140

acc ccg cag gtc gtg cgg tac cgc gcg gct ggc ctc acg cgc aac gcc 480
Thr Pro Gln Val Val Arg Tyr Arg Ala Ala Gly Leu Thr Arg Asn Ala
145 150 155 160

gac ggc tcg gtc aac atc cgc aac cgt atc att ggc aag gtc tcg cgc 528
Asp Gly Ser Val Asn Ile Arg Asn Arg Ile Ile Gly Lys Val Ser Arg
165 170 175

acc gag ctc gcc gag atg ttc atg cgt cct gcg ccc gag cac ctt ctt 576
Thr Glu Leu Ala Glu Met Phe Met Arg Pro Ala Pro Glu His Leu Leu
180 185 190

cag aag ctc att gct tcc ggc gag atc aac cag gag cag gcc gag ctc 624
Gln Lys Leu Ile Ala Ser Gly Glu Ile Asn Gln Glu Gln Ala Glu Leu
195 200 205

2997-49-2-pct_ST25																
gcc Ala	cgc Arg 210	cgt Arg	gtt Val	ccc Pro	gtc Val	gct Ala 215	gac Asp	gac Asp	atc Ile	gcg Ala	gtc Val 220	gaa Glu	gct Ala	gac Asp	tcg Ser	672
ggt Gly 225	ggc Gly	cac His	acc Thr	gac Asp	aac Asn 230	cgc Arg	ccc Pro	atc Ile	cac His	gtc Val 235	att Ile	ctg Leu	ccc Pro	ctc Leu	atc Ile 240	720
atc Ile	aac Asn	ctt Leu	cgc Arg	gac Asp 245	cgc Arg	ctt Leu	cac His	cgc Arg	gag Glu 250	tgc Cys	ggc Gly	tac Tyr	ccg Pro	gcc Ala 255	aac Asn	768
ctt Leu	cgc Arg	gtc Val	cgt Arg 260	gtg Val	ggc Gly	gcc Ala	ggc Gly	ggt Gly 265	ggc Gly	att Ile	ggg Gly	tgc Cys	ccc Pro 270	cag Gln	gcg Ala	816
gcg Ala	ctg Leu	gcc Ala 275	acc Thr	ttc Phe	aac Asn	atg Met	ggt Gly 280	gcc Ala	tcc Ser	ttt Phe	att Ile	gtc Val 285	acc Thr	ggc Gly	acc Thr	864
gtg Val	aac Asn 290	cag Gln	gtc Val	gcc Ala	aag Lys	cag Gln 295	tcg Ser	ggc Gly	acg Thr	tgc Cys	gac Asp 300	aat Asn	gtg Val	cgc Arg	aag Lys	912
cag Gln 305	ctc Leu	gcg Ala	aag Lys	gcc Ala	act Thr 310	tac Tyr	tcg Ser	gac Asp	gta Val	tgc Cys 315	atg Met	gcc Ala	ccg Pro	gct Ala	gcc Ala 320	960
gac Asp	atg Met	ttc Phe	gag Glu	gaa Glu 325	ggc Gly	gtc Val	aag Lys	ctt Leu	cag Gln 330	gtc Val	ctc Leu	aag Lys	aag Lys	gga Gly 335	acc Thr	1008
atg Met	ttt Phe	ccc Pro	tcg Ser 340	cgc Arg	gcc Ala	aac Asn	aag Lys	ctc Leu 345	tac Tyr	gag Glu	ctc Leu	ttt Phe	tgc Cys 350	aag Lys	tac Tyr	1056
gac Asp	tcg Ser	ttc Phe 355	gag Glu	tcc Ser	atg Met	ccc Pro	ccc Pro 360	gca Ala	gag Glu	ctt Leu	gcg Ala	cgc Arg 365	gtc Val	gag Glu	aag Lys	1104
cgc Arg	atc Ile 370	ttc Phe	agc Ser	cgc Arg	gcg Ala	ctc Leu 375	gaa Glu	gag Glu	gtc Val	tgg Trp	gac Asp 380	gag Glu	acc Thr	aaa Lys	aac Asn	1152
ttt Phe 385	tac Tyr	att Ile	aac Asn	cgt Arg	ctt Leu 390	cac His	aac Asn	ccg Pro	gag Glu	aag Lys 395	atc Ile	cag Gln	cgc Arg	gcc Ala	gag Glu 400	1200
cgc Arg	gac Asp	ccc Pro	aag Lys	ctc Leu 405	aag Lys	atg Met	tcg Ser	ctg Leu	tgc Cys 410	ttt Phe	cgc Arg	tgg Trp	tac Tyr	ctg Leu 415	agc Ser	1248
ctg Leu	gcg Ala	agc Ser	cgc Arg 420	tgg Trp	gcc Ala	aac Asn	act Thr	gga Gly 425	gct Ala	tcc Ser	gat Asp	cgc Arg	gtc Val 430	atg Met	gac Asp	1296
tac Tyr	cag Gln 435	gtc Val	tgg Trp	tgc Cys	ggt Gly	cct Pro	gcc Ala 440	att Ile	ggt Gly	tcc Ser	ttc Phe	aac Asn 445	gat Asp	ttc Phe	atc Ile	1344
aag Lys	gga Gly 450	act Thr	tac Tyr	ctt Leu	gat Asp	ccg Pro 455	gcc Ala	gtc Val	gca Ala	aac Asn	gag Glu 460	tac Tyr	ccg Pro	tgc Cys	gtc Val	1392
gtt Val 465	cag Gln	att Ile	aac Asn	aag Lys	cag Gln 470	atc Ile	ctt Leu	cgt Arg	gga Gly	gcg Ala 475	tgc Cys	ttc Phe	ttg Leu	cgc Arg	cgt Arg 480	1440

2997-49-2-pct_ST25

ctc gaa att ctg cgc aac gca cgc ctt tcc gat ggc gct gcc gct ctt 1488
Leu Glu Ile Leu Arg Asn Ala Arg Leu Ser Asp Gly Ala Ala Ala Leu
485 490 495

gtg gcc agc atc gat gac aca tac gtc ccg gcc gag aag ctg 1530
Val Ala Ser Ile Asp Asp Thr Tyr Val Pro Ala Glu Lys Leu
500 505 510

<210> 26
<211> 510
<212> PRT
<213> Schizochytrium sp.

<400> 26

Leu Leu Asp Leu Asp Ser Met Leu Ala Leu Ser Ser Ala Ser Ala Ser
1 5 10 15

Gly Asn Leu Val Glu Thr Ala Pro Ser Asp Ala Ser Val Ile Val Pro
20 25 30

Pro Cys Asn Ile Ala Asp Leu Gly Ser Arg Ala Phe Met Lys Thr Tyr
35 40 45

Gly Val Ser Ala Pro Leu Tyr Thr Gly Ala Met Ala Lys Gly Ile Ala
50 55 60

Ser Ala Asp Leu Val Ile Ala Ala Gly Arg Gln Gly Ile Leu Ala Ser
65 70 75 80

Phe Gly Ala Gly Gly Leu Pro Met Gln Val Val Arg Glu Ser Ile Glu
85 90 95

Lys Ile Gln Ala Ala Leu Pro Asn Gly Pro Tyr Ala Val Asn Leu Ile
100 105 110

His Ser Pro Phe Asp Ser Asn Leu Glu Lys Gly Asn Val Asp Leu Phe
115 120 125

Leu Glu Lys Gly Val Thr Phe Val Glu Ala Ser Ala Phe Met Thr Leu
130 135 140

Thr Pro Gln Val Val Arg Tyr Arg Ala Ala Gly Leu Thr Arg Asn Ala
145 150 155 160

Asp Gly Ser Val Asn Ile Arg Asn Arg Ile Ile Gly Lys Val Ser Arg
165 170 175

Thr Glu Leu Ala Glu Met Phe Met Arg Pro Ala Pro Glu His Leu Leu
180 185 190

Gln Lys Leu Ile Ala Ser Gly Glu Ile Asn Gln Glu Gln Ala Glu Leu
195 200 205

2997-49-2-pct_ST25

Ala Arg Arg Val Pro Val Ala Asp Asp Ile Ala Val Glu Ala Asp Ser
210 215 220

Gly Gly His Thr Asp Asn Arg Pro Ile His Val Ile Leu Pro Leu Ile
225 230 235 240

Ile Asn Leu Arg Asp Arg Leu His Arg Glu Cys Gly Tyr Pro Ala Asn
245 250 255

Leu Arg Val Arg Val Gly Ala Gly Gly Ile Gly Cys Pro Gln Ala
260 265 270

Ala Leu Ala Thr Phe Asn Met Gly Ala Ser Phe Ile Val Thr Gly Thr
275 280 285

Val Asn Gln Val Ala Lys Gln Ser Gly Thr Cys Asp Asn Val Arg Lys
290 295 300

Gln Leu Ala Lys Ala Thr Tyr Ser Asp Val Cys Met Ala Pro Ala Ala
305 310 315 320

Asp Met Phe Glu Glu Gly Val Lys Leu Gln Val Leu Lys Lys Gly Thr
325 330 335

Met Phe Pro Ser Arg Ala Asn Lys Leu Tyr Glu Leu Phe Cys Lys Tyr
340 345 350

Asp Ser Phe Glu Ser Met Pro Pro Ala Glu Leu Ala Arg Val Glu Lys
355 360 365

Arg Ile Phe Ser Arg Ala Leu Glu Glu Val Trp Asp Glu Thr Lys Asn
370 375 380

Phe Tyr Ile Asn Arg Leu His Asn Pro Glu Lys Ile Gln Arg Ala Glu
385 390 395 400

Arg Asp Pro Lys Leu Lys Met Ser Leu Cys Phe Arg Trp Tyr Leu Ser
405 410 415

Leu Ala Ser Arg Trp Ala Asn Thr Gly Ala Ser Asp Arg Val Met Asp
420 425 430

Tyr Gln Val Trp Cys Gly Pro Ala Ile Gly Ser Phe Asn Asp Phe Ile
435 440 445

Lys Gly Thr Tyr Leu Asp Pro Ala Val Ala Asn Glu Tyr Pro Cys Val
450 455 460

Val Gln Ile Asn Lys Gln Ile Leu Arg Gly Ala Cys Phe Leu Arg Arg
465 470 475 480

2997-49-2-pct_ST25

Leu Glu Ile Leu Arg Asn Ala Arg Leu Ser Asp Gly Ala Ala Ala Leu
485 490 495

Val Ala Ser Ile Asp Asp Thr Tyr Val Pro Ala Glu Lys Leu
500 505 510

<210> 27
<211> 1350
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(1350)

<400> 27
atg gcg ctc cgt gtc aag acg aac aag aag cca tgc tgg gag atg acc 48
Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr
1 5 10 15
aag gag gag ctg acc agc ggc aag acc gag gtg ttc aac tat gag gaa 96
Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu
20 25 30
ctc ctc gag ttc gca gag ggc gac atc gcc aag gtc ttc gga ccc gag 144
Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu
35 40 45
ttc gcc gtc atc gac aag tac ccg cgc cgc gtg cgc ctg ccc gcc cgc 192
Phe Ala Val Ile Asp Lys Tyr Pro Arg Arg Val Arg Leu Pro Ala Arg
50 55 60
gag tac ctg ctc gtg acc cgc gtc acc ctc atg gac gcc gag gtc aac 240
Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Asn
65 70 75 80
aac tac cgc gtc ggc gcc cgc atg gtc acc gag tac gat ctc ccc gtc 288
Asn Tyr Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Leu Pro Val
85 90 95
aac gga gag ctc tcc gag ggc gga gac tgc ccc tgg gcc gtc ctg gtc 336
Asn Gly Glu Leu Ser Glu Gly Gly Asp Cys Pro Trp Ala Val Leu Val
100 105 110
gag agt ggc cag tgc gat ctc atg ctc atc tcc tac atg ggc att gac 384
Glu Ser Gly Gln Cys Asp Leu Met Leu Ile Ser Tyr Met Gly Ile Asp
115 120 125
ttc cag aac cag ggc gac cgc gtc tac cgc ctg ctc aac acc acg ctc 432
Phe Gln Asn Gln Gly Asp Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
130 135 140
acc ttt tac ggc gtg gcc cac gag ggc gag acc ctc gag tac gac att 480
Thr Phe Tyr Gly Val Ala His Glu Gly Glu Thr Leu Glu Tyr Asp Ile
145 150 155 160
cgc gtc acc ggc ttc gcc aag cgt ctc gac ggc ggc atc tcc atg ttc 528
Arg Val Thr Gly Phe Ala Lys Arg Leu Asp Gly Gly Ile Ser Met Phe
165 170 175
ttc ttc gag tac gac tgc tac gtc aac ggc cgc ctc ctc atc gag atg 576
Phe Phe Glu Tyr Asp Cys Tyr Val Asn Gly Arg Leu Leu Ile Glu Met
180 185 190
cgc gat ggc tgc gcc ggc ttc ttc acc aac gag gag ctc gac gcc ggc 624

2997-49-2-pct_ST25

Arg	Asp	Gly 195	Cys	Ala	Gly	Phe	Phe 200	Thr	Asn	Glu	Glu	Leu 205	Asp	Ala	Gly		
aag Lys	ggc Gly 210	gtc Val	gtc Val	ttc Phe	acc Thr	cgc Arg 215	ggc Gly	gac Asp	ctc Leu	gcc Ala	gcc Ala 220	cgc Arg	gcc Ala	aag Lys	atc Ile		672
cca Pro 225	aag Lys	cag Gln	gac Asp	gtc Val	tcc Ser 230	ccc Pro	tac Tyr	gcc Ala	gtc Val	gcc Ala 235	ccc Pro	tgc Cys	ctc Leu	cac His	aag Lys 240		720
acc Thr	aag Lys	ctc Leu	aac Asn	gaa Glu 245	aag Lys	gag Glu	atg Met	cag Gln	acc Thr 250	ctc Leu	gtc Val	gac Asp	aag Lys	gac Asp 255	tgg Trp		768
gca Ala	tcc Ser	gtc Val	ttt Phe 260	ggc Gly	tcc Ser	aag Lys	aac Asn	ggc Gly 265	atg Met	ccg Pro	gaa Glu	atc Ile	aac Asn 270	tac Tyr	aaa Lys		816
ctc Leu	tgc Cys	gcg Ala 275	cgt Arg	aag Lys	atg Met	ctc Leu	atg Met 280	att Ile	gac Asp	cgc Arg	gtc Val	acc Thr 285	agc Ser	att Ile	gac Asp		864
cac His	aag Lys 290	ggc Gly	ggt Gly	gtc Val	tac Tyr	ggc Gly 295	ctc Leu	ggt Gly	cag Gln	ctc Leu	gtc Val 300	ggt Gly	gaa Glu	aag Lys	atc Ile		912
ctc Leu 305	gag Glu	cgc Arg	gac Asp	cac His	tgg Trp 310	tac Tyr	ttt Phe	ccc Pro	tgc Cys	cac His 315	ttt Phe	gtc Val	aag Lys	gat Asp	cag Gln 320		960
gtc Val	atg Met	gcc Ala	gga Gly	tcc Ser 325	ctc Leu	gtc Val	tcc Ser	gac Asp	ggc Gly 330	tgc Cys	agc Ser	cag Gln	atg Met	ctc Leu 335	aag Lys		1008
atg Met	tac Tyr	atg Met	atc Ile 340	tgg Trp	ctc Leu	ggc Gly	ctc Leu	cac His 345	ctc Leu	acc Thr	acc Thr	gga Gly 350	ccc Pro	ttt Phe	gac Asp		1056
ttc Phe	cgc Arg	ccg Pro 355	gtc Val	aac Asn	ggc Gly	cac His	ccc Pro 360	aac Asn	aag Lys	gtc Val	cgc Arg	tgc Cys 365	cgc Arg	ggc Gly	caa Gln		1104
atc Ile	tcc Ser 370	ccg Pro	cac His	aag Lys	ggc Gly	aag Lys 375	ctc Leu	gtc Val	tac Tyr	gtc Val	atg Met 380	gag Glu	atc Ile	aag Lys	gag Glu		1152
atg Met 385	ggc Gly	ttc Phe	gac Asp	gag Glu	gac Asp 390	aac Asn	gac Asp	ccg Pro	tac Tyr	gcc Ala 395	att Ile	gcc Ala	gac Asp	gtc Val	aac Asn 400		1200
atc Ile	att Ile	gat Asp	gtc Val	gac Asp 405	ttc Phe	gaa Glu	aag Lys	ggc Gly	cag Gln 410	gac Asp	ttt Phe	agc Ser	ctc Leu	gac Asp 415	cgc Arg		1248
atc Ile	agc Ser	gac Asp	tac Tyr 420	ggc Gly	aag Lys	ggc Gly	gac Asp	ctc Leu 425	aac Asn	aag Lys	aag Lys	atc Ile	gtc Val 430	gtc Val	gac Asp		1296
ttt Phe	aag Lys	ggc Gly 435	atc Ile	gct Ala	ctc Leu	aag Lys	atg Met 440	cag Gln	aag Lys	cgc Arg	tcc Ser	acc Thr 445	aac Asn	aag Lys	aac Asn		1344
ccc Pro	tcc Ser 450																1350

<210> 28
 <211> 450
 <212> PRT
 <213> Schizochytrium sp.

<400> 28

Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr
 1 5 10 15

Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu
 20 25 30

Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu
 35 40 45

Phe Ala Val Ile Asp Lys Tyr Pro Arg Arg Val Arg Leu Pro Ala Arg
 50 55 60

Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Asn
 65 70 75 80

Asn Tyr Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Leu Pro Val
 85 90 95

Asn Gly Glu Leu Ser Glu Gly Gly Asp Cys Pro Trp Ala Val Leu Val
 100 105 110

Glu Ser Gly Gln Cys Asp Leu Met Leu Ile Ser Tyr Met Gly Ile Asp
 115 120 125

Phe Gln Asn Gln Gly Asp Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
 130 135 140

Thr Phe Tyr Gly Val Ala His Glu Gly Glu Thr Leu Glu Tyr Asp Ile
 145 150 155 160

Arg Val Thr Gly Phe Ala Lys Arg Leu Asp Gly Gly Ile Ser Met Phe
 165 170 175

Phe Phe Glu Tyr Asp Cys Tyr Val Asn Gly Arg Leu Leu Ile Glu Met
 180 185 190

Arg Asp Gly Cys Ala Gly Phe Phe Thr Asn Glu Glu Leu Asp Ala Gly
 195 200 205

Lys Gly Val Val Phe Thr Arg Gly Asp Leu Ala Ala Arg Ala Lys Ile
 210 215 220

Pro Lys Gln Asp Val Ser Pro Tyr Ala Val Ala Pro Cys Leu His Lys
 225 230 235 240

Thr Lys Leu Asn Glu Lys Glu Met Gln Thr Leu Val Asp Lys Asp Trp

245 2997-49-2-pct_ST25 250 255

Ala Ser Val Phe Gly Ser Lys Asn Gly Met Pro Glu Ile Asn Tyr Lys
260 265 270

Leu Cys Ala Arg Lys Met Leu Met Ile Asp Arg Val Thr Ser Ile Asp
275 280 285

His Lys Gly Gly Val Tyr Gly Leu Gly Gln Leu Val Gly Glu Lys Ile
290 295 300

Leu Glu Arg Asp His Trp Tyr Phe Pro Cys His Phe Val Lys Asp Gln
305 310 315 320

Val Met Ala Gly Ser Leu Val Ser Asp Gly Cys Ser Gln Met Leu Lys
325 330 335

Met Tyr Met Ile Trp Leu Gly Leu His Leu Thr Thr Gly Pro Phe Asp
340 345 350

Phe Arg Pro Val Asn Gly His Pro Asn Lys Val Arg Cys Arg Gly Gln
355 360 365

Ile Ser Pro His Lys Gly Lys Leu Val Tyr Val Met Glu Ile Lys Glu
370 375 380

Met Gly Phe Asp Glu Asp Asn Asp Pro Tyr Ala Ile Ala Asp Val Asn
385 390 395 400

Ile Ile Asp Val Asp Phe Glu Lys Gly Gln Asp Phe Ser Leu Asp Arg
405 410 415

Ile Ser Asp Tyr Gly Lys Gly Asp Leu Asn Lys Lys Ile Val Val Asp
420 425 430

Phe Lys Gly Ile Ala Leu Lys Met Gln Lys Arg Ser Thr Asn Lys Asn
435 440 445

Pro Ser
450

<210> 29
<211> 1497
<212> DNA
<213> Schizochytrium sp.

<220>
<221> CDS
<222> (1)..(1497)

<400> 29
aag gtt cag ccc gtc ttt gcc aac ggc gcc gcc act gtc ggc ccc gag
Lys Val Gln Pro Val Phe Ala Asn Gly Ala Ala Thr Val Gly Pro Glu

2997-49-2-pct_ST25																	
1	5				10				15								
gcc Ala	tcc Ser	aag Lys	gct Ala 20	tcc Ser	tcc Ser	ggc Gly	gcc Ala	agc Ser 25	gcc Ala	agc Ser	gcc Ala	agc Ser	gcc Ala 30	gcc Ala	ccc Pro		96
gcc Ala	aag Lys	cct Pro 35	gcc Ala	ttc Phe	agc Ser	gcc Ala	gat Asp 40	gtt Val	ctt Leu	gcg Ala	ccc Pro	aag Lys 45	ccc Pro	gtt Val	gcc Ala		144
ctt Leu	ccc Pro 50	gag Glu	cac His	atc Ile	ctc Leu	aag Lys 55	ggc Gly	gac Asp	gcc Ala	ctc Leu	gcc Ala 60	ccc Pro	aag Lys	gag Glu	atg Met		192
tcc Ser 65	tgg Trp	cac His	ccc Pro	atg Met	gcc Ala 70	cgc Arg	atc Ile	ccg Pro	ggc Gly	aac Asn 75	ccg Pro	acg Thr	ccc Pro	tct Ser	ttt Phe 80		240
gcg Ala	ccc Pro	tcg Ser	gcc Ala	tac Tyr 85	aag Lys	ccg Pro	cgc Arg	aac Asn	atc Ile 90	gcc Ala	ttt Phe	acg Thr	ccc Pro	ttc Phe 95	ccc Pro		288
ggc Gly	aac Asn	ccc Pro	aac Asn 100	gat Asp	aac Asn	gac Asp	cac His	acc Thr 105	ccg Pro	ggc Gly	aag Lys	atg Met	ccg Pro 110	ctc Leu	acc Thr		336
tgg Trp	ttc Phe	aac Asn 115	atg Met	gcc Ala	gag Glu	ttc Phe	atg Met 120	gcc Ala	ggc Gly	aag Lys	gtc Val	agc Ser 125	atg Met	tgc Cys	ctc Leu		384
ggc Gly	ccc Pro 130	gag Glu	ttc Phe	gcc Ala	aag Lys	ttc Phe 135	gac Asp	gac Asp	tcg Ser	aac Asn	acc Thr 140	agc Ser	cgc Arg	agc Ser	ccc Pro		432
gct Ala 145	tgg Trp	gac Asp	ctc Leu	gct Ala	ctc Leu 150	gtc Val	acc Thr	cgc Arg	gcc Ala	gtg Val 155	tct Ser	gtg Val	tct Ser	gac Asp	ctc Leu 160		480
aag Lys	cac His	gtc Val	aac Asn	tac Tyr 165	cgc Arg	aac Asn	atc Ile	gac Asp	ctc Leu 170	gac Asp	ccc Pro	tcc Ser	aag Lys	ggt Gly 175	acc Thr		528
atg Met	gtc Val	ggc Gly	gag Glu 180	ttc Phe	gac Asp	tgc Cys	ccc Pro	gcg Ala 185	gac Asp	gcc Ala	tgg Trp	ttc Phe	tac Tyr 190	aag Lys	ggc Gly		576
gcc Ala	tgc Cys	aac Asn 195	gat Asp	gcc Ala	cac His	atg Met	ccg Pro 200	tac Tyr	tcg Ser	atc Ile	ctc Leu	atg Met 205	gag Glu	atc Ile	gcc Ala		624
ctc Leu	cag Gln 210	acc Thr	tcg Ser	ggt Gly	gtg Val	ctc Leu 215	acc Thr	tcg Ser	gtg Val	ctc Leu	aag Lys 220	gcg Ala	ccc Pro	ctg Leu	acc Thr		672
atg Met 225	gag Glu	aag Lys	gac Asp	gac Asp	atc Ile 230	ctc Leu	ttc Phe	cgc Arg	aac Asn	ctc Leu 235	gac Asp	gcc Ala	aac Asn	gcc Ala	gag Glu 240		720
ttc Phe	gtg Val	cgc Arg	gcc Ala	gac Asp 245	ctc Leu	gac Asp	tac Tyr	cgc Arg	ggc Gly 250	aag Lys	act Thr	atc Ile	cgc Arg	aac Asn 255	gtc Val		768
acc Thr	aag Lys	tgc Cys	act Thr 260	ggc Gly	tac Tyr	agc Ser	atg Met	ctc Leu 265	ggc Gly	gag Glu	atg Met	ggc Gly	gtc Val 270	cac His	cgc Arg		816
ttc Phe	acc Thr	ttt Phe	gag Glu	ctc Leu	tac Tyr	gtc Val	gat Asp	gat Asp	gtg Val	ctc Leu	ttt Phe	tac Tyr	aag Lys	ggc Gly	tcg Ser		864

2997-49-2-pct_ST25

275	280	285	
acc ttc ggc tgg ttc gtg ccc gag gtc ttt gcc gcc cag gcc ggc	Thr Ser Phe Gly Trp Phe Val 295	Pro Glu Val Phe Ala 300	912
ctc gac aac ggc cgc aag tcg gag ccc tgg ttc att gag aac aag gtt	Leu Asp Asn Gly Arg Lys 310	Leu Ile Glu Asn Lys Val 320	960
ccg gcc tcg cag gtc tcc tcc ttt gag gtg cgc ccc aac ggc agc ggc	Pro Ala Ser Gln Val 325	Pro Arg Val 330	1008
cgc acc gcc atc ttc gcc aac gcc ccc agc ggc gcc cag ctc aac cgc	Arg Thr Ala Ile Phe Ala Asn Ala 345	Pro Ser Gly Ala Gln Leu 350	1056
cgc acg gac cag ggc cag tac ctc gag gcc gtc gac att gtc tcc ggc	Arg Thr Asp 355	Arg Asp Ala Val Asp 365	1104
agc ggc aag aag agc ctc ggc tac gcc cac ggt tcc aag acg gtc aac	Ser Gly Lys Lys Ser Leu Gly 375	Ser Tyr Ala His Gly 380	1152
ccg aac gac tgg ttc ttc tcg tgc cac ttt tgg ttt gag tcg gtc atg	Pro Asn Asp Trp Phe Phe Ser Cys His Phe Trp 395	Pro Asp Ser Val Met 400	1200
ccc gga agt ctc ggt gtc gag tcc atg ttc cag ctc gtc gag gcc atc	Pro Gly Ser Leu Gly 405	Pro Met Phe Gln Leu Val 415	1248
gcc gcc cac gag gat ctc gct ggc aag cac ggc att gcc aac ccc acc	Ala Ala His Glu Asp Leu Ala Gly 425	Ala Ile Ala Asn Pro Thr 430	1296
ttt gtg cac gcc ccg ggc aag atc agc tgg aag tac cgc ggc cag ctc	Phe Val His 435	Phe Lys Ile Ser Trp Lys Tyr Arg 445	1344
acg ccc aag agc aag aag atg gag tcg gag gtc cac atc gtg tcc gtg	Thr Pro Lys Ser Lys Lys Met 455	Thr Pro Glu Val His 460	1392
gac gcc cac gag ggc gtt gtc gac ctc gtc gcc gac ggc ttc ctc tgg	Asp Ala His Asp Gly Val 470	Asp Ala Asp Gly Phe Leu Trp 480	1440
gcc gac agc ctc cgc gtc tac tcg gtg agc aac att cgc gtg cgc atc	Ala Asp Ser Leu Arg 485	Ala Ser Val Ser 490	1488
gcc tcc ggt	Ala Ser Gly		1497

<210> 30
 <211> 499
 <212> PRT
 <213> Schizochytrium sp.

<400> 30

Lys Val Gln Pro Val Phe Ala Asn Gly Ala Ala Thr Val Gly Pro Glu
 1 5 10 15

2997-49-2-pct_ST25

Ala Ser Lys Ala Ser Ser Gly Ala Ser Ala Ser Ala Ala Pro
20 25 30

Ala Lys Pro Ala Phe Ser Ala Asp Val Leu Ala Pro Lys Pro Val Ala
35 40 45

Leu Pro Glu His Ile Leu Lys Gly Asp Ala Leu Ala Pro Lys Glu Met
50 55 60

Ser Trp His Pro Met Ala Arg Ile Pro Gly Asn Pro Thr Pro Ser Phe
65 70 75 80

Ala Pro Ser Ala Tyr Lys Pro Arg Asn Ile Ala Phe Thr Pro Phe Pro
85 90 95

Gly Asn Pro Asn Asp Asn Asp His Thr Pro Gly Lys Met Pro Leu Thr
100 105 110

Trp Phe Asn Met Ala Glu Phe Met Ala Gly Lys Val Ser Met Cys Leu
115 120 125

Gly Pro Glu Phe Ala Lys Phe Asp Asp Ser Asn Thr Ser Arg Ser Pro
130 135 140

Ala Trp Asp Leu Ala Leu Val Thr Arg Ala Val Ser Val Ser Asp Leu
145 150 155 160

Lys His Val Asn Tyr Arg Asn Ile Asp Leu Asp Pro Ser Lys Gly Thr
165 170 175

Met Val Gly Glu Phe Asp Cys Pro Ala Asp Ala Trp Phe Tyr Lys Gly
180 185 190

Ala Cys Asn Asp Ala His Met Pro Tyr Ser Ile Leu Met Glu Ile Ala
195 200 205

Leu Gln Thr Ser Gly Val Leu Thr Ser Val Leu Lys Ala Pro Leu Thr
210 215 220

Met Glu Lys Asp Asp Ile Leu Phe Arg Asn Leu Asp Ala Asn Ala Glu
225 230 235 240

Phe Val Arg Ala Asp Leu Asp Tyr Arg Gly Lys Thr Ile Arg Asn Val
245 250 255

Thr Lys Cys Thr Gly Tyr Ser Met Leu Gly Glu Met Gly Val His Arg
260 265 270

Phe Thr Phe Glu Leu Tyr Val Asp Asp Val Leu Phe Tyr Lys Gly Ser
275 280 285

2997-49-2-pct_ST25

Thr Ser Phe Gly Trp Phe Val Pro Glu Val Phe Ala Ala Gln Ala Gly
 290 295 300

Leu Asp Asn Gly Arg Lys Ser Glu Pro Trp Phe Ile Glu Asn Lys Val
 305 310 315 320

Pro Ala Ser Gln Val Ser Ser Phe Asp Val Arg Pro Asn Gly Ser Gly
 325 330 335

Arg Thr Ala Ile Phe Ala Asn Ala Pro Ser Gly Ala Gln Leu Asn Arg
 340 345 350

Arg Thr Asp Gln Gly Gln Tyr Leu Asp Ala Val Asp Ile Val Ser Gly
 355 360 365

Ser Gly Lys Lys Ser Leu Gly Tyr Ala His Gly Ser Lys Thr Val Asn
 370 375 380

Pro Asn Asp Trp Phe Phe Ser Cys His Phe Trp Phe Asp Ser Val Met
 385 390 395 400

Pro Gly Ser Leu Gly Val Glu Ser Met Phe Gln Leu Val Glu Ala Ile
 405 410 415

Ala Ala His Glu Asp Leu Ala Gly Lys His Gly Ile Ala Asn Pro Thr
 420 425 430

Phe Val His Ala Pro Gly Lys Ile Ser Trp Lys Tyr Arg Gly Gln Leu
 435 440 445

Thr Pro Lys Ser Lys Lys Met Asp Ser Glu Val His Ile Val Ser Val
 450 455 460

Asp Ala His Asp Gly Val Val Asp Leu Val Ala Asp Gly Phe Leu Trp
 465 470 475 480

Ala Asp Ser Leu Arg Val Tyr Ser Val Ser Asn Ile Arg Val Arg Ile
 485 490 495

Ala Ser Gly

<210> 31
 <211> 1512
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1512)

400	>31	gcc Ala 1	ccg Pro	ctc Leu	tac Tyr	ctc Leu 5	tcg Ser	cag Gln	gac Asp	ccg Pro	acc Thr 10	agc Ser	ggc Gly	cag Gln	ctc Leu	aag Lys 15	aag Lys	48
		cac His	acc Thr	gac Asp	gtg Val 20	gcc Ala	tcc Ser	ggc Gly	cag Gln	gcc Ala 25	acc Thr	atc Ile	gtg Val	cag Gln	ccc Pro 30	tgc Cys	acg Thr	96
		ctc Leu	ggc Gly	gac Asp 35	ctc Leu	ggt Gly	gac Asp	cgc Arg	tcc Ser 40	ttc Phe	atg Met	gag Glu	acc Thr	tac Tyr 45	ggc Gly	gtc Val	gtc Val	144
		gcc Ala	ccg Pro 50	ctg Leu	tac Tyr	acg Thr	ggc Gly	gcc Ala 55	atg Met	gcc Ala	aag Lys	ggc Gly	att Ile 60	gcc Ala	tcg Ser	gcg Ala	gac Asp	192
		ctc Leu 65	gtc Val	atc Ile	gcc Ala	gcc Ala	ggc Gly 70	aag Lys	cgc Arg	aag Lys	atc Ile	ctc Leu 75	ggc Gly	tcc Ser	ttt Phe	ggc Gly	gcc Ala 80	240
		ggc Gly	ggc Gly	ctc Leu	ccc Pro	atg Met 85	cac His	cac His	gtg Val	cgc Arg	gcc Ala 90	gcc Ala	ctc Leu	gag Glu	aag Lys	atc Ile 95	cag Gln	288
		gcc Ala	gcc Ala	ctg Leu	cct Pro 100	cag Gln	ggc Gly	ccc Pro	tac Tyr	gcc Ala 105	gtc Val	aac Asn	ctc Leu	atc Ile	cac His 110	tcg Ser	cct Pro	336
		ttt Phe	gac Asp	agc Ser 115	aac Asn	ctc Leu	gag Glu	aag Lys	ggc Gly 120	aac Asn	gtc Val	gat Asp	ctc Leu	ttc Phe 125	ctc Leu	gag Glu	aag Lys	384
		ggc Gly	gtc Val 130	act Thr	gtg Val	gtg Val	gag Glu	gcc Ala 135	tcg Ser	gca Ala	ttc Phe	atg Met	acc Thr 140	ctc Leu	acc Thr	ccg Pro	cag Gln	432
		gtc Val 145	gtg Val	cgc Arg	tac Tyr	cgc Arg	gcc Ala 150	gcc Ala	ggc Gly	ctc Leu	tcg Ser	cgc Arg 155	aac Asn	gcc Ala	gac Asp	ggt Gly	tcg Ser 160	480
		gtc Val	aac Asn	atc Ile	cgc Arg	aac Asn 165	cgc Arg	atc Ile	atc Ile	ggc Gly	aag Lys 170	gtc Val	tcg Ser	cgc Arg	acc Thr	gag Glu 175	ctc Leu	528
		gcc Ala	gag Glu	atg Met	ttc Phe 180	atc Ile	cgc Arg	ccg Pro	gcc Ala	ccg Pro 185	gag Glu	cac His	ctc Leu	ctc Leu	gag Glu 190	aag Lys	ctc Leu	576
		atc Ile	gcc Ala	tcg Ser 195	ggc Gly	gag Glu	atc Ile	acc Thr	cag Gln 200	gag Glu	cag Gln	gcc Ala	gag Glu	ctc Leu 205	gcg Ala	cgc Arg	cgc Arg	624
		gtt Val	ccc Pro 210	gtc Val	gcc Ala	gac Asp	gat Asp	atc Ile 215	gct Ala	gtc Val	gag Glu	gct Ala	gac Asp 220	tcg Ser	ggc Gly	ggc Gly	cac His	672
		acc Thr 225	gac Asp	aac Asn	cgc Arg	ccc Pro	atc Ile 230	cac His	gtc Val	atc Ile	ctc Leu	ccg Pro 235	ctc Leu	atc Ile	atc Ile	aac Asn	ctc Leu 240	720
		cgc Arg	aac Asn	cgc Arg	ctg Leu	cac His 245	cgc Arg	gag Glu	tgc Cys	ggc Gly	tac Tyr 250	ccc Pro	gcg Ala	cac His	ctc Leu	cgc Arg 255	gtc Val	768
	cgc Arg	gtt Val	ggc Gly	gcc Ala 260	ggc Gly	ggt Gly	ggc Gly	gtc Val	ggc Gly 265	tgc Cys	ccg Pro	cag Gln	gcc Ala	gcc Ala 270	gcc Ala	gcc Ala	816	

2997-49-2-pct_ST25

gcg	ctc	acc	atg	ggc	gcc	gcc	ttc	atc	gtc	acc	ggc	act	gtc	aac	cag	864
Ala	Leu	Thr	Met	Gly	Ala	Ala	Phe	Ile	Val	Thr	Gly	Thr	Val	Asn	Gln	
		275					280					285				
gtc	gcc	aag	cag	tcc	ggc	acc	tgc	gac	aac	gtg	cgc	aag	cag	ctc	tcg	912
Val	Ala	Lys	Gln	Ser	Gly	Thr	Cys	Asp	Asn	Val	Arg	Lys	Gln	Leu	Ser	
		290				295					300					
cag	gcc	acc	tac	tcg	gat	atc	tgc	atg	gcc	ccg	gcc	gcc	gac	atg	ttc	960
Gln	Ala	Thr	Tyr	Ser	Asp	Ile	Cys	Met	Ala	Pro	Ala	Ala	Asp	Met	Phe	
305					310					315					320	
gag	gag	ggc	gtc	aag	ctc	cag	gtc	ctc	aag	aag	gga	acc	atg	ttc	ccc	1008
Glu	Glu	Gly	Val	Lys	Leu	Gln	Val	Leu	Lys	Lys	Gly	Thr	Met	Phe	Pro	
				325					330					335		
tcg	cgc	gcc	aac	aag	ctc	tac	gag	ctc	ttt	tgc	aag	tac	gac	tcc	ttc	1056
Ser	Arg	Ala	Asn	Lys	Leu	Tyr	Glu	Leu	Phe	Cys	Lys	Tyr	Asp	Ser	Phe	
			340					345					350			
gac	tcc	atg	cct	cct	gcc	gag	ctc	gag	cgc	atc	gag	aag	cgt	atc	ttc	1104
Asp	Ser	Met	Pro	Pro	Ala	Glu	Leu	Glu	Arg	Ile	Glu	Lys	Arg	Ile	Phe	
		355					360					365				
aag	cgc	gca	ctc	cag	gag	gtc	tgg	gag	gag	acc	aag	gac	ttt	tac	att	1152
Lys	Arg	Ala	Leu	Gln	Glu	Val	Trp	Glu	Glu	Thr	Lys	Asp	Phe	Tyr	Ile	
		370				375					380					
aac	ggt	ctc	aag	aac	ccg	gag	aag	atc	cag	cgc	gcc	gag	cac	gac	ccc	1200
Asn	Gly	Leu	Lys	Asn	Pro	Glu	Lys	Ile	Gln	Arg	Ala	Glu	His	Asp	Pro	
385					390					395					400	
aag	ctc	aag	atg	tcg	ctc	tgc	ttc	cgc	tgg	tac	ctt	ggt	ctt	gcc	agc	1248
Lys	Leu	Lys	Met	Ser	Leu	Cys	Phe	Arg	Trp	Tyr	Leu	Gly	Leu	Ala	Ser	
				405					410					415		
cgc	tgg	gcc	aac	atg	ggc	gcc	ccg	gac	cgc	gtc	atg	gac	tac	cag	gtc	1296
Arg	Trp	Ala	Asn	Met	Gly	Ala	Pro	Asp	Arg	Val	Met	Asp	Tyr	Gln	Val	
			420					425					430			
tgg	tgt	ggc	ccg	gcc	att	ggc	gcc	ttc	aac	gac	ttc	atc	aag	ggc	acc	1344
Trp	Cys	Gly	Pro	Ala	Ile	Gly	Ala	Phe	Asn	Asp	Phe	Ile	Lys	Gly	Thr	
		435					440					445				
tac	ctc	gac	ccc	gct	gtc	tcc	aac	gag	tac	ccc	tgt	gtc	gtc	cag	atc	1392
Tyr	Leu	Asp	Pro	Ala	Val	Ser	Asn	Glu	Tyr	Pro	Cys	Val	Val	Gln	Ile	
		450				455					460					
aac	ctg	caa	atc	ctc	cgt	ggt	gcc	tgc	tac	ctg	cgc	cgt	ctc	aac	gcc	1440
Asn	Leu	Gln	Ile	Leu	Arg	Gly	Ala	Cys	Tyr	Leu	Arg	Arg	Leu	Asn	Ala	
465					470					475					480	
ctg	cgc	aac	gac	ccg	cgc	att	gac	ctc	gag	acc	gag	gat	gct	gcc	ttt	1488
Leu	Arg	Asn	Asp	Pro	Arg	Ile	Asp	Leu	Glu	Thr	Glu	Asp	Ala	Ala	Phe	
				485					490					495		
gtc	tac	gag	ccc	acc	aac	gcg	ctc									1512
Val	Tyr	Glu	Pro	Thr	Asn	Ala	Leu									
			500													

<210> 32
 <211> 504
 <212> PRT
 <213> Schizochytrium sp.

<400> 32

2997-49-2-pct_ST25

Ala Pro Leu Tyr Leu Ser Gln Asp Pro Thr Ser Gly Gln Leu Lys Lys
1 5 10 15

His Thr Asp Val Ala Ser Gly Gln Ala Thr Ile Val Gln Pro Cys Thr
20 25 30

Leu Gly Asp Leu Gly Asp Arg Ser Phe Met Glu Thr Tyr Gly Val Val
35 40 45

Ala Pro Leu Tyr Thr Gly Ala Met Ala Lys Gly Ile Ala Ser Ala Asp
50 55 60

Leu Val Ile Ala Ala Gly Lys Arg Lys Ile Leu Gly Ser Phe Gly Ala
65 70 75 80

Gly Gly Leu Pro Met His His Val Arg Ala Ala Leu Glu Lys Ile Gln
85 90 95

Ala Ala Leu Pro Gln Gly Pro Tyr Ala Val Asn Leu Ile His Ser Pro
100 105 110

Phe Asp Ser Asn Leu Glu Lys Gly Asn Val Asp Leu Phe Leu Glu Lys
115 120 125

Gly Val Thr Val Val Glu Ala Ser Ala Phe Met Thr Leu Thr Pro Gln
130 135 140

Val Val Arg Tyr Arg Ala Ala Gly Leu Ser Arg Asn Ala Asp Gly Ser
145 150 155 160

Val Asn Ile Arg Asn Arg Ile Ile Gly Lys Val Ser Arg Thr Glu Leu
165 170 175

Ala Glu Met Phe Ile Arg Pro Ala Pro Glu His Leu Leu Glu Lys Leu
180 185 190

Ile Ala Ser Gly Glu Ile Thr Gln Glu Gln Ala Glu Leu Ala Arg Arg
195 200 205

Val Pro Val Ala Asp Asp Ile Ala Val Glu Ala Asp Ser Gly Gly His
210 215 220

Thr Asp Asn Arg Pro Ile His Val Ile Leu Pro Leu Ile Ile Asn Leu
225 230 235 240

Arg Asn Arg Leu His Arg Glu Cys Gly Tyr Pro Ala His Leu Arg Val
245 250 255

Arg Val Gly Ala Gly Gly Gly Val Gly Cys Pro Gln Ala Ala Ala Ala
260 265 270

2997-49-2-pct_ST25

Ala Leu Thr Met Gly Ala Ala Phe Ile Val Thr Gly Thr Val Asn Gln
275 280 285

Val Ala Lys Gln Ser Gly Thr Cys Asp Asn Val Arg Lys Gln Leu Ser
290 295 300

Gln Ala Thr Tyr Ser Asp Ile Cys Met Ala Pro Ala Ala Asp Met Phe
305 310 315 320

Glu Glu Gly Val Lys Leu Gln Val Leu Lys Lys Gly Thr Met Phe Pro
325 330 335

Ser Arg Ala Asn Lys Leu Tyr Glu Leu Phe Cys Lys Tyr Asp Ser Phe
340 345 350

Asp Ser Met Pro Pro Ala Glu Leu Glu Arg Ile Glu Lys Arg Ile Phe
355 360 365

Lys Arg Ala Leu Gln Glu Val Trp Glu Glu Thr Lys Asp Phe Tyr Ile
370 375 380

Asn Gly Leu Lys Asn Pro Glu Lys Ile Gln Arg Ala Glu His Asp Pro
385 390 395 400

Lys Leu Lys Met Ser Leu Cys Phe Arg Trp Tyr Leu Gly Leu Ala Ser
405 410 415

Arg Trp Ala Asn Met Gly Ala Pro Asp Arg Val Met Asp Tyr Gln Val
420 425 430

Trp Cys Gly Pro Ala Ile Gly Ala Phe Asn Asp Phe Ile Lys Gly Thr
435 440 445

Tyr Leu Asp Pro Ala Val Ser Asn Glu Tyr Pro Cys Val Val Gln Ile
450 455 460

Asn Leu Gln Ile Leu Arg Gly Ala Cys Tyr Leu Arg Arg Leu Asn Ala
465 470 475 480

Leu Arg Asn Asp Pro Arg Ile Asp Leu Glu Thr Glu Asp Ala Ala Phe
485 490 495

Val Tyr Glu Pro Thr Asn Ala Leu
500

<210> 33
<211> 714
<212> DNA
<213> Nostoc sp.

<400> 33
atgttgcagc atacttggct accaaaaccc ccaaatttaa ccttattgtc agatgaagtt

2997-49-2-pct_ST25

catctctggc gcattcccct tgaccaacca gaatcacagc tacaggattt agccgctacc 120
 ttatctagtg acgaattagc ccgtgcaaac agatttttatt ttcccgaaca tcgccggcgt 180
 tttactgctg gtcgtggtat tctccgcagt atcttggggg gctatttggg tgtggaacca 240
 gggcaagtta aatttgatta tgaatcccgt ggtaaacc aa tattaggcga tcgctttgcc 300
 gagagtgggt tattatttaa cttgtcacac tcccagaact tggccttggtg tgcagtcaat 360
 tacacgcgcc aaatcggcat cgatttagaa tatctccgcc ccacatctga tttagaatcc 420
 cttgccaaaa gggtcttttt accgcgagaa tatgaattat tgcgatcgct acccgatgag 480
 caaaaacaaa aaatttttctt tcgttactgg acttgtaaag aggcttatct taaagcaacg 540
 ggtgacggca tcgctaaatt agaggaaatt gaaatagcac taactccac agaaccagct 600
 aagttacaga cagctccagc gtggagtctc ctagagctag tgccagatga taattgtgtt 660
 gctgctgttg ccgtggcggg ttttggctgg cagccaaaat tctggcatta ttga 714

<210> 34
 <211> 237
 <212> PRT
 <213> Nostoc sp.

<400> 34

Met Leu Gln His Thr Trp Leu Pro Lys Pro Pro Asn Leu Thr Leu Leu
 1 5 10 15

Ser Asp Glu Val His Leu Trp Arg Ile Pro Leu Asp Gln Pro Glu Ser
 20 25 30

Gln Leu Gln Asp Leu Ala Ala Thr Leu Ser Ser Asp Glu Leu Ala Arg
 35 40 45

Ala Asn Arg Phe Tyr Phe Pro Glu His Arg Arg Arg Phe Thr Ala Gly
 50 55 60

Arg Gly Ile Leu Arg Ser Ile Leu Gly Gly Tyr Leu Gly Val Glu Pro
 65 70 75 80

Gly Gln Val Lys Phe Asp Tyr Glu Ser Arg Gly Lys Pro Ile Leu Gly
 85 90 95

Asp Arg Phe Ala Glu Ser Gly Leu Leu Phe Asn Leu Ser His Ser Gln
 100 105 110

Asn Leu Ala Leu Cys Ala Val Asn Tyr Thr Arg Gln Ile Gly Ile Asp
 115 120 125

Leu Glu Tyr Leu Arg Pro Thr Ser Asp Leu Glu Ser Leu Ala Lys Arg
 130 135 140

Phe Phe Leu Pro Arg Glu Tyr Glu Leu Leu Arg Ser Leu Pro Asp Glu

2997-49-2-pct_ST25

145 150 155 160

Gln Lys Gln Lys Ile Phe Phe Arg Tyr Trp Thr Cys Lys Glu Ala Tyr
165 170 175

Leu Lys Ala Thr Gly Asp Gly Ile Ala Lys Leu Glu Glu Ile Glu Ile
180 185 190

Ala Leu Thr Pro Thr Glu Pro Ala Lys Leu Gln Thr Ala Pro Ala Trp
195 200 205

Ser Leu Leu Glu Leu Val Pro Asp Asp Asn Cys Val Ala Ala Val Ala
210 215 220

Val Ala Gly Phe Gly Trp Gln Pro Lys Phe Trp His Tyr
225 230 235

<210> 35
<211> 8733
<212> DNA
<213> Artificial

<220>
<223> synthetic

<400> 35
atggctgcta gggtgcaaga acaaaaaggt ggtgagatgg atactagaat tgctatcatt 60
ggaatgtctg ctatcttgcc atgtggtact actgttagag aatcttgga aactattaga 120
gctggatttg attgtttgtc tgatttgctt gaagatagag ttgatgttac tgcttacttt 180
gatccagtta aaactactaa agataaaatc tattgtaaga gaggtggttt cattccagaa 240
tatgattttg atgctagaga atttggtttg aatatgtttc agatggaaga ttctgatgct 300
aatcaaaacta tttctttgtt gaaagttaa gaagcattgc aagatgctgg catcgatgct 360
ttgggttaaag agaagaagaa tattggttgt gttttgggta ttggtggtgg tcaaaaatct 420
tctcatgaat tttactcaag attgaattat gttgttggtg agaaggtatt gagaaaaatg 480
ggatgccag aagaagatgt taaagttgct gttgaaaaat acaaagctaa tttccagag 540
tgagattgg attcttttcc aggtttcttg ggaaatgtta ctgcaggaag atgtactaat 600
acttttaatc ttgatggcat gaattgtgtt gttgatgctg cttgtgcttc ttctttgatt 660
gctgttaaag ttgctattga tgaattgttg tacggtgatt gtgatatgat ggttactggt 720
gctacttgta ctgataattc tattggaatg tacatggctt tttctaaaac tccagttttc 780
tctactgatc catctgttag agcttatgat gaaaaaacta aaggaatgtt gattggtgaa 840
ggttctgcta tggtggtttt gaaaagatat gctgatgctg ttagagatgg tgatgaaatt 900
catgctgtta ttagagggtg tgcttcttct tctgatggta aagctgctgg tatctatact 960
ccaactatct ctggtcaaga agaagcattg agaagagctt ataataagagc ttgtgttgat 1020
ccagctactg ttactttggt tgaaggtcat ggtactggta ctccagttgg tgatagaatt 1080

2997-49-2-pct_ST25

gaattgactg	ctttgagaaa	tttgtttgat	aaagcatatg	gtgaaggtaa	tactgaaaaa	1140
gttgctgttg	gttctattaa	atcttctatt	ggtcatttga	aagctgttgc	tggtttggct	1200
ggaatgatta	aagttatcat	ggctttgaaa	cataaaactt	tgccaggaac	tattaatggt	1260
gataatccac	caaacttgta	cgataatact	ccaattaacg	aatcttcttt	gtacattaat	1320
actatgaata	gaccttggtt	tccaccacca	gggtgttcaa	gaagagctgg	tattttcttct	1380
tttggttttg	gtgggtgctaa	ttatcatgct	gttttggaag	aagctgaacc	agaacatact	1440
actgcttata	ggttgaacaa	aagaccacaa	ccagttttga	tgatggctgc	tactccagct	1500
gctttgcaat	ctttgtgtga	agctcaattg	aaagaatttg	aagctgctat	taaagaaaac	1560
gaaactgtta	aaaatactgc	ttatattaaa	tgtgtttaat	ttggtgaaca	attcaaattc	1620
cctggtagta	ttccagctac	taatgctagg	ttgggtttct	tggttaaaga	tgctgaagat	1680
gcttgttcta	ctttgagagc	tatttgtgct	caatttgcta	aagatgttac	taaagaagca	1740
tgagattgc	caagagaagg	tgtttctttt	agagctaaag	gtattgctac	taatggtgct	1800
gttgctgctt	tgttttctgg	tcaaggtgct	caatatactc	atatgttttc	tgaagttgct	1860
atgaattggc	cacaattcag	acaatctatt	gctgctatgg	atgctgctca	atctaaagtt	1920
gctggttctg	ataaagattt	tgaaagagtt	tctcaagttt	tgtatccaag	aaaaccatac	1980
gagagagaac	cagagcaaga	tcataagaag	atttctttga	ctgcttattc	tcaaccatct	2040
actttggctt	gtgctttggg	tgcttttgaa	atttttaaag	aagctggttt	tactccagat	2100
tttgctgctg	gtcattcttt	gggtgaattt	gctgctttgt	acgctgctgg	ttgtgttgat	2160
agagatgaat	tgtttgaatt	ggttttaga	agagctagaa	ttatgggtgg	taaagatgct	2220
ccagctactc	caaaggttg	catggctgct	gttattggct	caaagtctga	aaatattaaa	2280
gttcaagctg	ctaattgttg	gttaggaaat	tctaattctc	catctcaaac	tgttattact	2340
ggttctgttg	aaggtattca	agctgaatct	gctaggttgc	aaaaagaagg	ttttagagtt	2400
gttccattgg	cttgtgaatc	tgcttttcat	tctccacaga	tggaatatgc	ttcttctgct	2460
tttaaagatg	ttatctctaa	agtttctttt	agaactccaa	aagctgaaac	taaattgttt	2520
tctaattgtt	ctggtgaaac	ttatccaact	gatgctagag	aatgttgac	tcaacatatg	2580
acttcttctg	ttaaattttt	gactcaagtt	agaaatatgc	atcaagctgg	tgctagaatt	2640
tttgttgaat	tcgggtccaa	acaagttttg	tctaaattgg	tttctgaaac	tttgaaagat	2700
gatccatctg	ttgttactgt	ttctgttaat	ccagcttctg	gtactgattc	tgatattcaa	2760
ttgagagatg	ctgctgttca	attggttgtt	gctgggtgta	atttgcaagg	ttttgataaa	2820
tgggatgctc	cagatgctac	tagaatgcaa	gctattaaaa	aaaaaagaac	tactttgaga	2880
ttgtctgctg	ctacttatgt	ttctgataaa	actaagaaag	ttagagatgc	tgctatgaat	2940
gatggtagat	gtgttactta	cttgaaaggt	gctgctccat	tgattaaagc	tccagaacca	3000
gttgttgatg	aagctgctaa	aagagaagct	gaaagattgc	aaaaagaatt	gcaagatgct	3060
caaagacaat	tggtatgatgc	taaaagagct	gctgctgaag	ctaattctaa	attggctgct	3120

2997-49-2-pct_ST25

gctaaagaag	aagctaaaac	tgctgctgct	tctgctaaac	cagctgttga	tactgctgtt	3180
gttgaaaaac	atagagctat	tttgaaatct	atgttggtg	aattggatgg	ttatggttct	3240
gttgatgctt	cttctttgca	acaacaacaa	caacaacaaa	ctgctccagc	tccagttaaa	3300
gctgctgctc	cagctgctcc	agttgcttct	gctccagcac	ccgcagttag	caacgaactc	3360
ttagaaaaag	ccgagacagt	agtgatggaa	gttcttgcag	ctaaaacggg	gtacgaaaca	3420
gatatgattg	aagcagatat	ggaacttgaa	actgaactgg	gcattgattc	gattaaacgc	3480
gtggaaattc	tgtcagaagt	gcaagctatg	ttaaattgtt	aagcgaaaga	tgttgatgca	3540
ctgtcacgca	cacgcaccgt	gggcgaagta	gtgaacgcca	tgaaagcaga	aattgcaggc	3600
tcctcagcac	ccgcgccggc	cgcagcagca	ccagcccccg	caaaagccgc	ccccgcagcg	3660
gcggctccag	ccgtttcaaa	cgaattactc	gaaaaagcag	aaaccgtagt	gatggaagtc	3720
cttgccgcca	aaacgggtta	tgagaccgat	atgatcgaaa	gcgatatgga	attagaaacc	3780
gaattaggga	ttgatagtat	taaacgcgta	gaaattctgt	ccgaagtaca	agctatgctg	3840
aatgtagaag	caaaagatgt	agatgcgtta	agccgcacac	gcactgttgg	tgaagttgtg	3900
aatgctatga	aagctgaaat	tgcaggaggt	tcagcaccgg	ccccagcagc	cgcagcccca	3960
ggtcacgag	cagccgcacc	ggcccccgcc	gccgccgcac	cggcagtatc	aaacgagttg	4020
ttagagaaa	cggaaccgt	tgtgatggaa	gtacttgccg	cgaagacagg	ttacgagacc	4080
gatatgatcg	aaagtacat	ggaattagaa	accgaattgg	gcattgatag	cattaaacgc	4140
gtagaaattt	tatccgaagt	tcaagccatg	ttaaattgtt	aagccaaaga	tgtggatgcg	4200
ttatcccga	cgcgtaccgt	cggagaagta	gtggacgcta	tgaaagcaga	gattgcagga	4260
ggaagtgcac	gggtccagc	agcagcagca	cccgccccag	cggcagcggc	gccggcaccg	4320
gccgctccgg	ccccagccgt	tagttcagaa	ctcctcgaaa	aagcagaaac	tgttgatcatg	4380
gaagtattag	ctgcaaaaac	aggttacgag	acggatatga	ttgaaagcga	tatggaatta	4440
gaaaccgaat	taggcattga	ttcaattaaa	cgtgttgaaa	tcttaagtga	agtccaagcc	4500
atgcttaatg	ttgaagccaa	agatgtagat	gcattatctc	gcacgcgtac	agtgggtgaa	4560
gttgctgatg	cgatgaaagc	agaaatcgcg	ggaggatcag	cgccagcccc	ggcagcagca	4620
gcccccgcg	ccgcccgggc	cgcacctgcg	ccggccgccc	cagcccctgc	agcaccggcc	4680
ccagcagtgt	cgtcggaatt	actcgaaaaa	gctgaaacgg	tcgttatgga	agtacttgct	4740
gcaaagacgg	gctatgaaac	ggatatgatt	gaatcgata	tggaattaga	aacagaactt	4800
ggatttgact	ctattaaacg	cgtggaaatt	ctgagcgaag	tacaggcaat	gttaaacgta	4860
gaagccaaag	atgtagacgc	tttgtcacgc	acacggacgg	taggagaagt	tgtggatgcg	4920
atgaaagctg	aaattgccgg	ttcaagtgct	agcggcccctg	ctgccgccgc	ccctgcccct	4980
gccgccgag	caccggcccc	ggcagccgca	gctccagcag	ttagtaacga	attactcgaa	5040
aaagcagaaa	cggtggtcat	ggaagtgtta	gcagcaaaaa	ctggatatga	aacggacatg	5100
attgaaagcg	atatggaatt	agaaacagaa	ctgggaattg	atagtattaa	acgtgttgag	5160

2997-49-2-pct_ST25

attttatctg	aggttcaagc	tatgctgaat	gttgaagcga	aagatgtaga	cgcactgtct	5220
cggacccgca	cagtaggtga	agtgggtggac	gcgatgaaag	cagaaatcgc	aggtggaagt	5280
gctccggccc	cggcggcagc	cgcacccgcg	cccgcggccg	cagccccagc	agttagcaac	5340
gaattactcg	agaaagcaga	aactgtagtg	atggaagtgt	tagccgcaaa	aacgggttat	5400
gaaacggata	tgattgaaag	cgatatggaa	ctggaaaccg	aactgggcat	tgattctatt	5460
aaacgtgtcg	aaatcttatc	ggaagtccaa	gcaatgctga	acgtagaggc	aaaggatggt	5520
gatgccctgt	cacgtacccg	taccgtaggt	gaagttgtag	atgccatgaa	agctgaaatc	5580
gcaggcagta	gcgccccggc	accagccgcc	gccgcccccg	cgccggcagc	cgccgcaccc	5640
gcgccagccg	cagctgtctc	agctgtatct	agtgaagtgc	tcgaaaaagc	agaaaccgtg	5700
gttatggaag	tgctcgccgc	taaaacagga	tatgaaaccg	atatgattga	aagcgatatg	5760
gaattagaaa	ccgaactggg	tattgatagt	attaagcgtg	ttgaaatfff	gtcagaagtt	5820
caagctatgt	tgaatgtaga	agccaaagat	gtagacgctt	taagtcggac	gcgtactggt	5880
ggagaagtcg	tagacgcat	gaaagcagag	attgcaggcg	gaagtgcacc	ggccccggca	5940
gcagcagccc	cagcaccagc	ggccgccgct	cctgcagtgt	caaacgaact	tctggaaaaa	6000
gctgaaaccg	tcgtcatgga	agtgtgtggc	gcaaaaactg	gatatgaaac	agacatgatt	6060
gaatcagata	tggaactcga	aaccgaactg	gggattgata	gcattaaacg	tgtggaaatt	6120
ttatcggagg	tacaagcaat	gttaaattgtg	gaagcaaaag	atgtggatgc	actgagccgt	6180
actcgtactg	ttgggtgaggt	cgtggatgcg	atgaaagcag	aaattgctgg	agggagtgcg	6240
cctgccccgg	ccgccgccgc	acccgcgtct	gccggtgctg	cccccgctgt	caaaattgat	6300
tctgttcatg	gtgctgattg	tgatgatttg	tctttgatgc	atgctaaagt	tgttgatatt	6360
agaagaccag	atgaattgat	tttggaaga	ccagaaaata	gaccagtttt	ggttgttgat	6420
gatggttctg	aattgacttt	ggctttggtt	agagttttgg	gtgcttgtgc	tgttgttttg	6480
acttttgaag	gtttgcaatt	ggctcaaaga	gctggtgctg	ctgctattag	acatgttttg	6540
gctaaagatt	tgtctgctga	atctgctgaa	aaagctatta	aagaagctga	acaaagattt	6600
ggtgcttttg	gtggttttat	ctctcaacaa	gctgaaagat	ttgaaccagc	tgaaatfttg	6660
ggttttactt	tgatgtgtgc	taaatttgct	aaagcatctt	tgtgcactgc	tgttgctggt	6720
ggtagaccag	ctttcattgg	tgttgctagg	ttggatggta	ggttgggttt	tactttctcaa	6780
ggaacttctg	atgctttgaa	aagagctcaa	agaggtgcta	tttttggttt	gtgcaagact	6840
attggtttgg	aatggctcga	atctgatgtt	ttctcaagag	gtgttgatat	tgctcaaggt	6900
atgcatccag	aagatgctgc	tgttgctatt	gttagagaaa	tggcttgtgc	tgatattaga	6960
attagagaag	ttggatttgg	tgctaataca	caaagatgta	ctattagagc	tgctaaattg	7020
gaaactggaa	atccacaaag	acaaattgct	aaagatgatg	ttttgttggt	ttctgggtggt	7080
gctagaggaa	ttactccatt	gtgcattaga	gaaattacta	gacaaattgc	tggtggaaag	7140
tatattttgt	tgggtaggtc	taaagtttct	gcttctgaac	cagcttggtg	tgctggtatt	7200

2997-49-2-pct_ST25

actgatgaaa aagctgttca aaaagctgct actcaagaat tgaaaagagc tttttctgct	7260
ggtgaagggtc caaaaccaac tccaagagct gttactaaat tggttggttc tgttttgggt	7320
gctagagaag ttaggtcttc tattgctgct attgaagcat tgggtggaag agctatctat	7380
tcttcttggtg atgttaattc tgctgctgat gttgctaaag ctgttagaga tgctgaatct	7440
caattgggtg ctagagtttc tggatttgtt catgcttctg gtgttttgag agatagggtg	7500
attgaaaaaa aattgccaga tgaatttgat gctgtttttg gtactaaagt tactggtttg	7560
gaaaatttgt tggctgctgt tgatagagct aatttgaaac atatggtttt gttttcttct	7620
ttggctgggtt ttcattgtaa tgttggtcaa tctgattatg ctatggctaa cgaagcattg	7680
aacaaaatgg gtttggaatt ggctaaagat gtttctgtta aatctatttg ttttggtcct	7740
tgggatgggtg gtatgggtac tccacaattg aaaaaacaat ttcaagaaat ggggtgttcaa	7800
attattccaa gagaagggtg tgctgatact gttgctagaa ttgttttggg ttttcttcca	7860
gctgaaattt tgggttgtaa ttggagaact ccatctaaaa aagttggttc tgatactatt	7920
actttgcaca gaaaaatttc tgctaaatct aatccatttt tggaagatca tgctattcaa	7980
ggtagaagag ttttgccaat gactttggct attgggttctt tggctgaaac ttgtttgggt	8040
ttgtttcctg gatattcttt gtgggctatt gatgatgctc aattgtttta aggtgttact	8100
gttgatgggtg atgttaattg tgaagttact ttgactccat ctactgctcc ttctggtaga	8160
gttaatgttc aagctacttt gaaaactttt tcttctggta aattgggttc agcttataga	8220
gctgttattg ttttgcttaa tcaagggtgct ccaccagcta atgctactat gcaaccacca	8280
tctttggatg ctgatccagc tttgcaagggt tctgtttatg atggaaagac tttgtttcat	8340
gggtccagctt ttagagggtat tgatgatgtt ttgtcttgta cttaaattctca attggttgct	8400
aaatgttctg ctgttccagg ttctgatgct gctagagggtg aatttgctac tgatactgat	8460
gctcatgatc catttggtta tgatttggtt tttcaagcta tggttggttg ggttagaaga	8520
actttgggtc aagctgcttt gccaaattct attcaaagaa ttgttcaaca cagaccagtt	8580
ccacaagata aaccatttta tattactttg agatctaata aatctggttg tcattctcaa	8640
cataaacatg ctttgcaatt tcataacgaa caagggtgatt tgttcattga tgttcaagca	8700
tctgttattg ctactgattc tttggctttt taa	8733

<210> 36
 <211> 6180
 <212> DNA
 <213> Artificial

<220>
 <223> synthetic

<400> 36	
atggctgcta gaaatgtttc tgctgctcat gaaatgcatg atgaaaaaag aattgctgtt	60
gttggtatgg ctgttcaata tgctgggttg aagactaaag atgaattttg ggaagttttg	120
atgaatggta aagttgaatc taaagttatc tctgataaaa gattgggttc taattaccga	180

2997-49-2-pct_ST25

gctgaacatt	acaaggctga	aagatccaaa	tacgctgata	ctttttgtaa	cgaaacttat	240
ggtacttttg	atgaaaacga	aattgataac	gaacatgaat	tggttggtgaa	tttggctaaa	300
caagcattgg	ctgaaacttc	tgtaaagat	tctactagat	gtggtattgt	ttctggttgt	360
ttgtcttttc	ctatggataa	tttgcaaggt	gaattgttga	atgtctatca	aaatcatggt	420
gagaagaaat	tggtgctag	agtttttaa	gatgcttctc	attggtctga	aagagaacaa	480
tctaacaac	cagaagctgg	tgatagaaga	atcttcatgg	accagcttc	ttttgttgct	540
gaagaattga	atttgggtgc	tttg cattat	tctgttgatg	ctgcttggtc	tactgcttta	600
tacgttttga	gattggctca	agatcatttg	gtttctggtg	ctgctgatgt	tatgttggtg	660
ggtgctactt	gtttgccaga	accattcttt	atcttgtctg	gtttttctac	ttttcaagct	720
atgccagttg	gtactggtca	aatgtttct	atgccattgc	ataaagattc	tcaaggtttg	780
actccaggtg	aagggtggtc	tatcatgggt	ttgaaaagat	tggtgatgc	tattagagat	840
ggtgatcata	tctatggtac	tttgttggtg	gctaattgtt	ctaattctgg	cactggtttg	900
ccattgaaac	cattgttgcc	atctgaaaa	aatgtttga	tgatactta	tactagaatt	960
aatgttcac	cacataaaat	tcaatatgtt	gaatgtcatg	ctactggtac	tccacaaggt	1020
gatagggttg	aaattgatgc	tgtaaagca	tgttttgaag	gaaaagtcc	aagatttggt	1080
actactaaag	gaaactttgg	tcatactttg	gttgctgctg	gttttgctgg	aatgtgcaaa	1140
gttttggtgt	ctatgaaaca	tggtatcatt	ccaccaactc	caggtattga	tgatgaaact	1200
aagatggacc	cattggttgt	ttctggtgaa	gctattcctt	ggccagaaac	taatggtgaa	1260
ccaaaaagag	ctggtttgtc	tgcttttggt	tttggtggtg	ctaattgctca	tgctgttttt	1320
gaagaacatg	atccatctaa	tgctgcttgt	actggtcatg	attctatttc	tgctttgtct	1380
gctagatgtg	gtggtgaatc	taatatgaga	attgctatta	ctggtatgga	tgctactttt	1440
ggtgctttga	aaggtttgga	tgcttttgaa	agagccatct	acactggtgc	tcatggtgct	1500
attccattgc	cagaaaagag	atggagattt	ttgggcaaa	ataaagattt	cttggttttg	1560
tgtggtgtta	aagctactcc	acatggttgt	tatattgaag	atgttgaagt	tgattttcaa	1620
agattgagaa	ctccaatgac	tccagaagat	atgttggtgc	cacaacaatt	gttggctggt	1680
actactattg	atagagctat	tttggtattc	ggtatgaaaa	aagggtggtg	tggtgctggt	1740
tttgttggtt	tggttaccga	tttggaattg	tacagacata	gagctagagt	tgctttgaaa	1800
gaaagagtta	gaccagaagc	atctaaaaaa	ttgaatgata	tgatgcagta	cattaatgat	1860
tgtggcacct	ctacttctta	tacttcttat	attggtaatt	tggttgctac	tagagtttct	1920
tctcaatggg	gttttactgg	tccatctttt	actattactg	aagggaataa	ctctgtttat	1980
agatgtgctg	aattgggaaa	gtatttggtg	gaaactggtg	aagttgatgg	tggtgttggt	2040
gctggtgttg	atttgtgtgg	ttctgctgaa	aacttatacg	ttaaatcaag	aagattcaaa	2100
gtttctactt	ctgatactcc	aagagcttct	tttgatgctg	ctgctgatgg	ttactttggt	2160
ggtgaagggt	gtggtgcttt	tgttttgaaa	agagaaactt	cttgactaa	agatgataga	2220

2997-49-2-pct_ST25

atctatgctt	gcatggatgc	tattgttcca	ggtaatgttc	catctgcttg	tttgagagaa	2280
gcattggatc	aagctagagt	taaaccaggt	gatattgaaa	tgttggaatt	gtctgctgat	2340
tctgctagac	atttgaaaga	tccatctgtt	ttgccaaaag	aattgactgc	tgaagaagaa	2400
attggtgggt	tgcaaactat	tttgagagat	gatgataaat	tgccaagaaa	tgttgctact	2460
ggttctgtta	aagctactgt	tggtgatact	ggttatgctt	ctggtgctgc	ttctttgatt	2520
aaagctgctt	tgtgcatcta	taataggtat	ttgccatcta	atggtgatga	ttgggatgaa	2580
ccagctccag	aagctccttg	ggattctact	ttgtttgctt	gtcaaacttc	aagagcttgg	2640
ttgaaaaatc	ctggagagag	aagatatgct	gctgtttctg	gtgtttctga	aactaggtct	2700
tgttattctg	ttttgttgct	tgaagctgaa	ggctattatg	aaagagaaaa	tagaatttct	2760
ttggatgaag	aagctccaaa	attgattgtt	ttgagagctg	attctcatga	agaaattttg	2820
ggtaggttgg	ataaaattag	agaaagattt	ttgcaaccaa	ctggtgctgc	tccaagagaa	2880
tctgaattga	aagctcaagc	tagaagaatt	ttcttggaat	tgttgggtga	aactttggct	2940
caagatgctg	cttcttctgg	ttctcaaaaa	ccattggctt	tgtctttggt	ttctactcca	3000
tctaaattgc	aaagagaagt	tgaattggct	gctaaaggta	ttccaagatg	tttgaaaatg	3060
agaagagatt	ggcttcttcc	agctggttca	agatatgctc	cagaaccatt	ggcttctgat	3120
agagttgctt	tcatgtacgg	tgaaggaagg	tctccatact	atggaatcac	tcaagatatt	3180
catagaattt	ggccagaatt	gcatgaagtt	attaacgaaa	aaactaatag	gttgtgggct	3240
gaaggtgata	gatgggttat	gccaagagct	tctttttaat	ctgaattgga	atctcaacaa	3300
caagaatttg	atagaaatat	gattgaaatg	tttaggttgg	gtattttgac	ttctattgct	3360
tttactaatt	tggttagaga	tgttttgaat	attactccaa	aagctgcttt	tggtttgtct	3420
ttgggtgaaa	tttctatgat	ttttgctttt	tctaaaaaaa	atggtttgat	ttctgatcaa	3480
ttgactaaag	atttgagaga	atctgatgtt	tggaacaaag	cattggctgt	tgaattcaat	3540
gctttgagag	aagcatgggg	tattccacaa	tctgttccaa	aagatgaatt	ttggcaagggt	3600
tatattgtta	gaggtactaa	acaagatatt	gaagctgcta	ttgctccaga	ttccaaatac	3660
gtaggttga	ctatcattaa	tgatgcta	actgctttga	tttctggtaa	accagatgct	3720
tgtaaagctg	ctattgctag	gttgggtggt	aatattccag	ctttgccagt	tactcaagga	3780
atgtgtggtc	attgtccaga	agttggtcca	tatactaaag	atattgctaa	aattcatgct	3840
aatttggaat	ttccagttgt	tgatggtttg	gatttgtgga	ctactattaa	tcaaaaaaga	3900
ttggttccaa	gagctactgg	tgctaaagat	gaatgggctc	catcttcttt	tggtgaatat	3960
gctggtcaac	tttacgaaaa	acaagcta	tttccacaaa	ttgttgaaac	tatctacaaa	4020
caaaattatg	atgtttttgt	tgaggttgggt	ccaacaacc	ataggtctac	tgctgttaga	4080
actactttgg	gtccacaaag	aaatcatttg	gctggtgcta	ttgataaaca	aaacgaagat	4140
gcttggacta	ctattgttaa	attggttgct	tctttgaaag	ctcatttggt	tccaggtggt	4200
actatttctc	cattgtatca	ttctaaattg	gttgctgaag	ctgaagcatg	ttatgctgct	4260

2997-49-2-pct_ST25

ctgtgcaaag	gagaaaaacc	taagaagaac	aaatttggtta	gaaaaattca	attgaatggt	4320
aggttcaatt	ctaaagctga	tccaatttct	tctgctgatt	tggcttcttt	tccaccagct	4380
gatccagcta	ttgaagctgc	tatttcttca	agaattatga	aaccagttgc	tccaaaattt	4440
tatgctaggt	tgaatattga	tgaacaagac	gaaacaagag	atccaatttt	gaacaaagat	4500
aatgctccat	ctagttcatc	tagttcctct	tcacttagtt	cttcatctag	ttctccatct	4560
ccagctcctt	ctgctccagt	tcaaaaaaaaa	gctgctccag	ctgctgaaac	taaagctggt	4620
gcttctgctg	atgctttgag	atctgctttg	ttggatttgg	attctatggt	ggctttgtct	4680
tctgcttctg	cttctggtaa	tttggttgaa	actgctccat	ctgatgcttc	tgttattggt	4740
ccaccatgta	atattgctga	tttgggttca	agagctttta	tgaaaactta	tggtgtttct	4800
gctccattgt	acactggtgc	tatggctaaa	ggtattgctt	ctgctgattt	ggttattgct	4860
gctggtagac	aaggcatttt	ggcttctttt	ggtgctggtg	gtttgccaat	gcaagttggt	4920
agagaatcta	ttgaaaaaat	tcaagctgct	ttgccaaatg	gtccatatgc	tgtaaatttg	4980
attcattctc	catttgattc	taatttgga	aaaggtaatg	ttgatttggt	tttggaaaaa	5040
ggtgttactt	ttgttgaagc	atctgctttt	atgactttga	ctccacaagt	tgttaggtac	5100
agagctgctg	gtttgactag	aaatgctgat	ggttctgtta	atattagaaa	tagaattatc	5160
ggaaagggtt	caagaactga	attggctgaa	atgtttatga	gacctgcccc	agaacacttg	5220
ttgcaaaaat	tgattgcttc	tggtgaaatt	aatcaagaac	aagctgaatt	ggctagaaga	5280
gttccagttg	ctgatgatat	tgctgttgaa	gctgattctg	gtggtcatac	tgataataga	5340
ccaattcatg	ttatcttgcc	attgattatt	aatttgagag	acagattgca	tagagaatgt	5400
ggttatccag	ctaatttgag	agttagagtt	ggtgctggtg	gtggtattgg	ttgtccacaa	5460
gctgctttgg	ctacttttaa	tatgggtgct	tctttcattg	ttactggcac	tgtaaataca	5520
gttgctaaac	aatctggtac	ttgtgataat	gttagaaaac	aattggctaa	agctacttat	5580
tctgatgttt	gcatggctcc	agctgctgat	atgtttgaag	aagggtgtta	attgcaagtt	5640
ttgaagaaag	ggacaatggt	tccatcaaga	gctaataagt	tatacgaatt	gttttgcaag	5700
tatgattctt	ttgaatctat	gccaccagct	gaattggcta	gagttgaaaa	aagaattttc	5760
tcaagagctt	tggaagaagt	ttgggatgaa	actaaaaatt	tttacattaa	taggttgcac	5820
aatccagaaa	aaattcaaag	agctgaaaga	gatccaaaat	tgaaaatgtc	tttgtgtttt	5880
agatggtatt	tgtctttggc	ttcaagatgg	gctaatactg	gtgcttctga	tagagttatg	5940
gattatcaag	tttgggtgtg	tccagctatt	ggttctttta	atgatttcat	taaaggcacc	6000
tacttgacc	cagctgttgc	taacgaatat	ccatgcgttg	ttcaaattaa	caaacaaatt	6060
ttgagaggtg	cttgtttcct	cagaagattg	gaaattttga	gaaatgctag	gttgtctgat	6120
ggtgctgctg	ctttggttgc	ttctattgat	gatacttatg	ttccagctga	aaaattgtaa	6180

<210> 37
 <211> 6180
 <212> DNA

<213> Artificial

<220>

<223> synthetic

<400> 37

atggccgctc	gcaacgtgtc	tgcagcgc	gagatgcacg	atgaaaagcg	catcgccgctc	60
gtcggcatgg	ccgtccagta	cgccggatgc	aaaaccaagg	acgagttctg	ggaggtgctc	120
atgaacggca	aggctcagtc	caaggtgatc	agcgacaaac	gactcggctc	caactaccgc	180
gccgagcact	acaaagcaga	gcgagcaag	tatgccgaca	ccttttgcaa	cgaaacgtac	240
ggcacccttg	acgagaacga	gatcgacaac	gagcacgaac	tcctcctcaa	cctcgccaag	300
caggcactcg	cagagacatc	cgtcaaagac	tcgacacgct	gcggcatcgt	cagcggctgc	360
ctctcgttcc	ccatggacaa	cctccagggt	gaactcctca	acgtgtacca	aaaccatgtc	420
gagaaaaagc	tcggggcccc	cgtcttcaag	gacgcctccc	attggtccga	acgcgagcag	480
tccaacaaac	ccgaggccgg	tgaccgccgc	atcttcatgg	acccggcctc	cttcgtcgcc	540
gaagaactca	acctcggcgc	ccttcactac	tccgtcgacg	cagcatgcgc	cacggcgctc	600
tacgtgctcc	gcctcgcgca	ggatcatctc	gtctccggcg	ccgccgacgt	catgctctgc	660
ggtgccacct	gcctgccgga	gccctttttc	atcctttcgg	gcttttccac	cttccaggcc	720
atgcccgtcg	gcacgggcca	gaacgtgtcc	atgccgctgc	acaaggacag	ccagggcctc	780
accccggttg	agggcggtc	catcatggtc	ctcaagcgtc	tcgatgatgc	catccgcgac	840
ggcgaccaca	tctacggcac	ccttctcggc	gccaatgtca	gcaactccgg	cacaggtctg	900
cccctcaagc	cccttctccc	cagcgagaaa	aagtgcctca	tggacaccta	cacgcgcatt	960
aacgtgcacc	cgcacaaagt	tcagtacgtc	gagtgccacg	ccaccggcac	gccccagggt	1020
gatcgtgtgg	aaatcgacgc	cgtcaaggcc	tgctttgaag	gcaagggtccc	ccgtttcgggt	1080
accacaaagg	gcaacttttg	acacaccctc	gtcgcagccg	gctttgccgg	tatgtgcaag	1140
gtcctcctct	ccatgaagca	tggcatcatc	ccgccacccc	cgggtatcga	tgacgagacc	1200
aagatggacc	ctctcgtcgt	ctccggtgag	gccatcccat	ggccagagac	caacggcgag	1260
cccaagcgcg	ccggtctctc	ggcctttggc	tttgggtggc	ccaacgccc	tgccgtcttt	1320
gaggagcatg	acccctccaa	cgccgcctgc	acggggccacg	actccatttc	tgcgctctcg	1380
gcccgtgctg	gcggtgaaa	caacatgcgc	atcgccatca	ctggtatgga	cgccaccttt	1440
ggcgctctca	agggactcga	cgccttcgag	cgcgccattt	acaccggcgc	tcacgggtgcc	1500
atcccactcc	cagaaaagcg	ctggcgcttt	ctcggcaagg	acaaggactt	tcttgacctc	1560
tgcggcgtca	aggccacccc	gcacggctgc	tacattgaag	atgttgaggt	cgacttccag	1620
cgcctccgca	cgcccatgac	ccctgaagac	atgctcctcc	ctcagcagct	tctggccgctc	1680
accaccattg	accgcgcat	cctcgactcg	ggaatgaaaa	agggtggcaa	tgctcgccgctc	1740
tttgtcggcc	tcggcaccga	cctcgagctc	taccgtcacc	gtgctcgcgt	cgctctcaag	1800
gagcgcgtcc	gccctgaagc	ctccaagaag	ctcaatgaca	tgatgcagta	cattaacgac	1860

2997-49-2-pct_ST25

tgcggcacat	ccacatcgta	cacctcgta	attggcaacc	tcgtcgccac	gcgcgtctcg	1920
tcgcagtggg	gcttcacggg	cccctccttt	acgatcaccg	agggaacaa	ctccgtctac	1980
cgctgcgccg	agctcggcaa	gtacctctc	gagaccggcg	aggtcgatgg	cgctcgtcgtt	2040
gcgggtgtcg	atctctgcgg	cagtgccgaa	aacctttacg	tcaagtctcg	ccgcttcaag	2100
gtgtccacct	ccgatacccc	gcgcgccagc	tttgacgccg	ccgccgatgg	ctactttgtc	2160
ggcgagggct	gcgggtgcctt	tgtgctcaag	cgtgagacta	gctgcaccaa	ggacgaccgt	2220
atctacgctt	gcatggatgc	catcgtccct	ggcaacgtcc	ctagcgcttg	cttgcgcgag	2280
gccctcgacc	aggcgcgctg	caagccgggc	gatatcgaga	tgctcgagct	cagcgccgac	2340
tccgcccgcc	acctcaagga	cccgtccgtc	ctgcccgaag	agctcactgc	cgaggaggaa	2400
atcggcgggc	ttcagacgat	ccttcgtgac	gatgacaagc	tcccgcgcaa	cgtcgcaacg	2460
ggcagtgtca	aggccaccgt	cgggtgacacc	ggttatgcct	ctggtgctgc	cagcctcatc	2520
aaggctgctc	tttgcatcta	caaccgctac	ctgcccagca	acggcgacga	ctgggatgaa	2580
cccgcccctg	aggcgccctg	ggacagcacc	ctctttgcgt	gccagacctc	gcgcgcttgg	2640
ctcaagaacc	ctggcgagcg	tcgctatgcg	gccgtctcgg	gcgtctccga	gacgcgctcg	2700
tgctattccg	tgctcctctc	cgaagccgag	ggccactacg	agcgcgagaa	ccgcatctcg	2760
ctcgacgagg	aggcgcccaa	gctcattgtg	cttcgcgccg	actcccacga	ggagatcctt	2820
ggtcgcctcg	acaagatccg	cgagcgcttc	ttgcagccca	cgggcgccgc	ccgcgcgag	2880
tccgagctca	aggcgaggc	ccgccgcata	ttcctcgagc	tcctcggcga	gacccttgcc	2940
caggatgccg	cttcttcagg	ctcgcaaaag	cccctcgctc	tcagcctcgt	ctccacgccc	3000
tccaagctcc	agcgcgaggt	cgagctcgcg	gccaaaggta	tcccgcgctg	cctcaagatg	3060
cgccgcgatt	ggagctcccc	tgctggcagc	cgctacgcgc	ctgagccgct	cgccagcgac	3120
cgctgcctt	tcatgtacgg	cgaaggctgc	agcccttact	acggcatcac	ccaagacatt	3180
caccgcattt	ggcccgaact	ccacgaggtc	atcaacgaaa	agacgaaccg	tctctggggc	3240
gaaggcgacc	gctgggtcat	gccgcgcgcc	agcttcaagt	cggagctcga	gagccagcag	3300
caagagtttg	atcgcaacat	gattgaaatg	ttcgtcttg	gaatcctcac	ctcaattgcc	3360
ttcaccaatc	tggcgcgga	cgttctcaac	atcacgcca	aggccgcctt	tggcctcagt	3420
cttggcgaga	tttccatgat	ttttgccttt	tccaagaaga	acggtctcat	ctccgaccag	3480
ctcaccaagg	atcttcgga	gtccgacgtg	tggaacaagg	ctctggccgt	tgaatttaat	3540
gcgctgcgcg	aggcctgggg	cattccacag	agtgtcccca	aggacgagtt	ctggcaaggc	3600
tacattgtgc	gcggcaccaa	gcaggatatc	gaggcggcca	tcgccccgga	cagcaagtac	3660
gtgcgcctca	ccatcatcaa	tgatgccaac	accgccctca	ttagcgga	gcccgcgcgc	3720
tgcaaggctg	cgatcgcgcg	tctcggtggc	aacattcctg	cgcttcccgt	gacccagggc	3780
atgtgcggcc	actgccccga	ggtgggacct	tataccaagg	atatcgccaa	gatccatgcc	3840
aaccttgagt	tccccgttgt	cgacggcctt	gacctctgga	ccacaatcaa	ccagaagcgc	3900

2997-49-2-pct_ST25

ctcgtgccac	gcgccacggg	cgccaaggac	gaatgggccc	cttcttcctt	tggcgagtac	3960
gccggccagc	tctacgagaa	gcaggctaac	ttcccccaaa	tcgtcgagac	cattttacaag	4020
caaaactacg	acgtctttgt	cgaggttggg	cccaacaacc	accgtagcac	cgcagtgcgc	4080
accacgcttg	gtccccagcg	caaccacctt	gctggcgcca	tcgacaagca	gaacgaggat	4140
gcttggacga	ccatcgtcaa	gcttgtggct	tcgtcaagg	cccaccttgt	tcctggcgtc	4200
acgatctcgc	cgctgtacca	ctccaagctt	gtggcggagg	ctgaggcttg	ctacgctcgc	4260
ctctgcaagg	gtgaaaagcc	caagaagaac	aagtttgtgc	gcaagattca	gctcaacggt	4320
cgcttcaaca	gcaaggcgga	ccccatctcc	tcggccgata	ttgccagctt	tccgcctgcg	4380
gaccttgcca	ttgaagccgc	catctcgagc	cgcatcatga	agccggttgc	tccgaagtcc	4440
tacgcgcgtc	tcaacattga	cgagcaggac	gagaccctgt	atccgatcct	caacaaggac	4500
aacgcgccgt	cttcagctc	tagctcctct	tccagctctt	ccagctcttc	cagcccgtcg	4560
ccagctccgt	ccgccccagt	gcaaaagaag	gctgctccgg	ccgcggagac	caaggctggt	4620
gcttcggctg	acgcacttcg	cagtgccttg	ctcgatctcg	acagtatgct	tgcgctgagc	4680
tctgccagtg	cctccggcaa	ccttgttgag	actgcgctta	gcgacgcctc	ggtcattgtg	4740
ccgcccgtga	acattgcgga	tctcggcagc	cgcgccctta	tgaaaacgta	cggtgtttcg	4800
gcgcctctgt	acacgggctc	catggccaag	ggcattgcct	ctgcggacct	cgtcattgcc	4860
gccggccgcc	agggcatcct	tgcgtccttt	ggcgccggcg	gacttcccat	gcaggttgtg	4920
cgtgagtcca	tcgaaaagat	tcaggccgcc	ctgcccaatg	gcccgtacgc	tgtcaacctt	4980
atccattctc	cctttgacag	caacctcgaa	aagggcaatg	tcgatctctt	cctcgagaag	5040
gggtgtcacct	ttgtcgaggc	ctcggccttt	atgacgtca	ccccgcagg	cgtgcggtac	5100
cgcgcggtg	gcctcacgcg	caacgccgac	ggctcgggtca	acatccgcaa	ccgtatcatt	5160
ggcaaggctc	cgcgaccga	gctcgccgag	atgttcatgc	gtcctgcgcc	cgagcacctt	5220
cttcagaagc	tcattgcttc	cggcgagatc	aaccaggagc	aggccgagct	cgcccgcctg	5280
gttcccgtcg	ctgacgacat	cgcggtcgaa	gctgactcgg	gtggccacac	cgacaaccgc	5340
cccatccacg	tcattctgcc	cctcatcatc	aaccttcgcg	accgccttca	ccgcgagtgc	5400
ggctacccgg	ccaaccttcg	cgtccgtgtg	ggcgccggcg	gtggcattgg	gtgccccag	5460
gcggcgctgg	ccaccttcaa	catgggtgcc	tcctttattg	tcaccggcac	cgtgaaccag	5520
gtcgccaagc	agtcgggcac	gtgcgacaat	gtgcgcaagc	agctcgcgaa	ggccacttac	5580
tcggacgtat	gcatggcccc	ggctgccgac	atgttcgagg	aaggcgtcaa	gcttcaggctc	5640
ctcaagaagg	gaacctgtt	tccctcgcgc	gccaaacaagc	tctacgagct	cttttgcaag	5700
tacgactcgt	tcgagtccat	gccccccgca	gagcttgccg	gcgtcgagaa	gcgcattctc	5760
agccgcgcgc	tcgaagaggt	ctgggacgag	acaaaaaact	tttacattaa	ccgtcttcac	5820
aacccggaga	agatccagcg	cgccgagcgc	gaccccaagc	tcaagatgtc	gctgtgcttt	5880
cgctggtacc	tgagcctggc	gagccgctgg	gccaacactg	gagcttccga	tcgcgtcatg	5940

2997-49-2-pct_ST25

gactaccagg tctggtgcgg tcctgccatt ggttccttca acgatttcat caaggggaact 6000
 taccttgatc cggccgtcgc aaacgagtac ccgtgcgtcg ttcagattaa caagcagatc 6060
 cttcgtggag cgtgcttctt gcgccgtctc gaaattctgc gcaacgcacg cctttccgat 6120
 ggcgctgccg ctcttggtggc cagcatcgat gacacatacg tcccggccga gaagctgtaa 6180

<210> 38
 <211> 8436
 <212> DNA
 <213> Thraustochytrium sp.

<220>
 <221> CDS
 <222> (1)..(8433)

<400> 38
 atg aag gac atg gaa gat aga cgg gtc gct att gtg ggc atg tca gct 48
 Met Lys Asp Met Glu Asp Arg Arg Val Ala Ile Val Gly Met Ser Ala
 1 5 10 15
 cac ttg cct tgt ggg aca gat gtg aag gaa tca tgg cag gct att cgc 96
 His Leu Pro Cys Gly Thr Asp Val Lys Glu Ser Trp Gln Ala Ile Arg
 20 25 30
 gat gga atc gac tgt cta agt gac cta ccc gcg gat cgt ctc gac gtt 144
 Asp Gly Ile Asp Cys Leu Ser Asp Leu Pro Ala Asp Arg Leu Asp Val
 35 40 45
 aca gct tac tac aat ccc aac aaa gcc acg aaa gac aag atc tac tgc 192
 Thr Ala Tyr Tyr Asn Pro Asn Lys Ala Thr Lys Asp Lys Ile Tyr Cys
 50 55 60
 aaa cgg ggt ggc ttc atc ccg aac tat gac ttc gac ccc cgc gaa ttt 240
 Lys Arg Gly Gly Phe Ile Pro Asn Tyr Asp Phe Asp Pro Arg Glu Phe
 65 70 75 80
 ggg ctc aac atg ttt caa atg gaa gac tct gat gcg aat cag aca ctt 288
 Gly Leu Asn Met Phe Gln Met Glu Asp Ser Asp Ala Asn Gln Thr Leu
 85 90 95
 acc ttg ctc aaa gtc aaa caa gct ctc gaa gat gca agc ata gag cct 336
 Thr Leu Leu Lys Val Lys Gln Ala Leu Glu Asp Ala Ser Ile Glu Pro
 100 105 110
 ttc acc aag gag aag aag aac att gga tgt gtt tta ggt att ggt ggg 384
 Phe Thr Lys Glu Lys Lys Asn Ile Gly Cys Val Leu Gly Ile Gly Gly
 115 120 125
 ggc caa aag gcg agt cat gag ttc tac tct cgt ctc aac tac gtt gtc 432
 Gly Gln Lys Ala Ser His Glu Phe Tyr Ser Arg Leu Asn Tyr Val Val
 130 135 140
 gtt gaa aag gta ctt cgg aaa atg ggt tta cca gat gct gat gtt gaa 480
 Val Glu Lys Val Leu Arg Lys Met Gly Leu Pro Asp Ala Asp Val Glu
 145 150 155 160
 gaa gct gtg gag aaa tac aag gca aat ttt ccc gag tgg cgc cta gac 528
 Glu Ala Val Glu Lys Tyr Lys Ala Asn Phe Pro Glu Trp Arg Leu Asp
 165 170 175
 tct ttc cct ggg ttt ctt ggg aat gta acg gct ggt cgg tgc agt aac 576
 Ser Phe Pro Gly Phe Leu Gly Asn Val Thr Ala Gly Arg Cys Ser Asn
 180 185 190

2997-49-2-pct_ST25

acc	ttc	aac	atg	gaa	ggt	atg	aac	tgc	ggt	gtg	gat	gct	gca	tgt	gcc	624
Thr	Phe	Asn	Met	Glu	Gly	Met	Asn	Cys	Val	Val	Asp	Ala	Ala	Cys	Ala	
		195					200					205				
agt	tct	cta	att	gca	atc	aag	ggt	gca	ggt	gaa	gag	cta	ctc	ttt	ggt	672
Ser	Ser	Leu	Ile	Ala	Ile	Lys	Val	Ala	Val	Glu	Glu	Leu	Leu	Phe	Gly	
	210					215					220					
gac	tgt	gac	acc	atg	att	gca	ggt	gcc	acc	tgc	acg	gac	aat	tca	ctt	720
Asp	Cys	Asp	Thr	Met	Ile	Ala	Gly	Ala	Thr	Cys	Thr	Asp	Asn	Ser	Leu	
225					230					235					240	
ggc	atg	tac	atg	gcc	ttc	tct	aaa	acg	cca	ggt	ttt	tct	act	gac	cca	768
Gly	Met	Tyr	Met	Ala	Phe	Ser	Lys	Thr	Pro	Val	Phe	Ser	Thr	Asp	Pro	
				245					250					255		
agt	gtc	cgc	gcg	tat	gat	gag	aaa	aca	aaa	ggg	atg	cta	att	gga	gaa	816
Ser	Val	Arg	Ala	Tyr	Asp	Glu	Lys	Thr	Lys	Gly	Met	Leu	Ile	Gly	Glu	
			260					265					270			
ggt	tca	gca	atg	ttc	ggt	ctt	aaa	cgc	tat	gcg	gat	gcc	gta	cgt	gat	864
Gly	Ser	Ala	Met	Phe	Val	Leu	Lys	Arg	Tyr	Ala	Asp	Ala	Val	Arg	Asp	
		275					280					285				
ggc	gac	aca	att	cac	gcg	ggt	ctg	cgt	tct	tgc	tct	tcg	tct	agt	gat	912
Gly	Asp	Thr	Ile	His	Ala	Val	Leu	Arg	Ser	Cys	Ser	Ser	Ser	Ser	Asp	
	290					295					300					
gga	aaa	gcg	gca	gga	att	tat	act	cct	act	ata	tct	gga	caa	gaa	gaa	960
Gly	Lys	Ala	Ala	Gly	Ile	Tyr	Thr	Pro	Thr	Ile	Ser	Gly	Gln	Glu	Glu	
305					310					315					320	
gct	ttg	cgt	cga	gcg	tat	gcc	cgt	gcg	ggg	gta	tgt	cca	tct	acg	atc	1008
Ala	Leu	Arg	Arg	Ala	Tyr	Ala	Arg	Ala	Gly	Val	Cys	Pro	Ser	Thr	Ile	
				325					330					335		
ggg	ctt	ggt	gag	ggt	cac	ggg	aca	ggg	acc	cct	ggt	gga	gat	cgc	att	1056
Gly	Leu	Val	Glu	Gly	His	Gly	Thr	Gly	Thr	Pro	Val	Gly	Asp	Arg	Ile	
			340					345					350			
gag	tta	aca	gct	ctg	cgg	aac	ttg	ttt	gac	aaa	gct	ttt	ggt	agc	aag	1104
Glu	Leu	Thr	Ala	Leu	Arg	Asn	Leu	Phe	Asp	Lys	Ala	Phe	Gly	Ser	Lys	
		355					360					365				
aag	gaa	caa	ata	gca	ggt	ggc	agc	ata	aag	tct	cag	ata	ggt	cac	ctg	1152
Lys	Glu	Gln	Ile	Ala	Val	Gly	Ser	Ile	Lys	Ser	Gln	Ile	Gly	His	Leu	
	370					375					380					
aaa	tct	ggt	gcc	ggc	ttt	gcc	ggc	ttg	gtc	aaa	gct	gtg	ctt	gcg	ctt	1200
Lys	Ser	Val	Ala	Gly	Phe	Ala	Gly	Leu	Val	Lys	Ala	Val	Leu	Ala	Leu	
385					390					395					400	
aaa	cac	aaa	acg	ctc	cca	ggt	tcg	att	aat	gtc	gac	cag	cca	cct	ttg	1248
Lys	His	Lys	Thr	Leu	Pro	Gly	Ser	Ile	Asn	Val	Asp	Gln	Pro	Pro	Leu	
				405					410					415		
ttg	tat	gac	ggt	act	caa	att	caa	gac	tct	tct	tta	tat	atc	aac	aag	1296
Leu	Tyr	Asp	Gly	Thr	Gln	Ile	Gln	Asp	Ser	Ser	Leu	Tyr	Ile	Asn	Lys	
			420					425					430			
aca	aat	aga	cca	tgg	ttt	acg	caa	aac	aag	ctt	ccg	cgt	cgg	gct	ggt	1344
Thr	Asn	Arg	Pro	Trp	Phe	Thr	Gln	Asn	Lys	Leu	Pro	Arg	Arg	Ala	Gly	
		435					440					445				
gtc	tca	agt	ttt	gga	ttt	gga	ggt	gca	aac	tac	cac	gcg	ggt	ctg	gaa	1392
Val	Ser	Ser	Phe	Gly	Phe	Gly	Gly	Ala	Asn	Tyr	His	Ala	Val	Leu	Glu	
	450					455					460					

2997-49-2-pct_ST25																
gaa Glu 465	ttc Phe	gag Glu	ccc Pro	gag Glu	cat His 470	gaa Glu	aaa Lys	cca Pro	tac Tyr	cgc Arg 475	ctc Leu	aat Asn	act Thr	gtt Val	gga Gly 480	1440
cat His	cct Pro	gtc Val	ctc Leu	ttg Leu 485	tac Tyr	gct Ala	ccg Pro	tct Ser	gtg Val 490	gaa Glu	gcc Ala	ctc Leu	aaa Lys	gta Val 495	ctt Leu	1488
tgc Cys	aac Asn	gac Asp	cag Gln 500	ctt Leu	gcg Ala	gag Glu	ctc Leu	aca Thr 505	att Ile	gca Ala	ttg Leu	gaa Glu	gag Glu 510	gca Ala	aaa Lys	1536
aca Thr	cat His	aaa Lys 515	aat Asn	gtt Val	gac Asp	aaa Lys	gtt Val 520	tgt Cys	ggc Gly	tac Tyr	aag Lys	ttt Phe 525	att Ile	gac Asp	gaa Glu	1584
ttt Phe 530	cag Gln	ctc Leu	caa Gln	gga Gly	agc Ser	tgt Cys 535	cct Pro	cca Pro	gaa Glu	aat Asn	ccg Pro 540	aga Arg	gta Val	gga Gly	ttt Phe	1632
tta Leu 545	gca Ala	aca Thr	ctg Leu	cct Pro	act Thr 550	tca Ser	aat Asn	atc Ile	att Ile	gtc Val 555	gcg Ala	ctt Leu	aag Lys	gca Ala	att Ile 560	1680
ctc Leu	gcg Ala	cag Gln	ctt Leu	gat Asp 565	gca Ala	aaa Lys	cca Pro	gat Asp	gcg Ala 570	aag Lys	aaa Lys	tgg Trp	gat Asp	ttg Leu 575	cct Pro	1728
cat His	aaa Lys	aag Lys	gct Ala 580	ttt Phe	ggg Gly	gct Ala	acc Thr	ttc Phe 585	gca Ala	tcg Ser	tct Ser	tca Ser	gtg Val 590	aaa Lys	ggc Gly	1776
tct Ser	gtt Val	gct Ala 595	gcg Ala	ctc Leu	ttc Phe	gca Ala	gga Gly 600	cag Gln	ggt Gly	acc Thr	cag Gln	tac Tyr 605	tta Leu	aac Asn	atg Met	1824
ttc Phe 610	tct Ser	gat Asp	gtg Val	gca Ala	atg Met	aac Asn 615	tgg Trp	cca Pro	ccg Pro	ttc Phe	cgt Arg 620	gac Asp	agc Ser	att Ile	gtc Val	1872
gca Ala 625	atg Met	gaa Glu	gaa Glu	gct Ala	caa Gln 630	act Thr	gag Glu	gta Val	ttt Phe	gag Glu 635	ggc Gly	caa Gln	gtt Val	gaa Glu	cca Pro 640	1920
att Ile	agc Ser	aaa Lys	gtt Val	ctg Leu 645	ttt Phe	cca Pro	cga Arg	gag Glu	cgc Arg 650	tat Tyr	gca Ala	tcc Ser	gaa Glu	agt Ser 655	gaa Glu	1968
cag Gln	ggg Gly	aat Asn	gaa Glu 660	ctt Leu	ctt Leu	tgc Cys	tta Leu	aca Thr 665	gag Glu	tac Tyr	tct Ser	cag Gln	cca Pro 670	act Thr	acg Thr	2016
ata Ile	gca Ala	gcc Ala 675	gca Ala	gta Val	ggg Gly	gcc Ala	ttc Phe 680	gat Asp	att Ile	ttc Phe	aaa Lys	gcg Ala 685	gct Ala	ggc Gly	ttt Phe	2064
aag Lys 690	cca Pro	gac Asp	atg Met	gtt Val	gga Gly	ggg Gly 695	cat His	tca Ser	ctt Leu	ggc Gly	gaa Glu 700	ttt Phe	gct Ala	gct Ala	ttg Leu	2112
tac Tyr 705	gcg Ala	gct Ala	ggg Gly	tcc Ser	att Ile 710	tcg Ser	cgt Arg	gac Asp	gac Asp	ctg Leu 715	tac Tyr	aag Lys	ctt Leu	gtg Val	tgc Cys 720	2160
aaa Lys	cgg Arg	gca Ala	aag Lys	gca Ala 725	atg Met	gcg Ala	aac Asn	gct Ala	agt Ser 730	gac Asp	gga Gly	gct Ala	atg Met	gca Ala 735	gca Ala	2208

2997-49-2-pct_ST25

gtg Val	att Ile	ggc Gly	cca Pro 740	gat Asp	gca Ala	cgt Arg	cta Leu	gtt Val 745	acg Thr	cca Pro	caa Gln	aat Asn	agt Ser 750	gac Asp	gtt Val	2256
tat Tyr	gtc Val	gca Ala 755	aac Asn	ttc Phe	aac Asn	tcc Ser	gca Ala 760	act Thr	caa Gln	gta Val	gtc Val	atc Ile 765	agt Ser	ggc Gly	act Thr	2304
gtt Val	caa Gln 770	ggc Gly	gtg Val	aaa Lys	gaa Glu	gag Glu 775	tcg Ser	aaa Lys	ttg Leu	ctc Leu	att Ile 780	tca Ser	aag Lys	ggg Gly	ttc Phe	2352
cgc Arg 785	gta Val	ctg Leu	cca Pro	ctt Leu	aaa Lys 790	tgc Cys	cag Gln	ggc Gly	gcc Ala	ttc Phe 795	cat His	tct Ser	cct Pro	ttg Leu	atg Met 800	2400
ggg Gly	cct Pro	tct Ser	gag Glu	gat Asp 805	agt Ser	ttc Phe	aaa Lys	tca Ser	ctt Leu 810	gtg Val	gag Glu	act Thr	tgt Cys	acc Thr 815	atc Ile	2448
tcg Ser	ccg Pro	cca Pro	aaa Lys 820	aat Asn	gtg Val	aaa Lys	ttc Phe	ttt Phe 825	tgc Cys	aat Asn	gtt Val	agt Ser	ggc Gly 830	aag Lys	gaa Glu	2496
agc Ser	cca Pro	aac Asn 835	cca Pro	aaa Lys	cag Gln	acc Thr	ctc Leu 840	aag Lys	tca Ser	cac His	atg Met	acg Thr 845	tct Ser	agc Ser	gtt Val	2544
cag Gln	ttc Phe 850	gag Glu	gag Glu	cag Gln	att Ile	cgt Arg 855	aac Asn	atg Met	tac Tyr	gat Asp	gcc Ala 860	gga Gly	gca Ala	cgt Arg	gtt Val	2592
ttt Phe 865	ctg Leu	gag Glu	ttt Phe	gga Gly	ccc Pro 870	cgc Arg	caa Gln	gtc Val	ctt Leu	gca Ala 875	aag Lys	ctt Leu	atc Ile	gcg Ala	gaa Glu 880	2640
atg Met	ttt Phe	ccc Pro	tcg Ser	tgt Cys 885	aca Thr	gct Ala	atc Ile	agc Ser	gtt Val 890	aac Asn	ccc Pro	gcg Ala	agc Ser	agt Ser 895	ggc Gly	2688
gac Asp	agt Ser	gac Asp	gtg Val 900	caa Gln	ctc Leu	cgc Arg	ctc Leu	gcc Ala 905	gcc Ala	gta Val	aaa Lys	ttc Phe	gcg Ala 910	gtc Val	tcg Ser	2736
ggc Gly	gca Ala	gcc Ala 915	ctt Leu	agc Ser	acc Thr	ttt Phe	gat Asp 920	cca Pro	tgg Trp	gag Glu	tat Tyr	cgc Arg 925	aag Lys	cca Pro	caa Gln	2784
gat Asp	ctt Leu 930	ctt Leu	att Ile	cga Arg	aaa Lys	cca Pro 935	cga Arg	aaa Lys	act Thr	gcc Ala	ctt Leu 940	gtt Val	cta Leu	tca Ser	gca Ala	2832
gca Ala 945	aca Thr	tat Tyr	gtt Val	tcc Ser	cca Pro 950	aag Lys	act Thr	ctt Leu	gca Ala	gaa Glu 955	cgt Arg	aaa Lys	aag Lys	gct Ala	atg Met 960	2880
gaa Glu	gat Asp	atc Ile	aag Lys	cta Leu 965	gta Val	tcc Ser	att Ile	aca Thr	cca Pro 970	aga Arg	gat Asp	agt Ser	atg Met	gta Val 975	tca Ser	2928
att Ile	gga Gly	aaa Lys	atc Ile 980	gcg Ala	caa Gln	gaa Glu	gta Val	cgg Arg 985	aca Thr	gct Ala	aaa Lys	cag Gln	cct Pro 990	tta Leu	gaa Glu	2976
acc Thr	gaa Glu	att Ile 995	cga Arg	aga Arg	ctc Leu	aac Asn	aaa Lys 1000	gaa Glu	tta Leu	gaa Glu	cat His	ctc Leu 1005	aag Lys	aga Arg	gag Glu	3024

2997-49-2-pct_ST25

cta Leu	gca Ala 1010	gca Ala	gcc Ala	aaa Lys	gcg Ala	agt Ser 1015	gtc Val	aag Lys	tct Ser	gca Ala	tca Ser 1020	aaa Lys	agc Ser	tct Ser	3069
aaa Lys	gag Glu 1025	cga Arg	tct Ser	gtc Val	cta Leu	tca Ser 1030	aag Lys	cac His	cgc Arg	gct Ala	ttg Leu 1035	ctt Leu	caa Gln	aac Asn	3114
att Ile 1040	ttg Leu	caa Gln	gac Asp	tac Tyr	gat Asp	gat Asp 1045	ctt Leu	cg Arg	gtg Val	gtg Val	cca Pro 1050	ttc Phe	gct Ala	gtt Val	3159
cgt Arg 1055	tct Ser	gtt Val	gca Ala	gtg Val	gac Asp	aac Asn 1060	acc Thr	gcg Ala	ccg Pro	tat Tyr	gct Ala 1065	gac Asp	caa Gln	gtt Val	3204
tcg Ser 1070	acc Thr	cca Pro	gcg Ala	tca Ser	gag Glu	cg Arg 1075	tcg Ser	gct Ala	tca Ser	ccg Pro	ctt Leu 1080	ttc Phe	gag Glu	aaa Lys	3249
cg Arg 1085	agt Ser	tcg Ser	gtt Val	tcg Ser	tca Ser	gca Ala 1090	cg Arg	ctc Leu	gct Ala	gaa Glu	gct Ala 1095	gaa Glu	gcc Ala	gcg Ala	3294
gta Val 1100	ctg Leu	agc Ser	gtt Val	ctc Leu	gca Ala	gac Asp 1105	aag Lys	aca Thr	ggc Gly	tac Tyr	gac Asp 1110	agc Ser	tca Ser	atg Met	3339
atc Ile 1115	gag Glu	atg Met	gac Asp	atg Met	gac Asp	ctg Leu 1120	gag Glu	agt Ser	gag Glu	ctt Leu	ggc Gly 1125	gtt Val	gat Asp	agc Ser	3384
atc Ile 1130	aaa Lys	cg Arg	gtg Val	gag Glu	atc Ile	atg Met 1135	agc Ser	gag Glu	gtt Val	caa Gln	acg Thr 1140	ctg Leu	ctc Leu	agc Ser	3429
gtg Val 1145	gaa Glu	gtc Val	tcc Ser	gac Asp	gtt Val	gac Asp 1150	gct Ala	ctg Leu	tca Ser	aga Arg	acc Thr 1155	aag Lys	act Thr	gtt Val	3474
ggc Gly 1160	gac Asp	gtc Val	atc Ile	gag Glu	gcg Ala	atg Met 1165	aag Lys	ctg Leu	gaa Glu	ctc Leu	ggc Gly 1170	gga Gly	ccc Pro	caa Gln	3519
ggc Gly 1175	cag Gln	act Thr	ttg Leu	acc Thr	gcg Ala	gaa Glu 1180	tcg Ser	atc Ile	cg Arg	cag Gln	cca Pro 1185	ccg Pro	gtg Val	tcc Ser	3564
gag Glu 1190	cct Pro	gct Ala	gta Val	ccg Pro	acc Thr	tca Ser 1195	tcg Ser	tca Ser	agc Ser	agt Ser	att Ile 1200	gct Ala	aat Asn	gtt Val	3609
tcg Ser 1205	tca Ser	gca Ala	cg Arg	ctc Leu	gct Ala	gaa Glu 1210	gct Ala	gaa Glu	gct Ala	gcg Ala	gta Val 1215	ctg Leu	agc Ser	gtt Val	3654
ctc Leu 1220	gca Ala	gac Asp	aag Lys	aca Thr	ggc Gly	tac Tyr 1225	gac Asp	agc Ser	tca Ser	atg Met	atc Ile 1230	gag Glu	atg Met	gac Asp	3699
atg Met 1235	gac Asp	ctg Leu	gag Glu	agc Ser	gag Glu	ctt Leu 1240	ggc Gly	gtt Val	gat Asp	agc Ser	atc Ile 1245	aaa Lys	cg Arg	gtg Val	3744
gag Glu 1250	atc Ile	atg Met	agc Ser	gag Glu	gtt Val	caa Gln 1255	acg Thr	ctg Leu	ctc Leu	agc Ser	gtg Val 1260	gaa Glu	gtc Val	tcc Ser	3789

2997-49-2-pct_ST25															
gac Asp	gtt Val 1265	gac Asp	gct Ala	ctg Leu	tca Ser	aga Arg 1270	act Thr	aag Lys	act Thr	gtt Val	ggc Gly 1275	gac Asp	gtc Val	atc Ile	3834
gag Glu	gcg Ala 1280	atg Met	aag Lys	ctg Leu	gaa Glu	ctc Leu 1285	ggg Gly	gga Gly	ccc Pro	caa Gln	ggc Gly 1290	cag Gln	act Thr	ttg Leu	3879
acc Thr	gcg Ala 1295	gaa Glu	tcg Ser	atc Ile	cgt Arg	cag Gln 1300	cca Pro	ccg Pro	gtg Val	tct Ser	gag Glu 1305	cct Pro	gct Ala	gta Val	3924
ccg Pro	acc Thr 1310	tca Ser	tcg Ser	tca Ser	agc Ser	agt Ser 1315	att Ile	gct Ala	aat Asn	gtt Val	tcg Ser 1320	tca Ser	gca Ala	cgc Arg	3969
ctc Leu	gct Ala 1325	gaa Glu	gct Ala	gaa Glu	gcg Ala	gcg Ala 1330	gta Val	ctg Leu	agc Ser	gtt Val	ctc Leu 1335	gca Ala	gac Asp	aag Lys	4014
aca Thr	ggc Gly 1340	tac Tyr	gac Asp	agc Ser	tca Ser	atg Met 1345	atc Ile	gag Glu	atg Met	gac Asp	atg Met 1350	gac Asp	ctg Leu	gag Glu	4059
agc Ser	gag Glu 1355	ctt Leu	ggc Gly	gtc Val	gac Asp	agc Ser 1360	atc Ile	aaa Lys	cgc Arg	gtg Val	gag Glu 1365	atc Ile	atg Met	agc Ser	4104
gag Glu	gtt Val 1370	caa Gln	acg Thr	ctg Leu	ctc Leu	agc Ser 1375	gtg Val	gaa Glu	gtc Val	tcc Ser	gac Asp 1380	gtt Val	gac Asp	gct Ala	4149
ctg Leu	tca Ser 1385	aga Arg	acc Thr	aag Lys	act Thr	gtt Val 1390	ggc Gly	gac Asp	gtc Val	atc Ile	gag Glu 1395	gcg Ala	atg Met	aag Lys	4194
ctg Leu	gaa Glu 1400	ctc Leu	ggg Gly	gga Gly	ccc Pro	caa Gln 1405	ggc Gly	cag Gln	act Thr	ttg Leu	acc Thr 1410	gcg Ala	gaa Glu	tcg Ser	4239
atc Ile	cgt Arg 1415	cag Gln	cca Pro	ccg Pro	gtg Val	tcc Ser 1420	gag Glu	cct Pro	gct Ala	gta Val	ccg Pro 1425	acc Thr	tca Ser	tcg Ser	4284
tca Ser	agc Ser 1430	agt Ser	att Ile	gct Ala	aat Asn	gtt Val 1435	ttg Leu	tca Ser	gca Ala	cgc Arg	ctc Leu 1440	gct Ala	gaa Glu	gct Ala	4329
gaa Glu	gcc Ala 1445	gcg Ala	gta Val	ctg Leu	agc Ser	gtt Val 1450	ctc Leu	gca Ala	gac Asp	aag Lys	aca Thr 1455	ggc Gly	tac Tyr	gac Asp	4374
agc Ser	tca Ser 1460	atg Met	atc Ile	gag Glu	atg Met	gac Asp 1465	atg Met	gac Asp	ctg Leu	gag Glu	agc Ser 1470	gag Glu	ctt Leu	ggc Gly	4419
gtt Val	gat Asp 1475	agc Ser	atc Ile	aaa Lys	cgc Arg	gtg Val 1480	gag Glu	atc Ile	atg Met	agc Ser	gag Glu 1485	gtt Val	caa Gln	acg Thr	4464
ttg Leu	ctc Leu 1490	agc Ser	gtg Val	gaa Glu	gtc Val	tcc Ser 1495	gac Asp	gtt Val	gac Asp	gct Ala	ctg Leu 1500	tca Ser	aga Arg	acc Thr	4509
aag Lys	act Thr 1505	gtt Val	ggc Gly	gac Asp	gtc Val	atc Ile 1510	gag Glu	gcg Ala	atg Met	aag Lys	ctg Leu 1515	gaa Glu	ctc Leu	ggg Gly	4554

2997-49-2-pct_ST25															
gga Gly	ccc Pro 1520	caa Gln	ggc Gly	cag Gln	act Thr	ttg Leu 1525	acc Thr	gcg Ala	gaa Glu	tcg Ser	atc Ile 1530	cgt Arg	cag Gln	cca Pro	4599
ccg Pro	gtg Val 1535	tct Ser	gag Glu	cct Pro	gct Ala	gta Val 1540	ccg Pro	acc Thr	tca Ser	tcg Ser	tca Ser 1545	agc Ser	agt Ser	att Ile	4644
gct Ala	aat Asn 1550	gtt Val	tcg Ser	tca Ser	gca Ala	cgc Arg 1555	ctc Leu	gct Ala	gaa Glu	gct Ala	gaa Glu 1560	gcc Ala	gcg Ala	gta Val	4689
ctg Leu	agc Ser 1565	gtt Val	ctc Leu	gca Ala	gac Asp	aag Lys 1570	aca Thr	ggc Gly	tac Tyr	gac Asp	agc Ser 1575	tca Ser	atg Met	atc Ile	4734
gag Glu	atg Met 1580	gac Asp	atg Met	gac Asp	ctg Leu	gag Glu 1585	agt Ser	gag Glu	ctt Leu	ggc Gly	gtc Val 1590	gac Asp	agc Ser	atc Ile	4779
aaa Lys	cgc Arg 1595	gtg Val	gag Glu	atc Ile	atg Met	agc Ser 1600	gag Glu	gtt Val	caa Gln	acg Thr	ctg Leu 1605	ctc Leu	agc Ser	gtg Val	4824
gaa Glu	gtc Val 1610	tcc Ser	gac Asp	gtt Val	gac Asp	gct Ala 1615	ctg Leu	tca Ser	aga Arg	acc Thr	aag Lys 1620	act Thr	gtt Val	ggc Gly	4869
gac Asp	gtc Val 1625	atc Ile	gag Glu	gcg Ala	atg Met	aag Lys 1630	ctg Leu	gaa Glu	ctc Leu	ggc Gly	gga Gly 1635	ccc Pro	caa Gln	ggc Gly	4914
cag Gln	act Thr 1640	ttg Leu	acc Thr	tct Ser	gaa Glu	ccg Pro 1645	atc Ile	cat His	cag Gln	cca Pro	cca Pro 1650	gtg Val	tcc Ser	gag Glu	4959
cct Pro	gct Ala 1655	gta Val	ccg Pro	acc Thr	tca Ser	tcg Ser 1660	tca Ser	agc Ser	agt Ser	att Ile	gct Ala 1665	aat Asn	gtt Val	tct Ser	5004
tca Ser	gca Ala 1670	cgc Arg	ctc Leu	gct Ala	gaa Glu	gct Ala 1675	gaa Glu	gcc Ala	gcg Ala	gta Val	ctg Leu 1680	agc Ser	gtt Val	ctc Leu	5049
gca Ala	gac Asp 1685	aag Lys	aca Thr	ggc Gly	tac Tyr	gac Asp 1690	agc Ser	tca Ser	atg Met	atc Ile	gag Glu 1695	atg Met	gac Asp	atg Met	5094
gac Asp	ctg Leu 1700	gag Glu	agc Ser	gag Glu	ctt Leu	ggc Gly 1705	gtt Val	gat Asp	agc Ser	atc Ile	aaa Lys 1710	cgc Arg	gtg Val	gaa Glu	5139
atc Ile	atg Met 1715	agc Ser	gag Glu	gtt Val	caa Gln	acg Thr 1720	ctg Leu	ctc Leu	agc Ser	gtg Val	gaa Glu 1725	gtc Val	tcc Ser	gac Asp	5184
gtt Val	gac Asp 1730	gct Ala	ctg Leu	tca Ser	aga Arg	acc Thr 1735	aag Lys	act Thr	gtt Val	ggc Gly	gac Asp 1740	gtc Val	atc Ile	gag Glu	5229
gcg Ala	atg Met 1745	aag Lys	atg Met	gaa Glu	ctc Leu	ggc Gly 1750	gga Gly	ccc Pro	caa Gln	ggc Gly	cag Gln 1755	act Thr	ttg Leu	acc Thr	5274
gcg Ala	gaa Glu 1760	tcg Ser	atc Ile	cgt Arg	cag Gln	cca Pro 1765	ccg Pro	gtg Val	tct Ser	gag Glu	cct Pro 1770	gct Ala	gta Val	ccg Pro	5319

2997-49-2-pct_ST25															
acc Thr	tca Ser 1775	tcg Ser	tca Ser	agc Ser	agt Ser	att Ile 1780	gct Ala	aat Asn	gtt Val	tcg Ser	tca Ser 1785	gca Ala	cgc Arg	ctc Leu	5364
gct Ala	gaa Glu 1790	gct Ala	gaa Glu	gcg Ala	gcg Ala	gta Val 1795	ctg Leu	agc Ser	gtt Val	ctc Leu	gca Ala 1800	gac Asp	aag Lys	aca Thr	5409
ggc Gly	tac Tyr 1805	gac Asp	agc Ser	tca Ser	atg Met	atc Ile 1810	gag Glu	atg Met	gac Asp	atg Met	gac Asp 1815	ctg Leu	gag Glu	agc Ser	5454
gag Glu	ctt Leu 1820	ggc Gly	gtt Val	gat Asp	agc Ser	atc Ile 1825	aaa Lys	cgc Arg	gtg Val	gag Glu	atc Ile 1830	atg Met	agc Ser	gag Glu	5499
gtt Val	caa Gln 1835	gcg Ala	ctg Leu	ctc Leu	agc Ser	gtg Val 1840	gaa Glu	gtc Val	tcc Ser	gac Asp	gtt Val 1845	gac Asp	gct Ala	ctg Leu	5544
tca Ser	aga Arg 1850	acc Thr	aag Lys	act Thr	gtt Val	ggc Gly 1855	gac Asp	gtc Val	atc Ile	gag Glu	gcg Ala 1860	atg Met	aag Lys	atg Met	5589
gaa Glu	ctc Leu 1865	ggc Gly	gga Gly	ccc Pro	caa Gln	ggc Gly 1870	cag Gln	act Thr	ttg Leu	acc Thr	gca Ala 1875	gaa Glu	tcg Ser	atc Ile	5634
cgt Arg	gag Glu 1880	cca Pro	ccg Pro	gtg Val	tct Ser	gag Glu 1885	cct Pro	gct Ala	gta Val	ccg Pro	acc Thr 1890	tca Ser	tcg Ser	tca Ser	5679
agt Ser	agt Ser 1895	atc Ile	gct Ala	aat Asn	gtt Val	tct Ser 1900	tca Ser	gct Ala	cgc Arg	ctc Leu	gct Ala 1905	gaa Glu	gct Ala	gaa Glu	5724
gcc Ala	gcg Ala 1910	gta Val	ctg Leu	agc Ser	gtt Val	ctc Leu 1915	gca Ala	gac Asp	aag Lys	aca Thr	ggc Gly 1920	tac Tyr	gac Asp	agc Ser	5769
tca Ser	atg Met 1925	atc Ile	gag Glu	atg Met	gac Asp	atg Met 1930	gac Asp	ctg Leu	gag Glu	agt Ser	gag Glu 1935	ctt Leu	ggc Gly	gtc Val	5814
gac Asp	agc Ser 1940	atc Ile	aaa Lys	cgc Arg	gtg Val	gag Glu 1945	atc Ile	atg Met	agc Ser	gag Glu	gtt Val 1950	caa Gln	acg Thr	ttg Leu	5859
ctc Leu	agc Ser 1955	gtg Val	gaa Glu	gtc Val	tcc Ser	gac Asp 1960	gtt Val	gac Asp	gct Ala	ctg Leu	tca Ser 1965	aga Arg	acc Thr	aag Lys	5904
act Thr	gtt Val 1970	ggc Gly	gac Asp	gtc Val	atc Ile	gag Glu 1975	gcg Ala	atg Met	aag Lys	ctg Leu	gaa Glu 1980	ctt Leu	ggg Gly	gaa Glu	5949
tca Ser	tca Ser 1985	agt Ser	att Ile	gag Glu	act Thr	ctc Leu 1990	aat Asn	tgt Cys	acc Thr	gag Glu	gtt Val 1995	gag Glu	cac His	acg Thr	5994
agc Ser	tac Tyr 2000	aaa Lys	agt Ser	gtc Val	aag Lys	gct Ala 2005	tca Ser	ggg Gly	tgt Cys	gag Glu	aat Asn 2010	gta Val	gat Asp	acc Thr	6039
cgt Arg	ttc Phe 2015	gct Ala	aag Lys	gtt Val	gta Val	caa Gln 2020	atc Ile	tcg Ser	ctt Leu	cct Pro	agc Ser 2025	aag Lys	ctg Leu	aaa Lys	6084

2997-49-2-pct_ST25

tcc Ser	act Thr 2030	gtg Val	tcg Ser	cac His	gat Asp	cga Arg 2035	cct Pro	gta Val	att Ile	gtt Val	gta Val 2040	gat Asp	gat Asp	gga Gly	6129
acg Thr	ccc Pro 2045	tta Leu	acc Thr	acg Thr	gag Glu	ctt Leu 2050	tgt Cys	aaa Lys	att Ile	ctt Leu	ggg Gly 2055	ggg Gly	aat Asn	att Ile	6174
gtg Val	gtt Val 2060	ctc Leu	tct Ser	tat Tyr	caa Gln	ggg Gly 2065	aag Lys	ccc Pro	gct Ala	ggg Gly	cca Pro 2070	cgg Arg	gga Gly	gtc Val	6219
gag Glu	gtg Val 2075	cca Pro	gat Asp	ctt Leu	tcc Ser	gag Glu 2080	gaa Glu	gcc Ala	cta Leu	att Ile	caa Gln 2085	gct Ala	ctt Leu	gca Ala	6264
ttg Leu	att Ile 2090	cgg Arg	tct Ser	aca Thr	tat Tyr	gga Gly 2095	gtt Val	cca Pro	att Ile	ggg Gly	ttt Phe 2100	att Ile	tgt Cys	cag Gln	6309
caa Gln	gtg Val 2105	tct Ser	aat Asn	gtg Val	agc Ser	acc Thr 2110	aag Lys	gca Ala	cag Gln	ctt Leu	tgt Cys 2115	tgg Trp	gca Ala	ctc Leu	6354
ctc Leu	gca Ala 2120	gcg Ala	aag Lys	cat His	ctc Leu	aag Lys 2125	aag Lys	gat Asp	ttg Leu	aat Asn	gct Ala 2130	gtc Val	tta Leu	ccc Pro	6399
gat Asp	tca Ser 2135	aga Arg	tcc Ser	ttc Phe	ttc Phe	gtc Val 2140	gga Gly	gtt Val	gta Val	cgc Arg	ttg Leu 2145	aac Asn	ggg Gly	aaa Lys	6444
ctt Leu	gga Gly 2150	act Thr	ttc Phe	gaa Glu	aac Asn	atc Ile 2155	agc Ser	gac Asp	ttc Phe	tct Ser	aaa Lys 2160	ttt Phe	gat Asp	ttg Leu	6489
acg Thr	aaa Lys 2165	gcc Ala	cta Leu	gat Asp	tac Tyr	gga Gly 2170	cag Gln	cgt Arg	ggg Gly	tct Ser	ctc Leu 2175	tta Leu	ggc Gly	ctg Leu	6534
tgc Cys	aag Lys 2180	tca Ser	cta Leu	gac Asp	tta Leu	gaa Glu 2185	tgg Trp	gaa Glu	cag Gln	gtg Val	ttt Phe 2190	tgc Cys	cgt Arg	gga Gly	6579
ata Ile	gat Asp 2195	ctt Leu	gcg Ala	tgt Cys	gat Asp	ctt Leu 2200	atg Met	cca Pro	ctc Leu	cag Gln	gcc Ala 2205	gca Ala	agg Arg	ata Ile	6624
ctc Leu	aga Arg 2210	aat Asn	gag Glu	ctt Leu	cag Gln	tgt Cys 2215	ccc Pro	aat Asn	atg Met	cgc Arg	ctt Leu 2220	cgc Arg	gag Glu	gtt Val	6669
ggg Gly	tac Tyr 2225	gat Asp	att Ile	tct Ser	ggc Gly	gcc Ala 2230	agg Arg	tac Tyr	acc Thr	att Ile	tca Ser 2235	acc Thr	gat Asp	gac Asp	6714
ctg Leu	cta Leu 2240	tgt Cys	gga Gly	ccc Pro	tcg Ser	aag Lys 2245	gct Ala	aaa Lys	gta Val	gag Glu	gcc Ala 2250	gca Ala	gac Asp	ttg Leu	6759
ttt Phe	ctt Leu 2255	gtg Val	aca Thr	ggg Gly	ggc Gly	gca Ala 2260	cga Arg	ggg Gly	att Ile	aca Thr	cct Pro 2265	cat His	tgt Cys	gtt Val	6804
cgt Arg	gag Glu 2270	att Ile	gca Ala	agt Ser	cga Arg	tcc Ser 2275	ccc Pro	gga Gly	acc Thr	aca Thr	ttt Phe 2280	gtg Val	ctg Leu	gtt Val	6849

2997-49-2-pct_ST25															
gga Gly	aga Arg 2285	agc Ser	gaa Glu	atg Met	tcc Ser	gac Asp 2290	gag Glu	cct Pro	gac Asp	tgg Trp	gct Ala 2295	gtt Val	ggc Gly	cac His	6894
tac Tyr	aat Asn 2300	aaa Lys	gac Asp	ctg Leu	gac Asp	caa Gln 2305	agc Ser	aca Thr	atg Met	aaa Lys	cac His 2310	ttg Leu	aaa Lys	gca Ala	6939
acg Thr	cat His 2315	gct Ala	gct Ala	gga Gly	ggg Gly	gta Val 2320	aaa Lys	cct Pro	acg Thr	cct Pro	aaa Lys 2325	gca Ala	cat His	cgt Arg	6984
gca Ala	ctt Leu 2330	gtg Val	aac Asn	agg Arg	gtc Val	act Thr 2335	ggc Gly	tca Ser	cgg Arg	gag Glu	gta Val 2340	cga Arg	gaa Glu	tct Ser	7029
ctt Leu	aga Arg 2345	gca Ala	atc Ile	cag Gln	gag Glu	gca Ala 2350	ggg Gly	gca Ala	aat Asn	gtc Val	gaa Glu 2355	tat Tyr	atc Ile	gcc Ala	7074
tgt Cys	gat Asp 2360	gtt Val	tcg Ser	gat Asp	gaa Glu	aac Asn 2365	aag Lys	gtc Val	cgc Arg	caa Gln	ctt Leu 2370	gtg Val	caa Gln	aga Arg	7119
gtg Val	gag Glu 2375	caa Gln	aag Lys	tat Tyr	ggc Gly	tgt Cys 2380	gaa Glu	ata Ile	act Thr	ggg Gly	att Ile 2385	tggt Trp	cat His	gca Ala	7164
agc Ser	ggg Gly 2390	gtt Val	ctt Leu	cgt Arg	gac Asp	aaa Lys 2395	ctt Leu	gtc Val	gag Glu	caa Gln	aag Lys 2400	act Thr	aca Thr	gac Asp	7209
gac Asp	ttt Phe 2405	gag Glu	gca Ala	gtt Val	ttt Phe	ggg Gly 2410	acc Thr	aag Lys	gtg Val	act Thr	ggc Gly 2415	ctt Leu	gta Val	aac Asn	7254
atc Ile	gtg Val 2420	tca Ser	caa Gln	gtc Val	aat Asn	atg Met 2425	tct Ser	aag Lys	cta Leu	cga Arg	cac His 2430	ttc Phe	atc Ile	ctc Leu	7299
ttc Phe	agt Ser 2435	tct Ser	ttg Leu	gct Ala	gga Gly	ttt Phe 2440	cat His	ggg Gly	aac Asn	aag Lys	ggc Gly 2445	caa Gln	acg Thr	gat Asp	7344
tat Tyr	gca Ala 2450	att Ile	gct Ala	aat Asn	gaa Glu	gcc Ala 2455	ttg Leu	aac Asn	aaa Lys	atc Ile	gcg Ala 2460	cat His	act Thr	ctc Leu	7389
tca Ser	gcg Ala 2465	ttt Phe	ttg Leu	ccc Pro	aaa Lys	ctg Leu 2470	aat Asn	gca Ala	aag Lys	gtg Val	cta Leu 2475	gac Asp	ttc Phe	ggg Gly	7434
ccg Pro	tggt Trp 2480	gta Val	ggg Gly	tca Ser	gga Gly	atg Met 2485	gta Val	acc Thr	gaa Glu	aca Thr	ctt Leu 2490	gag Glu	aag Lys	cat His	7479
ttt Phe	aaa Lys 2495	gct Ala	atg Met	ggg Gly	gtt Val	cag Gln 2500	act Thr	att Ile	cct Pro	ctc Leu	gag Glu 2505	cca Pro	gga Gly	gca Ala	7524
cggt Arg	act Thr 2510	gtt Val	gcg Ala	caa Gln	atc Ile	att Ile 2515	ttg Leu	gca Ala	agt Ser	tcg Ser	cca Pro 2520	ccg Pro	caa Gln	tcg Ser	7569
ctt Leu	ttg Leu 2525	ggg Gly	aac Asn	tggt Trp	ggc Gly	ttt Phe 2530	cca Pro	gcc Ala	acc Thr	aaa Lys	ccg Pro 2535	cta Leu	caa Gln	cgc Arg	7614

2997-49-2-pct_ST25															
tct Ser	aat Asn 2540	gta Val	gtc Val	acg Thr	ggc Gly	aca Thr 2545	ctc Leu	tct Ser	ccg Pro	gaa Glu	gag Glu 2550	ata Ile	gaa Glu	ttc Phe	7659
atc Ile	gca Ala 2555	gac Asp	cac His	aaa Lys	att Ile	caa Gln 2560	ggc Gly	cgc Arg	aag Lys	gtg Val	ctt Leu 2565	ccc Pro	atg Met	atg Met	7704
gct Ala	gca Ala 2570	atc Ile	ggg Gly	ttc Phe	atg Met	gcc Ala 2575	tct Ser	att Ile	gcg Ala	gaa Glu	gga Gly 2580	ctc Leu	tac Tyr	ccg Pro	7749
ggg Gly	tac Tyr 2585	aat Asn	ctg Leu	caa Gln	ggc Gly	gtg Val 2590	gaa Glu	aat Asn	gct Ala	cag Gln	ctc Leu 2595	ttt Phe	caa Gln	ggc Gly	7794
ttg Leu	act Thr 2600	atc Ile	aac Asn	caa Gln	gag Glu	aca Thr 2605	aaa Lys	ttt Phe	caa Gln	atc Ile	act Thr 2610	ctc Leu	att Ile	gag Glu	7839
gag Glu	cac His 2615	aac Asn	tct Ser	gag Glu	gaa Glu	aac Asn 2620	ctg Leu	gat Asp	gtc Val	ctg Leu	aca Thr 2625	tcc Ser	ctt Leu	ggt Gly	7884
gta Val	atg Met 2630	ttg Leu	gaa Glu	agc Ser	ggg Gly	aag Lys 2635	gtg Val	ctt Leu	ccc Pro	gct Ala	tac Tyr 2640	cga Arg	tgt Cys	gtt Val	7929
gta Val	tgc Cys 2645	ttg Leu	aat Asn	aca Thr	acc Thr	cag Gln 2650	cag Gln	cag Gln	ccc Pro	aag Lys	cta Leu 2655	tct Ser	cca Pro	aaa Lys	7974
att Ile	ctt Leu 2660	aac Asn	ttg Leu	gaa Glu	gtt Val	gac Asp 2665	cct Pro	gca Ala	tgc Cys	gag Glu	gtt Val 2670	aac Asn	ccc Pro	tat Tyr	8019
gat Asp	gga Gly 2675	aag Lys	tcg Ser	ttg Leu	ttc Phe	cac His 2680	ggt Gly	ccg Pro	ctt Leu	ttg Leu	caa Gln 2685	ttc Phe	gtt Val	caa Gln	8064
caa Gln	gtg Val 2690	ttg Leu	cac His	tca Ser	agt Ser	acc Thr 2695	aaa Lys	ggc Gly	ctc Leu	gtt Val	gcc Ala 2700	aag Lys	tgc Cys	cgc Arg	8109
gcg Ala	ctt Leu 2705	cca Pro	atc Ile	aaa Lys	gaa Glu	gcc Ala 2710	atc Ile	cga Arg	ggg Gly	cca Pro	ttt Phe 2715	atc Ile	aag Lys	caa Gln	8154
aca Thr	ctc Leu 2720	cat His	gat Asp	cca Pro	att Ile	cta Leu 2725	gac Asp	gac Asp	gtc Val	att Ile	ttt Phe 2730	cag Gln	cta Leu	atg Met	8199
ctc Leu	gtg Val 2735	tgg Trp	tgt Cys	cgt Arg	aat Asn	gct Ala 2740	cta Leu	gga Gly	agt Ser	gca Ala	tcg Ser 2745	cta Leu	ccc Pro	aac Asn	8244
aga Arg	att Ile 2750	gaa Glu	aag Lys	atg Met	tca Ser	tac Tyr 2755	ttt Phe	ggg Gly	aat Asn	gtc Val	tca Ser 2760	gaa Glu	ggt Gly	agc Ser	8289
act Thr	ttc Phe 2765	ttt Phe	gcc Ala	tca Ser	gtt Val	aca Thr 2770	cct Pro	gtg Val	gga Gly	cca Pro	aga Arg 2775	gta Val	cca Pro	aag Lys	8334
gat Asp	ccc Pro 2780	gtg Val	atc Ile	aaa Lys	atg Met	cag Gln 2785	ttt Phe	ctt Leu	ctc Leu	caa Gln	gat Asp 2790	gaa Glu	tcc Ser	ggc Gly	8379

2997-49-2-pct_ST25
aac aca ttt tca tcg ggg gag ggc tcg gtt gtg ctt agt gac gaa 8424
Asn Thr Phe Ser Ser Gly Glu Gly Ser Val Val Leu Ser Asp Glu
2795 2800 2805

ctc gtc ttt tga 8436
Leu Val Phe
2810

<210> 39
<211> 2811
<212> PRT
<213> Thraustochytrium sp.
<400> 39

Met Lys Asp Met Glu Asp Arg Arg Val Ala Ile Val Gly Met Ser Ala
1 5 10 15

His Leu Pro Cys Gly Thr Asp Val Lys Glu Ser Trp Gln Ala Ile Arg
20 25 30

Asp Gly Ile Asp Cys Leu Ser Asp Leu Pro Ala Asp Arg Leu Asp Val
35 40 45

Thr Ala Tyr Tyr Asn Pro Asn Lys Ala Thr Lys Asp Lys Ile Tyr Cys
50 55 60

Lys Arg Gly Gly Phe Ile Pro Asn Tyr Asp Phe Asp Pro Arg Glu Phe
65 70 75 80

Gly Leu Asn Met Phe Gln Met Glu Asp Ser Asp Ala Asn Gln Thr Leu
85 90 95

Thr Leu Leu Lys Val Lys Gln Ala Leu Glu Asp Ala Ser Ile Glu Pro
100 105 110

Phe Thr Lys Glu Lys Lys Asn Ile Gly Cys Val Leu Gly Ile Gly Gly
115 120 125

Gly Gln Lys Ala Ser His Glu Phe Tyr Ser Arg Leu Asn Tyr Val Val
130 135 140

Val Glu Lys Val Leu Arg Lys Met Gly Leu Pro Asp Ala Asp Val Glu
145 150 155 160

Glu Ala Val Glu Lys Tyr Lys Ala Asn Phe Pro Glu Trp Arg Leu Asp
165 170 175

Ser Phe Pro Gly Phe Leu Gly Asn Val Thr Ala Gly Arg Cys Ser Asn
180 185 190

Thr Phe Asn Met Glu Gly Met Asn Cys Val Val Asp Ala Ala Cys Ala
195 200 205

2997-49-2-pct_ST25

Ser Ser Leu Ile Ala Ile Lys Val Ala Val Glu Glu Leu Leu Phe Gly
 210 215 220
 Asp Cys Asp Thr Met Ile Ala Gly Ala Thr Cys Thr Asp Asn Ser Leu
 225 230 235 240
 Gly Met Tyr Met Ala Phe Ser Lys Thr Pro Val Phe Ser Thr Asp Pro
 245 250 255
 Ser Val Arg Ala Tyr Asp Glu Lys Thr Lys Gly Met Leu Ile Gly Glu
 260 265 270
 Gly Ser Ala Met Phe Val Leu Lys Arg Tyr Ala Asp Ala Val Arg Asp
 275 280 285
 Gly Asp Thr Ile His Ala Val Leu Arg Ser Cys Ser Ser Ser Ser Asp
 290 295 300
 Gly Lys Ala Ala Gly Ile Tyr Thr Pro Thr Ile Ser Gly Gln Glu Glu
 305 310 315 320
 Ala Leu Arg Arg Ala Tyr Ala Arg Ala Gly Val Cys Pro Ser Thr Ile
 325 330 335
 Gly Leu Val Glu Gly His Gly Thr Gly Thr Pro Val Gly Asp Arg Ile
 340 345 350
 Glu Leu Thr Ala Leu Arg Asn Leu Phe Asp Lys Ala Phe Gly Ser Lys
 355 360 365
 Lys Glu Gln Ile Ala Val Gly Ser Ile Lys Ser Gln Ile Gly His Leu
 370 375 380
 Lys Ser Val Ala Gly Phe Ala Gly Leu Val Lys Ala Val Leu Ala Leu
 385 390 395 400
 Lys His Lys Thr Leu Pro Gly Ser Ile Asn Val Asp Gln Pro Pro Leu
 405 410 415
 Leu Tyr Asp Gly Thr Gln Ile Gln Asp Ser Ser Leu Tyr Ile Asn Lys
 420 425 430
 Thr Asn Arg Pro Trp Phe Thr Gln Asn Lys Leu Pro Arg Arg Ala Gly
 435 440 445
 Val Ser Ser Phe Gly Phe Gly Gly Ala Asn Tyr His Ala Val Leu Glu
 450 455 460
 Glu Phe Glu Pro Glu His Glu Lys Pro Tyr Arg Leu Asn Thr Val Gly
 465 470 475 480

2997-49-2-pct_ST25

His Pro Val Leu₄₈₅ Tyr Ala Pro Ser Val₄₉₀ Glu Ala Leu Lys Val₄₉₅ Leu

Cys Asn Asp Gln₅₀₀ Leu Ala Glu Leu Thr₅₀₅ Ile Ala Leu Glu Glu₅₁₀ Ala Lys

Thr His Lys₅₁₅ Asn Val Asp Lys Val₅₂₀ Cys Gly Tyr Lys Phe₅₂₅ Ile Asp Glu

Phe Gln₅₃₀ Leu Gln Gly Ser Cys₅₃₅ Pro Pro Glu Asn Pro₅₄₀ Arg Val Gly Phe

Leu Ala Thr Leu Pro Thr₅₅₀ Ser Asn Ile Ile Val₅₅₅ Ala Leu Lys Ala Ile₅₆₀

Leu Ala Gln Leu Asp₅₆₅ Ala Lys Pro Asp Ala₅₇₀ Lys Lys Trp Asp Leu₅₇₅ Pro

His Lys Lys Ala₅₈₀ Phe Gly Ala Thr Phe₅₈₅ Ala Ser Ser Ser Val₅₉₀ Lys Gly

Ser Val Ala₅₉₅ Ala Leu Phe Ala Gly₆₀₀ Gln Gly Thr Gln Tyr₆₀₅ Leu Asn Met

Phe Ser₆₁₀ Asp Val Ala Met Asn₆₁₅ Trp Pro Pro Phe Arg₆₂₀ Asp Ser Ile Val

Ala Met Glu Glu Ala Gln₆₃₀ Thr Glu Val Phe Glu₆₃₅ Gly Gln Val Glu Pro₆₄₀

Ile Ser Lys Val Leu₆₄₅ Phe Pro Arg Glu Arg₆₅₀ Tyr Ala Ser Glu Ser₆₅₅ Glu

Gln Gly Asn Glu₆₆₀ Leu Leu Cys Leu Thr₆₆₅ Glu Tyr Ser Gln Pro₆₇₀ Thr Thr

Ile Ala Ala Ala Val Gly Ala Phe₆₈₀ Asp Ile Phe Lys Ala₆₈₅ Ala Gly Phe

Lys Pro₆₉₀ Asp Met Val Gly Gly₆₉₅ His Ser Leu Gly Glu₇₀₀ Phe Ala Ala Leu

Tyr Ala Ala Gly Ser Ile₇₁₀ Ser Arg Asp Asp Leu₇₁₅ Tyr Lys Leu Val Cys₇₂₀

Lys Arg Ala Lys Ala₇₂₅ Met Ala Asn Ala Ser₇₃₀ Asp Gly Ala Met Ala₇₃₅ Ala

Val Ile Gly Pro₇₄₀ Asp Ala Arg Leu Val₇₄₅ Thr Pro Gln Asn Ser₇₅₀ Asp Val

2997-49-2-pct_ST25

Tyr Val Ala Asn Phe Asn Ser Ala Thr Gln Val Val Ile Ser Gly Thr
 755 760 765
 Val Gln Gly Val Lys Glu Glu Ser Lys Leu Leu Ile Ser Lys Gly Phe
 770 775 780
 Arg Val Leu Pro Leu Lys Cys Gln Gly Ala Phe His Ser Pro Leu Met
 785 790 795 800
 Gly Pro Ser Glu Asp Ser Phe Lys Ser Leu Val Glu Thr Cys Thr Ile
 805 810 815
 Ser Pro Pro Lys Asn Val Lys Phe Phe Cys Asn Val Ser Gly Lys Glu
 820 825 830
 Ser Pro Asn Pro Lys Gln Thr Leu Lys Ser His Met Thr Ser Ser Val
 835 840 845
 Gln Phe Glu Glu Gln Ile Arg Asn Met Tyr Asp Ala Gly Ala Arg Val
 850 855 860
 Phe Leu Glu Phe Gly Pro Arg Gln Val Leu Ala Lys Leu Ile Ala Glu
 865 870 875 880
 Met Phe Pro Ser Cys Thr Ala Ile Ser Val Asn Pro Ala Ser Ser Gly
 885 890 895
 Asp Ser Asp Val Gln Leu Arg Leu Ala Ala Val Lys Phe Ala Val Ser
 900 905 910
 Gly Ala Ala Leu Ser Thr Phe Asp Pro Trp Glu Tyr Arg Lys Pro Gln
 915 920 925
 Asp Leu Leu Ile Arg Lys Pro Arg Lys Thr Ala Leu Val Leu Ser Ala
 930 935 940
 Ala Thr Tyr Val Ser Pro Lys Thr Leu Ala Glu Arg Lys Lys Ala Met
 945 950 955 960
 Glu Asp Ile Lys Leu Val Ser Ile Thr Pro Arg Asp Ser Met Val Ser
 965 970 975
 Ile Gly Lys Ile Ala Gln Glu Val Arg Thr Ala Lys Gln Pro Leu Glu
 980 985 990
 Thr Glu Ile Arg Arg Leu Asn Lys Glu Leu Glu His Leu Lys Arg Glu
 995 1000 1005
 Leu Ala Ala Ala Lys Ala Ser Val Lys Ser Ala Ser Lys Ser Ser
 1010 1015 1020

2997-49-2-pct_ST25

Lys	Glu	Arg	Ser	Val	Leu	Ser	Lys	His	Arg	Ala	Leu	Leu	Gln	Asn
	1025					1030					1035			
Ile	Leu	Gln	Asp	Tyr	Asp	Asp	Leu	Arg	Val	Val	Pro	Phe	Ala	Val
	1040					1045					1050			
Arg	Ser	Val	Ala	Val	Asp	Asn	Thr	Ala	Pro	Tyr	Ala	Asp	Gln	Val
	1055					1060					1065			
Ser	Thr	Pro	Ala	Ser	Glu	Arg	Ser	Ala	Ser	Pro	Leu	Phe	Glu	Lys
	1070					1075					1080			
Arg	Ser	Ser	Val	Ser	Ser	Ala	Arg	Leu	Ala	Glu	Ala	Glu	Ala	Ala
	1085					1090					1095			
Val	Leu	Ser	Val	Leu	Ala	Asp	Lys	Thr	Gly	Tyr	Asp	Ser	Ser	Met
	1100					1105					1110			
Ile	Glu	Met	Asp	Met	Asp	Leu	Glu	Ser	Glu	Leu	Gly	Val	Asp	Ser
	1115					1120					1125			
Ile	Lys	Arg	Val	Glu	Ile	Met	Ser	Glu	Val	Gln	Thr	Leu	Leu	Ser
	1130					1135					1140			
Val	Glu	Val	Ser	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Lys	Thr	Val
	1145					1150					1155			
Gly	Asp	Val	Ile	Glu	Ala	Met	Lys	Leu	Glu	Leu	Gly	Gly	Pro	Gln
	1160					1165					1170			
Gly	Gln	Thr	Leu	Thr	Ala	Glu	Ser	Ile	Arg	Gln	Pro	Pro	Val	Ser
	1175					1180					1185			
Glu	Pro	Ala	Val	Pro	Thr	Ser	Ser	Ser	Ser	Ser	Ile	Ala	Asn	Val
	1190					1195					1200			
Ser	Ser	Ala	Arg	Leu	Ala	Glu	Ala	Glu	Ala	Ala	Val	Leu	Ser	Val
	1205					1210					1215			
Leu	Ala	Asp	Lys	Thr	Gly	Tyr	Asp	Ser	Ser	Met	Ile	Glu	Met	Asp
	1220					1225					1230			
Met	Asp	Leu	Glu	Ser	Glu	Leu	Gly	Val	Asp	Ser	Ile	Lys	Arg	Val
	1235					1240					1245			
Glu	Ile	Met	Ser	Glu	Val	Gln	Thr	Leu	Leu	Ser	Val	Glu	Val	Ser
	1250					1255					1260			
Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Lys	Thr	Val	Gly	Asp	Val	Ile
	1265					1270					1275			

2997-49-2-pct_ST25

Glu	Ala	Met	Lys	Leu	Glu	Leu	Gly	Gly	Pro	Gln	Gly	Gln	Thr	Leu
	1280					1285					1290			
Thr	Ala	Glu	Ser	Ile	Arg	Gln	Pro	Pro	Val	Ser	Glu	Pro	Ala	Val
	1295					1300					1305			
Pro	Thr	Ser	Ser	Ser	Ser	Ser	Ile	Ala	Asn	Val	Ser	Ser	Ala	Arg
	1310					1315					1320			
Leu	Ala	Glu	Ala	Glu	Ala	Ala	Val	Leu	Ser	Val	Leu	Ala	Asp	Lys
	1325					1330					1335			
Thr	Gly	Tyr	Asp	Ser	Ser	Met	Ile	Glu	Met	Asp	Met	Asp	Leu	Glu
	1340					1345					1350			
Ser	Glu	Leu	Gly	Val	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Met	Ser
	1355					1360					1365			
Glu	Val	Gln	Thr	Leu	Leu	Ser	Val	Glu	Val	Ser	Asp	Val	Asp	Ala
	1370					1375					1380			
Leu	Ser	Arg	Thr	Lys	Thr	Val	Gly	Asp	Val	Ile	Glu	Ala	Met	Lys
	1385					1390					1395			
Leu	Glu	Leu	Gly	Gly	Pro	Gln	Gly	Gln	Thr	Leu	Thr	Ala	Glu	Ser
	1400					1405					1410			
Ile	Arg	Gln	Pro	Pro	Val	Ser	Glu	Pro	Ala	Val	Pro	Thr	Ser	Ser
	1415					1420					1425			
Ser	Ser	Ser	Ile	Ala	Asn	Val	Leu	Ser	Ala	Arg	Leu	Ala	Glu	Ala
	1430					1435					1440			
Glu	Ala	Ala	Val	Leu	Ser	Val	Leu	Ala	Asp	Lys	Thr	Gly	Tyr	Asp
	1445					1450					1455			
Ser	Ser	Met	Ile	Glu	Met	Asp	Met	Asp	Leu	Glu	Ser	Glu	Leu	Gly
	1460					1465					1470			
Val	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Met	Ser	Glu	Val	Gln	Thr
	1475					1480					1485			
Leu	Leu	Ser	Val	Glu	Val	Ser	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr
	1490					1495					1500			
Lys	Thr	Val	Gly	Asp	Val	Ile	Glu	Ala	Met	Lys	Leu	Glu	Leu	Gly
	1505					1510					1515			
Gly	Pro	Gln	Gly	Gln	Thr	Leu	Thr	Ala	Glu	Ser	Ile	Arg	Gln	Pro
	1520					1525					1530			

2997-49-2-pct_ST25

Pro	Val	Ser	Glu	Pro	Ala	Val	Pro	Thr	Ser	Ser	Ser	Ser	Ser	Ser	Ile
	1535					1540						1545			
Ala	Asn	Val	Ser	Ser	Ala	Arg	Leu	Ala	Glu	Ala	Glu	Ala	Ala	Val	
	1550					1555					1560				
Leu	Ser	Val	Leu	Ala	Asp	Lys	Thr	Gly	Tyr	Asp	Ser	Ser	Met	Ile	
	1565					1570					1575				
Glu	Met	Asp	Met	Asp	Leu	Glu	Ser	Glu	Leu	Gly	Val	Asp	Ser	Ile	
	1580					1585					1590				
Lys	Arg	Val	Glu	Ile	Met	Ser	Glu	Val	Gln	Thr	Leu	Leu	Ser	Val	
	1595					1600					1605				
Glu	Val	Ser	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Lys	Thr	Val	Gly	
	1610					1615					1620				
Asp	Val	Ile	Glu	Ala	Met	Lys	Leu	Glu	Leu	Gly	Gly	Pro	Gln	Gly	
	1625					1630					1635				
Gln	Thr	Leu	Thr	Ser	Glu	Pro	Ile	His	Gln	Pro	Pro	Val	Ser	Glu	
	1640					1645					1650				
Pro	Ala	Val	Pro	Thr	Ser	Ser	Ser	Ser	Ser	Ile	Ala	Asn	Val	Ser	
	1655					1660					1665				
Ser	Ala	Arg	Leu	Ala	Glu	Ala	Glu	Ala	Ala	Val	Leu	Ser	Val	Leu	
	1670					1675					1680				
Ala	Asp	Lys	Thr	Gly	Tyr	Asp	Ser	Ser	Met	Ile	Glu	Met	Asp	Met	
	1685					1690					1695				
Asp	Leu	Glu	Ser	Glu	Leu	Gly	Val	Asp	Ser	Ile	Lys	Arg	Val	Glu	
	1700					1705					1710				
Ile	Met	Ser	Glu	Val	Gln	Thr	Leu	Leu	Ser	Val	Glu	Val	Ser	Asp	
	1715					1720					1725				
Val	Asp	Ala	Leu	Ser	Arg	Thr	Lys	Thr	Val	Gly	Asp	Val	Ile	Glu	
	1730					1735					1740				
Ala	Met	Lys	Met	Glu	Leu	Gly	Gly	Pro	Gln	Gly	Gln	Thr	Leu	Thr	
	1745					1750					1755				
Ala	Glu	Ser	Ile	Arg	Gln	Pro	Pro	Val	Ser	Glu	Pro	Ala	Val	Pro	
	1760					1765					1770				
Thr	Ser	Ser	Ser	Ser	Ser	Ile	Ala	Asn	Val	Ser	Ser	Ala	Arg	Leu	
	1775					1780					1785				

2997-49-2-pct_ST25

Ala	Glu	Ala	Glu	Ala	Ala	Val	Leu	Ser	Val	Leu	Ala	Asp	Lys	Thr
	1790					1795					1800			
Gly	Tyr	Asp	Ser	Ser	Met	Ile	Glu	Met	Asp	Met	Asp	Leu	Glu	Ser
	1805					1810					1815			
Glu	Leu	Gly	Val	Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Met	Ser	Glu
	1820					1825					1830			
Val	Gln	Ala	Leu	Leu	Ser	Val	Glu	Val	Ser	Asp	Val	Asp	Ala	Leu
	1835					1840					1845			
Ser	Arg	Thr	Lys	Thr	Val	Gly	Asp	Val	Ile	Glu	Ala	Met	Lys	Met
	1850					1855					1860			
Glu	Leu	Gly	Gly	Pro	Gln	Gly	Gln	Thr	Leu	Thr	Ala	Glu	Ser	Ile
	1865					1870					1875			
Arg	Glu	Pro	Pro	Val	Ser	Glu	Pro	Ala	Val	Pro	Thr	Ser	Ser	Ser
	1880					1885					1890			
Ser	Ser	Ile	Ala	Asn	Val	Ser	Ser	Ala	Arg	Leu	Ala	Glu	Ala	Glu
	1895					1900					1905			
Ala	Ala	Val	Leu	Ser	Val	Leu	Ala	Asp	Lys	Thr	Gly	Tyr	Asp	Ser
	1910					1915					1920			
Ser	Met	Ile	Glu	Met	Asp	Met	Asp	Leu	Glu	Ser	Glu	Leu	Gly	Val
	1925					1930					1935			
Asp	Ser	Ile	Lys	Arg	Val	Glu	Ile	Met	Ser	Glu	Val	Gln	Thr	Leu
	1940					1945					1950			
Leu	Ser	Val	Glu	Val	Ser	Asp	Val	Asp	Ala	Leu	Ser	Arg	Thr	Lys
	1955					1960					1965			
Thr	Val	Gly	Asp	Val	Ile	Glu	Ala	Met	Lys	Leu	Glu	Leu	Gly	Glu
	1970					1975					1980			
Ser	Ser	Ser	Ile	Glu	Thr	Leu	Asn	Cys	Thr	Glu	Val	Glu	His	Thr
	1985					1990					1995			
Ser	Tyr	Lys	Ser	Val	Lys	Ala	Ser	Gly	Cys	Glu	Asn	Val	Asp	Thr
	2000					2005					2010			
Arg	Phe	Ala	Lys	Val	Val	Gln	Ile	Ser	Leu	Pro	Ser	Lys	Leu	Lys
	2015					2020					2025			
Ser	Thr	Val	Ser	His	Asp	Arg	Pro	Val	Ile	Val	Val	Asp	Asp	Gly
	2030					2035					2040			

2997-49-2-pct_ST25

Thr	Pro	Leu	Thr	Thr	Glu	Leu	Cys	Lys	Ile	Leu	Gly	Gly	Asn	Ile
	2045					2050					2055			
Val	Val	Leu	Ser	Tyr	Gln	Gly	Lys	Pro	Ala	Gly	Pro	Arg	Gly	Val
	2060					2065					2070			
Glu	Val	Pro	Asp	Leu	Ser	Glu	Glu	Ala	Leu	Ile	Gln	Ala	Leu	Ala
	2075					2080					2085			
Leu	Ile	Arg	Ser	Thr	Tyr	Gly	Val	Pro	Ile	Gly	Phe	Ile	Cys	Gln
	2090					2095					2100			
Gln	Val	Ser	Asn	Val	Ser	Thr	Lys	Ala	Gln	Leu	Cys	Trp	Ala	Leu
	2105					2110					2115			
Leu	Ala	Ala	Lys	His	Leu	Lys	Lys	Asp	Leu	Asn	Ala	Val	Leu	Pro
	2120					2125					2130			
Asp	Ser	Arg	Ser	Phe	Phe	Val	Gly	Val	Val	Arg	Leu	Asn	Gly	Lys
	2135					2140					2145			
Leu	Gly	Thr	Phe	Glu	Asn	Ile	Ser	Asp	Phe	Ser	Lys	Phe	Asp	Leu
	2150					2155					2160			
Thr	Lys	Ala	Leu	Asp	Tyr	Gly	Gln	Arg	Gly	Ser	Leu	Leu	Gly	Leu
	2165					2170					2175			
Cys	Lys	Ser	Leu	Asp	Leu	Glu	Trp	Glu	Gln	Val	Phe	Cys	Arg	Gly
	2180					2185					2190			
Ile	Asp	Leu	Ala	Cys	Asp	Leu	Met	Pro	Leu	Gln	Ala	Ala	Arg	Ile
	2195					2200					2205			
Leu	Arg	Asn	Glu	Leu	Gln	Cys	Pro	Asn	Met	Arg	Leu	Arg	Glu	Val
	2210					2215					2220			
Gly	Tyr	Asp	Ile	Ser	Gly	Ala	Arg	Tyr	Thr	Ile	Ser	Thr	Asp	Asp
	2225					2230					2235			
Leu	Leu	Cys	Gly	Pro	Ser	Lys	Ala	Lys	Val	Glu	Ala	Ala	Asp	Leu
	2240					2245					2250			
Phe	Leu	Val	Thr	Gly	Gly	Ala	Arg	Gly	Ile	Thr	Pro	His	Cys	Val
	2255					2260					2265			
Arg	Glu	Ile	Ala	Ser	Arg	Ser	Pro	Gly	Thr	Thr	Phe	Val	Leu	Val
	2270					2275					2280			
Gly	Arg	Ser	Glu	Met	Ser	Asp	Glu	Pro	Asp	Trp	Ala	Val	Gly	His
	2285					2290					2295			

2997-49-2-pct_ST25

Tyr	Asn	Lys	Asp	Leu	Asp	Gln	Ser	Thr	Met	Lys	His	Leu	Lys	Ala
	2300					2305					2310			
Thr	His	Ala	Ala	Gly	Gly	Val	Lys	Pro	Thr	Pro	Lys	Ala	His	Arg
	2315					2320					2325			
Ala	Leu	Val	Asn	Arg	Val	Thr	Gly	Ser	Arg	Glu	Val	Arg	Glu	Ser
	2330					2335					2340			
Leu	Arg	Ala	Ile	Gln	Glu	Ala	Gly	Ala	Asn	Val	Glu	Tyr	Ile	Ala
	2345					2350					2355			
Cys	Asp	Val	Ser	Asp	Glu	Asn	Lys	Val	Arg	Gln	Leu	Val	Gln	Arg
	2360					2365					2370			
Val	Glu	Gln	Lys	Tyr	Gly	Cys	Glu	Ile	Thr	Gly	Ile	Trp	His	Ala
	2375					2380					2385			
Ser	Gly	Val	Leu	Arg	Asp	Lys	Leu	Val	Glu	Gln	Lys	Thr	Thr	Asp
	2390					2395					2400			
Asp	Phe	Glu	Ala	Val	Phe	Gly	Thr	Lys	Val	Thr	Gly	Leu	Val	Asn
	2405					2410					2415			
Ile	Val	Ser	Gln	Val	Asn	Met	Ser	Lys	Leu	Arg	His	Phe	Ile	Leu
	2420					2425					2430			
Phe	Ser	Ser	Leu	Ala	Gly	Phe	His	Gly	Asn	Lys	Gly	Gln	Thr	Asp
	2435					2440					2445			
Tyr	Ala	Ile	Ala	Asn	Glu	Ala	Leu	Asn	Lys	Ile	Ala	His	Thr	Leu
	2450					2455					2460			
Ser	Ala	Phe	Leu	Pro	Lys	Leu	Asn	Ala	Lys	Val	Leu	Asp	Phe	Gly
	2465					2470					2475			
Pro	Trp	Val	Gly	Ser	Gly	Met	Val	Thr	Glu	Thr	Leu	Glu	Lys	His
	2480					2485					2490			
Phe	Lys	Ala	Met	Gly	Val	Gln	Thr	Ile	Pro	Leu	Glu	Pro	Gly	Ala
	2495					2500					2505			
Arg	Thr	Val	Ala	Gln	Ile	Ile	Leu	Ala	Ser	Ser	Pro	Pro	Gln	Ser
	2510					2515					2520			
Leu	Leu	Gly	Asn	Trp	Gly	Phe	Pro	Ala	Thr	Lys	Pro	Leu	Gln	Arg
	2525					2530					2535			
Ser	Asn	Val	Val	Thr	Gly	Thr	Leu	Ser	Pro	Glu	Glu	Ile	Glu	Phe
	2540					2545					2550			

2997-49-2-pct_ST25

Ile	Ala	Asp	His	Lys	Ile	Gln	Gly	Arg	Lys	Val	Leu	Pro	Met	Met
	2555					2560					2565			
Ala	Ala	Ile	Gly	Phe	Met	Ala	Ser	Ile	Ala	Glu	Gly	Leu	Tyr	Pro
	2570					2575					2580			
Gly	Tyr	Asn	Leu	Gln	Gly	Val	Glu	Asn	Ala	Gln	Leu	Phe	Gln	Gly
	2585					2590					2595			
Leu	Thr	Ile	Asn	Gln	Glu	Thr	Lys	Phe	Gln	Ile	Thr	Leu	Ile	Glu
	2600					2605					2610			
Glu	His	Asn	Ser	Glu	Glu	Asn	Leu	Asp	Val	Leu	Thr	Ser	Leu	Gly
	2615					2620					2625			
Val	Met	Leu	Glu	Ser	Gly	Lys	Val	Leu	Pro	Ala	Tyr	Arg	Cys	Val
	2630					2635					2640			
Val	Cys	Leu	Asn	Thr	Thr	Gln	Gln	Gln	Pro	Lys	Leu	Ser	Pro	Lys
	2645					2650					2655			
Ile	Leu	Asn	Leu	Glu	Val	Asp	Pro	Ala	Cys	Glu	Val	Asn	Pro	Tyr
	2660					2665					2670			
Asp	Gly	Lys	Ser	Leu	Phe	His	Gly	Pro	Leu	Leu	Gln	Phe	Val	Gln
	2675					2680					2685			
Gln	Val	Leu	His	Ser	Ser	Thr	Lys	Gly	Leu	Val	Ala	Lys	Cys	Arg
	2690					2695					2700			
Ala	Leu	Pro	Ile	Lys	Glu	Ala	Ile	Arg	Gly	Pro	Phe	Ile	Lys	Gln
	2705					2710					2715			
Thr	Leu	His	Asp	Pro	Ile	Leu	Asp	Asp	Val	Ile	Phe	Gln	Leu	Met
	2720					2725					2730			
Leu	Val	Trp	Cys	Arg	Asn	Ala	Leu	Gly	Ser	Ala	Ser	Leu	Pro	Asn
	2735					2740					2745			
Arg	Ile	Glu	Lys	Met	Ser	Tyr	Phe	Gly	Asn	Val	Ser	Glu	Gly	Ser
	2750					2755					2760			
Thr	Phe	Phe	Ala	Ser	Val	Thr	Pro	Val	Gly	Pro	Arg	Val	Pro	Lys
	2765					2770					2775			
Asp	Pro	Val	Ile	Lys	Met	Gln	Phe	Leu	Leu	Gln	Asp	Glu	Ser	Gly
	2780					2785					2790			
Asn	Thr	Phe	Ser	Ser	Gly	Glu	Gly	Ser	Val	Val	Leu	Ser	Asp	Glu
	2795					2800					2805			

Leu Val Phe
2810

<210> 40
<211> 1500
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1500)

<400> 40
atg aag gac atg gaa gat aga cgg gtc gct att gtg ggc atg tca gct 48
Met Lys Asp Met Glu Asp Arg Arg Val Ala Ile Val Gly Met Ser Ala
1 5 10 15
cac ttg cct tgt ggg aca gat gtg aag gaa tca tgg cag gct att cgc 96
His Leu Pro Cys Gly Thr Asp Val Lys Glu Ser Trp Gln Ala Ile Arg
20 25 30
gat gga atc gac tgt cta agt gac cta ccc gcg gat cgt ctc gac gtt 144
Asp Gly Ile Asp Cys Leu Ser Asp Leu Pro Ala Asp Arg Leu Asp Val
35 40 45
aca gct tac tac aat ccc aac aaa gcc acg aaa gac aag atc tac tgc 192
Thr Ala Tyr Tyr Asn Pro Asn Lys Ala Thr Lys Asp Lys Ile Tyr Cys
50 55 60
aaa cgg ggt ggc ttc atc ccg aac tat gac ttc gac ccc cgc gaa ttt 240
Lys Arg Gly Gly Phe Ile Pro Asn Tyr Asp Phe Asp Pro Arg Glu Phe
65 70 75 80
ggg ctc aac atg ttt caa atg gaa gac tct gat gcg aat cag aca ctt 288
Gly Leu Asn Met Phe Gln Met Glu Asp Ser Asp Ala Asn Gln Thr Leu
85 90 95
acc ttg ctc aaa gtc aaa caa gct ctc gaa gat gca agc ata gag cct 336
Thr Leu Leu Lys Val Lys Gln Ala Leu Glu Asp Ala Ser Ile Glu Pro
100 105 110
ttc acc aag gag aag aag aac att gga tgt gtt tta ggt att ggt ggg 384
Phe Thr Lys Glu Lys Lys Asn Ile Gly Cys Val Leu Gly Ile Gly Gly
115 120 125
ggc caa aag gcg agt cat gag ttc tac tct cgt ctc aac tac gtt gtc 432
Gly Gln Lys Ala Ser His Glu Phe Tyr Ser Arg Leu Asn Tyr Val Val
130 135 140
gtt gaa aag gta ctt cgg aaa atg ggt tta cca gat gct gat gtt gaa 480
Val Glu Lys Val Leu Arg Lys Met Gly Leu Pro Asp Ala Asp Val Glu
145 150 155 160
gaa gct gtg gag aaa tac aag gca aat ttt ccc gag tgg cgc cta gac 528
Glu Ala Val Glu Lys Tyr Lys Ala Asn Phe Pro Glu Trp Arg Leu Asp
165 170 175
tct ttc cct ggg ttt ctt ggg aat gta acg gct ggt cgg tgc agt aac 576
Ser Phe Pro Gly Phe Leu Gly Asn Val Thr Ala Gly Arg Cys Ser Asn
180 185 190
acc ttc aac atg gaa ggt atg aac tgc gtt gtg gat gct gca tgt gcc 624
Thr Phe Asn Met Glu Gly Met Asn Cys Val Val Asp Ala Ala Cys Ala
195 200 205
agt tct cta att gca atc aag gtt gca gtt gaa gag cta ctc ttt ggt 672

2997-49-2-pct_ST25

Ser	Ser	Leu	Ile	Ala	Ile	Lys	Val	Ala	Val	Glu	Glu	Leu	Leu	Phe	Gly	
210						215				220						
gac	tgt	gac	acc	atg	att	gca	ggt	gcc	acc	tgc	acg	gac	aat	tca	ctt	720
Asp	Cys	Asp	Thr	Met	Ile	Ala	Gly	Ala	Thr	Cys	Thr	Asp	Asn	Ser	Leu	
225					230					235					240	
ggc	atg	tac	atg	gcc	ttc	tct	aaa	acg	cca	ggt	ttt	tct	act	gac	cca	768
Gly	Met	Tyr	Met	Ala	Phe	Ser	Lys	Thr	Pro	Val	Phe	Ser	Thr	Asp	Pro	
				245					250					255		
agt	gtc	cgc	gcg	tat	gat	gag	aaa	aca	aaa	ggg	atg	cta	att	gga	gaa	816
Ser	Val	Arg	Ala	Tyr	Asp	Glu	Lys	Thr	Lys	Gly	Met	Leu	Ile	Gly	Glu	
			260					265					270			
ggt	tca	gca	atg	ttc	gtt	ctt	aaa	cgc	tat	gcg	gat	gcc	gta	cgt	gat	864
Gly	Ser	Ala	Met	Phe	Val	Leu	Lys	Arg	Tyr	Ala	Asp	Ala	Val	Arg	Asp	
		275					280					285				
ggc	gac	aca	att	cac	gcg	gtt	ctg	cgt	tct	tgc	tct	tcg	tct	agt	gat	912
Gly	Asp	Thr	Ile	His	Ala	Val	Leu	Arg	Ser	Cys	Ser	Ser	Ser	Ser	Asp	
	290					295					300					
gga	aaa	gcg	gca	gga	att	tat	act	cct	act	ata	tct	gga	caa	gaa	gaa	960
Gly	Lys	Ala	Ala	Gly	Ile	Tyr	Thr	Pro	Thr	Ile	Ser	Gly	Gln	Glu	Glu	
305					310					315				320		
gct	ttg	cgt	cga	gcg	tat	gcc	cgt	gcg	ggg	gta	tgt	cca	tct	acg	atc	1008
Ala	Leu	Arg	Arg	Ala	Tyr	Ala	Arg	Ala	Gly	Val	Cys	Pro	Ser	Thr	Ile	
				325					330					335		
ggg	ctt	gtt	gag	ggt	cac	ggg	aca	ggg	acc	cct	gtt	gga	gat	cgc	att	1056
Gly	Leu	Val	Glu	Gly	His	Gly	Thr	Gly	Thr	Pro	Val	Gly	Asp	Arg	Ile	
			340					345					350			
gag	tta	aca	gct	ctg	cgg	aac	ttg	ttt	gac	aaa	gct	ttt	ggt	agc	aag	1104
Glu	Leu	Thr	Ala	Leu	Arg	Asn	Leu	Phe	Asp	Lys	Ala	Phe	Gly	Ser	Lys	
		355					360					365				
aag	gaa	caa	ata	gca	gtt	ggc	agc	ata	aag	tct	cag	ata	ggt	cac	ctg	1152
Lys	Glu	Gln	Ile	Ala	Val	Gly	Ser	Ile	Lys	Ser	Gln	Ile	Gly	His	Leu	
	370					375					380					
aaa	tct	gtt	gcc	ggc	ttt	gcc	ggc	ttg	gtc	aaa	gct	gtg	ctt	gcg	ctt	1200
Lys	Ser	Val	Ala	Gly	Phe	Ala	Gly	Leu	Val	Lys	Ala	Val	Leu	Ala	Leu	
385					390					395					400	
aaa	cac	aaa	acg	ctc	cca	ggt	tcg	att	aat	gtc	gac	cag	cca	cct	ttg	1248
Lys	His	Lys	Thr	Leu	Pro	Gly	Ser	Ile	Asn	Val	Asp	Gln	Pro	Pro	Leu	
				405					410					415		
ttg	tat	gac	ggt	act	caa	att	caa	gac	tct	tct	tta	tat	atc	aac	aag	1296
Leu	Tyr	Asp	Gly	Thr	Gln	Ile	Gln	Asp	Ser	Ser	Leu	Tyr	Ile	Asn	Lys	
			420					425					430			
aca	aat	aga	cca	tggt	ttt	acg	caa	aac	aag	ctt	ccg	cgt	cgg	gct	ggt	1344
Thr	Asn	Arg	Pro	Trp	Phe	Thr	Gln	Asn	Lys	Leu	Pro	Arg	Arg	Ala	Gly	
		435					440					445				
gtc	tca	agt	ttt	gga	ttt	gga	ggt	gca	aac	tac	cac	gcg	gtt	ctg	gaa	1392
Val	Ser	Ser	Phe	Gly	Phe	Gly	Gly	Ala	Asn	Tyr	His	Ala	Val	Leu	Glu	
	450					455					460					
gaa	ttc	gag	ccc	gag	cat	gaa	aaa	cca	tac	cgc	ctc	aat	act	gtt	gga	1440
Glu	Phe	Glu	Pro	Glu	His	Glu	Lys	Pro	Tyr	Arg	Leu	Asn	Thr	Val	Gly	
465					470					475					480	
cat	cct	gtc	ctc	ttg	tac	gct	ccg	tct	gtg	gaa	gcc	ctc	aaa	gta	ctt	1488

2997-49-2-pct_ST25

His Pro Val Leu 485 Tyr Ala Pro Ser Val Glu Ala Leu Lys Val Leu 495

tgc aac gac cag
Cys Asn Asp Gln
500

1500

<210> 41
<211> 500
<212> PRT
<213> Thraustochytrium sp.
<400> 41

Met Lys Asp Met Glu Asp Arg Arg Val Ala Ile Val Gly Met Ser Ala
1 5 10 15

His Leu Pro Cys Gly Thr Asp Val Lys Glu Ser Trp Gln Ala Ile Arg
20 25 30

Asp Gly Ile Asp Cys Leu Ser Asp Leu Pro Ala Asp Arg Leu Asp Val
35 40 45

Thr Ala Tyr Tyr Asn Pro Asn Lys Ala Thr Lys Asp Lys Ile Tyr Cys
50 55 60

Lys Arg Gly Gly Phe Ile Pro Asn Tyr Asp Phe Asp Pro Arg Glu Phe
65 70 75 80

Gly Leu Asn Met Phe Gln Met Glu Asp Ser Asp Ala Asn Gln Thr Leu
85 90 95

Thr Leu Leu Lys Val Lys Gln Ala Leu Glu Asp Ala Ser Ile Glu Pro
100 105 110

Phe Thr Lys Glu Lys Lys Asn Ile Gly Cys Val Leu Gly Ile Gly Gly
115 120 125

Gly Gln Lys Ala Ser His Glu Phe Tyr Ser Arg Leu Asn Tyr Val Val
130 135 140

Val Glu Lys Val Leu Arg Lys Met Gly Leu Pro Asp Ala Asp Val Glu
145 150 155 160

Glu Ala Val Glu Lys Tyr Lys Ala Asn Phe Pro Glu Trp Arg Leu Asp
165 170 175

Ser Phe Pro Gly Phe Leu Gly Asn Val Thr Ala Gly Arg Cys Ser Asn
180 185 190

Thr Phe Asn Met Glu Gly Met Asn Cys Val Val Asp Ala Ala Cys Ala
195 200 205

Ser Ser Leu Ile Ala Ile Lys Val Ala Val Glu Glu Leu Leu Phe Gly

210

215

220

Asp Cys Asp Thr Met Ile Ala Gly Ala Thr Cys Thr Asp Asn Ser Leu
 225 230 235 240

Gly Met Tyr Met Ala Phe Ser Lys Thr Pro Val Phe Ser Thr Asp Pro
 245 250 255

Ser Val Arg Ala Tyr Asp Glu Lys Thr Lys Gly Met Leu Ile Gly Glu
 260 265 270

Gly Ser Ala Met Phe Val Leu Lys Arg Tyr Ala Asp Ala Val Arg Asp
 275 280 285

Gly Asp Thr Ile His Ala Val Leu Arg Ser Cys Ser Ser Ser Ser Asp
 290 295 300

Gly Lys Ala Ala Gly Ile Tyr Thr Pro Thr Ile Ser Gly Gln Glu Glu
 305 310 315 320

Ala Leu Arg Arg Ala Tyr Ala Arg Ala Gly Val Cys Pro Ser Thr Ile
 325 330 335

Gly Leu Val Glu Gly His Gly Thr Gly Thr Pro Val Gly Asp Arg Ile
 340 345 350

Glu Leu Thr Ala Leu Arg Asn Leu Phe Asp Lys Ala Phe Gly Ser Lys
 355 360 365

Lys Glu Gln Ile Ala Val Gly Ser Ile Lys Ser Gln Ile Gly His Leu
 370 375 380

Lys Ser Val Ala Gly Phe Ala Gly Leu Val Lys Ala Val Leu Ala Leu
 385 390 395 400

Lys His Lys Thr Leu Pro Gly Ser Ile Asn Val Asp Gln Pro Pro Leu
 405 410 415

Leu Tyr Asp Gly Thr Gln Ile Gln Asp Ser Ser Leu Tyr Ile Asn Lys
 420 425 430

Thr Asn Arg Pro Trp Phe Thr Gln Asn Lys Leu Pro Arg Arg Ala Gly
 435 440 445

Val Ser Ser Phe Gly Phe Gly Gly Ala Asn Tyr His Ala Val Leu Glu
 450 455 460

Glu Phe Glu Pro Glu His Glu Lys Pro Tyr Arg Leu Asn Thr Val Gly
 465 470 475 480

His Pro Val Leu Leu Tyr Ala Pro Ser Val Glu Ala Leu Lys Val Leu

Cys Asn Asp Gln
500

<210> 42
<211> 1500
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1500)

<400> 42
ctt gcg gag ctc aca att gca ttg gaa gag gca aaa aca cat aaa aat 48
Leu Ala Glu Leu Thr Ile Ala Leu Glu Glu Ala Lys Thr His Lys Asn
1 5 10 15
gtt gac aaa gtt tgt ggc tac aag ttt att gac gaa ttt cag ctc caa 96
Val Asp Lys Val Cys Gly Tyr Lys Phe Ile Asp Glu Phe Gln Leu Gln
20 25 30
gga agc tgt cct cca gaa aat ccg aga gta gga ttt tta gca aca ctg 144
Gly Ser Cys Pro Pro Glu Asn Pro Arg Val Gly Phe Leu Ala Thr Leu
35 40 45
cct act tca aat atc att gtc gcg ctt aag gca att ctc gcg cag ctt 192
Pro Thr Ser Asn Ile Ile Val Ala Leu Lys Ala Ile Leu Ala Gln Leu
50 55 60
gat gca aaa cca gat gcg aag aaa tgg gat ttg cct cat aaa aag gct 240
Asp Ala Lys Pro Asp Ala Lys Lys Trp Asp Leu Pro His Lys Lys Ala
65 70 75 80
ttt ggg gct acc ttc gca tcg tct tca gtg aaa ggc tct gtt gct gcg 288
Phe Gly Ala Thr Phe Ala Ser Ser Ser Val Lys Gly Ser Val Ala Ala
85 90 95
ctc ttc gca gga cag ggt acc cag tac tta aac atg ttc tct gat gtg 336
Leu Phe Ala Gly Gln Gly Thr Gln Tyr Leu Asn Met Phe Ser Asp Val
100 105 110
gca atg aac tgg cca ccg ttc cgt gac agc att gtc gca atg gaa gaa 384
Ala Met Asn Trp Pro Pro Phe Arg Asp Ser Ile Val Ala Met Glu Glu
115 120 125
gct caa act gag gta ttt gag ggc caa gtt gaa cca att agc aaa gtt 432
Ala Gln Thr Glu Val Phe Glu Gly Gln Val Glu Pro Ile Ser Lys Val
130 135 140
ctg ttt cca cga gag cgc tat gca tcc gaa agt gaa cag ggg aat gaa 480
Leu Phe Pro Arg Glu Arg Tyr Ala Ser Glu Ser Glu Gln Gly Asn Glu
145 150 155 160
ctt ctt tgc tta aca gag tac tct cag cca act acg ata gca gcc gca 528
Leu Leu Cys Leu Thr Glu Tyr Ser Gln Pro Thr Thr Ile Ala Ala Ala
165 170 175
gta ggg gcc ttc gat att ttc aaa gcg gct ggc ttt aag cca gac atg 576
Val Gly Ala Phe Asp Ile Phe Lys Ala Ala Gly Phe Lys Pro Asp Met
180 185 190
gtt gga ggg cat tca ctt ggc gaa ttt gct gct ttg tac gcg gct ggg 624
Val Gly Gly His Ser Leu Gly Glu Phe Ala Ala Leu Tyr Ala Ala Gly

2997-49-2-pct_ST25																
195					200					205						
tcc Ser	att Ile 210	tcg Ser	cgt Arg	gac Asp	gac Asp	ctg Leu 215	tac Tyr	aag Lys	ctt Leu	gtg Val	tgc Cys 220	aaa Lys	cgg Arg	gca Ala	aag Lys	672
gca Ala 225	atg Met	gcg Ala	aac Asn	gct Ala	agt Ser 230	gac Asp	gga Gly	gct Ala	atg Met	gca Ala 235	gca Ala	gtg Val	att Ile	ggc Gly	cca Pro 240	720
gat Asp	gca Ala	cgt Arg	cta Leu	gtt Val 245	acg Thr	cca Pro	caa Gln	aat Asn	agt Ser 250	gac Asp	gtt Val	tat Tyr	gtc Val	gca Ala 255	aac Asn	768
ttc Phe	aac Asn	tcc Ser	gca Ala 260	act Thr	caa Gln	gta Val	gtc Val	atc Ile 265	agt Ser	ggc Gly	act Thr	gtt Val	caa Gln 270	ggg Gly	gtg Val	816
aaa Lys	gaa Glu	gag Glu 275	tcg Ser	aaa Lys	ttg Leu	ctc Leu	att Ile 280	tca Ser	aag Lys	ggg Gly	ttc Phe	cgc Arg 285	gta Val	ctg Leu	cca Pro	864
ctt Leu	aaa Lys 290	tgc Cys	cag Gln	ggc Gly	gcc Ala	ttc Phe 295	cat His	tct Ser	cct Pro	ttg Leu	atg Met 300	ggg Gly	cct Pro	tct Ser	gag Glu	912
gat Asp 305	agt Ser	ttc Phe	aaa Lys	tca Ser	ctt Leu 310	gtg Val	gag Glu	act Thr	tgt Cys	acc Thr 315	atc Ile	tcg Ser	ccg Pro	cca Pro	aaa Lys 320	960
aat Asn	gtg Val	aaa Lys	ttc Phe	ttt Phe 325	tgc Cys	aat Asn	gtt Val	agt Ser	ggc Gly 330	aag Lys	gaa Glu	agc Ser	cca Pro	aac Asn 335	cca Pro	1008
aaa Lys	cag Gln	acc Thr	ctc Leu 340	aag Lys	tca Ser	cac His	atg Met	acg Thr 345	tct Ser	agc Ser	gtt Val	cag Gln	ttc Phe 350	gag Glu	gag Glu	1056
cag Gln	att Ile	cgt Arg 355	aac Asn	atg Met	tac Tyr	gat Asp	gcc Ala 360	gga Gly	gca Ala	cgt Arg	gtt Val	ttt Phe 365	ctg Leu	gag Glu	ttt Phe	1104
gga Gly	ccc Pro 370	cgc Arg	caa Gln	gtc Val	ctt Leu	gca Ala 375	aag Lys	ctt Leu	atc Ile	gcg Ala	gaa Glu 380	atg Met	ttt Phe	ccc Pro	tcg Ser	1152
tgt Cys 385	aca Thr	gct Ala	atc Ile	agc Ser	gtt Val 390	aac Asn	ccc Pro	gcg Ala	agc Ser	agt Ser 395	ggg Gly	gac Asp	agt Ser	gac Asp	gtg Val 400	1200
caa Gln	ctc Leu	cgc Arg	ctc Leu	gcc Ala 405	gcc Ala	gta Val	aaa Lys	ttc Phe	gcg Ala 410	gtc Val	tcg Ser	ggg Gly	gca Ala	gcc Ala 415	ctt Leu	1248
agc Ser	acc Thr	ttt Phe	gat Asp 420	cca Pro	tgg Trp	gag Glu	tat Tyr	cgc Arg 425	aag Lys	cca Pro	caa Gln	gat Asp	ctt Leu 430	ctt Leu	att Ile	1296
cga Arg	aaa Lys	cca Pro 435	cga Arg	aaa Lys	act Thr	gcc Ala	ctt Leu 440	gtt Val	cta Leu	tca Ser	gca Ala	gca Ala 445	aca Thr	tat Tyr	gtt Val	1344
tcc Ser	cca Pro 450	aag Lys	act Thr	ctt Leu	gca Ala	gaa Glu 455	cgt Arg	aaa Lys	aag Lys	gct Ala	atg Met 460	gaa Glu	gat Asp	atc Ile	aag Lys	1392
cta Leu	gta Val	tcc Ser	att Ile	aca Thr	cca Pro	aga Arg	gat Asp	agt Ser	atg Met	gta Val	tca Ser	att Ile	gga Gly	aaa Lys	atc Ile	1440

2997-49-2-pct_ST25																				
465											470					475			480	
gcg	caa	gaa	gta	cgg	aca	gct	aaa	cag	cct	tta	gaa	acc	gaa	att	cga	1488				
Ala	Gln	Glu	Val	Arg	Thr	Ala	Lys	Gln	Pro	Leu	Glu	Thr	Glu	Ile	Arg					
				485											490			495		
aga	ctc	aac	aaa													1500				
Arg	Leu	Asn	Lys																	
				500																
<div> <div><210></div> <div>43</div> </div> <div> <div><211></div> <div>500</div> </div> <div> <div><212></div> <div>PRT</div> </div> <div> <div><213></div> <div>Thraustochytrium sp.</div> </div> <div> <div><400></div> <div>43</div> </div>																				
Leu	Ala	Glu	Leu	Thr	Ile	Ala	Leu	Glu	Glu	Ala	Lys	Thr	His	Lys	Asn					
1				5				10				15								
Val	Asp	Lys	Val	Cys	Gly	Tyr	Lys	Phe	Ile	Asp	Glu	Phe	Gln	Leu	Gln					
			20				25				30									
Gly	Ser	Cys	Pro	Pro	Glu	Asn	Pro	Arg	Val	Gly	Phe	Leu	Ala	Thr	Leu					
		35				40				45										
Pro	Thr	Ser	Asn	Ile	Ile	Val	Ala	Leu	Lys	Ala	Ile	Leu	Ala	Gln	Leu					
		50				55				60										
Asp	Ala	Lys	Pro	Asp	Ala	Lys	Lys	Trp	Asp	Leu	Pro	His	Lys	Lys	Ala					
65				70				75				80								
Phe	Gly	Ala	Thr	Phe	Ala	Ser	Ser	Ser	Val	Lys	Gly	Ser	Val	Ala	Ala					
			85				90				95									
Leu	Phe	Ala	Gly	Gln	Gly	Thr	Gln	Tyr	Leu	Asn	Met	Phe	Ser	Asp	Val					
		100				105				110										
Ala	Met	Asn	Trp	Pro	Pro	Phe	Arg	Asp	Ser	Ile	Val	Ala	Met	Glu	Glu					
		115				120				125										
Ala	Gln	Thr	Glu	Val	Phe	Glu	Gly	Gln	Val	Glu	Pro	Ile	Ser	Lys	Val					
		130				135				140										
Leu	Phe	Pro	Arg	Glu	Arg	Tyr	Ala	Ser	Glu	Ser	Glu	Gln	Gly	Asn	Glu					
145				150				155				160								
Leu	Leu	Cys	Leu	Thr	Glu	Tyr	Ser	Gln	Pro	Thr	Thr	Ile	Ala	Ala	Ala					
			165				170				175									
Val	Gly	Ala	Phe	Asp	Ile	Phe	Lys	Ala	Ala	Gly	Phe	Lys	Pro	Asp	Met					
			180				185				190									
Val	Gly	Gly	His	Ser	Leu	Gly	Glu	Phe	Ala	Ala	Leu	Tyr	Ala	Ala	Gly					
		195				200				205										

2997-49-2-pct_ST25

Ser Ile Ser Arg Asp Asp Leu Tyr Lys Leu Val Cys Lys Arg Ala Lys
 210 215 220
 Ala Met Ala Asn Ala Ser Asp Gly Ala Met Ala Ala Val Ile Gly Pro
 225 230 235 240
 Asp Ala Arg Leu Val Thr Pro Gln Asn Ser Asp Val Tyr Val Ala Asn
 245 250 255
 Phe Asn Ser Ala Thr Gln Val Val Ile Ser Gly Thr Val Gln Gly Val
 260 265 270
 Lys Glu Glu Ser Lys Leu Leu Ile Ser Lys Gly Phe Arg Val Leu Pro
 275 280 285
 Leu Lys Cys Gln Gly Ala Phe His Ser Pro Leu Met Gly Pro Ser Glu
 290 295 300
 Asp Ser Phe Lys Ser Leu Val Glu Thr Cys Thr Ile Ser Pro Pro Lys
 305 310 315 320
 Asn Val Lys Phe Phe Cys Asn Val Ser Gly Lys Glu Ser Pro Asn Pro
 325 330 335
 Lys Gln Thr Leu Lys Ser His Met Thr Ser Ser Val Gln Phe Glu Glu
 340 345 350
 Gln Ile Arg Asn Met Tyr Asp Ala Gly Ala Arg Val Phe Leu Glu Phe
 355 360 365
 Gly Pro Arg Gln Val Leu Ala Lys Leu Ile Ala Glu Met Phe Pro Ser
 370 375 380
 Cys Thr Ala Ile Ser Val Asn Pro Ala Ser Ser Gly Asp Ser Asp Val
 385 390 395 400
 Gln Leu Arg Leu Ala Ala Val Lys Phe Ala Val Ser Gly Ala Ala Leu
 405 410 415
 Ser Thr Phe Asp Pro Trp Glu Tyr Arg Lys Pro Gln Asp Leu Leu Ile
 420 425 430
 Arg Lys Pro Arg Lys Thr Ala Leu Val Leu Ser Ala Ala Thr Tyr Val
 435 440 445
 Ser Pro Lys Thr Leu Ala Glu Arg Lys Lys Ala Met Glu Asp Ile Lys
 450 455 460
 Leu Val Ser Ile Thr Pro Arg Asp Ser Met Val Ser Ile Gly Lys Ile
 465 470 475 480

2997-49-2-pct_ST25

Ala Gln Glu Val Arg Thr Ala Lys Gln Pro Leu Glu Thr Glu Ile Arg
485 490 495

Arg Leu Asn Lys
500

<210> 44
<211> 351
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(351)

<400> 44
tcg acc cca gcg tca gag cgg tcg gct tca ccg ctt ttc gag aaa cgc 48
Ser Thr Pro Ala Ser Glu Arg Ser Ala Ser Pro Leu Phe Glu Lys Arg
1 5 10 15
agt tcg gtt tcg tca gca cgc ctc gct gaa gct gaa gcc gcg gta ctg 96
Ser Ser Val Ser Ser Ala Arg Leu Ala Glu Ala Glu Ala Val Leu
20 25 30
agc gtt ctc gca gac aag aca ggc tac gac agc tca atg atc gag atg 144
Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met
35 40 45
gac atg gac ctg gag agt gag ctt ggc gtt gat agc atc aaa cgc gtg 192
Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val
50 55 60
gag atc atg agc gag gtt caa acg ctg ctc agc gtg gaa gtc tcc gac 240
Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp
65 70 75 80
gtt gac gct ctg tca aga acc aag act gtt ggc gac gtc atc gag gcg 288
Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala
85 90 95
atg aag ctg gaa ctc ggt gga ccc caa ggc cag act ttg acc gcg gaa 336
Met Lys Leu Glu Leu Gly Gly Pro Gln Gly Gln Thr Leu Thr Ala Glu
100 105 110
tcg atc cgt cag cca 351
Ser Ile Arg Gln Pro
115

<210> 45
<211> 117
<212> PRT
<213> Thraustochytrium sp.

<400> 45
Ser Thr Pro Ala Ser Glu Arg Ser Ala Ser Pro Leu Phe Glu Lys Arg
1 5 10 15
ser ser val ser ser ala arg leu ala glu ala glu ala ala val leu
20 25 30

2997-49-2-pct_ST25

Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met
35 40 45

Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val
50 55 60

Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp
65 70 75 80

Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala
85 90 95

Met Lys Leu Glu Leu Gly Gly Pro Gln Gly Gln Thr Leu Thr Ala Glu
100 105 110

Ser Ile Arg Gln Pro
115

<210> 46
<211> 5
<212> PRT
<213> Thraustochytrium sp.

<220>
<221> MISC_FEATURE
<222> (1)..(5)
<223> Xaa = any amino acid

<400> 46

Leu Gly Xaa Asp Ser
1 5

<210> 47
<211> 2790
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(2790)

<400> 47
tcg acc cca gcg tca gag cgg tcg gct tca ccg ctt ttc gag aaa cgc 48
Ser Thr Pro Ala Ser Glu Arg Ser Ala Ser Pro Leu Phe Glu Lys Arg
1 5 10 15

agt tcg gtt tcg tca gca cgc ctc gct gaa gct gaa gcc gcg gta ctg 96
Ser Ser Val Ser Ser Ala Arg Leu Ala Glu Ala Glu Ala Val Leu
20 25 30

agc gtt ctc gca gac aag aca ggc tac gac agc tca atg atc gag atg 144
Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met
35 40 45

gac atg gac ctg gag agt gag ctt ggc gtt gat agc atc aaa cgc gtg 192
Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val
50 55 60

2997-49-2-pct_ST25

gag Glu 65	atc Ile	atg Met	agc Ser	gag Glu	gtt Val 70	caa Gln	acg Thr	ctg Leu	ctc Leu	agc Ser 75	gtg Val	gaa Glu	gtc Val	tcc Ser	gac Asp 80	240
gtt Val	gac Asp	gct Ala	ctg Leu	tca Ser 85	aga Arg	acc Thr	aag Lys	act Thr	gtt Val 90	ggc Gly	gac Asp	gtc Val	atc Ile	gag Glu 95	gcg Ala	288
atg Met	aag Lys	ctg Leu	gaa Glu 100	ctc Leu	ggc Gly	gga Gly	ccc Pro	caa Gln 105	ggc Gly	cag Gln	act Thr	ttg Leu	acc Thr 110	gag Ala	gaa Glu	336
tcg Ser	atc Ile	cgt Arg 115	cag Gln	cca Pro	ccg Pro	gtg Val	tcc Ser 120	gag Glu	cct Pro	gct Ala	gta Val	ccg Pro 125	acc Thr	tca Ser	tcg Ser	384
tca Ser	agc Ser 130	agt Ser	att Ile	gct Ala	aat Asn	gtt Val 135	tcg Ser	tca Ser	gca Ala	cgc Arg	ctc Leu 140	gct Ala	gaa Glu	gct Ala	gaa Glu	432
gct Ala 145	gag Ala	gta Val	ctg Leu	agc Ser	gtt Val 150	ctc Leu	gca Ala	gac Asp	aag Lys	aca Thr 155	ggc Gly	tac Tyr	gac Asp	agc Ser	tca Ser 160	480
atg Met	atc Ile	gag Glu	atg Met	gac Asp 165	atg Met	gac Asp	ctg Leu	gag Glu	agc Ser 170	gag Glu	ctt Leu	ggc Gly	gtt Val	gat Asp 175	agc Ser	528
atc Ile	aaa Lys	cgc Arg	gtg Val 180	gag Glu	atc Ile	atg Met	agc Ser	gag Glu 185	gtt Val	caa Gln	acg Thr	ctg Leu	ctc Leu 190	agc Ser	gtg Val	576
gaa Glu	gtc Val	tcc Ser 195	gac Asp	gtt Val	gac Asp	gct Ala	ctg Leu 200	tca Ser	aga Arg	act Thr	aag Lys	act Thr 205	gtt Val	ggc Gly	gac Asp	624
gtc Val 210	atc Ile	gag Glu	gag Ala	atg Met	aag Lys	ctg Leu 215	gaa Glu	ctc Leu	ggc Gly	ggc Gly	ccc Pro 220	caa Gln	ggc Gly	cag Gln	act Thr	672
ttg Leu 225	acc Thr	gag Ala	gaa Glu	tcg Ser	atc Ile 230	cgt Arg	cag Gln	cca Pro	ccg Pro	gtg Val 235	tct Ser	gag Glu	cct Pro	gct Ala	gta Val 240	720
ccg Pro	acc Thr	tca Ser	tcg Ser	tca Ser 245	agc Ser	agt Ser	att Ile	gct Ala	aat Asn 250	gtt Val	tcg Ser	tca Ser	gca Ala	cgc Arg 255	ctc Leu	768
gct Ala	gaa Glu	gct Ala	gaa Glu 260	gag Ala	gag Ala	gta Val	ctg Leu	agc Ser 265	gtt Val	ctc Leu	gca Ala	gac Asp	aag Lys 270	aca Thr	ggc Gly	816
tac Tyr	gac Asp	agc Ser 275	tca Ser	atg Met	atc Ile	gag Glu	atg Met 280	gac Asp	atg Met	gac Asp	ctg Leu	gag Glu 285	agc Ser	gag Glu	ctt Leu	864
ggc Gly	gtc Val 290	gac Asp	agc Ser	atc Ile	aaa Lys	cgc Arg 295	gtg Val	gag Glu	atc Ile	atg Met	agc Ser 300	gag Glu	gtt Val	caa Gln	acg Thr	912
ctg Leu 305	ctc Leu	agc Ser	gtg Val	gaa Glu	gtc Val 310	tcc Ser	gac Asp	gtt Val	gac Asp	gct Ala 315	ctg Leu	tca Ser	aga Arg	acc Thr	aag Lys 320	960
act Thr	gtt Val	ggc Gly	gac Asp	gtc Val 325	atc Ile	gag Glu	gag Ala	atg Met	aag Lys 330	ctg Leu	gaa Glu	ctc Leu	ggc Gly	gga Gly 335	ccc Pro	1008

2997-49-2-pct_ST25

caa Gln	ggc Gly	cag Gln	act Thr 340	ttg Leu	acc Thr	gcg Ala	gaa Glu	tcg Ser 345	atc Ile	cgt Arg	cag Gln	cca Pro	ccg Pro 350	gtg Val	tcc Ser	1056
gag Glu	cct Pro	gct Ala 355	gta Val	ccg Pro	acc Thr	tca Ser	tcg Ser 360	tca Ser	agc Ser	agt Ser	att Ile	gct Ala 365	aat Asn	gtt Val	ttg Leu	1104
tca Ser	gca Ala 370	cg Arg	ctc Leu	gct Ala	gaa Glu	gct Ala 375	gaa Glu	gcc Ala	gcg Ala	gta Val	ctg Leu 380	agc Ser	ggt Val	ctc Leu	gca Ala	1152
gac Asp 385	aag Lys	aca Thr	ggc Gly	tac Tyr	gac Asp 390	agc Ser	tca Ser	atg Met	atc Ile	gag Glu 395	atg Met	gac Asp	atg Met	gac Asp	ctg Leu 400	1200
gag Glu	agc Ser	gag Glu	ctt Leu	ggc Gly 405	gtt Val	gat Asp	agc Ser	atc Ile	aaa Lys 410	cg Arg	gtg Val	gag Glu	atc Ile	atg Met 415	agc Ser	1248
gag Glu	gtt Val	caa Gln	acg Thr 420	ttg Leu	ctc Leu	agc Ser	gtg Val	gaa Glu 425	gtc Val	tcc Ser	gac Asp	gtt Val	gac Asp 430	gct Ala	ctg Leu	1296
tca Ser	aga Arg	acc Thr 435	aag Lys	act Thr	gtt Val	ggc Gly	gac Asp 440	gtc Val	atc Ile	gag Glu	gag Ala	atg Met 445	aag Lys	ctg Leu	gaa Glu	1344
ctc Leu	ggt Gly 450	gga Gly	ccc Pro	caa Gln	ggc Gly	cag Gln 455	act Thr	ttg Leu	acc Thr	gag Ala	gaa Glu 460	tcg Ser	atc Ile	cgt Arg	cag Gln	1392
cca Pro 465	ccg Pro	gtg Val	tct Ser	gag Glu	cct Pro 470	gct Ala	gta Val	ccg Pro	acc Thr	tca Ser 475	tcg Ser	tca Ser	agc Ser	agt Ser	att Ile 480	1440
gct Ala	aat Asn	gtt Val	tcg Ser	tca Ser 485	gca Ala	cg Arg	ctc Leu	gct Ala	gaa Glu 490	gct Ala	gaa Glu	gcc Ala	gag Ala	gta Val 495	ctg Leu	1488
agc Ser	gtt Val	ctc Leu	gca Ala 500	gac Asp	aag Lys	aca Thr	ggc Gly	tac Tyr 505	gac Asp	agc Ser	tca Ser	atg Met	atc Ile 510	gag Glu	atg Met	1536
gac Asp	atg Met	gac Asp 515	ctg Leu	gag Glu	agt Ser	gag Glu	ctt Leu 520	ggc Gly	gtc Val	gac Asp	agc Ser	atc Ile 525	aaa Lys	cg Arg	gtg Val	1584
gag Glu	atc Ile 530	atg Met	agc Ser	gag Glu	gtt Val	caa Gln 535	acg Thr	ctg Leu	ctc Leu	agc Ser	gtg Val 540	gaa Glu	gtc Val	tcc Ser	gac Asp	1632
gtt Val 545	gac Asp	gct Ala	ctg Leu	tca Ser	aga Arg 550	acc Thr	aag Lys	act Thr	gtt Val	ggc Gly 555	gac Asp	gtc Val	atc Ile	gag Glu	gcg Ala 560	1680
atg Met	aag Lys	ctg Leu	gaa Glu	ctc Leu 565	ggt Gly	gga Gly	ccc Pro	caa Gln	ggc Gly 570	cag Gln	act Thr	ttg Leu	acc Thr	tct Ser 575	gaa Glu	1728
ccg Pro	atc Ile	cat His 580	cag Gln	cca Pro	cca Pro	gtg Val	tcc Ser	gag Glu 585	cct Pro	gct Ala	gta Val	ccg Pro	acc Thr 590	tca Ser	tcg Ser	1776
tca Ser	agc Ser	agt Ser 595	att Ile	gct Ala	aat Asn	gtt Val	tct Ser 600	tca Ser	gca Ala	cg Arg	ctc Leu	gct Ala 605	gaa Glu	gct Ala	gaa Glu	1824

2997-49-2-pct_ST25

gcc Ala 610	gcg Ala 610	gta Val	ctg Leu	agc Ser	gtt Val	ctc Leu 615	gca Ala	gac Asp	aag Lys	aca Thr	ggc Gly 620	tac Tyr	gac Asp	agc Ser	tca Ser	1872
atg Met 625	atc Ile	gag Glu	atg Met	gac Asp	atg Met 630	gac Asp	ctg Leu	gag Glu	agc Ser	gag Glu 635	ctt Leu	ggc Gly	gtt Val	gat Asp	agc Ser 640	1920
atc Ile	aaa Lys	cgc Arg	gtg Val	gaa Glu 645	atc Ile	atg Met	agc Ser	gag Glu	gtt Val 650	caa Gln	acg Thr	ctg Leu	ctc Leu	agc Ser 655	gtg Val	1968
gaa Glu	gtc Val	tcc Ser	gac Asp 660	gtt Val	gac Asp	gct Ala	ctg Leu	tca Ser 665	aga Arg	acc Thr	aag Lys	act Thr	gtt Val 670	ggc Gly	gac Asp	2016
gtc Val	atc Ile	gag Glu 675	gcg Ala	atg Met	aag Lys	atg Met	gaa Glu 680	ctc Leu	ggg Gly	gga Gly	ccc Pro	caa Gln 685	ggc Gly	cag Gln	act Thr	2064
ttg Leu 690	acc Thr	gcg Ala	gaa Glu	tcg Ser	atc Ile	cgt Arg 695	cag Gln	cca Pro	ccg Pro	gtg Val	tct Ser 700	gag Glu	cct Pro	gct Ala	gta Val	2112
ccg Pro 705	acc Thr	tca Ser	tcg Ser	tca Ser	agc Ser 710	agt Ser	att Ile	gct Ala	aat Asn	gtt Val 715	tcg Ser	tca Ser	gca Ala	cgc Arg	ctc Leu 720	2160
gct Ala	gaa Glu	gct Ala	gaa Glu	gcg Ala 725	gcg Ala	gta Val	ctg Leu	agc Ser	gtt Val 730	ctc Leu	gca Ala	gac Asp	aag Lys	aca Thr 735	ggc Gly	2208
tac Tyr	gac Asp	agc Ser	tca Ser 740	atg Met	atc Ile	gag Glu	atg Met	gac Asp 745	atg Met	gac Asp	ctg Leu	gag Glu	agc Ser 750	gag Glu	ctt Leu	2256
ggc Gly	gtt Val	gat Asp 755	agc Ser	atc Ile	aaa Lys	cgc Arg	gtg Val 760	gag Glu	atc Ile	atg Met	agc Ser	gag Glu 765	gtt Val	caa Gln	gcg Ala	2304
ctg Leu 770	ctc Leu	agc Ser	gtg Val	gaa Glu	gtc Val	tcc Ser 775	gac Asp	gtt Val	gac Asp	gct Ala	ctg Leu 780	tca Ser	aga Arg	acc Thr	aag Lys	2352
act Thr 785	gtt Val	ggc Gly	gac Asp	gtc Val	atc Ile 790	gag Glu	gcg Ala	atg Met	aag Lys	atg Met 795	gaa Glu	ctc Leu	ggg Gly	gga Gly	ccc Pro 800	2400
caa Gln	ggc Gly	cag Gln	act Thr	ttg Leu 805	acc Thr	gca Ala	gaa Glu	tcg Ser	atc Ile 810	cgt Arg	gag Glu	cca Pro	ccg Pro	gtg Val 815	tct Ser	2448
gag Glu	cct Pro	gct Ala	gta Val 820	ccg Pro	acc Thr	tca Ser	tcg Ser	tca Ser 825	agt Ser	agt Ser	atc Ile	gct Ala	aat Asn 830	gtt Val	tct Ser	2496
tca Ser	gct Ala	cgc Arg 835	ctc Leu	gct Ala	gaa Glu	gct Ala	gaa Glu 840	gcc Ala	gcg Ala	gta Val	ctg Leu	agc Ser 845	gtt Val	ctc Leu	gca Ala	2544
gac Asp	aag Lys 850	aca Thr	ggc Gly	tac Tyr	gac Asp	agc Ser 855	tca Ser	atg Met	atc Ile	gag Glu	atg Met 860	gac Asp	atg Met	gac Asp	ctg Leu	2592
gag Glu 865	agt Ser	gag Glu	ctt Leu	ggc Gly	gtc Val 870	gac Asp	agc Ser	atc Ile	aaa Lys	cgc Arg 875	gtg Val	gag Glu	atc Ile	atg Met	agc Ser 880	2640

2997-49-2-pct_ST25

gag gtt caa acg ttg ctc agc gtg gaa gtc tcc gac gtt gac gct ctg 2688
Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp Val Asp Ala Leu
885 890 895

tca aga acc aag act gtt ggc gac gtc atc gag gcg atg aag ctg gaa 2736
Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala Met Lys Leu Glu
900 905 910

ctt ggg gaa tca tca agt att gag act ctc aat tgt acc gag gtt gag 2784
Leu Gly Glu Ser Ser Ser Ile Glu Thr Leu Asn Cys Thr Glu Val Glu
915 920 925

cac acg 2790
His Thr
930

<210> 48
<211> 930
<212> PRT
<213> Thraustochytrium sp.

<400> 48

Ser Thr Pro Ala Ser Glu Arg Ser Ala Ser Pro Leu Phe Glu Lys Arg
1 5 10 15

Ser Ser Val Ser Ser Ala Arg Leu Ala Glu Ala Glu Ala Ala Val Leu
20 25 30

Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met
35 40 45

Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val
50 55 60

Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp
65 70 75 80

Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala
85 90 95

Met Lys Leu Glu Leu Gly Gly Pro Gln Gly Gln Thr Leu Thr Ala Glu
100 105 110

Ser Ile Arg Gln Pro Pro Val Ser Glu Pro Ala Val Pro Thr Ser Ser
115 120 125

Ser Ser Ser Ile Ala Asn Val Ser Ser Ala Arg Leu Ala Glu Ala Glu
130 135 140

Ala Ala Val Leu Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser
145 150 155 160

Met Ile Glu Met Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser
165 170 175

2997-49-2-pct_ST25

Ile Lys Arg Val Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val
180 185 190

Glu Val Ser Asp Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp
195 200 205

Val Ile Glu Ala Met Lys Leu Glu Leu Gly Gly Pro Gln Gly Gln Thr
210 215 220

Leu Thr Ala Glu Ser Ile Arg Gln Pro Pro Val Ser Glu Pro Ala Val
225 230 235 240

Pro Thr Ser Ser Ser Ser Ser Ile Ala Asn Val Ser Ser Ala Arg Leu
245 250 255

Ala Glu Ala Glu Ala Ala Val Leu Ser Val Leu Ala Asp Lys Thr Gly
260 265 270

Tyr Asp Ser Ser Met Ile Glu Met Asp Met Asp Leu Glu Ser Glu Leu
275 280 285

Gly Val Asp Ser Ile Lys Arg Val Glu Ile Met Ser Glu Val Gln Thr
290 295 300

Leu Leu Ser Val Glu Val Ser Asp Val Asp Ala Leu Ser Arg Thr Lys
305 310 315 320

Thr Val Gly Asp Val Ile Glu Ala Met Lys Leu Glu Leu Gly Gly Pro
325 330 335

Gln Gly Gln Thr Leu Thr Ala Glu Ser Ile Arg Gln Pro Pro Val Ser
340 345 350

Glu Pro Ala Val Pro Thr Ser Ser Ser Ser Ile Ala Asn Val Leu
355 360 365

Ser Ala Arg Leu Ala Glu Ala Glu Ala Ala Val Leu Ser Val Leu Ala
370 375 380

Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met Asp Met Asp Leu
385 390 395 400

Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val Glu Ile Met Ser
405 410 415

Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp Val Asp Ala Leu
420 425 430

Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala Met Lys Leu Glu
435 440 445

2997-49-2-pct_ST25

Leu Gly Gly Pro Gln Gly Gln Thr Leu Thr Ala Glu Ser Ile Arg Gln
 450 455 460
 Pro Pro Val Ser Glu Pro Ala Val Pro Thr Ser Ser Ser Ser Ile
 465 470 475 480
 Ala Asn Val Ser Ser Ala Arg Leu Ala Glu Ala Glu Ala Ala Val Leu
 485 490 495
 Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met
 500 505 510
 Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val
 515 520 525
 Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp
 530 535 540
 Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala
 545 550 555 560
 Met Lys Leu Glu Leu Gly Gly Pro Gln Gly Gln Thr Leu Thr Ser Glu
 565 570 575
 Pro Ile His Gln Pro Pro Val Ser Glu Pro Ala Val Pro Thr Ser Ser
 580 585 590
 Ser Ser Ser Ile Ala Asn Val Ser Ser Ala Arg Leu Ala Glu Ala Glu
 595 600 605
 Ala Ala Val Leu Ser Val Leu Ala Asp Lys Thr Gly Tyr Asp Ser Ser
 610 615 620
 Met Ile Glu Met Asp Met Asp Leu Glu Ser Glu Leu Gly Val Asp Ser
 625 630 635 640
 Ile Lys Arg Val Glu Ile Met Ser Glu Val Gln Thr Leu Leu Ser Val
 645 650 655
 Glu Val Ser Asp Val Asp Ala Leu Ser Arg Thr Lys Thr Val Gly Asp
 660 665 670
 Val Ile Glu Ala Met Lys Met Glu Leu Gly Gly Pro Gln Gly Gln Thr
 675 680 685
 Leu Thr Ala Glu Ser Ile Arg Gln Pro Pro Val Ser Glu Pro Ala Val
 690 695 700
 Pro Thr Ser Ser Ser Ser Ser Ile Ala Asn Val Ser Ser Ala Arg Leu
 705 710 715 720

2997-49-2-pct_ST25

Ala Glu Ala Glu Ala Ala Val Leu Ser Val Leu Ala Asp Lys Thr Gly
725 730 735

Tyr Asp Ser Ser Met Ile Glu Met Asp Met Asp Leu Glu Ser Glu Leu
740 745 750

Gly Val Asp Ser Ile Lys Arg Val Glu Ile Met Ser Glu Val Gln Ala
755 760 765

Leu Leu Ser Val Glu Val Ser Asp Val Asp Ala Leu Ser Arg Thr Lys
770 775 780

Thr Val Gly Asp Val Ile Glu Ala Met Lys Met Glu Leu Gly Gly Pro
785 790 795 800

Gln Gly Gln Thr Leu Thr Ala Glu Ser Ile Arg Glu Pro Pro Val Ser
805 810 815

Glu Pro Ala Val Pro Thr Ser Ser Ser Ser Ile Ala Asn Val Ser
820 825 830

Ser Ala Arg Leu Ala Glu Ala Glu Ala Ala Val Leu Ser Val Leu Ala
835 840 845

Asp Lys Thr Gly Tyr Asp Ser Ser Met Ile Glu Met Asp Met Asp Leu
850 855 860

Glu Ser Glu Leu Gly Val Asp Ser Ile Lys Arg Val Glu Ile Met Ser
865 870 875 880

Glu Val Gln Thr Leu Leu Ser Val Glu Val Ser Asp Val Asp Ala Leu
885 890 895

Ser Arg Thr Lys Thr Val Gly Asp Val Ile Glu Ala Met Lys Leu Glu
900 905 910

Leu Gly Glu Ser Ser Ser Ile Glu Thr Leu Asn Cys Thr Glu Val Glu
915 920 925

His Thr
930

<210> 49
<211> 2433
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(2433)

<400> 49

2997-49-2-pct_ST25

aaa Lys 1	agt Ser	gtc Val	aag Lys	gct Ala 5	tca Ser	ggg Gly	tgt Cys	gag Glu 10	aat Asn	gta Val	gat Asp	acc Thr	cgt Arg	ttc Phe 15	gct Ala	48
aag Lys	gtt Val	gta Val	caa Gln 20	atc Ile	tcg Ser	ctt Leu	cct Pro	agc Ser 25	aag Lys	ctg Leu	aaa Lys	tcc Ser	act Thr 30	gtg Val	tcg Ser	96
cac His	gat Asp	cga Arg 35	cct Pro	gta Val	att Ile	gtt Val	gta Val 40	gat Asp	gat Asp	gga Gly	acg Thr	ccc Pro 45	tta Leu	acc Thr	acg Thr	144
gag Glu	ctt Leu 50	tgt Cys	aaa Lys	att Ile	ctt Leu	ggg Gly 55	ggt Gly	aat Asn	att Ile	gtg Val	gtt Val 60	ctc Leu	tct Ser	tat Tyr	caa Gln	192
ggg Gly 65	aag Lys	ccc Pro	gct Ala	ggt Gly	cca Pro 70	cgg Arg	gga Gly	gtc Val	gag Glu	gtg Val 75	cca Pro	gat Asp	ctt Leu	tcc Ser	gag Glu 80	240
gaa Glu	gcc Ala	cta Leu	att Ile	caa Gln 85	gct Ala	ctt Leu	gca Ala	ttg Leu	att Ile 90	cgg Arg	tct Ser	aca Thr	tat Tyr	gga Gly 95	gtt Val	288
cca Pro	att Ile	ggt Gly	ttt Phe 100	att Ile	tgt Cys	cag Gln	caa Gln	gtg Val 105	tct Ser	aat Asn	gtg Val	agc Ser	acc Thr 110	aag Lys	gca Ala	336
cag Gln	ctt Leu	tgt Cys 115	tgg Trp	gca Ala	ctc Leu	ctc Leu	gca Ala 120	gcg Ala	aag Lys	cat His	ctc Leu	aag Lys 125	aag Lys	gat Asp	ttg Leu	384
aat Asn 130	gct Ala	gtc Val	tta Leu	ccc Pro	gat Asp	tca Ser 135	aga Arg	tcc Ser	ttc Phe	ttc Phe	gtc Val 140	gga Gly	gtt Val	gta Val	cgc Arg	432
ttg Leu 145	aac Asn	ggg Gly	aaa Lys	ctt Leu	gga Gly 150	act Thr	ttc Phe	gaa Glu	aac Asn	atc Ile 155	agc Ser	gac Asp	ttc Phe	tct Ser	aaa Lys 160	480
ttt Phe	gat Asp	ttg Leu	acg Thr	aaa Lys 165	gcc Ala	cta Leu	gat Asp	tac Tyr	gga Gly 170	cag Gln	cgt Arg	ggt Gly	tct Ser	ctc Leu 175	tta Leu	528
ggc Gly	ctg Leu	tgc Cys	aag Lys 180	tca Ser	cta Leu	gac Asp	tta Leu	gaa Glu 185	tgg Trp	gaa Glu	cag Gln	gtg Val	ttt Phe 190	tgc Cys	cgt Arg	576
gga Gly	ata Ile	gat Asp 195	ctt Leu	gcg Ala	tgt Cys	gat Asp	ctt Leu 200	atg Met	cca Pro	ctc Leu	cag Gln	gcc Ala 205	gca Ala	agg Arg	ata Ile	624
ctc Leu 210	aga Arg	aat Asn	gag Glu	ctt Leu	cag Gln	tgt Cys 215	ccc Pro	aat Asn	atg Met	cgc Arg	ctt Leu 220	cgc Arg	gag Glu	gtt Val	ggg Gly	672
tac Tyr 225	gat Asp	att Ile	tct Ser	ggc Gly	gcc Ala 230	agg Arg	tac Tyr	acc Thr	att Ile	tca Ser 235	acc Thr	gat Asp	gac Asp	ctg Leu	cta Leu 240	720
tgt Cys	gga Gly	ccc Pro	tcg Ser	aag Lys 245	gct Ala	aaa Lys	gta Val	gag Glu	gcc Ala 250	gca Ala	gac Asp	ttg Leu	ttt Phe	ctt Leu 255	gtg Val	768
aca Thr	ggt Gly	ggc Gly	gca Ala 260	cga Arg	ggt Gly	att Ile	aca Thr	cct Pro 265	cat His	tgt Cys	gtt Val	cgt Arg	gag Glu 270	att Ile	gca Ala	816

2997-49-2-pct_ST25

agt Ser	cga Arg	tcc Ser 275	ccc Pro	gga Gly	acc Thr	aca Thr	ttt Phe 280	gtg Val	ctg Leu	gtt Val	gga Gly	aga Arg 285	agc Ser	gaa Glu	atg Met	864
tcc Ser	gac Asp 290	gag Glu	cct Pro	gac Asp	tgg Trp	gct Ala 295	gtt Val	ggc Gly	cac His	tac Tyr	aat Asn 300	aaa Lys	gac Asp	ctg Leu	gac Asp	912
caa Gln 305	agc Ser	aca Thr	atg Met	aaa Lys	cac His 310	ttg Leu	aaa Lys	gca Ala	acg Thr	cat His 315	gct Ala	gct Ala	gga Gly	ggg Gly	gta Val 320	960
aaa Lys	cct Pro	acg Thr	cct Pro	aaa Lys 325	gca Ala	cat His	cgt Arg	gca Ala	ctt Leu 330	gtg Val	aac Asn	agg Arg	gtc Val	act Thr 335	ggc Gly	1008
tca Ser	cgg Arg	gag Glu	gta Val 340	cga Arg	gaa Glu	tct Ser	ctt Leu	aga Arg 345	gca Ala	atc Ile	cag Gln	gag Glu	gca Ala 350	ggg Gly	gca Ala	1056
aat Asn	gtc Val	gaa Glu 355	tat Tyr	atc Ile	gcc Ala	tgt Cys	gat Asp 360	gtt Val	tgc Ser	gat Asp	gaa Glu	aac Asn 365	aag Lys	gtc Val	cgc Arg	1104
caa Gln	ctt Leu 370	gtg Val	caa Gln	aga Arg	gtg Val	gag Glu 375	caa Gln	aag Lys	tat Tyr	ggc Gly	tgt Cys 380	gaa Glu	ata Ile	act Thr	ggg Gly	1152
att Ile 385	tgg Trp	cat His	gca Ala	agc Ser	ggg Gly 390	gtt Val	ctt Leu	cgt Arg	gac Asp	aaa Lys 395	ctt Leu	gtc Val	gag Glu	caa Gln	aag Lys 400	1200
act Thr	aca Thr	gac Asp	gac Asp	ttt Phe 405	gag Glu	gca Ala	gtt Val	ttt Phe	ggg Gly 410	acc Thr	aag Lys	gtg Val	act Thr	ggc Gly 415	ctt Leu	1248
gta Val	aac Asn	atc Ile	gtg Val 420	tca Ser	caa Gln	gtc Val	aat Asn	atg Met 425	tct Ser	aag Lys	cta Leu	cga Arg	cac His 430	ttc Phe	atc Ile	1296
ctc Leu	ttc Phe	agt Ser 435	tct Ser	ttg Leu	gct Ala	gga Gly	ttt Phe 440	cat His	ggg Gly	aac Asn	aag Lys	ggc Gly 445	caa Gln	acg Thr	gat Asp	1344
tat Tyr	gca Ala 450	att Ile	gct Ala	aat Asn	gaa Glu	gcc Ala 455	ttg Leu	aac Asn	aaa Lys	atc Ile	gcg Ala 460	cat His	act Thr	ctc Leu	tca Ser	1392
gcg Ala 465	ttt Phe	ttg Leu	ccc Pro	aaa Lys	ctg Leu 470	aat Asn	gca Ala	aag Lys	gtg Val	cta Leu 475	gac Asp	ttc Phe	ggg Gly	ccg Pro	tgg Trp 480	1440
gta Val	ggg Gly	tca Ser	gga Gly	atg Met 485	gta Val	acc Thr	gaa Glu	aca Thr	ctt Leu 490	gag Glu	aag Lys	cat His	ttt Phe	aaa Lys 495	gct Ala	1488
atg Met	ggg Gly	gtt Val	cag Gln 500	act Thr	att Ile	cct Pro	ctc Leu	gag Glu 505	cca Pro	gga Gly	gca Ala	cgg Arg	act Thr 510	gtt Val	gcg Ala	1536
caa Gln	atc Ile	att Ile 515	ttg Leu	gca Ala	agt Ser	tcg Ser	cca Pro 520	ccg Pro	caa Gln	tcg Ser	ctt Leu	ttg Leu 525	ggg Gly	aac Asn	tgg Trp	1584
ggc Gly	ttt Phe 530	cca Pro	gcc Ala	acc Thr	aaa Lys	ccg Pro 535	cta Leu	caa Gln	cgc Arg	tct Ser	aat Asn 540	gta Val	gtc Val	acg Thr	ggc Gly	1632

2997-49-2-pct_ST25

aca Thr 545	ctc Leu	tct Ser	ccg Pro	gaa Glu 550	gag Glu 550	ata Ile	gaa Glu	ttc Phe	atc Ile	gca Ala 555	gac Asp	cac His	aaa Lys	att Ile	caa Gln 560	1680
ggc Gly	cgc Arg	aag Lys	gtg Val 565	ctt Leu 565	ccc Pro	atg Met	atg Met	gct Ala	gca Ala 570	atc Ile	ggg Gly	ttc Phe	atg Met	gcc Ala 575	tct Ser	1728
att Ile	gcg Ala	gaa Glu	gga Gly 580	ctc Leu	tac Tyr	ccg Pro	ggg Gly	tac Tyr 585	aat Asn	ctg Leu	caa Gln	ggc Gly	gtg Val 590	gaa Glu	aat Asn	1776
gct Ala	cag Gln	ctc Leu 595	ttt Phe	caa Gln	ggc Gly	ttg Leu	act Thr 600	atc Ile	aac Asn	caa Gln	gag Glu	aca Thr 605	aaa Lys	ttt Phe	caa Gln	1824
atc Ile	act Thr 610	ctc Leu	att Ile	gag Glu	gag Glu	cac His 615	aac Asn	tct Ser	gag Glu	gaa Glu	aac Asn 620	ctg Leu	gat Asp	gtc Val	ctg Leu	1872
aca Thr 625	tcc Ser	ctt Leu	ggt Gly	gta Val	atg Met 630	ttg Leu	gaa Glu	agc Ser	ggg Gly	aag Lys 635	gtg Val	ctt Leu	ccc Pro	gct Ala	tac Tyr 640	1920
cga Arg	tgt Cys	gtt Val	gta Val	tgc Cys 645	ttg Leu	aat Asn	aca Thr	acc Thr	cag Gln 650	cag Gln	cag Gln	ccc Pro	aag Lys	cta Leu 655	tct Ser	1968
cca Pro	aaa Lys	att Ile	ctt Leu 660	aac Asn	ttg Leu	gaa Glu	gtt Val	gac Asp 665	cct Pro	gca Ala	tgc Cys	gag Glu	gtt Val 670	aac Asn	ccc Pro	2016
tat Tyr	gat Asp	gga Gly 675	aag Lys	tgc Ser	ttg Leu	ttc Phe	cac His 680	ggt Gly	ccg Pro	ctt Leu	ttg Leu	caa Gln 685	ttc Phe	gtt Val	caa Gln	2064
caa Gln 690	gtg Val	ttg Leu	cac His	tca Ser	agt Ser	acc Thr 695	aaa Lys	ggc Gly	ctc Leu	gtt Val	gcc Ala 700	aag Lys	tgc Cys	cgc Arg	gcg Ala	2112
ctt Leu 705	cca Pro	atc Ile	aaa Lys	gaa Glu	gcc Ala 710	atc Ile	cga Arg	ggg Gly	cca Pro	ttt Phe 715	atc Ile	aag Lys	caa Gln	aca Thr	ctc Leu 720	2160
cat His	gat Asp	cca Pro	att Ile	cta Leu 725	gac Asp	gac Asp	gtc Val	att Ile	ttt Phe 730	cag Gln	cta Leu	atg Met	ctc Leu	gtg Val 735	tgg Trp	2208
tgt Cys	cgf Arg	aat Asn	gct Ala 740	cta Leu	gga Gly	agt Ser	gca Ala	tgc Ser 745	cta Leu	ccc Pro	aac Asn	aga Arg	att Ile 750	gaa Glu	aag Lys	2256
atg Met	tca Ser	tac Tyr 755	ttt Phe	ggg Gly	aat Asn	gtc Val	tca Ser 760	gaa Glu	ggt Gly	agc Ser	act Thr	ttc Phe 765	ttt Phe	gcc Ala	tca Ser	2304
gtt Val 770	aca Thr	cct Pro	gtg Val	gga Gly	cca Pro	aga Arg 775	gta Val	cca Pro	aag Lys	gat Asp	ccc Pro	gtg Val	atc Ile	aaa Lys	atg Met	2352
cag Gln 785	ttt Phe	ctt Leu	ctc Leu	caa Gln	gat Asp 790	gaa Glu	tcc Ser	ggc Gly	aac Asn	aca Thr 795	ttt Phe	tca Ser	tcg Ser	ggg Gly	gag Glu 800	2400
ggc Gly	tcg Ser	gtt Val	gtg Val	ctt Leu 805	agt Ser	gac Asp	gaa Glu	ctc Leu	gtc Val 810	ttt Phe						2433

<210> 50
 <211> 811
 <212> PRT
 <213> Thraustochytrium sp.

<400> 50

Lys Ser Val Lys Ala Ser Gly Cys Glu Asn Val Asp Thr Arg Phe Ala
 1 5 10 15

Lys Val Val Gln Ile Ser Leu Pro Ser Lys Leu Lys Ser Thr Val Ser
 20 25 30

His Asp Arg Pro Val Ile Val Val Asp Asp Gly Thr Pro Leu Thr Thr
 35 40 45

Glu Leu Cys Lys Ile Leu Gly Gly Asn Ile Val Val Leu Ser Tyr Gln
 50 55 60

Gly Lys Pro Ala Gly Pro Arg Gly Val Glu Val Pro Asp Leu Ser Glu
 65 70 75 80

Glu Ala Leu Ile Gln Ala Leu Ala Leu Ile Arg Ser Thr Tyr Gly Val
 85 90 95

Pro Ile Gly Phe Ile Cys Gln Gln Val Ser Asn Val Ser Thr Lys Ala
 100 105 110

Gln Leu Cys Trp Ala Leu Leu Ala Ala Lys His Leu Lys Lys Asp Leu
 115 120 125

Asn Ala Val Leu Pro Asp Ser Arg Ser Phe Phe Val Gly Val Val Arg
 130 135 140

Leu Asn Gly Lys Leu Gly Thr Phe Glu Asn Ile Ser Asp Phe Ser Lys
 145 150 155 160

Phe Asp Leu Thr Lys Ala Leu Asp Tyr Gly Gln Arg Gly Ser Leu Leu
 165 170 175

Gly Leu Cys Lys Ser Leu Asp Leu Glu Trp Glu Gln Val Phe Cys Arg
 180 185 190

Gly Ile Asp Leu Ala Cys Asp Leu Met Pro Leu Gln Ala Ala Arg Ile
 195 200 205

Leu Arg Asn Glu Leu Gln Cys Pro Asn Met Arg Leu Arg Glu Val Gly
 210 215 220

Tyr Asp Ile Ser Gly Ala Arg Tyr Thr Ile Ser Thr Asp Asp Leu Leu
 225 230 235 240

2997-49-2-pct_ST25

Cys Gly Pro Ser Lys₂₄₅ Ala Lys Val Glu₂₅₀ Ala Ala Asp Leu Phe₂₅₅ Leu Val

Thr Gly Gly Ala₂₆₀ Arg Gly Ile Thr Pro₂₆₅ His Cys Val Arg Glu₂₇₀ Ile Ala

Ser Arg Ser₂₇₅ Pro Gly Thr Thr Phe₂₈₀ Val Leu Val Gly Arg₂₈₅ Ser Glu Met

Ser Asp₂₉₀ Glu Pro Asp Trp Ala₂₉₅ Val Gly His Tyr Asn₃₀₀ Lys Asp Leu Asp

Gln₃₀₅ Ser Thr Met Lys His₃₁₀ Leu Lys Ala Thr His₃₁₅ Ala Ala Gly Gly Val₃₂₀

Lys Pro Thr Pro Lys₃₂₅ Ala His Arg Ala Leu₃₃₀ Val Asn Arg Val Thr₃₃₅ Gly

Ser Arg Glu Val₃₄₀ Arg Glu Ser Leu Arg₃₄₅ Ala Ile Gln Glu Ala₃₅₀ Gly Ala

Asn Val Glu₃₅₅ Tyr Ile Ala Cys Asp₃₆₀ Val Ser Asp Glu Asn₃₆₅ Lys Val Arg

Gln Leu Val Gln Arg Val Glu₃₇₅ Gln Lys Tyr Gly Cys₃₈₀ Glu Ile Thr Gly

Ile Trp His Ala Ser Gly₃₉₀ Val Leu Arg Asp Lys₃₉₅ Leu Val Glu Gln Lys₄₀₀

Thr Thr Asp Asp Phe₄₀₅ Glu Ala Val Phe Gly₄₁₀ Thr Lys Val Thr Gly₄₁₅ Leu

Val Asn Ile Val₄₂₀ Ser Gln Val Asn Met₄₂₅ Ser Lys Leu Arg His₄₃₀ Phe Ile

Leu Phe Ser₄₃₅ Ser Leu Ala Gly Phe₄₄₀ His Gly Asn Lys Gly₄₄₅ Gln Thr Asp

Tyr Ala₄₅₀ Ile Ala Asn Glu Ala₄₅₅ Leu Asn Lys Ile Ala₄₆₀ His Thr Leu Ser

Ala Phe Leu Pro Lys Leu₄₇₀ Asn Ala Lys Val Leu₄₇₅ Asp Phe Gly Pro Trp₄₈₀

Val Gly Ser Gly Met₄₈₅ Val Thr Glu Thr Leu₄₉₀ Glu Lys His Phe Lys₄₉₅ Ala

Met Gly Val Gln₅₀₀ Thr Ile Pro Leu Glu₅₀₅ Pro Gly Ala Arg Thr₅₁₀ Val Ala

2997-49-2-pct_ST25

Gln Ile Ile Leu Ala Ser Ser Pro Pro Gln Ser Leu Leu Gly Asn Trp
 515 520 525

Gly Phe Pro Ala Thr Lys Pro Leu Gln Arg Ser Asn Val Val Thr Gly
 530 535 540

Thr Leu Ser Pro Glu Glu Ile Glu Phe Ile Ala Asp His Lys Ile Gln
 545 550 555 560

Gly Arg Lys Val Leu Pro Met Met Ala Ala Ile Gly Phe Met Ala Ser
 565 570 575

Ile Ala Glu Gly Leu Tyr Pro Gly Tyr Asn Leu Gln Gly Val Glu Asn
 580 585 590

Ala Gln Leu Phe Gln Gly Leu Thr Ile Asn Gln Glu Thr Lys Phe Gln
 595 600 605

Ile Thr Leu Ile Glu Glu His Asn Ser Glu Glu Asn Leu Asp Val Leu
 610 615 620

Thr Ser Leu Gly Val Met Leu Glu Ser Gly Lys Val Leu Pro Ala Tyr
 625 630 635 640

Arg Cys Val Val Cys Leu Asn Thr Thr Gln Gln Gln Pro Lys Leu Ser
 645 650 655

Pro Lys Ile Leu Asn Leu Glu Val Asp Pro Ala Cys Glu Val Asn Pro
 660 665 670

Tyr Asp Gly Lys Ser Leu Phe His Gly Pro Leu Leu Gln Phe Val Gln
 675 680 685

Gln Val Leu His Ser Ser Thr Lys Gly Leu Val Ala Lys Cys Arg Ala
 690 695 700

Leu Pro Ile Lys Glu Ala Ile Arg Gly Pro Phe Ile Lys Gln Thr Leu
 705 710 715 720

His Asp Pro Ile Leu Asp Asp Val Ile Phe Gln Leu Met Leu Val Trp
 725 730 735

Cys Arg Asn Ala Leu Gly Ser Ala Ser Leu Pro Asn Arg Ile Glu Lys
 740 745 750

Met Ser Tyr Phe Gly Asn Val Ser Glu Gly Ser Thr Phe Phe Ala Ser
 755 760 765

Val Thr Pro Val Gly Pro Arg Val Pro Lys Asp Pro Val Ile Lys Met
 770 775 780

2997-49-2-pct_ST25

Gln Phe Leu Leu Gln Asp Glu Ser Gly Asn Thr Phe Ser Ser Gly Glu
785 790 795 800

Gly Ser Val Val Leu Ser Asp Glu Leu Val Phe
805 810

<210> 51
<211> 5808
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(5805)

<220>
<221> misc_feature
<222> (1)..(5808)
<223> n = a c t o r g

<400> 51		
atg caa ctt cct cca gcg cat tct gcc gat gag aat cgc atc gcg gtc		48
Met Gln Leu Pro Pro Ala His Ser Ala Asp Glu Asn Arg Ile Ala Val		
1 5 10 15		
gtg ggc atg gcc gtc aaa tat gcg ggc tgt gac aat aaa gaa gag ttt		96
Val Gly Met Ala Val Lys Tyr Ala Gly Cys Asp Asn Lys Glu Glu Phe		
20 25 30		
tgg aag act ttg atg aat ggt agt atc aat acc aag tcg att tcg gca		144
Trp Lys Thr Leu Met Asn Gly Ser Ile Asn Thr Lys Ser Ile Ser Ala		
35 40 45		
gca agg ttg ggc agc aat aag cgt gac gaa cac tat gtt cct gaa cga		192
Ala Arg Leu Gly Ser Asn Lys Arg Asp Glu His Tyr Val Pro Glu Arg		
50 55 60		
tcg aaa tat gca gat acg ttc tgt aac gaa agg tac ggt tgt atc cag		240
Ser Lys Tyr Ala Asp Thr Phe Cys Asn Glu Arg Tyr Gly Cys Ile Gln		
65 70 75 80		
caa ggt acg gat aat gag cat gac ctc ctc cta ggt ctt gct caa gaa		288
Gln Gly Thr Asp Asn Glu His Asp Leu Leu Leu Gly Leu Ala Gln Glu		
85 90 95		
gct ctc gct gac gct gcc ggg cgg atg gag aaa caa cct tcg gag gcg		336
Ala Leu Ala Asp Ala Ala Gly Arg Met Glu Lys Gln Pro Ser Glu Ala		
100 105 110		
ttc gat ctg gaa aat act ggc atc gtg agt ggg tgc tta tct ttt cca		384
Phe Asp Leu Glu Asn Thr Gly Ile Val Ser Gly Cys Leu Ser Phe Pro		
115 120 125		
atg gat aac ctg caa gga gag ttg ttg aac ttg tat caa agc cat gtg		432
Met Asp Asn Leu Gln Gly Glu Leu Leu Asn Leu Tyr Gln Ser His Val		
130 135 140		
gag aaa caa ctt cca cct agt gcc ttg gta gaa gcc gtg aag ctt tgg		480
Glu Lys Gln Leu Pro Pro Ser Ala Leu Val Glu Ala Val Lys Leu Trp		
145 150 155 160		
tct gag cga cag aaa tct acg aaa gca cat gca ggg gac aag cgc cgg		528
Ser Glu Arg Gln Lys Ser Thr Lys Ala His Ala Gly Asp Lys Arg Arg		
165 170 175		

2997-49-2-pct_ST25

ttc	att	gac	cca	gct	tct	ttt	gta	gct	gat	aaa	ctg	aac	cta	ggc	cca	576
Phe	Ile	Asp	Pro	Ala	Ser	Phe	Val	Ala	Asp	Lys	Leu	Asn	Leu	Gly	Pro	
			180					185					190			
cta	cat	tat	gcg	atc	gat	gca	gca	tgc	gct	tct	gca	ttg	tac	gtg	tta	624
Leu	His	Tyr	Ala	Ile	Asp	Ala	Ala	Cys	Ala	Ser	Ala	Leu	Tyr	Val	Leu	
		195					200					205				
aaa	tta	gct	caa	gac	cac	ctt	ggt	tca	ggc	ggt	gat	atg	atg	tta	672	
Lys	Leu	Ala	Gln	Asp	His	Leu	Val	Ser	Gly	Ala	Val	Asp	Met	Met	Leu	
	210					215					220					
tgt	gga	gcg	acg	tgc	ttc	cca	gaa	cca	ttc	ttc	atc	ttg	tct	ggg	ttc	720
Cys	Gly	Ala	Thr	Cys	Phe	Pro	Glu	Pro	Phe	Phe	Ile	Leu	Ser	Gly	Phe	
225					230				235						240	
tcg	act	ttt	caa	gcg	atg	cct	gnt	ggg	gca	gat	gga	gtc	tca	cta	cct	768
Ser	Thr	Phe	Gln	Ala	Met	Pro	Xaa	Gly	Ala	Asp	Gly	Val	Ser	Leu	Pro	
				245					250					255		
ctc	cat	aaa	acg	agt	gct	ggg	ctc	act	cca	ggc	gaa	ggg	ggg	tcc	att	816
Leu	His	Lys	Thr	Ser	Ala	Gly	Leu	Thr	Pro	Gly	Glu	Gly	Gly	Ser	Ile	
			260					265					270			
atg	gtg	ctc	aag	cga	ctg	aaa	gac	gct	atc	aga	gat	gga	aat	cac	att	864
Met	Val	Leu	Lys	Arg	Leu	Lys	Asp	Ala	Ile	Arg	Asp	Gly	Asn	His	Ile	
		275					280					285				
tat	ggt	gtg	ctc	ctt	gaa	gca	aat	tta	agt	aac	gca	ggt	tgt	ggg	ctt	912
Tyr	Gly	Val	Leu	Leu	Glu	Ala	Asn	Leu	Ser	Asn	Ala	Gly	Cys	Gly	Leu	
	290					295					300					
cca	ctc	agc	ccg	cac	tta	ccg	agc	gaa	gaa	tca	tgt	att	cgt	gat	acc	960
Pro	Leu	Ser	Pro	His	Leu	Pro	Ser	Glu	Glu	Ser	Cys	Ile	Arg	Asp	Thr	
305					310					315					320	
tac	cgc	cgt	gct	gga	ggt	gct	gca	gat	caa	agt	att	cag	tat	att	gag	1008
Tyr	Arg	Arg	Ala	Gly	Val	Ala	Ala	Asp	Gln	Ser	Ile	Gln	Tyr	Ile	Glu	
				325					330					335		
tgc	cac	gct	acg	gga	acc	cct	cga	ggg	gat	gtc	gtg	gaa	att	gag	gcg	1056
Cys	His	Ala	Thr	Gly	Thr	Pro	Arg	Gly	Asp	Val	Val	Glu	Ile	Glu	Ala	
			340					345					350			
ggt	gaa	aga	ggt	ttc	aag	aaa	aac	ggt	cca	cgc	tta	ggc	tcg	acg	aaa	1104
Val	Glu	Arg	Val	Phe	Lys	Lys	Asn	Val	Pro	Arg	Leu	Gly	Ser	Thr	Lys	
		355					360					365				
gga	aat	ttt	ggt	cac	tcg	tta	ggt	gcg	gct	ggc	ttc	gca	ggc	atg	gca	1152
Gly	Asn	Phe	Gly	His	Ser	Leu	Val	Ala	Ala	Gly	Phe	Ala	Gly	Met	Ala	
	370					375					380					
aag	ctt	ctt	ctt	gca	atg	gaa	cat	gga	gtg	att	cct	ccc	aca	cca	ggt	1200
Lys	Leu	Leu	Leu	Ala	Met	Glu	His	Gly	Val	Ile	Pro	Pro	Thr	Pro	Gly	
385					390					395					400	
ctt	gat	gct	tcg	aac	cag	gca	agt	gag	cac	ggt	gtg	aca	aag	gct	atc	1248
Leu	Asp	Ala	Ser	Asn	Gln	Ala	Ser	Glu	His	Val	Val	Thr	Lys	Ala	Ile	
				405					410					415		
act	tgg	cct	gag	aca	cat	ggg	gct	cca	aaa	cga	gct	ggc	ctt	tca	gca	1296
Thr	Trp	Pro	Glu	Thr	His	Gly	Ala	Pro	Lys	Arg	Ala	Gly	Leu	Ser	Ala	
			420					425					430			
ttt	gga	ttt	ggt	ggg	act	aat	gcg	cat	gca	ctc	ttc	gaa	gag	ttt	aat	1344
Phe	Gly	Phe	Gly	Gly	Thr	Asn	Ala	His	Ala	Leu	Phe	Glu	Glu	Phe	Asn	
		435					440					445				

2997-49-2-pct_ST25																
gcc Ala	gag Glu 450	ggc Gly	ata Ile	agt Ser	tat Tyr	cgc Arg 455	cct Pro	gga Gly	aag Lys	cct Pro	cca Pro 460	gtc Val	gaa Glu	tcg Ser	aat Asn	1392
acc Thr 465	cgt Arg	cct Pro	tcc Ser	gtc Val	gta Val 470	ata Ile	act Thr	ggg Gly	atg Met	gac Asp 475	tgt Cys	acc Thr	ttt Phe	ggg Gly	agc Ser 480	1440
ctt Leu	gaa Glu	ggg Gly	att Ile	gat Asp 485	gcg Ala	ttc Phe	gag Glu	act Thr	gcc Ala 490	ctg Leu	tac Tyr	gag Glu	ggg Gly	cgt Arg 495	gac Asp	1488
gca Ala	gct Ala	cgt Arg	gac Asp 500	tta Leu	ccc Pro	gcc Ala	aaa Lys	cgt Arg 505	tgg Trp	agg Arg	ttc Phe	cta Leu	ggt Gly 510	gag Glu	gac Asp	1536
ttg Leu	gag Glu	ttt Phe 515	ctc Leu	cga Arg	gcc Ala	atc Ile	agg Arg 520	ctc Leu	aag Lys	gaa Glu	aag Lys	cct Pro 525	agg Arg	ggt Gly	tgt Cys	1584
ttt Phe	gtg Val 530	gag Glu	agt Ser	gtt Val	gac Asp	gtt Val 535	aac Asn	ttt Phe	aga Arg	cgg Arg	ctg Leu 540	aaa Lys	acg Thr	ccc Pro	ttg Leu	1632
aca Thr 545	cca Pro	gaa Glu	gat Asp	atg Met	ttg Leu 550	cgg Arg	ccc Pro	caa Gln	caa Gln	ctc Leu 555	ttg Leu	gcg Ala	gtt Val	tct Ser	acg Thr 560	1680
atg Met	gac Asp	cga Arg	gca Ala	att Ile 565	atc Ile	gat Asp	gca Ala	ggt Gly	cta Leu 570	aag Lys	aag Lys	ggc Gly	caa Gln	cat His 575	gta Val	1728
gca Ala	gtt Val	ctt Leu	gtt Val 580	ggc Gly	cta Leu	gga Gly	act Thr	gac Asp 585	ctg Leu	gaa Glu	ctt Leu	tac Tyr	cgt Arg 590	cat His	cga Arg	1776
gca Ala	aga Arg	gtc Val 595	gcg Ala	ctt Leu	aaa Lys	gag Glu	gtt Val 600	ttg Leu	cac His	ccg Pro	agc Ser	tta Leu 605	aag Lys	tca Ser	gac Asp	1824
act Thr	gca Ala 610	att Ile	ctc Leu	cag Gln	aaa Lys	ata Ile 615	atg Met	caa Gln	tat Tyr	gtg Val	aat Asn 620	gat Asp	gca Ala	gga Gly	act Thr	1872
tcg Ser 625	act Thr	tca Ser	tac Tyr	aca Thr	tct Ser 630	tac Tyr	att Ile	gga Gly	aac Asn	ctc Leu 635	gtt Val	gcc Ala	acg Thr	cgt Arg	att Ile 640	1920
tcg Ser	tct Ser	cag Gln	tgg Trp	gga Gly 645	ttc Phe	aca Thr	ggg Gly	ccg Pro 650	tcc Ser	ttt Phe	act Thr	gtc Val	aca Thr	gaa Glu 655	gga Gly	1968
aat Asn	aat Asn	tcc Ser	gtg Val 660	tac Tyr	aga Arg	tgt Cys	gca Ala	caa Gln 665	cta Leu	gcc Ala	aaa Lys	gat Asp 670	atg Met	ctt Leu	cag Gln	2016
gtt Val	aac Asn	cga Arg 675	gtt Val	gat Asp	gct Ala	gtc Val	gtc Val 680	atc Ile	gca Ala	ggc Gly	ggt Val	gat Asp 685	ctc Leu	aac Asn	gga Gly	2064
agc Ser	gcc Ala 690	gaa Glu	agt Ser	ttt Phe	ttt Phe	gtc Val 695	cga Arg	gca Ala	aat Asn	cgt Arg	caa Gln 700	aag Lys	ata Ile	tcc Ser	aag Lys	2112
cta Leu 705	agt Ser	cat His	cca Pro	tgt Cys	gca Ala 710	agc Ser	ttc Phe	gac Asp	aga Arg	gat Asp 715	gca Ala	gat Asp	gga Gly	ttt Phe	ttc Phe 720	2160

2997-49-2-pct_ST25																
gca Ala	ggt Gly	gag Glu	ggc Gly	tgt Cys 725	ggt Gly	gcc Ala	cta Leu	gtt Val	ttc Phe 730	aag Lys	agg Arg	tta Leu	gaa Glu	gac Asp 735	tgt Cys	2208
gct Ala	cct Pro	cag Gln	gaa Glu 740	aaa Lys	att Ile	tat Tyr	gct Ala	agt Ser 745	ata Ile	gac Asp	tct Ser	atc Ile	gca Ala 750	ata Ile	gat Asp	2256
aaa Lys	gag Glu	cct Pro 755	act Thr	agc Ser	tca Ser	gct Ala	gtg Val 760	aaa Lys	gct Ala	gtc Val	tac Tyr	caa Gln 765	agt Ser	gat Asp	tcg Ser	2304
agt Ser	ctc Leu 770	tcc Ser	gat Asp	att Ile	gag Glu	ctg Leu 775	tta Leu	gaa Glu	atc Ile	agt Ser	gga Gly 780	gac Asp	tcc Ser	aaa Lys	cgg Arg	2352
ttt Phe 785	gca Ala	gca Ala	ttc Phe	gaa Glu	ggc Gly 790	gct Ala	gtg Val	gaa Glu	att Ile	caa Gln 795	tca Ser	agt Ser	gtg Val	gaa Glu	gcc Ala 800	2400
cag Gln	cta Leu	aaa Lys	gga Gly	ctt Leu 805	tcc Ser	aaa Lys	gtc Val	ctt Leu	gaa Glu 810	cct Pro	gca Ala	aaa Lys	ggc Gly	caa Gln 815	ggc Gly	2448
gta Val	gcg Ala	gtg Val	gga Gly 820	agt Ser	act Thr	cga Arg	gca Ala	acc Thr 825	ggt Val	ggg Gly	gat Asp	ata Ile	ggg Gly 830	tat Tyr	gct Ala	2496
aca Thr	gga Gly	gcg Ala 835	gca Ala	agc Ser	ctg Leu	att Ile	aaa Lys 840	act Thr	gca Ala	ctc Leu	tgc Cys	tta Leu 845	tat Tyr	aat Asn	cgc Arg	2544
tac Tyr	ctt Leu 850	ccg Pro	gca Ala	tta Leu	gca Ala	aac Asn 855	tgg Trp	agt Ser	ggc Gly	cca Pro	tgt Cys 860	gaa Glu	cag Gln	tcc Ser	gcc Ala	2592
tgg Trp 865	ggc Gly	tca Ser	aac Asn	atg Met	ttc Phe 870	gtt Val	tgc Cys	cat His	gaa Glu	aca Thr 875	cgg Arg	ccg Pro	tgg Trp	atg Met	aaa Lys 880	2640
aac Asn	cag Gln	aat Asn	gaa Glu	aag Lys 885	aga Arg	tgt Cys	gcc Ala	ctc Leu	att Ile 890	tct Ser	gga Gly	aca Thr	gat Asp	cca Pro 895	tct Ser	2688
cat His	aca Thr	tgc Cys	ttt Phe 900	tcc Ser	ctc Leu	gta Val	cta Leu	tcg Ser 905	gat Asp	act Thr	ggg Gly	tgt Cys	tat Tyr 910	gaa Glu	gag Glu	2736
cac His	aat Asn	cga Arg 915	acg Thr	tgc Cys	ttt Phe	gat Asp	gtg Val 920	caa Gln	gcg Ala	cca Pro	cag Gln	cta Leu 925	gtt Val	ctg Leu	ata Ile	2784
cac His	gga Gly 930	ttc Phe	gat Asp	gga Gly	aaa Lys	act Thr 935	att Ile	gtg Val	cgg Arg	cga Arg	ctt Leu 940	gaa Glu	gga Gly	tat Tyr	ctc Leu	2832
ctt Leu 945	gaa Glu	ctt Leu	gtt Val	gaa Glu	ggg Gly 950	cat His	gca Ala	agc Ser	cct Pro	tca Ser 955	gag Glu	tat Tyr	ttc Phe	cac His	aaa Lys 960	2880
ctg Leu	att Ile	gga Gly	caa Gln	agt Ser 965	cta Leu	ctt Leu	gag Glu	aac Asn	tcg Ser 970	aaa Lys	gaa Glu	agt Ser	aaa Lys	ctc Leu 975	aca Thr	2928
ctt Leu	tcg Ser	ctt Leu	gtg Val 980	tgc Cys	aat Asn	ccg Pro	aac Asn	cag Gln 985	ctc Leu	caa Gln	aag Lys	gag Glu	ctc Leu 990	atg Met	ctt Leu	2976

2997-49-2-pct_ST25

gct atc aaa gga gta caa cga agc atg tta aca ggg aag gat tgg gtc	3024
Ala Ile Lys Gly Val Gln Arg Ser Met Leu Thr Gly Lys Asp Trp Val	
995 1000 1005	
agt cca tca gga agt tgt ttt gcc cca aat ccg tta tca agc gca	3069
Ser Pro Ser Gly Ser Cys Phe Ala Pro Asn Pro Leu Ser Ser Ala	
1010 1015 1020	
aaa gtg gca ttc atg tac gga gaa ggc cga agc ccg tac tgt ggt	3114
Lys Val Ala Phe Met Tyr Gly Glu Gly Arg Ser Pro Tyr Cys Gly	
1025 1030 1035	
gta ggc ttg ggt cta cat cgt ttg tgg ccc ggt ctc cat gaa aat	3159
Val Gly Leu Gly Leu His Arg Leu Trp Pro Gly Leu His Glu Asn	
1040 1045 1050	
gtg aac aat aag aca gtc gat tta tgg acg gaa gga gat ggt tgg	3204
Val Asn Asn Lys Thr Val Asp Leu Trp Thr Glu Gly Asp Gly Trp	
1055 1060 1065	
tta tat cct cga acg ttg aca cga gaa gag cat aca aaa gcc atc	3249
Leu Tyr Pro Arg Thr Leu Thr Arg Glu Glu His Thr Lys Ala Ile	
1070 1075 1080	
gaa tct ttc aac gca aat caa att gaa atg ttt cgc gct ggg att	3294
Glu Ser Phe Asn Ala Asn Gln Ile Glu Met Phe Arg Ala Gly Ile	
1085 1090 1095	
ttc atc tca atg tgt cag aca gac tat gtc atg aat gtt ctc ggt	3339
Phe Ile Ser Met Cys Gln Thr Asp Tyr Val Met Asn Val Leu Gly	
1100 1105 1110	
gtc cag cct aag gcc gga ttt ggg ctg agc ttg gga gaa att tca	3384
Val Gln Pro Lys Ala Gly Phe Gly Leu Ser Leu Gly Glu Ile Ser	
1115 1120 1125	
atg ctc ttt gcg atg tca aag gag aac tgc agg cag tca cag gaa	3429
Met Leu Phe Ala Met Ser Lys Glu Asn Cys Arg Gln Ser Gln Glu	
1130 1135 1140	
atg acc aat cgt ttg cgc ggt tct cca gtg tgg tct aac gag ctt	3474
Met Thr Asn Arg Leu Arg Gly Ser Pro Val Trp Ser Asn Glu Leu	
1145 1150 1155	
gct atc aac ttc aat gca att cgc aag tta tgg aaa atc ccc cga	3519
Ala Ile Asn Phe Asn Ala Ile Arg Lys Leu Trp Lys Ile Pro Arg	
1160 1165 1170	
gga gct ccc tta gaa tcc ttt tgg caa gga tac ttg gtt cac ggc	3564
Gly Ala Pro Leu Glu Ser Phe Trp Gln Gly Tyr Leu Val His Gly	
1175 1180 1185	
aca aga gaa gaa gta gag cat gct att ggt ctt tct gag cct tat	3609
Thr Arg Glu Glu Val Glu His Ala Ile Gly Leu Ser Glu Pro Tyr	
1190 1195 1200	
gta cgt ctg ctt att gtg aac gat tca agg agt gcc ttg att gct	3654
Val Arg Leu Leu Ile Val Asn Asp Ser Arg Ser Ala Leu Ile Ala	
1205 1210 1215	
gga aaa cca gac gcc tgt cag gca gta atc agt aga cta aac tcc	3699
Gly Lys Pro Asp Ala Cys Gln Ala Val Ile Ser Arg Leu Asn Ser	
1220 1225 1230	
aag ttc cct tct ctg ccg gta aag caa gga atg att ggt cat tgc	3744
Lys Phe Pro Ser Leu Pro Val Lys Gln Gly Met Ile Gly His Cys	
1235 1240 1245	

2997-49-2-pct_ST25

cca Pro	gaa Glu 1250	gtt Val	cgt Arg	gcg Ala	ttc Phe	atc Ile 1255	aaa Lys	gat Asp	att Ile	ggg Gly	tac Tyr 1260	atc Ile	cat His	gaa Glu	3789
aca Thr	ctc Leu 1265	cga Arg	att Ile	tcc Ser	aat Asn	gac Asp 1270	tat Tyr	tcg Ser	gat Asp	tgt Cys	cag Gln 1275	ctt Leu	ttc Phe	tca Ser	3834
gcg Ala	gta Val 1280	acc Thr	aag Lys	ggc Gly	gca Ala	ctt Leu 1285	gac Asp	agc Ser	tcc Ser	aca Thr	atg Met 1290	gaa Glu	atc Ile	aaa Lys	3879
cac His	ttt Phe 1295	gtg Val	gga Gly	gag Glu	gtc Val	tac Tyr 1300	tcc Ser	cgg Arg	atc Ile	gca Ala	gac Asp 1305	ttt Phe	cct Pro	caa Gln	3924
atc Ile	gtc Val 1310	aac Asn	acg Thr	gtg Val	cat His	tcg Ser 1315	gct Ala	ggg Gly	tat Tyr	gac Asp	gta Val 1320	ttt Phe	ctt Leu	gag Glu	3969
ctt Leu	ggc Gly 1325	tgt Cys	gat Asp	gct Ala	tct Ser	aga Arg 1330	tct Ser	gca Ala	gca Ala	gtt Val	caa Gln 1335	aac Asn	att Ile	ctt Leu	4014
ggg Gly	ggg Gly 1340	caa Gln	gga Gly	aag Lys	ttc Phe	ttg Leu 1345	tct Ser	aca Thr	gct Ala	att Ile	gac Asp 1350	aaa Lys	aaa Lys	gga Gly	4059
cac His	tcc Ser 1355	gcc Ala	tgg Trp	tca Ser	caa Gln	gta Val 1360	ctt Leu	cgg Arg	gct Ala	acc Thr	gca Ala 1365	tca Ser	tta Leu	gct Ala	4104
gca Ala	cat His 1370	cga Arg	gta Val	ccg Pro	gga Gly	atc Ile 1375	tca Ser	att Ile	ttg Leu	gat Asp	ttg Leu 1380	ttt Phe	cac His	cca Pro	4149
aat Asn	ttc Phe 1385	cga Arg	gaa Glu	atg Met	tgc Cys	tgt Cys 1390	aca Thr	atg Met	gca Ala	acc Thr	aca Thr 1395	cct Pro	aaa Lys	gtg Val	4194
gaa Glu	gat Asp 1400	aag Lys	ttc Phe	ctg Leu	cgc Arg	acg Thr 1405	att Ile	caa Gln	atc Ile	aat Asn	ggg Gly 1410	cgg Arg	ttt Phe	gaa Glu	4239
aaa Lys	gaa Glu 1415	atg Met	att Ile	cac His	cta Leu	gaa Glu 1420	gat Asp	aca Thr	aca Thr	tta Leu	agt Ser 1425	tgc Cys	tta Leu	ccc Pro	4284
gct Ala	cca Pro 1430	agt Ser	gaa Glu	gca Ala	aat Asn	atc Ile 1435	gca Ala	gct Ala	att Ile	caa Gln	tct Ser 1440	cgg Arg	tca Ser	att Ile	4329
cga Arg	tct Ser 1445	gct Ala	gcg Ala	gcg Ala	cgt Arg	tct Ser 1450	gga Gly	caa Gln	tcc Ser	cat His	gat Asp 1455	tgt Cys	gca Ala	tcc Ser	4374
cat His	agc Ser 1460	cat His	gaa Glu	gaa Glu	aat Asn	aag Lys 1465	gat Asp	tca Ser	tgc Cys	cct Pro	gaa Glu 1470	aag Lys	ctg Leu	aag Lys	4419
ctt Leu	gat Asp 1475	tct Ser	gtg Val	tcc Ser	gtc Val	gcc Ala 1480	ata Ile	aat Asn	ttc Phe	gac Asp	aat Asn 1485	gat Asp	gac Asp	cgc Arg	4464
att Ile	cag Gln 1490	ctt Leu	ggg Gly	cac His	gcg Ala	ggg Gly 1495	ttt Phe	cgg Arg	gag Glu	atg Met	tac Tyr 1500	aat Asn	aca Thr	aga Arg	4509

2997-49-2-pct_ST25

tat Tyr	agc Ser 1505	ttg Leu	tac Tyr	aca Thr	ggg Gly	gcg Ala 1510	atg Met	gca Ala	aag Lys	gga Gly	att Ile 1515	gca Ala	tct Ser	gca Ala	4554
gat Asp	ctt Leu 1520	gtc Val	att Ile	gcc Ala	gct Ala	ggg Gly 1525	aaa Lys	gag Glu	ggc Gly	atc Ile	cta Leu 1530	gct Ala	tcc Ser	tat Tyr	4599
gga Gly	gct Ala 1535	gga Gly	gga Gly	cta Leu	cct Pro	ctt Leu 1540	gct Ala	act Thr	ggt Val	cga Arg	aag Lys 1545	gga Gly	ata Ile	gac Asp	4644
aaa Lys	att Ile 1550	caa Gln	caa Gln	gcc Ala	ttg Leu	cca Pro 1555	agt Ser	ggc Gly	cca Pro	tat Tyr	gct Ala 1560	gta Val	aat Asn	ctt Leu	4689
att Ile	cac His 1565	tct Ser	ccc Pro	ttt Phe	gac Asp	ggc Gly 1570	aac Asn	ttg Leu	gag Glu	cag Gln	gga Gly 1575	aac Asn	gtc Val	gat Asp	4734
ttg Leu	ttc Phe 1580	ttg Leu	gaa Glu	aag Lys	aac Asn	gtc Val 1585	cgc Arg	gtg Val	gcg Ala	gaa Glu	tgt Cys 1590	tcc Ser	gcg Ala	ttt Phe	4779
aca Thr	acg Thr 1595	cta Leu	aca Thr	gtg Val	cca Pro	gta Val 1600	gta Val	cac His	tat Tyr	cgt Arg	gct Ala 1605	gca Ala	ggg Gly	ctt Leu	4824
gtt Val	cgg Arg 1610	cgc Arg	caa Gln	gat Asp	gga Gly	agc Ser 1615	att Ile	ttg Leu	atc Ile	aag Lys	aac Asn 1620	cga Arg	atc Ile	att Ile	4869
gct Ala	aaa Lys 1625	gta Val	tct Ser	agg Arg	aca Thr	gaa Glu 1630	ctc Leu	gct Ala	gag Glu	atg Met	ttc Phe 1635	ctt Leu	cgt Arg	ccg Pro	4914
gca Ala	cct Pro 1640	caa Gln	atc Ile	atc Ile	ctc Leu	gaa Glu 1645	aaa Lys	ctg Leu	gta Val	gca Ala	gca Ala 1650	gaa Glu	atc Ile	att Ile	4959
tca Ser	tct Ser 1655	gac Asp	caa Gln	gcg Ala	cgt Arg	atg Met 1660	gca Ala	gcc Ala	aaa Lys	ggt Val	ccc Pro 1665	atg Met	gcg Ala	gac Asp	5004
gac Asp	atc Ile 1670	gca Ala	gtc Val	gaa Glu	gcc Ala	gac Asp 1675	tct Ser	ggt Gly	ggg Gly	cac His	acg Thr 1680	gat Asp	aat Asn	cgg Arg	5049
cct Pro	atg Met 1685	cac His	gtc Val	att Ile	ttg Leu	ccc Pro 1690	ctg Leu	ata Ile	att Ile	caa Gln	ctc Leu 1695	cgc Arg	aat Asn	act Thr	5094
ata Ile	ctt Leu 1700	gca Ala	gag Glu	tat Tyr	ggc Gly	tgt Cys 1705	gcc Ala	acg Thr	gct Ala	ttt Phe	cgt Arg 1710	acc Thr	cgt Arg	ata Ile	5139
ggc Gly	gct Ala 1715	gga Gly	gga Gly	ggc Gly	att Ile	ggg Gly 1720	tgt Cys	cct Pro	tca Ser	gcg Ala	gcc Ala 1725	ctc Leu	gca Ala	gcc Ala	5184
ttt Phe	gat Asp 1730	atg Met	ggt Gly	gcg Ala	agt Ser	ttt Phe 1735	gtc Val	gtg Val	act Thr	gga Gly	agc Ser 1740	ata Ile	aat Asn	caa Gln	5229
att Ile	tgc Cys 1745	cgc Arg	gag Glu	gca Ala	ggg Gly	act Thr 1750	tgc Cys	gat Asp	act Thr	ggt Val	cgg Arg 1755	gag Glu	cta Leu	ctt Leu	5274

2997-49-2-pct_ST25

gcc Ala	aac Asn 1760	tca Ser	agc Ser	tac Tyr	tcg Ser	gac Asp 1765	gtg Val	acg Thr	atg Met	gcg Ala	cca Pro 1770	gca Ala	gca Ala	gac Asp	5319
atg Met	ttt Phe 1775	gac Asp	caa Gln	ggg Gly	gtg Val	aaa Lys 1780	ctc Leu	caa Gln	gtc Val	tta Leu	aaa Lys 1785	cga Arg	gga Gly	acg Thr	5364
atg Met	ttt Phe 1790	cca Pro	agc Ser	aga Arg	gca Ala	aat Asn 1795	aaa Lys	ctc Leu	cgg Arg	aag Lys	ctc Leu 1800	ttt Phe	gtg Val	aac Asn	5409
tac Tyr	gaa Glu 1805	tct Ser	cta Leu	gaa Glu	aca Thr	ctc Leu 1810	ccg Pro	tcg Ser	aaa Lys	gag Glu	ttg Leu 1815	aaa Lys	tac Tyr	ctg Leu	5454
gaa Glu	aac Asn 1820	atc Ile	ata Ile	ttc Phe	aag Lys	caa Gln 1825	gca Ala	gta Val	gac Asp	cag Gln	gtg Val 1830	tgg Trp	gag Glu	gaa Glu	5499
aca Thr	aag Lys 1835	cgc Arg	ttt Phe	tac Tyr	tgt Cys	gaa Glu 1840	aaa Lys	ctg Leu	aac Asn	aat Asn	cca Pro 1845	gat Asp	aaa Lys	att Ile	5544
gca Ala	agg Arg 1850	gcc Ala	atg Met	aaa Lys	gat Asp	cct Pro 1855	aaa Lys	ttg Leu	aag Lys	atg Met	tcg Ser 1860	ctt Leu	tgc Cys	ttt Phe	5589
cgg Arg	tgg Trp 1865	tat Tyr	ctc Leu	tcc Ser	aag Lys	agc Ser 1870	tct Ser	ggg Gly	tgg Trp	gcc Ala	aac Asn 1875	gca Ala	gga Gly	att Ile	5634
aaa Lys	tct Ser 1880	cgt Arg	gca Ala	ctc Leu	gac Asp	tac Tyr 1885	cag Gln	atc Ile	tgg Trp	tgt Cys	ggc Gly 1890	ccg Pro	gca Ala	atg Met	5679
ggc Gly	tcg Ser 1895	ttc Phe	aac Asn	aat Asn	ttc Phe	gcc Ala 1900	agc Ser	ggc Gly	aca Thr	tcc Ser	ctc Leu 1905	gat Asp	tgg Trp	aaa Lys	5724
gtg Val	act Thr 1910	ggg Gly	gtt Val	ttc Phe	cct Pro	ggc Gly 1915	gtt Val	gcg Ala	gaa Glu	gta Val	aac Asn 1920	atg Met	gcc Ala	att Ile	5769
tta Leu	gat Asp 1925	ggc Gly	gcg Ala	cga Arg	gaa Glu	cta Leu 1930	gct Ala	gct Ala	aaa Lys	cga Arg	aat Asn 1935	taa			5808

<210> 52

<211> 1935

<212> PRT

<213> Thraustochytrium sp.

<220>

<221> misc_feature

<222> (248)..(248)

<223> The 'Xaa' at location 248 stands for Asp, Gly, Ala, or Val.

<400> 52

Met Gln Leu Pro Pro Ala His Ser Ala Asp Glu Asn Arg Ile Ala Val
1 5 10 15

Val Gly Met Ala Val Lys Tyr Ala Gly Cys Asp Asn Lys Glu Glu Phe
20 25 30

2997-49-2-pct_ST25

Trp Lys Thr Leu Met Asn Gly Ser Ile Asn Thr Lys Ser Ile Ser Ala
35 40 45

Ala Arg Leu Gly Ser Asn Lys Arg Asp Glu His Tyr Val Pro Glu Arg
50 55 60

Ser Lys Tyr Ala Asp Thr Phe Cys Asn Glu Arg Tyr Gly Cys Ile Gln
65 70 75 80

Gln Gly Thr Asp Asn Glu His Asp Leu Leu Leu Gly Leu Ala Gln Glu
85 90 95

Ala Leu Ala Asp Ala Ala Gly Arg Met Glu Lys Gln Pro Ser Glu Ala
100 105 110

Phe Asp Leu Glu Asn Thr Gly Ile Val Ser Gly Cys Leu Ser Phe Pro
115 120 125

Met Asp Asn Leu Gln Gly Glu Leu Leu Asn Leu Tyr Gln Ser His Val
130 135 140

Glu Lys Gln Leu Pro Pro Ser Ala Leu Val Glu Ala Val Lys Leu Trp
145 150 155 160

Ser Glu Arg Gln Lys Ser Thr Lys Ala His Ala Gly Asp Lys Arg Arg
165 170 175

Phe Ile Asp Pro Ala Ser Phe Val Ala Asp Lys Leu Asn Leu Gly Pro
180 185 190

Leu His Tyr Ala Ile Asp Ala Ala Cys Ala Ser Ala Leu Tyr Val Leu
195 200 205

Lys Leu Ala Gln Asp His Leu Val Ser Gly Ala Val Asp Met Met Leu
210 215 220

Cys Gly Ala Thr Cys Phe Pro Glu Pro Phe Phe Ile Leu Ser Gly Phe
225 230 235 240

Ser Thr Phe Gln Ala Met Pro Xaa Gly Ala Asp Gly Val Ser Leu Pro
245 250 255

Leu His Lys Thr Ser Ala Gly Leu Thr Pro Gly Glu Gly Gly Ser Ile
260 265 270

Met Val Leu Lys Arg Leu Lys Asp Ala Ile Arg Asp Gly Asn His Ile
275 280 285

Tyr Gly Val Leu Leu Glu Ala Asn Leu Ser Asn Ala Gly Cys Gly Leu
290 295 300

2997-49-2-pct_ST25

Pro Leu Ser Pro His Leu Pro Ser Glu Glu Ser Cys Ile Arg Asp Thr
 305 310 315 320
 Tyr Arg Arg Ala Gly Val Ala Ala Asp Gln Ser Ile Gln Tyr Ile Glu
 325 330 335
 Cys His Ala Thr Gly Thr Pro Arg Gly Asp Val Val Glu Ile Glu Ala
 340 345 350
 Val Glu Arg Val Phe Lys Lys Asn Val Pro Arg Leu Gly Ser Thr Lys
 355 360 365
 Gly Asn Phe Gly His Ser Leu Val Ala Ala Gly Phe Ala Gly Met Ala
 370 375 380
 Lys Leu Leu Leu Ala Met Glu His Gly Val Ile Pro Pro Thr Pro Gly
 385 390 395 400
 Leu Asp Ala Ser Asn Gln Ala Ser Glu His Val Val Thr Lys Ala Ile
 405 410 415
 Thr Trp Pro Glu Thr His Gly Ala Pro Lys Arg Ala Gly Leu Ser Ala
 420 425 430
 Phe Gly Phe Gly Gly Thr Asn Ala His Ala Leu Phe Glu Glu Phe Asn
 435 440 445
 Ala Glu Gly Ile Ser Tyr Arg Pro Gly Lys Pro Pro Val Glu Ser Asn
 450 455 460
 Thr Arg Pro Ser Val Val Ile Thr Gly Met Asp Cys Thr Phe Gly Ser
 465 470 475 480
 Leu Glu Gly Ile Asp Ala Phe Glu Thr Ala Leu Tyr Glu Gly Arg Asp
 485 490 495
 Ala Ala Arg Asp Leu Pro Ala Lys Arg Trp Arg Phe Leu Gly Glu Asp
 500 505 510
 Leu Glu Phe Leu Arg Ala Ile Arg Leu Lys Glu Lys Pro Arg Gly Cys
 515 520 525
 Phe Val Glu Ser Val Asp Val Asn Phe Arg Arg Leu Lys Thr Pro Leu
 530 535 540
 Thr Pro Glu Asp Met Leu Arg Pro Gln Gln Leu Leu Ala Val Ser Thr
 545 550 555 560
 Met Asp Arg Ala Ile Ile Asp Ala Gly Leu Lys Lys Gly Gln His Val
 565 570 575

2997-49-2-pct_ST25

Ala Val Leu Val Gly Leu Gly Thr Asp Leu Glu Leu Tyr Arg His Arg
580 585 590

Ala Arg Val Ala Leu Lys Glu Val Leu His Pro Ser Leu Lys Ser Asp
595 600 605

Thr Ala Ile Leu Gln Lys Ile Met Gln Tyr Val Asn Asp Ala Gly Thr
610 615 620

Ser Thr Ser Tyr Thr Ser Tyr Ile Gly Asn Leu Val Ala Thr Arg Ile
625 630 635 640

Ser Ser Gln Trp Gly Phe Thr Gly Pro Ser Phe Thr Val Thr Glu Gly
645 650 655

Asn Asn Ser Val Tyr Arg Cys Ala Gln Leu Ala Lys Asp Met Leu Gln
660 665 670

Val Asn Arg Val Asp Ala Val Val Ile Ala Gly Val Asp Leu Asn Gly
675 680 685

Ser Ala Glu Ser Phe Phe Val Arg Ala Asn Arg Gln Lys Ile Ser Lys
690 695 700

Leu Ser His Pro Cys Ala Ser Phe Asp Arg Asp Ala Asp Gly Phe Phe
705 710 715 720

Ala Gly Glu Gly Cys Gly Ala Leu Val Phe Lys Arg Leu Glu Asp Cys
725 730 735

Ala Pro Gln Glu Lys Ile Tyr Ala Ser Ile Asp Ser Ile Ala Ile Asp
740 745 750

Lys Glu Pro Thr Ser Ser Ala Val Lys Ala Val Tyr Gln Ser Asp Ser
755 760 765

Ser Leu Ser Asp Ile Glu Leu Leu Glu Ile Ser Gly Asp Ser Lys Arg
770 775 780

Phe Ala Ala Phe Glu Gly Ala Val Glu Ile Gln Ser Ser Val Glu Ala
785 790 795 800

Gln Leu Lys Gly Leu Ser Lys Val Leu Glu Pro Ala Lys Gly Gln Gly
805 810 815

Val Ala Val Gly Ser Thr Arg Ala Thr Val Gly Asp Ile Gly Tyr Ala
820 825 830

Thr Gly Ala Ala Ser Leu Ile Lys Thr Ala Leu Cys Leu Tyr Asn Arg
835 840 845

2997-49-2-pct_ST25

Tyr Leu Pro Ala Leu Ala Asn Trp Ser Gly Pro Cys Glu Gln Ser Ala
 850 855 860
 Trp Gly Ser Asn Met Phe Val Cys His Glu Thr Arg Pro Trp Met Lys
 865 870 875 880
 Asn Gln Asn Glu Lys Arg Cys Ala Leu Ile Ser Gly Thr Asp Pro Ser
 885 890 895
 His Thr Cys Phe Ser Leu Val Leu Ser Asp Thr Gly Cys Tyr Glu Glu
 900 905 910
 His Asn Arg Thr Cys Phe Asp Val Gln Ala Pro Gln Leu Val Leu Ile
 915 920 925
 His Gly Phe Asp Gly Lys Thr Ile Val Arg Arg Leu Glu Gly Tyr Leu
 930 935 940
 Leu Glu Leu Val Glu Gly His Ala Ser Pro Ser Glu Tyr Phe His Lys
 945 950 955 960
 Leu Ile Gly Gln Ser Leu Leu Glu Asn Ser Lys Glu Ser Lys Leu Thr
 965 970 975
 Leu Ser Leu Val Cys Asn Pro Asn Gln Leu Gln Lys Glu Leu Met Leu
 980 985 990
 Ala Ile Lys Gly Val Gln Arg Ser Met Leu Thr Gly Lys Asp Trp Val
 995 1000 1005
 Ser Pro Ser Gly Ser Cys Phe Ala Pro Asn Pro Leu Ser Ser Ala
 1010 1015 1020
 Lys Val Ala Phe Met Tyr Gly Glu Gly Arg Ser Pro Tyr Cys Gly
 1025 1030 1035
 Val Gly Leu Gly Leu His Arg Leu Trp Pro Gly Leu His Glu Asn
 1040 1045 1050
 Val Asn Asn Lys Thr Val Asp Leu Trp Thr Glu Gly Asp Gly Trp
 1055 1060 1065
 Leu Tyr Pro Arg Thr Leu Thr Arg Glu Glu His Thr Lys Ala Ile
 1070 1075 1080
 Glu Ser Phe Asn Ala Asn Gln Ile Glu Met Phe Arg Ala Gly Ile
 1085 1090 1095
 Phe Ile Ser Met Cys Gln Thr Asp Tyr Val Met Asn Val Leu Gly
 1100 1105 1110

2997-49-2-pct_ST25

Val	Gln	Pro	Lys	Ala	Gly	Phe	Gly	Leu	Ser	Leu	Gly	Glu	Ile	Ser
	1115					1120					1125			
Met	Leu	Phe	Ala	Met	Ser	Lys	Glu	Asn	Cys	Arg	Gln	Ser	Gln	Glu
	1130					1135					1140			
Met	Thr	Asn	Arg	Leu	Arg	Gly	Ser	Pro	Val	Trp	Ser	Asn	Glu	Leu
	1145					1150					1155			
Ala	Ile	Asn	Phe	Asn	Ala	Ile	Arg	Lys	Leu	Trp	Lys	Ile	Pro	Arg
	1160					1165					1170			
Gly	Ala	Pro	Leu	Glu	Ser	Phe	Trp	Gln	Gly	Tyr	Leu	Val	His	Gly
	1175					1180					1185			
Thr	Arg	Glu	Glu	Val	Glu	His	Ala	Ile	Gly	Leu	Ser	Glu	Pro	Tyr
	1190					1195					1200			
Val	Arg	Leu	Leu	Ile	Val	Asn	Asp	Ser	Arg	Ser	Ala	Leu	Ile	Ala
	1205					1210					1215			
Gly	Lys	Pro	Asp	Ala	Cys	Gln	Ala	Val	Ile	Ser	Arg	Leu	Asn	Ser
	1220					1225					1230			
Lys	Phe	Pro	Ser	Leu	Pro	Val	Lys	Gln	Gly	Met	Ile	Gly	His	Cys
	1235					1240					1245			
Pro	Glu	Val	Arg	Ala	Phe	Ile	Lys	Asp	Ile	Gly	Tyr	Ile	His	Glu
	1250					1255					1260			
Thr	Leu	Arg	Ile	Ser	Asn	Asp	Tyr	Ser	Asp	Cys	Gln	Leu	Phe	Ser
	1265					1270					1275			
Ala	Val	Thr	Lys	Gly	Ala	Leu	Asp	Ser	Ser	Thr	Met	Glu	Ile	Lys
	1280					1285					1290			
His	Phe	Val	Gly	Glu	Val	Tyr	Ser	Arg	Ile	Ala	Asp	Phe	Pro	Gln
	1295					1300					1305			
Ile	Val	Asn	Thr	Val	His	Ser	Ala	Gly	Tyr	Asp	Val	Phe	Leu	Glu
	1310					1315					1320			
Leu	Gly	Cys	Asp	Ala	Ser	Arg	Ser	Ala	Ala	Val	Gln	Asn	Ile	Leu
	1325					1330					1335			
Gly	Gly	Gln	Gly	Lys	Phe	Leu	Ser	Thr	Ala	Ile	Asp	Lys	Lys	Gly
	1340					1345					1350			
His	Ser	Ala	Trp	Ser	Gln	Val	Leu	Arg	Ala	Thr	Ala	Ser	Leu	Ala
	1355					1360					1365			

2997-49-2-pct_ST25

Ala	His 1370	Arg	Val	Pro	Gly	Ile 1375	Ser	Ile	Leu	Asp	Leu 1380	Phe	His	Pro
Asn	Phe 1385	Arg	Glu	Met	Cys	Cys 1390	Thr	Met	Ala	Thr	Thr 1395	Pro	Lys	Val
Glu	Asp 1400	Lys	Phe	Leu	Arg	Thr 1405	Ile	Gln	Ile	Asn	Gly 1410	Arg	Phe	Glu
Lys	Glu 1415	Met	Ile	His	Leu	Glu 1420	Asp	Thr	Thr	Leu	Ser 1425	Cys	Leu	Pro
Ala	Pro 1430	Ser	Glu	Ala	Asn	Ile 1435	Ala	Ala	Ile	Gln	Ser 1440	Arg	Ser	Ile
Arg	Ser 1445	Ala	Ala	Ala	Arg	Ser 1450	Gly	Gln	Ser	His	Asp 1455	Cys	Ala	Ser
His	Ser 1460	His	Glu	Glu	Asn	Lys 1465	Asp	Ser	Cys	Pro	Glu 1470	Lys	Leu	Lys
Leu	Asp 1475	Ser	Val	Ser	Val	Ala 1480	Ile	Asn	Phe	Asp	Asn 1485	Asp	Asp	Arg
Ile	Gln 1490	Leu	Gly	His	Ala	Gly 1495	Phe	Arg	Glu	Met	Tyr 1500	Asn	Thr	Arg
Tyr	Ser 1505	Leu	Tyr	Thr	Gly	Ala 1510	Met	Ala	Lys	Gly	Ile 1515	Ala	Ser	Ala
Asp	Leu 1520	Val	Ile	Ala	Ala	Gly 1525	Lys	Glu	Gly	Ile	Leu 1530	Ala	Ser	Tyr
Gly	Ala 1535	Gly	Gly	Leu	Pro	Leu 1540	Ala	Thr	Val	Arg	Lys 1545	Gly	Ile	Asp
Lys	Ile 1550	Gln	Gln	Ala	Leu	Pro 1555	Ser	Gly	Pro	Tyr	Ala 1560	Val	Asn	Leu
Ile	His 1565	Ser	Pro	Phe	Asp	Gly 1570	Asn	Leu	Glu	Gln	Gly 1575	Asn	Val	Asp
Leu	Phe 1580	Leu	Glu	Lys	Asn	Val 1585	Arg	Val	Ala	Glu	Cys 1590	Ser	Ala	Phe
Thr	Thr 1595	Leu	Thr	Val	Pro	Val 1600	Val	His	Tyr	Arg	Ala 1605	Ala	Gly	Leu
Val	Arg 1610	Arg	Gln	Asp	Gly	Ser 1615	Ile	Leu	Ile	Lys	Asn 1620	Arg	Ile	Ile

2997-49-2-pct_ST25

Ala	Lys 1625	Val	Ser	Arg	Thr	Glu 1630	Leu	Ala	Glu	Met	Phe 1635	Leu	Arg	Pro
Ala	Pro 1640	Gln	Ile	Ile	Leu	Glu 1645	Lys	Leu	Val	Ala	Ala 1650	Glu	Ile	Ile
Ser	Ser 1655	Asp	Gln	Ala	Arg	Met 1660	Ala	Ala	Lys	Val	Pro 1665	Met	Ala	Asp
Asp	Ile 1670	Ala	Val	Glu	Ala	Asp 1675	Ser	Gly	Gly	His	Thr 1680	Asp	Asn	Arg
Pro	Met 1685	His	Val	Ile	Leu	Pro 1690	Leu	Ile	Ile	Gln	Leu 1695	Arg	Asn	Thr
Ile	Leu 1700	Ala	Glu	Tyr	Gly	Cys 1705	Ala	Thr	Ala	Phe	Arg 1710	Thr	Arg	Ile
Gly	Ala 1715	Gly	Gly	Gly	Ile	Gly 1720	Cys	Pro	Ser	Ala	Ala 1725	Leu	Ala	Ala
Phe	Asp 1730	Met	Gly	Ala	Ser	Phe 1735	Val	Val	Thr	Gly	Ser 1740	Ile	Asn	Gln
Ile	Cys 1745	Arg	Glu	Ala	Gly	Thr 1750	Cys	Asp	Thr	Val	Arg 1755	Glu	Leu	Leu
Ala	Asn 1760	Ser	Ser	Tyr	Ser	Asp 1765	Val	Thr	Met	Ala	Pro 1770	Ala	Ala	Asp
Met	Phe 1775	Asp	Gln	Gly	Val	Lys 1780	Leu	Gln	Val	Leu	Lys 1785	Arg	Gly	Thr
Met	Phe 1790	Pro	Ser	Arg	Ala	Asn 1795	Lys	Leu	Arg	Lys	Leu 1800	Phe	Val	Asn
Tyr	Glu 1805	Ser	Leu	Glu	Thr	Leu 1810	Pro	Ser	Lys	Glu	Leu 1815	Lys	Tyr	Leu
Glu	Asn 1820	Ile	Ile	Phe	Lys	Gln 1825	Ala	Val	Asp	Gln	Val 1830	Trp	Glu	Glu
Thr	Lys 1835	Arg	Phe	Tyr	Cys	Glu 1840	Lys	Leu	Asn	Asn	Pro 1845	Asp	Lys	Ile
Ala	Arg 1850	Ala	Met	Lys	Asp	Pro 1855	Lys	Leu	Lys	Met	Ser 1860	Leu	Cys	Phe
Arg	Trp 1865	Tyr	Leu	Ser	Lys	Ser 1870	Ser	Gly	Trp	Ala	Asn 1875	Ala	Gly	Ile

2997-49-2-pct_ST25

Lys Ser Arg Ala Leu Asp Tyr Gln Ile Trp Cys Gly Pro Ala Met
1880 1885 1890

Gly Ser Phe Asn Asn Phe Ala Ser Gly Thr Ser Leu Asp Trp Lys
1895 1900 1905

Val Thr Gly Val Phe Pro Gly Val Ala Glu Val Asn Met Ala Ile
1910 1915 1920

Leu Asp Gly Ala Arg Glu Leu Ala Ala Lys Arg Asn
1925 1930 1935

<210> 53
<211> 1500
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1500)

<220>
<221> misc_feature
<222> (1)..(1500)
<223> n = a c t o r g

<400> 53
atg caa ctt cct cca gcg cat tct gcc gat gag aat cgc atc gcg gtc 48
Met Gln Leu Pro Pro Ala His Ser Ala Asp Glu Asn Arg Ile Ala Val
1 5 10 15

gtg ggc atg gcc gtc aaa tat gcg ggc tgt gac aat aaa gaa gag ttt 96
Val Gly Met Ala Val Lys Tyr Ala Gly Cys Asp Asn Lys Glu Glu Phe
20 25 30

tgg aag act ttg atg aat ggt agt atc aat acc aag tcg att tcg gca 144
Trp Lys Thr Leu Met Asn Gly Ser Ile Asn Thr Lys Ser Ile Ser Ala
35 40 45

gca agg ttg ggc agc aat aag cgt gac gaa cac tat gtt cct gaa cga 192
Ala Arg Leu Gly Ser Asn Lys Arg Asp Glu His Tyr Val Pro Glu Arg
50 55 60

tcg aaa tat gca gat acg ttc tgt aac gaa agg tac ggt tgt atc cag 240
Ser Lys Tyr Ala Asp Thr Phe Cys Asn Glu Arg Tyr Gly Cys Ile Gln
65 70 75 80

caa ggt acg gat aat gag cat gac ctc ctc cta ggt ctt gct caa gaa 288
Gln Gly Thr Asp Asn Glu His Asp Leu Leu Leu Gly Leu Ala Gln Glu
85 90 95

gct ctc gct gac gct gcc ggg cgg atg gag aaa caa cct tcg gag gcg 336
Ala Leu Ala Asp Ala Ala Gly Arg Met Glu Lys Gln Pro Ser Glu Ala
100 105 110

ttc gat ctg gaa aat act ggc atc gtg agt ggg tgc tta tct ttt cca 384
Phe Asp Leu Glu Asn Thr Gly Ile Val Ser Gly Cys Leu Ser Phe Pro
115 120 125

atg gat aac ctg caa gga gag ttg ttg aac ttg tat caa agc cat gtg 432
Met Asp Asn Leu Gln Gly Glu Leu Leu Asn Leu Tyr Gln Ser His Val
130 135 140

2997-49-2-pct_ST25

gag Glu 145	aaa Lys	caa Gln	ctt Leu	cca Pro	cct Pro 150	agt Ser	gcc Ala	ttg Leu	gta Val	gaa Glu 155	gcc Ala	gtg Val	aag Lys	ctt Leu	tgg Trp 160	480
tct Ser	gag Glu	cga Arg	cag Gln	aaa Lys 165	tct Ser	acg Thr	aaa Lys	gca Ala	cat His 170	gca Ala	ggg Gly	gac Asp	aag Lys	cgc Arg 175	cgg Arg	528
ttc Phe	att Ile	gac Asp	cca Pro 180	gct Ala	tct Ser	ttt Phe	gta Val	gct Ala 185	gat Asp	aaa Lys	ctg Leu	aac Asn	cta Leu 190	ggc Gly	cca Pro	576
cta Leu	cat His	tat Tyr 195	gcg Ala	atc Ile	gat Asp	gca Ala	gca Ala 200	tgc Cys	gct Ala	tct Ser	gca Ala 205	ttg Leu 205	tac Tyr	gtg Val	tta Leu	624
aaa Lys	tta Leu 210	gct Ala	caa Gln	gac Asp	cac His	ctt Leu 215	gtt Val	tca Ser	ggt Gly	gcc Ala	ggt Val 220	gat Asp	atg Met	atg Met	tta Leu	672
tgt Cys 225	gga Gly	gcg Ala	acg Thr	tgc Cys	ttc Phe 230	cca Pro	gaa Glu	cca Pro	ttc Phe	ttc Phe 235	atc Ile	ttg Leu	tct Ser	ggg Gly	ttc Phe 240	720
tcg Ser	act Thr	ttt Phe	caa Gln	gcg Ala 245	atg Met	cct Pro	gnt Xaa	ggg Gly	gca Ala 250	gat Asp	gga Gly	gtc Val	tca Ser	cta Leu 255	cct Pro	768
ctc Leu	cat His	aaa Lys	acg Thr 260	agt Ser	gct Ala	ggg Gly	ctc Leu	act Thr 265	cca Pro	ggt Gly	gaa Glu	ggg Gly	ggg Gly 270	tcc Ser	att Ile	816
atg Met	gtg Val	ctc Leu 275	aag Lys	cga Arg	ctg Leu	aaa Lys	gac Asp 280	gct Ala	atc Ile	aga Arg	gat Asp	gga Gly 285	aat Asn	cac His	att Ile	864
tat Tyr	ggt Gly 290	gtg Val	ctc Leu	ctt Leu	gaa Glu	gca Ala 295	aat Asn	tta Leu	agt Ser	aac Asn	gca Ala 300	ggt Gly	tgt Cys	ggg Gly	ctt Leu	912
cca Pro 305	ctc Leu	agc Ser	ccg Pro	cac His	tta Leu 310	ccg Pro	agc Ser	gaa Glu	gaa Glu	tca Ser 315	tgt Cys	att Ile	cgt Arg	gat Asp	acc Thr 320	960
tac Tyr	cgc Arg	cgt Arg	gct Ala	gga Gly 325	gtt Val	gct Ala	gca Ala	gat Asp	caa Gln 330	agt Ser	att Ile	cag Gln	tat Tyr	att Ile 335	gag Glu	1008
tgc Cys	cac His	gct Ala	acg Thr 340	gga Gly	acc Thr	cct Pro	cga Arg	ggg Gly 345	gat Asp	gtc Val	gtg Val	gaa Glu	att Ile 350	gag Glu	gcg Ala	1056
ggt Val	gaa Glu	aga Arg 355	ggt Val	ttc Phe	aag Lys	aaa Lys	aac Asn 360	ggt Val	cca Pro	cgc Arg	tta Leu	ggc Gly 365	tcg Ser	acg Thr	aaa Lys	1104
gga Gly	aat Asn 370	ttt Phe	ggt Gly	cac His	tcg Ser	tta Leu 375	ggt Val	gcg Ala	gct Ala	ggt Gly	ttc Phe 380	gca Ala	ggg Gly	atg Met	gca Ala	1152
aag Lys 385	ctt Leu	ctt Leu	ctt Leu	gca Ala	atg Met 390	gaa Glu	cat His	gga Gly	gtg Val	att Ile 395	cct Pro	ccc Pro	aca Thr	cca Pro	ggt Gly 400	1200
ctt Leu	gat Asp	gct Ala	tcg Ser	aac Asn 405	cag Gln	gca Ala	agt Ser	gag Glu	cac His 410	ggt Val	gtg Val	aca Thr	aag Lys	gct Ala 415	atc Ile	1248

2997-49-2-pct_ST25

act tgg cct gag aca cat ggg gct cca aaa cga gct ggc ctt tca gca	1296
Thr Trp Pro Glu Thr His Gly Ala Pro Lys Arg Ala Gly Leu Ser Ala	
420 425 430	
ttt gga ttt ggt ggg act aat gcg cat gca ctc ttc gaa gag ttt aat	1344
Phe Gly Phe Gly Gly Thr Asn Ala His Ala Leu Phe Glu Glu Phe Asn	
435 440 445	
gcc gag ggc ata agt tat cgc cct gga aag cct cca gtc gaa tcg aat	1392
Ala Glu Gly Ile Ser Tyr Arg Pro Gly Lys Pro Pro Val Glu Ser Asn	
450 455 460	
acc cgt cct tcc gtc gta ata act ggg atg gac tgt acc ttt ggg agc	1440
Thr Arg Pro Ser Val Val Ile Thr Gly Met Asp Cys Thr Phe Gly Ser	
465 470 475 480	
ctt gaa ggg att gat gcg ttc gag act gcc ctg tac gag ggg cgt gac	1488
Leu Glu Gly Ile Asp Ala Phe Glu Thr Ala Leu Tyr Glu Gly Arg Asp	
485 490 495	
gca gct cgt gac	1500
Ala Ala Arg Asp	
500	

<210> 54
 <211> 500
 <212> PRT
 <213> Thraustochytrium sp.

<220>
 <221> misc_feature
 <222> (248)..(248)
 <223> The 'Xaa' at location 248 stands for Asp, Gly, Ala, or Val.

<400> 54

Met Gln Leu Pro Pro Ala His Ser Ala Asp Glu Asn Arg Ile Ala Val	
1 5 10 15	
Val Gly Met Ala Val Lys Tyr Ala Gly Cys Asp Asn Lys Glu Glu Phe	
20 25 30	
Trp Lys Thr Leu Met Asn Gly Ser Ile Asn Thr Lys Ser Ile Ser Ala	
35 40 45	
Ala Arg Leu Gly Ser Asn Lys Arg Asp Glu His Tyr Val Pro Glu Arg	
50 55 60	
Ser Lys Tyr Ala Asp Thr Phe Cys Asn Glu Arg Tyr Gly Cys Ile Gln	
65 70 75 80	
Gln Gly Thr Asp Asn Glu His Asp Leu Leu Leu Gly Leu Ala Gln Glu	
85 90 95	
Ala Leu Ala Asp Ala Ala Gly Arg Met Glu Lys Gln Pro Ser Glu Ala	
100 105 110	
Phe Asp Leu Glu Asn Thr Gly Ile Val Ser Gly Cys Leu Ser Phe Pro	
115 120 125	

2997-49-2-pct_ST25

Met Asp Asn Leu Gln Gly Glu Leu Leu Asn Leu Tyr Gln Ser His Val
 130 135 140
 Glu Lys Gln Leu Pro Pro Ser Ala Leu Val Glu Ala Val Lys Leu Trp
 145 150 155 160
 Ser Glu Arg Gln Lys Ser Thr Lys Ala His Ala Gly Asp Lys Arg Arg
 165 170 175
 Phe Ile Asp Pro Ala Ser Phe Val Ala Asp Lys Leu Asn Leu Gly Pro
 180 185 190
 Leu His Tyr Ala Ile Asp Ala Ala Cys Ala Ser Ala Leu Tyr Val Leu
 195 200 205
 Lys Leu Ala Gln Asp His Leu Val Ser Gly Ala Val Asp Met Met Leu
 210 215 220
 Cys Gly Ala Thr Cys Phe Pro Glu Pro Phe Phe Ile Leu Ser Gly Phe
 225 230 235 240
 Ser Thr Phe Gln Ala Met Pro Xaa Gly Ala Asp Gly Val Ser Leu Pro
 245 250 255
 Leu His Lys Thr Ser Ala Gly Leu Thr Pro Gly Glu Gly Gly Ser Ile
 260 265 270
 Met Val Leu Lys Arg Leu Lys Asp Ala Ile Arg Asp Gly Asn His Ile
 275 280 285
 Tyr Gly Val Leu Leu Glu Ala Asn Leu Ser Asn Ala Gly Cys Gly Leu
 290 295 300
 Pro Leu Ser Pro His Leu Pro Ser Glu Glu Ser Cys Ile Arg Asp Thr
 305 310 315 320
 Tyr Arg Arg Ala Gly Val Ala Ala Asp Gln Ser Ile Gln Tyr Ile Glu
 325 330 335
 Cys His Ala Thr Gly Thr Pro Arg Gly Asp Val Val Glu Ile Glu Ala
 340 345 350
 Val Glu Arg Val Phe Lys Lys Asn Val Pro Arg Leu Gly Ser Thr Lys
 355 360 365
 Gly Asn Phe Gly His Ser Leu Val Ala Ala Gly Phe Ala Gly Met Ala
 370 375 380
 Lys Leu Leu Leu Ala Met Glu His Gly Val Ile Pro Pro Thr Pro Gly
 385 390 395 400

2997-49-2-pct_ST25

Leu Asp Ala Ser Asn Gln Ala Ser Glu His Val Val Thr Lys Ala Ile
405 410 415

Thr Trp Pro Glu Thr His Gly Ala Pro Lys Arg Ala Gly Leu Ser Ala
420 425 430

Phe Gly Phe Gly Gly Thr Asn Ala His Ala Leu Phe Glu Glu Phe Asn
435 440 445

Ala Glu Gly Ile Ser Tyr Arg Pro Gly Lys Pro Pro Val Glu Ser Asn
450 455 460

Thr Arg Pro Ser Val Val Ile Thr Gly Met Asp Cys Thr Phe Gly Ser
465 470 475 480

Leu Glu Gly Ile Asp Ala Phe Glu Thr Ala Leu Tyr Glu Gly Arg Asp
485 490 495

Ala Ala Arg Asp
500

<210> 55
<211> 1500
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1500)

<400> 55
tta ccc gcc aaa cgt tgg agg ttc cta ggt gag gac ttg gag ttt ctc 48
Leu Pro Ala Lys Arg Trp Arg Phe Leu Gly Glu Asp Leu Glu Phe Leu
1 5 10 15

cga gcc atc agg ctc aag gaa aag cct agg ggt tgt ttt gtg gag agt 96
Arg Ala Ile Arg Leu Lys Glu Lys Pro Arg Gly Cys Phe Val Glu Ser
20 25 30

gtt gac gtt aac ttt aga cgg ctg aaa acg ccc ttg aca cca gaa gat 144
Val Asp Val Asn Phe Arg Arg Leu Lys Thr Pro Leu Thr Pro Glu Asp
35 40 45

atg ttg cgg ccc caa caa ctc ttg gcg gtt tct acg atg gac cga gca 192
Met Leu Arg Pro Gln Gln Leu Leu Ala Val Ser Thr Met Asp Arg Ala
50 55 60

att atc gat gca ggt cta aag aag ggc caa cat gta gca gtt ctt gtt 240
Ile Ile Asp Ala Gly Leu Lys Lys Gly Gln His Val Ala Val Leu Val
65 70 75 80

ggc cta gga act gac ctg gaa ctt tac cgt cat cga gca aga gtc gcg 288
Gly Leu Gly Thr Asp Leu Glu Leu Tyr Arg His Arg Ala Arg Val Ala
85 90 95

ctt aaa gag gtt ttg cac ccg agc tta aag tca gac act gca att ctc 336
Leu Lys Glu Val Leu His Pro Ser Leu Lys Ser Asp Thr Ala Ile Leu
100 105 110

2997-49-2-pct_ST25

cag Gln	aaa Lys	ata Ile 115	atg Met	caa Gln	tat Tyr	gtg Val	aat Asn 120	gat Asp	gca Ala	gga Gly	act Thr	tcg Ser 125	act Thr	tca Ser	tac Tyr	384
aca Thr	tct Ser 130	tac Tyr	att Ile	gga Gly	aac Asn	ctc Leu 135	gtt Val	gcc Ala	acg Thr	cgt Arg	att Ile 140	tcg Ser	tct Ser	cag Gln	tgg Trp	432
gga Gly 145	ttc Phe	aca Thr	ggg Gly	ccg Pro	tcc Ser 150	ttt Phe	act Thr	gtc Val	aca Thr	gaa Glu 155	gga Gly	aat Asn	aat Asn	tcc Ser	gtg Val 160	480
tac Tyr	aga Arg	tgt Cys	gca Ala	caa Gln 165	cta Leu	gcc Ala	aaa Lys	gat Asp	atg Met 170	ctt Leu	cag Gln	gtt Val	aac Asn	cga Arg 175	gtt Val	528
gat Asp	gct Ala	gtc Val 180	gtc Val	atc Ile	gca Ala	ggc Gly	gtt Val	gat Asp 185	ctc Leu	aac Asn	gga Gly	agc Ser	gcc Ala 190	gaa Glu	agt Ser	576
ttt Phe	ttt Phe	gtc Val 195	cga Arg	gca Ala	aat Asn	cgt Arg	caa Gln 200	aag Lys	ata Ile	tcc Ser	aag Lys	cta Leu 205	agt Ser	cat His	cca Pro	624
tgt Cys	gca Ala 210	agc Ser	ttc Phe	gac Asp	aga Arg	gat Asp 215	gca Ala	gat Asp	gga Gly	ttt Phe	ttc Phe 220	gca Ala	ggt Gly	gag Glu	ggc Gly	672
tgt Cys 225	ggt Gly	gcc Ala	cta Leu	gtt Val	ttc Phe 230	aag Lys	agg Arg	tta Leu	gaa Glu	gac Asp 235	tgt Cys	gct Ala	cct Pro	cag Gln	gaa Glu 240	720
aaa Lys	att Ile	tat Tyr	gct Ala	agt Ser 245	ata Ile	gac Asp	tct Ser	atc Ile	gca Ala 250	ata Ile	gat Asp	aaa Lys	gag Glu	cct Pro 255	act Thr	768
agc Ser	tca Ser	gct Ala	gtg Val 260	aaa Lys	gct Ala	gtc Val	tac Tyr	caa Gln 265	agt Ser	gat Asp	tcg Ser	agt Ser	ctc Leu 270	tcc Ser	gat Asp	816
att Ile	gag Glu	ctg Leu 275	tta Leu	gaa Glu	atc Ile	agt Ser	gga Gly 280	gac Asp	tcc Ser	aaa Lys	cgg Arg	ttt Phe 285	gca Ala	gca Ala	ttc Phe	864
gaa Glu	ggc Gly 290	gct Ala	gtg Val	gaa Glu	att Ile	caa Gln 295	tca Ser	agt Ser	gtg Val	gaa Glu	gcc Ala 300	cag Gln	cta Leu	aaa Lys	gga Gly	912
ctt Leu 305	tcc Ser	aaa Lys	gtc Val	ctt Leu	gaa Glu 310	cct Pro	gca Ala	aaa Lys	ggc Gly	caa Gln 315	ggc Gly	gta Val	gcg Ala	gtg Val	gga Gly 320	960
agt Ser	act Thr	cga Arg	gca Ala	acc Thr 325	gtt Val	ggg Gly	gat Asp	ata Ile	ggg Gly 330	tat Tyr	gct Ala	aca Thr	gga Gly	gcg Ala 335	gca Ala	1008
agc Ser	ctg Leu	att Ile	aaa Lys 340	act Thr	gca Ala	ctc Leu	tgc Cys	tta Leu 345	tat Tyr	aat Asn	cgc Arg	tac Tyr	ctt Leu 350	ccg Pro	gca Ala	1056
tta Leu	gca Ala	aac Asn 355	tgg Trp	agt Ser	ggc Gly	cca Pro	tgt Cys 360	gaa Glu	cag Gln	tcc Ser	gcc Ala	tgg Trp 365	ggc Gly	tca Ser	aac Asn	1104
atg Met	ttc Phe 370	gtt Val	tgc Cys	cat His	gaa Glu	aca Thr 375	cgg Arg	ccg Pro	tgg Trp	atg Met	aaa Lys 380	aac Asn	cag Gln	aat Asn	gaa Glu	1152

2997-49-2-pct_ST25

aag Lys 385	aga Arg	tgt Cys	gcc Ala	ctc Leu	att Ile 390	tct Ser	gga Gly	aca Thr	gat Asp	cca Pro 395	tct Ser	cat His	aca Thr	tgc Cys	ttt Phe 400	1200
tcc Ser	ctc Leu	gta Val	cta Leu	tcg Ser 405	gat Asp	act Thr	ggg Gly	tgt Cys	tat Tyr 410	gaa Glu	gag Glu	cac His	aat Asn	cga Arg 415	acg Thr	1248
tgc Cys	ttt Phe	gat Asp	gtg Val 420	caa Gln	gcg Ala	cca Pro	cag Gln	cta Leu 425	ggt Val	ctg Leu	ata Ile	cac His	gga Gly 430	ttc Phe	gat Asp	1296
gga Gly	aaa Lys	act Thr 435	att Ile	gtg Val	cgg Arg	cga Arg	ctt Leu 440	gaa Glu	gga Gly	tat Tyr	ctc Leu	ctt Leu 445	gaa Glu	ctt Leu	gtt Val	1344
gaa Glu	ggg Gly 450	cat His	gca Ala	agc Ser	cct Pro	tca Ser 455	gag Glu	tat Tyr	ttc Phe	cac His	aaa Lys 460	ctg Leu	att Ile	gga Gly	caa Gln	1392
agt Ser 465	cta Leu	ctt Leu	gag Glu	aac Asn	tcg Ser 470	aaa Lys	gaa Glu	agt Ser	aaa Lys	ctc Leu 475	aca Thr	ctt Leu	tcg Ser	ctt Leu	gtg Val 480	1440
tgc Cys	aat Asn	ccg Pro	aac Asn	cag Gln 485	ctc Leu	caa Gln	aag Lys	gag Glu	ctc Leu 490	atg Met	ctt Leu	gct Ala	atc Ile	aaa Lys 495	gga Gly	1488
gta Val	caa Gln	cga Arg	agc Ser 500													1500

<210> 56
 <211> 500
 <212> PRT
 <213> Thraustochytrium sp.

<400> 56

Leu 1	Pro	Ala	Lys	Arg 5	Trp	Arg	Phe	Leu	Gly 10	Glu	Asp	Leu	Glu	Phe 15	Leu
Arg	Ala	Ile	Arg 20	Leu	Lys	Glu	Lys	Pro 25	Arg	Gly	Cys	Phe	Val 30	Glu	Ser
Val	Asp	Val 35	Asn	Phe	Arg	Arg	Leu 40	Lys	Thr	Pro	Leu	Thr 45	Pro	Glu	Asp
Met	Leu 50	Arg	Pro	Gln	Gln	Leu 55	Leu	Ala	Val	Ser 60	Thr	Met	Asp	Arg	Ala
Ile 65	Ile	Asp	Ala	Gly 70	Leu	Lys	Lys	Gly	Gln	His 75	Val	Ala	Val	Leu	Val 80
Gly	Leu	Gly	Thr	Asp 85	Leu	Glu	Leu	Tyr	Arg 90	His	Arg	Ala	Arg	Val 95	Ala
Leu	Lys	Glu	Val 100	Leu	His	Pro	Ser	Leu 105	Lys	Ser	Asp	Thr	Ala 110	Ile	Leu

2997-49-2-pct_ST25

Gln Lys Ile Met Gln Tyr Val Asn Asp Ala Gly Thr Ser Thr Ser Tyr
 115 120 125
 Thr Ser Tyr Ile Gly Asn Leu Val Ala Thr Arg Ile Ser Ser Gln Trp
 130 135 140
 Gly Phe Thr Gly Pro Ser Phe Thr Val Thr Glu Gly Asn Asn Ser Val
 145 150 155 160
 Tyr Arg Cys Ala Gln Leu Ala Lys Asp Met Leu Gln Val Asn Arg Val
 165 170 175
 Asp Ala Val Val Ile Ala Gly Val Asp Leu Asn Gly Ser Ala Glu Ser
 180 185 190
 Phe Phe Val Arg Ala Asn Arg Gln Lys Ile Ser Lys Leu Ser His Pro
 195 200 205
 Cys Ala Ser Phe Asp Arg Asp Ala Asp Gly Phe Phe Ala Gly Glu Gly
 210 215 220
 Cys Gly Ala Leu Val Phe Lys Arg Leu Glu Asp Cys Ala Pro Gln Glu
 225 230 235 240
 Lys Ile Tyr Ala Ser Ile Asp Ser Ile Ala Ile Asp Lys Glu Pro Thr
 245 250 255
 Ser Ser Ala Val Lys Ala Val Tyr Gln Ser Asp Ser Ser Leu Ser Asp
 260 265 270
 Ile Glu Leu Leu Glu Ile Ser Gly Asp Ser Lys Arg Phe Ala Ala Phe
 275 280 285
 Glu Gly Ala Val Glu Ile Gln Ser Ser Val Glu Ala Gln Leu Lys Gly
 290 295 300
 Leu Ser Lys Val Leu Glu Pro Ala Lys Gly Gln Gly Val Ala Val Gly
 305 310 315 320
 Ser Thr Arg Ala Thr Val Gly Asp Ile Gly Tyr Ala Thr Gly Ala Ala
 325 330 335
 Ser Leu Ile Lys Thr Ala Leu Cys Leu Tyr Asn Arg Tyr Leu Pro Ala
 340 345 350
 Leu Ala Asn Trp Ser Gly Pro Cys Glu Gln Ser Ala Trp Gly Ser Asn
 355 360 365
 Met Phe Val Cys His Glu Thr Arg Pro Trp Met Lys Asn Gln Asn Glu
 370 375 380

2997-49-2-pct_ST25

Lys Arg Cys Ala Leu Ile Ser Gly Thr Asp Pro Ser His Thr Cys Phe
 385 390 395 400

Ser Leu Val Leu Ser Asp Thr Gly Cys Tyr Glu Glu His Asn Arg Thr
 405 410 415

Cys Phe Asp Val Gln Ala Pro Gln Leu Val Leu Ile His Gly Phe Asp
 420 425 430

Gly Lys Thr Ile Val Arg Arg Leu Glu Gly Tyr Leu Leu Glu Leu Val
 435 440 445

Glu Gly His Ala Ser Pro Ser Glu Tyr Phe His Lys Leu Ile Gly Gln
 450 455 460

Ser Leu Leu Glu Asn Ser Lys Glu Ser Lys Leu Thr Leu Ser Leu Val
 465 470 475 480

Cys Asn Pro Asn Gln Leu Gln Lys Glu Leu Met Leu Ala Ile Lys Gly
 485 490 495

Val Gln Arg Ser
 500

<210> 57
 <211> 1500
 <212> DNA
 <213> Thraustochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1500)

<400> 57
 atg tta aca ggg aag gat tgg gtc agt cca tca gga agt tgt ttt gcc 48
 Met Leu Thr Gly Lys Asp Trp Val Ser Pro Ser Gly Ser Cys Phe Ala
 1 5 10 15

cca aat ccg tta tca agc gca aaa gtg gca ttc atg tac gga gaa ggc 96
 Pro Asn Pro Leu Ser Ser Ala Lys Val Ala Phe Met Tyr Gly Glu Gly
 20 25 30

cga agc ccg tac tgt ggt gta ggc ttg ggt cta cat cgt ttg tgg ccc 144
 Arg Ser Pro Tyr Cys Gly Val Gly Leu Gly Leu His Arg Leu Trp Pro
 35 40 45

ggt ctc cat gaa aat gtg aac aat aag aca gtc gat tta tgg acg gaa 192
 Gly Leu His Glu Asn Val Asn Asn Lys Thr Val Asp Leu Trp Thr Glu
 50 55 60

gga gat ggt tgg tta tat cct cga acg ttg aca cga gaa gag cat aca 240
 Gly Asp Gly Trp Leu Tyr Pro Arg Thr Leu Thr Arg Glu Glu His Thr
 65 70 75 80

aaa gcc atc gaa tct ttc aac gca aat caa att gaa atg ttt cgc gct 288
 Lys Ala Ile Glu Ser Phe Asn Ala Asn Gln Ile Glu Met Phe Arg Ala
 85 90 95

2997-49-2-pct_ST25

ggg Gly	att Ile	ttc Phe	atc Ile 100	tca Ser	atg Met	tgt Cys	cag Gln	aca Thr 105	gac Asp	tat Tyr	gtc Val	atg Met	aat Asn 110	gtt Val	ctc Leu	336
ggg Gly	gtc Val	cag Gln 115	cct Pro	aag Lys	gcc Ala	gga Gly	ttt Phe 120	ggg Gly	ctg Leu	agc Ser	ttg Leu	gga Gly 125	gaa Glu	att Ile	tca Ser	384
atg Met 130	ctc Leu	ttt Phe	gcg Ala	atg Met	tca Ser	aag Lys 135	gag Glu	aac Asn	tgc Cys	agg Arg	cag Gln 140	tca Ser	cag Gln	gaa Glu	atg Met	432
acc Thr 145	aat Asn	cgt Arg	ttg Leu	cgc Arg	ggg Gly 150	tct Ser	cca Pro	gtg Val	tgg Trp	tct Ser 155	aac Asn	gag Glu	ctt Leu	gct Ala	atc Ile 160	480
aac Asn	ttc Phe	aat Asn	gca Ala 165	att Ile	cgc Arg	aag Lys	tta Leu	tgg Trp	aaa Lys 170	atc Ile	ccc Pro	cga Arg	gga Gly	gct Ala 175	ccc Pro	528
tta Leu	gaa Glu	tcc Ser	ttt Phe 180	tgg Trp	caa Gln	gga Gly	tac Tyr	ttg Leu 185	ggt Val	cac His	ggc Gly	aca Thr	aga Arg 190	gaa Glu	gaa Glu	576
gta Val	gag Glu	cat His 195	gct Ala	att Ile	ggg Gly	ctt Leu	tct Ser 200	gag Glu	cct Pro	tat Tyr	gta Val 205	cgt Arg	ctg Leu	ctt Leu	att Ile	624
gtg Val 210	aac Asn	gat Asp	tca Ser	agg Arg	agt Ser	gcc Ala 215	ttg Leu	att Ile	gct Ala	gga Gly	aaa Lys 220	cca Pro	gac Asp	gcc Ala	tgt Cys	672
cag Gln 225	gca Ala	gta Val	atc Ile	agt Ser	aga Arg 230	cta Leu	aac Asn	tcc Ser	aag Lys	ttc Phe 235	cct Pro	tct Ser	ctg Leu	ccg Pro	gta Val 240	720
aag Lys	caa Gln	gga Gly	atg Met	att Ile 245	ggg Gly	cat His	tgc Cys	cca Pro	gaa Glu 250	ggt Val	cgt Arg	gcg Ala	ttc Phe	atc Ile 255	aaa Lys	768
gat Asp	att Ile	ggg Gly	tac Tyr 260	atc Ile	cat His	gaa Glu	aca Thr	ctc Leu 265	cga Arg	att Ile	tcc Ser	aat Asn	gac Asp 270	tat Tyr	tcg Ser	816
gat Asp	tgt Cys	cag Gln 275	ctt Leu	ttc Phe	tca Ser	gcg Ala	gta Val 280	acc Thr	aag Lys	ggc Gly	gca Ala	ctt Leu 285	gac Asp	agc Ser	tcc Ser	864
aca Thr 290	atg Met	gaa Glu	atc Ile	aaa Lys	cac His	ttt Phe 295	gtg Val	gga Gly	gag Glu	gtc Val	tac Tyr 300	tcc Ser	cgg Arg	atc Ile	gca Ala	912
gac Asp 305	ttt Phe	cct Pro	caa Gln	atc Ile	gtc Val 310	aac Asn	acg Thr	gtg Val	cat His	tcg Ser 315	gct Ala	ggg Gly	tat Tyr	gac Asp	gta Val 320	960
ttt Phe	ctt Leu	gag Glu	ctt Leu	ggc Gly 325	tgt Cys	gat Asp	gct Ala	tct Ser	aga Arg 330	tct Ser	gca Ala	gca Ala	ggt Val	caa Gln 335	aac Asn	1008
att Ile	ctt Leu	ggg Gly	ggg Gly 340	caa Gln	gga Gly	aag Lys	ttc Phe	ttg Leu 345	tct Ser	aca Thr	gct Ala	att Ile	gac Asp 350	aaa Lys	aaa Lys	1056
gga Gly	cac His	tcc Ser 355	gcc Ala	tgg Trp	tca Ser	caa Gln	gta Val 360	ctt Leu	cgg Arg	gct Ala	acc Thr	gca Ala 365	tca Ser	tta Leu	gct Ala	1104

2997-49-2-pct_ST25

gca cat cga gta ccg gga atc tca att ttg gat ttg ttt cac cca aat	1152
Ala His Arg Val Pro Gly Ile Ser Ile Leu Asp Leu Phe His Pro Asn	
370 375 380	
ttc cga gaa atg tgc tgt aca atg gca acc aca cct aaa gtg gaa gat	1200
Phe Arg Glu Met Cys Cys Thr Met Ala Thr Thr Pro Lys Val Glu Asp	
385 390 395 400	
aag ttc ctg cgc acg att caa atc aat ggt cgg ttt gaa aaa gaa atg	1248
Lys Phe Leu Arg Thr Ile Gln Ile Asn Gly Arg Phe Glu Lys Glu Met	
405 410 415	
att cac cta gaa gat aca aca tta agt tgc tta ccc gct cca agt gaa	1296
Ile His Leu Glu Asp Thr Thr Leu Ser Cys Leu Pro Ala Pro Ser Glu	
420 425 430	
gca aat atc gca gct att caa tct cgg tca att cga tct gct gcg gcg	1344
Ala Asn Ile Ala Ala Ile Gln Ser Arg Ser Ile Arg Ser Ala Ala Ala	
435 440 445	
cgt tct gga caa tcc cat gat tgt gca tcc cat agc cat gaa gaa aat	1392
Arg Ser Gly Gln Ser His Asp Cys Ala Ser His Ser His Glu Glu Asn	
450 455 460	
aag gat tca tgc cct gaa aag ctg aag ctt gat tct gtg tcc gtc gcc	1440
Lys Asp Ser Cys Pro Glu Lys Leu Lys Leu Asp Ser Val Ser Val Ala	
465 470 475 480	
ata aat ttc gac aat gat gac cgc att cag ctt ggg cac gcg ggt ttt	1488
Ile Asn Phe Asp Asn Asp Asp Arg Ile Gln Leu Gly His Ala Gly Phe	
485 490 495	
cgg gag atg tac	1500
Arg Glu Met Tyr	
500	

<210> 58
 <211> 500
 <212> PRT
 <213> Thraustochytrium sp.

<400> 58

Met Leu Thr Gly Lys Asp Trp Val Ser Pro Ser Gly Ser Cys Phe Ala	
1 5 10 15	
Pro Asn Pro Leu Ser Ser Ala Lys Val Ala Phe Met Tyr Gly Glu Gly	
20 25 30	
Arg Ser Pro Tyr Cys Gly Val Gly Leu Gly Leu His Arg Leu Trp Pro	
35 40 45	
Gly Leu His Glu Asn Val Asn Asn Lys Thr Val Asp Leu Trp Thr Glu	
50 55 60	
Gly Asp Gly Trp Leu Tyr Pro Arg Thr Leu Thr Arg Glu Glu His Thr	
65 70 75 80	
Lys Ala Ile Glu Ser Phe Asn Ala Asn Gln Ile Glu Met Phe Arg Ala	
85 90 95	

2997-49-2-pct_ST25

Gly Ile Phe Ile Ser Met Cys Gln Thr Asp Tyr Val Met Asn Val Leu
 100 105 110
 Gly Val Gln Pro Lys Ala Gly Phe Gly Leu Ser Leu Gly Glu Ile Ser
 115 120 125
 Met Leu Phe Ala Met Ser Lys Glu Asn Cys Arg Gln Ser Gln Glu Met
 130 135 140
 Thr Asn Arg Leu Arg Gly Ser Pro Val Trp Ser Asn Glu Leu Ala Ile
 145 150 155 160
 Asn Phe Asn Ala Ile Arg Lys Leu Trp Lys Ile Pro Arg Gly Ala Pro
 165 170 175
 Leu Glu Ser Phe Trp Gln Gly Tyr Leu Val His Gly Thr Arg Glu Glu
 180 185 190
 Val Glu His Ala Ile Gly Leu Ser Glu Pro Tyr Val Arg Leu Leu Ile
 195 200 205
 Val Asn Asp Ser Arg Ser Ala Leu Ile Ala Gly Lys Pro Asp Ala Cys
 210 215 220
 Gln Ala Val Ile Ser Arg Leu Asn Ser Lys Phe Pro Ser Leu Pro Val
 225 230 235 240
 Lys Gln Gly Met Ile Gly His Cys Pro Glu Val Arg Ala Phe Ile Lys
 245 250 255
 Asp Ile Gly Tyr Ile His Glu Thr Leu Arg Ile Ser Asn Asp Tyr Ser
 260 265 270
 Asp Cys Gln Leu Phe Ser Ala Val Thr Lys Gly Ala Leu Asp Ser Ser
 275 280 285
 Thr Met Glu Ile Lys His Phe Val Gly Glu Val Tyr Ser Arg Ile Ala
 290 295 300
 Asp Phe Pro Gln Ile Val Asn Thr Val His Ser Ala Gly Tyr Asp Val
 305 310 315 320
 Phe Leu Glu Leu Gly Cys Asp Ala Ser Arg Ser Ala Ala Val Gln Asn
 325 330 335
 Ile Leu Gly Gly Gln Gly Lys Phe Leu Ser Thr Ala Ile Asp Lys Lys
 340 345 350
 Gly His Ser Ala Trp Ser Gln Val Leu Arg Ala Thr Ala Ser Leu Ala
 355 360 365

2997-49-2-pct_ST25

Ala His Arg Val Pro Gly Ile Ser Ile Leu Asp Leu Phe His Pro Asn
370 375 380

Phe Arg Glu Met Cys Cys Thr Met Ala Thr Thr Pro Lys Val Glu Asp
385 390 395 400

Lys Phe Leu Arg Thr Ile Gln Ile Asn Gly Arg Phe Glu Lys Glu Met
405 410 415

Ile His Leu Glu Asp Thr Thr Leu Ser Cys Leu Pro Ala Pro Ser Glu
420 425 430

Ala Asn Ile Ala Ala Ile Gln Ser Arg Ser Ile Arg Ser Ala Ala Ala
435 440 445

Arg Ser Gly Gln Ser His Asp Cys Ala Ser His Ser His Glu Glu Asn
450 455 460

Lys Asp Ser Cys Pro Glu Lys Leu Lys Leu Asp Ser Val Ser Val Ala
465 470 475 480

Ile Asn Phe Asp Asn Asp Asp Arg Ile Gln Leu Gly His Ala Gly Phe
485 490 495

Arg Glu Met Tyr
500

<210> 59
<211> 1305
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1305)

<400> 59	
aat aca aga tat agc ttg tac aca ggg gcg atg gca aag gga att gca	48
Asn Thr Arg Tyr Ser Leu Tyr Thr Gly Ala Met Ala Lys Gly Ile Ala	
1 5 10 15	
tct gca gat ctt gtc att gcc gct ggg aaa gag ggc atc cta gct tcc	96
Ser Ala Asp Leu Val Ile Ala Ala Gly Lys Glu Gly Ile Leu Ala Ser	
20 25 30	
tat gga gct gga gga cta cct ctt gct act gtt cga aag gga ata gac	144
Tyr Gly Ala Gly Gly Leu Pro Leu Ala Thr Val Arg Lys Gly Ile Asp	
35 40 45	
aaa att caa caa gcc ttg cca agt ggc cca tat gct gta aat ctt att	192
Lys Ile Gln Gln Ala Leu Pro Ser Gly Pro Tyr Ala Val Asn Leu Ile	
50 55 60	
cac tct ccc ttt gac ggc aac ttg gag cag gga aac gtc gat ttg ttc	240
His Ser Pro Phe Asp Gly Asn Leu Glu Gln Gly Asn Val Asp Leu Phe	
65 70 75 80	
ttg gaa aag aac gtc cgc gtg gcg gaa tgt tcc gcg ttt aca acg cta	288

2997-49-2-pct_ST25

Leu	Glu	Lys	Asn	Val 85	Arg	Val	Ala	Glu	Cys 90	Ser	Ala	Phe	Thr	Thr 95	Leu		
aca	gtg	cca	gta	gta	cac	tat	cgt	gct	gca	ggg	ctt	gtt	cgg	cgc	caa		336
Thr	Val	Pro	Val 100	Val	His	Tyr	Arg	Ala 105	Ala	Gly	Leu	Val	Arg 110	Arg	Gln		
gat	gga	agc	att	ttg	atc	aag	aac	cga	atc	att	gct	aaa	gta	tct	agg		384
Asp	Gly	Ser 115	Ile	Leu	Ile	Lys	Asn 120	Arg	Ile	Ile	Ala	Lys 125	Val	Ser	Arg		
aca	gaa	ctc	gct	gag	atg	ttc	ctt	cgt	ccg	gca	cct	caa	atc	atc	ctc		432
Thr	Glu 130	Leu	Ala	Glu	Met	Phe 135	Leu	Arg	Pro	Ala	Pro 140	Gln	Ile	Ile	Leu		
gaa	aaa	ctg	gta	gca	gca	gaa	atc	att	tca	tct	gac	caa	gcg	cgt	atg		480
Glu 145	Lys	Leu	Val	Ala 150	Ala	Glu	Ile	Ile	Ser	Ser 155	Asp	Gln	Ala	Arg	Met 160		
gca	gcc	aaa	gtt	ccc	atg	gcg	gac	gac	atc	gca	gtc	gaa	gcc	gac	tct		528
Ala	Ala	Lys	Val 165	Pro	Met	Ala	Asp	Asp	Ile 170	Ala	Val	Glu	Ala	Asp 175	Ser		
ggc	ggg	cac	acg	gat	aat	cgg	cct	atg	cac	gtc	att	ttg	ccc	ctg	ata		576
Gly	Gly	His	Thr 180	Asp	Asn	Arg	Pro	Met 185	His	Val	Ile	Leu	Pro 190	Leu	Ile		
att	caa	ctc	cg	aat	act	ata	ctt	gca	gag	tat	ggc	tgt	gcc	acg	gct		624
Ile	Gln	Leu 195	Arg	Asn	Thr	Ile	Leu 200	Ala	Glu	Tyr	Gly	Cys 205	Ala	Thr	Ala		
ttt	cgt	acc	cgt	ata	ggc	gct	gga	gga	ggc	att	ggc	tgt	cct	tca	gcg		672
Phe	Arg 210	Thr	Arg	Ile	Gly	Ala 215	Gly	Gly	Gly	Ile	Gly 220	Cys	Pro	Ser	Ala		
gcc	ctc	gca	gcc	ttt	gat	atg	ggc	gcg	agt	ttt	gtc	gtg	act	gga	agc		720
Ala 225	Leu	Ala	Ala	Phe	Asp 230	Met	Gly	Ala	Ser	Phe 235	Val	Val	Thr	Gly	Ser 240		
ata	aat	caa	att	tgc	cg	gag	gca	ggg	act	tgc	gat	act	gtt	cgg	gag		768
Ile	Asn	Gln	Ile	Cys 245	Arg	Glu	Ala	Gly	Thr 250	Cys	Asp	Thr	Val	Arg 255	Glu		
cta	ctt	gcc	aac	tca	agc	tac	tcg	gac	gtg	acg	atg	gcg	cca	gca	gca		816
Leu	Leu	Ala 260	Asn	Ser	Ser	Tyr	Ser	Asp 265	Val	Thr	Met	Ala	Pro 270	Ala	Ala		
gac	atg	ttt	gac	caa	ggc	gtg	aaa	ctc	caa	gtc	tta	aaa	cga	gga	acg		864
Asp	Met	Phe 275	Asp	Gln	Gly	Val	Lys 280	Leu	Gln	Val	Leu	Lys 285	Arg	Gly	Thr		
atg	ttt	cca	agc	aga	gca	aat	aaa	ctc	cgg	aag	ctc	ttt	gtg	aac	tac		912
Met	Phe 290	Pro	Ser	Arg	Ala	Asn 295	Lys	Leu	Arg	Lys	Leu 300	Phe	Val	Asn	Tyr		
gaa	tct	cta	gaa	aca	ctc	ccg	tcg	aaa	gag	ttg	aaa	tac	ctg	gaa	aac		960
Glu 305	Ser	Leu	Glu	Thr 310	Leu	Pro	Ser	Lys	Glu	Leu 315	Lys	Tyr	Leu	Glu	Asn 320		
atc	ata	ttc	aag	caa	gca	gta	gac	cag	gtg	tgg	gag	gaa	aca	aag	cgc		1008
Ile	Ile	Phe	Lys	Gln 325	Ala	Val	Asp	Gln	Val 330	Trp	Glu	Glu	Thr	Lys 335	Arg		
ttt	tac	tgt	gaa	aaa	ctg	aac	aat	cca	gat	aaa	att	gca	agg	gcc	atg		1056
Phe	Tyr	Cys	Glu 340	Lys	Leu	Asn	Asn	Pro 345	Asp	Lys	Ile	Ala	Arg 350	Ala	Met		
aaa	gat	cct	aaa	ttg	aag	atg	tcg	ctt	tgc	ttt	cgg	tgg	tat	ctc	tcc		1104

2997-49-2-pct_ST25

Lys	Asp	Pro	Lys	Leu	Lys	Met	Ser	Leu	Cys	Phe	Arg	Trp	Tyr	Leu	Ser		
		355					360					365					
aag	agc	tct	ggg	tgg	gcc	aac	gca	gga	att	aaa	tct	cgt	gca	ctc	gac	1152	
Lys	Ser	Ser	Gly	Trp	Ala	Asn	Ala	Gly	Ile	Lys	Ser	Arg	Ala	Leu	Asp		
	370					375					380						
tac	cag	atc	tgg	tgt	ggc	ccg	gca	atg	ggc	tcg	ttc	aac	aat	ttc	gcc	1200	
Tyr	Gln	Ile	Trp	Cys	Gly	Pro	Ala	Met	Gly	Ser	Phe	Asn	Asn	Phe	Ala		
385					390					395					400		
agc	ggc	aca	tcc	ctc	gat	tgg	aaa	gtg	act	ggg	ggt	ttc	cct	ggc	ggt	1248	
Ser	Gly	Thr	Ser	Leu	Asp	Trp	Lys	Val	Thr	Gly	Val	Phe	Pro	Gly	Val		
				405					410					415			
gcg	gaa	gta	aac	atg	gcc	att	tta	gat	ggc	gcg	cga	gaa	cta	gct	gct	1296	
Ala	Glu	Val	Asn	Met	Ala	Ile	Leu	Asp	Gly	Ala	Arg	Glu	Leu	Ala	Ala		
			420					425					430				
aaa	cga	aat														1305	
Lys	Arg	Asn															
		435															

<210> 60
 <211> 435
 <212> PRT
 <213> Thraustochytrium sp.

<400> 60

Asn	Thr	Arg	Tyr	Ser	Leu	Tyr	Thr	Gly	Ala	Met	Ala	Lys	Gly	Ile	Ala		
1				5				10						15			
Ser	Ala	Asp	Leu	Val	Ile	Ala	Ala	Gly	Lys	Glu	Gly	Ile	Leu	Ala	Ser		
			20					25					30				
Tyr	Gly	Ala	Gly	Gly	Leu	Pro	Leu	Ala	Thr	Val	Arg	Lys	Gly	Ile	Asp		
		35					40					45					
Lys	Ile	Gln	Gln	Ala	Leu	Pro	Ser	Gly	Pro	Tyr	Ala	Val	Asn	Leu	Ile		
	50					55					60						
His	Ser	Pro	Phe	Asp	Gly	Asn	Leu	Glu	Gln	Gly	Asn	Val	Asp	Leu	Phe		
65				70					75						80		
Leu	Glu	Lys	Asn	Val	Arg	Val	Ala	Glu	Cys	Ser	Ala	Phe	Thr	Thr	Leu		
			85						90					95			
Thr	Val	Pro	Val	Val	His	Tyr	Arg	Ala	Ala	Gly	Leu	Val	Arg	Arg	Gln		
		100						105					110				
Asp	Gly	Ser	Ile	Leu	Ile	Lys	Asn	Arg	Ile	Ile	Ala	Lys	Val	Ser	Arg		
		115					120					125					
Thr	Glu	Leu	Ala	Glu	Met	Phe	Leu	Arg	Pro	Ala	Pro	Gln	Ile	Ile	Leu		
	130					135					140						
Glu	Lys	Leu	Val	Ala	Ala	Glu	Ile	Ile	Ser	Ser	Asp	Gln	Ala	Arg	Met		

2997-49-2-pct_ST25

145		150		155		160
Ala	Ala	Lys	Val	Pro	Met	Ala
				165		170
Ala	Ala	Lys	Val	Pro	Met	Ala
				175		180
Gly	Gly	His	Thr	Asp	Asn	Arg
			180			185
Gly	Gly	His	Thr	Asp	Asn	Arg
			185			190
Ile	Gln	Leu	Arg	Asn	Thr	Ile
		195				200
Ile	Gln	Leu	Arg	Asn	Thr	Ile
		200				205
Phe	Arg	Thr	Arg	Ile	Gly	Ala
	210					215
Phe	Arg	Thr	Arg	Ile	Gly	Ala
	215					220
Ala	Leu	Ala	Ala	Phe	Asp	Met
				230		235
Ala	Leu	Ala	Ala	Phe	Asp	Met
				235		240
Ile	Asn	Gln	Ile	Cys	Arg	Glu
				245		250
Ile	Asn	Gln	Ile	Cys	Arg	Glu
				250		255
Leu	Leu	Ala	Asn	Ser	Ser	Tyr
			260			265
Leu	Leu	Ala	Asn	Ser	Ser	Tyr
			265			270
Asp	Met	Phe	Asp	Gln	Gly	Val
		275				280
Asp	Met	Phe	Asp	Gln	Gly	Val
		280				285
Met	Phe	Pro	Ser	Arg	Ala	Asn
	290					295
Met	Phe	Pro	Ser	Arg	Ala	Asn
	295					300
Glu	Ser	Leu	Glu	Thr	Leu	Pro
					310	315
Glu	Ser	Leu	Glu	Thr	Leu	Pro
					315	320
Ile	Ile	Phe	Lys	Gln	Ala	Val
				325		330
Ile	Ile	Phe	Lys	Gln	Ala	Val
				330		335
Phe	Tyr	Cys	Glu	Lys	Leu	Asn
			340			345
Phe	Tyr	Cys	Glu	Lys	Leu	Asn
			345			350
Lys	Asp	Pro	Lys	Leu	Lys	Met
		355				360
Lys	Asp	Pro	Lys	Leu	Lys	Met
		360				365
Lys	Ser	Ser	Gly	Trp	Ala	Asn
	370					375
Lys	Ser	Ser	Gly	Trp	Ala	Asn
	375					380
Tyr	Gln	Ile	Trp	Cys	Gly	Pro
					390	395
Tyr	Gln	Ile	Trp	Cys	Gly	Pro
					395	400
Ser	Gly	Thr	Ser	Leu	Asp	Trp
				405		410
Ser	Gly	Thr	Ser	Leu	Asp	Trp
				410		415
Ala	Glu	Val	Asn	Met	Ala	Ile
						Leu
Ala	Glu	Val	Asn	Met	Ala	Ile
						Leu

420

425

430

Lys Arg Asn
435

<210> 61
<211> 4410
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(4410)

<400> 61
atg ggc ccg cga gtg gcg tca ggc aag gtg ccg gct tgg gag atg agc 48
Met Gly Pro Arg Val Ala Ser Gly Lys Val Pro Ala Trp Glu Met Ser
1 5 10 15
aag tcc gag ctg tgt gat gac cgc acg gta gtc ttt gac tat gag gag 96
Lys Ser Glu Leu Cys Asp Asp Arg Thr Val Val Phe Asp Tyr Glu Glu
20 25 30
ctg ctg gag ttc gct gag ggc gat atc agt aag gtt ttt ggg ccg gag 144
Leu Leu Glu Phe Ala Glu Gly Asp Ile Ser Lys Val Phe Gly Pro Glu
35 40 45
ttc aaa gtg gtg gac ggg ttt agg cgc agg gtg agg ttg ccc gct cga 192
Phe Lys Val Val Asp Gly Phe Arg Arg Arg Val Arg Leu Pro Ala Arg
50 55 60
gag tac ctg ctg gtg acc cgg gtt acg ctg atg gat gcc gag gtg ggc 240
Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Gly
65 70 75 80
aac ttt cga gtg gga gca cgt atg gtg aca gag tat gac gta cct gtg 288
Asn Phe Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Val Pro Val
85 90 95
aac gga gag ctc tcg gaa ggg gga gat gtg ccg tgg gct gtg ttg gtg 336
Asn Gly Glu Leu Ser Glu Gly Gly Asp Val Pro Trp Ala Val Leu Val
100 105 110
gaa gcc ggg cag tgc gac ttg ctg cta att tct tac atg ggc atc gat 384
Glu Ala Gly Gln Cys Asp Leu Leu Leu Ile Ser Tyr Met Gly Ile Asp
115 120 125
ttc cag tgc aaa gga gag cgg gtc tac cgg ctg ctg aac acc acc ttg 432
Phe Gln Cys Lys Gly Glu Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
130 135 140
acg ttt ttt ggc gtc gcg aaa gaa ggg gaa acg ctt gtg tac gat att 480
Thr Phe Phe Gly Val Ala Lys Glu Gly Glu Thr Leu Val Tyr Asp Ile
145 150 155 160
cgc gtc acg ggt ttc gcc aag agg ccg gac gga gat atc tcc atg ttc 528
Arg Val Thr Gly Phe Ala Lys Arg Pro Asp Gly Asp Ile Ser Met Phe
165 170 175
ttt ttc gaa tat gat tgc tac tgc aat ggc aag ctt ctc atc gaa atg 576
Phe Phe Glu Tyr Asp Cys Tyr Cys Asn Gly Lys Leu Leu Ile Glu Met
180 185 190
cga gat ggc tct gca ggc ttc ttc acg gac gaa gag ctc gct gcc ggc 624
Arg Asp Gly Ser Ala Gly Phe Phe Thr Asp Glu Glu Leu Ala Ala Gly

2997-49-2-pct_ST25																
195					200					205						
aaa Lys	gga Gly 210	gtg Val	gtc Val	gtc Val	act Thr	cgt Arg 215	gca Ala	cag Gln	caa Gln	aac Asn	atg Met 220	cgg Arg	gac Asp	aaa Lys	att Ile	672
gta Val 225	cgg Arg	cag Gln	tcc Ser	att Ile	gag Glu 230	cct Pro	ttt Phe	gca Ala	ctg Leu	gcg Ala 235	gct Ala	tgc Cys	acg Thr	cac His	aaa Lys 240	720
acg Thr	act Thr	ctg Leu	aac Asn	gag Glu 245	agt Ser	gac Asp	atg Met	cag Gln	tcc Ser 250	ctt Leu	gtg Val	gag Glu	cga Arg	aac Asn 255	tgg Trp	768
gca Ala	aac Asn	gtt Val	ttt Phe 260	ggc Gly	acc Thr	agt Ser	aac Asn	aag Lys 265	atg Met	gcg Ala	gag Glu	ctc Leu	aac Asn 270	tat Tyr	aaa Lys	816
att Ile	tgc Cys	gcc Ala 275	agg Arg	aaa Lys	atg Met	ctc Leu	atg Met 280	atc Ile	gac Asp	agg Arg	gtt Val	acc Thr 285	cac His	att Ile	gac Asp	864
cac His	cac His 290	ggt Gly	ggg Gly	gcg Ala	tat Tyr	ggc Gly 295	ctc Leu	gga Gly	cta Leu	ctt Leu	gtt Val 300	gga Gly	gag Glu	aag Lys	atc Ile	912
ttg Leu 305	gat Asp	cga Arg	aac Asn	cat His	tgg Trp 310	tac Tyr	ttt Phe	cct Pro	tgt Cys	cac His 315	ttt Phe	gtc Val	aat Asn	gat Asp	caa Gln 320	960
gtc Val	atg Met	gca Ala	ggg Gly	tca Ser 325	ctg Leu	gtc Val	agc Ser	gat Asp	ggg Gly 330	tgc Cys	agc Ser	cag Gln	ctc Leu	tta Leu 335	aaa Lys	1008
ctc Leu	tat Tyr	atg Met	atc Ile 340	tgg Trp	ctt Leu	ggc Gly	ctc Leu	cac His 345	ctg Leu	aaa Lys	atg Met	gag Glu	gaa Glu 350	ttt Phe	gat Asp	1056
ttt Phe	ctc Leu	cca Pro 355	gtt Val	agc Ser	ggc Gly	cac His	aaa Lys 360	aac Asn	aag Lys	gtg Val	cga Arg	tgc Cys 365	agg Arg	gga Gly	caa Gln	1104
att Ile	tca Ser 370	ccg Pro	cat His	aaa Lys	ggc Gly	aag Lys 375	ctt Leu	gtc Val	tac Tyr	gtc Val	atg Met 380	gaa Glu	atc Ile	aaa Lys	aag Lys	1152
atg Met 385	ggt Gly	tac Tyr	gat Asp	caa Gln	gca Ala 390	tct Ser	gga Gly	agc Ser	cca Pro	tac Tyr 395	gcc Ala	atc Ile	gcg Ala	gac Asp	gtt Val 400	1200
gat Asp	atc Ile	att Ile	gac Asp	gtc Val 405	aac Asn	gaa Glu	gag Glu	ctg Leu	ggg Gly 410	caa Gln	agt Ser	ttt Phe	gac Asp	atc Ile 415	aac Asn	1248
gac Asp	ctt Leu	gcg Ala	agc Ser 420	tac Tyr	gga Gly	aaa Lys	ggg Gly	gac Asp 425	ctg Leu	agc Ser	aaa Lys	aaa Lys	atc Ile 430	gtg Val	gtt Val	1296
gac Asp	ttc Phe	aaa Lys 435	gga Gly	att Ile	gct Ala	ttg Leu	cag Gln 440	ctc Leu	aaa Lys	ggc Gly	cgc Arg	gct Ala 445	ttt Phe	tca Ser	cgc Arg	1344
atg Met	agt Ser 450	tcc Ser	agc Ser	tcg Ser	tcc Ser	ttg Leu 455	aac Asn	gaa Glu	gga Gly	tgg Trp	caa Gln 460	tgt Cys	gtt Val	cca Pro	aaa Lys	1392
cca Pro	agc Ser	cag Gln	aga Arg	atg Met	gaa Glu	cac His	gaa Glu	cag Gln	ccc Pro	cct Pro	gct Ala	cac His	tgc Cys	ctt Leu	gca Ala	1440

2997-49-2-pct_ST25																
465	470										475	480				
agc Ser	gac Asp	ccc Pro	gaa Glu	gcc Ala 485	cct Pro	tca Ser	act Thr	gtg Val	acc Thr 490	tgg Trp	cac His	cca Pro	atg Met	tca Ser 495	aag Lys	1488
ctt Leu	cct Pro	ggc Gly	aac Asn 500	cct Pro	acg Thr	ccg Pro	ttc Phe	ttc Phe 505	tcc Ser	cct Pro	tca Ser	tct Ser	tac Tyr 510	cct Pro	ccg Pro	1536
agg Arg	gca Ala	att Ile 515	tgc Cys	ttc Phe	atc Ile	cct Pro	ttc Phe 520	ccg Pro	ggc Gly	aat Asn	ccc Pro	ctt Leu 525	gac Asp	aac Asn	aac Asn	1584
tgc Cys	aag Lys 530	gct Ala	gga Gly	gaa Glu	atg Met	ccc Pro 535	ctg Leu	aac Asn	tgg Trp	tac Tyr	aac Asn 540	atg Met	tca Ser	gag Glu	ttc Phe	1632
atg Met 545	tgt Cys	ggc Gly	aag Lys	gtt Val	tct Ser 550	aac Asn	tgc Cys	ttg Leu	ggc Gly	cca Pro 555	gaa Glu	ttc Phe	gca Ala	cgc Arg	ttt Phe 560	1680
gac Asp	aag Lys	tcg Ser	aac Asn	acc Thr 565	agc Ser	cgg Arg	agc Ser	cct Pro	gct Ala 570	ttt Phe	gac Asp	ttg Leu	gct Ala	ctg Leu 575	gtg Val	1728
acc Thr	cga Arg	gtt Val	gtt Val 580	gaa Glu	gtc Val	aca Thr	aac Asn	atg Met 585	gaa Glu	cac His	ggc Gly	aag Lys	ttt Phe 590	cta Leu	aac Asn	1776
gtt Val	gat Asp	tgc Cys 595	aat Asn	cca Pro	agc Ser	aaa Lys	ggc Gly 600	aca Thr	atg Met	gtg Val	ggg Gly	gag Glu 605	ttt Phe	gac Asp	tgt Cys	1824
ccc Pro	caa Gln 610	gac Asp	gcg Ala	tgg Trp	ttc Phe	ttt Phe 615	gat Asp	ggt Gly	tcg Ser	tgc Cys	aac Asn 620	gac Asp	ggc Gly	cat His	atg Met	1872
ccg Pro 625	tat Tyr	tcc Ser	att Ile	atc Ile	atg Met 630	gaa Glu	atc Ile	gga Gly	ctg Leu	caa Gln 635	acc Thr	tca Ser	ggt Gly	gtt Val	ctc Leu 640	1920
acc Thr	tcg Ser	gtg Val	ttg Leu	aag Lys 645	gca Ala	ccg Pro	ctg Leu	act Thr	atg Met 650	gac Asp	aag Lys	gat Asp	gac Asp	att Ile 655	ctc Leu	1968
ttt Phe	cga Arg	aac Asn	ctc Leu 660	gat Asp	gca Ala	agt Ser	gct Ala	gaa Glu 665	atg Met	gtg Val	cgt Arg	cca Pro	gac Asp 670	gtg Val	gat Asp	2016
gtt Val	cgc Arg	ggc Gly 675	aaa Lys	acg Thr	att Ile	cga Arg	aac Asn 680	gtg Val	acc Thr	aag Lys	tgt Cys	acc Thr 685	ggc Gly	tat Tyr	gca Ala	2064
atg Met	ttg Leu 690	gga Gly	aag Lys	atg Met	ggg Gly	att Ile 695	cac His	cgg Arg	ttc Phe	acg Thr	ttt Phe 700	gag Glu	ttg Leu	agc Ser	gtt Val	2112
gac Asp 705	ggc Gly	gtg Val	gta Val	ttt Phe	tat Tyr 710	aaa Lys	gga Gly	tcc Ser	act Thr	tcc Ser 715	ttt Phe	gga Gly	tgg Trp	ttc Phe	act Thr 720	2160
ccc Pro	gag Glu	gtg Val	ttt Phe	gct Ala 725	cag Gln	caa Gln	gct Ala	gga Gly	ctc Leu 730	gac Asp	aac Asn	ggg Gly	aaa Lys	aag Lys 735	acg Thr	2208
gag Glu	ccc Pro	tgg Trp	tgc Cys	aag Lys	act Thr	aac Asn	aac Asn	acc Thr	tcg Ser	gtt Val	cga Arg	aga Arg	gtt Val	gaa Glu	atc Ile	2256

2997-49-2-pct_ST25																
740				745				750								
gca	tcc	gcc	aaa	gga	aaa	gag	cag	ctg	act	gag	aag	ctt	ccc	gac	gca	2304
Ala	Ser	Ala	Lys	Gly	Lys	Glu	Gln	Leu	Thr	Glu	Lys	Leu	Pro	Asp	Ala	
		755					760					765				
act	aat	gct	caa	gtt	ctt	cgg	cgt	tca	gag	cag	tgt	gaa	tac	ctc	gat	2352
Thr	Asn	Ala	Gln	Val	Leu	Arg	Arg	Ser	Glu	Gln	Cys	Glu	Tyr	Leu	Asp	
	770					775					780					
tac	ctc	aat	att	gcc	cct	gac	tct	ggg	ctg	cat	ggg	aag	ggc	tac	gcc	2400
Tyr	Leu	Asn	Ile	Ala	Pro	Asp	Ser	Gly	Leu	His	Gly	Lys	Gly	Tyr	Ala	
	785				790					795					800	
cac	gga	cac	aaa	gac	gtt	aac	ccg	caa	gac	tgg	ttc	ttc	tct	tgc	cac	2448
His	Gly	His	Lys	Asp	Val	Asn	Pro	Gln	Asp	Trp	Phe	Phe	Ser	Cys	His	
				805					810					815		
ttt	tgg	ttc	gat	cct	gta	atg	cca	gga	tct	tta	gga	att	gaa	tca	atg	2496
Phe	Trp	Phe	Asp	Pro	Val	Met	Pro	Gly	Ser	Leu	Gly	Ile	Glu	Ser	Met	
			820					825					830			
ttc	cag	ctt	atc	gag	gcc	ttt	gcg	gtg	gac	caa	aac	att	cct	gga	gag	2544
Phe	Gln	Leu	Ile	Glu	Ala	Phe	Ala	Val	Asp	Gln	Asn	Ile	Pro	Gly	Glu	
		835					840					845				
tac	aac	gta	tcc	aat	ccg	acc	ttt	gcc	cat	gca	cca	ggc	aaa	acg	gcg	2592
Tyr	Asn	Val	Ser	Asn	Pro	Thr	Phe	Ala	His	Ala	Pro	Gly	Lys	Thr	Ala	
	850					855					860					
tgg	aaa	tac	cga	ggc	cag	ctc	aca	cca	aag	aac	cgt	gcg	atg	gac	tgc	2640
Trp	Lys	Tyr	Arg	Gly	Gln	Leu	Thr	Pro	Lys	Asn	Arg	Ala	Met	Asp	Cys	
	865				870				875						880	
gag	gtg	cat	atc	gtt	tca	att	acc	gcc	tcc	ccc	gag	aac	ggg	ggc	tac	2688
Glu	Val	His	Ile	Val	Ser	Ile	Thr	Ala	Ser	Pro	Glu	Asn	Gly	Gly	Tyr	
				885					890					895		
gtt	gac	atc	gtg	gcc	gat	gga	gcg	ctt	tgg	gta	gat	gga	ctt	cgc	gtg	2736
Val	Asp	Ile	Val	Ala	Asp	Gly	Ala	Leu	Trp	Val	Asp	Gly	Leu	Arg	Val	
			900					905					910			
tac	gaa	gcc	aaa	gag	ctt	cga	gtt	cgt	gtc	gtt	tcg	gca	aaa	cct	caa	2784
Tyr	Glu	Ala	Lys	Glu	Leu	Arg	Val	Arg	Val	Val	Ser	Ala	Lys	Pro	Gln	
		915					920					925				
gca	att	ccg	gat	gta	caa	caa	cag	cca	cct	agc	gca	aag	gcg	gac	ccg	2832
Ala	Ile	Pro	Asp	Val	Gln	Gln	Gln	Pro	Pro	Ser	Ala	Lys	Ala	Asp	Pro	
	930					935					940					
ggg	aaa	aca	gga	gtt	gca	ctt	tcg	ccc	act	cag	cta	cgc	gac	gtc	ctg	2880
Gly	Lys	Thr	Gly	Val	Ala	Leu	Ser	Pro	Thr	Gln	Leu	Arg	Asp	Val	Leu	
	945				950					955					960	
ctt	gaa	gtg	gac	aat	cca	ttg	tat	ctt	ggt	gta	gag	aac	tcc	aat	ttg	2928
Leu	Glu	Val	Asp	Asn	Pro	Leu	Tyr	Leu	Gly	Val	Glu	Asn	Ser	Asn	Leu	
				965					970					975		
gtg	cag	ttt	gag	tcg	aaa	cct	gca	act	tct	tca	cgt	atc	gtt	tcg	atc	2976
Val	Gln	Phe	Glu	Ser	Lys	Pro	Ala	Thr	Ser	Ser	Arg	Ile	Val	Ser	Ile	
			980					985					990			
aaa	ccg	tgc	tcg	att	agt	gac	ctt	ggc	gat	aag	tct	ttt	atg	gaa	acg	3024
Lys	Pro	Cys	Ser	Ile	Ser	Asp	Leu	Gly	Asp	Lys	Ser	Phe	Met	Glu	Thr	
		995					1000					1005				
tac	aac	gtg	tca	gca	cct	ctg	tat	act	gga	gca	atg	gcc	aag	ggc		3069
Tyr	Asn	Val	Ser	Ala	Pro	Leu	Tyr	Thr	Gly	Ala	Met	Ala	Lys	Gly		

2997-49-2-pct_ST25															
1010				1015				1020							
att Ile	gca Ala 1025	tcc Ser	gcc Ala	gac Asp	ttg Leu	gtc Val 1030	att Ile	gct Ala	gct Ala	ggg Gly 1035	aaa Lys 1035	cgc Arg	aag Lys	ata Ile	3114
ctt Leu	gga Gly 1040	tcg Ser	ttt Phe	ggt Gly	gcg Ala	gga Gly 1045	ggg Gly	ctg Leu	cct Pro	att Ile	tcc Ser 1050	ata Ile	gtc Val	cgt Arg	3159
gaa Glu	gca Ala 1055	ctg Leu	gag Glu	aaa Lys	att Ile	caa Gln 1060	caa Gln	cac His	ctg Leu	ccc Pro	cac His 1065	ggc Gly	ccc Pro	tac Tyr	3204
gct Ala	gtt Val 1070	aac Asn	ctc Leu	att Ile	cac His	tcg Ser 1075	cct Pro	ttc Phe	gac Asp	agc Ser	aac Asn 1080	ttg Leu	gaa Glu	aag Lys	3249
ggc Gly	aac Asn 1085	gtt Val	gac Asp	ctc Leu	ttt Phe	ctc Leu 1090	gag Glu	atg Met	ggc Gly	gtg Val	aca Thr 1095	gtg Val	gta Val	gaa Glu	3294
tgc Cys	agc Ser 1100	gcg Ala	ttc Phe	atg Met	gaa Glu	ctc Leu 1105	acg Thr	gcc Ala	cag Gln	gtt Val	gtc Val 1110	cgg Arg	tac Tyr	cgc Arg	3339
gcg Ala	tct Ser 1115	ggt Gly	cta Leu	agc Ser	aaa Lys	agt Ser 1120	gcg Ala	gac Asp	ggt Gly	tcg Ser	att Ile 1125	cgc Arg	att Ile	gct Ala	3384
cac His	cgt Arg 1130	att Ile	att Ile	ggc Gly	aag Lys	gtt Val 1135	tcc Ser	aga Arg	acc Thr	gag Glu	ctg Leu 1140	gca Ala	gaa Glu	atg Met	3429
ttt Phe	att Ile 1145	cgt Arg	cca Pro	gca Ala	cca Pro	cag Gln 1150	cac His	ctc Leu	ctc Leu	caa Gln	aaa Lys 1155	ctc Leu	gta Val	gcc Ala	3474
tcc Ser	ggc Gly 1160	gag Glu	ctg Leu	aca Thr	gct Ala	gag Glu 1165	caa Gln	gcc Ala	gag Glu	ctt Leu	gca Ala 1170	aca Thr	cag Gln	gtt Val	3519
ccg Pro	gtg Val 1175	gcg Ala	gat Asp	gac Asp	att Ile	gcg Ala 1180	gtc Val	gaa Glu	gcc Ala	gac Asp	tcg Ser 1185	ggg Gly	ggg Gly	cat His	3564
acc Thr	gac Asp 1190	aac Asn	agg Arg	cct Pro	att Ile	cac His 1195	gtc Val	att Ile	ctt Leu	cct Pro	cta Leu 1200	atc Ile	atc Ile	aac Asn	3609
cta Leu	cgc Arg 1205	aac Asn	cgt Arg	ttg Leu	cat His	aaa Lys 1210	gag Glu	ctt Leu	gac Asp	tac Tyr	cct Pro 1215	tcg Ser	cat His	ctc Leu	3654
cgg Arg	gta Val 1220	cgt Arg	gtg Val	ggt Gly	gct Ala	ggt Gly 1225	ggt Gly	ggt Gly	att Ile	gga Gly	tgt Cys 1230	cct Pro	caa Gln	gcc Ala	3699
gct Ala	ctt Leu 1235	gca Ala	gca Ala	ttt Phe	caa Gln	atg Met 1240	ggg Gly	gca Ala	gcg Ala	ttt Phe	tta Leu 1245	atc Ile	act Thr	gga Gly	3744
acg Thr	gtg Val 1250	aac Asn	cag Gln	ctt Leu	gct Ala	cgt Arg 1255	gaa Glu	agt Ser	ggc Gly	act Thr	tgt Cys 1260	gac Asp	aac Asn	gtc Val	3789
cgg Arg	tta Leu	cag Gln	ctc Leu	tca Ser	aag Lys	gcc Ala	acg Thr	tat Tyr	agc Ser	gac Asp	gtg Val	tgt Cys	atg Met	gct Ala	3834

2997-49-2-pct_ST25

1265	1270	1275	
cct gct gcc gat atg ttt gac caa ggc gtg gag ctg caa gta ttg	3879		
Pro Ala Ala Asp Met Phe Asp Gln Gly Val Glu Leu Gln Val Leu			
1280	1285	1290	
aag aaa ggc acg ctg ttc cca agt cgt gct aag aag ctg tac gag	3924		
Lys Lys Gly Thr Leu Phe Pro Ser Arg Ala Lys Lys Leu Tyr Glu			
1295	1300	1305	
ctg ttc tgc aag tat gac tcg ttt gag gca atg ccg gct gaa gaa	3969		
Leu Phe Cys Lys Tyr Asp Ser Phe Glu Ala Met Pro Ala Glu Glu			
1310	1315	1320	
ttg caa cgg gtt gaa aag cgg att ttt caa aag tcg ctt gct gaa	4014		
Leu Gln Arg Val Glu Lys Arg Ile Phe Gln Lys Ser Leu Ala Glu			
1325	1330	1335	
gtt tgg cag gag acc agt gac ttt tac att cat cgt atc aag aac	4059		
Val Trp Gln Glu Thr Ser Asp Phe Tyr Ile His Arg Ile Lys Asn			
1340	1345	1350	
cct gag aaa atc aat cgt gct gca agc gat ggc aaa ctg aaa atg	4104		
Pro Glu Lys Ile Asn Arg Ala Ala Ser Asp Gly Lys Leu Lys Met			
1355	1360	1365	
tcg ctt tgc ttt cgc tgg tac ctt ggg ctt tcc tca ttt tgg gcc	4149		
Ser Leu Cys Phe Arg Trp Tyr Leu Gly Leu Ser Ser Phe Trp Ala			
1370	1375	1380	
aac tct ggg gca caa gat cgc gtc atg gac tat caa att tgg tgt	4194		
Asn Ser Gly Ala Gln Asp Arg Val Met Asp Tyr Gln Ile Trp Cys			
1385	1390	1395	
ggc cct gct att ggc gct ttc aat gat ttt acc aag ggc acg tac	4239		
Gly Pro Ala Ile Gly Ala Phe Asn Asp Phe Thr Lys Gly Thr Tyr			
1400	1405	1410	
ctt gac gtg act gtt gca aag agt tac cct tgt gtg gca cag atc	4284		
Leu Asp Val Thr Val Ala Lys Ser Tyr Pro Cys Val Ala Gln Ile			
1415	1420	1425	
aat ttg caa att ttg caa gga gct gcg tat ctg aaa cgc ctt ggt	4329		
Asn Leu Gln Ile Leu Gln Gly Ala Ala Tyr Leu Lys Arg Leu Gly			
1430	1435	1440	
gtc att cgt ttt gac cgc atg ctg ctg cag gcc gtc gat atc gac	4374		
Val Ile Arg Phe Asp Arg Met Leu Leu Gln Ala Val Asp Ile Asp			
1445	1450	1455	
gat cct gta ttt act tac gtg ccg acc cag cca ctt	4410		
Asp Pro Val Phe Thr Tyr Val Pro Thr Gln Pro Leu			
1460	1465	1470	

<210> 62
 <211> 1470
 <212> PRT
 <213> Thraustochytrium sp.

<400> 62

Met Gly Pro Arg Val Ala Ser Gly Lys Val Pro Ala Trp Glu Met Ser
 1 5 10 15

Lys Ser Glu Leu Cys Asp Asp Arg Thr Val Val Phe Asp Tyr Glu Glu
 20 25 30

2997-49-2-pct_ST25

Leu Leu Glu Phe Ala Glu Gly Asp Ile Ser Lys Val Phe Gly Pro Glu
 35 40 45
 Phe Lys Val Val Asp Gly Phe Arg Arg Arg Val Arg Leu Pro Ala Arg
 50 55 60
 Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Gly
 65 70 75 80
 Asn Phe Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Val Pro Val
 85 90 95
 Asn Gly Glu Leu Ser Glu Gly Gly Asp Val Pro Trp Ala Val Leu Val
 100 105 110
 Glu Ala Gly Gln Cys Asp Leu Leu Leu Ile Ser Tyr Met Gly Ile Asp
 115 120 125
 Phe Gln Cys Lys Gly Glu Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
 130 135 140
 Thr Phe Phe Gly Val Ala Lys Glu Gly Glu Thr Leu Val Tyr Asp Ile
 145 150 155 160
 Arg Val Thr Gly Phe Ala Lys Arg Pro Asp Gly Asp Ile Ser Met Phe
 165 170 175
 Phe Phe Glu Tyr Asp Cys Tyr Cys Asn Gly Lys Leu Leu Ile Glu Met
 180 185 190
 Arg Asp Gly Ser Ala Gly Phe Phe Thr Asp Glu Glu Leu Ala Ala Gly
 195 200 205
 Lys Gly Val Val Val Thr Arg Ala Gln Gln Asn Met Arg Asp Lys Ile
 210 215 220
 Val Arg Gln Ser Ile Glu Pro Phe Ala Leu Ala Ala Cys Thr His Lys
 225 230 235 240
 Thr Thr Leu Asn Glu Ser Asp Met Gln Ser Leu Val Glu Arg Asn Trp
 245 250 255
 Ala Asn Val Phe Gly Thr Ser Asn Lys Met Ala Glu Leu Asn Tyr Lys
 260 265 270
 Ile Cys Ala Arg Lys Met Leu Met Ile Asp Arg Val Thr His Ile Asp
 275 280 285
 His His Gly Gly Ala Tyr Gly Leu Gly Leu Leu Val Gly Glu Lys Ile
 290 295 300

2997-49-2-pct_ST25

Leu Asp Arg Asn His Trp Tyr Phe Pro Cys His Phe Val Asn Asp Gln
 305 310 315 320
 Val Met Ala Gly Ser Leu Val Ser Asp Gly Cys Ser Gln Leu Leu Lys
 325 330 335
 Leu Tyr Met Ile Trp Leu Gly Leu His Leu Lys Met Glu Glu Phe Asp
 340 345 350
 Phe Leu Pro Val Ser Gly His Lys Asn Lys Val Arg Cys Arg Gly Gln
 355 360 365
 Ile Ser Pro His Lys Gly Lys Leu Val Tyr Val Met Glu Ile Lys Lys
 370 375 380
 Met Gly Tyr Asp Gln Ala Ser Gly Ser Pro Tyr Ala Ile Ala Asp Val
 385 390 395 400
 Asp Ile Ile Asp Val Asn Glu Glu Leu Gly Gln Ser Phe Asp Ile Asn
 405 410 415
 Asp Leu Ala Ser Tyr Gly Lys Gly Asp Leu Ser Lys Lys Ile Val Val
 420 425 430
 Asp Phe Lys Gly Ile Ala Leu Gln Leu Lys Gly Arg Ala Phe Ser Arg
 435 440 445
 Met Ser Ser Ser Ser Ser Leu Asn Glu Gly Trp Gln Cys Val Pro Lys
 450 455 460
 Pro Ser Gln Arg Met Glu His Glu Gln Pro Pro Ala His Cys Leu Ala
 465 470 475 480
 Ser Asp Pro Glu Ala Pro Ser Thr Val Thr Trp His Pro Met Ser Lys
 485 490 495
 Leu Pro Gly Asn Pro Thr Pro Phe Phe Ser Pro Ser Ser Tyr Pro Pro
 500 505 510
 Arg Ala Ile Cys Phe Ile Pro Phe Pro Gly Asn Pro Leu Asp Asn Asn
 515 520 525
 Cys Lys Ala Gly Glu Met Pro Leu Asn Trp Tyr Asn Met Ser Glu Phe
 530 535 540
 Met Cys Gly Lys Val Ser Asn Cys Leu Gly Pro Glu Phe Ala Arg Phe
 545 550 555 560
 Asp Lys Ser Asn Thr Ser Arg Ser Pro Ala Phe Asp Leu Ala Leu Val
 565 570 575

2997-49-2-pct_ST25

Thr Arg Val Val Glu Val Thr Asn Met Glu His Gly Lys Phe Leu Asn
 580 585 590
 Val Asp Cys Asn Pro Ser Lys Gly Thr Met Val Gly Glu Phe Asp Cys
 595 600 605
 Pro Gln Asp Ala Trp Phe Phe Asp Gly Ser Cys Asn Asp Gly His Met
 610 615 620
 Pro Tyr Ser Ile Ile Met Glu Ile Gly Leu Gln Thr Ser Gly Val Leu
 625 630 635 640
 Thr Ser Val Leu Lys Ala Pro Leu Thr Met Asp Lys Asp Asp Ile Leu
 645 650 655
 Phe Arg Asn Leu Asp Ala Ser Ala Glu Met Val Arg Pro Asp Val Asp
 660 665 670
 Val Arg Gly Lys Thr Ile Arg Asn Val Thr Lys Cys Thr Gly Tyr Ala
 675 680 685
 Met Leu Gly Lys Met Gly Ile His Arg Phe Thr Phe Glu Leu Ser Val
 690 695 700
 Asp Gly Val Val Phe Tyr Lys Gly Ser Thr Ser Phe Gly Trp Phe Thr
 705 710 715 720
 Pro Glu Val Phe Ala Gln Gln Ala Gly Leu Asp Asn Gly Lys Lys Thr
 725 730 735
 Glu Pro Trp Cys Lys Thr Asn Asn Thr Ser Val Arg Arg Val Glu Ile
 740 745 750
 Ala Ser Ala Lys Gly Lys Glu Gln Leu Thr Glu Lys Leu Pro Asp Ala
 755 760 765
 Thr Asn Ala Gln Val Leu Arg Arg Ser Glu Gln Cys Glu Tyr Leu Asp
 770 775 780
 Tyr Leu Asn Ile Ala Pro Asp Ser Gly Leu His Gly Lys Gly Tyr Ala
 785 790 795 800
 His Gly His Lys Asp Val Asn Pro Gln Asp Trp Phe Phe Ser Cys His
 805 810 815
 Phe Trp Phe Asp Pro Val Met Pro Gly Ser Leu Gly Ile Glu Ser Met
 820 825 830
 Phe Gln Leu Ile Glu Ala Phe Ala Val Asp Gln Asn Ile Pro Gly Glu
 835 840 845

Tyr Asn Val Ser Asn Pro Thr Phe Ala His Ala Pro Gly Lys Thr Ala
 850 855 860
 Trp Lys Tyr Arg Gly Gln Leu Thr Pro Lys Asn Arg Ala Met Asp Cys
 865 870 875 880
 Glu Val His Ile Val Ser Ile Thr Ala Ser Pro Glu Asn Gly Gly Tyr
 885 890 895
 Val Asp Ile Val Ala Asp Gly Ala Leu Trp Val Asp Gly Leu Arg Val
 900 905 910
 Tyr Glu Ala Lys Glu Leu Arg Val Arg Val Val Ser Ala Lys Pro Gln
 915 920 925
 Ala Ile Pro Asp Val Gln Gln Gln Pro Pro Ser Ala Lys Ala Asp Pro
 930 935 940
 Gly Lys Thr Gly Val Ala Leu Ser Pro Thr Gln Leu Arg Asp Val Leu
 945 950 955 960
 Leu Glu Val Asp Asn Pro Leu Tyr Leu Gly Val Glu Asn Ser Asn Leu
 965 970 975
 Val Gln Phe Glu Ser Lys Pro Ala Thr Ser Ser Arg Ile Val Ser Ile
 980 985 990
 Lys Pro Cys Ser Ile Ser Asp Leu Gly Asp Lys Ser Phe Met Glu Thr
 995 1000 1005
 Tyr Asn Val Ser Ala Pro Leu Tyr Thr Gly Ala Met Ala Lys Gly
 1010 1015 1020
 Ile Ala Ser Ala Asp Leu Val Ile Ala Ala Gly Lys Arg Lys Ile
 1025 1030 1035
 Leu Gly Ser Phe Gly Ala Gly Gly Leu Pro Ile Ser Ile Val Arg
 1040 1045 1050
 Glu Ala Leu Glu Lys Ile Gln Gln His Leu Pro His Gly Pro Tyr
 1055 1060 1065
 Ala Val Asn Leu Ile His Ser Pro Phe Asp Ser Asn Leu Glu Lys
 1070 1075 1080
 Gly Asn Val Asp Leu Phe Leu Glu Met Gly Val Thr Val Val Glu
 1085 1090 1095
 Cys Ser Ala Phe Met Glu Leu Thr Ala Gln Val Val Arg Tyr Arg
 1100 1105 1110

2997-49-2-pct_ST25

Ala	Ser	Gly	Leu	Ser	Lys	Ser	Ala	Asp	Gly	Ser	Ile	Arg	Ile	Ala
	1115					1120					1125			
His	Arg	Ile	Ile	Gly	Lys	Val	Ser	Arg	Thr	Glu	Leu	Ala	Glu	Met
	1130					1135					1140			
Phe	Ile	Arg	Pro	Ala	Pro	Gln	His	Leu	Leu	Gln	Lys	Leu	Val	Ala
	1145					1150					1155			
Ser	Gly	Glu	Leu	Thr	Ala	Glu	Gln	Ala	Glu	Leu	Ala	Thr	Gln	Val
	1160					1165					1170			
Pro	Val	Ala	Asp	Asp	Ile	Ala	Val	Glu	Ala	Asp	Ser	Gly	Gly	His
	1175					1180					1185			
Thr	Asp	Asn	Arg	Pro	Ile	His	Val	Ile	Leu	Pro	Leu	Ile	Ile	Asn
	1190					1195					1200			
Leu	Arg	Asn	Arg	Leu	His	Lys	Glu	Leu	Asp	Tyr	Pro	Ser	His	Leu
	1205					1210					1215			
Arg	Val	Arg	Val	Gly	Ala	Gly	Gly	Gly	Ile	Gly	Cys	Pro	Gln	Ala
	1220					1225					1230			
Ala	Leu	Ala	Ala	Phe	Gln	Met	Gly	Ala	Ala	Phe	Leu	Ile	Thr	Gly
	1235					1240					1245			
Thr	Val	Asn	Gln	Leu	Ala	Arg	Glu	Ser	Gly	Thr	Cys	Asp	Asn	Val
	1250					1255					1260			
Arg	Leu	Gln	Leu	Ser	Lys	Ala	Thr	Tyr	Ser	Asp	Val	Cys	Met	Ala
	1265					1270					1275			
Pro	Ala	Ala	Asp	Met	Phe	Asp	Gln	Gly	Val	Glu	Leu	Gln	Val	Leu
	1280					1285					1290			
Lys	Lys	Gly	Thr	Leu	Phe	Pro	Ser	Arg	Ala	Lys	Lys	Leu	Tyr	Glu
	1295					1300					1305			
Leu	Phe	Cys	Lys	Tyr	Asp	Ser	Phe	Glu	Ala	Met	Pro	Ala	Glu	Glu
	1310					1315					1320			
Leu	Gln	Arg	Val	Glu	Lys	Arg	Ile	Phe	Gln	Lys	Ser	Leu	Ala	Glu
	1325					1330					1335			
Val	Trp	Gln	Glu	Thr	Ser	Asp	Phe	Tyr	Ile	His	Arg	Ile	Lys	Asn
	1340					1345					1350			
Pro	Glu	Lys	Ile	Asn	Arg	Ala	Ala	Ser	Asp	Gly	Lys	Leu	Lys	Met
	1355					1360					1365			

2997-49-2-pct_ST25

Ser Leu Cys Phe Arg Trp Tyr Leu Gly Leu Ser Ser Phe Trp Ala
 1370 1375 1380

Asn Ser Gly Ala Gln Asp Arg Val Met Asp Tyr Gln Ile Trp Cys
 1385 1390 1395

Gly Pro Ala Ile Gly Ala Phe Asn Asp Phe Thr Lys Gly Thr Tyr
 1400 1405 1410

Leu Asp Val Thr Val Ala Lys Ser Tyr Pro Cys Val Ala Gln Ile
 1415 1420 1425

Asn Leu Gln Ile Leu Gln Gly Ala Ala Tyr Leu Lys Arg Leu Gly
 1430 1435 1440

Val Ile Arg Phe Asp Arg Met Leu Leu Gln Ala Val Asp Ile Asp
 1445 1450 1455

Asp Pro Val Phe Thr Tyr Val Pro Thr Gln Pro Leu
 1460 1465 1470

<210> 63
 <211> 1500
 <212> DNA
 <213> Thraustochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1500)

<400> 63
 atg ggc ccg cga gtg gcg tca ggc aag gtg ccg gct tgg gag atg agc 48
 Met Gly Pro Arg Val Ala Ser Gly Lys Val Pro Ala Trp Glu Met Ser
 1 5 10 15

aag tcc gag ctg tgt gat gac cgc acg gta gtc ttt gac tat gag gag 96
 Lys Ser Glu Leu Cys Asp Asp Arg Thr Val Val Phe Asp Tyr Glu Glu
 20 25 30

ctg ctg gag ttc gct gag ggc gat atc agt aag gtt ttt ggg ccg gag 144
 Leu Leu Glu Phe Ala Glu Gly Asp Ile Ser Lys Val Phe Gly Pro Glu
 35 40 45

ttc aaa gtg gtg gac ggg ttt agg cgc agg gtg agg ttg ccc gct cga 192
 Phe Lys Val Val Asp Gly Phe Arg Arg Arg Val Arg Leu Pro Ala Arg
 50 55 60

gag tac ctg ctg gtg acc cgg gtt acg ctg atg gat gcc gag gtg ggc 240
 Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Gly
 65 70 75 80

aac ttt cga gtg gga gca cgt atg gtg aca gag tat gac gta cct gtg 288
 Asn Phe Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Val Pro Val
 85 90 95

aac gga gag ctc tcg gaa ggg gga gat gtg ccg tgg gct gtg ttg gtg 336
 Asn Gly Glu Leu Ser Glu Gly Gly Asp Val Pro Trp Ala Val Leu Val
 100 105 110

2997-49-2-pct_ST25

gaa Glu	gcc Ala	ggg Gly 115	cag Gln	tgc Cys	gac Asp	ttg Leu	ctg Leu 120	cta Leu	att Ile	tct Ser	tac Tyr	atg Met 125	ggc Gly	atc Ile	gat Asp	384
ttc Phe	cag Gln 130	tgc Cys	aaa Lys	gga Gly	gag Glu	cgg Arg 135	gtc Val	tac Tyr	cgg Arg	ctg Leu	ctg Leu 140	aac Asn	acc Thr	acc Thr	ttg Leu	432
acg Thr 145	ttt Phe	ttt Phe	ggc Gly	gtc Val	gcg Ala 150	aaa Lys	gaa Glu	ggg Gly	gaa Glu	acg Thr 155	ctt Leu	gtg Val	tac Tyr	gat Asp	att Ile 160	480
cgc Arg	gtc Val	acg Thr	ggt Gly	ttc Phe 165	gcc Ala	aag Lys	agg Arg	ccg Pro	gac Asp 170	gga Gly	gat Asp	atc Ile	tcc Ser	atg Met 175	ttc Phe	528
ttt Phe	ttc Phe	gaa Glu	tat Tyr 180	gat Asp	tgc Cys	tac Tyr	tgc Cys	aat Asn 185	ggc Gly	aag Lys	ctt Leu	ctc Leu	atc Ile 190	gaa Glu	atg Met	576
cga Arg	gat Asp	ggc Gly 195	tct Ser	gca Ala	ggc Gly	ttc Phe	ttc Phe 200	acg Thr	gac Asp	gaa Glu	gag Glu	ctc Leu 205	gct Ala	gcc Ala	ggc Gly	624
aaa Lys	gga Gly 210	gtg Val	gtc Val	gtc Val	act Thr	cgt Arg 215	gca Ala	cag Gln	caa Gln	aac Asn	atg Met 220	cgg Arg	gac Asp	aaa Lys	att Ile	672
gta Val 225	cgg Arg	cag Gln	tcc Ser	att Ile	gag Glu 230	cct Pro	ttt Phe	gca Ala	ctg Leu	gcg Ala 235	gct Ala	tgc Cys	acg Thr	cac His	aaa Lys 240	720
acg Thr	act Thr	ctg Leu	aac Asn	gag Glu 245	agt Ser	gac Asp	atg Met	cag Gln	tcc Ser 250	ctt Leu	gtg Val	gag Glu	cga Arg	aac Asn 255	tgg Trp	768
gca Ala	aac Asn	gtt Val	ttt Phe 260	ggc Gly	acc Thr	agt Ser	aac Asn	aag Lys 265	atg Met	gcg Ala	gag Glu	ctc Leu	aac Asn 270	tat Tyr	aaa Lys	816
att Ile	tgc Cys	gcc Ala 275	agg Arg	aaa Lys	atg Met	ctc Leu	atg Met 280	atc Ile	gac Asp	agg Arg	gtt Val	acc Thr 285	cac His	att Ile	gac Asp	864
cac His 290	cac His	ggt Gly	ggg Gly	gcg Ala	tat Tyr	ggc Gly 295	ctc Leu	gga Gly	cta Leu	ctt Leu	gtt Val 300	gga Gly	gag Glu	aag Lys	atc Ile	912
ttg Leu 305	gat Asp	cga Arg	aac Asn	cat His	tgg Trp 310	tac Tyr	ttt Phe	cct Pro	tgt Cys	cac His 315	ttt Phe	gtc Val	aat Asn	gat Asp	caa Gln 320	960
gtc Val	atg Met	gca Ala	ggg Gly	tca Ser 325	ctg Leu	gtc Val	agc Ser	gat Asp	ggt Gly 330	tgc Cys	agc Ser	cag Gln	ctc Leu	tta Leu 335	aaa Lys	1008
ctc Leu	tat Tyr	atg Met	atc Ile 340	tgg Trp	ctt Leu	ggc Gly	ctc Leu	cac His 345	ctg Leu	aaa Lys	atg Met	gag Glu	gaa Glu	ttt Phe	gat Asp	1056
ttt Phe	ctc Leu	cca Pro 355	gtt Val	agc Ser	ggc Gly	cac His	aaa Lys 360	aac Asn	aag Lys	gtg Val	cga Arg	tgc Cys 365	agg Arg	gga Gly	caa Gln	1104
att Ile	tca Ser 370	ccg Pro	cat His	aaa Lys	ggc Gly	aag Lys 375	ctt Leu	gtc Val	tac Tyr	gtc Val	atg Met 380	gaa Glu	atc Ile	aaa Lys	aag Lys	1152

2997-49-2-pct_ST25

atg ggt tac gat caa gca tct gga agc cca tac gcc atc gcg gac gtt Met Gly Tyr Asp Gln Ala Ser Gly Ser Pro Tyr Ala Ile Ala Asp Val 385 390 395 400	1200
gat atc att gac gtc aac gaa gag ctg ggt caa agt ttt gac atc aac Asp Ile Ile Asp Val Asn Glu Glu Leu Gly Gln Ser Phe Asp Ile Asn 405 410 415	1248
gac ctt gcg agc tac gga aaa ggt gac ctg agc aaa aaa atc gtg gtt Asp Leu Ala Ser Tyr Gly Lys Gly Asp Leu Ser Lys Lys Ile Val Val 420 425 430	1296
gac ttc aaa gga att gct ttg cag ctc aaa ggc cgc gct ttt tca cgc Asp Phe Lys Gly Ile Ala Leu Gln Leu Lys Gly Arg Ala Phe Ser Arg 435 440 445	1344
atg agt tcc agc tcg tcc ttg aac gaa gga tgg caa tgt gtt cca aaa Met Ser Ser Ser Ser Ser Leu Asn Glu Gly Trp Gln Cys Val Pro Lys 450 455 460	1392
cca agc cag aga atg gaa cac gaa cag ccc cct gct cac tgc ctt gca Pro Ser Gln Arg Met Glu His Glu Gln Pro Pro Ala His Cys Leu Ala 465 470 475 480	1440
agc gac ccc gaa gcc cct tca act gtg acc tgg cac cca atg tca aag Ser Asp Pro Glu Ala Pro Ser Thr Val Thr Trp His Pro Met Ser Lys 485 490 495	1488
ctt cct ggc aac Leu Pro Gly Asn 500	1500

<210> 64
 <211> 500
 <212> PRT
 <213> Thraustochytrium sp.

<400> 64

Met Gly Pro Arg Val Ala Ser Gly Lys Val Pro Ala Trp Glu Met Ser 1 5 10 15
Lys Ser Glu Leu Cys Asp Asp Arg Thr Val Val Phe Asp Tyr Glu Glu 20 25 30
Leu Leu Glu Phe Ala Glu Gly Asp Ile Ser Lys Val Phe Gly Pro Glu 35 40 45
Phe Lys Val Val Asp Gly Phe Arg Arg Arg Val Arg Leu Pro Ala Arg 50 55 60
Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Gly 65 70 75 80
Asn Phe Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Val Pro Val 85 90 95
Asn Gly Glu Leu Ser Glu Gly Gly Asp Val Pro Trp Ala Val Leu Val 100 105 110

2997-49-2-pct_ST25

Glu Ala Gly Gln Cys Asp Leu Leu Leu Ile Ser Tyr Met Gly Ile Asp
 115 120 125
 Phe Gln Cys Lys Gly Glu Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
 130 135 140
 Thr Phe Phe Gly Val Ala Lys Glu Gly Glu Thr Leu Val Tyr Asp Ile
 145 150 155 160
 Arg Val Thr Gly Phe Ala Lys Arg Pro Asp Gly Asp Ile Ser Met Phe
 165 170 175
 Phe Phe Glu Tyr Asp Cys Tyr Cys Asn Gly Lys Leu Leu Ile Glu Met
 180 185 190
 Arg Asp Gly Ser Ala Gly Phe Phe Thr Asp Glu Glu Leu Ala Ala Gly
 195 200 205
 Lys Gly Val Val Val Thr Arg Ala Gln Gln Asn Met Arg Asp Lys Ile
 210 215 220
 Val Arg Gln Ser Ile Glu Pro Phe Ala Leu Ala Ala Cys Thr His Lys
 225 230 235 240
 Thr Thr Leu Asn Glu Ser Asp Met Gln Ser Leu Val Glu Arg Asn Trp
 245 250 255
 Ala Asn Val Phe Gly Thr Ser Asn Lys Met Ala Glu Leu Asn Tyr Lys
 260 265 270
 Ile Cys Ala Arg Lys Met Leu Met Ile Asp Arg Val Thr His Ile Asp
 275 280 285
 His His Gly Gly Ala Tyr Gly Leu Gly Leu Leu Val Gly Glu Lys Ile
 290 295 300
 Leu Asp Arg Asn His Trp Tyr Phe Pro Cys His Phe Val Asn Asp Gln
 305 310 315 320
 Val Met Ala Gly Ser Leu Val Ser Asp Gly Cys Ser Gln Leu Leu Lys
 325 330 335
 Leu Tyr Met Ile Trp Leu Gly Leu His Leu Lys Met Glu Glu Phe Asp
 340 345 350
 Phe Leu Pro Val Ser Gly His Lys Asn Lys Val Arg Cys Arg Gly Gln
 355 360 365
 Ile Ser Pro His Lys Gly Lys Leu Val Tyr Val Met Glu Ile Lys Lys
 370 375 380

2997-49-2-pct_ST25

Met Gly Tyr Asp Gln Ala Ser Gly Ser Pro Tyr Ala Ile Ala Asp Val
 385 390 395 400

Asp Ile Ile Asp Val Asn Glu Glu Leu Gly Gln Ser Phe Asp Ile Asn
 405 410 415

Asp Leu Ala Ser Tyr Gly Lys Gly Asp Leu Ser Lys Lys Ile Val Val
 420 425 430

Asp Phe Lys Gly Ile Ala Leu Gln Leu Lys Gly Arg Ala Phe Ser Arg
 435 440 445

Met Ser Ser Ser Ser Ser Leu Asn Glu Gly Trp Gln Cys Val Pro Lys
 450 455 460

Pro Ser Gln Arg Met Glu His Glu Gln Pro Pro Ala His Cys Leu Ala
 465 470 475 480

Ser Asp Pro Glu Ala Pro Ser Thr Val Thr Trp His Pro Met Ser Lys
 485 490 495

Leu Pro Gly Asn
 500

<210> 65
 <211> 1500
 <212> DNA
 <213> Thraustochytrium sp.

<220>
 <221> CDS
 <222> (1)..(1500)

<400> 65
 cct acg ccg ttc ttc tcc cct tca tct tac cct ccg agg gca att tgc 48
 Pro Thr Pro Phe Phe Ser Pro Ser Ser Tyr Pro Pro Arg Ala Ile Cys
 1 5 10 15

ttc atc cct ttc ccg ggc aat ccc ctt gac aac aac tgc aag gct gga 96
 Phe Ile Pro Phe Pro Gly Asn Pro Leu Asp Asn Asn Cys Lys Ala Gly
 20 25 30

gaa atg ccc ctg aac tgg tac aac atg tca gag ttc atg tgt ggc aag 144
 Glu Met Pro Leu Asn Trp Tyr Asn Met Ser Glu Phe Met Cys Gly Lys
 35 40 45

gtt tct aac tgc ttg ggc cca gaa ttc gca cgc ttt gac aag tcg aac 192
 Val Ser Asn Cys Leu Gly Pro Glu Phe Ala Arg Phe Asp Lys Ser Asn
 50 55 60

acc agc cgg agc cct gct ttt gac ttg gct ctg gtg acc cga gtt gtt 240
 Thr Ser Arg Ser Pro Ala Phe Asp Leu Ala Leu Val Thr Arg Val Val
 65 70 75 80

gaa gtc aca aac atg gaa cac ggc aag ttt cta aac gtt gat tgc aat 288
 Glu Val Thr Asn Met Glu His Gly Lys Phe Leu Asn Val Asp Cys Asn
 85 90 95

2997-49-2-pct_ST25

cca	agc	aaa	ggc	aca	atg	gtg	ggg	gag	ttt	gac	tgt	ccc	caa	gac	gcg	336
Pro	Ser	Lys	Gly	Thr	Met	Val	Gly	Glu	Phe	Asp	Cys	Pro	Gln	Asp	Ala	
			100					105					110			
tgg	ttc	ttt	gat	ggt	tcg	tgc	aac	gac	ggc	cat	atg	ccg	tat	tcc	att	384
Trp	Phe	Phe	Asp	Gly	Ser	Cys	Asn	Asp	Gly	His	Met	Pro	Tyr	Ser	Ile	
		115					120					125				
atc	atg	gaa	atc	gga	ctg	caa	acc	tca	ggt	ggt	ctc	acc	tcg	gtg	ttg	432
Ile	Met	Glu	Ile	Gly	Leu	Gln	Thr	Ser	Gly	Val	Leu	Thr	Ser	Val	Leu	
	130					135					140					
aag	gca	ccg	ctg	act	atg	gac	aag	gat	gac	att	ctc	ttt	cga	aac	ctc	480
Lys	Ala	Pro	Leu	Thr	Met	Asp	Lys	Asp	Asp	Ile	Leu	Phe	Arg	Asn	Leu	
	145				150					155					160	
gat	gca	agt	gct	gaa	atg	gtg	cgt	cca	gac	gtg	gat	ggt	cgc	ggc	aaa	528
Asp	Ala	Ser	Ala	Glu	Met	Val	Arg	Pro	Asp	Val	Asp	Val	Arg	Gly	Lys	
				165					170					175		
acg	att	cga	aac	gtg	acc	aag	tgt	acc	ggc	tat	gca	atg	ttg	gga	aag	576
Thr	Ile	Arg	Asn	Val	Thr	Lys	Cys	Thr	Gly	Tyr	Ala	Met	Leu	Gly	Lys	
			180					185					190			
atg	ggg	att	cac	cgg	ttc	acg	ttt	gag	ttg	agc	gtt	gac	ggc	gtg	gta	624
Met	Gly	Ile	His	Arg	Phe	Thr	Phe	Glu	Leu	Ser	Val	Asp	Gly	Val	Val	
		195					200					205				
ttt	tat	aaa	gga	tcc	act	tcc	ttt	gga	tgg	ttc	act	ccc	gag	gtg	ttt	672
Phe	Tyr	Lys	Gly	Ser	Thr	Ser	Phe	Gly	Trp	Phe	Thr	Pro	Glu	Val	Phe	
	210					215					220					
gct	cag	caa	gct	gga	ctc	gac	aac	ggg	aaa	aag	acg	gag	ccc	tgg	tgc	720
Ala	Gln	Gln	Ala	Gly	Leu	Asp	Asn	Gly	Lys	Lys	Thr	Glu	Pro	Trp	Cys	
	225				230					235					240	
aag	act	aac	aac	acc	tcg	gtt	cga	aga	gtt	gaa	atc	gca	tcc	gcc	aaa	768
Lys	Thr	Asn	Asn	Thr	Ser	Val	Arg	Arg	Val	Glu	Ile	Ala	Ser	Ala	Lys	
				245					250					255		
gga	aaa	gag	cag	ctg	act	gag	aag	ctt	ccc	gac	gca	act	aat	gct	caa	816
Gly	Lys	Glu	Gln	Leu	Thr	Glu	Lys	Leu	Pro	Asp	Ala	Thr	Asn	Ala	Gln	
			260					265					270			
gtt	ctt	cgg	cgt	tca	gag	cag	tgt	gaa	tac	ctc	gat	tac	ctc	aat	att	864
Val	Leu	Arg	Arg	Ser	Glu	Gln	Cys	Glu	Tyr	Leu	Asp	Tyr	Leu	Asn	Ile	
		275					280					285				
gcc	cct	gac	tct	ggg	ctg	cat	ggg	aag	ggc	tac	gcc	cac	gga	cac	aaa	912
Ala	Pro	Asp	Ser	Gly	Leu	His	Gly	Lys	Gly	Tyr	Ala	His	Gly	His	Lys	
	290					295					300					
gac	gtt	aac	ccg	caa	gac	tgg	ttc	ttc	tct	tgc	cac	ttt	tgg	ttc	gat	960
Asp	Val	Asn	Pro	Gln	Asp	Trp	Phe	Phe	Ser	Cys	His	Phe	Trp	Phe	Asp	
	305				310					315					320	
cct	gta	atg	cca	gga	tct	tta	gga	att	gaa	tca	atg	ttc	cag	ctt	atc	1008
Pro	Val	Met	Pro	Gly	Ser	Leu	Gly	Ile	Glu	Ser	Met	Phe	Gln	Leu	Ile	
				325					330					335		
gag	gcc	ttt	gcg	gtg	gac	caa	aac	att	cct	gga	gag	tac	aac	gta	tcc	1056
Glu	Ala	Phe	Ala	Val	Asp	Gln	Asn	Ile	Pro	Gly	Glu	Tyr	Asn	Val	Ser	
			340					345					350			
aat	ccg	acc	ttt	gcc	cat	gca	cca	ggc	aaa	acg	gcg	tgg	aaa	tac	cga	1104
Asn	Pro	Thr	Phe	Ala	His	Ala	Pro	Gly	Lys	Thr	Ala	Trp	Lys	Tyr	Arg	
		355					360					365				

2997-49-2-pct_ST25

ggc	cag	ctc	aca	cca	aag	aac	cgt	gcg	atg	gac	tgc	gag	gtg	cat	atc	1152
Gly	Gln	Leu	Thr	Pro	Lys	Asn	Arg	Ala	Met	Asp	Cys	Glu	Val	His	Ile	
	370					375					380					
gtt	tca	att	acc	gcc	tcc	ccc	gag	aac	ggg	ggc	tac	gtt	gac	atc	gtg	1200
Val	Ser	Ile	Thr	Ala	Ser	Pro	Glu	Asn	Gly	Gly	Tyr	Val	Asp	Ile	Val	
	385				390					395					400	
gcc	gat	gga	gcg	ctt	tgg	gta	gat	gga	ctt	cgc	gtg	tac	gaa	gcc	aaa	1248
Ala	Asp	Gly	Ala	Leu	Trp	Val	Asp	Gly	Leu	Arg	Val	Tyr	Glu	Ala	Lys	
				405					410					415		
gag	ctt	cga	gtt	cgt	gtc	gtt	tcg	gca	aaa	cct	caa	gca	att	ccg	gat	1296
Glu	Leu	Arg	Val	Arg	Val	Val	Ser	Ala	Lys	Pro	Gln	Ala	Ile	Pro	Asp	
			420					425					430			
gta	caa	caa	cag	cca	cct	agc	gca	aag	gcg	gac	ccg	ggg	aaa	aca	gga	1344
Val	Gln	Gln	Gln	Pro	Pro	Ser	Ala	Lys	Ala	Asp	Pro	Gly	Lys	Thr	Gly	
		435					440					445				
gtt	gca	ctt	tcg	ccc	act	cag	cta	cgc	gac	gtc	ctg	ctt	gaa	gtg	gac	1392
Val	Ala	Leu	Ser	Pro	Thr	Gln	Leu	Arg	Asp	Val	Leu	Leu	Glu	Val	Asp	
	450					455					460					
aat	cca	ttg	tat	ctt	ggt	gta	gag	aac	tcc	aat	ttg	gtg	cag	ttt	gag	1440
Asn	Pro	Leu	Tyr	Leu	Gly	Val	Glu	Asn	Ser	Asn	Leu	Val	Gln	Phe	Glu	
					470					475					480	
tcg	aaa	cct	gca	act	tct	tca	cgt	atc	gtt	tcg	atc	aaa	ccg	tgc	tcg	1488
Ser	Lys	Pro	Ala	Thr	Ser	Ser	Arg	Ile	Val	Ser	Ile	Lys	Pro	Cys	Ser	
				485					490					495		
att	agt	gac	ctt													1500
Ile	Ser	Asp	Leu													
			500													

<210> 66
 <211> 500
 <212> PRT
 <213> Thraustochytrium sp.

<400> 66

Pro Thr Pro Phe Phe Ser Pro Ser Ser Tyr Pro Pro Arg Ala Ile Cys
 1 5 10 15

Phe Ile Pro Phe Pro Gly Asn Pro Leu Asp Asn Asn Cys Lys Ala Gly
 20 25 30

Glu Met Pro Leu Asn Trp Tyr Asn Met Ser Glu Phe Met Cys Gly Lys
 35 40 45

Val Ser Asn Cys Leu Gly Pro Glu Phe Ala Arg Phe Asp Lys Ser Asn
 50 55 60

Thr Ser Arg Ser Pro Ala Phe Asp Leu Ala Leu Val Thr Arg Val Val
 65 70 75 80

Glu Val Thr Asn Met Glu His Gly Lys Phe Leu Asn Val Asp Cys Asn
 85 90 95

2997-49-2-pct_ST25

Pro Ser Lys Gly Thr Met Val Gly Glu Phe Asp Cys Pro Gln Asp Ala
 100 105 110
 Trp Phe Phe Asp Gly Ser Cys Asn Asp Gly His Met Pro Tyr Ser Ile
 115 120 125
 Ile Met Glu Ile Gly Leu Gln Thr Ser Gly Val Leu Thr Ser Val Leu
 130 135 140
 Lys Ala Pro Leu Thr Met Asp Lys Asp Asp Ile Leu Phe Arg Asn Leu
 145 150 155 160
 Asp Ala Ser Ala Glu Met Val Arg Pro Asp Val Asp Val Arg Gly Lys
 165 170 175
 Thr Ile Arg Asn Val Thr Lys Cys Thr Gly Tyr Ala Met Leu Gly Lys
 180 185 190
 Met Gly Ile His Arg Phe Thr Phe Glu Leu Ser Val Asp Gly Val Val
 195 200 205
 Phe Tyr Lys Gly Ser Thr Ser Phe Gly Trp Phe Thr Pro Glu Val Phe
 210 215 220
 Ala Gln Gln Ala Gly Leu Asp Asn Gly Lys Lys Thr Glu Pro Trp Cys
 225 230 235 240
 Lys Thr Asn Asn Thr Ser Val Arg Arg Val Glu Ile Ala Ser Ala Lys
 245 250 255
 Gly Lys Glu Gln Leu Thr Glu Lys Leu Pro Asp Ala Thr Asn Ala Gln
 260 265 270
 Val Leu Arg Arg Ser Glu Gln Cys Glu Tyr Leu Asp Tyr Leu Asn Ile
 275 280 285
 Ala Pro Asp Ser Gly Leu His Gly Lys Gly Tyr Ala His Gly His Lys
 290 295 300
 Asp Val Asn Pro Gln Asp Trp Phe Phe Ser Cys His Phe Trp Phe Asp
 305 310 315 320
 Pro Val Met Pro Gly Ser Leu Gly Ile Glu Ser Met Phe Gln Leu Ile
 325 330 335
 Glu Ala Phe Ala Val Asp Gln Asn Ile Pro Gly Glu Tyr Asn Val Ser
 340 345 350
 Asn Pro Thr Phe Ala His Ala Pro Gly Lys Thr Ala Trp Lys Tyr Arg
 355 360 365

2997-49-2-pct_ST25

Gly Gln Leu Thr Pro Lys Asn Arg Ala Met Asp Cys Glu Val His Ile
370 375 380

Val Ser Ile Thr Ala Ser Pro Glu Asn Gly Gly Tyr Val Asp Ile Val
385 390 395 400

Ala Asp Gly Ala Leu Trp Val Asp Gly Leu Arg Val Tyr Glu Ala Lys
405 410 415

Glu Leu Arg Val Arg Val Val Ser Ala Lys Pro Gln Ala Ile Pro Asp
420 425 430

Val Gln Gln Gln Pro Pro Ser Ala Lys Ala Asp Pro Gly Lys Thr Gly
435 440 445

Val Ala Leu Ser Pro Thr Gln Leu Arg Asp Val Leu Leu Glu Val Asp
450 455 460

Asn Pro Leu Tyr Leu Gly Val Glu Asn Ser Asn Leu Val Gln Phe Glu
465 470 475 480

Ser Lys Pro Ala Thr Ser Ser Arg Ile Val Ser Ile Lys Pro Cys Ser
485 490 495

Ile Ser Asp Leu
500

<210> 67
<211> 1410
<212> DNA
<213> Thraustochytrium sp.

<220>
<221> CDS
<222> (1)..(1410)

<400> 67	
ggc gat aag tct ttt atg gaa acg tac aac gtg tca gca cct ctg tat	48
Gly Asp Lys Ser Phe Met Glu Thr Tyr Asn Val Ser Ala Pro Leu Tyr	
1 5 10 15	
act gga gca atg gcc aag ggc att gca tcc gcc gac ttg gtc att gct	96
Thr Gly Ala Met Ala Lys Gly Ile Ala Ser Ala Asp Leu Val Ile Ala	
20 25 30	
gct ggg aaa cgc aag ata ctt gga tcg ttt ggt gcg gga ggg ctg cct	144
Ala Gly Lys Arg Lys Ile Leu Gly Ser Phe Gly Ala Gly Gly Leu Pro	
35 40 45	
att tcc ata gtc cgt gaa gca ctg gag aaa att caa caa cac ctg ccc	192
Ile Ser Ile Val Arg Glu Ala Leu Glu Lys Ile Gln Gln His Leu Pro	
50 55 60	
cac ggc ccc tac gct gtt aac ctc att cac tcg cct ttc gac agc aac	240
His Gly Pro Tyr Ala Val Asn Leu Ile His Ser Pro Phe Asp Ser Asn	
65 70 75 80	
ttg gaa aag ggc aac gtt gac ctc ttt ctc gag atg ggc gtg aca gtg	288

2997-49-2-pct_ST25

Leu	Glu	Lys	Gly	Asn 85	Val	Asp	Leu	Phe	Leu 90	Glu	Met	Gly	Val	Thr 95	Val		
gta	gaa	tgc	agc	gcg	ttc	atg	gaa	ctc	acg	gcc	cag	gtt	gtc	cgg	tac		336
Val	Glu	Cys	Ser 100	Ala	Phe	Met	Glu	Leu 105	Thr	Ala	Gln	Val	Val 110	Arg	Tyr		
cgc	gcg	tct	ggt	cta	agc	aaa	agt	gcg	gac	ggt	tcg	att	cgc	att	gct		384
Arg	Ala	Ser 115	Gly	Leu	Ser	Lys	Ser 120	Ala	Asp	Gly	Ser	Ile 125	Arg	Ile	Ala		
cac	cgt	att	att	ggc	aag	gtt	tcc	aga	acc	gag	ctg	gca	gaa	atg	ttt		432
His	Arg 130	Ile	Ile	Gly	Lys	Val 135	Ser	Arg	Thr	Glu	Leu 140	Ala	Glu	Met	Phe		
att	cgt	cca	gca	cca	cag	cac	ctc	ctc	caa	aaa	ctc	gta	gcc	tcc	ggc		480
Ile 145	Arg	Pro	Ala	Pro	Gln 150	His	Leu	Leu	Gln	Lys 155	Leu	Val	Ala	Ser	Gly 160		
gag	ctg	aca	gct	gag	caa	gcc	gag	ctt	gca	aca	cag	gtt	ccg	gtg	gcg		528
Glu	Leu	Thr	Ala	Glu 165	Gln	Ala	Glu	Leu	Ala 170	Thr	Gln	Val	Pro	Val 175	Ala		
gat	gac	att	gcg	gtc	gaa	gcc	gac	tcg	ggg	ggg	cat	acc	gac	aac	agg		576
Asp	Asp	Ile	Ala 180	Val	Glu	Ala	Asp	Ser 185	Gly	Gly	His	Thr	Asp 190	Asn	Arg		
cct	att	cac	gtc	att	ctt	cct	cta	atc	atc	aac	cta	cgc	aac	cgt	ttg		624
Pro	Ile	His 195	Val	Ile	Leu	Pro	Leu 200	Ile	Ile	Asn	Leu	Arg 205	Asn	Arg	Leu		
cat	aaa	gag	ctt	gac	tac	cct	tcg	cat	ctc	cgg	gta	cgt	gtg	ggc	gct		672
His	Lys 210	Glu	Leu	Asp	Tyr	Pro 215	Ser	His	Leu	Arg	Val 220	Arg	Val	Gly	Ala		
ggc	ggc	ggc	att	gga	tgt	cct	caa	gcc	gct	ctt	gca	gca	ttt	caa	atg		720
Gly 225	Gly	Gly	Ile	Gly	Cys 230	Pro	Gln	Ala	Ala	Leu 235	Ala	Ala	Phe	Gln	Met 240		
ggg	gca	gcg	ttt	tta	atc	act	gga	acg	gtg	aac	cag	ctt	gct	cgt	gaa		768
Gly	Ala	Ala	Phe	Leu 245	Ile	Thr	Gly	Thr	Val 250	Asn	Gln	Leu	Ala	Arg 255	Glu		
agt	ggc	act	tgt	gac	aac	gtc	cgg	tta	cag	ctc	tca	aag	gcc	acg	tat		816
Ser	Gly	Thr	Cys 260	Asp	Asn	Val	Arg	Leu 265	Gln	Leu	Ser	Lys	Ala 270	Thr	Tyr		
agc	gac	gtg	tgt	atg	gct	cct	gct	gcc	gat	atg	ttt	gac	caa	ggc	gtg		864
Ser	Asp	Val 275	Cys	Met	Ala	Pro	Ala 280	Ala	Asp	Met	Phe	Asp 285	Gln	Gly	Val		
gag	ctg	caa	gta	ttg	aag	aaa	ggc	acg	ctg	ttc	cca	agt	cgt	gct	aag		912
Glu	Leu 290	Gln	Val	Leu	Lys	Lys 295	Gly	Thr	Leu	Phe	Pro 300	Ser	Arg	Ala	Lys		
aag	ctg	tac	gag	ctg	ttc	tgc	aag	tat	gac	tcg	ttt	gag	gca	atg	ccg		960
Lys 305	Leu	Tyr	Glu	Leu	Phe 310	Cys	Lys	Tyr	Asp	Ser 315	Phe	Glu	Ala	Met	Pro 320		
gct	gaa	gaa	ttg	caa	cgg	gtt	gaa	aag	cgg	att	ttt	caa	aag	tcg	ctt		1008
Ala	Glu	Glu	Leu	Gln 325	Arg	Val	Glu	Lys	Arg 330	Ile	Phe	Gln	Lys	Ser 335	Leu		
gct	gaa	gtt	tgg	cag	gag	acc	agt	gac	ttt	tac	att	cat	cgt	atc	aag		1056
Ala	Glu	Val	Trp 340	Gln	Glu	Thr	Ser	Asp 345	Phe	Tyr	Ile	His	Arg 350	Ile	Lys		
aac	cct	gag	aaa	atc	aat	cgt	gct	gca	agc	gat	ggc	aaa	ctg	aaa	atg		1104

2997-49-2-pct_ST25

Asn	Pro	Glu	Lys	Ile	Asn	Arg	Ala	Ala	Ser	Asp	Gly	Lys	Leu	Lys	Met		
		355					360					365					
tct	ctt	tgc	ttt	cgc	tgg	tac	ctt	ggg	ctt	tcc	tca	ttt	tgg	gcc	aac	1152	
Ser	Leu	Cys	Phe	Arg	Trp	Tyr	Leu	Gly	Leu	Ser	Ser	Phe	Trp	Ala	Asn		
	370					375					380						
tct	ggg	gca	caa	gat	cgc	gtc	atg	gac	tat	caa	att	tgg	tgt	ggc	cct	1200	
Ser	Gly	Ala	Gln	Asp	Arg	Val	Met	Asp	Tyr	Gln	Ile	Trp	Cys	Gly	Pro		
	385				390					395					400		
gct	att	ggc	gct	ttc	aat	gat	ttt	acc	aag	ggc	acg	tac	ctt	gac	gtg	1248	
Ala	Ile	Gly	Ala	Phe	Asn	Asp	Phe	Thr	Lys	Gly	Thr	Tyr	Leu	Asp	Val		
				405					410					415			
act	gtt	gca	aag	agt	tac	cct	tgt	gtg	gca	cag	atc	aat	ttg	caa	att	1296	
Thr	Val	Ala	Lys	Ser	Tyr	Pro	Cys	Val	Ala	Gln	Ile	Asn	Leu	Gln	Ile		
			420					425					430				
ttg	caa	gga	gct	gcg	tat	ctg	aaa	cgc	ctt	ggg	gtc	att	cgt	ttt	gac	1344	
Leu	Gln	Gly	Ala	Ala	Tyr	Leu	Lys	Arg	Leu	Gly	Val	Ile	Arg	Phe	Asp		
		435					440					445					
cgc	atg	ctg	ctg	cag	gcc	gtc	gat	atc	gac	gat	cct	gta	ttt	act	tac	1392	
Arg	Met	Leu	Leu	Gln	Ala	Val	Asp	Ile	Asp	Asp	Pro	Val	Phe	Thr	Tyr		
	450					455					460						
gtg	ccg	acc	cag	cca	ctt											1410	
Val	Pro	Thr	Gln	Pro	Leu												
					470												

<210> 68
 <211> 470
 <212> PRT
 <213> Thraustochytrium sp.

<400> 68

Gly	Asp	Lys	Ser	Phe	Met	Glu	Thr	Tyr	Asn	Val	Ser	Ala	Pro	Leu	Tyr
1				5					10					15	

Thr	Gly	Ala	Met	Ala	Lys	Gly	Ile	Ala	Ser	Ala	Asp	Leu	Val	Ile	Ala
			20					25					30		

Ala	Gly	Lys	Arg	Lys	Ile	Leu	Gly	Ser	Phe	Gly	Ala	Gly	Gly	Leu	Pro
		35					40					45			

Ile	Ser	Ile	Val	Arg	Glu	Ala	Leu	Glu	Lys	Ile	Gln	Gln	His	Leu	Pro
	50					55					60				

His	Gly	Pro	Tyr	Ala	Val	Asn	Leu	Ile	His	Ser	Pro	Phe	Asp	Ser	Asn
65					70					75					80

Leu	Glu	Lys	Gly	Asn	Val	Asp	Leu	Phe	Leu	Glu	Met	Gly	Val	Thr	Val
				85					90					95	

Val	Glu	Cys	Ser	Ala	Phe	Met	Glu	Leu	Thr	Ala	Gln	Val	Val	Arg	Tyr
			100					105					110		

Arg	Ala	Ser	Gly	Leu	Ser	Lys	Ser	Ala	Asp	Gly	Ser	Ile	Arg	Ile	Ala
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

115

120

125

His Arg Ile Ile Gly Lys Val Ser Arg Thr Glu Leu Ala Glu Met Phe
 130 135 140

Ile Arg Pro Ala Pro Gln His Leu Leu Gln Lys Leu Val Ala Ser Gly
 145 150 155 160

Glu Leu Thr Ala Glu Gln Ala Glu Leu Ala Thr Gln Val Pro Val Ala
 165 170 175

Asp Asp Ile Ala Val Glu Ala Asp Ser Gly Gly His Thr Asp Asn Arg
 180 185 190

Pro Ile His Val Ile Leu Pro Leu Ile Ile Asn Leu Arg Asn Arg Leu
 195 200 205

His Lys Glu Leu Asp Tyr Pro Ser His Leu Arg Val Arg Val Gly Ala
 210 215 220

Gly Gly Gly Ile Gly Cys Pro Gln Ala Ala Leu Ala Ala Phe Gln Met
 225 230 235 240

Gly Ala Ala Phe Leu Ile Thr Gly Thr Val Asn Gln Leu Ala Arg Glu
 245 250 255

Ser Gly Thr Cys Asp Asn Val Arg Leu Gln Leu Ser Lys Ala Thr Tyr
 260 265 270

Ser Asp Val Cys Met Ala Pro Ala Ala Asp Met Phe Asp Gln Gly Val
 275 280 285

Glu Leu Gln Val Leu Lys Lys Gly Thr Leu Phe Pro Ser Arg Ala Lys
 290 295 300

Lys Leu Tyr Glu Leu Phe Cys Lys Tyr Asp Ser Phe Glu Ala Met Pro
 305 310 315 320

Ala Glu Glu Leu Gln Arg Val Glu Lys Arg Ile Phe Gln Lys Ser Leu
 325 330 335

Ala Glu Val Trp Gln Glu Thr Ser Asp Phe Tyr Ile His Arg Ile Lys
 340 345 350

Asn Pro Glu Lys Ile Asn Arg Ala Ala Ser Asp Gly Lys Leu Lys Met
 355 360 365

Ser Leu Cys Phe Arg Trp Tyr Leu Gly Leu Ser Ser Phe Trp Ala Asn
 370 375 380

Ser Gly Ala Gln Asp Arg Val Met Asp Tyr Gln Ile Trp Cys Gly Pro
 Page 205

385 390 395 400

Ala Ile Gly Ala Phe Asn Asp Phe Thr Lys Gly Thr Tyr Leu Asp Val
405 410 415

Thr Val Ala Lys Ser Tyr Pro Cys Val Ala Gln Ile Asn Leu Gln Ile
420 425 430

Leu Gln Gly Ala Ala Tyr Leu Lys Arg Leu Gly Val Ile Arg Phe Asp
435 440 445

Arg Met Leu Leu Gln Ala Val Asp Ile Asp Asp Pro Val Phe Thr Tyr
450 455 460

Val Pro Thr Gln Pro Leu
465 470

<210>	69
<211>	6180
<212>	DNA
<213>	Artificial

<220>
<223> synthetic

<400>	69						
atggccgctc	gcaacgtgag	cgccgcgcat	gagatgcacg	atgaaaagcg	catcgccgctc		60
gtcggcatgg	ccgtccagta	cgccgggatgc	aaaaccaagg	acgagttctg	ggagggtgctc		120
atgaacggca	aggtcgagtc	caagggtgatc	agcgacaaac	gactcgggctc	caactaccgc		180
gccgagcact	acaaagcaga	gcgcagcaag	tatgccgaca	ccttttgcaa	cgaaacgtac		240
ggcacccttg	acgagaacga	gatcgacaac	gagcacgaac	tcctcctcaa	cctcgccaag		300
caggcactcg	cagagacatc	cgtcaaagac	tcgacacgct	gcggcatcgt	cagcgggctgc		360
ctctcgttcc	ccatggacaa	cctccagggg	gaactcctca	acgtgtacca	aaaccatgtc		420
gagaaaaagc	tcggggcccg	cgtcttcaag	gacgcctccc	attggtccga	acgcgagcag		480
tccaacaaac	ccgaggccgg	tgaccgccgc	atcttcatgg	acccggcctc	cttcgtcgcc		540
gaagaactca	acctcggcgc	ccttcaactac	tccgtcgacg	cagcatgcgc	cacggcgctc		600
tacgtgctcc	gcctcgcgca	ggatcatctc	gtctccggcg	ccgccgacgt	catgctctgc		660
ggtgccacct	gcctgccgga	gccctttttc	atccttttcgg	gctttttccac	cttccaggcc		720
atgcccgtcg	gcacgggcca	gaacgtgtcc	atgccgctgc	acaaggacag	ccagggcctc		780
accccgggtg	agggcggtc	catcatggtc	ctcaagcgtc	tcgatgatgc	catccgcgac		840
ggcgaccaca	tctacggcac	ccttctcggc	gccaatgtca	gcaactccgg	cacagggtctg		900
cccctcaagc	cccttctccc	cagcgagaaa	aagtgcctca	tggacaccta	cacgcgcatt		960
aacgtgcacc	cgcacaaagt	tcagtacgtc	gagtgccacg	ccaccggcac	gccccagggt		1020
gatcgtgtgg	aatcgacgc	cgtcaaggcc	tgctttgaag	gcaagggtccc	ccgtttcggg		1080

2997-49-2-pct_ST25

accacaaagg	gcaacttttg	acacaccctc	gtcgcagccg	gctttgccgg	tatgtgcaag	1140
gtcctcctct	ccatgaagca	tggcatcatc	ccgcccaccc	cgggtatcga	tgacgagacc	1200
aagatggacc	ctctcgtcgt	ctccggtgag	gccatcccat	ggccagagac	caacggcgag	1260
cccaagcgcg	ccggtctctc	ggcctttggc	tttgggtggca	ccaacgcca	tgccgtcttt	1320
gaggagcatg	acccctccaa	cgccgcctgc	acggggccacg	actccatttc	tgcgctctcg	1380
gcccgcgtcg	gcggtgaaag	caacatgcgc	atcgccatca	ctggtatgga	cgccaccttt	1440
ggcgctctca	agggactcga	cgccttcgag	cgcgccattt	acaccggcgc	tcacggtgcc	1500
atcccactcc	cagaaaagcg	ctggcgcttt	ctcggcaagg	acaaggactt	tcttgacctc	1560
tgcgggctca	aggccacccc	gcacggctgc	tacattgaag	atgttgaggt	cgacttcag	1620
cgctccgca	cgcccatgac	ccctgaagac	atgctcctcc	ctcagcagct	tctggccgtc	1680
accaccattg	accgcgcat	cctcgactcg	ggaatgaaaa	agggtggcaa	tgctgccgtc	1740
tttgtcggcc	tcggcaccga	cctcgagctc	taccgtcacc	gtgctcgcgt	cgctctcaag	1800
gagcggtcc	gccctgaagc	ctccaagaag	ctcaatgaca	tgatgcagta	cattaacgac	1860
tgcggcacat	ccacatcgta	cacctgtac	attggcaacc	tcgtcgccac	gcgcgtctcg	1920
tcgcagtggg	gcttcacggg	cccctccttt	acgatcaccg	agggaacaa	ctccgtctac	1980
cgctgcgccg	agctcggcaa	gtacctctc	gagaccggcg	aggtcgatgg	cgctcgtgtt	2040
gcgggtgtcg	atctctgcgg	cagtgccgaa	aacctttacg	tcaagtctcg	ccgcttcaag	2100
gtgtccacct	ccgatacccc	gcgcgccagc	tttgacgccg	ccgccgatgg	ctactttgtc	2160
ggcgagggct	gcggtgcctt	tgtgctcaag	cgtgagacta	gctgcaccaa	ggacgaccgt	2220
atctacgctt	gcatggatgc	catcgtccct	ggcaacgtcc	ctagcgcttg	cttgcgcgag	2280
gccctcgacc	aggcgcgcgt	caagccgggc	gatatcgaga	tgctcgagct	cagcgccgac	2340
tccgcccgcc	acctcaagga	cccgtccgtc	ctgcccgaag	agctcactgc	cgaggaggaa	2400
atcgggcgcc	ttcagacgat	ccttcgtgac	gatgacaagc	tcccgcgcaa	cgtcgcaacg	2460
ggcagtgtca	aggccaccgt	cggtgacacc	ggttatgcct	ctggtgctgc	cagcctcatc	2520
aaggctgcgc	tttgcatact	caaccgctac	ctgcccagca	acggcgacga	ctgggatgaa	2580
cccgcccctg	aggcgccttg	ggacagcacc	ctctttgcgt	gccagacctc	gcgcgcttgg	2640
ctcaagaacc	ctggcgagcg	tcgctatgcg	gccgtctcgg	gcgtctccga	gacgcgctcg	2700
tgctattccg	tgctcctctc	cgaagccgag	ggccactacg	agcgcgagaa	ccgcatctcg	2760
ctcgacgagg	aggcgcccaa	gctcattgtg	cttcgcgccg	actcccacga	ggagatcctt	2820
ggtcgcctcg	acaagatccg	cgagcgcttc	ttgcagccca	cgggcgccgc	cccgcgcgag	2880
tccgagctca	aggcgcaggc	ccgccgcata	ttcctcgagc	tcctcggcga	gacccttgcc	2940
caggatgccg	cttcttcagg	ctcgcaaaag	cccctcgctc	tcagcctcgt	ctccacgccc	3000
tccaagctcc	agcgcgaggt	cgagctcgcg	gccaaaggta	tcccgcgctg	cctcaagatg	3060
cgccgcgatt	ggagctcccc	tgctggcagc	cgctacgcgc	ctgagccgct	cgccagcgac	3120

2997-49-2-pct_ST25

cgcgctgcct	tcatgtacgg	cgaaggtcgc	agcccttact	acggcatcac	ccaagacatt	3180
caccgcattt	ggcccgaact	ccacgaggtc	atcaacgaaa	agacgaaccg	tctctgggcc	3240
gaaggcgacc	gctgggtcat	gccgcgcgcc	agcttcaagt	cggagctcga	gagccagcag	3300
caagagtttg	atcgcaacat	gattgaaatg	ttccgtcttg	gaatcctcac	ctcaattgcc	3360
ttcaccaatc	tggcgcgcga	cgttctcaac	atcacgcccc	aggccgcctt	tggcctcagt	3420
cttggcgaga	tttccatgat	ttttgccttt	tccaagaaga	acggtctcat	ctccgaccag	3480
ctcaccaagg	atcttcgcga	gtccgacgtg	tggacaagg	ctctggccgt	tgaatttaat	3540
gcgctgcgcg	aggcctgggg	cattccacag	agtgtcccca	aggacgagtt	ctggcaaggc	3600
tacattgtgc	gcggcaccaa	gcaggatatc	gaggcggcca	tcgccccgga	cagcaagtac	3660
gtgcgctca	ccatcatcaa	tgatgccaac	accgccctca	ttagcggcaa	gcccgcgcgc	3720
tgcaaggctg	cgatcgcgcg	tctcggtagc	aacattcctg	cgcttcccgt	gaccagggc	3780
atgtgcgcc	actgccccga	ggtgggacct	tataccaagg	atatcgccaa	gatccatgcc	3840
aaccttgagt	tccccgttgt	cgacggcctt	gacctctgga	ccacaatcaa	ccagaagcgc	3900
ctcgtgccac	gcgccacggg	cgccaaggac	gaatggggcc	cttcttcctt	tggcgagtac	3960
gccggccagc	tctacgagaa	gcaggctaac	ttcccccaaa	tcgtcgagac	catttacaag	4020
caaaactacg	acgtctttgt	cgaggttggg	cccaacaacc	accgtagcac	cgcagtgcgc	4080
accacgcttg	gtccccagcg	caaccacctt	gctggcgcca	tcgacaagca	gaacgaggat	4140
gcttggacga	ccatcgtcaa	gcttgtggct	tcgctcaagg	cccaccttgt	tcctggcgctc	4200
acgatctcgc	cgctgtacca	ctccaagctt	gtggcggagg	ctgaggcttg	ctacgctgcg	4260
ctctgcaagg	gtgaaaagcc	caagaagaac	aagtttgtgc	gcaagattca	gctcaacggt	4320
cgcttcaaca	gcaaggcgga	ccccatctcc	tcggccgata	ttgccagctt	tccgcctgcg	4380
gaccctgcca	ttgaagccgc	catctcgagc	cgcatcatga	agccggttgc	tccgaagtgc	4440
tacgcgcgtc	tcaacattga	cgagcaggac	gagacccttg	atccgatcct	caacaaggac	4500
aacgcgccgt	cttccagctc	tagctcctct	tccagctctt	ccagctcttc	cagcccgtcg	4560
ccagctccgt	ccgccccagt	gcaaaagaag	gctgctccgg	ccgcggagac	caaggctggt	4620
gcttcggctg	acgcacttcg	cagtgccctg	ctcgatctcg	acagtatgct	tgcgctgagc	4680
tctgccagtg	cctccggcaa	ccttgttgag	actgcgccct	gcgacgcctc	ggtcattgtg	4740
ccgccctgca	acattgcgga	tctcggcagc	cgcgccctca	tgaaaacgta	cggtgtttcg	4800
gcgcctctgt	acacgggcgc	catggccaag	ggcattgcct	ctgcggacct	cgtcattgcc	4860
gccggccgcc	agggcacctt	tgcgtccttt	ggcgccggcg	gacttcccat	gcaggttgtg	4920
cgtgagtcca	tcgaaaagat	tcaggccgcc	ctgcccgaat	gcccgtacgc	tgtcaacctt	4980
atccattctc	cctttgacag	caacctcgaa	aagggcaatg	tcgatctctt	cctcgagaag	5040
ggtgtcacct	ttgtcgaggc	ctcggccttt	atgacgtcca	ccccgcaggt	cgtgcggtag	5100
cgcgcggtg	gcctcacgcg	caacgccgac	ggctcgggtc	acatccgcaa	ccgtatcatt	5160

2997-49-2-pct_ST25

ggcaaggtct cgcgaccga gctcgccgag atgttcatgc gtcctgcgcc cgagcacctt 5220
cttcagaagc tcattgcttc cggcgagatc aaccaggagc aggccgagct cgcccgccgt 5280
gttcccgtcg ctgacgacat cgcggtcgaa gctgactcgg gtggccacac cgacaaccgc 5340
cccatccacg tcattctgcc cctcatcatc aaccttcgcg accgccttca ccgcgagtgc 5400
ggctacccgg ccaaccttcg cgtccgtgtg ggcgccggcg gtggcattgg gtgccccag 5460
gcggcgctgg ccacettcaa catgggtgcc tcctttattg tcaccggcac cgtgaaccag 5520
gtcgccaagc agtcgggcac gtgcgacaat gtgcgcaagc agctcgcgaa ggccacttac 5580
tcggacgtat gcatggcccc ggctgccgac atgttcgagg aaggcgtcaa gcttcaggtc 5640
ctcaagaagg gaaccatggt tccctcgcgc gccacaagc tctacgagct cttttgcaag 5700
tacgactcgt tcgagtccat gcccccgca gagcttgccg gcgtcgagaa gcgcatcttc 5760
agccgcgcgc tcgaagaggt ctgggacgag accaaaaact ttacattaa ccgtcttcac 5820
aaccgggaga agatccagcg cgccgagcgc gacccaagc tcaagatgtc gctgtgcttt 5880
cgctggtacc tgagcctggc gagccgctgg gccaaactg gagcttccga tcgcgtcatg 5940
gactaccagg tctggtgcgg tcctgccatt ggttccttca acgatttcat caagggaact 6000
taccttgatc cggccgtcgc aaacgagtac ccgtgcgtcg ttcagattaa caagcagatc 6060
cttcgtggag cgtgcttctt gcgccgtctc gaaattctgc gcaacgcacg cttttccgat 6120
ggcgctgccg ctcttggtggc cagcatcgat gacacatacg tcccggccga gaagctgtaa 6180

<210> 70
<211> 8394
<212> DNA
<213> Artificial

<220>
<223> synthetic

<220>
<221> misc_feature
<222> (227)..(227)

<220>
<221> misc_feature
<222> (227)..(227)
<223> n is a, c, g, or t

<400> 70
ccgcgaatca agaaggtagg cgcgctgcga ggcgcgccgg cggagcggag cgagggagag 60
ggagagggag agagagggag ggagacgtcg ccgcggcggg gcctggcctg gcctgggttg 120
gcttggtcag cgcgcccttg tccgagcgtg cagctggagt tgggtggatt catttggtt 180
ttcttttgtt tttgtttttc tctctttccc ggaaagtgtt ggccggnccg tggtctttgt 240
tttgatttct tcaaaagttt tgggtggttg ttctctctct tggctctctg tcaggcggtc 300
cgggccacgc cccggcctct cctctcctct cctctcctct cctctccgtg cgtatacgta 360
cgtacgtttg tatacgtaca tacatccgcg ccgccgtgcc ggcgaggggt tgctcagcct 420

2997-49-2-pct_ST25

ggagcaatgc	gatgcatgac	gatgcatgac	gacgcatgac	gacgcatgac	actggttcgc	480
gctgtggctg	tggcttgctt	gcttacttgc	tttcgagctc	tcccgccttc	ttctttcctt	540
ctcacgccac	caccaacgaa	agaagatcgg	ccccggcacg	ccgctgagaa	gggctggcgg	600
cgatgacggc	acgcgcgccc	gctgccacgt	tggcgctcgc	tgctgctgct	gctgctgctg	660
ctgctgctgc	tgctgctgct	gctgctgctt	ctgcgcgcag	gctttgccac	gaggccggcg	720
tgctggccgc	tgccgcttcc	agtccgcgtg	gagagatcga	atgagagata	aactggatgg	780
attcatcgag	ggatgaatga	acgatgggtt	gatgcctttt	tcctttttca	ggtccacagc	840
gggaagcagg	agcgcgtaaa	tctgccgcca	tccgcatacg	tctgcatcgc	atcgcatcgc	900
atgcacgcat	cgctcgccgg	gagccacaga	cgggcgacag	ggcgccagc	cagccaggca	960
gccagccagg	caggcaccag	agggccagag	agcgcgcttc	acgcacgcgc	cgcagtgcgc	1020
gcatcgctcg	cagtgcagac	cttgattccc	cgcgcggtac	tccgcgagcc	cgaaacgaag	1080
agcgccgtac	gggcccattc	tagcgctgcc	tcgcaccgca	tcgcatcgca	tcgcgttccc	1140
tagagagtag	tactcgacga	aggcaccatt	tccgcgctcc	tcttcggcgc	gatcgaggcc	1200
cccggcgccg	cgacgatcgc	ggcgggccgc	gcgctggcgg	cggccctggc	gctcgcgctg	1260
gcggccgccc	cgggctgctg	gccctggcgc	gcgcgggcgc	cgcaggagga	gcggcagcgg	1320
ctgctcgccg	ccagagaagg	agcgcgccgg	gcccggggag	ggacggggag	gagaaggaga	1380
aggcgcgcaa	ggcgggcccc	aaagagaaga	ccctggactt	gaacgcgaag	aagaagaaga	1440
aggagaagaa	gttgaagaag	aagaagaaga	aggagaggaa	gttgaagaag	acgaggagca	1500
ggcgcggttc	aaggcgctt	ctcttccgga	ggcgcggttc	agctgcggcg	gcggggcggg	1560
ctgccccggc	ggcgggggcg	cgggtgcggg	cagaggggac	gcgcgcgcgg	aggcggaagg	1620
ggccgagcgg	gagccccctg	tgctgcgggg	cggccgggac	gcaggtgtgg	cgcgcgcgac	1680
gacggaggcg	acgacgccag	cggccgcgac	gacaaggccg	gcggcgctcg	cgggcggaag	1740
gccccgcgcg	gagcaggggc	gggagcagga	caaggcgagc	gagcaggagc	agggccggga	1800
gcgggagcgg	gagcggggcg	cggagccccg	ggcagaaccc	aatcgagatc	cagagcgagc	1860
agaggccggc	cgcgagcccc	agcccgcgcc	gcagatcact	agtaccgctg	cggaatcaca	1920
gcagcagcag	cagcagcagc	agcagcagca	gcagcagcag	cagccacgag	aggagataaa	1980
agaaaaagcg	gcagagacga	tgggtccccg	tggtgcttcc	ggtaagggtt	cggcctggga	2040
gatgtcgaag	tcggagctct	gcgatgaccg	cacggtcgtg	tttgattacg	aggagctcct	2100
tgagttcgcc	gagggtgaca	tctccaaggt	gttcgggtccg	gagtttaaag	tcgttgacgg	2160
ctttcgctgc	cgcgctccgc	tccccgcgcg	tgagtacctc	cttgctaccc	gcgtcacgct	2220
tatggacgcc	gaggtgggta	actttcgctg	ggcgctcgc	atggttactg	agtacgacgt	2280
tccggtcaac	ggcgagctgt	ctgagggcgg	cgacgtgccc	tgggcccgtt	ttgtcgaggc	2340
cggccagtgc	gacctcctcc	tcattctgta	catgggcata	gacttccagt	gcaagggaga	2400
gcgcgtctac	cgctcctca	acaccacct	tacgttcttc	ggcgctcgca	aggagggcga	2460

2997-49-2-pct_ST25

gactctcgtg	tacgacatcc	gcgctcactgg	tttcgccaag	cgccctgacg	gcgacatctc	2520
gatgttcttc	tttgagtacg	actgctactg	caacggtaag	ctcctcatcg	agatgcgcga	2580
tggttctgcc	ggctttttca	ctgatgagga	gctcgctgcc	ggcaagggcg	tcgtcgtcac	2640
gcggtgcccag	caaaacatgc	gcgacaagat	cgtccgtcag	tccatcgagc	cgtttgcgct	2700
cgccgcctgc	actcacaaga	cgaccctcaa	cgagtccgac	atgcagtccc	tcgtcgaagc	2760
caactggggcg	aacgtgttcg	gcaccagcaa	caagatggcc	gagctcaact	acaagatttg	2820
cgcccgcaag	atgctcatga	tcgaccgctg	gacccacatc	gaccatcatg	gcggcgctta	2880
cggcctcggc	ctccttgtcg	gcgaaaagat	cctcgatcgt	aaccattggg	acttcccctg	2940
ccactttgtg	aatgaccaag	ttatggccgg	ctcccttgtc	tctgacggct	gttcgcagct	3000
gcttaagctt	tacatgatct	ggctcggcct	ccacctcaag	atggaggagt	tcgattttct	3060
ccccgtcagc	ggccacaaga	acaaggtccg	ctgccgcgga	cagatttctgc	cccacaaggg	3120
taagctcgtc	tacgtgatgg	agattaagaa	gatgggctac	gaccaggctt	cgggcagccc	3180
ctacgccatt	gcggacgttg	atatcattga	tgtcaacgag	gagctcggcc	agtcgtttga	3240
catcaacgat	ctcgcgtcgt	acggtaaggg	cgacctctcg	aagaagattg	ttgtcgattt	3300
caaaggtatc	gctctccagc	tgaaaggccg	cgcttctctc	cgcatgtcct	cctcgtcctc	3360
cctcaacgag	ggctggcagt	gcggtgcccc	gccgtcgcag	cgcatggagc	acgagcaacc	3420
ccctgccccat	tgcttcgcct	ccgatccgga	ggccccctagc	acggtgacgt	ggcaccat	3480
gagcaagctc	cccggcaacc	ccacccccct	cttttctctc	tcgtcgtatc	cgccccgtgc	3540
tatctgcttc	atcccttttc	cgggcaaccc	gctcgacaac	aactgcaagg	cgggcgagat	3600
gccccctaac	tggtacaaca	tgagcgaatt	catgtgcggt	aaggctcagca	actgcctcgg	3660
cccggagttc	gcccgccttg	acaagagcaa	cacctccgc	tccccgcct	tcgaccttgc	3720
gctcgtcacg	cggtcgtcg	aggtcaccaa	catggagcac	ggcaagtcc	tcaacgtcga	3780
ctgtaaccct	tcgaagggca	cgatggtggg	agagttcgac	tgcccgagg	acgcctgggt	3840
ctttgacggc	tcctgcaatg	acggtcatat	gccgtactcc	atcatcatgg	agatcggcct	3900
tcagacgtct	ggtgtcctca	cgtcggtgct	caaggctcct	ctcacgatgg	acaaggacga	3960
catcctcttt	cgcaaccttg	atgcctcggc	tgagatggtg	cgccctgacg	tcgatgtccg	4020
cggcaagacc	atccgcaacg	tgaccaagtg	taccggctac	gcatgtcttg	gtaagatggg	4080
tatccatcgc	tttacctttg	agctctccgt	ggacggcgct	gtcttttaca	agggcagcac	4140
cagcttcggc	tggtttacgc	cggaagtgtt	tgcccagcag	gccggtctgg	acaacggcaa	4200
gaagaccgag	ccctggtgca	agaccaacaa	cacctccgtc	cgccgcgtcg	agatcgccag	4260
cgctaagggg	aaggagcagc	tcacggagaa	gctccctgat	gctaccaacg	cccaggttct	4320
ccgccgctcc	gagcagtgcg	agtacctcga	ctacctcaac	atcgcccccg	actccggcct	4380
tcacggcaag	ggttacgcgc	acggccacaa	ggacgtcaac	ccccaggact	ggtttttctc	4440
gtgccacttc	tggttcgacc	cgggtgatgcc	cggctcgctt	ggcattgagt	ccatgttcca	4500

2997-49-2-pct_ST25

gctcatcgaa	gcctttgctg	tcgaccagaa	tatccctggc	gagtacaatg	tttcgaaccc	4560
gacctttgcc	catgcccccg	gtaagaccgc	ttggaagtat	cgcgccagc	tactcccaa	4620
gaaccgcgct	atggactgcg	aggtccacat	cgtcagcatc	acggcgagcc	cggagaacgg	4680
cggctacgtc	gacatcgtcg	ccgacggcgc	cctttgggtc	gatggcctcc	gcgtttacga	4740
ggccaaggag	ctccgtgtcc	gcgtcgtcag	cgccaagccg	caagctatcc	cggatgtcca	4800
gcagcagcct	ccctcggtta	aggccgaccc	tggcaagacc	ggtgtcgccc	tcagccccac	4860
ccagctccgc	gatgtcctcc	tggaggtcga	caaccctctg	tacctcggtg	tcgagaactc	4920
caaccttgtc	cagttcgaaa	gcaagccggc	gacgtcctcc	cgcacgtgtg	ccattaagcc	4980
gtgtttctatc	tccgacctcg	gcgacaagtc	tttcatggag	acttacaacg	tgtctgcgcc	5040
tctttacacc	ggcgcgatgg	ccaaggggat	tgccagcgct	gacctcgtca	tcgccgctgg	5100
caagcgtaag	atcctcgggt	cgttcgggtgc	cggtgccctc	ccgatctcca	tcgttcgcga	5160
ggcccttgag	aagatccagc	agcacctccc	ccacggccct	tacgccgtca	accttatcca	5220
ctccccgttc	gactcgaacc	tggagaaggg	caatgtcgac	ctttttcttg	aaatgggtgt	5280
caccgtcgtc	gagtgtcggg	ctttcatgga	gctcacggct	caggtcgttc	gctaccgcgc	5340
ttccggcctc	tccaagagcg	cggacggcag	catccgcac	gcgcaccgca	tcacggcaa	5400
ggtgagccgc	actgagcttg	ccgagatggt	catccgtcct	gcccctcagc	accttctcca	5460
gaagctggtc	gccagcggcg	agctcaccgc	cgaacaggcc	gagcttgcca	cgcaagtccc	5520
ggtcgccgat	gacatcgcg	tcgaggccga	ttcgggcggg	cacaccgaca	accgcccgat	5580
ccacgtgatt	ctccccctta	ttatcaacct	ccgcaaccgc	cttcacaagg	agctcgacta	5640
cccctcgcac	ctgcgcgtgc	gcgtgggagc	cggcgggtgg	atcggtgcc	ctcaggcggc	5700
cctggcggcc	tttcagatgg	gcgctgcttt	cctgattacc	ggcaccgtca	accagctcgc	5760
ccgtgagtcg	ggcacctgcg	acaacgtccg	ccttcagctc	tccaaggcca	cctacagcga	5820
cgtgtgcatg	gcccctgccg	cggacatggt	tgaccagggc	gtggagcttc	aggtgtcaa	5880
gaagggcacg	ctgttcccca	gccgcgccaa	gaagctctac	gagctcttct	gcaagtacga	5940
ctccttcgag	gccatgccgg	ccgaggagct	tcagcgtgtc	gagaagcgca	tctttcagaa	6000
gtcgtgggcc	gaggtttggc	aggagacttc	ggattttctac	attcaccgca	ttaagaaccc	6060
tgagaagatc	aatcgcgctg	ccagcgacgg	taaactcaag	atgtcgcttt	gcttccgctg	6120
gtatcttggc	ctctcgtcgt	tctgggccaa	ctccggtgcc	caggaccgcg	tcattggacta	6180
ccagatttgg	tgcggtcccc	cgatcgagc	cttcaacgat	tttaccaagg	gcacctacct	6240
cgacgtcacg	gttgccaagt	cttaccctg	cgttgcccag	atcaacctcc	aaatccttca	6300
gggtgcggct	tacctcaagc	gcctcgggtg	gatccgcttc	gaccgcatgc	tcctccaggc	6360
ggtcgacatc	gatgaccggg	ttttcacgta	cgtccccacc	cagccccctc	aagaaagtga	6420
accttgtcct	aaccgacag	cgaatggcgg	gagggggcgg	gctaaaagat	cgtattacat	6480
agtatttttc	ccctactctt	tgtgtttgtc	tttttttttt	tttgaacgca	ttcaagccac	6540

2997-49-2-pct_ST25

ttgtctbggg	ttacttgttt	gttygcttgc	ttgcttgctt	gcttgccctgc	ttcttgggtca	6600
gacggcccaa	aaaagggaaa	aaattcattc	atggcacaga	taagaaaaag	aaaargtttg	6660
tcgaccaccg	tcatcagaaa	gcaagagaag	agaaacactc	gcgctcacat	tctcgctcgc	6720
gtaagaatct	tagccacgca	tacgaagtaa	tttgtccatc	tggcgaatct	ttacatgagc	6780
gttttcaagc	tggagcgtga	gatcatacct	ttcttgatcg	taatgttcca	accttgcata	6840
ggcctcgttg	cgatccgcta	gcaatgcgtc	gtactcccgt	tgcarctgcg	ccatcgccctc	6900
attgtgacgt	gagttcagat	tcttctcgag	accttcgagc	gctgctaatt	tcgcctgacg	6960
ctccttcttt	tgtgcttcca	tgacacgccg	cttcaccgtg	cgttccactt	cttcctcaga	7020
catgcccttg	gctgcctcga	cctgctcggg	aagcttcgtc	gtaatctcct	cgatctcgga	7080
attcttcttg	ccctccatcc	actcggcacc	atacttggca	gcctgttcaa	cacgctcatt	7140
gaaaaacttt	tcattctctt	ccagctccgc	aaccgcgcgt	cgaagctcat	tcacttccgc	7200
caccacggct	tcggcatcga	gcgccgaatc	agtcgccgaa	ctttccgaaa	gatacaccac	7260
ggccccctccg	ctgctgctgc	gcagcgtcat	catcagtcgc	gtgttatckt	cgcgagatt	7320
ctccacctgc	tccgtaagca	gcttcacggg	ggcctcttga	ttctgagggc	tcacgtcgtg	7380
gattagcgct	tgagctctt	gcagctccgt	cagcttgcaa	gagctcgtaa	tcattggcttt	7440
gcacttgccc	agacgtcgca	gagcgttcga	gagccgcttc	gcgttatctg	ccatggacgc	7500
ttctgcgctc	gcggcctccc	tgacgacagt	ctcttgagct	ttcactagat	catgtccaat	7560
cagcttgagg	tgagctctc	caatcacggt	ctgcatcttg	tttgtgtgtc	cgggccgcgc	7620
ctcgtcttgc	gatttgcgaa	tttcctctc	gagctcgcgt	tcgagctcca	rggcgccttt	7680
aagtagctcg	aagtcagccg	ccgttagccc	cagctccgtc	gccgcgttca	gacagtcggt	7740
tagcttgatt	cgattccgct	tttccatggc	aagtttaaga	tcctggccca	gctgcacctc	7800
ctgcgccttg	cgcatcatgc	gcgggtccgc	ctggcgcaaa	agcttcgagt	cgtatcctgc	7860
ctgccatgcc	agcgcaatgg	cacgcacgag	cgacttgagt	tgccmactat	tcatcgccga	7920
gatgagcagc	atcttgatct	gcatgaacac	ctcgtcagag	tcgtcatcct	ctgcctcctc	7980
cagctctgcg	ggcgagcgac	gctctccttg	cagatgaagc	gagggccgca	ggcctccgaa	8040
gagcacctct	tgcgcgagat	cctcctccgt	cgtcgccctc	cgcaggatyg	cggycggtgc	8100
cgccatcttg	ccgccacagc	agcttttgst	cgctctgcac	cttcaatttc	tggtgccgct	8160
ggtgccgctg	gtgccgcttg	tgctggtgct	ggtgctggtg	ctggtgctgg	tgcttctgtc	8220
tggtgctgcc	acagacaccg	ccgctcctgc	tgctgctctt	ccggccccct	cgccgccgcc	8280
gcgagcccc	gccgcgcgcc	gtgcctgggc	tctccgcgct	ctccgcgggc	tcctcggcct	8340
cggcctcgcc	gtccgcgacg	acgtctgcgc	ggccgatggt	gcggatctgc	tcta	8394

<210> 71
 <211> 12495
 <212> DNA
 <213> Artificial

<220>

<223> synthetic

<400> 71

cgactgcgag	ggctcttgcg	tcatccgcct	gatgcgggccg	ccggccggaa	gaggccgccc	60
cgcagcctcc	ccggtgctggg	gccgcgccgg	gatgcctcgc	ctgcgctccc	agcgatgcga	120
ggcggcgacg	tctgtgctgc	cgtcagggtcc	tgtgcgaggt	cccactgtta	atattaagta	180
cgtaccgcac	aggacccgga	gtagcgcggc	gcggggacga	cctccgacgc	ggccggaaga	240
cggcgcccac	agcacgcgct	cgggttcgcg	ggcggcgggc	gcgcgaagtg	cgtaagcaga	300
cggcgcgcg	tccggctgcg	ggggaagaag	gtgtggaagg	tgcgggggga	accctgggcc	360
gcctacgtgt	gcctgcgacg	gaggcgcggc	ggcggccggc	acctaggaac	tgtctaagag	420
ggcttacaac	ggacagccc	tcacaggcgc	agaggcgggc	gcggcgggtc	tttccttctc	480
tcccggcaga	aagagagga	gggagagaga	gagaaagcct	gaatgtggct	gcgatggaga	540
cttgggcagc	gataatgact	tgggtgggctg	aagattactc	tcagcattgc	tgcgcgctta	600
gcattcttgc	ggcattggcc	aggtcggcgt	cgggtttcgc	ttgcggcgac	gaccgaggg	660
cgttggatcg	cgcggcagat	tagacaggca	gctgggacgc	acgcacgcac	gcacgaacga	720
acaacaaac	gagagaacgt	gcgtacgggc	ctgctggccg	cggatgcaga	aaagtgaatg	780
gaattttcca	ctacagccag	cgagccctgt	cagccagcta	gctgcagctt	gagcggagcg	840
gcggctgttg	ctgctgtctt	tgaacttgaa	ttcgaatgga	tgtatgtact	tgcttgccctc	900
ttgatgctgc	gttgacttgt	ggatgatgtt	caaagtggca	ggcacaccac	ctaaaatcaa	960
aaaatgtaaa	ggcgcggcgc	agaaccgtgc	atctgccgag	gagcgcgtgc	accgctgccg	1020
tgcgtgcggt	gcgtgcgtgc	tcgcctgcat	ccgcgtcgcc	ggcaagggtct	ctgtgctgta	1080
tctatcgctc	gcattcgaat	cgctcgcgcc	ttctgctccg	acgtgcccta	aaacatagag	1140
tccatcatta	ggctagtgat	actctatgtg	acttgcttcc	ttcctggaga	ggaagaatga	1200
ataccgtatg	gtatcaggtg	tgaagaaaac	caacctcgcg	cctccggacc	caccgccgcg	1260
cggccagcca	gatccgcgcg	gccagctcgt	ccatgccagc	ctcgggaggt	atccatcccc	1320
tccgcgccgg	cagctgtcgg	tctctcgcca	tcgcctgtgc	cgctcgaaga	agtttcagca	1380
acctctccgt	cctgcgccat	ggcaccatct	tatcttctcc	gcgtcccact	cttctctccc	1440
aaagcctgca	cctcaaaggc	gaggccgggc	caggccgcag	ccgcgccacg	agaagcccca	1500
tcacgccgcc	tcgcacgcgg	ccgcgcgcgt	ctgcgcgaga	cggcgctgtt	atcttctttt	1560
cttttctttt	cttttcttct	ctcctccccg	ctctcctcgc	ttcctgcgcg	ccgctgcggg	1620
ggcgaaggaa	gacagggggg	ctcgggagga	agaggaggcg	aggggaaggaa	ggagggcggc	1680
gacggcatcg	ccagacgacg	acggcgggcg	cgggggacgc	ggggcgcgcg	tcccccgctg	1740
cgtggcagca	tgatgcatgc	gatgcgcgcg	atgcgtgcgg	cgcgaggagg	cgaggcccgga	1800
tgggcggagg	cgagcggggg	ggatacgggc	ggcggcgggc	gggagcggga	ggcaggcaga	1860
ccccgaacct	cgagggtaaa	actacacaaa	cagacagaca	gcctgcggct	gcctggcaac	1920

2997-49-2-pct_ST25

aagactcacg	cacgcacgca	cgcaccgatc	ggtcgagcga	gcgagcgctt	gatcgaacgg	1980
acgtgagaac	cagcaaggaa	gcagcagcag	cagcagcagc	agcaacagct	cgagagagag	2040
aaaatgaagg	atatggagga	tcgccgcgtc	gccattgtcg	gtatgtcggc	ccatctcccc	2100
tgccggcaccg	acgtgaagga	gtcgtggcag	gccattcgtg	atggtatcga	ttgcctgtct	2160
gacctccccg	ccgaccgcct	cgacgtcacg	gcgtactaca	acccaacaa	ggccactaag	2220
gataagattt	actgcaagcg	cggtggcttt	attcccaact	acgattttga	tcctcgcgag	2280
tttggcctta	acatgttcca	gatggaggac	tccgacgcca	accagactct	cactcttctg	2340
aagggtcaagc	aggccctgga	ggacgcttcc	attgagccct	ttaccaagga	gaagaagaac	2400
atcggtgcg	tcctcggaat	cggcggtggc	cagaaggcca	gccacgagtt	ttactctcgc	2460
ctcaactacg	ttgtcgtcga	gaaggctctc	cgcaagatgg	gcctccctga	tgccgacgtt	2520
gaggaggccg	tggagaagta	caaggccaat	tttctgagt	ggcgctcga	cagcttccct	2580
ggcttcctcg	gcaacgtcac	tgctggccgc	tgctccaaca	cctttaacat	ggagggtatg	2640
aactgctgg	tggacgccgc	ctgcgcctcc	tccctcatcg	ccattaaggt	ggcggtgag	2700
gagctcctct	tcggcgactg	cgacaccatg	attgccggtg	ccacctgcac	ggataactcg	2760
ctcggcatgt	acatggcttt	ttccaagacg	ccggtgttca	gcaccgaccc	ctccgtccgc	2820
gcctacgatg	aaaagactaa	gggcatgctt	atcggcgagg	gctccgccat	gttcgtgctc	2880
aagcgctacg	ccgacgcggt	ccgtgatggc	gacactatcc	acgccgttct	ccgtagctgc	2940
tcgtccagca	gcgacggcaa	ggccgctgga	atttacacgc	ctacgatctc	gggccaggag	3000
gaggccctcc	gccgtgccta	cgcgcgcgt	ggcgtctgcc	cctcgaccat	cggcctcgtt	3060
gagggtcacg	gcaccggcac	gccggtcggc	gaccgcatcg	agctcactgc	cctccgcaat	3120
cttttcgaca	aggcttttgg	ctccaagaag	gaacaaatcg	ctgtcggttc	catcaagtct	3180
cagatcggcc	acctcaagag	cgtggccggc	tttgttggcc	tgggtcaaggc	ggtcctggcc	3240
ctcaagcaca	agacgtctcc	tggctcgatt	aacgtggacc	agcctcccct	cctttacgac	3300
ggcacgcaga	tccaggactc	gtccctgtac	attaacaaga	ctaaccgccc	ctggtttacc	3360
caaaacaagc	tcctcgcgcg	tgccgggtgtc	agctccttcg	gttttggtgg	cgccaactac	3420
cacgccgtcc	tcgaagagtt	tgagcccgag	cacgagaagc	cttaccgcct	caacacggtc	3480
ggccacccccg	tcctcctcta	cgcgcgcgcg	gtcagggccc	tcaaggctct	ttgcaacgac	3540
cagctcgcgcg	aactcaccat	cgcgcttgag	gaggccaaga	cccacaagaa	cgtggacaag	3600
gtttgcgggt	acaagtttat	cgacgagttc	cagctccagg	gtagctgccc	tcctgagaac	3660
ccccgcgtcg	gctttctcgc	cactctccccg	acgtccaaca	tcctcgtcgc	tctcaaggcg	3720
atcctcgtc	agctcgtatg	caagcctgac	gccagaagt	gggacctccc	gcacaagaag	3780
gctttcgggtg	ctaccttcgc	ctcgtcgtcg	gtcaagggct	cggttgccgc	gctgttcgcc	3840
ggccaggggca	ctcagtacct	caacatgttt	tccgatgtcg	cgatgaactg	gccccctttc	3900
cgcgattcga	tcgtggccat	ggaggaggcc	cagaccgagg	tgttcgaggg	ccagggtgaa	3960

2997-49-2-pct_ST25

cccatttcga	aggctcctctt	tccgcgcgag	cgttacgcct	cggagtcgga	gcagggcaac	4020
gagctgctct	gcctcaccga	gtactcgcag	cccactacaa	ttgccgccgc	tgctggcgcc	4080
tttgacatct	tcaaggcggc	tggttttaag	cccgatatgg	tcggaggcca	ctcccttggc	4140
gagtttgctg	ccctgtacgc	cgctggctcg	atctctcgcg	atgacctcta	caagctcgtc	4200
tgcaagcgtg	ccaaggcgat	ggcgaacgcg	agcgatggag	ccatggccgc	tgtgatcggg	4260
cccgatgctc	gcctcgtcac	tcctcagaac	tccgacgtct	acgtcgccaa	tttcaatagc	4320
gcgacgcagg	tcgtcatcag	cggcacggtg	cagggcgctca	aagaggagag	caagctcctt	4380
attagcaagg	gttttcgcgt	cctgcctctg	aagtgccagg	gcgccctcca	ctccccgctc	4440
atgggacctt	ccgaggactc	cttcaagtcg	ctcgttgaga	cttgacttat	ctccccgcct	4500
aagaacgtca	agttcttttg	caacgtgagc	ggcaaggagt	cgcctaatacc	gaagcagact	4560
ctcaagtctc	acatgaccag	ctccgtccag	tttgaggagc	agatccgcaa	catgtacgat	4620
gccggtgccc	gtgtctttct	ggagtttggc	cctcgccagg	tgctcgccaa	gctcatcgcc	4680
gagatgttcc	cctcgtgcac	cgccatctcg	gtcaaccggg	cctcctcggg	cgactcggac	4740
gtccagctcc	gcctcgcggc	cgtcaagttt	gcggtgtccg	gcgctgccct	ctcgacgttt	4800
gaccctggg	agtaccgcaa	gccccaggac	ctccttatcc	gcaagccccg	caagaccgcg	4860
ctcgtcctct	ctgctgccac	gtacgtttcg	cctaagacct	tcgccgagcg	caagaaggcc	4920
atggaggaca	tcaagctcgt	gtcgatcacc	cctcgcgact	cgatggtttc	gatttggaag	4980
atcgctcaag	aggctccgac	tgctaagcag	cccctcgaaa	ccgagattcg	ccgcctcaac	5040
aaggagctcg	aacacctcaa	gcgcgagctc	gcggctgcca	aagcttcggg	caagtctgcc	5100
tccaagtcct	ctaaggagcg	cagcgtcctc	tccaagcacc	gcgccctcct	ccagaacatc	5160
ctccaagact	acgacgacct	ccgcgtcgtc	cccttcgccg	tccgctcggt	cgccgtggac	5220
aacaccgcgc	cgtacgccga	ccaggtcagc	accctgcct	cggagcgtag	cgcgctgccc	5280
cttttcgaga	agcgttcctc	cgtttcgtcg	gctcgcctgg	ccgaggcgga	ggccgcccgc	5340
ctctctgtgc	tcgccgacaa	gacgggctac	gacagctcga	tgatcgagat	ggacatggac	5400
ctggagagcg	agcttgccgt	ggactccatc	aagcgcgtcg	agatcatgtc	cgagggtccag	5460
actcttctct	cggctcgagg	cagcgatggt	gacgctctca	gccgcaccaa	aacggtcggc	5520
gacgtgatcg	aggctatgaa	gctcgaactt	ggcggacccc	aaggccagac	cctcaccgcc	5580
gagtcgatcc	gtcagcctcc	cgtgtcggag	cccgccgtcc	cgacgtcctc	ctcttctctc	5640
atcgctaacg	tctcttctgc	tcgcctcgcc	gaggctgaag	ctgctgttct	ttctgtcctc	5700
gccgacaaga	ccggctacga	ctcgtccatg	attgagatgg	acatggacct	cgaaagcgag	5760
ctcggcgctg	acagcattaa	gcgcgtcgag	atcatgtccg	aggtgcagac	ccttctcagc	5820
gtggaggttt	cggacgtcga	tgccctctcc	cgcactaaga	ccgtcggcga	tgtcatcgag	5880
gcatgaagc	tcgaactcgg	cggctctcag	ggtcaaacgc	tgaccgccga	gtcgattcgc	5940
cagccccctg	tttccgagcc	ggccgtgccg	acgtcgtcgt	cgagctcgat	cgccaacggt	6000

2997-49-2-pct_ST25

tccagcgc	cccgcctc	gagccga	agccgcc	gccgtcctct	ccgtcctcgc	ggacaagacc	6060
ggttacgact	cctcgatgat	tgaaatggac	atggatcttg	agtctgagct	tggcgtcgat		6120
tccatcaagc	gcgttgagat	catgtcggaa	gtgcaaactc	tcctttctgt	tgaagtctct		6180
gatgtcgatg	ctctcagccg	cacgaaaacc	gtcggtgacg	tcatcgaggc	catgaagctc		6240
gaactcgggtg	gccctcaggg	ccagaccctc	accgccgagt	ccatccgtca	accgcccgtg		6300
tccgagcccc	ccgtccccgac	ctcctcgtcg	agctcgattg	cgaacgttct	ctcggcgcgt		6360
ctcgcggagg	ccgaggccgc	ggtcctctcg	gtcctcgcgc	acaagacggg	ctacgactcc		6420
agcatgatcg	agatggacat	ggacctcgaa	tctgagctcg	gcgtcgacag	cattaagcgc		6480
gtcgagatta	tgagcgaggt	ccagaccctc	ctctccgtgg	aggtttcgga	cgtggacgcg		6540
ctctcgcgta	ccaagaccgt	tggcgacgtt	attgaggcca	tgaaactcga	actcgggtggc		6600
cctcagggac	agaccctcac	tgccgagtcg	attcgccagc	ctccggtttc	tgagcctgct		6660
gttcctacgt	cctcttcttc	ttctattgct	aatgtcagct	cggcgcgcct	cgcgagggcc		6720
gaggctgccg	tgctctcggg	tctcgcggac	aagaccggct	atgactcgtc	catgattgag		6780
atggatatgg	atcttgagtc	cgagctgggc	gtcgatagca	tcaagcgtgt	ggaaatcatg		6840
tccgaagtcc	agaccctcct	ctcggtcgag	gtcagcgatg	tcgacgccct	ctcgcgcacc		6900
aagaccgtcg	gcgatgtcat	cgaggccatg	aaacttgagc	tcggcggacc	tcagggacag		6960
accctcacgt	ccgagccgat	ccaccagccg	cccgtgagcg	agccggccgt	cccgaacttcg		7020
agtcctcgt	ccatcgccaa	tgtctctagc	gctcgcctcg	ccgaggccga	ggccgccgtg		7080
ctgtccgtcc	tcgccgataa	gaccggatat	gactccagca	tgatcgagat	ggacatggac		7140
cttgagtccg	agctgggtgt	tgattctatt	aagcgtgttg	agattatgtc	ggagggtgcag		7200
acccttctct	cggtcgaagt	ctctgatgtc	gatgccctct	ctcgtaccaa	gactgtcggc		7260
gacgtcatcg	aggctatgaa	gatggagctc	ggcggacccc	agggccagac	tcttaccgcc		7320
gaatctatcc	gccagccgcc	tgtcagcgag	cctgccgtcc	ctacctctc	gtcctcgtcg		7380
attgccaaacg	tttcttctgc	ccgtcttgcc	gaggccgagg	cggccgtcct	ctcggtcctc		7440
gcggacaaga	ccggttatga	ttcgtcgatg	attgagatgg	acatggacct	tgagtcggag		7500
ctcggagtcg	acagcatcaa	gcgcgtcgag	atcatgtcgg	aggtccaggc	tctcctctcc		7560
gtcgagggtta	gcgatgtcga	cgccctctcg	cgcaccaaga	ccgttggcga	tgttattgag		7620
gcatgaaaa	tggagctcgg	tggctccgag	ggccagaccc	tactgccga	gtcgattcgc		7680
gagccgccgg	tttccgagcc	ggccgtgccc	acgagcagct	cgtcgagcat	cgtaacgtc		7740
agctcggccc	gccttgccga	ggccgaggct	gctgtcctct	ccgtgctcgc	cgataagact		7800
ggttatgact	cgtccatgat	tgagatggac	atggacctgg	agtccgagct	cggcgtggac		7860
tcgatcaagc	gcgttgagat	catgtctgag	gtgcagaccc	tgctttccgt	cgagggtgagc		7920
gacgtcgatg	ccctgtcgcg	taccaagact	gtgggtgacg	tcatcgaggc	gatgaagctg		7980
gagctcggag	agtcgagctc	gattgagact	cttaattgca	ccgaggtcga	gcacacgtcc		8040

2997-49-2-pct_ST25

tacaagagcg	tcaaggccag	cggatgcbag	aacgtggaca	cccgtttcgc	caaagtggtc	8100
cagatcagcc	tcccgtccaa	gcttaagagc	accgtcagcc	atgaccgccc	ggtcattggt	8160
gtggatgacg	gcaccccgt	taccacggag	ctctgcaaga	ttctcggtgg	caacattgtc	8220
gttctcagct	accagggcaa	gcctgccggc	cctcgtggcg	tcgaggttcc	cgacctctcg	8280
gaggaggccc	tcattccaggc	gctcgccctc	attcgctcga	cctacggcgt	ccccattggt	8340
ttcatctgcc	agcaggtttc	caacgtcagc	accaaggccc	agctctgctg	ggcgctgctg	8400
gccgctaagc	acctcaagaa	ggacctcaat	gccgtcctcc	ctgactcccg	ctcgtttttc	8460
gtgggcgttg	tccgcctcaa	cggcaagctg	ggcacctttg	agaacatttc	cgacttttagc	8520
aagttcgatc	tcactaaggc	gctcgactac	ggccagcgcg	gctccctcct	cggcctgtgc	8580
aagagcctcg	atcttgagtg	ggagcaggtt	ttctgccgcg	gcatcgacct	ggcctgcgac	8640
ctcatgcctc	tccaagccgc	gcgtatcctc	cgcaacgagc	tccagtggcc	gaacatgcgc	8700
ctgcgcgagg	tcggctacga	tatctcgggc	gctcgctaca	ccatctccac	cgacgacctt	8760
ctttgcggcc	ctagcaaggc	caaggtcgaa	gcggcggacc	tctttcttgt	cacgggtggt	8820
gcccgcggta	tcactcccca	ctgcgtccgc	gagatcgctt	cgcgtagccc	cggcacgacg	8880
tttgttctcg	tcggccgctc	cgagatgagc	gacgagcccc	actgggcccgt	gggtcactac	8940
aacaaggatc	tcgaccagtc	cacgatgaag	cacctgaagg	ccacgcatgc	tgccggaggc	9000
gtgaagccga	ctcccaaggc	gcaccgcgcc	cttgtcaacc	gtgtcaccgg	ctcgcgcgag	9060
gtccgcgaga	gcctgcgcgc	cattcaggag	gcgggtgcga	acgttgagta	catcgccctgc	9120
gacgtcagcg	acgagaacaa	ggtgcgccag	ctcgtccagc	gcgtggagca	gaagtacggt	9180
tgcgagatta	cgggcatctg	gcacgcctcg	ggtgtttctc	gcgacaagct	cgtggagcaa	9240
aagaccacgg	acgacttcga	ggccgtgttt	ggcactaagg	tcacgggcct	cgtgaacatc	9300
gtcagccagg	tcaacatgtc	caagctgcgc	catttcatcc	tcttctcctc	gctcgcgggc	9360
tttcacggca	acaagggcca	gaccgactac	gccatcgcca	acgaggccct	caacaagatc	9420
gcccacaccc	tttccgcctt	tctccccaag	ctcaacgcga	aggtcctcga	ctttggcccc	9480
tgggtcggct	ccggcatggt	cacggagact	cttgagaagc	actttaaggc	catgggcgtc	9540
cagaccatcc	ccctcgaacc	gggtgcccgc	accgtggccc	agatcatcct	cgccagctct	9600
ccgccccagt	ccctcctcgg	taactggggc	ttccccgcca	cgaaacccct	tcagcgctcc	9660
aacgtggtca	ccggcacctt	ctcgccggag	gagatcgaat	ttatcgccga	tcacaagatc	9720
cagggccgca	aggttctccc	gatgatggcc	gccatcggct	tcatggcgtc	gatcgccgag	9780
ggcctctacc	ctggctacaa	ccttcagggc	gttgagaacg	ctcagctttt	tcagggcctc	9840
accatcaacc	aggaaaccaa	gttcagatc	acgctcatcg	aggagcacia	ctccgaggag	9900
aacctcgacg	tcctcaccag	cctcggtgtc	atgctcgaaa	gcggcaaggt	gcttcccgcc	9960
taccgttgcg	tcgtctgcct	caacactacc	cagcagcagc	ccaagctcag	ccccaagatc	10020
ctcaacctgg	aggttgacct	cgcctgcgag	gtcaaccctt	acgacggcaa	gtccctcttt	10080

2997-49-2-pct_ST25

cacggccccgc	tcctccaatt	tgtccagcag	gtcctccact	cgtcgacgaa	aggcctcgtg	10140
gcgaagtgcc	gtgccctgcc	gattaaggag	gccatccgtg	gcccgttcat	caagcagacg	10200
ctccacgacc	cgatcctcga	cgacgtcatc	tttcagctca	tgctcgtgtg	gtgccgcaac	10260
gccctcggct	cggcctccct	cccgaaccgc	attgagaaga	tgagctactt	cggtaatgtg	10320
tcggagggca	gcacttttctt	cgccagcggt	acccccgtcg	gcccccggtg	cccgaaggat	10380
cccgtgatca	agatgcagtt	tctcctccag	gacgagtcgg	gcaacacctt	ttcgtccggc	10440
gagggcagcg	tcgtcctcag	cgatgagctc	gtgttctaaa	tctaaactag	tgaatcgcg	10500
caagttgtct	ttttgttact	ctacgtactg	ctctttctaa	ttttacgacg	tatgcttctg	10560
ctcttgacga	cgacaaccat	ggcaataaaa	gtaaggcaag	aaagtgagtg	cgtgctcgct	10620
cacaaggtct	aggccgaaac	gaggcgcctt	aggattgggt	gtctccgctg	taagtcatga	10680
cggagcgtag	gacaccgacg	gcctgccgcg	caaataatcg	aaccgctgca	caattctttt	10740
cgttgagaac	aacctcgaac	ggcctgcctt	gctgagctgc	cgacacggtg	gaaggaagca	10800
tagcggccaa	tcgaggggat	gctattaatt	aggcttggcg	ctgctgccgc	cgtgcctgaa	10860
gatgtgcgca	agcgtggcaa	caccgtccac	cttgccatta	aagtcatgca	ctccaaatac	10920
ctcgaacaga	gcctctcgca	tgtttgacca	agcaccttcg	agagagtctg	gactctcact	10980
ccttcctcac	cgttgctgcc	attctcagcg	agctcatgca	atcaccagga	cggagagacg	11040
gccagctgct	tttctgcttt	ccattgttat	tagagaaacg	cttctcgctc	tcatcgtctt	11100
agtagacatt	ccgatggcct	cgttcgccaa	tttgtcacct	aagtaagcta	gagtgttaag	11160
tctaaatgcc	tttgacccgc	gtacggcgtc	acgtagatgc	ctgtccttgc	cagcaaacgc	11220
tagttcgcg	tgtgcgtaat	ttggcccgca	ttatgctggc	tctcaaaatc	aaccgccacc	11280
actcgcggt	gcacgatgat	tttcgtgcac	tcacgacatg	agaaatgtga	tactcaaact	11340
agtatagacc	tcctactcct	actgctgctt	ttctcgtcag	agctgtctcc	ggaaaagtgt	11400
acaagttgtt	ggccttcttc	ttctctgcta	gtaagtagat	catcatggat	gagacgatga	11460
tgataatgat	gatgatgata	gcgaagagct	tttgggactc	gagcttgagc	tgatgtggct	11520
tattttatta	ctcaaaaacc	aatgcaccgt	tgcgagctct	cgagagtgga	gcaaagttgc	11580
aacagcgcac	acacaaagaa	cacatagaaa	tagacatcaa	aaatagtact	tttacaatcc	11640
agccgaggca	gcgcgaaaag	tcagcatctg	cgaactgcc	caaaagccgt	agatcaagtt	11700
ttgacacaac	gctcatgcac	gtctacgtgc	tcgcgcata	aggaaaacaa	atcacatcga	11760
gagattccca	ctcaggtcgt	gcgtggcctt	ttgggcatac	tcttgccgcg	cagcagccca	11820
caacgcctca	tcttctccca	taccaaggtc	aaaggatgg	tgtattttgt	cgtgaagttg	11880
gggcggcatt	ttctctaaaa	gcattgatgc	aatagatttc	gggctgtagc	gcgcggaaaa	11940
atgcatgagc	agaagcgtat	cgacgcgatc	aaacaagcct	cgatgaccga	acgctgcaag	12000
ttggtcaaca	tgaatatggc	cgtggtcttc	ggccttgga	atgtcgccat	cgaaaaaggt	12060
cacctccacg	cagagcgtct	ttgcacggag	aaaggagat	tcagggtccc	gttccaaagc	12120

2997-49-2-pct_ST25

agcagcgacc	gtgtcgcccc	tgtaagcaaa	gtcgacaacc	tcgtgtatga	cgtagtcctc	12180
aggctttggt	ggcgaggtct	tgaagcgagt	gcgctttgtc	gcaacgggga	gctccgcaag	12240
ttccggacgt	aactcctttt	tgatattaat	gaccgcatat	cctacagaag	gcacacgatg	12300
ctcggttgca	aggactgcaa	cgcgcggtatt	cccgttcaac	tctacgctgt	cgccgggggtt	12360
gacgcccgtg	atcttcatat	tgaaggggtc	ctgggtgtcg	tcaacatctc	ctcctccgtc	12420
gagggcttgc	atcgctcgcc	ctgcaactgcg	aaaatcctcc	acagcctccg	caggcatgta	12480
gacgcgcgtc	tcctt					12495

<210> 72
 <211> 8647
 <212> DNA
 <213> Artificial

<220>
 <223> synthetic

<400> 72	
ctatactggt	gctcttcggt gctgatttag ctcgacttgg gtccacacca ctgcccctct 60
actgtgaatg	gatcaatgga cgcacgacgg gccgacgaaa gtgcgcgagt gaggtaacct 120
aagcaacggc	ggtcttcaga ggggacgcac gccctccgtc gcagtcagtc cagacaggca 180
gaaaagcgtc	ttagggacca cgcacgcacg cacgcacgca cgcacgcccg cacgcacgct 240
ccctccctcg	cgtgcctatt tttttaggct tccttccgca cgggcctacc tctcgctccc 300
tcgcctcgcc	gcaccaggcg gcagcagcga tacctgccgg tgccgcctcc gtcacgcgct 360
cagccgcagc	tcagcccagc cgcgagctag ggtttggttcg tcctgaattg tttgatttga 420
tttgatttga	tttgatccga tccgatccga tctgatctga tttgctttgc tttgctttgt 480
ctccctcccc	gcgcggacca agcgtccgtc tgcgcgccgc agcttccctt cttctcccag 540
ccctccttct	gctcccgctt ctcgcgcaag cacgcagctt cgccgccgca tccggtcggt 600
cggtcggtcg	atcgaccgcg ctgccgctgc tgctgtggcc gggcttttct ccatcggcga 660
ctctttcttc	tccatacgtc ctactacgta catacatact gccggcttcc tcctcttcca 720
gcgcggcgac	ggcggcaggc tgcgacgtcg tcgccgccgc gggcgccgcg cgcgccgccg 780
ccgccgcccc	cgtcgcaggg cctcgctcgcc gccgccgctc cgctccgctc cgaggccgcg 840
agagggccgc	ggcggcgcgga tggatggatg gatggatgga tggatggatg gattttgttg 900
atcgatggcg	gcgcatgggc ggagatgagc gaggacgagc gcgcgagcgc ggcagccgga 960
ttcgcagggc	ctcgctcgcc tcgcgccgcg tgccgcgccg gccttgcgag cctgcgccgc 1020
gagcgagcga	gcgagcgagc ggggctttct ttgtctcgcg cgccgcttgg cctcgtgtgt 1080
cttgtgcttg	cgtagcgggc gccgcggttg aagatggctc attcaatcga cccattcacg 1140
cacgcactcc	ggcgcgcaga gaaggccgag gaggagcagc aagcaaacca aaagctctcg 1200
cgctcgcggt	ctcgggctcg agcggctctg gagagagagt cttgcggcga ccaccggcag 1260
cagcagcagc	agcagcagcg ctgtcgagca cgagcacgag cacgagcacg agcacgagca 1320

2997-49-2-pct_ST25

ttcgagcaag	aggacagaca	cggttgtcag	cgcctagctc	gctcgataca	gaaagaggcg	1380
ggttgggctg	aaaaaaaaag	gagcacgcaa	gccgccagcc	agccagctag	ctagccagcc	1440
tgcttgccaa	aatgcagctc	ccgcccgcctc	actccgctga	tgagaaccgc	attgccgtgg	1500
tcggcatggc	cgtgaagtac	gctggctgctg	acaacaagga	ggaattcttg	aaaaccctca	1560
tgaacgggtc	gattaacacc	aaaagcatta	gcgcggctcg	ccttggctcg	aacaagcgcg	1620
acgagcacta	cgtcccggag	cgcagcaagt	acgccgacac	gttctgcaac	gagcgttacg	1680
gctgcatcca	gcagggcacg	gataacgagc	acgacctcct	cctcggcctc	gcccaggagg	1740
ccctcgccga	tgctgccggc	cgtatggaga	agcagccgtc	ggaggccttc	gatcttgaga	1800
ataccggcat	cgtgtcgggc	tgctgagct	ttccgatgga	taacctccag	ggcgagctcc	1860
tcaacctcta	ccagtccac	gtcgagaagc	agcttcccc	gtctgctctc	gtggaggccg	1920
tcaagctctg	gagcgagcgc	cagaagtcca	ctaaggccca	cgcgggcgac	aagcgccgct	1980
ttatcgatcc	ggcgtctttc	gtcgccgaca	agctgaacct	cggccccctc	cactacgcca	2040
tcgacgccgc	ctgcgcctcg	gcgctctacg	tgctgaagct	cggccaggac	cacctcgta	2100
gcggcgctgt	cgatatgatg	ctctgcgggc	ccacttgttt	cccggagccg	ttcttcatcc	2160
tctcgggctt	cagcaccttc	caagccatgc	cggtcggctg	ggacggcgctg	tcgctcccc	2220
tccacaagac	ctcggctggc	ctcacccccg	gtgagggcgg	ctccatcatg	gttctcaagc	2280
gcctcaagga	cgccatccgc	gacggcaacc	acatctacgg	cgtgctcctt	gaggccaacc	2340
tctcgaacgc	cggatgcggc	ctcccgtctt	cgccgcacct	cccttccgag	gagtcgtgca	2400
ttcgcgacac	ctatcgccgc	gctggcgctg	ctgccgacca	gagcatccag	tacatcgagt	2460
gccacgccac	cggcacccccg	cgtggcgacg	tcgtcgagat	cgaggctgtc	gagcgcgctt	2520
ttaagaagaa	tgtgccccgc	cttggttcta	ccaagggcaa	cttcggccac	tcctctgctg	2580
ctgccggctt	cgcggggatg	gcgaagctgc	tcctcgctat	ggagcacggc	gtcatccccg	2640
ccacccctgg	cctggacgcc	agcaatcagg	cttcgagca	cgtcgtcact	aaggcgatta	2700
cctggccgga	aaccacggc	gctcctaagc	gcgccggcct	ctccgccttc	ggctttggcg	2760
gcacgaacgc	gcatgccctt	tttgaggagt	tcaatgccga	gggcatttcc	taccgccccg	2820
gtaagcctcc	ggtcgagtcg	aacacccgcc	cctctgtggt	catcactggc	atggactgca	2880
cgtttggcag	cctggagggg	atcgacgcct	ttgagactgc	cctctacgag	ggccgtgatg	2940
ccgcccgtga	tcttctgccc	aagcgttggc	gcttcctcgg	cgaggatctg	gagtttctcc	3000
gcgccatccg	cctgaaggag	aagccccgtg	gctgctttgt	tgagtccgtt	gacgtgaact	3060
ttcgccgcct	caagaccctt	ctcacccccg	aggatatgct	ccgcccgcag	cagctcctcg	3120
ctgtctccac	tatggaccgc	gcgatcatcg	acgccggcct	caagaagggc	cagcatgtcg	3180
ccgtcctcgt	cggcctcggc	accgatctgg	agctttaccg	ccaccgtgcc	cgtgtggccc	3240
tcaaggaggt	gctccacccc	tcgctgaaga	gcgacaccgc	catcctccag	aagatcatgc	3300
agtacgtcaa	cgacgcgggc	acctcgacct	cctacacctc	gtacatcggc	aacctcgtcg	3360

2997-49-2-pct_ST25

ccacccgtat	cagctcgcag	tggggcttta	ccggcccag	ctttactgtc	acggagggta	3420
acaacagcgt	ctaccgttgc	gcccagctcg	ctaaggacat	gctgcaagtc	aaccgcgtcg	3480
atgccgtcgt	cattgccggg	gtggacctga	acggctccgc	cgagagcttc	ttcgtccgcg	3540
ctaaccgtca	aaagatcagc	aagctttccc	acccgtgcgc	cagcttcgac	cgcgacgccg	3600
acggcttctt	tgccggcgaa	ggctgcggcg	ctctcgtggt	caagcgcctt	gaggactgcg	3660
cccctcagga	gaagatttac	gcttccatcg	acagcatcgc	catcgacaag	gagcctacct	3720
cctcggccgt	caaggctgtc	taccagtccg	actcctccct	ctccgacatc	gagcttcttg	3780
agatcagcgg	cgactccaag	cgttttgcgg	ccttcgaggg	cgctgtcgag	atccagtcct	3840
ctgtggaggc	gcagctcaag	ggcctttcca	aggttcttga	gcccgcgaag	ggccaaggcg	3900
tcgccgttgg	ctcgaccgcg	gccactgtcg	gtgatatcgg	ctacgccact	ggcgcggctt	3960
cgctcatcaa	gacggccctg	tgctctaca	accgttacct	gcctgccctc	gccaactgga	4020
gcggccctg	cgaacagagc	gcctggggta	gcaacatggt	cgtctgccac	gagactcgtc	4080
cttgatgaa	gaaccagaac	gagaagcgct	gcgcgctcat	ctcgggcacg	gaccgcgtcc	4140
acacctgctt	cagcctcgtg	ctctccgata	ctggttgcta	cgaggagcac	aaccgcacgt	4200
gctttgacgt	gcaggccccc	cagctcgttc	tcattcatgg	ttttgatggc	aagaccattg	4260
tgcgccgcct	tgagggtat	ctccttgagc	ttgtcgaggg	ccatgcctcg	ccgtccgagt	4320
actttcacia	gctcatcggc	cagagcctcc	ttgagaactc	caaggagtcg	aagctcacgc	4380
tctcgtcgt	ctgcaacccc	aaccaactcc	agaaggagct	catgctcgcc	atcaaggggtg	4440
tgacgcgtc	tatgctgacg	ggtaaggact	gggtttcccc	ctcgggctct	tgctttgctc	4500
cgaaccctct	ctcgtccgcc	aaggctcgctt	tcatgtacgg	cgaaggccgc	ttcccctact	4560
gcggtgtggg	ccttggcctc	caccgcctct	ggcctggcct	ccacgaaaac	gtgaacaaca	4620
agacggtgga	cctctggacg	gagggcgacg	gttggctcta	cccgcgcacc	ctcactcgtg	4680
aggagcacac	taaggccatc	gagtcgttta	acgctaacca	gatcgagatg	ttccgtgccg	4740
gtatctttat	ctccatgtgc	cagacggact	acgtgatgaa	cgtcctcggc	gtgcagccca	4800
aggccggctt	tggcctctcg	ctcggcgaga	tcagcatgct	cttcgccatg	tccaaggaga	4860
actgccgcca	gagccaggag	atgaccaacc	gccttcgtgg	cagccccgtc	tggtcgaacg	4920
agcttgccat	taacttcaat	gcgatccgta	agctctggaa	gattccccgc	ggtgccccgc	4980
ttgagtcctt	ctggcagggc	tacctcgtcc	acggcacccg	cgaggaggtc	gagcacgcca	5040
tcggcctcag	cgagccctac	gtccgcctgc	ttatcgtgaa	tgacagccgc	tcggccctta	5100
tcgcgggtaa	gcctgacgcc	tgccaggccg	tgatctcgcg	cctcaactcg	aagtccctt	5160
ctctccctgt	gaagcagggc	atgatcggcc	actgcccgga	ggtgcgcgcc	ttcatcaagg	5220
acattggtta	catccacgag	actctccgta	tctctaacga	ttactcggac	tgccagctct	5280
tttcggccgt	caccaagggg	gcccttgact	cgtctactat	ggagatcaag	cacttcgtcg	5340
gtgagggtcta	cagccgcatt	gccgattttc	cccagattgt	caacacggtg	cactcggccg	5400

2997-49-2-pct_ST25

gctacgacgt	gtttctcgaa	ctcggctgcg	acgcctccc	cagcgccgct	gttcagaaca	5460
tcctcggcgg	tcagggcaag	tttctgtcta	ctgccattga	caagaagggt	cactctgcct	5520
ggtcgcaggt	tctccgcgct	accgcctcgc	tcgctgccc	ccgcgtgccc	ggcatctcga	5580
tcctcgatct	ctttcacccg	aatttccgcg	agatgtgctg	cacgatggct	acgaccccc	5640
aggtggagga	caagtttctc	cgcaccatcc	agattaacgg	ccgtttcgag	aaggagatga	5700
tccacctga	agataccact	ctctcctgcc	ttcccgcgcc	ttcggaggcc	aacattgccg	5760
ccattcagtc	gcgctcgatt	cgcagcgctg	cggcccgtag	cggccagtcg	cacgactgcg	5820
cgtcccacag	ccatgaggag	aataaggact	cctgcccgga	gaagctcaaa	cttgactcgg	5880
tcagcgtcgc	gatcaacttt	gacaacgacg	accgtattca	gctcggccac	gcgggttttc	5940
gcgagatgta	caacacccgc	tactcgtctt	acacgggcgc	tatggctaaa	ggcatcgctt	6000
cggccgacct	cgtcatcgct	gcgggcaagg	agggtatcct	cgccagctac	ggtgctggcg	6060
gcctcccgct	cgccaccgtc	cgcaagggtg	tcgacaagat	ccagcaggcg	ctccccagcg	6120
gtccttacgc	cgtcaacctc	atccactccc	cgtttgacgg	caacctggag	cagggaacg	6180
tcgacctctt	tctcgaaaag	aacgtccgcg	tcgccgagtg	ttctgccttt	acgacctca	6240
ccgtgcccgt	cgtccattat	cgcgccgctg	gcctcgttcg	ccgccaggac	ggctcgatcc	6300
tcattaagaa	ccgcatcatc	gccaagggtc	gccgcaccga	gctcgtgag	atgttcctcc	6360
gccctgcgcc	gcagattatc	ctcgaaaagc	tggtcgccgc	cgagatcatc	tccagcgatc	6420
aggcgcgtat	ggccgcgaag	gtgccgatgg	ccgacgacat	cgccgtcgag	gccgacagcg	6480
gcggccacac	ggacaaccgc	ccgatgcatg	ttattctccc	cctcattatc	cagctccgca	6540
acaccattct	cgcgaggtag	ggctgcgcta	ctgcctttcg	cacgcgtatt	ggcgtgggtg	6600
gcggcatcgg	ttgcccgagc	gccgctctcg	ccgccttcga	catgggtgcc	tctttcgtcg	6660
tcaccggctc	catcaatcag	atttgccgcg	aggcgggcac	ctgcgacacg	gttcgcgagc	6720
tcctcgccaa	ctcgtcgtac	agcgatgtca	cgatggctcc	tgccgccgac	atgttcgac	6780
agggcgtgaa	gctccaagtc	ctcaagcgcg	gcaccatggt	cccctcgcgc	gctaacaagc	6840
ttcgcaagct	ctttgtgaac	tacgagtccc	tcgaaactct	cccctccaag	gagctcaagt	6900
accttgagaa	cattattttc	aagcaggctg	tggaccaggt	gtgggaggag	actaagcgct	6960
tctactgcga	gaagctgaac	aaccccgaca	agatcgctcg	cgctatgaag	gaccccaagc	7020
tcaagatgtc	gctctgcttc	cgctggtatc	tcagcaagtc	gtcgggctgg	gccaacgccg	7080
gcatcaagtc	tcgcgccctc	gactacaaa	tctggtgcgg	accgcgatg	ggcagcttta	7140
acaacttcgc	ctccggcacg	agcctcgact	ggaaagtgac	cgggtgtctt	cccggcgctc	7200
ccgaggtgaa	catggccatc	ctcgatggcg	cccgcgagct	cgctgccaag	cgcaactaag	7260
taagctctca	tatatgttag	ttgcgtgaga	ccgacacgaa	gataatatca	catacgcttt	7320
tgtttgttct	ttcaattatt	tgtctgtgct	tcattgttgc	cctcagtatc	tagctggcgg	7380
ctcttatctt	cttttaaaat	atctggacaa	ggacaaaaac	aagaataaag	gcgagaagat	7440

2997-49-2-pct_ST25

gtgaatttca tttcgacttg agaactcgaa gagcattgat gcggttagta tatgggtatt	7500
ttccagacac ttttcatcat catcatcatc atcatcatta tgaagaagta gtagctgata	7560
aagtagactc actgttttga gcgagaacca ggcccttttcg gtccgtaacc ttggtgaaaa	7620
atcgaggagc gatcatgcct tgtgcgtcgc cggggctaag aatgaccccg ttgtctgatt	7680
cgaaaaattt gatgccagcc tcggcagctg cagcagcagc gtctacatac acgaagtacg	7740
tcacaaggac ttgcgcatcc cgctgatcac acccgtctcc gaggacggaa gcccgtagac	7800
aaagtgaatg tgattccgtt tcattcgcga caaaccttg tcctggatct gagcccaggc	7860
agaagtattt gttccgtgca agcacgtctc aatgcttgct ggatcgagtg gacgcaacaa	7920
actcgtctct ttgacaactg acatggagtg tccctgattc gcacgaatca accagcttcc	7980
gtccgtgtcc tggcgcaacg tgaaccgctg cttgtcgttg tctcgcacga cagcctcaat	8040
gtccgaaaag gagatccctt tgaagcgctt gagcttgccc tgtagctcag ccagacgaac	8100
aaatccatct tcgcgcactt cgagaccctc ctgaacggcc gagtgccgca gcacacggct	8160
tagcatgtgc gaaagcttct tgttatgcgc cttggctttt gaaggcagcg ttggcgcgct	8220
gcgagagtgt ttacttggtt gcgcagcttc actatcacga gcagcacttc gtttattcat	8280
ttcatgttg tttgcaggtt cagtggtagc cccatccggc acgggccaga gcaccctgtg	8340
agagcgccgt tcctcgacct tgaggaaaag ctccgtaggt atggctcctg tatcgcccag	8400
accaggggta agtaggacgc cattgcttga ttggaacatt tccaagcccg catcatgtgc	8460
gcgcgcggta tcgaggaaga tgagcacctc tgcggagccg cgaaagccac tgagcactcc	8520
gtcctgacca ggaagtcccg aggcaaatg aatgtgattt cggcccatgc ggcggaggcc	8580
ctggcgttgg attgcaggcc agtggcgaag atacgttccg tgaatacaca gcggaagcaa	8640
tgagaga	8647

<210> 73
 <211> 4479
 <212> DNA
 <213> Artificial

<220>
 <223> synthetic

<220>
 <221> CDS
 <222> (1)..(4479)

<400> 73	
atg gcg ctc cgt gtc aag acg aac aag aag cca tgc tgg gag atg acc	48
Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr	
1 5 10 15	
aag gag gag ctg acc agc ggc aag acc gag gtg ttc aac tat gag gaa	96
Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu	
20 25 30	
ctc ctc gag ttc gca gag ggc gac atc gcc aag gtc ttc gga ccc gag	144
Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu	
35 40 45	

2997-49-2-pct_ST25

ttc Phe	gcc Ala 50	gtc Val	atc Ile	gac Asp	aag Lys	tac Tyr 55	ccg Pro	cgc Arg	cgc Arg	gtg Val	cgc Arg 60	ctg Leu	ccc Pro	gcc Ala	cgc Arg	192
gag Glu 65	tac Tyr	ctg Leu	ctc Leu	gtg Val	acc Thr 70	cgc Arg	gtc Val	acc Thr	ctc Leu	atg Met 75	gac Asp	gcc Ala	gag Glu	gtc Val	aac Asn 80	240
aac Asn	tac Tyr	cgc Arg	gtc Val	ggc Gly 85	gcc Ala	cgc Arg	atg Met	gtc Val	acc Thr 90	gag Glu	tac Tyr	gat Asp	ctc Leu	ccc Pro 95	gtc Val	288
aac Asn	gga Gly	gag Glu	ctc Leu 100	tcc Ser	gag Glu	ggc Gly	gga Gly	gac Asp 105	tgc Cys	ccc Pro	tgg Trp	gcc Ala	gtc Val 110	ctg Leu	gtc Val	336
gag Glu	agt Ser	ggc Gly 115	cag Gln	tgc Cys	gat Asp	ctc Leu	atg Met 120	ctc Leu	atc Ile	tcc Ser	tac Tyr	atg Met 125	ggc Gly	att Ile	gac Asp	384
ttc Phe 130	cag Gln	aac Asn	cag Gln	ggc Gly	gac Asp	cgc Arg 135	gtc Val	tac Tyr	cgc Arg	ctg Leu	ctc Leu 140	aac Asn	acc Thr	acg Thr	ctc Leu	432
acc Thr 145	ttt Phe	tac Tyr	ggc Gly	gtg Val	gcc Ala 150	cac His	gag Glu	ggc Gly	gag Glu	acc Thr 155	ctc Leu	gag Glu	tac Tyr	gac Asp	att Ile 160	480
cgc Arg	gtc Val	acc Thr	ggc Gly	ttc Phe 165	gcc Ala	aag Lys	cgt Arg	ctc Leu	gac Asp 170	ggc Gly	ggc Gly	atc Ile	tcc Ser	atg Met 175	ttc Phe	528
ttc Phe	ttc Phe	gag Glu	tac Tyr 180	gac Asp	tgc Cys	tac Tyr	gtc Val	aac Asn 185	ggc Gly	cgc Arg	ctc Leu	ctc Leu	atc Ile 190	gag Glu	atg Met	576
cgc Arg	gat Asp	ggc Gly 195	tgc Cys	gcc Ala	ggc Gly	ttc Phe	ttc Phe 200	acc Thr	aac Asn	gag Glu	gag Glu	ctc Leu 205	gac Asp	gcc Ala	ggc Gly	624
aag Lys	ggc Gly 210	gtc Val	gtc Val	ttc Phe	acc Thr	cgc Arg 215	ggc Gly	gac Asp	ctc Leu	gcc Ala	gcc Ala 220	cgc Arg	gcc Ala	aag Lys	atc Ile	672
cca Pro 225	aag Lys	cag Gln	gac Asp	gtc Val	tcc Ser 230	ccc Pro	tac Tyr	gcc Ala	gtc Val	gcc Ala 235	ccc Pro	tgc Cys	ctc Leu	cac His	aag Lys 240	720
acc Thr	aag Lys	ctc Leu	aac Asn	gaa Glu 245	aag Lys	gag Glu	atg Met	cag Gln	acc Thr 250	ctc Leu	gtc Val	gac Asp	aag Lys	gac Asp 255	tgg Trp	768
gca Ala	tcc Ser	gtc Val	ttt Phe 260	ggc Gly	tcc Ser	aag Lys	aac Asn	ggc Gly 265	atg Met	ccg Pro	gaa Glu	atc Ile 270	aac Asn	tac Tyr	aaa Lys	816
ctc Leu	tgc Cys	gcg Ala 275	cgt Arg	aag Lys	atg Met	ctc Leu	atg Met 280	att Ile	gac Asp	cgc Arg	gtc Val	acc Thr 285	agc Ser	att Ile	gac Asp	864
cac His	aag Lys 290	ggc Gly	ggt Gly	gtc Val	tac Tyr	ggc Gly 295	ctc Leu	ggt Gly	cag Gln	ctc Leu	gtc Val 300	ggt Gly	gaa Glu	aag Lys	atc Ile	912
ctc Leu 305	gag Glu	cgc Arg	gac Asp	cac His	tgg Trp 310	tac Tyr	ttt Phe	ccc Pro	tgc Cys	cac His 315	ttt Phe	gtc Val	aag Lys	gat Asp	cag Gln 320	960

2997-49-2-pct_ST25

gtc Val	atg Met	gcc Ala	gga Gly	tcc Ser 325	ctc Leu	gtc Val	tcc Ser	gac Asp	ggc Gly 330	tgc Cys	agc Ser	cag Gln	atg Met	ctc Leu 335	aag Lys	1008
atg Met	tac Tyr	atg Met	atc Ile 340	tgg Trp	ctc Leu	ggc Gly	ctc Leu	cac His 345	ctc Leu	acc Thr	acc Thr	gga Gly	ccc Pro 350	ttt Phe	gac Asp	1056
ttc Phe	cgc Arg	ccg Pro 355	gtc Val	aac Asn	ggc Gly	cac His	ccc Pro 360	aac Asn	aag Lys	gtc Val	cgc Arg	tgc Cys 365	cgc Arg	ggc Gly	caa Gln	1104
atc Ile	tcc Ser 370	ccg Pro	cac His	aag Lys	ggc Gly	aag Lys 375	ctc Leu	gtc Val	tac Tyr	gtc Val	atg Met 380	gag Glu	atc Ile	aag Lys	gag Glu	1152
atg Met 385	ggc Gly	ttc Phe	gac Asp	gag Glu	gac Asp 390	aac Asn	gac Asp	ccg Pro	tac Tyr	gcc Ala 395	att Ile	gcc Ala	gac Asp	gtc Val	aac Asn 400	1200
atc Ile	att Ile	gat Asp	gtc Val	gac Asp 405	ttc Phe	gaa Glu	aag Lys	ggc Gly	cag Gln 410	gac Asp	ttt Phe	agc Ser	ctc Leu	gac Asp 415	cgc Arg	1248
atc Ile	agc Ser	gac Asp	tac Tyr 420	ggc Gly	aag Lys	ggc Gly	gac Asp	ctc Leu 425	aac Asn	aag Lys	aag Lys	atc Ile	gtc Val 430	gtc Val	gac Asp	1296
ttt Phe	aag Lys	ggc Gly 435	atc Ile	gct Ala	ctc Leu	aag Lys	atg Met 440	cag Gln	aag Lys	cgc Arg	tcc Ser	acc Thr 445	aac Asn	aag Lys	aac Asn	1344
ccc Pro	tcc Ser 450	aag Lys	ggt Val	cag Gln	ccc Pro	gtc Val 455	ttt Phe	gcc Ala	aac Asn	ggc Gly	gcc Ala 460	gcc Ala	act Thr	gtc Val	ggc Gly	1392
ccc Pro 465	gag Glu	gcc Ala	tcc Ser	aag Lys	gct Ala 470	tcc Ser	tcc Ser	ggc Gly	gcc Ala	agc Ser 475	gcc Ala	agc Ser	gcc Ala	agc Ser	gcc Ala 480	1440
gcc Ala	ccg Pro	gcc Ala	aag Lys	cct Pro 485	gcc Ala	ttc Phe	agc Ser	gcc Ala	gat Asp 490	gtt Val	ctt Leu	gcg Ala	ccc Pro	aag Lys 495	ccc Pro	1488
gtt Val	gcc Ala	ctt Leu	ccc Pro 500	gag Glu	cac His	atc Ile	ctc Leu	aag Lys 505	ggc Gly	gac Asp	gcc Ala	ctc Leu	gcc Ala 510	ccc Pro	aag Lys	1536
gag Glu	atg Met	tcc Ser 515	tgg Trp	cac His	ccc Pro	atg Met	tca Ser 520	aag Lys	ctt Leu	cct Pro	ggc Gly	aac Asn 525	cct Pro	acg Thr	ccg Pro	1584
ttc Phe	ttc Phe 530	tcc Ser	cct Pro	tca Ser	tct Ser	tac Tyr 535	cct Pro	ccg Pro	agg Arg	gca Ala	att Ile 540	tgc Cys	ttc Phe	atc Ile	cct Pro	1632
ttc Phe 545	ccg Pro	ggc Gly	aat Asn	ccc Pro	ctt Leu 550	gac Asp	aac Asn	aac Asn	tgc Cys	aag Lys 555	gct Ala	gga Gly	gaa Glu	atg Met	ccc Pro 560	1680
ctg Leu	aac Asn	tgg Trp	tac Tyr	aac Asn 565	atg Met	tca Ser	gag Glu	ttc Phe	atg Met 570	tgt Cys	ggc Gly	aag Lys	gtt Val	tct Ser 575	aac Asn	1728
tgc Cys	ttg Leu	ggc Gly	cca Pro 580	gaa Glu	ttc Phe	gca Ala	cgc Arg	ttt Phe 585	gac Asp	aag Lys	tcg Ser	aac Asn	acc Thr 590	agc Ser	cgg Arg	1776

2997-49-2-pct_ST25

agc Ser	cct Pro	gct Ala 595	ttt Phe	gac Asp	ttg Leu	gct Ala	ctg Leu 600	gtg Val	acc Thr	cga Arg	gtt Val 605	gaa Glu	gtc Val	aca Thr	1824	
aac Asn	atg Met 610	gaa Glu	cac His	ggc Gly	aag Lys	ttt Phe 615	cta Leu	aac Asn	gtt Val	gat Asp	tgc Cys 620	aat Asn	cca Pro	agc Ser	aaa Lys	1872
ggc Gly 625	aca Thr	atg Met	gtg Val	ggg Gly	gag Glu 630	ttt Phe	gac Asp	tgt Cys	ccc Pro	caa Gln 635	gac Asp	gcg Ala	tgg Trp	ttc Phe	ttt Phe 640	1920
gat Asp	ggt Gly	tcg Ser	tgc Cys	aac Asn 645	gac Asp	ggc Gly	cat His	atg Met	ccg Pro 650	tat Tyr	tcc Ser	att Ile	atc Ile	atg Met 655	gaa Glu	1968
atc Ile	gga Gly	ctg Leu	caa Gln 660	acc Thr	tca Ser	ggt Gly	gtt Val 665	ctc Leu	acc Thr	tcg Ser	gtg Val	ttg Leu 670	aag Lys	gca Ala	ccg Pro	2016
ctg Leu	act Thr	atg Met 675	gac Asp	aag Lys	gat Asp	gac Asp	att Ile 680	ctc Leu	ttt Phe	cga Arg	aac Asn	ctc Leu 685	gat Asp	gca Ala	agt Ser	2064
gct Ala	gaa Glu 690	atg Met	gtg Val	cgt Arg	cca Pro	gac Asp 695	gtg Val	gat Asp	gtt Val	cgc Arg	ggc Gly 700	aaa Lys	acg Thr	att Ile	cga Arg	2112
aac Asn 705	gtg Val	acc Thr	aag Lys	tgt Cys	acc Thr 710	ggc Gly	tat Tyr	gca Ala	atg Met	ttg Leu 715	gga Gly	aag Lys	atg Met	ggg Gly 720	att Ile 720	2160
cac His	cgg Arg	ttc Phe	acg Thr	ttt Phe 725	gag Glu	ttg Leu	agc Ser	gtt Val	gac Asp 730	ggc Gly	gtg Val	gta Val	ttt Phe	tat Tyr 735	aaa Lys	2208
gga Gly	tcc Ser	act Thr	tcc Ser 740	ttt Phe	gga Gly	tgg Trp	ttc Phe	act Thr 745	ccc Pro	gag Glu	gtg Val	ttt Phe	gct Ala 750	cag Gln	caa Gln	2256
gct Ala	gga Gly	ctc Leu 755	gac Asp	aac Asn	ggg Gly	aaa Lys	aag Lys 760	acg Thr	gag Glu	ccc Pro	tgg Trp	tgc Cys 765	aag Lys	act Thr	aac Asn	2304
aac Asn 770	acc Thr	tcg Ser	gtt Val	cga Arg	aga Arg	gtt Val 775	gaa Glu	atc Ile	gca Ala	tcc Ser	gcc Ala 780	aaa Lys	gga Gly	aaa Lys	gag Glu	2352
cag Gln 785	ctg Leu	act Thr	gag Glu	aag Lys	ctt Leu 790	ccc Pro	gac Asp	gca Ala	act Thr	aat Asn 795	gct Ala	caa Gln	gtt Val	ctt Leu	cgg Arg 800	2400
cgt Arg	tca Ser	gag Glu	cag Gln	tgt Cys 805	gaa Glu	tac Tyr	ctc Leu	gat Asp	tac Tyr 810	ctc Leu	aat Asn	att Ile	gcc Ala	cct Pro 815	gac Asp	2448
tct Ser	ggg Gly	ctg Leu	cat His 820	ggg Gly	aag Lys	ggc Gly	tac Tyr	gcc Ala 825	cac His	gga Gly	cac His	aaa Lys	gac Asp 830	gtt Val	aac Asn	2496
ccg Pro	caa Gln 835	gac Asp	tgg Trp	ttc Phe	ttc Phe	tct Ser	tgc Cys 840	cac His	ttt Phe	tgg Trp	ttc Phe	gat Asp 845	cct Pro	gta Val	atg Met	2544
cca Pro	gga Gly 850	tct Ser	tta Leu	gga Gly	att Ile	gaa Glu 855	tca Ser	atg Met	ttc Phe	cag Gln 860	ctt Leu 860	atc Ile	gag Glu	gcc Ala	ttt Phe	2592

2997-49-2-pct_ST25

gcg Ala 865	gtg Val	gac Asp	caa Gln	aac Asn	att Ile 870	cct Pro	gga Gly	gag Glu	tac Tyr	aac Asn 875	gta Val	tcc Ser	aat Asn	ccg Pro	acc Thr 880	2640
ttt Phe	gcc Ala	cat His	gca Ala	cca Pro 885	ggc Gly	aaa Lys	acg Thr	gcg Ala	tgg Trp 890	aaa Lys	tac Tyr	cga Arg	ggc Gly	cag Gln 895	ctc Leu	2688
aca Thr	cca Pro	aag Lys	aac Asn 900	cgt Arg	gcg Ala	atg Met	gac Asp	tgc Cys 905	gag Glu	gtg Val	cat His	atc Ile	gtt Val 910	tca Ser	att Ile	2736
acc Thr	gcc Ala	tcc Ser 915	ccc Pro	gag Glu	aac Asn	ggg Gly	ggc Gly 920	tac Tyr	gtt Val	gac Asp	atc Ile	gtg Val 925	gcc Ala	gat Asp	gga Gly	2784
gcg Ala 930	ctt Leu	tgg Trp	gta Val	gat Asp	gga Gly 935	ctt Leu	cgc Arg	gtg Val	tac Tyr	gaa Glu	gcc Ala 940	aaa Lys	gag Glu	ctt Leu	cga Arg	2832
gtt Val 945	cgt Arg	gtc Val	gtt Val	tgc Ser 950	gca Ala	aaa Lys	cct Pro	caa Gln	gca Ala	att Ile 955	ccg Pro	gat Asp	gta Val	caa Gln	caa Gln 960	2880
cag Gln	cca Pro	cct Pro	agc Ser	gca Ala 965	aag Lys	gcg Ala	gac Asp	ccg Pro	ggg Gly 970	aaa Lys	aca Thr	gga Gly	ggt Val	gca Ala 975	ctt Leu	2928
tcg Ser	ccc Pro	act Thr	cag Gln 980	cta Leu	cgc Arg	gac Asp	gtc Val	ctg Leu 985	ctt Leu	gaa Glu	gtg Val	gac Asp	aat Asn 990	cca Pro	ttg Leu	2976
tat Tyr	ctt Leu	ggt Gly 995	gta Val	gag Glu	aac Asn	tcc Ser	aat Asn 1000	ttg Leu	gtg Val	cag Gln	ttt Phe	gag Glu 1005	tcg Ser	aaa Lys	cct Pro	3024
gca Ala	act Thr 1010	tct Ser	tca Ser	cgt Arg	atc Ile	gtt Val 1015	tcg Ser	atc Ile	aaa Lys	ccg Pro	tgc Cys 1020	tcg Ser	att Ile	agt Ser		3069
gac Asp	ctt Leu 1025	ggc Gly	gat Asp	aag Lys	tct Ser	ttt Phe 1030	atg Met	gaa Glu	acg Thr	tac Tyr	aac Asn 1035	gtg Val	tca Ser	gca Ala		3114
cct Pro	ctg Leu 1040	tat Tyr	act Thr	ggc Gly	gcc Ala	atg Met 1045	gcc Ala	aag Lys	ggc Gly	att Ile	gcc Ala 1050	tcg Ser	gcg Ala	gac Asp		3159
ctc Leu	gtc Val 1055	atc Ile	gcc Ala	gcc Ala	ggc Gly	aag Lys 1060	cgc Arg	aag Lys	atc Ile	ctc Leu	ggc Gly 1065	tcc Ser	ttt Phe	ggc Gly		3204
gcc Ala	ggc Gly 1070	ggc Gly	ctc Leu	ccc Pro	atg Met	cac His 1075	cac His	gtg Val	cgc Arg	gcc Ala	gcc Ala 1080	ctc Leu	gag Glu	aag Lys		3249
atc Ile	cag Gln 1085	gcc Ala	gcc Ala	ctg Leu	cct Pro	cag Gln 1090	ggc Gly	ccc Pro	tac Tyr	gcc Ala	gtc Val 1095	aac Asn	ctc Leu	atc Ile		3294
cac His	tcg Ser 1100	cct Pro	ttt Phe	gac Asp	agc Ser	aac Asn 1105	ctc Leu	gag Glu	aag Lys	ggc Gly	aac Asn 1110	gtc Val	gat Asp	ctc Leu		3339
ttc Phe	ctc Leu 1115	gag Glu	aag Lys	ggc Gly	gtc Val	act Thr 1120	gtg Val	gtg Val	gag Glu	gcc Ala	tcg Ser 1125	gca Ala	ttc Phe	atg Met		3384

2997-49-2-pct_ST25

acc Thr	ctc Leu 1130	acc Thr	ccg Pro	cag Gln	gtc Val	gtg Val 1135	cgc Arg	tac Tyr	cgc Arg	gcc Ala	gcc Ala 1140	ggc Gly	ctc Leu	tcg Ser	3429
cgc Arg	aac Asn 1145	gcc Ala	gac Asp	ggc Gly	tcg Ser	gtc Val 1150	aac Asn	atc Ile	cgc Arg	aac Asn	cgc Arg 1155	atc Ile	atc Ile	ggc Gly	3474
aag Lys	gtc Val 1160	tcg Ser	cgc Arg	acc Thr	gag Glu	ctc Leu 1165	gcc Ala	gag Glu	atg Met	ttc Phe	atc Ile 1170	cgc Arg	ccg Pro	gcc Ala	3519
ccg Pro	gag Glu 1175	cac His	ctc Leu	ctc Leu	gag Glu	aag Lys 1180	ctc Leu	atc Ile	gcc Ala	tcg Ser	ggc Gly 1185	gag Glu	atc Ile	acc Thr	3564
cag Gln	gag Glu 1190	cag Gln	gcc Ala	gag Glu	ctc Leu	gcg Ala 1195	cgc Arg	cgc Arg	gtt Val	ccc Pro	gtc Val 1200	gcc Ala	gac Asp	gat Asp	3609
atc Ile	gct Ala 1205	gtc Val	gag Glu	gct Ala	gac Asp	tcg Ser 1210	ggc Gly	ggc Gly	cac His	acc Thr	gac Asp 1215	aac Asn	cgc Arg	ccc Pro	3654
atc Ile	cac His 1220	gtc Val	atc Ile	ctc Leu	ccg Pro	ctc Leu 1225	atc Ile	atc Ile	aac Asn	ctc Leu	cgc Arg 1230	aac Asn	cgc Arg	ctg Leu	3699
cac His	cgc Arg 1235	gag Glu	tgc Cys	ggc Gly	tac Tyr	ccc Pro 1240	gcg Ala	cac His	ctc Leu	cgc Arg	gtc Val 1245	cgc Arg	gtt Val	ggc Gly	3744
gcc Ala	gga Gly 1250	ggc Gly	ggc Gly	gtc Val	ggc Gly	tgc Cys 1255	ccg Pro	cag Gln	gcc Ala	gcc Ala	gcc Ala 1260	gcc Ala	gcg Ala	ctc Leu	3789
acc Thr	atg Met 1265	ggc Gly	gcc Ala	gcc Ala	ttc Phe	atc Ile 1270	gtc Val	acc Thr	ggc Gly	act Thr	gtc Val 1275	aac Asn	cag Gln	gtc Val	3834
gcc Ala	aag Lys 1280	cag Gln	tcc Ser	ggc Gly	acc Thr	tgc Cys 1285	gac Asp	aac Asn	gtg Val	cgc Arg	aag Lys 1290	cag Gln	ctc Leu	tcg Ser	3879
cag Gln	gcc Ala 1295	acc Thr	tac Tyr	tcg Ser	gat Asp	atc Ile 1300	tgc Cys	atg Met	gcc Ala	ccg Pro	gcc Ala 1305	gcc Ala	gac Asp	atg Met	3924
ttc Phe	gag Glu 1310	gag Glu	ggc Gly	gtc Val	aag Lys	ctc Leu 1315	cag Gln	gtc Val	ctc Leu	aag Lys	aag Lys 1320	gga Gly	acc Thr	atg Met	3969
ttc Phe	ccc Pro 1325	tcg Ser	cgc Arg	gcc Ala	aac Asn	aag Lys 1330	ctc Leu	tac Tyr	gag Glu	ctc Leu	ttt Phe 1335	tgc Cys	aag Lys	tac Tyr	4014
gac Asp	tcc Ser 1340	ttc Phe	gac Asp	tcc Ser	atg Met	cct Pro 1345	cct Pro	gcc Ala	gag Glu	ctc Leu	gag Glu 1350	cgc Arg	atc Ile	gag Glu	4059
aag Lys	cgt Arg 1355	atc Ile	ttc Phe	aag Lys	cgc Arg	gca Ala 1360	ctc Leu	cag Gln	gag Glu	gtc Val	tgg Trp 1365	gag Glu	gag Glu	acc Thr	4104
aag Lys	gac Asp 1370	ttt Phe	tac Tyr	att Ile	aac Asn	ggc Gly 1375	ctc Leu	aag Lys	aac Asn	ccg Pro	gag Glu 1380	aag Lys	atc Ile	cag Gln	4149

2997-49-2-pct_ST25

[illegible]

<210>	74
<211>	1493
<212>	PRT
<213>	Artificial

<220>
<223> Synthetic Construct

<400> 74

Met Ala Leu Arg Val Lys Thr Asn Lys Lys Pro Cys Trp Glu Met Thr
1 5 10 15

Lys Glu Glu Leu Thr Ser Gly Lys Thr Glu Val Phe Asn Tyr Glu Glu
20 25 30

Leu Leu Glu Phe Ala Glu Gly Asp Ile Ala Lys Val Phe Gly Pro Glu
35 40 45

Phe Ala Val Ile Asp Lys Tyr Pro Arg Arg Val Arg Leu Pro Ala Arg
50 55 60

Glu Tyr Leu Leu Val Thr Arg Val Thr Leu Met Asp Ala Glu Val Asn
65 70 75 80

Asn Tyr Arg Val Gly Ala Arg Met Val Thr Glu Tyr Asp Leu Pro Val
85 90 95

2997-49-2-pct_ST25

Asn Gly Glu Leu Ser Glu Gly Gly Asp Cys Pro Trp Ala Val Leu Val
100 105 110

Glu Ser Gly Gln Cys Asp Leu Met Leu Ile Ser Tyr Met Gly Ile Asp
115 120 125

Phe Gln Asn Gln Gly Asp Arg Val Tyr Arg Leu Leu Asn Thr Thr Leu
130 135 140

Thr Phe Tyr Gly Val Ala His Glu Gly Glu Thr Leu Glu Tyr Asp Ile
145 150 155 160

Arg Val Thr Gly Phe Ala Lys Arg Leu Asp Gly Gly Ile Ser Met Phe
165 170 175

Phe Phe Glu Tyr Asp Cys Tyr Val Asn Gly Arg Leu Leu Ile Glu Met
180 185 190

Arg Asp Gly Cys Ala Gly Phe Phe Thr Asn Glu Glu Leu Asp Ala Gly
195 200 205

Lys Gly Val Val Phe Thr Arg Gly Asp Leu Ala Ala Arg Ala Lys Ile
210 215 220

Pro Lys Gln Asp Val Ser Pro Tyr Ala Val Ala Pro Cys Leu His Lys
225 230 235 240

Thr Lys Leu Asn Glu Lys Glu Met Gln Thr Leu Val Asp Lys Asp Trp
245 250 255

Ala Ser Val Phe Gly Ser Lys Asn Gly Met Pro Glu Ile Asn Tyr Lys
260 265 270

Leu Cys Ala Arg Lys Met Leu Met Ile Asp Arg Val Thr Ser Ile Asp
275 280 285

His Lys Gly Gly Val Tyr Gly Leu Gly Gln Leu Val Gly Glu Lys Ile
290 295 300

Leu Glu Arg Asp His Trp Tyr Phe Pro Cys His Phe Val Lys Asp Gln
305 310 315 320

Val Met Ala Gly Ser Leu Val Ser Asp Gly Cys Ser Gln Met Leu Lys
325 330 335

Met Tyr Met Ile Trp Leu Gly Leu His Leu Thr Thr Gly Pro Phe Asp
340 345 350

Phe Arg Pro Val Asn Gly His Pro Asn Lys Val Arg Cys Arg Gly Gln
355 360 365

2997-49-2-pct_ST25

Ile Ser Pro His Lys Gly Lys Leu Val Tyr Val Met Glu Ile Lys Glu
 370 375 380
 Met Gly Phe Asp Glu Asp Asn Asp Pro Tyr Ala Ile Ala Asp Val Asn
 385 390 400
 Ile Ile Asp Val Asp Phe Glu Lys Gly Gln Asp Phe Ser Leu Asp Arg
 405 410 415
 Ile Ser Asp Tyr Gly Lys Gly Asp Leu Asn Lys Lys Ile Val Val Asp
 420 425 430
 Phe Lys Gly Ile Ala Leu Lys Met Gln Lys Arg Ser Thr Asn Lys Asn
 435 440 445
 Pro Ser Lys Val Gln Pro Val Phe Ala Asn Gly Ala Ala Thr Val Gly
 450 455 460
 Pro Glu Ala Ser Lys Ala Ser Ser Gly Ala Ser Ala Ser Ala Ser Ala
 465 470 475 480
 Ala Pro Ala Lys Pro Ala Phe Ser Ala Asp Val Leu Ala Pro Lys Pro
 485 490 495
 Val Ala Leu Pro Glu His Ile Leu Lys Gly Asp Ala Leu Ala Pro Lys
 500 505 510
 Glu Met Ser Trp His Pro Met Ser Lys Leu Pro Gly Asn Pro Thr Pro
 515 520 525
 Phe Phe Ser Pro Ser Ser Tyr Pro Pro Arg Ala Ile Cys Phe Ile Pro
 530 535 540
 Phe Pro Gly Asn Pro Leu Asp Asn Asn Cys Lys Ala Gly Glu Met Pro
 545 550 555 560
 Leu Asn Trp Tyr Asn Met Ser Glu Phe Met Cys Gly Lys Val Ser Asn
 565 570 575
 Cys Leu Gly Pro Glu Phe Ala Arg Phe Asp Lys Ser Asn Thr Ser Arg
 580 585 590
 Ser Pro Ala Phe Asp Leu Ala Leu Val Thr Arg Val Val Glu Val Thr
 595 600 605
 Asn Met Glu His Gly Lys Phe Leu Asn Val Asp Cys Asn Pro Ser Lys
 610 615 620
 Gly Thr Met Val Gly Glu Phe Asp Cys Pro Gln Asp Ala Trp Phe Phe
 625 630 635 640

2997-49-2-pct_ST25

Asp Gly Ser Cys Asn 645 Asp Gly His Met 650 Pro Tyr Ser Ile Ile Met 655 Glu

Ile Gly Leu Gln 660 Thr Ser Gly Val Leu 665 Thr Ser Val Leu Lys 670 Ala Pro

Leu Thr Met 675 Asp Lys Asp Asp Ile 680 Leu Phe Arg Asn Leu 685 Asp Ala Ser

Ala Glu 690 Met Val Arg Pro Asp 695 Val Asp Val Arg Gly 700 Lys Thr Ile Arg

Asn Val 705 Thr Lys Cys Thr 710 Gly Tyr Ala Met Leu 715 Gly Lys Met Gly Ile 720

His Arg Phe Thr Phe 725 Glu Leu Ser Val Asp 730 Gly Val Val Phe Tyr 735 Lys

Gly Ser Thr Ser 740 Phe Gly Trp Phe Thr 745 Pro Glu Val Phe Ala 750 Gln Gln

Ala Gly Leu 755 Asp Asn Gly Lys Lys 760 Thr Glu Pro Trp Cys 765 Lys Thr Asn

Asn Thr 770 Ser Val Arg Arg Val 775 Glu Ile Ala Ser Ala 780 Lys Gly Lys Glu

Gln Leu Thr Glu Lys Leu 790 Pro Asp Ala Thr Asn 795 Ala Gln Val Leu Arg 800

Arg Ser Glu Gln Cys 805 Glu Tyr Leu Asp Tyr 810 Leu Asn Ile Ala Pro 815 Asp

Ser Gly Leu His 820 Gly Lys Gly Tyr Ala 825 His Gly His Lys Asp 830 Val Asn

Pro Gln Asp 835 Trp Phe Phe Ser Cys 840 His Phe Trp Phe Asp 845 Pro Val Met

Pro Gly 850 Ser Leu Gly Ile Glu 855 Ser Met Phe Gln Leu 860 Ile Glu Ala Phe

Ala Val 865 Asp Gln Asn Ile 870 Pro Gly Glu Tyr Asn 875 Val Ser Asn Pro Thr 880

Phe Ala His Ala Pro 885 Gly Lys Thr Ala Trp 890 Lys Tyr Arg Gly Gln 895 Leu

Thr Pro Lys Asn 900 Arg Ala Met Asp Cys 905 Glu Val His Ile Val 910 Ser Ile

2997-49-2-pct_ST25

Thr Ala Ser Pro Glu Asn Gly Gly Tyr Val Asp Ile Val Ala Asp Gly
 915 920 925

Ala Leu Trp Val Asp Gly Leu Arg Val Tyr Glu Ala Lys Glu Leu Arg
 930 935 940

Val Arg Val Val Ser Ala Lys Pro Gln Ala Ile Pro Asp Val Gln Gln
 945 950 955 960

Gln Pro Pro Ser Ala Lys Ala Asp Pro Gly Lys Thr Gly Val Ala Leu
 965 970 975

Ser Pro Thr Gln Leu Arg Asp Val Leu Leu Glu Val Asp Asn Pro Leu
 980 985 990

Tyr Leu Gly Val Glu Asn Ser Asn Leu Val Gln Phe Glu Ser Lys Pro
 995 1000 1005

Ala Thr Ser Ser Arg Ile Val Ser Ile Lys Pro Cys Ser Ile Ser
 1010 1015 1020

Asp Leu Gly Asp Lys Ser Phe Met Glu Thr Tyr Asn Val Ser Ala
 1025 1030 1035

Pro Leu Tyr Thr Gly Ala Met Ala Lys Gly Ile Ala Ser Ala Asp
 1040 1045 1050

Leu Val Ile Ala Ala Gly Lys Arg Lys Ile Leu Gly Ser Phe Gly
 1055 1060 1065

Ala Gly Gly Leu Pro Met His His Val Arg Ala Ala Leu Glu Lys
 1070 1075 1080

Ile Gln Ala Ala Leu Pro Gln Gly Pro Tyr Ala Val Asn Leu Ile
 1085 1090 1095

His Ser Pro Phe Asp Ser Asn Leu Glu Lys Gly Asn Val Asp Leu
 1100 1105 1110

Phe Leu Glu Lys Gly Val Thr Val Val Glu Ala Ser Ala Phe Met
 1115 1120 1125

Thr Leu Thr Pro Gln Val Val Arg Tyr Arg Ala Ala Gly Leu Ser
 1130 1135 1140

Arg Asn Ala Asp Gly Ser Val Asn Ile Arg Asn Arg Ile Ile Gly
 1145 1150 1155

Lys Val Ser Arg Thr Glu Leu Ala Glu Met Phe Ile Arg Pro Ala
 1160 1165 1170

2997-49-2-pct_ST25

Pro	Glu 1175	His	Leu	Leu	Glu	Lys 1180	Leu	Ile	Ala	Ser	Gly 1185	Glu	Ile	Thr
Gln	Glu 1190	Gln	Ala	Glu	Leu	Ala 1195	Arg	Arg	Val	Pro	Val 1200	Ala	Asp	Asp
Ile	Ala 1205	Val	Glu	Ala	Asp	Ser 1210	Gly	Gly	His	Thr	Asp 1215	Asn	Arg	Pro
Ile	His 1220	Val	Ile	Leu	Pro	Leu 1225	Ile	Ile	Asn	Leu	Arg 1230	Asn	Arg	Leu
His	Arg 1235	Glu	Cys	Gly	Tyr	Pro 1240	Ala	His	Leu	Arg	Val 1245	Arg	Val	Gly
Ala	Gly 1250	Gly	Gly	Val	Gly	Cys 1255	Pro	Gln	Ala	Ala	Ala 1260	Ala	Ala	Leu
Thr	Met 1265	Gly	Ala	Ala	Phe	Ile 1270	Val	Thr	Gly	Thr	Val 1275	Asn	Gln	Val
Ala	Lys 1280	Gln	Ser	Gly	Thr	Cys 1285	Asp	Asn	Val	Arg	Lys 1290	Gln	Leu	Ser
Gln	Ala 1295	Thr	Tyr	Ser	Asp	Ile 1300	Cys	Met	Ala	Pro	Ala 1305	Ala	Asp	Met
Phe	Glu 1310	Glu	Gly	Val	Lys	Leu 1315	Gln	Val	Leu	Lys	Lys 1320	Gly	Thr	Met
Phe	Pro 1325	Ser	Arg	Ala	Asn	Lys 1330	Leu	Tyr	Glu	Leu	Phe 1335	Cys	Lys	Tyr
Asp	Ser 1340	Phe	Asp	Ser	Met	Pro 1345	Pro	Ala	Glu	Leu	Glu 1350	Arg	Ile	Glu
Lys	Arg 1355	Ile	Phe	Lys	Arg	Ala 1360	Leu	Gln	Glu	Val	Trp 1365	Glu	Glu	Thr
Lys	Asp 1370	Phe	Tyr	Ile	Asn	Gly 1375	Leu	Lys	Asn	Pro	Glu 1380	Lys	Ile	Gln
Arg	Ala 1385	Glu	His	Asp	Pro	Lys 1390	Leu	Lys	Met	Ser	Leu 1395	Cys	Phe	Arg
Trp	Tyr 1400	Leu	Gly	Leu	Ala	Ser 1405	Arg	Trp	Ala	Asn	Met 1410	Gly	Ala	Pro
Asp	Arg 1415	Val	Met	Asp	Tyr	Gln 1420	Val	Trp	Cys	Gly	Pro 1425	Ala	Ile	Gly

2997-49-2-pct_ST25

Ala Phe Asn Asp Phe Ile Lys Gly Thr Tyr Leu Asp Pro Ala Val
 1430 1435 1440

Ser Asn Glu Tyr Pro Cys Val Val Gln Ile Asn Leu Gln Ile Leu
 1445 1450 1455

Arg Gly Ala Cys Tyr Leu Arg Arg Leu Asn Ala Leu Arg Asn Asp
 1460 1465 1470

Pro Arg Ile Asp Leu Glu Thr Glu Asp Ala Ala Phe Val Tyr Glu
 1475 1480 1485

Pro Thr Asn Ala Leu
 1490

<210> 75
 <211> 4479
 <212> DNA
 <213> artificial

<220>
 <223> synthetic

<400> 75
 atggcgctcc gtgtcaagac gaacaagaag ccatgctggg agatgaccaa ggaggagctg 60
 accagcggca agaccgaggt gttcaactat gaggaactcc tcgagttcgc agagggcgac 120
 atcgccaagg ttttcggacc cgagttcgcc gtcacgaca agtaccgcgc ccgcgtgcgc 180
 ctgcccggcc gcgagtacct gctcgtgacc cgcgtcacc tcattggacgc cgaggtcaac 240
 aactaccgcg tcggcgcccg catggtcacc gactacgac tccccgtcaa cggagagctc 300
 tccgagggcg gagactgccc ctggggccgtc ctgggtcgaga gtggccagtg cgatctcatg 360
 ctcatctcct acatgggcat tgacttccag aaccagggcg accgcgtcta ccgcctgctc 420
 aacaccacgc tcacctttta cggcgtggcc caccagggcg agaccctcga gtacgacatt 480
 cgcgtcaccg gtttcgcaa gcgtctcgac ggcggcattc ccatgttctt cttcgagtac 540
 gactgctacg tcaacggccg cctcctcatc gagatgcgcg atggctgcgc cggcttcttc 600
 accaacgagg agctcgacgc cggcaagggc gtcgtcttca cccgcggcga cctcgccgcc 660
 cgcgccaaga tcccaaagca ggacgtctcc ccctacgccg tcgccccctg cctccacaag 720
 accaagctca acgaaaagga gatgcagacc ctgctcgaca aggactgggc atccgtcttt 780
 ggctccaaga acggcatgcc ggaaatcaac tacaaactct gcgcgcgtaa gatgctcatg 840
 attgaccgcg tcaccagcat tgaccacaag ggcggtgtct acggcctcgg tcagctcgtc 900
 ggtgaaaaga tcctcgagcg cgaccactgg tactttccct gccactttgt caaggatcag 960
 gtcattggccg gatccctcgt ctccgacggc tgcagccaga tgctcaagat gtacatgac 1020
 tggctcggcc tccacctcac caccggaccc tttgacttcc gcccggtcaa cggccacccc 1080
 aacaaggtcc gctgccgcgg ccaaattctc ccgcacaagg gcaagctcgt ctacgtcatg 1140
 gagatcaagg agatgggctt cgacgaggac aacgaccgt acgccattgc cgacgtcaac 1200

2997-49-2-pct_ST25

atcattgatg	tcgacttcga	aaagggccag	gacttttagcc	tcgaccgcat	cagcgactac	1260
ggcaagggcg	acctcaacaa	gaagatcgtc	gtcgacttta	agggcatcgc	tctcaagatg	1320
cagaagcgct	ccaccaacaa	gaacccctcc	aaggttcagc	ccgtctttgc	caacggcgcc	1380
gccactgtcg	gccccgaggc	ctccaaggct	tcctccggcg	ccagcgccag	cgccagcgcc	1440
gccccggcca	agcctgcctt	cagcgccgat	gttcttgcg	ccaagcccgt	tgcccttccc	1500
gagcacatcc	tcaagggcga	cgccctcgcc	cccaaggaga	tgtcctggca	ccccatgagc	1560
aagctccccg	gcaacccac	ccccttcttt	tctccctcgt	cgtatccgcc	ccgtgctatc	1620
tgcttcatcc	cttttccggg	caaccgcgtc	gacaacaact	gcaaggccgg	cgagatgccc	1680
ctcaactggg	acaacatgag	cgaattcatg	tgcggtaagg	tcagcaactg	cctcggcccc	1740
gagttcgccc	gctttgacaa	gagcaacacc	tcctcgctccc	ccgccttcga	ccttgcgctc	1800
gtcacgcg	tcgtcgaggt	caccaacatg	gagcacggca	agttcctcaa	cgtcgactgt	1860
aacccttcga	agggcacgat	ggtgggagag	ttcgactgcc	cgcaggacgc	ctggttcttt	1920
gacggctcct	gcaatgacgg	tcatatgccg	tactccatca	tcattggagat	cggccttcag	1980
acgtctggtg	tcctcacgtc	ggtgctcaag	gtcctctca	cgatggacaa	ggacgacatc	2040
ctctttcgca	accttgatgc	ctcggctgag	atggtgcgcc	ctgacgtcga	tgtccgcggc	2100
aagaccatcc	gcaacgtgac	caagtgtacc	ggctacgcca	tgcttggtaa	gatgggtatc	2160
catcgcttta	cctttgagct	ctccgtggac	ggcgctcgtc	tttacaaggg	cagcaccagc	2220
ttcggctggg	ttacgccgga	agtgtttgcc	cagcaggccg	gtctggacaa	cggcaagaag	2280
accgagccct	ggtgcaagac	caacaacacc	tcctgcccgc	gcgtcgagat	cgccagcgct	2340
aagggttaagg	agcagctcac	ggagaagctc	cctgatgcta	ccaacgccc	ggttctccgc	2400
cgctccgagc	agtgcgagta	cctcgactac	ctcaacatcg	ccccgactc	cggccttcac	2460
ggcaaggggt	acgcgcacgg	ccacaaggac	gtcaaccccc	aggactgggt	tttctcgtgc	2520
cacttctggg	tcgaccgggt	gatgcccggc	tcgcttgga	ttgagtccat	gttccagctc	2580
atcgaagcct	ttgctgtcga	ccagaatatc	cctggcgagt	acaatgtttc	gaacccgacc	2640
tttgcccatg	ccccggtaa	gaccgcttgg	aagtatcgcg	gccagctcac	tccaagaac	2700
cgcgctatgg	actgcgaggt	ccacatcgtc	agcatcacgg	cgagcccga	gaacggcggc	2760
tacgtcgaca	tcgtcgccga	cggcgccctt	tgggtcgatg	gcctccgcgt	ttacgaggcc	2820
aaggagctcc	gtgtccgcgt	cgtcagcgcc	aagccgaag	ctatcccga	tgtccagcag	2880
cagcctccct	cggctaaggc	cgaccctggc	aagaccggtg	tcgccctcag	ccccaccag	2940
ctccgcgatg	tcctctgga	ggtcgacaac	cctctgtacc	tcggtgtcga	gaactccaac	3000
cttgtccagt	tcgaaagcaa	gccggcgacg	tcctcccga	tcgtgtccat	taagccgtgt	3060
tctatctccg	acctcggcga	caagtctttc	atggagactt	acaacgtgtc	tgcgctctg	3120
tatactggcg	ccatggccaa	gggcattgcc	tcggcggacc	tcgtcatcgc	cgccggcaag	3180
cgcaagatcc	tcggctcctt	tggcgccggc	ggcctccca	tgcaccacgt	gcgcgccgcc	3240

2997-49-2-pct_ST25

ctcgagaaga	tccaggccgc	cctgcctcag	ggcccctacg	ccgtcaacct	catccactcg	3300
ccttttgaca	gcaacctcga	gaagggcaac	gtcgatctct	tcctcgagaa	gggcgtcact	3360
gtggtggagg	cctcggcatt	catgaccctc	accccgagc	tcgtgcgcta	ccgcgccgcc	3420
ggcctctcgc	gcaacgccga	cggttcggtc	aacatccgca	accgcatcat	cggcaagggtc	3480
tcgcgcaccg	agctcgccga	gatgttcata	cgcccgcccc	cggagcacct	cctcgagaag	3540
ctcatcgcct	cgggcgagat	cacccaggag	caggccgagc	tcgcgcgccg	cgttcccgtc	3600
gccgacgata	tcgtgtcga	ggctgactcg	ggcggccaca	ccgacaaccg	ccccatccac	3660
gtcatcctcc	cgctcatcat	caacctccgc	aaccgcctgc	accgcgagt	cggctacccc	3720
gcgcacctcc	gcgtccgct	tggcgccgga	ggtggcgctc	gctgcccgc	ggccgccgcc	3780
gccgcgtca	ccatgggcgc	cgccttcata	gtcaccggca	ctgtcaacca	ggtcgcccaag	3840
cagtcgggca	cctgcgacaa	cgtgcgcaag	cagctctcgc	aggccacct	ctcgatatc	3900
tgcatggccc	cggccgccga	catgttcgag	gagggcgctc	agctccaggt	cctcaagaag	3960
ggaaccatgt	tcccctcgcg	cgccaacaag	ctctacgagc	tcttttgcaa	gtacgactcc	4020
ttcgactcca	tgctctctgc	cgagctcgag	cgcctcgaga	agcgtatctt	caagcgcgca	4080
ctccaggagg	tctgggagga	gaccaaggac	ttttacatta	acggctctca	gaacccggag	4140
aagatccagc	gcgccgagca	cgaccccaag	ctcaagatgt	cgctctgctt	ccgctggtac	4200
cttggctctg	ccagccgctg	ggccaacatg	ggcgccccgg	accgcgtcat	ggactaccag	4260
gtctggtgtg	gcccggccat	tggcgcttc	aacgacttca	tcaagggcac	ctacctcgac	4320
cccgtgtct	ccaacgagta	cccctgtgtc	gtccagatca	acctgcaa	cctccgtggt	4380
gcctgtacc	tgcgccgtct	caacgcctg	cgcaacgacc	cgcgcatgga	cctcgagacc	4440
gaggatgctg	cctttgtcta	cgagcccacc	aacgcgctc			4479

<210> 76
 <211> 4200
 <212> DNA
 <213> Schizochytrium sp.

<400> 76	
tttctctctc	tcgagctggt
gctgctgctg	ctgctgctgc
tgcttccttg	ctggttctca
60	
cgtccgttcg	atcaagcgct
cgctcgctcg	accgatcggt
gcgtgcgtgc	gtgcgtgagt
120	
cttgttgcca	ggcagccgca
ggctgtctgt	ctgtttgtgt
agttttaccc	tcggggttcg
180	
gggtctgcct	gcctcccgt
cccggccgcc	gccggccgta
tccacccgc	tcgcctccgc
240	
ccatcggggc	tcgcctcctc
gcgccgcacg	catcgcgcg
atcgcatgca	tcagtctgcc
300	
acgcacgggg	ggacgcgcgc
cccgcgtccc	ccgccgccgc
cgtcgtcgtc	tggcgatgcc
360	
gtcgccgcc	tccttccttc
cctcgctccc	tcttcctccc
gagccccct	gtcttccttc
420	
gccccgcag	cggcgcgag
gaagcgagga	gagcggggag
gagagaagaa	aagaaaagaa
480	
aagaaaagaa	aataacagcg
ccgtctcgcg	cagacgcgcg
cggccgcgtg	cgaggcggcg
540	

2997-49-2-pct_ST25

tgatggggct	tctcgtggcg	cggctgcggc	ctggcccggc	ctcgcctttg	aggtgcaggc	600
tttgggagag	aagagtggga	cgcggagaag	ataagatggt	gccatggcgc	aggacggaga	660
ggttgctgaa	acttcttcga	gcggcacagg	cgatggcgag	agaccgacag	ctgccggcgc	720
ggaggggatg	gatacctccc	gaggctggca	tggacgagct	ggccgcgcgg	atctggctgg	780
ccgcgcggcg	gtgggtccgg	aggcgcgagg	ttggttttct	tcatacctga	taccatacgg	840
tattcattct	tcctctccag	gaaggaagca	agtcacatag	agtatcacta	gcctaataat	900
ggactctatg	ttttagggca	cgtcggagca	gaaggcgcga	gcgattcgaa	tgcgagcgat	960
agatacagca	cagagacctt	gccggcgacg	cggatgcagg	cgagcacgca	cgcaccgcac	1020
gcacggcagc	ggtgcacgcg	ctcctcggca	gatgcacggt	tctgcgccgc	gcctttacat	1080
tttttgattt	taggtggtgt	gcctgccact	ttgaacatca	tccacaagtc	aacgcagcat	1140
caagaggcaa	gcaagtacat	acatccattc	gaattcaagt	tcaagagacg	cagcaacagc	1200
cgccgctccg	ctcaagctgc	agctagctgg	ctgacagggc	tcgctggctg	tagtggaana	1260
ttccattcac	ttttctgcat	ccgcggccag	caggcccgtg	cgcacgttct	ctcgtttggt	1320
tgttcgttcg	tgcgtgctg	cgtgcgtccc	agctgcctgt	ctaatactgc	gcgcgatcca	1380
acgaccctcg	gtcgtcgccg	caagcgaaac	ccgacgccga	cctggccaat	gccgcaagaa	1440
tgctaagcgc	gcagcaatgc	tgagagtaat	cttcagccca	ccaagtcatt	atcgtgccc	1500
aagtctccat	cgcagccaca	ttcaggcttt	ctctctctct	ccctccctct	ctttctgccg	1560
ggagagaagg	aaagacccgc	cgccgccgcc	tctgcgcctg	tgacgggctg	tccgttgtaa	1620
gccctcttag	acagttccta	ggtgccgggc	gccgccgcgc	ctccgtcgca	ggcacacgta	1680
ggcggccacg	ggttcccccc	gcaccttcca	caccttcttc	ccccgcagcc	ggaccgcgcg	1740
ccgtctgctt	acgcacttcg	cgcggccgcc	gcccgcgaac	ccgagcgcgt	gctgtgggcg	1800
ccgtcttccg	gccgcgtcgg	aggtcgtccc	cgcgccgcgc	tactccgggt	cctgtgcggt	1860
acgtacttaa	tattaacagt	gggacctcgc	acaggacctg	acggcagcac	agacgtcgcc	1920
gcctcgcata	gctggggacg	caggcgaggc	atcccggcgc	ggccccgcac	cggggagggt	1980
gcggggcggc	ctcttcgggc	cggcggccgc	atcaggcgga	tgacgcaaga	gccctcgcag	2040
tcgctcgctc	gcgggagcgc	agcgcggcgc	cagcgtggcc	aagctcccgc	cccttctggc	2100
tggctgcatg	cctgcctgcc	tgcctgcctg	cgtgcgtgcg	tgcgtgctg	ccttcgtgcg	2160
tgctgcctt	cgtgcgtgcg	tgcgtgagtg	cggcggaaga	gggatcatgc	gaggatcaat	2220
cacccgccgc	acctcgactt	ttgaagaagc	cgcgatgcga	tgcgatgcga	tgcgatgcga	2280
cgcgataccg	tgcgaggcta	cgaagcgagt	ctggccggcc	gtcatacaac	gcacgttttc	2340
gagaaggagg	gctggcggag	gcgtgcatgc	cggcgaccat	tgcgaacgcg	gcgtctcgtg	2400
gctggcgaag	gtgcctggag	gatctaacga	tcgctgctat	gatgctatag	ctgtgctgat	2460
ccccggtcca	ttccaccacg	tctgtgcctg	ccgcctgacc	tgcgcttggc	tttccttcaa	2520
gttctcctcc	gccgggcctt	caggaccgag	acgagacctg	cagctgcagc	tagactcgcg	2580

2997-49-2-pct_ST25

ctcgtctcgcg	gaggattcgc	cggccgcccgcg	gccggacggg	actcgcgagg	tcacacggcc	2640
gccggcgatc	gcgatggctg	tgctgacgta	ctcgtgcgtg	gcagccgtac	gtcagcgacg	2700
ccgcctccgt	attgtggatt	cgttagttgg	ttgttggttg	atttgttgat	taatTTTTTT	2760
gttcgtaggc	ttggttatag	ctaatagttt	agtttatact	ggtgctcttc	ggtgctgatt	2820
tagctcgact	tggtgccaca	ccactgcccc	tctactgtga	atggatcaat	ggacgcacga	2880
cgggcccgcg	aaagtgcgcg	agtgaggtaa	cctaagcaac	ggcgggtcttc	agagggggacg	2940
cacgccctcc	gtcgcagtca	gtccagacag	gcagaaaagc	gtcttaggga	ccacgcacgc	3000
acgcacgcac	gcacgcacgc	ccgcacgcac	gctccctccc	tcgcgtgcct	atttttttag	3060
gcttccttcc	gcacgggcct	acctctcgct	ccctcgcctc	gccgcaccag	gcggcagcag	3120
cgatacctgc	cggtgccgcc	tccgtcacgc	gctcagccgc	agctcagccc	agccgcgagc	3180
tagggtttgt	tcgtcctgaa	ttgtttgatt	tgatttgatt	tgatttgatc	cgatccgatc	3240
cgatctgatc	tgatttgctt	tgctttgctt	tgtctccctc	ccggcgcgga	ccaagcgccc	3300
gtctgcgcgc	cgcagcttcc	cttcttctcc	cagccctcct	tctgctcccg	cctctcgcgc	3360
aagcacgcag	cttcgccgcc	gcatccggtc	ggtcggtcgg	tcgatcgacc	cgccctgccgc	3420
tgctgctgtg	gccgggcttt	tctccatcgg	cgactctttc	ttctccatac	gtcctactac	3480
gtacatacat	actgccggct	tcctcctctt	ccagcgcggc	gacggcgcca	ggctgcgacg	3540
tcgtcgccgc	cgcgggcgcc	gcgcgcgcgc	ccgccgccgc	ccgcgtcgca	gggcctcgtc	3600
gccgcccgcg	ctccgctccg	ctccgaggcc	gcgagagggc	cgcgggcgcg	cgatggatgg	3660
atggatggat	ggatggatgg	atggattttg	ttgatcgatg	gcggcgcatg	ggcggagatg	3720
agcgaggacg	agcgcgcgag	cgcggcagcc	ggattcgcag	ggcctcgttc	gcctcgcgcc	3780
cgctgccgcg	cccgcccttg	gagcctgcgc	cgcgagcgag	cgagcgagcg	agcggggctt	3840
tctttgtctc	gcgcgccgct	tggcctcgtg	tgtcttgtgc	ttgcgtagcg	ggcgccgcgg	3900
tggaagatgg	ctcattcaat	cgacccattc	acgcacgcac	tccggcgcg	agagaaggcc	3960
gaggaggagc	agcaagcaaa	ccaaaagctc	tcgcgctcgc	ggtctcgggc	tcgagcggtc	4020
tcggagagag	agtcttgccg	cgaccaccgg	cagcagcagc	agcagcagca	gcgctgtcga	4080
gcacgagcac	gagcacgagc	acgagcacga	gcattcgagc	aagaggacag	acacggttgt	4140
cagcgcctag	ctcgtctgat	acagaaagag	gcgggttggg	cgtaaaaaaa	aaggagcacg	4200

<210> 77
 <211> 3886
 <212> DNA
 <213> Schizochytrium sp.

<220>
 <221> misc_feature
 <222> (2115)..(2115)
 <223> n = a, c, g, or t

<400> 77	
gatcttgatt	gccaaagctct ggattgtcga ttccgatgaa tcgagctctt tgttgtcgag 60

2997-49-2-pct_ST25

ctctggcttg	ccgagctttc	agaaatagac	aaaattgccg	agttcctgat	tgcggggctc	120
tcgattgcca	aggtctgggtg	gattctcgaa	ctctcgattg	tcaaaatctt	ggtcgtctcg	180
tcggattctt	tcctgatttg	ttttgtcaag	accttgagat	tgtgcaaaac	cttgatcggt	240
gacaaaccct	tgatcgacag	cagcctttca	tcacgctcag	ctcttgatcat	tgattatatt	300
ccccctgaca	gccaacacct	tgatgcaggg	tctcaacctt	gattttttgga	ggccatcatc	360
agcatcacgc	cccggcactc	accctcaaca	ttcgacagcc	aacgcttttt	tttcttcgac	420
taggatctga	gaataaaagc	aggtcaccac	gaccgtaggc	caacgcgaca	accatggaaa	480
taaagtgaca	acgaacgact	tgcaagttta	aatgtaaaga	gcagcaattg	cccggcccaca	540
gacaaatgaa	agcaggcgcc	gagtcttatt	tgaggagggtg	ggcctgtggc	aatgggcgaa	600
agaaaatcaa	ggacaaggag	agcaggttac	gtaccggtat	actggtatac	gtacatggat	660
ggttcttggc	aagttgacgg	gatgtgtgcg	agtgaccgtg	gtagttaacg	aaagagccgc	720
aagggcaagg	aaagcaagag	aatgcagact	tttcacagag	atggatgggt	ccgcagcttg	780
ccgcatgatg	aaacgctgta	tttcacctgg	cacgtggtgg	cgacgcgcc	cacatatgat	840
cgcgggcgcg	ggtgtattat	acattttccc	cctcaggctc	actgccatcc	ctccatgcgt	900
cgctcgtgcg	aacgacgcaa	gcctttcgca	tcgtgcagcc	tctttctggt	aaggcaagag	960
ctaaacccaa	acctaaacga	aagaacattt	ttacctctct	ctctctccca	ttggtcgcgt	1020
gcgctccgcc	gctcgtctct	cctcctgcca	gtgtcgcgcc	ctaacttccc	ccctccctcc	1080
ctccctccct	ccctccctct	ctcctgccac	cgccccctct	tccgcgctgc	gtgcggtgct	1140
gccctggacc	aatggcatgc	tgctgcacgc	tcggcggtatg	acgcaagccg	cttcgcaatt	1200
tccggatcag	atctcggcgg	ggcgtgcgcc	gcggggctac	tcgggacctg	ccgcggcccc	1260
tgcttctttc	acatccatca	tgtcctccaa	acctccgcct	cctccacgca	cgtaggcacg	1320
cccgtcgcga	cgcgcgact	gccgctgcga	aagcaagcgc	ccgcccgcgc	cccggcgacg	1380
ggaaggcggc	cgcggtctcc	ctccgcgggt	gcctcgtctc	cgcgcggggc	tgggcgggca	1440
gcagaaggcg	ggtggcggcg	gcggcttccg	tcttcgtcag	cggcctacgt	cggcggcggc	1500
gcgcgagact	acgcatgccc	ttgcgtcatg	cgctcgcagg	tagccgccgc	gggcctagcg	1560
tttccgctgg	cgccgcgcct	aagcccccg	cgcgcacggt	attgccgcga	taccgtacgg	1620
ccaagaccgc	cgagacgctc	ggccctctcg	cggccagcca	gccagcagcg	cagcggagga	1680
agagcgcgca	ggcgcggcgg	gagggcggcc	gcggagcagc	gcagagcggg	gcggagcagc	1740
gcggagcaga	acgggcagac	tcggagcggg	cagggcgggc	agagctttgg	ggtttaagga	1800
ccgggttacc	ggcgaagtga	gcggctgcgg	ggagcggctg	tgggaggggt	gagtacgcaa	1860
gcacgatgcg	agcgagagag	agacgctgcc	gcgaatcaag	aaggtaggcg	cgctgcgagg	1920
cgcggcggcg	gagcggagcg	agggagaggg	agaggagag	agaggagggg	agacgtcgcc	1980
gcggcggggc	ctggcctggc	ctggtttggc	ttggtcagcg	cggccttgct	cgagcgtgca	2040
gctggagttg	ggtggattca	tttgattttt	cttttgtttt	tgtttttctc	tctttcccg	2100

2997-49-2-pct_ST25

aaagtgttgg	ccggnccggtg	ttctttgttt	tgattttcttc	aaaagttttg	gtggttggtt	2160
ctctctcttg	gctctctgtc	aggcgggtccg	gtccacgccc	cggcctctcc	tctcctctcc	2220
tctcctctcc	tctccgtgcg	tatacgtacg	tacgtttgta	tacgtacata	catcccgc	2280
gccgtgccgg	cgagggtttg	ctcagcctgg	agcaatgcga	tgcgatgcga	tgcgatgcga	2340
cgcgacgcga	cgcgagtcac	tggttcgcgc	tgtggctgtg	gcttgcttgc	ttacttgctt	2400
tcgagctctc	ccgctttctt	ctttccttct	cacgccacca	ccaacgaaag	aagatcggcc	2460
ccggcacgcc	gctgagaagg	gctggcggcg	atgacggcac	gcgcgcccgc	tgccacgttg	2520
gcgctcgctg	ctgctgctgc	tgctgctgct	gctgctgctg	ctgctgctgc	tgctgcttct	2580
gcgcgcaggc	tttgccacga	ggccggcgctg	ctggccgctg	ccgcttccag	tccgcgtgga	2640
gagatcgaat	gagagataaa	ctggatggat	tcatcgaggg	atgaatgaac	gatggttgga	2700
tgcttttttc	ctttttcagg	tccacagcgg	gaagcaggag	cgctggaatc	tgccgccatc	2760
cgcatacgtc	tgcatcgc	cgcatcgc	gcacgcacgc	ctcgccggga	gccacagacg	2820
ggcgacaggg	cggccagcca	gccaggcagc	cagccaggca	ggcaccagag	ggccagagag	2880
cgcgccctcac	gcacgcgccg	cagtgcgcgc	atcgctcgca	gtgcagacct	tgattccccg	2940
cgcggtatctc	cgcgagcccc	aaacgaagag	cgccgtacgg	gcccataccta	gcgtcgcctc	3000
gcaccgcac	gcacgcac	gcgttccta	gagagtagta	ctcgacgaag	gcaccatttc	3060
cgcgctcctc	ttcggcgcg	tcgaggcccc	cggcgccgcg	acgatcgcg	cggccgcggc	3120
gctggcggcg	gccctggcg	tcgcgctggc	ggccgcccgcg	ggcgtctggc	cctggcgcg	3180
gcgggcgcg	caggaggagc	ggcagcggct	gctcgccgcc	agagaagagc	gcgccggg	3240
cggggaggga	cggggaggag	aaggagaagg	cgcgcaaggc	ggccccgaaa	gagaagaccc	3300
tggacttgaa	cggaagaag	aagaagaagg	agaagaagtt	gaagaagaag	aagaagaagg	3360
agagggaagtt	gaagaagacg	aggagcaggc	gcgttccaag	gcgcgttctc	ttccggaggc	3420
gcgttccagc	tgcggcggcg	gggcgggctg	cggggcgggc	gcgggcgcgg	gtgcgggcag	3480
aggggacgcg	cgcgcgagg	cggagggggc	cgagcgggag	cccctgctgc	tgcggggcgc	3540
ccggggccgca	ggtgtggcg	gcgcgacgac	ggaggcgacg	acgccagcgg	ccgcgacgac	3600
aaggccggcg	gcgtcggcg	gcggaaggcc	ccgcgcggag	caggggcggg	agcaggacaa	3660
ggcgaggag	caggagcagg	gccgggagcg	ggagcgggag	cgggcggcgg	agcccagggc	3720
agaaccaat	cgagatccag	agcgagcaga	ggccggccgc	gagcccagac	ccgcgccgca	3780
gatcactagt	accgctgcgg	aatcacagca	gcagcagcag	cagcagcagc	agcagcagca	3840
gcagcagcag	ccacgagagg	gagataaaga	aaaagcggca	gagacg		3886

<210> 78
 <211> 20
 <212> DNA
 <213> Artificial

<220>

<223> synthetic

<400> 78

catatggcgc tccgtgtcaa

20

<210> 79

<211> 35

<212> DNA

<213> Artificial

<220>

<223> synthetic

<400> 79

gccaggaagc tttgacatgg ggtgccagga catct

35

<210> 80

<211> 37

<212> DNA

<213> artificial

<220>

<223> synthetic

<400> 80

tcctggcacc ccatgtcaaa gcttcctggc aacccta

37

<210> 81

<211> 20

<212> DNA

<213> artificial

<220>

<223> synthetic

<400> 81

agtatacaga ggtgctgaca

20

<210> 82

<211> 28

<212> DNA

<213> artificial

<220>

<223> synthetic

<400> 82

gcaccccatg agcaagctcc ccggcaac

28

<210> 83

<211> 28

<212> DNA

<213> Artificial

<220>

<223> synthetic

<400> 83

gtatacagag gcgcagacac gttgtaag

28

<210> 84

<211> 28

<212> DNA
<213> Artificial

<220>
<223> synthetic

<400> 84
ctgcagccag atgctcaaga tgtacatg

28

<210> 85
<211> 31
<212> DNA
<213> artificial

<220>
<223> synthetic

<400> 85
ggagcttgct catggggtgc caggacatct c

31

<210> 86
<211> 10
<212> DNA
<213> artificial

<220>
<223> synthetic

<400> 86
ggatccatgg

10

<210> 87
<211> 31
<212> DNA
<213> Artificial

<220>
<223> synthetic

<400> 87
aagcttgtagc agtcaagtgc gcaaaaccat g

31

<210> 88
<211> 15
<212> DNA
<213> Artificial

<220>
<223> synthetic

<400> 88
taacccgggt ctaga

15

<210> 89
<211> 31
<212> DNA
<213> Artificial

<220>
<223> synthetic

<400> 89
gactgctagc ttaagcaagg attttcttaa c

31

<210> 90
 <211> 31
 <212> DNA
 <213> Artificial

 <220>
 <223> synthetic

 <400> 90
 gactggatcc tcctgatgcg gtattttctc c 31

<210> 91
 <211> 12
 <212> DNA
 <213> Artificial

 <220>
 <223> synthetic

 <400> 91
 ctaggcggcc gc 12

<210> 92
 <211> 31
 <212> DNA
 <213> Artificial

 <220>
 <223> synthetic

 <400> 92
 gactactagt ctaagaaacc attattatca t 31

<210> 93
 <211> 31
 <212> DNA
 <213> Artificial

 <220>
 <223> synthetic

 <400> 93
 gactggatcc agctttaaat aatcggtgtc a 31

<210> 94
 <211> 46
 <212> DNA
 <213> Artificial

 <220>
 <223> synthetic

 <400> 94
 gactggatcc gccaccatgt tgcagcatatc ttggctacca aaaccc 46

<210> 95
 <211> 35
 <212> DNA
 <213> Artificial

 <220>

2997-49-2-pct_ST25

<223> synthetic

<400> 95

gacttctaga tcaataatgc cagaattttg gctgc

35